article_id,entity,label,dataset,cui,preferred_name,rootSource,semantic_types
PMC11119140,appropriate treatment,TREATMENT,PMC,C3640049,Appropriate Treatment,NCI,Clinical Attribute
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC11119140,complex symptomatology,PROBLEM,PMC,,,,
PMC11119140,psychosocial implications,PROBLEM,PMC,,,,
PMC11119140,interprofessional supportive care management,TREATMENT,PMC,,,,
PMC11119140,these hurdles,PROBLEM,PMC,,,,
PMC11119140,interprofessional clinic approaches,TREATMENT,PMC,,,,
PMC11119140,an approach,TREATMENT,PMC,C0175672,Transvaginal approach,MTH,Spatial Concept
PMC11119140,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC11119140,standard therapies,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC11119140,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC11119140,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11119140,radiation therapy,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC11119140,survival,TEST,PMC,C0220921,survival aspects,MTH,Functional Concept
PMC11119140,disease stage,PROBLEM,PMC,C0699749,disease stage,MTH,Clinical Attribute
PMC11119140,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11119140,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11119140,the multivariate analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC11119140,ecog,TEST,PMC,C0430797,Electrocorticogram,MTH,Diagnostic Procedure
PMC11119140,biopsy,TEST,PMC,C0005558,Biopsy,MTH,Diagnostic Procedure
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC11119140,initial assessment,TEST,PMC,C0150637,assessment.initial,CHV,Health Care Activity
PMC11119140,pathological diagnosis,TEST,PMC,C5554790,Pathological Diagnosis,NCI,Diagnostic Procedure
PMC11119140,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC11119140,an interprofessional clinic model,TREATMENT,PMC,,,,
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC11119140,diagnostic biopsies,TEST,PMC,C2183263,diagnostic service sources renal lab (biopsies),MEDCIN,Finding
PMC11119140,symptom,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11119140,supportive care management,TREATMENT,PMC,C4683871,"Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management",NCI,Finding
PMC11119140,future care delivery models,TREATMENT,PMC,,,,
PMC11119140,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11119140,continuing such interventions,TREATMENT,PMC,,,,
PMC11119140,pdac,PROBLEM,PMC,,,,
PMC6852709,surgical techniques,TREATMENT,PMC,C2936334,Surgical Closure Techniques,MSH,Therapeutic or Preventive Procedure
PMC6852709,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6852709,complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC6852709,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC6852709,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC6852709,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6852709,metastatic cases,PROBLEM,PMC,,,,
PMC6852709,the present study,TEST,PMC,C2207391,nerve conduction study anomalous innervation screen anomalous innervation present,MEDCIN,Finding
PMC6852709,primary tumor resection,TREATMENT,PMC,C5409380,Initial resection of primary malignant tumor of peritoneum with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC6852709,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6852709,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6852709,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6852709,cancerspecific survival,TREATMENT,PMC,,,,
PMC6852709,treatment weightadjusted analysis,TEST,PMC,,,,
PMC6852709,propensity,TREATMENT,PMC,C2718044,Propensity Score,MSH,Quantitative Concept
PMC6852709,primary tumor resection,TREATMENT,PMC,C5409380,Initial resection of primary malignant tumor of peritoneum with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC6852709,propensity matching,TEST,PMC,,,,
PMC6852709,longer,PROBLEM,PMC,C1815234,Play Longer,MMSL,Pharmacologic Substance
PMC6852709,treatment weightadjusted analysis,TEST,PMC,,,,
PMC6852709,our study,TEST,PMC,,,,
PMC6852709,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC6852709,primary tumor surgery,TREATMENT,PMC,,,,
PMC6852709,the surgical inclusion criteria,TREATMENT,PMC,,,,
PMC6852709,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6852709,symptom control,TREATMENT,PMC,C1274136,Symptom control (regime/therapy),MTH,Therapeutic or Preventive Procedure
PMC6852709,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6852709,our study,TEST,PMC,,,,
PMC6852709,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC6852709,primary tumor surgery,TREATMENT,PMC,,,,
PMC6852709,the surgical inclusion criteria,TREATMENT,PMC,,,,
PMC6852709,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6852709,symptom control,TREATMENT,PMC,C1274136,Symptom control (regime/therapy),MTH,Therapeutic or Preventive Procedure
PMC6852709,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6852709,our study,TEST,PMC,,,,
PMC6852709,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC6852709,primary tumor surgery,TREATMENT,PMC,,,,
PMC6852709,oligometastasis,PROBLEM,PMC,C4682437,Oligometastasis,NCI,Pathologic Function
PMC6852709,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6852709,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC6852709,the surgical inclusion criteria,TREATMENT,PMC,,,,
PMC6852709,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6852709,symptom control,TREATMENT,PMC,C1274136,Symptom control (regime/therapy),MTH,Therapeutic or Preventive Procedure
PMC6852709,thorough evaluation,TEST,PMC,,,,
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,cancerrelated deaths,PROBLEM,PMC,,,,
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,a tumour,PROBLEM,PMC,C2362754,Tumour staging,MTH,Laboratory Procedure
PMC6420955,the latepresenting symptoms,PROBLEM,PMC,,,,
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,imaging techniques,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC6420955,magnetic resonance imaging,TEST,PMC,C0024485,Magnetic Resonance Imaging,MTH,Diagnostic Procedure
PMC6420955,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC6420955,computer topography,TEST,PMC,C2107014,computerized corneal topography,MEDCIN,Diagnostic Procedure
PMC6420955,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,reliable techniques,TREATMENT,PMC,,,,
PMC6420955,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6420955,pancreatic adenocarcinomas,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6420955,a microscopic marginnegative surgical resection,TREATMENT,PMC,,,,
PMC6420955,early tumour identification,PROBLEM,PMC,,,,
PMC6420955,considerable morbidity,PROBLEM,PMC,,,,
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6420955,a genetic screen,TEST,PMC,C0813145,Genetic Screening,MTH,Diagnostic Procedure
PMC6420955,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6420955,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC6420955,further screening modalities,TEST,PMC,,,,
PMC6420955,investigations,TEST,PMC,C1261322,Evaluation procedure,MTH,Health Care Activity
PMC6420955,imaging techniques,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC6420955,interventional radiology,TEST,PMC,C0034602,Interventional radiology,MTH,Biomedical Occupation or Discipline
PMC6420955,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6420955,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4547403,microrna mirna expression,TEST,PMC,,,,
PMC4547403,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC4547403,mirnas,TEST,PMC,C1101610,MicroRNAs,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC4547403,alternative diagnostic markers,TEST,PMC,,,,
PMC4547403,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4547403,a highly aggressive neoplasm,PROBLEM,PMC,,,,
PMC4547403,silent early symptoms,PROBLEM,PMC,,,,
PMC4547403,high metastatic potential,PROBLEM,PMC,,,,
PMC4547403,conventional therapies,TREATMENT,PMC,C5442354,Conventional oxygen therapy,MDR,Therapeutic or Preventive Procedure
PMC4547403,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4547403,multiomics data analysis,TEST,PMC,,,,
PMC4547403,integrating mirna,TEST,PMC,,,,
PMC4547403,mrna expression data,TEST,PMC,,,,
PMC4547403,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4547403,support vector machine,TREATMENT,PMC,C2699740,Support Vector Machine,MSH,Quantitative Concept
PMC4547403,mirna and mrna expression profiles,TEST,PMC,,,,
PMC4547403,104 pdac tissues,PROBLEM,PMC,,,,
PMC4547403,17 benign pancreatic tissues,PROBLEM,PMC,,,,
PMC4547403,robust markers,TEST,PMC,,,,
PMC4547403,validation,TEST,PMC,C1519941,Validation,MTH,Research Activity
PMC4547403,validation,TEST,PMC,C1519941,Validation,MTH,Research Activity
PMC4547403,mirna activity,TEST,PMC,C5815048,miRNA inhibitor activity,GO,Genetic Function
PMC4547403,mrna expression datasets,TEST,PMC,,,,
PMC4547403,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4547403,a comprehensive identification approach,TEST,PMC,,,,
PMC4547403,pdac,PROBLEM,PMC,,,,
PMC4547403,cancer pathways,PROBLEM,PMC,C2984249,Cancer Pathway,NCI,Functional Concept
PMC4547403,gene ontology analysis,TEST,PMC,,,,
PMC4547403,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4547403,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4547403,pdac diagnosis,PROBLEM,PMC,,,,
PMC4547403,mirna gene expression profiles,TEST,PMC,,,,
PMC4547403,a svm model,TREATMENT,PMC,,,,
PMC4547403,sample class weights,TREATMENT,PMC,,,,
PMC4547403,crossvalidation,TREATMENT,PMC,,,,
PMC4547403,sample partitioning,TEST,PMC,,,,
PMC4547403,27 mirnas,TEST,PMC,,,,
PMC4547403,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9656492,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9656492,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9656492,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,the treatment regimen,TREATMENT,PMC,C5204766,Treatment Regimen #1,NCI,Therapeutic or Preventive Procedure
PMC9656492,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9656492,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9656492,standardofcare treatment,TREATMENT,PMC,,,,
PMC9656492,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,stereotactic body radiotherapy,TREATMENT,PMC,C1720823,Stereotactic Body Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC9656492,an immunological adjuvant,TREATMENT,PMC,C0001551,Immunologic Adjuvants,MTH,"Pharmacologic Substance, Immunologic Factor"
PMC9656492,this combination treatment,TREATMENT,PMC,,,,
PMC9656492,a potent antitumor immune response,TREATMENT,PMC,,,,
PMC9656492,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9656492,immunomodulatory effects,TREATMENT,PMC,,,,
PMC9656492,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC9656492,the peripheral blood,TEST,PMC,C0229664,peripheral blood,MTH,Body Substance
PMC9656492,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC9656492,immune monitoring,TEST,PMC,C0026428,"Monitoring, Immunologic",MSH,Health Care Activity
PMC9656492,the peripheral blood,TEST,PMC,C0229664,peripheral blood,MTH,Body Substance
PMC9656492,transient lymphodepletion,PROBLEM,PMC,,,,
PMC9656492,immune activation,PROBLEM,PMC,C4049273,Systemic immune activation,MDR,Disease or Syndrome
PMC9656492,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9656492,immune activation,PROBLEM,PMC,C4049273,Systemic immune activation,MDR,Disease or Syndrome
PMC9656492,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9656492,improved progressionfree survival,PROBLEM,PMC,,,,
PMC9656492,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9656492,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,stereotactic body radiotherapy,TREATMENT,PMC,C1720823,Stereotactic Body Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC9656492,the regimen,TREATMENT,PMC,C3827418,XELIRI Regimen,MTH,Therapeutic or Preventive Procedure
PMC9656492,an adjuvant,TREATMENT,PMC,C1522673,Adjuvant,MTH,Functional Concept
PMC9656492,a heatkilled mycobacterium,TREATMENT,PMC,,,,
PMC9656492,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,beneficial immunomodulatory effects,TREATMENT,PMC,,,,
PMC9656492,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9656492,imm101,TREATMENT,PMC,C3501154,IMM-101,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9656492,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,the immunomodulatory effects,TREATMENT,PMC,,,,
PMC9656492,the combination treatment,TREATMENT,PMC,C2051544,patient combination lift,MEDCIN,Medical Device
PMC9656492,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,six intradermal vaccinations,TREATMENT,PMC,,,,
PMC9656492,an observed toxicity rate,PROBLEM,PMC,,,,
PMC9656492,grade 4,PROBLEM,PMC,C4284297,Simpson Grade 4,MTH,Intellectual Product
PMC9656492,targeted geneexpression profiling,TEST,PMC,,,,
PMC9656492,multicolor flow cytometry,TEST,PMC,,,,
PMC9656492,longitudinal immunemonitoring,TEST,PMC,,,,
PMC9656492,the peripheral blood,TEST,PMC,C0229664,peripheral blood,MTH,Body Substance
PMC9656492,study treatment,TREATMENT,PMC,C3641099,Study Treatment Causality,NCI,Idea or Concept
PMC9656492,treatmentrelated adverse events,PROBLEM,PMC,,,,
PMC9656492,sbrtimm101,TREATMENT,PMC,,,,
PMC9656492,a transient decrease in different lymphocyte subsets,PROBLEM,PMC,,,,
PMC9656492,an increase in cd14cd16cd11bhladrlowmyeloidderived,PROBLEM,PMC,,,,
PMC9656492,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9656492,increased activated icos,PROBLEM,PMC,,,,
PMC9656492,hladr,TEST,PMC,C1532177,Percentage count of cells positive for both CD34 antigen and HLA-DR antigen,SNOMEDCT_US,Laboratory Procedure
PMC9656492,ki67pd1,TEST,PMC,,,,
PMC9656492,nk cell frequencies,TEST,PMC,,,,
PMC9656492,increased levels,PROBLEM,PMC,C5775494,Increased ammonia levels,OMIM,Finding
PMC9656492,tim3,TEST,PMC,C3541254,HAVCR2 wt Allele,MTH,Gene or Genome
PMC9656492,lag3,TEST,PMC,C1416771,LAG3 gene,MTH,Gene or Genome
PMC9656492,combination therapy,TREATMENT,PMC,C0556895,Combination electrotherapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,a heatkilled mycobacterium vaccine,TREATMENT,PMC,,,,
PMC9656492,an immunestimulatory effect,TREATMENT,PMC,,,,
PMC9656492,phase i study,TEST,PMC,C0920321,Phase I Clinical Trials,MTH,Research Activity
PMC9656492,intradermal imm101,TREATMENT,PMC,,,,
PMC9656492,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,lapc,PROBLEM,PMC,,,,
PMC9656492,transient lymphodepletion,PROBLEM,PMC,,,,
PMC9656492,enhanced t cell activation,PROBLEM,PMC,C4551967,B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY,MTH,Disease or Syndrome
PMC9656492,the peripheral blood,TEST,PMC,C0229664,peripheral blood,MTH,Body Substance
PMC9656492,increased levels of activated t cells,PROBLEM,PMC,,,,
PMC9656492,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9656492,future studies,TEST,PMC,,,,
PMC9656492,the intratumoral administration of imm101,TREATMENT,PMC,,,,
PMC9656492,other immunotherapeutic agents,TREATMENT,PMC,,,,
PMC9656492,adaptive responses,TREATMENT,PMC,C1749719,Adaptive Immune Response,MSH,Organism Function
PMC9656492,immune checkpoint blockade,TREATMENT,PMC,C5392067,Immune Checkpoint Blockade,MSH,Cell Function
PMC9656492,adoptive cell transfer therapy,TREATMENT,PMC,C0079613,Adoptive Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC9656492,limited treatment options,TREATMENT,PMC,C5913286,"Provide information about risks, benefits, and limitations of treatment or management options, as well as options for dealing with recurrence risk",NIC,Health Care Activity
PMC8648660,the metal chelating portion,TREATMENT,PMC,,,,
PMC8648660,thiosemicarbazone,TREATMENT,PMC,C0039946,Thiosemicarbazones,MTH,Organic Chemical
PMC8648660,the cytotoxic activity of sigma2 receptors,TREATMENT,PMC,,,,
PMC8648660,a promising strategy,TREATMENT,PMC,C5144326,"Current level of confidence I can use a strategy (for example: humor, leaving a situation) to keep from getting upset:Find:Pt:^Patient:Ord:PROMIS",LNC,Clinical Attribute
PMC8648660,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC8648660,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC8648660,a novel sigma2 receptor targeting thiosemicarbazone,TREATMENT,PMC,,,,
PMC8648660,a moiety,TREATMENT,PMC,C1552018,active moiety,HL7V3.0,Chemical Viewed Functionally
PMC8648660,lysosome destabilization,PROBLEM,PMC,,,,
PMC8648660,ros increase,PROBLEM,PMC,C4476796,Increased reactive oxygen species production,HPO,Cell or Molecular Dysfunction
PMC8648660,efficient antitumor agents,TREATMENT,PMC,,,,
PMC8648660,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC8648660,flow cytometry,TEST,PMC,C0016263,Flow Cytometry,MSH,Laboratory Procedure
PMC8648660,these cells,TEST,PMC,,,,
PMC8648660,cytotoxicity,TEST,PMC,C0596402,cytotoxicity,MTH,Cell or Molecular Dysfunction
PMC8648660,activation of er and mitochondriadependent cell death pathways,PROBLEM,PMC,,,,
PMC8648660,grp78,TEST,PMC,C1415761,HSPA5 gene,MTH,Gene or Genome
PMC8648660,atf6,TEST,PMC,C1412622,ATF6 gene,MTH,Gene or Genome
PMC8648660,perk,TEST,PMC,C0683783,perquisite,MTH,Quantitative Concept
PMC8648660,ros levels,TEST,PMC,C1277853,Ross river fever antibody level,SNOMEDCT_US,Laboratory Procedure
PMC8648660,mitosox,TEST,PMC,C1958579,MitoSOX,MSH,Organic Chemical
PMC8648660,dcfdaam,TEST,PMC,,,,
PMC8648660,jc1 staining,TEST,PMC,,,,
PMC8648660,the thiosemicarbazones fa4,TREATMENT,PMC,,,,
PMC8648660,autophagic proteins,PROBLEM,PMC,C3884619,"atg-16.1 protein, C elegans",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8648660,atg12,TEST,PMC,C1865043,ATG12 gene,MTH,Gene or Genome
PMC8648660,beclin,TREATMENT,PMC,C4255099,Beclin-1,MTH,"Amino Acid, Peptide, or Protein"
PMC8648660,fa4 in xenograft models,TREATMENT,PMC,,,,
PMC8648660,gemcitabine challenge,TREATMENT,PMC,,,,
PMC8648660,a more potent cytotoxicity,PROBLEM,PMC,,,,
PMC8648660,thiosemicarbazones,TREATMENT,PMC,C0039946,Thiosemicarbazones,MTH,Organic Chemical
PMC8648660,variable effects on the er,PROBLEM,PMC,,,,
PMC8648660,the mitochondriadependent proapoptotic axis,PROBLEM,PMC,,,,
PMC8648660,fa4 activated proapoptotic pathways,PROBLEM,PMC,,,,
PMC8648660,decreased autophagy,PROBLEM,PMC,,,,
PMC8648660,miapaca2 cells,PROBLEM,PMC,,,,
PMC8648660,autophagic proteins,PROBLEM,PMC,C3884619,"atg-16.1 protein, C elegans",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8648660,fa4 treatment,TREATMENT,PMC,,,,
PMC8648660,panc1 xenografted mouse models,TREATMENT,PMC,,,,
PMC8648660,conventional chemotherapy,TREATMENT,PMC,,,,
PMC8648660,significantly reduced tumor volumes,PROBLEM,PMC,,,,
PMC8648660,increased intratumor apoptosis,PROBLEM,PMC,,,,
PMC8648660,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC8648660,our data,TEST,PMC,,,,
PMC8648660,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC8648660,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC8648660,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC8648660,patientderived pancreatic cancers,PROBLEM,PMC,,,,
PMC8648660,therapies,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC8648660,individual tumor types,PROBLEM,PMC,,,,
PMC8648660,our data,TEST,PMC,,,,
PMC8648660,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC8648660,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC8648660,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC8648660,patientderived pancreatic cancers,PROBLEM,PMC,,,,
PMC8648660,therapies,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC8648660,individual tumor types,PROBLEM,PMC,,,,
PMC7731834,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7731834,screening programs,TEST,PMC,C4704706,Diagnostic Screening Programs,MSH,Diagnostic Procedure
PMC7731834,moderate and highrisk people,PROBLEM,PMC,,,,
PMC7731834,a prospective study,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC7731834,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7731834,pancreatic cancer screening,PROBLEM,PMC,,,,
PMC7731834,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7731834,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7731834,pcassociated genetic mutations,PROBLEM,PMC,,,,
PMC7731834,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7731834,pcassociated mutations,PROBLEM,PMC,,,,
PMC7731834,brca2,PROBLEM,PMC,C0598034,BRCA2 gene,MTH,Gene or Genome
PMC7731834,lynch syndrome,PROBLEM,PMC,C4552100,Lynch Syndrome,MTH,Disease or Syndrome
PMC7731834,familial atypical multiple mole melanoma syndrome,PROBLEM,PMC,C2314896,Familial Atypical Mole Melanoma Syndrome,MTH,Neoplastic Process
PMC7731834,a screening eus,TEST,PMC,,,,
PMC7731834,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7731834,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7731834,psychological symptoms,PROBLEM,PMC,C0233397,Psychological symptom,SNOMEDCT_US,Sign or Symptom
PMC7731834,personal,TEST,PMC,C1519021,Personal Attribute,MTH,Organism Attribute
PMC7731834,the screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC7731834,a screening eus,TEST,PMC,,,,
PMC7731834,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7731834,pcassociated mutations,PROBLEM,PMC,,,,
PMC7731834,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC7731834,eus screening,TEST,PMC,,,,
PMC7731834,patients iespcq scores,TEST,PMC,,,,
PMC7731834,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC7731834,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC7731834,screening eus,TEST,PMC,,,,
PMC7731834,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7731834,any pcs,PROBLEM,PMC,,,,
PMC7731834,a moderate or highrisk population,PROBLEM,PMC,,,,
PMC7731834,a,TEST,PMC,,,,
PMC7731834,the eus procedure,TREATMENT,PMC,,,,
PMC7731834,genetic counseling,TREATMENT,PMC,C0017382,Genetic Counseling,MTH,Therapeutic or Preventive Procedure
PMC7731834,psychological symptoms,PROBLEM,PMC,C0233397,Psychological symptom,SNOMEDCT_US,Sign or Symptom
PMC7731834,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC7731834,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7731834,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC7731834,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7731834,computer tomographymagnetic,TEST,PMC,,,,
PMC7731834,such screening,TEST,PMC,C1978523,"Maternal screen for fetal abnormalities such as Open Neural Tube Defects, Trisomy 21 or Trisomy 18 panel",MTH,Laboratory Procedure
PMC7731834,our study,TEST,PMC,,,,
PMC7731834,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7731834,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7731834,any pcs,PROBLEM,PMC,,,,
PMC7731834,a moderate or highrisk population,PROBLEM,PMC,,,,
PMC7731834,a,TEST,PMC,,,,
PMC7731834,the eus procedure,TREATMENT,PMC,,,,
PMC7731834,genetic counseling,TREATMENT,PMC,C0017382,Genetic Counseling,MTH,Therapeutic or Preventive Procedure
PMC7731834,psychological symptoms,PROBLEM,PMC,C0233397,Psychological symptom,SNOMEDCT_US,Sign or Symptom
PMC6212542,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC6212542,cancer death,PROBLEM,PMC,C4722463,Cancer-Related Death,MTH,Finding
PMC6212542,curative resection,TREATMENT,PMC,,,,
PMC6212542,surgical palliation,TREATMENT,PMC,,,,
PMC6212542,a procedure,TREATMENT,PMC,C1546467,Act Class - procedure,MTH,Occupational Activity
PMC6212542,relieving symptoms,PROBLEM,PMC,C0436325,Food relieves symptom,SNOMEDCT_US,Finding
PMC6212542,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6212542,the palliative management,TREATMENT,PMC,C4683871,"Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management",NCI,Finding
PMC6212542,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC6212542,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC6212542,duodenal obstruction,PROBLEM,PMC,C0013292,Duodenal Obstruction,MTH,Disease or Syndrome
PMC6212542,pain control,TREATMENT,PMC,C1304888,Pain control,MTH,Therapeutic or Preventive Procedure
PMC6212542,celiac plexus block,TREATMENT,PMC,C0472438,Celiac plexus block,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6212542,surgical bypasses,TREATMENT,PMC,C2461341,Medical and Surgical @ Eye @ Bypass,ICD10PCS,Therapeutic or Preventive Procedure
PMC6212542,both biliary and duodenal obstructions,PROBLEM,PMC,,,,
PMC6212542,considerable perioperative morbidity,PROBLEM,PMC,,,,
PMC6212542,laparoscopically,TREATMENT,PMC,C0860487,Laparoscopically assisted hysterectomy,MDR,Therapeutic or Preventive Procedure
PMC6212542,selfexpanding metal stents,TREATMENT,PMC,,,,
PMC6212542,biliary drainage,TREATMENT,PMC,C0400745,Biliary drainage (procedure),MTH,Therapeutic or Preventive Procedure
PMC6212542,low morbidity,PROBLEM,PMC,C0580967,Morbidity index low,SNOMEDCT_US,Finding
PMC6212542,surgical gastrojejunostomy,TREATMENT,PMC,C4065014,"gastroscopy: post-surgical gastrojejunostomy, Billroth II",MEDCIN,Diagnostic Procedure
PMC6212542,duodenal obstruction,PROBLEM,PMC,C0013292,Duodenal Obstruction,MTH,Disease or Syndrome
PMC6212542,endoscopic stenting,TREATMENT,PMC,C0842857,Endoscopic stenting of biliary tract,ICD10AM,Therapeutic or Preventive Procedure
PMC6212542,good symptom relief,PROBLEM,PMC,C5244552,polyethylene glycol 400 10 MG/ML / tetrahydrozoline hydrochloride 0.5 MG/ML / zinc sulfate 2.5 MG/ML Ophthalmic Solution,RXNORM,Clinical Drug
PMC6212542,the palliative procedure,TREATMENT,PMC,C1285158,Palliative procedure,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6212542,life management,TREATMENT,PMC,C3887429,Life management service,SNOMEDCT_US,Health Care Activity
PMC6212542,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6212542,an extremely aggressive disease,PROBLEM,PMC,,,,
PMC6212542,a curable operation,TREATMENT,PMC,,,,
PMC6212542,treatment decisions,TREATMENT,PMC,C5934487,Participates in treatment decisions,NOC,Finding
PMC6212542,reducing morbidity,PROBLEM,PMC,,,,
PMC6212542,a palliative treatment,TREATMENT,PMC,C0920416,cancer palliative treatment,CHV,Therapeutic or Preventive Procedure
PMC6212542,durable symptom resolution,PROBLEM,PMC,,,,
PMC6212542,palliative treatment,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC6212542,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC6212542,duodenal obstruction,PROBLEM,PMC,C0013292,Duodenal Obstruction,MTH,Disease or Syndrome
PMC6212542,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6212542,surgical palliation,TREATMENT,PMC,,,,
PMC6212542,nonoperative palliative interventions,TREATMENT,PMC,,,,
PMC6212542,surgical bypasses,TREATMENT,PMC,C2461341,Medical and Surgical @ Eye @ Bypass,ICD10PCS,Therapeutic or Preventive Procedure
PMC6212542,both biliary and duodenal obstructions,PROBLEM,PMC,,,,
PMC6212542,considerable perioperative morbidity,PROBLEM,PMC,,,,
PMC6212542,laparoscopically,TREATMENT,PMC,C0860487,Laparoscopically assisted hysterectomy,MDR,Therapeutic or Preventive Procedure
PMC6212542,sems,TREATMENT,PMC,C0262878,"Microscopes, Electron, Scanning",MTH,Medical Device
PMC6212542,biliary drainage,TREATMENT,PMC,C0400745,Biliary drainage (procedure),MTH,Therapeutic or Preventive Procedure
PMC6212542,low morbidity,PROBLEM,PMC,C0580967,Morbidity index low,SNOMEDCT_US,Finding
PMC6212542,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC6212542,pruritus,PROBLEM,PMC,C0033774,Pruritus,MTH,Sign or Symptom
PMC6212542,surgical gj,TREATMENT,PMC,,,,
PMC6212542,duodenal obstruction,PROBLEM,PMC,C0013292,Duodenal Obstruction,MTH,Disease or Syndrome
PMC6212542,endoscopic stenting,TREATMENT,PMC,C0842857,Endoscopic stenting of biliary tract,ICD10AM,Therapeutic or Preventive Procedure
PMC6212542,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC6212542,emesis,PROBLEM,PMC,C2825053,Emesis [PE],MTH,Physiologic Function
PMC6212542,regional neurolysis of celiac plexus,TREATMENT,PMC,,,,
PMC6212542,better,TREATMENT,PMC,C0332272,Better,MTH,Qualitative Concept
PMC6212542,the palliative procedure,TREATMENT,PMC,C1285158,Palliative procedure,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6212542,life management,TREATMENT,PMC,C3887429,Life management service,SNOMEDCT_US,Health Care Activity
PMC8267412,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8267412,a lethal condition,PROBLEM,PMC,,,,
PMC8267412,poor outcomes,PROBLEM,PMC,C3841289,Previous poor pregnancy outcome,LNC,Finding
PMC8267412,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC8267412,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8267412,heparan,TREATMENT,PMC,C2327880,Heparan,FMA,Biologically Active Substance
PMC8267412,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC8267412,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC8267412,heparan sulfated proteoglycans,TREATMENT,PMC,C0062503,Heparan Sulfate Proteoglycans,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8267412,growth factors,PROBLEM,PMC,C0018284,Growth Factor,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8267412,tumor progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC8267412,glypicans syndecans,PROBLEM,PMC,,,,
PMC8267412,perlecan,TREATMENT,PMC,C0136134,perlecan,MTH,"Amino Acid, Peptide, or Protein"
PMC8267412,extracellular matrix modifying enzymes,TREATMENT,PMC,,,,
PMC8267412,heparanases,TREATMENT,PMC,C0062505,heparanase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8267412,sulfatases,TREATMENT,PMC,C0038717,Sulfatases,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8267412,potential diagnostics,TEST,PMC,C0492946,"MEDIA, POTENTIATING FOR IN VITRO DIAGNOSTIC USE",SPN,Medical Device
PMC8267412,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8267412,an analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC8267412,a multidimensional cancer genomics,TREATMENT,PMC,,,,
PMC8267412,heparan sulfated proteoglycanrelated genes,TREATMENT,PMC,,,,
PMC8267412,precision medicine,TREATMENT,PMC,C2718059,Precision Medicine,MSH,Therapeutic or Preventive Procedure
PMC8267412,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC8267412,a cuttingedge approach,TREATMENT,PMC,,,,
PMC8267412,pathology,PROBLEM,PMC,C0030664,Pathology,MTH,Biomedical Occupation or Discipline
PMC8267412,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8267412,blood sampling,TEST,PMC,C0190979,Venous blood sampling,MTH,Diagnostic Procedure
PMC8267412,specific markers,PROBLEM,PMC,C1300030,Cancer diagnosis based on specific tumor markers,SNOMEDCT_US,Finding
PMC8267412,treatment response,TREATMENT,PMC,C2127121,treatment response or compliance,MEDCIN,Finding
PMC8267412,resistance mechanisms,TREATMENT,PMC,C0236104,RESISTANCE MECHANISM DISORDERS,WHO,Disease or Syndrome
PMC8267412,circulating markers,TEST,PMC,C5944749,DNA next-generation sequencing of tumor methylation markers present in cell-free circulating tumor DNA in pan-solid tumor,CPT,Laboratory Procedure
PMC8267412,metastatic relapse,PROBLEM,PMC,C5667237,Recurrent Metastatic Melanoma,NCI,Neoplastic Process
PMC8267412,screening,TREATMENT,PMC,C1710032,Screening,MTH,Health Care Activity
PMC8267412,minimally invasive lowcost liquid biopsy,TREATMENT,PMC,,,,
PMC8267412,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC8267412,hspgs,PROBLEM,PMC,C0062503,Heparan Sulfate Proteoglycans,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8267412,hspgs,PROBLEM,PMC,C0062503,Heparan Sulfate Proteoglycans,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8267412,gpc1,TEST,PMC,C1415193,GPC1 gene,MTH,Gene or Genome
PMC8267412,gpc5,TEST,PMC,C1415197,GPC5 gene,MTH,Gene or Genome
PMC8267412,sdc3,PROBLEM,PMC,C1419893,SDC3 gene,MTH,Gene or Genome
PMC8267412,hspg2,PROBLEM,PMC,C1415793,HSPG2 gene,MTH,Gene or Genome
PMC8267412,some hspgrelated proteins,PROBLEM,PMC,,,,
PMC8267412,heparanase,TEST,PMC,C0062505,heparanase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8267412,four multidimensional cancer genomics data sets,PROBLEM,PMC,,,,
PMC8267412,cbioportal applications,TREATMENT,PMC,,,,
PMC8267412,gpc1,TEST,PMC,C1415193,GPC1 gene,MTH,Gene or Genome
PMC8267412,gpc2,TEST,PMC,C1415194,GPC2 gene,MTH,Gene or Genome
PMC8267412,gpc3,TEST,PMC,C1415195,GPC3 gene,MTH,Gene or Genome
PMC8267412,gpc4,TEST,PMC,C1415196,GPC4 gene,MTH,Gene or Genome
PMC8267412,gpc5,TEST,PMC,C1415197,GPC5 gene,MTH,Gene or Genome
PMC8267412,gpc6,TEST,PMC,C1415198,GPC6 gene,MTH,Gene or Genome
PMC8267412,sulf1,TEST,PMC,C1426908,SULF1 gene,MTH,Gene or Genome
PMC8267412,sulf2,TEST,PMC,C1426909,SULF2 gene,MTH,Gene or Genome
PMC8267412,hs6st1,TEST,PMC,C1415734,HS6ST1 gene,MTH,Gene or Genome
PMC8267412,ndst1,PROBLEM,PMC,C1417617,NDST1 gene,MTH,Gene or Genome
PMC8267412,ndst2,PROBLEM,PMC,C1417618,NDST2 gene,MTH,Gene or Genome
PMC8267412,ndst3,PROBLEM,PMC,C1417619,NDST3 gene,MTH,Gene or Genome
PMC8267412,ndst4,PROBLEM,PMC,C1427123,NDST4 gene,MTH,Gene or Genome
PMC8267412,hpse,PROBLEM,PMC,C1367469,HPSE gene,MTH,Gene or Genome
PMC8267412,a low copy number,PROBLEM,PMC,C5560397,"cytogenomic constitutional analysis for copy number, variants, low-pass sequencing analysis",MEDCIN,Finding
PMC8267412,hspg2,TEST,PMC,C1415793,HSPG2 gene,MTH,Gene or Genome
PMC8267412,gpc1,TEST,PMC,C1415193,GPC1 gene,MTH,Gene or Genome
PMC8267412,sdc2,TEST,PMC,C1419892,SDC2 gene,MTH,Gene or Genome
PMC8267412,sulf2,TEST,PMC,C1426909,SULF2 gene,MTH,Gene or Genome
PMC8267412,mutations,PROBLEM,PMC,C0026882,Mutation,MTH,Genetic Function
PMC8267412,next generation sequencing technologies,TREATMENT,PMC,,,,
PMC8267412,hspgrelated proteins,PROBLEM,PMC,,,,
PMC8267412,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8267412,precision medicine,TREATMENT,PMC,C2718059,Precision Medicine,MSH,Therapeutic or Preventive Procedure
PMC11807416,a common complication,PROBLEM,PMC,C4086602,Most Common Complication After Surgery for Prostate Cancer,NCI,Intellectual Product
PMC11807416,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11807416,obstructing oral intake,PROBLEM,PMC,,,,
PMC11807416,duodenal stenting,TREATMENT,PMC,C0940360,Duodenal stent,SNOMEDCT_US,Medical Device
PMC11807416,palliative intervention,TREATMENT,PMC,,,,
PMC11807416,minimally invasive symptom relief,TREATMENT,PMC,,,,
PMC11807416,systemic chemotherapy,TREATMENT,PMC,C1883256,Systemic Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC11807416,stent patency,TREATMENT,PMC,C0449591,Stent patency,SNOMEDCT_US,Spatial Concept
PMC11807416,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11807416,tumorrelated factors,PROBLEM,PMC,,,,
PMC11807416,uncovered duodenal stents,TREATMENT,PMC,,,,
PMC11807416,malignant duodenal stenosis,PROBLEM,PMC,C0940344,Malignant intrinsic appearance of duodenal stenosis,MTHMST,Finding
PMC11807416,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11807416,a retrospective cohort study,TEST,PMC,C2985505,Retrospective Cohort Study,NCI,Research Activity
PMC11807416,placement,TREATMENT,PMC,C1524072,Placement,MTH,Qualitative Concept
PMC11807416,22 mm uncovered duodenal stents,TREATMENT,PMC,,,,
PMC11807416,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC11807416,intestinal reconstruction,TREATMENT,PMC,C1293524,Large intestine reconstruction,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11807416,tumor characteristics,PROBLEM,PMC,C5444687,GCT Survival Characteristics Table,MTH,Intellectual Product
PMC11807416,procedural details,TREATMENT,PMC,C5204320,Surgical Procedure Details,NCI,Intellectual Product
PMC11807416,univariate and multivariate analyses,TEST,PMC,,,,
PMC11807416,stent patency,TREATMENT,PMC,C0449591,Stent patency,SNOMEDCT_US,Spatial Concept
PMC11807416,the kaplanmeier method,TEST,PMC,,,,
PMC11807416,cox proportional,TREATMENT,PMC,C0010235,Cox Proportional Hazards Models,MSH,Quantitative Concept
PMC11807416,the mean patency,TREATMENT,PMC,,,,
PMC11807416,uncovered duodenal stents,TREATMENT,PMC,,,,
PMC11807416,stent occlusion,PROBLEM,PMC,C0919560,Stent occlusion,MDR,Pathologic Function
PMC11807416,univariate analysis,TEST,PMC,C0683962,univariate statistics,CHV,Research Activity
PMC11807416,prior placement,TREATMENT,PMC,C2114504,previous stent placement,MEDCIN,Finding
PMC11807416,transpapillary biliary plastic stents,TREATMENT,PMC,,,,
PMC11807416,reduced stent patency,PROBLEM,PMC,,,,
PMC11807416,multivariate analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC11807416,shorter patency,PROBLEM,PMC,,,,
PMC11807416,tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC11807416,chemotherapy administration,TREATMENT,PMC,C3665478,chemotherapy administration,MEDCIN,Health Care Activity
PMC11807416,duodenal stenosis,PROBLEM,PMC,C0238093,Stenosis of duodenum,MTH,Anatomical Abnormality
PMC11807416,stent patency,TREATMENT,PMC,C0449591,Stent patency,SNOMEDCT_US,Spatial Concept
PMC11807416,prior placement,TREATMENT,PMC,C2114504,previous stent placement,MEDCIN,Finding
PMC11807416,transpapillary biliary plastic stents,TREATMENT,PMC,,,,
PMC11807416,uncovered duodenal stents,TREATMENT,PMC,,,,
PMC11807416,malignant duodenal stenosis,PROBLEM,PMC,C0940344,Malignant intrinsic appearance of duodenal stenosis,MTHMST,Finding
PMC11807416,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11807416,procedural planning,TREATMENT,PMC,C0580720,Operative procedure planned,SNOMEDCT_US,Finding
PMC11807416,alternative biliary drainage methods,TREATMENT,PMC,,,,
PMC11807416,stent performance,TREATMENT,PMC,C2114506,total number of previous stent placements performed (#___),MEDCIN,Finding
PMC11807416,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11807416,prior placement,TREATMENT,PMC,C2114504,previous stent placement,MEDCIN,Finding
PMC11807416,transpapillary biliary plastic stents,TREATMENT,PMC,,,,
PMC11807416,a significant factor,PROBLEM,PMC,C5913485,"Instruct person and significant others on signs and symptoms, risk factors, and treatment of hypoglycemia",NIC,Educational Activity
PMC11807416,uncovered duodenal stents,TREATMENT,PMC,,,,
PMC11807416,malignant duodenal stenosis,PROBLEM,PMC,C0940344,Malignant intrinsic appearance of duodenal stenosis,MTHMST,Finding
PMC11807416,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11807416,procedural planning,TREATMENT,PMC,C0580720,Operative procedure planned,SNOMEDCT_US,Finding
PMC11807416,appropriate biliary drainage methods,TREATMENT,PMC,,,,
PMC11807416,stent performance,TREATMENT,PMC,C2114506,total number of previous stent placements performed (#___),MEDCIN,Finding
PMC11807416,duodenal stenting,TREATMENT,PMC,C0940360,Duodenal stent,SNOMEDCT_US,Medical Device
PMC11807416,an effective palliative option,TREATMENT,PMC,,,,
PMC11807416,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC11807416,alternative techniques,TREATMENT,PMC,C1266847,Communication of alternative technique,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11807416,stent types,TREATMENT,PMC,C5784524,Multiple Stent Types Used,NCI,Finding
PMC11807416,multicenter prospective trials,TREATMENT,PMC,,,,
PMC11807416,larger sample sizes,TREATMENT,PMC,,,,
PMC3496532,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC3496532,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3496532,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3496532,496 pancreatic cancer,PROBLEM,PMC,,,,
PMC3496532,a,TEST,PMC,,,,
PMC3496532,a sevenpoint likert scale,TREATMENT,PMC,,,,
PMC3496532,cox regression,TEST,PMC,C0010235,Cox Proportional Hazards Models,MSH,Quantitative Concept
PMC3496532,the response rate,TEST,PMC,C5963169,Continued Response Rate,NCI,Quantitative Concept
PMC3496532,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC3496532,the care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC3496532,median overall survival,TREATMENT,PMC,,,,
PMC3496532,univariate analysis,TEST,PMC,C0683962,univariate statistics,CHV,Research Activity
PMC3496532,multivariate analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC3496532,specific ctca treatment center,TREATMENT,PMC,,,,
PMC3496532,significantly lower mortality,PROBLEM,PMC,,,,
PMC3496532,this exploratory analysis,TEST,PMC,,,,
PMC3496532,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3496532,further exploration,TEST,PMC,,,,
PMC3496532,this difficult malignancy,PROBLEM,PMC,,,,
PMC3496532,this exploratory analysis,TEST,PMC,,,,
PMC3496532,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3496532,further exploration,TEST,PMC,,,,
PMC3496532,this difficult malignancy,PROBLEM,PMC,,,,
PMC3496532,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3496532,patient survival,TREATMENT,PMC,C2728384,patient involved in water survival training at time of event,MEDCIN,Finding
PMC10670364,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10670364,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10670364,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10670364,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10670364,optimal care guidelines,TREATMENT,PMC,,,,
PMC10670364,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10670364,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10670364,the routine assessment,TEST,PMC,C5671166,Routine prenatal assessment panel,MTH,Health Care Activity
PMC10670364,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC10670364,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10670364,debilitating symptoms,PROBLEM,PMC,,,,
PMC10670364,essential daily care,TREATMENT,PMC,,,,
PMC10670364,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10670364,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10670364,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10670364,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10670364,a needs survey,TEST,PMC,C0814330,needs assessment survey,AOD,Intellectual Product
PMC10670364,log,TREATMENT,PMC,C1708728,Event Log,MTH,Intellectual Product
PMC10670364,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10670364,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10670364,moderatetohigh unmet needs,PROBLEM,PMC,,,,
PMC10670364,greater unmet needs,PROBLEM,PMC,,,,
PMC10670364,some,PROBLEM,PMC,C0205392,Some (qualifier value),MTH,Quantitative Concept
PMC10670364,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC10670364,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10670364,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10670364,concerns,PROBLEM,PMC,C0030544,parental concerns,MEDCIN,Finding
PMC10670364,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10670364,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10670364,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10670364,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10670364,our study,TEST,PMC,,,,
PMC10670364,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10670364,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10670364,cancers care,TREATMENT,PMC,C0920687,cancer care,CHV,Therapeutic or Preventive Procedure
PMC10670364,patient anxiety,PROBLEM,PMC,C0513589,Monitor patient for anxiety,NIC,Therapeutic or Preventive Procedure
PMC10670364,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10670364,optimal care guidelines,TREATMENT,PMC,,,,
PMC10670364,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10670364,routine assessments,TEST,PMC,C4710393,Perform or arrange for routine vision assessments and screenings,NIC,Health Care Activity
PMC10670364,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC10670364,effective interventions,TREATMENT,PMC,C1512173,Effectiveness of Interventions,NCI,Clinical Attribute
PMC6559437,pulmonary lymphangitic carcinomatosis,PROBLEM,PMC,,,,
PMC6559437,a tumor in the lung lymphatic vessels,PROBLEM,PMC,,,,
PMC6559437,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6559437,plc,PROBLEM,PMC,C0031669,Phospholipase C,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6559437,dyspnea,PROBLEM,PMC,C0013404,Dyspnea,MTH,Sign or Symptom
PMC6559437,stage 4 pancreatic cancer,PROBLEM,PMC,,,,
PMC6559437,a lymphangitic spread,PROBLEM,PMC,C3697833,Lymphangitic spread,SNOMEDCT_US,Functional Concept
PMC6559437,the tumor to the lungs,PROBLEM,PMC,C0280089,Carcinoid tumor of lung,SNOMEDCT_US,Neoplastic Process
PMC6559437,optimal treatment,TREATMENT,PMC,C5696347,Obtaining respiratory data needed to develop the optimal radiation treatment,CPT,Health Care Activity
PMC6559437,mechanical ventilation,TREATMENT,PMC,C0199470,Mechanical ventilation,MTH,Therapeutic or Preventive Procedure
PMC6559437,acute hypoxic respiratory failure,PROBLEM,PMC,C5442479,Acute hypoxic respiratory failure,MDR,Disease or Syndrome
PMC6559437,plc,PROBLEM,PMC,C0031669,Phospholipase C,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6559437,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6559437,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6559437,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6559437,plc,PROBLEM,PMC,C0031669,Phospholipase C,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6559437,timely treatment,TREATMENT,PMC,C3494202,Time-to-Treatment,MSH,Temporal Concept
PMC6559437,plc,PROBLEM,PMC,C0031669,Phospholipase C,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6559437,radiological support,TREATMENT,PMC,,,,
PMC6559437,other invasive measures,TREATMENT,PMC,C0199689,"Non-invasive studies of cerebral arteries other than carotid, vertebral arteries flow direction measurement",SNMI,Diagnostic Procedure
PMC6559437,a chronic cough,PROBLEM,PMC,C0010201,Chronic Cough,MTH,Sign or Symptom
PMC6559437,dyspnea,PROBLEM,PMC,C0013404,Dyspnea,MTH,Sign or Symptom
PMC6559437,a,PROBLEM,PMC,,,,
PMC6559437,ild,PROBLEM,PMC,C0206062,"Lung Diseases, Interstitial",MTH,Disease or Syndrome
PMC6559437,a significant weight loss,PROBLEM,PMC,,,,
PMC6559437,plc,PROBLEM,PMC,C0031669,Phospholipase C,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6559437,pld,PROBLEM,PMC,C0044369,1-dodecylpyridoxal,MSH,Organic Chemical
PMC6559437,radiological support,TREATMENT,PMC,,,,
PMC6559437,invasive measures,TREATMENT,PMC,C1715935,Invasive melanoma.uninvolved margin.closest:Find:Pt:Skin melanoma:Nom,LNC,Clinical Attribute
PMC9918012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9918012,the most malignant cancer,PROBLEM,PMC,,,,
PMC9918012,typical symptoms,PROBLEM,PMC,C3272268,Typical Coronary Artery Disease Symptom,NCI,Sign or Symptom
PMC9918012,a screening method,TEST,PMC,C0422392,Screening Method,NCI,Diagnostic Procedure
PMC9918012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9918012,a prospective validation study,TEST,PMC,,,,
PMC9918012,salivary polyamines,TREATMENT,PMC,,,,
PMC9918012,screening pancreatic diseases,PROBLEM,PMC,,,,
PMC9918012,cancers,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC9918012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9918012,other pancreatic diseases,PROBLEM,PMC,C0029771,Other specified diseases of pancreas,ICD10,Disease or Syndrome
PMC9918012,accuracy verification,TEST,PMC,,,,
PMC9918012,elevated salivary polyamine markers,PROBLEM,PMC,,,,
PMC9918012,pancreatic diseases,PROBLEM,PMC,C0030286,Pancreatic Diseases,MTH,Disease or Syndrome
PMC9918012,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC9918012,pancreatic cysts,PROBLEM,PMC,C0030283,Pancreatic Cyst,MSH,Disease or Syndrome
PMC9918012,gallbladder cancer,PROBLEM,PMC,C0235782,Gallbladder Carcinoma,MTH,Neoplastic Process
PMC9918012,the salivary polyamine panel,TEST,PMC,,,,
PMC9918012,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9918012,polyamines in saliva,PROBLEM,PMC,,,,
PMC9918012,a screening test,TEST,PMC,C0871311,Screening test,MTH,Health Care Activity
PMC9918012,pancreatic diseases,PROBLEM,PMC,C0030286,Pancreatic Diseases,MTH,Disease or Syndrome
PMC9918012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9918012,detecting,PROBLEM,PMC,C3865508,Test for detecting genes,CPT,Laboratory Procedure
PMC9918012,other pancreatic diseases,PROBLEM,PMC,C0029771,Other specified diseases of pancreas,ICD10,Disease or Syndrome
PMC9918012,the salivary polyamine test,TEST,PMC,,,,
PMC9918012,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC10705283,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC10705283,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC10705283,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10705283,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC10705283,recurrent disease,PROBLEM,PMC,C0277556,Recurrent disease,MTH,Disease or Syndrome
PMC10705283,palliative systemic therapy,TREATMENT,PMC,,,,
PMC10705283,delaying therapy,TREATMENT,PMC,C1299700,Delay of drug therapy,SNOMEDCT_US,Finding
PMC10705283,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10705283,therapyrelated toxicity,PROBLEM,PMC,,,,
PMC10705283,this approach,TREATMENT,PMC,,,,
PMC10705283,mpdac,TREATMENT,PMC,,,,
PMC10705283,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10705283,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10705283,delayed treatment,TREATMENT,PMC,C3693346,Treatment Delay,MSH,Finding
PMC10705283,one small lung metastasis,PROBLEM,PMC,,,,
PMC10705283,significant comorbidities,PROBLEM,PMC,C4540934,Significant medical comorbidity,NANDA-I,Finding
PMC10705283,delayed treatment,TREATMENT,PMC,C3693346,Treatment Delay,MSH,Finding
PMC10705283,the response,TEST,PMC,C0020964,Immune response,MTH,Organ or Tissue Function
PMC10705283,mpdac,TREATMENT,PMC,,,,
PMC10705283,immediate treatment,TREATMENT,PMC,C5396510,Teeth requiring immediate treatment,SNOMEDCT_US,Finding
PMC10705283,limited metastatic disease,PROBLEM,PMC,C1517886,Limited stage (cancer stage),MTH,Classification
PMC10705283,more comorbidities,PROBLEM,PMC,,,,
PMC10705283,delaying treatment,TREATMENT,PMC,C1298642,Reasons for treatment delay,SNOMEDCT_US,Finding
PMC10705283,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10705283,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC10705283,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC10705283,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10705283,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC10705283,palliative systemic therapy,TREATMENT,PMC,,,,
PMC10705283,tumordirected treatment option,TREATMENT,PMC,,,,
PMC10705283,delaying therapy,TREATMENT,PMC,C1299700,Delay of drug therapy,SNOMEDCT_US,Finding
PMC10705283,asymptomatic palliative patients,TREATMENT,PMC,,,,
PMC10705283,therapyrelated toxicity,PROBLEM,PMC,,,,
PMC10705283,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10705283,treatment initiation,TREATMENT,PMC,C2106642,compensatory strategies for initiation,MEDCIN,Therapeutic or Preventive Procedure
PMC10705283,asymptomatic mpdacmethods,PROBLEM,PMC,,,,
PMC10705283,mpdac,TREATMENT,PMC,,,,
PMC10705283,the kappa light test,TEST,PMC,C2702982,free kappa and lambda light chain assays,MEDCIN,Laboratory Procedure
PMC10705283,treatment initiation,TREATMENT,PMC,C2106642,compensatory strategies for initiation,MEDCIN,Therapeutic or Preventive Procedure
PMC10705283,fishers exact testresults,TEST,PMC,,,,
PMC10705283,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10705283,delayed treatment,TREATMENT,PMC,C3693346,Treatment Delay,MSH,Finding
PMC10705283,one small lung metastasis,PROBLEM,PMC,,,,
PMC10705283,significant comorbidities,PROBLEM,PMC,C4540934,Significant medical comorbidity,NANDA-I,Finding
PMC10705283,a significant degree of interrater variability,PROBLEM,PMC,,,,
PMC10705283,treatment initiation,TREATMENT,PMC,C2106642,compensatory strategies for initiation,MEDCIN,Therapeutic or Preventive Procedure
PMC10705283,mpdac,TREATMENT,PMC,,,,
PMC10705283,immediate treatment,TREATMENT,PMC,C5396510,Teeth requiring immediate treatment,SNOMEDCT_US,Finding
PMC10705283,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10705283,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10705283,limited metastatic disease,PROBLEM,PMC,C1517886,Limited stage (cancer stage),MTH,Classification
PMC10705283,more comorbidities,PROBLEM,PMC,,,,
PMC10705283,the response rate,TEST,PMC,C5963169,Continued Response Rate,NCI,Quantitative Concept
PMC10705283,treatment initiation,TREATMENT,PMC,C2106642,compensatory strategies for initiation,MEDCIN,Therapeutic or Preventive Procedure
PMC10705283,mpdac,TREATMENT,PMC,,,,
PMC10705283,immediate treatment,TREATMENT,PMC,C5396510,Teeth requiring immediate treatment,SNOMEDCT_US,Finding
PMC10705283,mpdac,TREATMENT,PMC,,,,
PMC10705283,interrater variability,PROBLEM,PMC,,,,
PMC10705283,delayed treatment initiation,TREATMENT,PMC,C2079501,permanent pacemaker initial programmed atrioventricular delay,MEDCIN,Therapeutic or Preventive Procedure
PMC10705283,systemic treatment initiation,TREATMENT,PMC,C5765824,"remote autonomous algorithm-based system for insulin dose calculation and titration, initial setup and patient education",MEDCIN,Therapeutic or Preventive Procedure
PMC10705283,mpdac,PROBLEM,PMC,,,,
PMC10705283,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC5093225,pancreatic cancer surgery,TREATMENT,PMC,,,,
PMC5093225,this prospective study,TEST,PMC,,,,
PMC5093225,pancreatic cancer surgery,TREATMENT,PMC,,,,
PMC5093225,body weight,TEST,PMC,C0005910,Body Weight,MTH,Organism Attribute
PMC5093225,body,PROBLEM,PMC,C0242821,Human body,MTH,Human
PMC5093225,nutritional risk index,PROBLEM,PMC,C1977905,Nutritional risk index,MTH,Laboratory Procedure
PMC5093225,malnutrition universal screening tool,TEST,PMC,C1532006,Malnutrition universal screening tool (assessment scale),MTH,Intellectual Product
PMC5093225,nutritional impact symptoms,PROBLEM,PMC,,,,
PMC5093225,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC5093225,nri,TEST,PMC,C0295421,NRI 757,MSH,"Organic Chemical, Pharmacologic Substance"
PMC5093225,must method,TEST,PMC,C5963597,Must Often Slow Work Pace or Change Methods,NCI,Finding
PMC5093225,operation,TREATMENT,PMC,C3241922,Operation Activity,MTH,Activity
PMC5093225,more symptoms,PROBLEM,PMC,C3251062,neuropsychiatric assessment showed one or more symptoms,MEDCIN,Therapeutic or Preventive Procedure
PMC5093225,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC5093225,abdominal bloating,PROBLEM,PMC,C1291077,Abdominal bloating,MTH,Sign or Symptom
PMC5093225,early satiety,PROBLEM,PMC,C0239233,Early satiety,SNOMEDCT_US,Sign or Symptom
PMC5093225,creactive protein crp levels,TEST,PMC,,,,
PMC5093225,total energy,TREATMENT,PMC,C0429629,Total energy expenditure,SNOMEDCT_US,Finding
PMC5093225,zinc,TREATMENT,PMC,C0043481,zinc,MTH,"Pharmacologic Substance, Biologically Active Substance, Element, Ion, or Isotope"
PMC5093225,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC5093225,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5093225,the inflammatory indicators,PROBLEM,PMC,,,,
PMC5093225,special therapeutic diets,TREATMENT,PMC,,,,
PMC5093225,pancreatic surgery,TREATMENT,PMC,C2033062,pancreatic surgery,MEDCIN,Therapeutic or Preventive Procedure
PMC5093225,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5093225,postoperative values,TEST,PMC,C0032790,Postoperative Period,MTH,Temporal Concept
PMC5093225,body weight,TEST,PMC,C0005910,Body Weight,MTH,Organism Attribute
PMC5093225,bmi,TEST,PMC,C1305855,Body mass index,MTH,Clinical Attribute
PMC5093225,nri,TEST,PMC,C0295421,NRI 757,MSH,"Organic Chemical, Pharmacologic Substance"
PMC5093225,must,TEST,PMC,C5962132,Must Carry an EpiPen,NCI,Intellectual Product
PMC5093225,pd surgery,TREATMENT,PMC,,,,
PMC5093225,malnutrition status,PROBLEM,PMC,C5781134,Nutritional assessment for malnutrition status,MTH,Health Care Activity
PMC5093225,oral,TREATMENT,PMC,C0442027,Oral,MTH,Spatial Concept
PMC5093225,total nutrient,TREATMENT,PMC,,,,
PMC5093225,en,TREATMENT,PMC,C1417861,NT5E gene,MTH,Gene or Genome
PMC5093225,pn,TREATMENT,PMC,C0219433,"POSTN protein, human",MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5093225,inflammatory indices,PROBLEM,PMC,,,,
PMC5093225,crp,TEST,PMC,C1413716,CRP gene,MTH,Gene or Genome
PMC5093225,wbc,TEST,PMC,C0023516,Leukocytes,MTH,Cell
PMC5093225,neutrophil,TEST,PMC,C0027950,neutrophil,MTH,Cell
PMC5093225,lymphocyte,TEST,PMC,C0024264,Lymphocyte,MTH,Cell
PMC5093225,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5093225,loss of appetite,PROBLEM,PMC,C3814874,Loss of Appetite question,MTH,Intellectual Product
PMC5093225,flatulence,PROBLEM,PMC,C0016204,Flatulence,MTH,Sign or Symptom
PMC5093225,early satiety,PROBLEM,PMC,C0239233,Early satiety,SNOMEDCT_US,Sign or Symptom
PMC5093225,these symptoms,PROBLEM,PMC,C3175527,How long did these symptoms last,LNC,Intellectual Product
PMC5093225,cereals,TREATMENT,PMC,C0007757,Cereals,MTH,Food
PMC5093225,sugar products,TREATMENT,PMC,C3214642,sugar beet pollen extract Injectable Product,RXNORM,Clinical Drug
PMC5093225,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5093225,meal prescriptions,TREATMENT,PMC,,,,
PMC11504882,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504882,dampheat syndrome,PROBLEM,PMC,,,,
PMC11504882,intestinal flora,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC11504882,model evaluation,TEST,PMC,C2016242,pacemaker manufacturer model,MEDCIN,Finding
PMC11504882,our study,TEST,PMC,,,,
PMC11504882,a classic dampheat syndrome group,PROBLEM,PMC,,,,
PMC11504882,cdhs,PROBLEM,PMC,C1852510,Craniofacial deafness hand syndrome,MTH,Disease or Syndrome
PMC11504882,cc groups,PROBLEM,PMC,C1419381,RHCE gene,MTH,Gene or Genome
PMC11504882,a highfat diet,TREATMENT,PMC,,,,
PMC11504882,glucose water,TREATMENT,PMC,C2707235,Glucose:MCnc:Pt:Water:Qn,LNC,Clinical Attribute
PMC11504882,the cdhs group,TREATMENT,PMC,,,,
PMC11504882,the cc group,TREATMENT,PMC,C1419381,RHCE gene,MTH,Gene or Genome
PMC11504882,a climatic chamber,TREATMENT,PMC,,,,
PMC11504882,a,TREATMENT,PMC,,,,
PMC11504882,the mod,TREATMENT,PMC,C5978875,Mokura Mod,MMSL,"Organic Chemical, Pharmacologic Substance"
PMC11504882,tumorbuilding experiments,TREATMENT,PMC,,,,
PMC11504882,tumorigenicity,PROBLEM,PMC,C1519697,Tumorigenicity,MDR,Pathologic Function
PMC11504882,feces colon tissue,PROBLEM,PMC,,,,
PMC11504882,tumor tissue,PROBLEM,PMC,C0475358,Tumor tissue sample,MTH,Tissue
PMC11504882,the cdhs,TEST,PMC,C4551649,Congenital Dysplasia Of The Hip,MTH,Congenital Abnormality
PMC11504882,cc groups,TEST,PMC,C1419381,RHCE gene,MTH,Gene or Genome
PMC11504882,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11504882,the clinical dampheat syndrome,PROBLEM,PMC,,,,
PMC11504882,a worse general condition,PROBLEM,PMC,,,,
PMC11504882,more rapid tumor growth trend,PROBLEM,PMC,,,,
PMC11504882,the pathological examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC11504882,inflammation,PROBLEM,PMC,C0021368,Inflammation,MTH,Pathologic Function
PMC11504882,a disrupted intestinal barrier,PROBLEM,PMC,,,,
PMC11504882,an overgrowth of pathogenic bacteria,PROBLEM,PMC,,,,
PMC11504882,their microbiota composition,TEST,PMC,,,,
PMC11504882,greater diversity,PROBLEM,PMC,C0194762,Urethroplasty for second stage hypospadias repair (including urinary diversion); greater than 3 cm,MTH,Therapeutic or Preventive Procedure
PMC11504882,intestinal flora,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC11504882,dampheat syndrome,PROBLEM,PMC,,,,
PMC11504882,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504882,two damp heat murine models,TREATMENT,PMC,,,,
PMC11504882,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11504882,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC11504882,their intestinal flora,PROBLEM,PMC,,,,
PMC11504882,the intestinal flora of mice,PROBLEM,PMC,,,,
PMC11504882,dampness,PROBLEM,PMC,C0557683,Damp course,SNOMEDCT_US,Manufactured Object
PMC11504882,specific marker flora,PROBLEM,PMC,,,,
PMC11504882,these flora,PROBLEM,PMC,,,,
PMC11504882,tumor progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC11504882,a vast exploration space,TREATMENT,PMC,,,,
PMC11504882,intestinal flora,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC11504882,disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC8871200,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC8871200,unknown clinical characteristics,PROBLEM,PMC,,,,
PMC8871200,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8871200,early stage pdac,PROBLEM,PMC,,,,
PMC8871200,wellknown symptoms,PROBLEM,PMC,,,,
PMC8871200,pdac,PROBLEM,PMC,,,,
PMC8871200,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC8871200,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC8871200,early stage pdac,PROBLEM,PMC,,,,
PMC8871200,early stage pdac,PROBLEM,PMC,,,,
PMC8871200,pdac,PROBLEM,PMC,,,,
PMC8871200,new diagnostic strategies,TREATMENT,PMC,,,,
PMC8871200,early stage pdac,PROBLEM,PMC,,,,
PMC8871200,pdac,PROBLEM,PMC,,,,
PMC8871200,clinical indicators,TEST,PMC,C5670000,Clinical indication,MTH,Functional Concept
PMC8871200,elevated pancreatic enzyme level,PROBLEM,PMC,,,,
PMC8871200,tumor biomarker level,PROBLEM,PMC,,,,
PMC8871200,acute pancreatitis history,PROBLEM,PMC,,,,
PMC8871200,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC8871200,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC8871200,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC8871200,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC8871200,main pancreatic duct dilation,PROBLEM,PMC,,,,
PMC8871200,significant factors,PROBLEM,PMC,C5913485,"Instruct person and significant others on signs and symptoms, risk factors, and treatment of hypoglycemia",NIC,Educational Activity
PMC8871200,early stage pdac detection,PROBLEM,PMC,,,,
PMC8871200,a new screening strategy,TREATMENT,PMC,,,,
PMC8871200,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC8871200,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC8871200,evaluating,TEST,PMC,C0557980,Evaluating interventions,SNOMEDCT_US,Health Care Activity
PMC8871200,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC8871200,early stage pdac detection,PROBLEM,PMC,,,,
PMC8871200,clinical indicators,TEST,PMC,C5670000,Clinical indication,MTH,Functional Concept
PMC8871200,elevated pancreatic enzyme level,PROBLEM,PMC,,,,
PMC8871200,tumor biomarker level,PROBLEM,PMC,,,,
PMC8871200,acute pancreatitis history,PROBLEM,PMC,,,,
PMC8871200,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC8871200,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC8871200,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC8871200,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC8871200,tumor,PROBLEM,PMC,C3273930,Tumor Mass,MTH,Finding
PMC8871200,mpd dilation,PROBLEM,PMC,,,,
PMC8871200,early stage pdac,PROBLEM,PMC,,,,
PMC8871200,pdac,PROBLEM,PMC,,,,
PMC8871200,a,TREATMENT,PMC,,,,
PMC8871200,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC8871200,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC8871200,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC8871200,early stage pdac detection,PROBLEM,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,saliva sampling,TEST,PMC,C1277701,Saliva sample obtained,SNOMEDCT_US,Finding
PMC7789059,microbiota profiles,TEST,PMC,,,,
PMC7789059,fecal and tissue sample collection,TEST,PMC,,,,
PMC7789059,the saliva,PROBLEM,PMC,C0036087,saliva,MTH,Body Substance
PMC7789059,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC7789059,oral microbiota profiles,TEST,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,a prospective study,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,bacterial taxa,PROBLEM,PMC,,,,
PMC7789059,16s ribosomal ribonucleic acid gene sequencing,TEST,PMC,C5381413,Bacterial 16S rRNA gene:Seq:Pt:Isolate:Nom:Sequencing,LNC,Clinical Attribute
PMC7789059,a linear discriminant analysis effect size algorithm,TEST,PMC,,,,
PMC7789059,differences in taxa,PROBLEM,PMC,,,,
PMC7789059,operational taxonomic unit values,TEST,PMC,,,,
PMC7789059,a normalized,TEST,PMC,C5444157,normalized,MTH,Quantitative Concept
PMC7789059,logistic regressions,TEST,PMC,C0206031,Logistic Regression,MSH,Research Activity
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,carriage ofstreptococcusandleptotrichinazscore,PROBLEM,PMC,,,,
PMC7789059,pdac,PROBLEM,PMC,,,,
PMC7789059,or,TEST,PMC,C0018026,gold,MTH,"Pharmacologic Substance, Element, Ion, or Isotope"
PMC7789059,a protective microbe,PROBLEM,PMC,,,,
PMC7789059,pdac,PROBLEM,PMC,,,,
PMC7789059,or,TEST,PMC,C0018026,gold,MTH,"Pharmacologic Substance, Element, Ion, or Isotope"
PMC7789059,pdac,PROBLEM,PMC,,,,
PMC7789059,bloating,PROBLEM,PMC,C1291077,Abdominal bloating,MTH,Sign or Symptom
PMC7789059,a higher abundance ofporphyromonasp,PROBLEM,PMC,,,,
PMC7789059,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC7789059,dark brown urine,PROBLEM,PMC,C4047947,Dark-brown colored urine,SNOMEDCT_US,Finding
PMC7789059,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC7789059,a lower amount ofneisseriaandcampylobacterp,PROBLEM,PMC,,,,
PMC7789059,vomiting,PROBLEM,PMC,C0042963,Vomiting,MTH,Sign or Symptom
PMC7789059,decreasedalloprevotellap,PROBLEM,PMC,,,,
PMC7789059,saliva microbiome,PROBLEM,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,symptomatic,PROBLEM,PMC,C0231220,Symptomatic,MTH,Functional Concept
PMC7789059,different bacteria profiles,PROBLEM,PMC,,,,
PMC7789059,combined symptom,PROBLEM,PMC,C0520684,Factitious disorder with combined physical AND psychological symptoms,SNOMEDCT_US,Mental or Behavioral Dysfunction
PMC7789059,microbiome evaluation,TEST,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,saliva microbiome,PROBLEM,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,symptomatic,PROBLEM,PMC,C0231220,Symptomatic,MTH,Functional Concept
PMC7789059,different bacteria profiles,PROBLEM,PMC,,,,
PMC7789059,combined symptom,PROBLEM,PMC,C0520684,Factitious disorder with combined physical AND psychological symptoms,SNOMEDCT_US,Mental or Behavioral Dysfunction
PMC7789059,microbiome evaluation,TEST,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,saliva microbiome,PROBLEM,PMC,,,,
PMC7789059,pdac,PROBLEM,PMC,,,,
PMC7789059,higherstreptococcusandleptotrichiaabundances,PROBLEM,PMC,,,,
PMC7789059,pdacveillonellaandneisseriawere,PROBLEM,PMC,,,,
PMC7789059,pdacneisseriawas,PROBLEM,PMC,,,,
PMC7789059,all studies,TEST,PMC,C5447928,ALL Study Identifier,NCI,Intellectual Product
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,our study,TEST,PMC,,,,
PMC7789059,pdac,PROBLEM,PMC,,,,
PMC7789059,symptomatic,PROBLEM,PMC,C0231220,Symptomatic,MTH,Functional Concept
PMC7789059,different bacteria profiles,PROBLEM,PMC,,,,
PMC7789059,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7789059,pdac,PROBLEM,PMC,,,,
PMC7789059,combined symptom,PROBLEM,PMC,C0520684,Factitious disorder with combined physical AND psychological symptoms,SNOMEDCT_US,Mental or Behavioral Dysfunction
PMC7789059,microbiome evaluation,TEST,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7789059,bacteria flora,PROBLEM,PMC,C1735624,Intestinal bacteria flora disturbance,MDR,Disease or Syndrome
PMC7789059,probiotic treatment plans,TREATMENT,PMC,,,,
PMC7789059,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9789314,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9789314,selected chemotherapy,TREATMENT,PMC,,,,
PMC9789314,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9789314,different grade toxicities,PROBLEM,PMC,,,,
PMC9789314,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9789314,the vignettebased method,TREATMENT,PMC,,,,
PMC9789314,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9789314,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9789314,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9789314,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9789314,neutropenia,PROBLEM,PMC,C0027947,Neutropenia,MTH,Disease or Syndrome
PMC9789314,febrile neutropenia,PROBLEM,PMC,C0746883,Febrile Neutropenia,MTH,Disease or Syndrome
PMC9789314,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC9789314,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC9789314,vomiting,PROBLEM,PMC,C0042963,Vomiting,MTH,Sign or Symptom
PMC9789314,neuropathy,PROBLEM,PMC,C0442874,Neuropathy,MTH,Disease or Syndrome
PMC9789314,representative aes,PROBLEM,PMC,,,,
PMC9789314,each ae,PROBLEM,PMC,,,,
PMC9789314,cognitive interviews,TEST,PMC,C5707255,CHART-SF Interview Version - Cognitive Independence Subscore,NCI,Intellectual Product
PMC9789314,a societalbased valuation study,TEST,PMC,,,,
PMC9789314,visual analog scale,TEST,PMC,C3536884,Visual Analog Scale,MTH,Intellectual Product
PMC9789314,this survey,TEST,PMC,,,,
PMC9789314,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC9789314,aes,PROBLEM,PMC,C2699274,Scanning Auger Spectrometer,MTH,Research Device
PMC9789314,a mean utility value,TEST,PMC,,,,
PMC9789314,ctto,TEST,PMC,,,,
PMC9789314,the lowest mean utility score,TEST,PMC,,,,
PMC9789314,grade 34 vomiting,PROBLEM,PMC,,,,
PMC9789314,vas results,TEST,PMC,,,,
PMC9789314,aes,PROBLEM,PMC,C2699274,Scanning Auger Spectrometer,MTH,Research Device
PMC9789314,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC9789314,grade 34 aes,PROBLEM,PMC,,,,
PMC9789314,grade 12 nauseavomiting,PROBLEM,PMC,,,,
PMC9789314,significantly greater disutility,PROBLEM,PMC,,,,
PMC9789314,utility values,TEST,PMC,C0586396,"Services, facilities and utilities",SNOMEDCT_US,Organization
PMC9789314,physical symptoms,PROBLEM,PMC,C0679309,physical symptom,CHV,Sign or Symptom
PMC9789314,the postresponse questionnaire,TREATMENT,PMC,,,,
PMC9789314,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9789314,serious aes,PROBLEM,PMC,,,,
PMC9789314,minor aes,PROBLEM,PMC,,,,
PMC9789314,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9789314,serious aes,PROBLEM,PMC,,,,
PMC9789314,minor aes,PROBLEM,PMC,,,,
PMC9789314,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC9789314,the chemotherapy aes,TREATMENT,PMC,,,,
PMC9789314,physical symptoms,PROBLEM,PMC,C0679309,physical symptom,CHV,Sign or Symptom
PMC9789314,serious and minor aes,PROBLEM,PMC,,,,
PMC11995310,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC11995310,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC11995310,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11995310,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11995310,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11995310,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC11995310,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC11995310,biliary stent placement,TREATMENT,PMC,C0741490,Biliary stent placement,MDR,Therapeutic or Preventive Procedure
PMC11995310,endoscopic retrograde cholangiopancreatography,TEST,PMC,C0008310,Endoscopic Retrograde Cholangiopancreatography,MTH,Diagnostic Procedure
PMC11995310,biliary obstruction,PROBLEM,PMC,C0400979,Obstruction of biliary tree,SNOMEDCT_US,Disease or Syndrome
PMC11995310,a few studies,TEST,PMC,C5413802,"Antimicrobial agent susceptibility study using disk method, per plate, 12 or fewer agents",CPT,Laboratory Procedure
PMC11995310,endoscopic pancreatic duct stenting,TREATMENT,PMC,C2223892,endoscopic insertion of stent of pancreatic duct,MEDCIN,Therapeutic or Preventive Procedure
PMC11995310,advanced pc,PROBLEM,PMC,,,,
PMC11995310,endoscopic treatment,TREATMENT,PMC,C2169949,Endoscopic cyclophotocoagulation,CPT,Therapeutic or Preventive Procedure
PMC11995310,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11995310,early pancreatic duct stenting,TREATMENT,PMC,,,,
PMC11995310,unresectable pc,PROBLEM,PMC,,,,
PMC11995310,unresectable pc,PROBLEM,PMC,,,,
PMC11995310,the doublestent group,TREATMENT,PMC,,,,
PMC11995310,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11995310,a fullycovered selfexpandable metallic biliary stent,TREATMENT,PMC,,,,
PMC11995310,a pancreatic duct stent,TREATMENT,PMC,C0400520,Open insertion of pancreatic duct stent,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11995310,the singlestent group,TREATMENT,PMC,,,,
PMC11995310,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11995310,an fcsems,TREATMENT,PMC,,,,
PMC11995310,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11995310,nutritional status,PROBLEM,PMC,C0392209,Nutritional status,MTH,Finding
PMC11995310,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC11995310,the spss software,TEST,PMC,,,,
PMC11995310,unresectable pc,PROBLEM,PMC,,,,
PMC11995310,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC11995310,the double and singlestent groups,TREATMENT,PMC,,,,
PMC11995310,the median pain scores,PROBLEM,PMC,,,,
PMC11995310,the doublestent group,TREATMENT,PMC,,,,
PMC11995310,the singlestent group,TREATMENT,PMC,,,,
PMC11995310,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11995310,total serum protein levels,TEST,PMC,C1318415,Serum total protein level,MTH,Laboratory or Test Result
PMC11995310,the doublestent group,TREATMENT,PMC,,,,
PMC11995310,the singlestent group,TREATMENT,PMC,,,,
PMC11995310,the body mass index,PROBLEM,PMC,C1305855,Body mass index,MTH,Clinical Attribute
PMC11995310,the bmi,TEST,PMC,C0910133,BMI 60,MSH,Organic Chemical
PMC11995310,the singlestent group,TREATMENT,PMC,,,,
PMC11995310,the doublestent group,TREATMENT,PMC,,,,
PMC11995310,early pancreatic duct stenting,TREATMENT,PMC,,,,
PMC11995310,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11995310,unresectable pc,PROBLEM,PMC,,,,
PMC11995310,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC11995310,early pancreatic duct stenting,TREATMENT,PMC,,,,
PMC11995310,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11995310,unresectable pc,PROBLEM,PMC,,,,
PMC11995310,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC11995310,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11995310,early pds,PROBLEM,PMC,,,,
PMC11995310,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11995310,unresectable pc,PROBLEM,PMC,,,,
PMC11995310,technical success rates,TEST,PMC,,,,
PMC11995310,aes,PROBLEM,PMC,C2699274,Scanning Auger Spectrometer,MTH,Research Device
PMC11470284,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,additional investigation,TEST,PMC,,,,
PMC11470284,this underresearched malignant tumor,PROBLEM,PMC,,,,
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,annual mortality rates,TEST,PMC,,,,
PMC11470284,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11470284,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11470284,a,TEST,PMC,,,,
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,specific clinical manifestations,PROBLEM,PMC,,,,
PMC11470284,tumor markers,PROBLEM,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC11470284,highrisk factors,PROBLEM,PMC,,,,
PMC11470284,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC11470284,abnormal microorganism metabolism,PROBLEM,PMC,,,,
PMC11470284,blood type,TEST,PMC,C1383165,Blood Type,MTH,Clinical Attribute
PMC11470284,glucose,TEST,PMC,C0017725,glucose,MTH,"Organic Chemical, Pharmacologic Substance, Biologically Active Substance"
PMC11470284,lipid levels,TEST,PMC,C4716812,Target lipid levels,NOC,Finding
PMC11470284,increased detection,PROBLEM,PMC,C2611732,detection of increased carbon dioxide by chemoreceptor signaling,GO,Cell Function
PMC11470284,survival rates,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,tumor,TEST,PMC,C3273930,Tumor Mass,MTH,Finding
PMC11470284,more study,TEST,PMC,C5415752,"Nerve conduction study, 13 or more studies",CPT,Diagnostic Procedure
PMC11470284,future treatment strategies,TREATMENT,PMC,,,,
PMC11470284,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11470284,a microbiologyfree system,TREATMENT,PMC,,,,
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,urgent attention,TREATMENT,PMC,,,,
PMC11470284,effective prevention strategies,TREATMENT,PMC,C0679723,effective prevention strategy or program,AOD,Qualitative Concept
PMC11470284,pc etiology,PROBLEM,PMC,,,,
PMC11470284,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC11470284,new diagnosis methods,TREATMENT,PMC,,,,
PMC11470284,treatment approaches,TREATMENT,PMC,C5933127,Treatment approaches aligned with personal preferences,NOC,Finding
PMC11470284,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC11470284,highrisk individuals,PROBLEM,PMC,,,,
PMC11470284,familial pc families,PROBLEM,PMC,C4331878,NXPE1 wt Allele,MTH,Gene or Genome
PMC11470284,earlystage pc patients,PROBLEM,PMC,,,,
PMC11470284,imaging techniques,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC11470284,the human microbial system,TREATMENT,PMC,,,,
PMC11470284,tumor sensitivity,PROBLEM,PMC,,,,
PMC11470284,therapeutic drugs,TREATMENT,PMC,C0580398,Drug level therapeutic,MDR,Laboratory or Test Result
PMC11470284,pc treatment,TREATMENT,PMC,C0962074,PC protocol (ovarian cancer treatment),MTH,Therapeutic or Preventive Procedure
PMC11470284,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11470284,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11470284,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC11470284,pc cell development,PROBLEM,PMC,,,,
PMC11470284,understanding pc occurrence,PROBLEM,PMC,,,,
PMC11470284,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11470284,treatment effectiveness,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC11470284,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC11470284,immunogenomics,TEST,PMC,,,,
PMC11470284,gut microgenomics,TEST,PMC,,,,
PMC11470284,breakthroughs,PROBLEM,PMC,C0444503,Breakthrough,SNOMEDCT_US,Qualitative Concept
PMC11470284,microbial systems,TREATMENT,PMC,C0201148,"Microbial identification, Minitek yeast system",SNOMEDCT_US,Laboratory Procedure
PMC11470284,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11470284,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,immune tolerance,PROBLEM,PMC,C0020963,Immune Tolerance,MTH,Pathologic Function
PMC11470284,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC11470284,new treatments,TREATMENT,PMC,C0514026,Obtain consultation from appropriate health care worker to initiate new treatment or change existing treatments,NIC,Health Care Activity
PMC11470284,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11470284,tumor markers,TEST,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC11470284,the resection,TREATMENT,PMC,C1533664,Endorectal resection,MTH,Therapeutic or Preventive Procedure
PMC11470284,postoperative,TEST,PMC,C0032790,Postoperative Period,MTH,Temporal Concept
PMC11470284,advanced carcinoma,PROBLEM,PMC,C4727070,Advanced Carcinoma,NCI,Neoplastic Process
PMC11470284,comprehensive treatment,TREATMENT,PMC,C0814471,comprehensive treatment program,AOD,Health Care Activity
PMC11470284,advanced carcinoma,PROBLEM,PMC,C4727070,Advanced Carcinoma,NCI,Neoplastic Process
PMC9123808,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9123808,its treatments,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC9123808,a randomized doubleblind placebocontrolled phase 3 trial,TREATMENT,PMC,,,,
PMC9123808,olaparib,TREATMENT,PMC,C2316164,olaparib,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC9123808,maintenance therapy,TREATMENT,PMC,C0677908,Maintenance therapy,MTH,Therapeutic or Preventive Procedure
PMC9123808,germline brca mutated mpc,PROBLEM,PMC,,,,
PMC9123808,firstline platinumbased chemotherapy,TREATMENT,PMC,,,,
PMC9123808,hrqol,TEST,PMC,C4300252,HRQOL method,MTH,Intellectual Product
PMC9123808,the eortc qlqc30,TEST,PMC,,,,
PMC9123808,enhance,TEST,PMC,C2349975,Enhance (action),MTH,Activity
PMC9123808,treatmentnave mpc,TREATMENT,PMC,,,,
PMC9123808,a targeted literature review,TEST,PMC,,,,
PMC9123808,eortc qlqc30,TEST,PMC,,,,
PMC9123808,treatmentnave mpc patients,TREATMENT,PMC,,,,
PMC9123808,reference values,TEST,PMC,C0086715,Normal Range,MTH,Quantitative Concept
PMC9123808,worse symptoms,PROBLEM,PMC,C2039349,allergy symptoms worse in fall,MEDCIN,Finding
PMC9123808,polo,TREATMENT,PMC,C2712390,Water Polo,MSH,Daily or Recreational Activity
PMC9123808,pooled baseline,TEST,PMC,,,,
PMC9123808,study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC9123808,four studies,TEST,PMC,,,,
PMC9123808,sample sizes,TEST,PMC,C0242618,Sample Size,MSH,Quantitative Concept
PMC9123808,markedly,PROBLEM,PMC,C0522501,Massive,MTH,Qualitative Concept
PMC9123808,the first study,TEST,PMC,C4684677,First-in-Human Study,NCI,Research Activity
PMC9123808,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC9123808,polo,TREATMENT,PMC,C2712390,Water Polo,MSH,Daily or Recreational Activity
PMC9123808,prior firstline treatment,TREATMENT,PMC,,,,
PMC9123808,chemotherapyrelated symptoms,PROBLEM,PMC,,,,
PMC9123808,response shift,PROBLEM,PMC,C0231759,Pivot shift test response,MTH,Finding
PMC9123808,newly derived reference values,PROBLEM,PMC,,,,
PMC9123808,mpc patients hrqol,PROBLEM,PMC,,,,
PMC9123808,the polo trial,TREATMENT,PMC,,,,
PMC9123808,the first study,TEST,PMC,C4684677,First-in-Human Study,NCI,Research Activity
PMC9123808,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC9123808,polo,TREATMENT,PMC,C2712390,Water Polo,MSH,Daily or Recreational Activity
PMC9123808,prior firstline treatment,TREATMENT,PMC,,,,
PMC9123808,chemotherapyrelated symptoms,PROBLEM,PMC,,,,
PMC9123808,response shift,PROBLEM,PMC,C0231759,Pivot shift test response,MTH,Finding
PMC9123808,newly derived reference values,PROBLEM,PMC,,,,
PMC9123808,mpc patients hrqol,PROBLEM,PMC,,,,
PMC9123808,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC9123808,its treatments,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC9123808,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC9123808,treatmentnave mpc,TREATMENT,PMC,,,,
PMC9123808,prior firstline treatment,TREATMENT,PMC,,,,
PMC9123808,chemotherapyrelated symptoms,PROBLEM,PMC,,,,
PMC9123808,response shift,PROBLEM,PMC,C0231759,Pivot shift test response,MTH,Finding
PMC9123808,norm data,TEST,PMC,C0509573,Compare results of data collected with preestablished norms,NIC,Health Care Activity
PMC9123808,maintenance treatment settings,TREATMENT,PMC,,,,
PMC4971692,radiation recall gastritis,PROBLEM,PMC,,,,
PMC4971692,concurrent chemoradiation,TREATMENT,PMC,C4688643,Concurrent Chemoradiation,NCI,Therapeutic or Preventive Procedure
PMC4971692,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4971692,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4971692,radiationrecall gastritis,PROBLEM,PMC,,,,
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,radiation therapy,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC4971692,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC4971692,epigastric pain,PROBLEM,PMC,C0232493,Epigastric pain,MTH,Sign or Symptom
PMC4971692,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC4971692,vomiting,PROBLEM,PMC,C0042963,Vomiting,MTH,Sign or Symptom
PMC4971692,abdominal computed tomography ct scan,TEST,PMC,,,,
PMC4971692,diffuse wall thickening of the stomach,PROBLEM,PMC,,,,
PMC4971692,esophagogastroduodenoscopy,TEST,PMC,C0079304,Esophagogastroduodenoscopy,MTH,Diagnostic Procedure
PMC4971692,multiple gastric ulcers,PROBLEM,PMC,C0341178,Multiple gastric ulcers,SNOMEDCT_US,Disease or Syndrome
PMC4971692,proton pump inhibitors,TREATMENT,PMC,C0358591,Proton Pump Inhibitors,MTH,Pharmacologic Substance
PMC4971692,maintenance chemotherapy,TREATMENT,PMC,C0481504,Maintenance Chemotherapy,MSH,Finding
PMC4971692,the similar symptoms,PROBLEM,PMC,C0239112,CONTACTS WITH SIMILAR SYMPTOMS,DXP,Finding
PMC4971692,persistent gastric ulcers,PROBLEM,PMC,,,,
PMC4971692,subsequent egd,TEST,PMC,,,,
PMC4971692,the patients symptom,PROBLEM,PMC,C1317600,patient symptoms,CHV,Finding
PMC4971692,ppi therapy,TREATMENT,PMC,C1541225,Proton pump inhibitor therapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC4971692,maintenance chemotherapy,TREATMENT,PMC,C0481504,Maintenance Chemotherapy,MSH,Finding
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,followup abdominal ct scan,TEST,PMC,,,,
PMC4971692,egd,TEST,PMC,C0079304,Esophagogastroduodenoscopy,MTH,Diagnostic Procedure
PMC4971692,the gastric ulcers,PROBLEM,PMC,C0038358,Gastric ulcer,MTH,Disease or Syndrome
PMC4971692,radiation recall gastritis,PROBLEM,PMC,,,,
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,ppis,TREATMENT,PMC,C0965389,PPI-149,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,radiation recall gastritis,PROBLEM,PMC,,,,
PMC4971692,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC4971692,radiation recall gastritis,PROBLEM,PMC,,,,
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,ppis,TREATMENT,PMC,C0965389,PPI-149,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,radiation recall gastritis,PROBLEM,PMC,,,,
PMC4971692,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC4971692,radiation recall gastritis,PROBLEM,PMC,,,,
PMC4971692,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4971692,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4971692,proton pump inhibitor,TREATMENT,PMC,C0358591,Proton Pump Inhibitors,MTH,Pharmacologic Substance
PMC4971692,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC4971692,withdrawal,PROBLEM,PMC,C2349954,Withdraw (activity),MTH,Activity
PMC10380009,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10380009,the most lethal malignancies,PROBLEM,PMC,,,,
PMC10380009,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC10380009,significant preoperative anxiety,PROBLEM,PMC,,,,
PMC10380009,worsening surgical outcomes,PROBLEM,PMC,,,,
PMC10380009,therapeutic methods,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC10380009,preoperative anxiety,PROBLEM,PMC,C0508734,"Assist in preoperative workup, as appropriate, helping to explain the tests and reduce anxiety for the patient who will undergo surgical repair",NIC,Therapeutic or Preventive Procedure
PMC10380009,this observational study,TEST,PMC,,,,
PMC10380009,preoperative anxiety,PROBLEM,PMC,C0508734,"Assist in preoperative workup, as appropriate, helping to explain the tests and reduce anxiety for the patient who will undergo surgical repair",NIC,Therapeutic or Preventive Procedure
PMC10380009,preoperative anxiety,PROBLEM,PMC,C0508734,"Assist in preoperative workup, as appropriate, helping to explain the tests and reduce anxiety for the patient who will undergo surgical repair",NIC,Therapeutic or Preventive Procedure
PMC10380009,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10380009,similar pancreatic major surgery,TREATMENT,PMC,,,,
PMC10380009,the stais,TEST,PMC,C0420512,Inpatient stay,SNOMEDCT_US,Functional Concept
PMC10380009,our data,TEST,PMC,,,,
PMC10380009,high stais,PROBLEM,PMC,,,,
PMC10380009,higher levels of apais,PROBLEM,PMC,,,,
PMC10380009,depressive symptoms,PROBLEM,PMC,C0086132,Depressive Symptoms,MSH,Mental or Behavioral Dysfunction
PMC10380009,trait anxiety,PROBLEM,PMC,C5190344,trait anxiety scale (T-Anxiety),MEDCIN,Intellectual Product
PMC10380009,risk,PROBLEM,PMC,C0035647,Risk,MTH,Idea or Concept
PMC10380009,preoperative anxiety,PROBLEM,PMC,C0508734,"Assist in preoperative workup, as appropriate, helping to explain the tests and reduce anxiety for the patient who will undergo surgical repair",NIC,Therapeutic or Preventive Procedure
PMC10380009,a specific psychological screening,TEST,PMC,,,,
PMC10380009,support,TREATMENT,PMC,C0344211,Supportive care,MTH,Health Care Activity
PMC10380009,state anxiety,PROBLEM,PMC,C1279420,"Neuroses, Anxiety",MTH,Mental or Behavioral Dysfunction
PMC10380009,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10380009,the operation,TREATMENT,PMC,C1880161,Computer Operation,MTH,Machine Activity
PMC10380009,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10380009,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10380009,the postoperative recovery process,TREATMENT,PMC,,,,
PMC10380009,our data,TEST,PMC,,,,
PMC10380009,high state anxiety,PROBLEM,PMC,,,,
PMC10380009,perioperative anxiety,PROBLEM,PMC,,,,
PMC10380009,depressive symptoms,PROBLEM,PMC,C0086132,Depressive Symptoms,MSH,Mental or Behavioral Dysfunction
PMC10380009,trait anxiety,PROBLEM,PMC,C5190344,trait anxiety scale (T-Anxiety),MEDCIN,Intellectual Product
PMC10380009,preoperative anxiety,PROBLEM,PMC,C0508734,"Assist in preoperative workup, as appropriate, helping to explain the tests and reduce anxiety for the patient who will undergo surgical repair",NIC,Therapeutic or Preventive Procedure
PMC10380009,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10380009,developing preoperative anxiety,PROBLEM,PMC,,,,
PMC10380009,a specific psychological screening,TEST,PMC,,,,
PMC10380009,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC10380009,the preoperative phase,TEST,PMC,,,,
PMC10380009,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10380009,state anxiety,PROBLEM,PMC,C1279420,"Neuroses, Anxiety",MTH,Mental or Behavioral Dysfunction
PMC10380009,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10380009,preoperative anxiety,PROBLEM,PMC,C0508734,"Assist in preoperative workup, as appropriate, helping to explain the tests and reduce anxiety for the patient who will undergo surgical repair",NIC,Therapeutic or Preventive Procedure
PMC10380009,appropriate communication protocols,TREATMENT,PMC,,,,
PMC10380009,preoperative anxiety levels,TEST,PMC,,,,
PMC10380009,surgeryspecific,TREATMENT,PMC,,,,
PMC10380009,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10380009,anxiety levels,PROBLEM,PMC,C0564474,Level of anxiety,SNOMEDCT_US,Finding
PMC10380009,patientcentered medical care communication,TREATMENT,PMC,,,,
PMC11930888,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11930888,unresectable disease,PROBLEM,PMC,C1618884,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; unresectable at diagnosis, m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC11930888,aggressive treatments,TREATMENT,PMC,C0510615,"Encourage early, aggressive treatment for endometriosis",NIC,Therapeutic or Preventive Procedure
PMC11930888,significant chronic and debilitating side effects,PROBLEM,PMC,,,,
PMC11930888,significant unmet,PROBLEM,PMC,,,,
PMC11930888,limited qualitative studies,TEST,PMC,,,,
PMC11930888,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11930888,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC11930888,paca survivors,PROBLEM,PMC,,,,
PMC11930888,a psychosocial symptom management intervention,TREATMENT,PMC,,,,
PMC11930888,semistructured,TREATMENT,PMC,,,,
PMC11930888,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11930888,qualitative data,TEST,PMC,C0681942,qualitative data analysis,AOD,Research Activity
PMC11930888,rapid qualitative analysis,TEST,PMC,,,,
PMC11930888,descriptive statistics,TEST,PMC,C5236893,Statistical Analysis Plan Version Description,NCI,Intellectual Product
PMC11930888,paca survivors,PROBLEM,PMC,,,,
PMC11930888,interviews,TEST,PMC,C0021822,Interview,MTH,Activity
PMC11930888,limited holistic care,TREATMENT,PMC,,,,
PMC11930888,posttreatment symptom management,TREATMENT,PMC,,,,
PMC11930888,persistent side effects,PROBLEM,PMC,,,,
PMC11930888,lifestyle changes,TREATMENT,PMC,C0870811,Lifestyle changes,MTH,Social Behavior
PMC11930888,unmet supportive care needs,TREATMENT,PMC,,,,
PMC11930888,paca survivors,PROBLEM,PMC,,,,
PMC11930888,developing interventions,TREATMENT,PMC,C1514724,Rapid Access to Intervention Development,NCI,Governmental or Regulatory Activity
PMC11930888,these gaps,PROBLEM,PMC,,,,
PMC11930888,unmet supportive care needs,TREATMENT,PMC,,,,
PMC11930888,paca survivors,PROBLEM,PMC,,,,
PMC11930888,developing interventions,TREATMENT,PMC,C1514724,Rapid Access to Intervention Development,NCI,Governmental or Regulatory Activity
PMC11930888,these gaps,PROBLEM,PMC,,,,
PMC11930888,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11930888,a comprehensive approach,TREATMENT,PMC,,,,
PMC11930888,holistic care,TREATMENT,PMC,,,,
PMC11930888,caregiver support,TREATMENT,PMC,C0150162,Caregiver support (regime/therapy),MTH,Health Care Activity
PMC11930888,structured rehabilitation,TREATMENT,PMC,,,,
PMC11930888,emotional and psychological support,TREATMENT,PMC,,,,
PMC11930888,psychosocial interventions,TREATMENT,PMC,C5392103,Psychosocial Intervention,MSH,Therapeutic or Preventive Procedure
PMC11930888,paca survivors,PROBLEM,PMC,,,,
PMC10177101,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10177101,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10177101,an extremely low survival rate,PROBLEM,PMC,,,,
PMC10177101,surgical removal,TREATMENT,PMC,C1293139,Surgical extraction,MTH,Therapeutic or Preventive Procedure
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,the liquid biomarkers,TEST,PMC,C5222689,analysis of functional biomarkers in urine by liquid chromatography with tandem mass spectrometry,MEDCIN,Laboratory Procedure
PMC10177101,liquid biomarkers,TEST,PMC,C5222689,analysis of functional biomarkers in urine by liquid chromatography with tandem mass spectrometry,MEDCIN,Laboratory Procedure
PMC10177101,routine examinations,TEST,PMC,C2063084,routine examination,MEDCIN,Finding
PMC10177101,pdac development,PROBLEM,PMC,,,,
PMC10177101,its precursors,PROBLEM,PMC,,,,
PMC10177101,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10177101,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10177101,efficient treatment options,TREATMENT,PMC,,,,
PMC10177101,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10177101,surgically unresectable cancer,PROBLEM,PMC,,,,
PMC10177101,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC10177101,low survival rates,PROBLEM,PMC,,,,
PMC10177101,cancers,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC10177101,surgically resectable pdac,PROBLEM,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10177101,specific biomarkers,PROBLEM,PMC,,,,
PMC10177101,routine examinations,TEST,PMC,C2063084,routine examination,MEDCIN,Finding
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,significant changes,PROBLEM,PMC,C5915914,Notify health care provider of significant changes,NIC,Health Care Activity
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,liquid biomarkers,TEST,PMC,C5222689,analysis of functional biomarkers in urine by liquid chromatography with tandem mass spectrometry,MEDCIN,Laboratory Procedure
PMC10177101,routine examinations,TEST,PMC,C2063084,routine examination,MEDCIN,Finding
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,pancreatic cancer cases,PROBLEM,PMC,,,,
PMC10177101,a fatal prognosis,PROBLEM,PMC,,,,
PMC10177101,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10177101,developing pancreatic cancer,PROBLEM,PMC,,,,
PMC10177101,the current protocolscreening,TREATMENT,PMC,,,,
PMC10177101,serumbased and other liquid biomarkers,TEST,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,serum biomarkerca199for,TEST,PMC,,,,
PMC10177101,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10177101,the biomarkers,TEST,PMC,C2735102,Cardiac biomarkers,MTH,Clinical Attribute
PMC10177101,the low sensitivity,PROBLEM,PMC,C5555911,Low Sensitivity Method,NCI,Qualitative Concept
PMC10177101,this marker,TEST,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,ongoing clinical studies,TEST,PMC,,,,
PMC10177101,a panel of biomarkers,TEST,PMC,C5451861,Prion disease biomarker panel,LNC,Laboratory Procedure
PMC10177101,proteins,TEST,PMC,C0033684,Proteins,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC10177101,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC10177101,cib1,TEST,PMC,C1424635,CIB1 gene,MTH,Gene or Genome
PMC10177101,mic1,TEST,PMC,C1428369,RMC1 gene,MTH,Gene or Genome
PMC10177101,rit2,TEST,PMC,C1419388,RIT2 gene,MTH,Gene or Genome
PMC10177101,tnp1,TEST,PMC,C1420830,TNP1 gene,MTH,Gene or Genome
PMC10177101,kiaa0409,TEST,PMC,,,,
PMC10177101,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,a significant increase,PROBLEM,PMC,C4062396,Significant increase in respiratory rate above baseline,NANDA-I,Finding
PMC10177101,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC10177101,other biomolecule secreting factors,PROBLEM,PMC,,,,
PMC10177101,circulating tumor dna,PROBLEM,PMC,C3827014,Circulating Tumor DNA,MSH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC10177101,circulating tumor rna,PROBLEM,PMC,C5446687,Circulating Tumor-Derived RNA,NCI,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC10177101,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC10177101,cancer exosomes,PROBLEM,PMC,C2984526,NSCLC Antigen-Loaded Dendritic Cell-derived Exosomes,NCI,Pharmacologic Substance
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,these studies,TEST,PMC,,,,
PMC10177101,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC10177101,the liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC10177101,mirnas,TEST,PMC,C1101610,MicroRNAs,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC10177101,migratory panin cells,PROBLEM,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,a panel of biomarkers,TEST,PMC,C5451861,Prion disease biomarker panel,LNC,Laboratory Procedure
PMC10177101,lewisnegative individuals,PROBLEM,PMC,,,,
PMC10177101,mic1,TEST,PMC,C1428369,RMC1 gene,MTH,Gene or Genome
PMC10177101,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC10177101,pdacspecific marker ca199,TEST,PMC,,,,
PMC10177101,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC10177101,numerous potential,PROBLEM,PMC,,,,
PMC10177101,liquid biomarkers,TEST,PMC,C5222689,analysis of functional biomarkers in urine by liquid chromatography with tandem mass spectrometry,MEDCIN,Laboratory Procedure
PMC10177101,these biomarkers,TEST,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,liquid biomarkers,TEST,PMC,C5222689,analysis of functional biomarkers in urine by liquid chromatography with tandem mass spectrometry,MEDCIN,Laboratory Procedure
PMC10177101,an unresectable disease,PROBLEM,PMC,C1618884,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; unresectable at diagnosis, m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC10177101,these liquid biomarkers,TEST,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,a diagnostic tool,TEST,PMC,,,,
PMC10177101,screening tools,TEST,PMC,C5912095,Administer screening tools at regular intervals to evaluate child growth and development,NIC,Health Care Activity
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,this screening strategy,TEST,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,novel screening tools,TEST,PMC,,,,
PMC10177101,pdac,PROBLEM,PMC,,,,
PMC10177101,research studies,TEST,PMC,C0681814,research study,MTH,Research Activity
PMC10177101,liquid biomarkers,TEST,PMC,C5222689,analysis of functional biomarkers in urine by liquid chromatography with tandem mass spectrometry,MEDCIN,Laboratory Procedure
PMC10177101,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC10177101,pdac precursor lesions,PROBLEM,PMC,,,,
PMC10177101,annual blood tests,TEST,PMC,C0580954,Annual diabetic blood test,SNOMEDCT_US,Diagnostic Procedure
PMC10374677,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10374677,a common and,PROBLEM,PMC,C0009443,Common Cold,MTH,Disease or Syndrome
PMC10374677,difficult cancer,PROBLEM,PMC,C5447302,Cancer Care Team Helped with Difficult Feelings,NCI,Intellectual Product
PMC10374677,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC10374677,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10374677,standard of care,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC10374677,oncolytic adenoviruses,PROBLEM,PMC,,,,
PMC10374677,a unique approach,TREATMENT,PMC,,,,
PMC10374677,this challenging cancer,PROBLEM,PMC,,,,
PMC10374677,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC10374677,standard therapies,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC10374677,conditionallyreplicative adenoviruses,PROBLEM,PMC,,,,
PMC10374677,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10374677,this therapy,TREATMENT,PMC,C3173305,Did you have this treatment or therapy for cancer,LNC,Intellectual Product
PMC10374677,conditionallyreplicative adenoviruses,TREATMENT,PMC,,,,
PMC10374677,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10374677,treatment protocol,TREATMENT,PMC,C0040808,Treatment Protocols,MTH,Therapeutic or Preventive Procedure
PMC10374677,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC10374677,survival rates,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC10374677,objective clinical responses,PROBLEM,PMC,,,,
PMC10374677,side effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC10374677,high viral doses,TREATMENT,PMC,,,,
PMC10374677,the more,TREATMENT,PMC,C3842906,Talk more,LNC,Finding
PMC10374677,oncolytic activity,PROBLEM,PMC,C5420431,Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein,NCI,Virus
PMC10374677,conditionallyreplicative adenoviruses,PROBLEM,PMC,,,,
PMC10374677,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10374677,the easier intravenous route of administration,TREATMENT,PMC,,,,
PMC10374677,further clinical evaluation,TEST,PMC,,,,
PMC10374677,this therapeutic approach,TREATMENT,PMC,,,,
PMC10374677,a currently intractable disease,PROBLEM,PMC,,,,
PMC10374677,oncolytic activity,PROBLEM,PMC,C5420431,Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein,NCI,Virus
PMC10374677,conditionallyreplicative adenoviruses,PROBLEM,PMC,,,,
PMC10374677,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10374677,the easier intravenous route of administration,TREATMENT,PMC,,,,
PMC10374677,further clinical evaluation,TEST,PMC,,,,
PMC10374677,this therapeutic approach,TREATMENT,PMC,,,,
PMC10374677,a currently intractable disease,PROBLEM,PMC,,,,
PMC8628685,highintensity focused ultrasound,TEST,PMC,,,,
PMC8628685,a novel advanced therapy,TREATMENT,PMC,,,,
PMC8628685,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,a novel method,TREATMENT,PMC,C0683465,novel AODU treatment method,AOD,Therapeutic or Preventive Procedure
PMC8628685,local advancement,TREATMENT,PMC,C0407168,Local muscle advancement flap,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC8628685,tumor ablation,TREATMENT,PMC,C4761028,Tumour ablation,MDR,Therapeutic or Preventive Procedure
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,locally advanced and metastatic pc,PROBLEM,PMC,,,,
PMC8628685,hifu,TREATMENT,PMC,C2348970,High-Intensity Focused Ultrasound Ablation,MTH,Therapeutic or Preventive Procedure
PMC8628685,an optional local therapy,TREATMENT,PMC,,,,
PMC8628685,systemic chemotherapy,TREATMENT,PMC,C1883256,Systemic Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC8628685,the fepby02,TREATMENT,PMC,,,,
PMC8628685,ultrasound guidance,TEST,PMC,C0442973,Ultrasonic guidance procedure,SNOMEDCT_US,Diagnostic Procedure
PMC8628685,stage iii,PROBLEM,PMC,C0441771,Stage level 3,MTH,Intellectual Product
PMC8628685,stage iv,PROBLEM,PMC,C0441772,Stage level 4,MTH,Intellectual Product
PMC8628685,complete tumor ablation,TREATMENT,PMC,C2106680,complete colonoscopy for ablation of tumor not amenable to removal,MEDCIN,Therapeutic or Preventive Procedure
PMC8628685,symptom relief,PROBLEM,PMC,C0719429,Cold Symptom Relief,MMSL,"Organic Chemical, Pharmacologic Substance"
PMC8628685,the primary lesions,PROBLEM,PMC,C1402294,Primary Lesion,NCI,Disease or Syndrome
PMC8628685,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC8628685,progressive disease pd,PROBLEM,PMC,,,,
PMC8628685,the primary disease control rate,TEST,PMC,,,,
PMC8628685,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC8628685,hifu,TREATMENT,PMC,C2348970,High-Intensity Focused Ultrasound Ablation,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,significant prolongation of prognosis,PROBLEM,PMC,,,,
PMC8628685,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,a novel combination therapy,TREATMENT,PMC,,,,
PMC8628685,unresectable pc,PROBLEM,PMC,,,,
PMC8628685,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8628685,a longterm prospective study,TEST,PMC,,,,
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,unresectable pc,PROBLEM,PMC,,,,
PMC8628685,a longterm clinical study,TEST,PMC,,,,
PMC8628685,a novel treatment,TREATMENT,PMC,C0683465,novel AODU treatment method,AOD,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,unresectable pc,PROBLEM,PMC,,,,
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8628685,a noninvasive treatment,TREATMENT,PMC,C5541629,noninvasive vagus nerve stimulator,MEDCIN,Medical Device
PMC8628685,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC8628685,detailed imaging,TEST,PMC,C5411335,"Real time ultrasound of pregnant uterus by transabdominal approach for fetal and maternal evaluation and detailed fetal anatomic examination, with image documentation, first gestation",CPT,Diagnostic Procedure
PMC8628685,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC8628685,an upper transducer,TREATMENT,PMC,,,,
PMC8628685,therapeutic effects,TREATMENT,PMC,C1527144,Therapeutic Effect,MTH,Clinical Attribute
PMC8628685,symptom relief,PROBLEM,PMC,C0719429,Cold Symptom Relief,MMSL,"Organic Chemical, Pharmacologic Substance"
PMC8628685,primary disease control,TREATMENT,PMC,,,,
PMC8628685,tumor reduction,PROBLEM,PMC,C4523152,Unilateral percutaneous cryoablation for reduction of pulmonary tumor,CPT,Therapeutic or Preventive Procedure
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,a significant prolongation of prognosis,PROBLEM,PMC,,,,
PMC8628685,prolonged prognosis,PROBLEM,PMC,,,,
PMC8628685,stage iii,PROBLEM,PMC,C0441771,Stage level 3,MTH,Intellectual Product
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,unresectable pc,PROBLEM,PMC,,,,
PMC8628685,antitumor effect,TREATMENT,PMC,,,,
PMC8628685,retreatmentadditional,TREATMENT,PMC,,,,
PMC8628685,prolongation of survival,TREATMENT,PMC,,,,
PMC8628685,symptom relief,PROBLEM,PMC,C0719429,Cold Symptom Relief,MMSL,"Organic Chemical, Pharmacologic Substance"
PMC8628685,hifu therapy,TREATMENT,PMC,C4318385,Extracorporeal High-Intensity Focused Ultrasound Therapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8628685,systemic therapy,TREATMENT,PMC,C1515119,Systemic Therapy,NCI,Therapeutic or Preventive Procedure
PMC8628685,a strategy,TREATMENT,PMC,C0679199,Strategy,NCI,Mental Process
PMC8628685,locally advanced unresectable pc,PROBLEM,PMC,,,,
PMC8794891,chemotherapyinduced toxicity,PROBLEM,PMC,,,,
PMC8794891,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC8794891,further treatment,TREATMENT,PMC,C5239246,Subject/Guardian Refused Further Treatment,NCI,Finding
PMC8794891,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8794891,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC8794891,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC8794891,folfirinox treatment,TREATMENT,PMC,,,,
PMC8794891,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC8794891,partial response,PROBLEM,PMC,C1521726,partial response,MTH,Finding
PMC8794891,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC8794891,the eortc qlqc30,TEST,PMC,,,,
PMC8794891,nrs pain scores,PROBLEM,PMC,,,,
PMC8794891,a geneactiv triaxial accelerometer,TREATMENT,PMC,,,,
PMC8794891,mean eortc qlqc30 score,TEST,PMC,,,,
PMC8794891,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC8794891,lapc,PROBLEM,PMC,,,,
PMC8794891,few diseaserelated symptoms,PROBLEM,PMC,,,,
PMC8794891,pain scores,PROBLEM,PMC,C0582148,Pain score,SNOMEDCT_US,Finding
PMC8794891,mean sleep duration,PROBLEM,PMC,,,,
PMC8794891,sleep efficiency,TEST,PMC,C0518595,Sleep Efficiency,MTH,Finding
PMC8794891,moderatevigorous activity,PROBLEM,PMC,,,,
PMC8794891,disease control,TREATMENT,PMC,C0920467,disorder control (procedure),MTH,Therapeutic or Preventive Procedure
PMC8794891,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC8794891,clinical deterioration,PROBLEM,PMC,C4505323,Clinical Deterioration,MSH,Organism Attribute
PMC8794891,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC8794891,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8794891,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8794891,disease control,TREATMENT,PMC,C0920467,disorder control (procedure),MTH,Therapeutic or Preventive Procedure
PMC8794891,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC8794891,clinical deterioration,PROBLEM,PMC,C4505323,Clinical Deterioration,MSH,Organism Attribute
PMC8794891,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC8794891,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8794891,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8794891,disease control,TREATMENT,PMC,C0920467,disorder control (procedure),MTH,Therapeutic or Preventive Procedure
PMC8794891,folfirinox treatment,TREATMENT,PMC,,,,
PMC8794891,very little symptoms,PROBLEM,PMC,,,,
PMC8794891,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC8794891,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8794891,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC12188535,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC12188535,its aggressive progression,PROBLEM,PMC,,,,
PMC12188535,improved early detection strategies,TREATMENT,PMC,,,,
PMC12188535,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC12188535,pdac,PROBLEM,PMC,,,,
PMC12188535,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12188535,pancreatic cancerassociated,PROBLEM,PMC,,,,
PMC12188535,two magneticbased diagnostic systems,TEST,PMC,,,,
PMC12188535,a comparative,TEST,PMC,C0002811,"Anatomy, Comparative",MSH,Biomedical Occupation or Discipline
PMC12188535,monoclonal antibodyconjugated magnetic nanoparticles,TREATMENT,PMC,,,,
PMC12188535,magnetized exosomes,TREATMENT,PMC,,,,
PMC12188535,antimesothelin,TREATMENT,PMC,,,,
PMC12188535,antivimentin,TREATMENT,PMC,C3495782,Anti-vimentin antibody negative,MDR,Laboratory or Test Result
PMC12188535,monoclonal antibodies,TREATMENT,PMC,C0003250,Monoclonal Antibodies,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC12188535,mesenchymal stem cells,PROBLEM,PMC,C1257975,Mesenchymal Stem Cells,MTH,Cell
PMC12188535,mnps,TREATMENT,PMC,C2717715,MNP 001,MSH,Organic Chemical
PMC12188535,magxosomes,TREATMENT,PMC,,,,
PMC12188535,characterization of,TEST,PMC,C1880022,Characterization,NCI,Activity
PMC12188535,dynamic light scattering,TEST,PMC,C1882368,Photon Correlation Spectroscopy,MTH,Laboratory Procedure
PMC12188535,inductively coupled plasma mass spectrometry,TEST,PMC,C1553183,Inductively-Coupled Plasma Mass Spectrometry,NCI,Laboratory Procedure
PMC12188535,nanoparticle tracking analysis,TEST,PMC,,,,
PMC12188535,transmission electron microscopy,TEST,PMC,C0678118,Transmission Electron Microscopy,MTH,Laboratory Procedure
PMC12188535,blood samples,TEST,PMC,C0178913,Blood specimen,MTH,Body Substance
PMC12188535,pancreatic cancer mouse models,PROBLEM,PMC,,,,
PMC12188535,nanotheranostic platforms,TREATMENT,PMC,,,,
PMC12188535,a homemade magnetic particle spectroscopy mps device,TREATMENT,PMC,,,,
PMC12188535,pancreatic cancerassociated,PROBLEM,PMC,,,,
PMC12188535,nanotheranostic platforms,TREATMENT,PMC,,,,
PMC12188535,an mps instrument,TEST,PMC,,,,
PMC12188535,the mabsmnps systems,TEST,PMC,,,,
PMC12188535,ctcs,PROBLEM,PMC,C0308749,CTC 70,SNMI,"Organic Chemical, Pharmacologic Substance"
PMC12188535,antvmnps,TREATMENT,PMC,,,,
PMC12188535,antmmnps,TREATMENT,PMC,,,,
PMC12188535,antmmnps,TREATMENT,PMC,,,,
PMC12188535,antvmnps,TREATMENT,PMC,,,,
PMC12188535,the efficiencies,TEST,PMC,C0013682,Efficiency,MSH,Quantitative Concept
PMC12188535,bone marrow,TEST,PMC,C0005953,Bone Marrow,MTH,Tissue
PMC12188535,adiposederived stem cell,TREATMENT,PMC,,,,
PMC12188535,an average,TEST,PMC,C1510992,Average,MTH,Quantitative Concept
PMC12188535,early pancreatic cancer,PROBLEM,PMC,,,,
PMC12188535,a noninvasive rapid test,TEST,PMC,,,,
PMC12188535,an advanced mps instrument,TREATMENT,PMC,,,,
PMC12188535,nanotheranostic platforms,TREATMENT,PMC,,,,
PMC12188535,pancreatic cancer ctcs,PROBLEM,PMC,,,,
PMC12188535,cancer diagnostics,TEST,PMC,C2698972,Cancer Diagnostic Procedure,NCI,Diagnostic Procedure
PMC12188535,monitoring,TEST,PMC,C1283169,Monitoring - action,MTH,Activity
PMC12188535,pdac,PROBLEM,PMC,,,,
PMC12188535,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12188535,its high fatality rate positions,PROBLEM,PMC,,,,
PMC12188535,cancerrelated deaths,PROBLEM,PMC,,,,
PMC12188535,ctcs,PROBLEM,PMC,C0308749,CTC 70,SNMI,"Organic Chemical, Pharmacologic Substance"
PMC12188535,immune cells,PROBLEM,PMC,C4329351,Antineoplastic Immune Cell,NCI,Cell
PMC12188535,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC12188535,the epithelialmesenchymal transition emt process,PROBLEM,PMC,,,,
PMC12188535,a heterogeneous population of cells,PROBLEM,PMC,,,,
PMC12188535,the transition from epithelial to mesenchymal cell shapes,PROBLEM,PMC,,,,
PMC12188535,changes in the protein content,PROBLEM,PMC,,,,
PMC12188535,different phenotypes of,PROBLEM,PMC,,,,
PMC12188535,ctcs,TEST,PMC,C0308749,CTC 70,SNMI,"Organic Chemical, Pharmacologic Substance"
PMC12188535,a promising solution,TREATMENT,PMC,,,,
PMC12188535,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12188535,advanced mps technology,TREATMENT,PMC,,,,
PMC12188535,nanotheranostic platforms,TREATMENT,PMC,,,,
PMC12188535,mabsmnps,TREATMENT,PMC,,,,
PMC12188535,magxosomes,TREATMENT,PMC,,,,
PMC12188535,a novel approach,TREATMENT,PMC,,,,
PMC12188535,pancreatic cancerassociated,PROBLEM,PMC,,,,
PMC12188535,blood samples,TEST,PMC,C0178913,Blood specimen,MTH,Body Substance
PMC12188535,antvmnps,PROBLEM,PMC,,,,
PMC12188535,antivimentin antibodies,TEST,PMC,,,,
PMC12188535,the mabsmnpsbased platforms,TREATMENT,PMC,,,,
PMC12188535,pancreatic cancerassociated,PROBLEM,PMC,,,,
PMC12188535,the optimized,TREATMENT,PMC,C0548686,Infant wellbeing will be optimized throughout postnatal period.,PCDS,Health Care Activity
PMC12188535,antvmnps,TREATMENT,PMC,,,,
PMC12188535,antvmmnps,TREATMENT,PMC,,,,
PMC12188535,antmmnps,TREATMENT,PMC,,,,
PMC12188535,mscbased magxosomes,TREATMENT,PMC,,,,
PMC12188535,bmmagxosomes,TREATMENT,PMC,,,,
PMC12188535,mscbased magxosomes,TREATMENT,PMC,,,,
PMC12188535,further experimentation,TEST,PMC,,,,
PMC12188535,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12188535,mscbased magxosomes,TREATMENT,PMC,,,,
PMC12188535,mabsmnpsbased platforms,TREATMENT,PMC,,,,
PMC12188535,ctcs,PROBLEM,PMC,C0308749,CTC 70,SNMI,"Organic Chemical, Pharmacologic Substance"
PMC12188535,magxosomes,TREATMENT,PMC,,,,
PMC12188535,mabsmnpsbased platforms,TREATMENT,PMC,,,,
PMC12188535,magxosomes,TEST,PMC,,,,
PMC12188535,mabsmnpsbased platforms,TEST,PMC,,,,
PMC12188535,ctcs,TEST,PMC,C0308749,CTC 70,SNMI,"Organic Chemical, Pharmacologic Substance"
PMC12188535,cancer diagnosis,PROBLEM,PMC,C0920688,Cancer Diagnosis,NCI,Diagnostic Procedure
PMC10078032,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10078032,a lethal disease,PROBLEM,PMC,C1842704,"GAUCHER DISEASE, PERINATAL LETHAL",MTH,Disease or Syndrome
PMC10078032,cancerassociated symptoms,PROBLEM,PMC,,,,
PMC10078032,poor quality of life,PROBLEM,PMC,C5968910,Low food and/or nutrition quality of life,SNOMEDCT_US,Finding
PMC10078032,early palliative care,TREATMENT,PMC,,,,
PMC10078032,standard oncologic care,TREATMENT,PMC,,,,
PMC10078032,some cancer types,PROBLEM,PMC,,,,
PMC10078032,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10078032,this prospective casecrossover study,TEST,PMC,,,,
PMC10078032,apc,PROBLEM,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC10078032,a palliative care consultation,TREATMENT,PMC,C5388346,palliative care consultation note,MEDCIN,Intellectual Product
PMC10078032,change in qol,PROBLEM,PMC,,,,
PMC10078032,functional assessment,TEST,PMC,C0278372,Functional assessment,SNOMEDCT_US,Diagnostic Procedure
PMC10078032,cancer therapy,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC10078032,symptom control,PROBLEM,PMC,C1274136,Symptom control (regime/therapy),MTH,Therapeutic or Preventive Procedure
PMC10078032,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10078032,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10078032,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10078032,ecog performance status,TEST,PMC,C1520224,ECOG performance status,MTH,Intellectual Product
PMC10078032,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10078032,mean facthep score,TEST,PMC,,,,
PMC10078032,multivariable analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC10078032,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10078032,improved,PROBLEM,PMC,C0184511,Improved,MTH,Finding
PMC10078032,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10078032,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC10078032,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC10078032,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10078032,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10078032,apc,TREATMENT,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC10078032,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC10078032,clinicaltrialsgov,TEST,PMC,,,,
PMC10078032,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10078032,apc,TREATMENT,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC10078032,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC11171605,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11171605,hypovascularity,PROBLEM,PMC,,,,
PMC11171605,hypoxia,PROBLEM,PMC,C0242184,Hypoxia,MTH,Pathologic Function
PMC11171605,desmoplastic stroma,PROBLEM,PMC,C5671213,Desmoplasia,MTH,Pathologic Function
PMC11171605,the deadliest malignancies,PROBLEM,PMC,,,,
PMC11171605,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11171605,disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11171605,nonresectable locally advanced,PROBLEM,PMC,,,,
PMC11171605,advanced metastatic disease,PROBLEM,PMC,,,,
PMC11171605,alternative therapies,TREATMENT,PMC,C0949216,Alternative Therapies,MTH,Therapeutic or Preventive Procedure
PMC11171605,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11171605,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11171605,these therapies,TREATMENT,PMC,C5916507,Guide to discuss these symptoms with health care provider who will be prescribing hormone therapy.,NIC,Health Care Activity
PMC11171605,disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11171605,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11171605,pdac models,TREATMENT,PMC,,,,
PMC11171605,preclinical studies,TEST,PMC,C1709631,Preclinical Study,MTH,Research Activity
PMC11171605,new therapeutics,TREATMENT,PMC,C1518319,New Avenues for the Development of Therapeutics,NCI,Research Activity
PMC11171605,treatment modalities,TREATMENT,PMC,C5234956,Physical Therapy Modalities,MTH,Therapeutic or Preventive Procedure
PMC11171605,cellbased,TREATMENT,PMC,,,,
PMC11171605,ultrasound imaging,TEST,PMC,C0041618,Ultrasonography,MTH,Diagnostic Procedure
PMC11171605,histological analysis,TEST,PMC,C3279285,Disarray and myocardial fibrosis on histologic analysis of myocardial biopsy,OMIM,Finding
PMC11171605,pancreatic stellate cells,PROBLEM,PMC,C2936598,Pancreatic Stellate Cells,MTH,Cell
PMC11171605,mature fibroblasts,PROBLEM,PMC,,,,
PMC11171605,collagen,TREATMENT,PMC,C0009325,collagen,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC11171605,earlystage primary tumors,PROBLEM,PMC,,,,
PMC11171605,implantation,TREATMENT,PMC,C0021107,Implantation procedure,MTH,Therapeutic or Preventive Procedure
PMC11171605,the bxpc3 and panc1 models,TREATMENT,PMC,,,,
PMC11171605,extensive growth,PROBLEM,PMC,C5692845,Extensive removal of growth of finger,CPT,Therapeutic or Preventive Procedure
PMC11171605,the infiltration of the omentum andor stomach wall,PROBLEM,PMC,,,,
PMC11171605,metastases,PROBLEM,PMC,C1513183,Metastatic Lesion,MTH,Finding
PMC11171605,augmented fibroblasts,PROBLEM,PMC,C3495825,Fibroblast growth factor 23 increased,MDR,Finding
PMC11171605,collagen levels,TEST,PMC,C1278223,Urine collagen measurement,SNOMEDCT_US,Laboratory Procedure
PMC11171605,orthotopic pancreatic cancer models,PROBLEM,PMC,,,,
PMC11171605,the preclinical testing,TEST,PMC,C1512070,"Drug Development, Preclinical",NCI,Research Activity
PMC11171605,drug efficacy,TREATMENT,PMC,C0598333,drug efficacy,CHV,Qualitative Concept
PMC11171605,standardized,PROBLEM,PMC,C0237892,standardized tests,CHV,Intellectual Product
PMC11171605,orthotopic pancreatic cancer models,PROBLEM,PMC,,,,
PMC11171605,ultrasound imaging,TEST,PMC,C0041618,Ultrasonography,MTH,Diagnostic Procedure
PMC11171605,histochemical analysis,TEST,PMC,C1838873,Muscle mitochondria normal by histochemical analysis,OMIM,Finding
PMC11171605,nave pancreatic stellate cells,PROBLEM,PMC,,,,
PMC11171605,mature fibroblasts,PROBLEM,PMC,,,,
PMC11171605,collagen,TREATMENT,PMC,C0009325,collagen,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC11171605,some morphological and molecular features,PROBLEM,PMC,,,,
PMC11171605,orthotopic pancreatic tumor progression,PROBLEM,PMC,,,,
PMC11171605,the tumor progressionbased,PROBLEM,PMC,,,,
PMC11171605,preclinical pancreatic,PROBLEM,PMC,,,,
PMC11171605,therapy testing purposes,TEST,PMC,,,,
PMC11171605,the preclinical testing,TEST,PMC,C1512070,"Drug Development, Preclinical",NCI,Research Activity
PMC11171605,suitable therapeutics,TREATMENT,PMC,,,,
PMC11171605,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC11171605,pancreatic adenocarcinomas,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11171605,other,TREATMENT,PMC,C0205394,Other,MTH,Qualitative Concept
PMC11171605,ovarian and colon carcinomas,PROBLEM,PMC,,,,
PMC6796693,analysing distress in laboratory mice,PROBLEM,PMC,,,,
PMC6796693,an orthotopic pancreatic cancer modeltransmitter,PROBLEM,PMC,,,,
PMC6796693,higher distress,PROBLEM,PMC,,,,
PMC6796693,laparotomy,TREATMENT,PMC,C0023038,Laparotomy,MTH,Therapeutic or Preventive Procedure
PMC6796693,carcinoma cell injectiontumour,TREATMENT,PMC,,,,
PMC6796693,very mild distressnoninvasive,PROBLEM,PMC,,,,
PMC6796693,telemetry,TEST,PMC,C0039451,Telemetry,MTH,Diagnostic Procedure
PMC6796693,distress analysis,TEST,PMC,,,,
PMC6796693,analysing distress in laboratory mice,PROBLEM,PMC,,,,
PMC6796693,noninvasivevstelemetric methods,TREATMENT,PMC,,,,
PMC6796693,an orthotopic pancreatic cancer model,PROBLEM,PMC,,,,
PMC6796693,transmitter implantation,TREATMENT,PMC,C0993776,"Receiver and/or transmitter, neurostimulator (implantable)",HCPCS,Medical Device
PMC6796693,higher distress,PROBLEM,PMC,,,,
PMC6796693,laparotomy,TREATMENT,PMC,C0023038,Laparotomy,MTH,Therapeutic or Preventive Procedure
PMC6796693,carcinoma cell injection,TREATMENT,PMC,,,,
PMC6796693,tumour growth,PROBLEM,PMC,C0201601,Tumor growth factor assay,SNOMEDCT_US,Laboratory Procedure
PMC6796693,very mild distress,PROBLEM,PMC,,,,
PMC6796693,noninvasive methods,TEST,PMC,,,,
PMC6796693,telemetry,TEST,PMC,C0039451,Telemetry,MTH,Diagnostic Procedure
PMC6796693,distress analysis,TEST,PMC,,,,
PMC6796693,prospective severity assessment,TEST,PMC,,,,
PMC6796693,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6796693,highly sensitive readout parameters,PROBLEM,PMC,,,,
PMC6796693,quantify distress,PROBLEM,PMC,,,,
PMC6796693,the present study,TEST,PMC,C2207391,nerve conduction study anomalous innervation screen anomalous innervation present,MEDCIN,Finding
PMC6796693,different,TREATMENT,PMC,C1705242,Different,MTH,Qualitative Concept
PMC6796693,animal distress,PROBLEM,PMC,C0237579,Animal Distress Calls,MTH,Social Behavior
PMC6796693,measuring body weight,TEST,PMC,C5566305,Pre-amputation measured body weight,SNOMEDCT_US,Organism Attribute
PMC6796693,distress score,PROBLEM,PMC,C4321508,Distress Score Visual Analogue Scale,MTH,Intellectual Product
PMC6796693,faecal corticosterone metabolites,TEST,PMC,,,,
PMC6796693,nesting behaviour,PROBLEM,PMC,,,,
PMC6796693,continuous monitoring,TEST,PMC,C0420200,Continuous ECG monitoring,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6796693,heart rate,TEST,PMC,C0018810,heart rate,MTH,Clinical Attribute
PMC6796693,body temperature,TEST,PMC,C0005903,Body Temperature,MTH,Organism Attribute
PMC6796693,telemetry,TEST,PMC,C0039451,Telemetry,MTH,Diagnostic Procedure
PMC6796693,the distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC6796693,two surgical interventions,TREATMENT,PMC,,,,
PMC6796693,the burden,PROBLEM,PMC,C2828008,Burden,NCI,Idea or Concept
PMC6796693,tumour growth,PROBLEM,PMC,C0201601,Tumor growth factor assay,SNOMEDCT_US,Laboratory Procedure
PMC6796693,transmitter implantation,TREATMENT,PMC,C0993776,"Receiver and/or transmitter, neurostimulator (implantable)",HCPCS,Medical Device
PMC6796693,higher distress,PROBLEM,PMC,,,,
PMC6796693,laparotomy,TREATMENT,PMC,C0023038,Laparotomy,MTH,Therapeutic or Preventive Procedure
PMC6796693,carcinoma cell injection into the pancreas,PROBLEM,PMC,,,,
PMC6796693,significant increase in distress,PROBLEM,PMC,,,,
PMC6796693,tumour growth,PROBLEM,PMC,C0201601,Tumor growth factor assay,SNOMEDCT_US,Laboratory Procedure
PMC6796693,the receiver operating characteristic curve analysis,TEST,PMC,,,,
PMC6796693,some noninvasive distressparameters,PROBLEM,PMC,,,,
PMC6796693,distressscore,PROBLEM,PMC,,,,
PMC6796693,burrowing activity,PROBLEM,PMC,,,,
PMC6796693,quantify distress,PROBLEM,PMC,,,,
PMC6796693,telemetry,TEST,PMC,C0039451,Telemetry,MTH,Diagnostic Procedure
PMC6796693,the high burden,PROBLEM,PMC,C5238971,High Transfusion Burden,MTH,Finding
PMC6796693,the telemetric device,TREATMENT,PMC,,,,
PMC6796693,noninvasive,TREATMENT,PMC,C2986496,Noninvasive,NCI,Qualitative Concept
PMC6796693,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC6796693,surgical interventions,TREATMENT,PMC,C0543467,Operative Surgical Procedures,MTH,Therapeutic or Preventive Procedure
PMC6796693,future studies,TEST,PMC,,,,
PMC6796693,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6796693,noninvasive distress parameters,PROBLEM,PMC,,,,
PMC6796693,distress score,PROBLEM,PMC,C4321508,Distress Score Visual Analogue Scale,MTH,Intellectual Product
PMC6796693,burrowing behaviour,PROBLEM,PMC,C1523631,larval burrowing behavior,GO,Individual Behavior
PMC6796693,telemetric monitoring,TEST,PMC,C3873729,Telemetric monitoring system,SNOMEDCT_US,Medical Device
PMC6796693,distress assessment,TEST,PMC,C4553732,Distress Assessment and Response Tool,MTH,Intellectual Product
PMC6796693,a murine pancreatic cancer model,PROBLEM,PMC,,,,
PMC6796693,the additional distress,PROBLEM,PMC,,,,
PMC6796693,transmitter implantation,TREATMENT,PMC,C0993776,"Receiver and/or transmitter, neurostimulator (implantable)",HCPCS,Medical Device
PMC6796693,the expensive hardware,TREATMENT,PMC,,,,
PMC6796693,microsurgical skills,TREATMENT,PMC,,,,
PMC6796693,noninvasive parameters,TREATMENT,PMC,C5927814,"noninvasive augmentative arrhythmia analysis of simulations based on selected 12-lead ECG intervals and uploaded parameters, with interpretation and report",MEDCIN,Diagnostic Procedure
PMC6796693,telemetry,TEST,PMC,C0039451,Telemetry,MTH,Diagnostic Procedure
PMC6796693,evidencebased severity assessment,TEST,PMC,,,,
PMC10139686,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,wasting of the body,PROBLEM,PMC,C0179959,"Cleaners, Bedpan",UMD,Medical Device
PMC10139686,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC10139686,these distressing symptoms,PROBLEM,PMC,,,,
PMC10139686,different interventions,TREATMENT,PMC,,,,
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC10139686,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10139686,systematic reviews,TEST,PMC,C1955832,Systematic Review,MSH,Intellectual Product
PMC10139686,network metaanalysis,TEST,PMC,,,,
PMC10139686,an evidencebased clinical care pathway,TREATMENT,PMC,,,,
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC10139686,treatmentrelated complications,PROBLEM,PMC,,,,
PMC10139686,resource utilisation,TREATMENT,PMC,C1704738,Healthcare Resource Utilization Domain,MTH,Intellectual Product
PMC10139686,network,TEST,PMC,C1882071,Network,MTH,Functional Concept
PMC10139686,multiple treatment comparisons,TREATMENT,PMC,C4277638,Network Meta-Analysis as Topic,MSH,Research Activity
PMC10139686,narrative,TEST,PMC,C1135957,Narration,MTH,Intellectual Product
PMC10139686,various,TEST,PMC,C3540763,VARIOUS DRUG CLASSES IN ATC,MTH,Pharmacologic Substance
PMC10139686,sensitivity analyses,TEST,PMC,,,,
PMC10139686,interventions,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC10139686,the care pathway,TREATMENT,PMC,C0282655,Critical Pathways,MTH,Intellectual Product
PMC10139686,both systematic review protocols,TREATMENT,PMC,,,,
PMC10139686,formal searches,TEST,PMC,C5418537,Formal Search,NCI,Health Care Activity
PMC10139686,data collection,TEST,PMC,C0010995,Data Collection,MTH,Research Activity
PMC10139686,data analysis,TEST,PMC,C0010992,Data Analysis,MSH,Occupational Activity
PMC10139686,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10139686,major interventions,TREATMENT,PMC,C2598127,"Major Procedures (Diagnostic, Surgical, and Therapeutic Interventions)",MTH,Therapeutic or Preventive Procedure
PMC10139686,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC10139686,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10139686,an evidencebased care pathway,TREATMENT,PMC,,,,
PMC10139686,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10139686,major interventions,TREATMENT,PMC,C2598127,"Major Procedures (Diagnostic, Surgical, and Therapeutic Interventions)",MTH,Therapeutic or Preventive Procedure
PMC10139686,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10139686,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC10139686,prevention,TREATMENT,PMC,C2700409,prevention aspects,MTH,Qualitative Concept
PMC10139686,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10139686,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10139686,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10139686,an evidencebased care pathway,TREATMENT,PMC,,,,
PMC5756395,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5756395,the most lethal cancers,PROBLEM,PMC,,,,
PMC5756395,its insidious symptoms,PROBLEM,PMC,,,,
PMC5756395,early metastasis,PROBLEM,PMC,,,,
PMC5756395,chemoresistance,PROBLEM,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC5756395,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC5756395,further exploration,TEST,PMC,,,,
PMC5756395,extracellular vesicles,PROBLEM,PMC,C3894683,Extracellular Vesicles,MSH,Cell Component
PMC5756395,exosomes and microvesicles,PROBLEM,PMC,,,,
PMC5756395,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC5756395,chemoresistance,PROBLEM,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC5756395,therapy targets,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC5756395,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5756395,indepth studies,TEST,PMC,,,,
PMC5756395,extracellular vesicles,PROBLEM,PMC,C3894683,Extracellular Vesicles,MSH,Cell Component
PMC5756395,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5756395,extracellular vesicles,PROBLEM,PMC,C3894683,Extracellular Vesicles,MSH,Cell Component
PMC5756395,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC5756395,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC5756395,cancerrelated immunity,PROBLEM,PMC,,,,
PMC5756395,chemoresistance,PROBLEM,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC5756395,therapeutic targets,TREATMENT,PMC,C4732277,"Cancer RNA gene expression profiling by whole transcriptome sequencing in fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",CPT,Laboratory Procedure
PMC5756395,chemoresistance,TREATMENT,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC5756395,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5756395,tumor cell proliferation,PROBLEM,PMC,C1266069,Clear cell cystic tumor of borderline malignancy,MTH,Neoplastic Process
PMC5756395,tumorassociated immunity,PROBLEM,PMC,,,,
PMC5756395,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC5756395,further investigations,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC5756395,evs,TREATMENT,PMC,C0560135,electronvolt,MTH,Quantitative Concept
PMC5756395,pc treatment,TREATMENT,PMC,C0962074,PC protocol (ovarian cancer treatment),MTH,Therapeutic or Preventive Procedure
PMC9048490,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC9048490,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9048490,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9048490,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9048490,direct locoregional therapy,TREATMENT,PMC,,,,
PMC9048490,palliation,TREATMENT,PMC,C0679251,disease palliation,AOD,Finding
PMC9048490,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9048490,inoperable pancreatic cancer,PROBLEM,PMC,,,,
PMC9048490,an upper eus,TEST,PMC,,,,
PMC9048490,lesions in the pancreatic body and tail,PROBLEM,PMC,,,,
PMC9048490,devices,TREATMENT,PMC,C0699733,Devices,MTH,Manufactured Object
PMC9048490,throughtheneedle interventions,TREATMENT,PMC,,,,
PMC9048490,placement of fiducial markers,TREATMENT,PMC,C2922954,rigid bronchoscopy with placement of fiducial markers,MEDCIN,Diagnostic Procedure
PMC9048490,brachytherapy,TREATMENT,PMC,C0006098,Brachytherapy,MTH,Therapeutic or Preventive Procedure
PMC9048490,intratumoral injection,TREATMENT,PMC,C1555370,"Injection, intratumor",LNC,Functional Concept
PMC9048490,gastroenterostomy creation,TREATMENT,PMC,,,,
PMC9048490,ablation,TREATMENT,PMC,C0547070,Ablation,MTH,Therapeutic or Preventive Procedure
PMC9048490,these techniques,TREATMENT,PMC,,,,
PMC9048490,some procedures,TREATMENT,PMC,,,,
PMC9048490,eusguided interventions,TREATMENT,PMC,,,,
PMC9048490,a broad spectrum of treatment modalities,TREATMENT,PMC,,,,
PMC9048490,borderline resectable locally advanced and inoperable pancreatic cancer,PROBLEM,PMC,,,,
PMC9048490,direct treatment,TREATMENT,PMC,C1704536,Direct Method,MTH,Therapeutic or Preventive Procedure
PMC9048490,locoregional stages,PROBLEM,PMC,,,,
PMC9048490,ablative therapies,TREATMENT,PMC,C0418982,Ablative hormone therapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC9048490,brachytherapy,TREATMENT,PMC,C0006098,Brachytherapy,MTH,Therapeutic or Preventive Procedure
PMC9048490,placement of fiducial markers,TREATMENT,PMC,C2922954,rigid bronchoscopy with placement of fiducial markers,MEDCIN,Diagnostic Procedure
PMC9048490,sbrtigrt,TREATMENT,PMC,,,,
PMC9048490,palliative treatments,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC9048490,eusguided gastroenterostomy creation,TREATMENT,PMC,,,,
PMC9048490,malignant gastric outlet obstruction,PROBLEM,PMC,,,,
PMC9048490,eusguided celiac plexus neurolysis,TREATMENT,PMC,,,,
PMC9048490,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC9048490,these procedures,TREATMENT,PMC,,,,
PMC9048490,these techniques,TREATMENT,PMC,,,,
PMC9048490,these procedures,TREATMENT,PMC,,,,
PMC11088938,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC11088938,leptomeningeal disease,PROBLEM,PMC,C0751297,Leptomeningeal Neoplasms,MSH,Neoplastic Process
PMC11088938,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11088938,leptomeningeal disease,PROBLEM,PMC,C0751297,Leptomeningeal Neoplasms,MSH,Neoplastic Process
PMC11088938,a catastrophic complication,PROBLEM,PMC,,,,
PMC11088938,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11088938,cranial nerve neuropathies,PROBLEM,PMC,C1698762,Cranial nerve sensory neuropathy,MDR,Disease or Syndrome
PMC11088938,headache,PROBLEM,PMC,C0018681,Headache,MTH,Sign or Symptom
PMC11088938,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC11088938,focal neurological deficits,PROBLEM,PMC,C0746857,Focal Neurologic Deficits,MSH,Finding
PMC11088938,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC11088938,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC11088938,leucovorin,TREATMENT,PMC,C0023413,leucovorin,MTH,"Organic Chemical, Pharmacologic Substance, Vitamin"
PMC11088938,irinotecan,TREATMENT,PMC,C0123931,irinotecan,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC11088938,oxaliplatin,TREATMENT,PMC,C0069717,oxaliplatin,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11088938,marked clinical and radiologic,PROBLEM,PMC,,,,
PMC11088938,severe peripheral neuropathy,PROBLEM,PMC,C1968787,"Peripheral motor neuropathy, severe",OMIM,Finding
PMC11088938,maintenance gemcitabine,TREATMENT,PMC,,,,
PMC11088938,nabpaclitaxel,TREATMENT,PMC,,,,
PMC11088938,this regimen,TREATMENT,PMC,,,,
PMC11088938,his systemic disease,PROBLEM,PMC,,,,
PMC11088938,leptomeningeal carcinomatosis,PROBLEM,PMC,C0220654,Meningeal Carcinomatosis,MTH,Neoplastic Process
PMC11088938,leptomeningeal metastases,PROBLEM,PMC,C1704231,Metastatic Malignant Neoplasm to the Leptomeninges,MTH,Neoplastic Process
PMC11088938,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11088938,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11088938,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11088938,nabpaclitaxel,TREATMENT,PMC,,,,
PMC11088938,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC11088938,leptomeningeal disease,PROBLEM,PMC,C0751297,Leptomeningeal Neoplasms,MSH,Neoplastic Process
PMC11088938,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11088938,systemic disease,PROBLEM,PMC,C0442893,Systemic disease,MTH,Disease or Syndrome
PMC11088938,the chemotherapeutic agents,TREATMENT,PMC,C0729502,Chemotherapeutic agent,MTH,Pharmacologic Substance
PMC11088938,the bloodbrain barrier,TREATMENT,PMC,,,,
PMC11088938,high morbidity and mortality,PROBLEM,PMC,C0479563,Exposure to high and low air pressure and changes in air pressure as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC11088938,leptomeningeal metastases,PROBLEM,PMC,C1704231,Metastatic Malignant Neoplasm to the Leptomeninges,MTH,Neoplastic Process
PMC11088938,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11088938,lmd in pancreatic cancer,PROBLEM,PMC,,,,
PMC11088938,the systemic disease,PROBLEM,PMC,C0442893,Systemic disease,MTH,Disease or Syndrome
PMC11088938,lmd,PROBLEM,PMC,C0432230,Langer Mesomelic Dysplasia Syndrome,MTH,Disease or Syndrome
PMC11088938,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11088938,the systemic disease,PROBLEM,PMC,C0442893,Systemic disease,MTH,Disease or Syndrome
PMC11088938,the chemotherapy agents,TREATMENT,PMC,C0854613,Chemotherapy multiple agents local,MDR,Therapeutic or Preventive Procedure
PMC11088938,the systemic disease,PROBLEM,PMC,C0442893,Systemic disease,MTH,Disease or Syndrome
PMC11088938,rapid progression,PROBLEM,PMC,C1838681,Rapidly progressive,HPO,Finding
PMC11088938,wholebrain radiation therapy,TREATMENT,PMC,,,,
PMC11088938,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC11088938,optimal management,TREATMENT,PMC,C5912150,"Optimize local wound environment through cleansing, debriding, managing bacterial balance and managing moisture balance, as appropriate",NIC,Health Care Activity
PMC11088938,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11088938,leptomeningeal metastases,PROBLEM,PMC,C1704231,Metastatic Malignant Neoplasm to the Leptomeninges,MTH,Neoplastic Process
PMC11088938,larger studies,TEST,PMC,C5890801,Results of a randomized controlled trial will be more reliable if a larger number of people are in the study:Find:Pt:^Patient:Ord,MTH,Clinical Attribute
PMC7080689,proton pump inhibitors,TREATMENT,PMC,C0358591,Proton Pump Inhibitors,MTH,Pharmacologic Substance
PMC7080689,our study,TEST,PMC,,,,
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,the standardized incidence rate ratios,TEST,PMC,,,,
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,longterm h2receptor antagonist users,TREATMENT,PMC,,,,
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,ppi users,TREATMENT,PMC,,,,
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,all subgroup analyses,TEST,PMC,,,,
PMC7080689,ppi use,TREATMENT,PMC,,,,
PMC7080689,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,sir,TEST,PMC,C0007968,Cheese,MTH,Food
PMC7080689,h2receptor antagonists,TREATMENT,PMC,,,,
PMC7080689,this large study,TEST,PMC,,,,
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,ppis,TREATMENT,PMC,C0965389,PPI-149,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC7080689,this large study,TEST,PMC,,,,
PMC7080689,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7080689,ppis,TREATMENT,PMC,C0965389,PPI-149,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC10885377,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10885377,global cancerrelated deaths,PROBLEM,PMC,,,,
PMC10885377,increasing,PROBLEM,PMC,C0442808,Increasing (qualifier value),MTH,Functional Concept
PMC10885377,low survival rates,PROBLEM,PMC,,,,
PMC10885377,symptom awareness,PROBLEM,PMC,C0221539,Transient alteration of awareness,SNOMEDCT_US,Finding
PMC10885377,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10885377,delayed helpseeking behaviour,PROBLEM,PMC,,,,
PMC10885377,innovative approaches,TREATMENT,PMC,,,,
PMC10885377,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10885377,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10885377,a quasiexperimental pretestposttest design,TEST,PMC,,,,
PMC10885377,pancreatic cancer awareness,PROBLEM,PMC,,,,
PMC10885377,symptom awareness,PROBLEM,PMC,C0221539,Transient alteration of awareness,SNOMEDCT_US,Finding
PMC10885377,a human anatomy diagram,TREATMENT,PMC,,,,
PMC10885377,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10885377,pancreatic cancer awareness,PROBLEM,PMC,,,,
PMC10885377,matched paired ttests,TEST,PMC,,,,
PMC10885377,missing data,PROBLEM,PMC,C4684714,Missing Data,NCI,Finding
PMC10885377,paired comparisons,TEST,PMC,C0086766,Paired Comparisons,MSH,Quantitative Concept
PMC10885377,symptom,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10885377,a statistically significant increase,PROBLEM,PMC,,,,
PMC10885377,a large effect size,PROBLEM,PMC,,,,
PMC10885377,a significant increase,PROBLEM,PMC,C4062396,Significant increase in respiratory rate above baseline,NANDA-I,Finding
PMC10885377,a large effect size,PROBLEM,PMC,,,,
PMC10885377,independentsamples ttests,TEST,PMC,,,,
PMC10885377,any,PROBLEM,PMC,C1552551,Any,MTH,Qualitative Concept
PMC10885377,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10885377,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10885377,pancreatic cancer awareness,PROBLEM,PMC,,,,
PMC10885377,such interventions,TREATMENT,PMC,C3844656,Initial GCS has legitimate values without interventions such as intubation and sedation,LNC,Finding
PMC10885377,the codesign process,TREATMENT,PMC,,,,
PMC10885377,diverse populations,PROBLEM,PMC,C1822564,Acceptance of population diversity,NOC,Finding
PMC10885377,both pancreatic symptom awareness,PROBLEM,PMC,,,,
PMC10885377,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC10885377,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10885377,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC10885377,an rct,TEST,PMC,C0035849,Root Canal Therapy,MTH,Therapeutic or Preventive Procedure
PMC5912007,hepatobiliary pancreatic cancer symptoms,PROBLEM,PMC,,,,
PMC5912007,fever,PROBLEM,PMC,C0015967,Fever,MTH,Sign or Symptom
PMC5912007,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC5912007,vomiting,PROBLEM,PMC,C0042963,Vomiting,MTH,Sign or Symptom
PMC5912007,medication,TREATMENT,PMC,C4284232,Medications,MTH,Intellectual Product
PMC5912007,clinical procedure,TREATMENT,PMC,C0586186,Clinical procedure report,MTH,Intellectual Product
PMC5912007,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5912007,medical care,TREATMENT,PMC,C0496675,Medical care,SNOMEDCT_US,Health Care Activity
PMC5912007,celiac axis occlusion,PROBLEM,PMC,,,,
PMC5912007,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC5912007,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC5912007,both oncologic curability,TREATMENT,PMC,,,,
PMC5912007,hepatic arterial flow,TREATMENT,PMC,C2609125,Hepatic artery flow decreased,MDR,Finding
PMC5912007,the operative strategy,TREATMENT,PMC,,,,
PMC5912007,hilar cholangiocarcinoma,PROBLEM,PMC,C4045991,Perihilar Cholangiocarcinoma,MTH,Neoplastic Process
PMC5912007,celiac axis stenosis,PROBLEM,PMC,,,,
PMC5912007,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC5912007,preoperative imaging,TEST,PMC,C2014645,computer-assisted navigational orthopedic procedure using preoperative images,MEDCIN,Therapeutic or Preventive Procedure
PMC5912007,hepatopancreatoduodenectomy,TREATMENT,PMC,,,,
PMC5912007,a collateral,TREATMENT,PMC,C1948058,Collateral,MTH,Spatial Concept
PMC5912007,pancreas head cancer,PROBLEM,PMC,C0861743,Cancer of pancreas (excl head) resectable,MDR,Neoplastic Process
PMC5912007,celiac axis occlusion,PROBLEM,PMC,,,,
PMC5912007,tumor invasion,PROBLEM,PMC,C1269955,Tumor Cell Invasion,MTH,Neoplastic Process
PMC5912007,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC5912007,bypass revascularization,TREATMENT,PMC,C0176589,Other bypass anastomosis for heart revascularization,ICD9CM,Therapeutic or Preventive Procedure
PMC5912007,a vein graft,TREATMENT,PMC,C0729542,Basilic vein graft,SNOMEDCT_US,"Body Part, Organ, or Organ Component"
PMC5912007,both operations,TREATMENT,PMC,C1959996,Open operation on both pulmonary arteries,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC5912007,computed tomographic angiography,TEST,PMC,C1536105,Computed Tomography Angiography,MTH,Diagnostic Procedure
PMC5912007,the operative procedure,TREATMENT,PMC,C0278255,Canceled operative procedure,SNOMEDCT_US,Health Care Activity
PMC5912007,perioperative blood flow,TEST,PMC,,,,
PMC5912007,doppler ultrasonography,TEST,PMC,C0162481,Doppler Ultrasound (procedure),MTH,Diagnostic Procedure
PMC5912007,clamping the gastroduodenal artery,TREATMENT,PMC,,,,
PMC5912007,arterial revascularization,TREATMENT,PMC,C5400304,Arterial revascularisation,MDR,Therapeutic or Preventive Procedure
PMC5912007,perioperative evaluation,TEST,PMC,C5969875,Perioperative evaluation of cardiac status,SNOMEDCT_US,Diagnostic Procedure
PMC5912007,blood flow,TEST,PMC,C0232338,Blood flow,MTH,Physiologic Function
PMC5912007,this procedure,TREATMENT,PMC,C2598204,Procedure this admission,LNC,Finding
PMC5912007,biliary pancreatic cancer,PROBLEM,PMC,,,,
PMC5912007,ca occlusion,TREATMENT,PMC,,,,
PMC5912007,an oncologic cure,TREATMENT,PMC,,,,
PMC5912007,preoperative simulation,TEST,PMC,,,,
PMC5912007,cta,TEST,PMC,C3540513,PCYT1A wt Allele,MTH,Gene or Genome
PMC5912007,the anastomotic site,TREATMENT,PMC,,,,
PMC5912007,the best graft,TREATMENT,PMC,,,,
PMC5912007,evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC5912007,the hepatic artery flow,TEST,PMC,C2609125,Hepatic artery flow decreased,MDR,Finding
PMC5912007,gda clamping,TREATMENT,PMC,,,,
PMC5912007,the median arcuate ligament,TREATMENT,PMC,C0929518,Median arcuate ligament,FMA,"Body Part, Organ, or Organ Component"
PMC5912007,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC5912007,the preoperative evaluation,TEST,PMC,C2024243,preoperative cardiac evaluation,MEDCIN,Finding
PMC5912007,revascularization,TREATMENT,PMC,C0581603,Revascularization - action,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC5912007,the gda,TREATMENT,PMC,C1415029,GDA gene,MTH,Gene or Genome
PMC5912007, preoperative simulation,TEST,PMC,,,,
PMC5912007,cta,TEST,PMC,C3540513,PCYT1A wt Allele,MTH,Gene or Genome
PMC5912007,the anastomotic site,TREATMENT,PMC,,,,
PMC5912007,the best graft,TREATMENT,PMC,,,,
PMC5912007,evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC5912007,the hepatic artery flow,TEST,PMC,C2609125,Hepatic artery flow decreased,MDR,Finding
PMC5912007,gda clamping,TREATMENT,PMC,,,,
PMC5912007,the operative findings,TEST,PMC,C0241311,post operative (finding),MTH,Finding
PMC5912007,the preoperative evaluation,TEST,PMC,C2024243,preoperative cardiac evaluation,MEDCIN,Finding
PMC5912007,revascularization,TREATMENT,PMC,C0581603,Revascularization - action,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC5912007,the gda,TREATMENT,PMC,C1415029,GDA gene,MTH,Gene or Genome
PMC11664036,adjuvant chemotherapy,TREATMENT,PMC,C0085533,"Chemotherapy, Adjuvant",MTH,Therapeutic or Preventive Procedure
PMC11664036,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11664036,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC11664036,their disease burden,PROBLEM,PMC,,,,
PMC11664036,pain symptoms,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11664036,their pain,PROBLEM,PMC,,,,
PMC11664036,an urgent issue,PROBLEM,PMC,,,,
PMC11664036,mindfulness meditation,TREATMENT,PMC,C5891058,Mindfulness Meditation,MTH,Therapeutic or Preventive Procedure
PMC11664036,the brainlink intelligent biofeedback instrument,TREATMENT,PMC,,,,
PMC11664036,the anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC11664036,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11664036,brain fatigue,PROBLEM,PMC,,,,
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11664036,hepatobiliary surgery,TREATMENT,PMC,C1319408,Hepatobiliary and pancreatic surgery,SNOMEDCT_US,Biomedical Occupation or Discipline
PMC11664036,study objects,TEST,PMC,C1705923,Study Object,MTH,Intellectual Product
PMC11664036,a test group,TEST,PMC,C2826900,Laboratory Test Group Identifier,NCI,Intellectual Product
PMC11664036,routine nursing treatment,TREATMENT,PMC,,,,
PMC11664036,mm,TREATMENT,PMC,C0439200,millimeter,MTH,Quantitative Concept
PMC11664036,an intelligent biofeedback instrument,TREATMENT,PMC,,,,
PMC11664036,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC11664036,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11664036,eeg signal data,TEST,PMC,,,,
PMC11664036,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC11664036,relaxation,PROBLEM,PMC,C0035028,Relaxation,MTH,Activity
PMC11664036,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC11664036,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC11664036,significant difference,PROBLEM,PMC,,,,
PMC11664036,pathological,PROBLEM,PMC,C1521733,Pathologic,MTH,Functional Concept
PMC11664036,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC11664036,the sas values,TEST,PMC,,,,
PMC11664036,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC11664036,the vas scores,TEST,PMC,C3639380,EQ-5D-3L - EQ VAS Score,NCI,Intellectual Product
PMC11664036,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC11664036,brain fatigue relief,PROBLEM,PMC,,,,
PMC11664036,relaxation levels,TEST,PMC,C1168123,Muscle relaxant drug level,MDR,Laboratory Procedure
PMC11664036,the wave,TEST,PMC,C1305738,Q wave,MTH,Clinical Attribute
PMC11664036,an upward trend,PROBLEM,PMC,,,,
PMC11664036,mm,TREATMENT,PMC,C0439200,millimeter,MTH,Quantitative Concept
PMC11664036,the brainlink intelligent biofeedback instrument,TREATMENT,PMC,,,,
PMC11664036,the anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC11664036,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11664036,brain fatigue,PROBLEM,PMC,,,,
PMC11664036,pc,TREATMENT,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11664036,a novel intervention,TREATMENT,PMC,,,,
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11664036,mindfulness meditation,TREATMENT,PMC,C5891058,Mindfulness Meditation,MTH,Therapeutic or Preventive Procedure
PMC11664036,the brainlink intelligent biofeedback instrument,TREATMENT,PMC,,,,
PMC11664036,the anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC11664036,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11664036,brain fatigue,PROBLEM,PMC,,,,
PMC11664036,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11664036,mm,TREATMENT,PMC,C0439200,millimeter,MTH,Quantitative Concept
PMC11664036,the brainlink intelligent biofeedback instrument,TREATMENT,PMC,,,,
PMC11664036,the anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC11664036,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11664036,brain fatigue,PROBLEM,PMC,,,,
PMC11664036,pc,TREATMENT,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11664036,a novel intervention,TREATMENT,PMC,,,,
PMC11664036,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8565992,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC8565992,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC8565992,low immunogenicity,PROBLEM,PMC,C3898798,Immunogenicity Specimen Assessments Lower Limit of Quantitation,NCI,Quantitative Concept
PMC8565992,an immunosuppressive microenvironment,TREATMENT,PMC,,,,
PMC8565992,high accumulation of dense stroma,PROBLEM,PMC,,,,
PMC8565992,mostly cancerassociated fibroblasts,PROBLEM,PMC,,,,
PMC8565992,multiple subsets of cafs,PROBLEM,PMC,,,,
PMC8565992,the transforming growth factor tgf coreceptor endoglin,TREATMENT,PMC,,,,
PMC8565992,endoglinexpressing cafs,PROBLEM,PMC,,,,
PMC8565992,tumor progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC8565992,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC8565992,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8565992,endoglinexpressing cafs,PROBLEM,PMC,,,,
PMC8565992,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC8565992,cafs in both human,PROBLEM,PMC,,,,
PMC8565992,a mouse model,TREATMENT,PMC,C2986594,Mouse Model,NCI,Experimental Model of Disease
PMC8565992,pdac,PROBLEM,PMC,,,,
PMC8565992,cafspecific endoglin expression,PROBLEM,PMC,,,,
PMC8565992,the endoglin neutralizing antibody,TEST,PMC,,,,
PMC8565992,the murine kpc model,TEST,PMC,,,,
PMC8565992,pdac,PROBLEM,PMC,,,,
PMC8565992,immune activation,PROBLEM,PMC,C4049273,Systemic immune activation,MDR,Disease or Syndrome
PMC8565992,trc105,TEST,PMC,C2346810,TRC105,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC8565992,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC8565992,the cd8 tcells,TEST,PMC,,,,
PMC8565992,the immune checkpoint pd1,PROBLEM,PMC,,,,
PMC8565992,a pd1 checkpoint inhibitor,TREATMENT,PMC,,,,
PMC8565992,genetic deletion,PROBLEM,PMC,C2010893,genetic analysis Y chromosome deletion,MEDCIN,Laboratory Procedure
PMC8565992,the mouse kpc tumors,PROBLEM,PMC,,,,
PMC8565992,pdaccafs,TEST,PMC,,,,
PMC8565992,decreased tumor growth,PROBLEM,PMC,,,,
PMC8565992,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC8565992,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8565992,pdaccafs,TEST,PMC,,,,
PMC8565992,decreased tumor growth,PROBLEM,PMC,,,,
PMC8565992,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC8565992,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8565992,high endoglin expression,PROBLEM,PMC,,,,
PMC8565992,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8565992,monotherapy,TREATMENT,PMC,C4763675,Single Agent Therapy,NCI,Therapeutic or Preventive Procedure
PMC8565992,pd1 checkpoint inhibitors,TREATMENT,PMC,,,,
PMC8565992,genetic deletion,TREATMENT,PMC,C2010893,genetic analysis Y chromosome deletion,MEDCIN,Laboratory Procedure
PMC8565992,endoglin,PROBLEM,PMC,C4255054,Endoglin,MTH,"Amino Acid, Peptide, or Protein, Receptor"
PMC8565992,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC8565992,the kpc,TEST,PMC,C5832447,KPC negative,LNC,Laboratory or Test Result
PMC8565992,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8565992,interesting changes,PROBLEM,PMC,C4061776,Change in interest toward others,NANDA-I,Finding
PMC8565992,endoglin,TREATMENT,PMC,C4255054,Endoglin,MTH,"Amino Acid, Peptide, or Protein, Receptor"
PMC8565992,additional studies,TEST,PMC,C5204583,Were Additional Molecular Studies Performed,NCI,Intellectual Product
PMC8565992,changes in,PROBLEM,PMC,C0392747,Changing,MTH,Functional Concept
PMC8565992,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC8565992,pancreatic tumor progression,PROBLEM,PMC,,,,
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,a fatal disease,PROBLEM,PMC,C2924592,Type of fatal coronary heart disease,MTH,Finding
PMC7793745,a very poor prognosis,PROBLEM,PMC,,,,
PMC7793745,its characteristic insidious symptoms,PROBLEM,PMC,,,,
PMC7793745,early metastasis,PROBLEM,PMC,,,,
PMC7793745,chemoresistance,PROBLEM,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC7793745,circular rnas,TEST,PMC,C0073432,"RNA, Circular",MSH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,circrna_000864,TEST,PMC,,,,
PMC7793745,mir3613p,TEST,PMC,,,,
PMC7793745,btg2 expression,PROBLEM,PMC,,,,
PMC7793745,the pancreatic cancer tissues,PROBLEM,PMC,C5976080,Hereditary pancreatic cancer multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC7793745,rtqpcr,TEST,PMC,,,,
PMC7793745,mir3613p,TEST,PMC,,,,
PMC7793745,btg2,TEST,PMC,C1366526,BTG2 gene,MTH,Gene or Genome
PMC7793745,rnapull down assay,TEST,PMC,,,,
PMC7793745,rna immunoprecipitation assay,TEST,PMC,,,,
PMC7793745,dualluciferase reporter gene assay,TEST,PMC,,,,
PMC7793745,ectopic,PROBLEM,PMC,C0574895,Ectopic,MTH,Spatial Concept
PMC7793745,depletion experiments,TEST,PMC,,,,
PMC7793745,5ethynyl2deoxyuridine assay,TEST,PMC,,,,
PMC7793745,transwell assay,TEST,PMC,,,,
PMC7793745,flow cytometry,TEST,PMC,C0016263,Flow Cytometry,MSH,Laboratory Procedure
PMC7793745,the cell proliferation,PROBLEM,PMC,C1155008,B Cell Proliferation,NCI,Cell Function
PMC7793745,migration and invasion,PROBLEM,PMC,C1434286,"MIIP protein, human",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7793745,cell cycle,TEST,PMC,C0007586,Cell Cycle,MTH,Cell Function
PMC7793745,apoptosis,TEST,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC7793745,xenotransplantation of nude mice,TREATMENT,PMC,,,,
PMC7793745,circrna_000864,TREATMENT,PMC,,,,
PMC7793745,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC7793745,circrna_000864,TEST,PMC,,,,
PMC7793745,btg2,TEST,PMC,C1366526,BTG2 gene,MTH,Gene or Genome
PMC7793745,mir3613p,TEST,PMC,,,,
PMC7793745,the pancreatic cancer tissues,PROBLEM,PMC,C5976080,Hereditary pancreatic cancer multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC7793745,circrna_000864,TREATMENT,PMC,,,,
PMC7793745,cell proliferation,PROBLEM,PMC,C0596290,Cell Proliferation,MTH,Cell Function
PMC7793745,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC7793745,the cell cycle arrest,PROBLEM,PMC,C1155873,Cell Cycle Arrest,MTH,Cell Function
PMC7793745,apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC7793745,circrna_000864,TREATMENT,PMC,,,,
PMC7793745,btg2,TREATMENT,PMC,C1366526,BTG2 gene,MTH,Gene or Genome
PMC7793745,overexpression of circrna_000864,PROBLEM,PMC,,,,
PMC7793745,downregulation of mir3613p,PROBLEM,PMC,,,,
PMC7793745,the tumor growthin,PROBLEM,PMC,,,,
PMC7793745,the overexpression,PROBLEM,PMC,C3862387,SHOX overexpression,MEDCIN,Finding
PMC7793745,btg2 expression,PROBLEM,PMC,,,,
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,the overexpression,PROBLEM,PMC,C3862387,SHOX overexpression,MEDCIN,Finding
PMC7793745,btg2 expression,PROBLEM,PMC,,,,
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,impaired btg2,PROBLEM,PMC,,,,
PMC7793745,the proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC7793745,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7793745,our,TEST,PMC,C4296191,Can pronounce our,LNC,Finding
PMC7793745,circrna_000864,TEST,PMC,,,,
PMC7793745,mir3613p,TEST,PMC,,,,
PMC7793745,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC7793745,other downstream,PROBLEM,PMC,,,,
PMC7793745,circrna_000864,TREATMENT,PMC,,,,
PMC7793745,additional studies,TEST,PMC,C5204583,Were Additional Molecular Studies Performed,NCI,Intellectual Product
PMC7793745,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7793745,mir3613pdependent btg2 downregulation,PROBLEM,PMC,,,,
PMC7793745,the proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC7793745,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC10251968,the very poor prognosis,PROBLEM,PMC,,,,
PMC10251968,radical treatment options,TREATMENT,PMC,,,,
PMC10251968,unresectable locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10251968,its management,TREATMENT,PMC,C5204378,Manage Child's Side Effects of Cancer or its Treatment,NCI,Intellectual Product
PMC10251968,palliation,TREATMENT,PMC,C0679251,disease palliation,AOD,Finding
PMC10251968,new systemic therapy agents,TREATMENT,PMC,,,,
PMC10251968,systemic treatments,TREATMENT,PMC,C3880657,Cryoceutical treatment system,SNOMEDCT_US,Medical Device
PMC10251968,lapc,PROBLEM,PMC,,,,
PMC10251968,a high symptom burden,PROBLEM,PMC,,,,
PMC10251968,radiation,TREATMENT,PMC,C0851346,Radiation,MTH,Natural Phenomenon or Process
PMC10251968,local progression cessation,TREATMENT,PMC,,,,
PMC10251968,other treatment sites,TREATMENT,PMC,C3248535,Specimen site other than anatomic location of prostate,HCPCS,Finding
PMC10251968,stereotactic body radiotherapy,TREATMENT,PMC,C1720823,Stereotactic Body Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC10251968,nonablative radiotherapy,TREATMENT,PMC,,,,
PMC10251968,the doselocal control,TREATMENT,PMC,,,,
PMC10251968,a nonradical treatment,TREATMENT,PMC,,,,
PMC10251968,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,conventional radiation,TREATMENT,PMC,C5236971,Conventional Radiotherapy,NCI,Therapeutic or Preventive Procedure
PMC10251968,a systematic search,TEST,PMC,,,,
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10251968,the search,TEST,PMC,C2348167,Search Engine,MSH,Intellectual Product
PMC10251968,embase,TEST,PMC,,,,
PMC10251968,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC10251968,12 studies,TEST,PMC,C3510338,"Nerve conduction, 11-12 studies",CPT,Diagnostic Procedure
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,conventional radiation,TREATMENT,PMC,C5236971,Conventional Radiotherapy,NCI,Therapeutic or Preventive Procedure
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,dose escalation,TREATMENT,PMC,C3816728,Dose Escalation,MTH,Functional Concept
PMC10251968,primary lapc,TREATMENT,PMC,,,,
PMC10251968,a nonneoadjuvant setting,TREATMENT,PMC,,,,
PMC10251968,sbrtp,TREATMENT,PMC,,,,
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,our sbrt patients,TREATMENT,PMC,,,,
PMC10251968,local progressions,PROBLEM,PMC,C2184183,localized convulsion progressed to involve one entire side,MEDCIN,Sign or Symptom
PMC10251968,palliating lapc,TREATMENT,PMC,,,,
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,conventional radiation,TREATMENT,PMC,C5236971,Conventional Radiotherapy,NCI,Therapeutic or Preventive Procedure
PMC10251968,a low disease burden,PROBLEM,PMC,,,,
PMC10251968,bed10,TREATMENT,PMC,,,,
PMC10251968,better local control,TREATMENT,PMC,,,,
PMC10251968,increasing toxicity rates,PROBLEM,PMC,,,,
PMC10251968,less local progression,PROBLEM,PMC,,,,
PMC10251968,a short life,PROBLEM,PMC,C1857399,Short stature in first year of life,OMIM,Finding
PMC10251968,sbrt,TREATMENT,PMC,C3896609,Stereotactic Body Radiation Therapy,MTH,Therapeutic or Preventive Procedure
PMC10251968,conventionally fractionated rt in lapc,TREATMENT,PMC,,,,
PMC10251968,a low disease burden,PROBLEM,PMC,,,,
PMC10251968,moderately higher bed10doses,TREATMENT,PMC,,,,
PMC10251968,better local control,TREATMENT,PMC,,,,
PMC10251968,acceptable toxicity rates,PROBLEM,PMC,,,,
PMC10251968,less local progression,PROBLEM,PMC,,,,
PMC10251968,prospective data over toxicity,PROBLEM,PMC,,,,
PMC10251968,higher sbrt doses in lapc,TREATMENT,PMC,,,,
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,the most common digestive system cancers,PROBLEM,PMC,,,,
PMC7841623,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC7841623,reliable biomarkers,TEST,PMC,,,,
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,newonset diabetes,PROBLEM,PMC,,,,
PMC7841623,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC7841623,microorganisms,PROBLEM,PMC,C0445623,Microorganism,MTH,Organism
PMC7841623,pancreatic cancer tissues,PROBLEM,PMC,C5976080,Hereditary pancreatic cancer multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,inflammatory induction,PROBLEM,PMC,,,,
PMC7841623,immune regulation,PROBLEM,PMC,C1512649,Immune Response Regulation Pathway,NCI,Conceptual Entity
PMC7841623,microenvironment changes,PROBLEM,PMC,,,,
PMC7841623,the pancreatic colonized microbiome,PROBLEM,PMC,,,,
PMC7841623,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC7841623,immunotherapy approaches,TREATMENT,PMC,C5539069,"Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7",ICD10PCS,Therapeutic or Preventive Procedure
PMC7841623,further study,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC7841623,the pancreatic colonized microbiome,PROBLEM,PMC,,,,
PMC7841623,pdac,PROBLEM,PMC,,,,
PMC7841623,relevant studies,TEST,PMC,C2114265,pre-procedure checklist: relevant imaging studies confirmed in chart,MEDCIN,Health Care Activity
PMC7841623,pdac development,PROBLEM,PMC,,,,
PMC7841623,treatment effectiveness,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC7841623,the microorganisms,PROBLEM,PMC,C0445623,Microorganism,MTH,Organism
PMC7841623,pancreatic cancer tissues,PROBLEM,PMC,C5976080,Hereditary pancreatic cancer multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC7841623,viruses,PROBLEM,PMC,C0042776,Virus,MTH,Virus
PMC7841623,bacteria,PROBLEM,PMC,C0004611,Bacteria,MTH,Bacterium
PMC7841623,fungi,PROBLEM,PMC,C0016832,Fungi,MTH,Fungus
PMC7841623,the microbial diversity,PROBLEM,PMC,,,,
PMC7841623,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC7841623,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC7841623,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,new therapeutic treatment,TREATMENT,PMC,C5427993,introduction of new technology therapeutic substance,MEDCIN,Therapeutic or Preventive Procedure
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,the pancreatic microbiome,PROBLEM,PMC,,,,
PMC7841623,pdac patients,TREATMENT,PMC,,,,
PMC7841623,chemotherapy drugs,TREATMENT,PMC,C0812987,Chemotherapy Drugs Adminstered,MTH,Clinical Drug
PMC7841623,reducing tumor burden,PROBLEM,PMC,,,,
PMC7841623,the colonization of microorganisms in the pancreas,PROBLEM,PMC,,,,
PMC7841623,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,the microbiome,PROBLEM,PMC,C1956108,Microbiome,MTH,Organism
PMC7841623,pancreatic tissue,PROBLEM,PMC,C0994638,Ectopic pancreatic tissue,HPO,Finding
PMC7841623,tumor,PROBLEM,PMC,C3273930,Tumor Mass,MTH,Finding
PMC7841623,treatment response,TREATMENT,PMC,C2127121,treatment response or compliance,MEDCIN,Finding
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,the pancreatic microbiome,PROBLEM,PMC,,,,
PMC7841623,pdac patients,TREATMENT,PMC,,,,
PMC7841623,chemotherapy drugs,TREATMENT,PMC,C0812987,Chemotherapy Drugs Adminstered,MTH,Clinical Drug
PMC7841623,reducing tumor burden,PROBLEM,PMC,,,,
PMC7841623,the sampling,PROBLEM,PMC,C0870078,Sampling,MTH,Idea or Concept
PMC7841623,human samples,TEST,PMC,C3494873,Human breast milk specimen,SNOMEDCT_US,Body Substance
PMC7841623,the study of microorganisms,TEST,PMC,C0596938,microorganism population study,CSP,Occupation or Discipline
PMC7841623,microorganisms,PROBLEM,PMC,C0445623,Microorganism,MTH,Organism
PMC7841623,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7841623,the pancreatic colonized microbiome,PROBLEM,PMC,,,,
PMC7841623,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC7841623,immunotherapy approaches,TREATMENT,PMC,C5539069,"Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7",ICD10PCS,Therapeutic or Preventive Procedure
PMC7841623,further study,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC7841623,the pancreatic colonized microbiome,PROBLEM,PMC,,,,
PMC7841623,pdac,PROBLEM,PMC,,,,
PMC7841623,relevant studies,TEST,PMC,C2114265,pre-procedure checklist: relevant imaging studies confirmed in chart,MEDCIN,Health Care Activity
PMC7841623,pdac development,PROBLEM,PMC,,,,
PMC7841623,treatment effectiveness,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC7841623,representative clinicals of microorganisms in pancreatic cancer,PROBLEM,PMC,,,,
PMC8411560,focal autoimmune pancreatitis,PROBLEM,PMC,,,,
PMC8411560,radiological overlap,PROBLEM,PMC,,,,
PMC8411560,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8411560,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8411560,a,TREATMENT,PMC,,,,
PMC8411560,eus characteristics,TEST,PMC,,,,
PMC8411560,faip,PROBLEM,PMC,,,,
PMC8411560,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC8411560,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC8411560,a derivation sample,TEST,PMC,C5235909,Blood Cancer-Derived Blood Specimen,NCI,Body Substance
PMC8411560,a validation sample,TEST,PMC,C5411917,"Presumptive drug test using method read by direct optical observation only, with sample validation, per date of service",CPT,Laboratory Procedure
PMC8411560,eus characteristics,TEST,PMC,,,,
PMC8411560,multivariate stepwise logistic regression,TEST,PMC,,,,
PMC8411560,receiver operating characteristics,TEST,PMC,C0034772,Receiver Operating Characteristic,MSH,Quantitative Concept
PMC8411560,eus characteristics,TEST,PMC,,,,
PMC8411560,faip,PROBLEM,PMC,,,,
PMC8411560,diffuse hypoechogenicity,PROBLEM,PMC,,,,
PMC8411560,hyperechoic focistands,PROBLEM,PMC,,,,
PMC8411560,lobularity,PROBLEM,PMC,C0205417,Lobular,SNOMEDCT_US,Qualitative Concept
PMC8411560,bile duct wall thickening,PROBLEM,PMC,,,,
PMC8411560,peripancreatic hypoechoic margin,PROBLEM,PMC,,,,
PMC8411560,eus features,TEST,PMC,,,,
PMC8411560,focal hypoechogenicity,PROBLEM,PMC,,,,
PMC8411560,parenchymal heterogeneity,PROBLEM,PMC,,,,
PMC8411560,pancreatic duct dilation,PROBLEM,PMC,C2021949,ERCP: size of pancreatic duct dilation,MEDCIN,Finding
PMC8411560,vessel involvement,PROBLEM,PMC,C1321241,Renal sinus vessel involved by tumor,SNOMEDCT_US,Finding
PMC8411560,the prediction model,TEST,PMC,C0451318,Mortality prediction model,SNOMEDCT_US,Intellectual Product
PMC8411560,an area under,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC8411560,the roc curve,TEST,PMC,C0035787,ROC Curve,MSH,Quantitative Concept
PMC8411560,diagnosing pc,PROBLEM,PMC,,,,
PMC8411560,faip,PROBLEM,PMC,,,,
PMC8411560,eus characteristics,TEST,PMC,,,,
PMC8411560,the prediction,TEST,PMC,C0681842,Prediction,NCI,Idea or Concept
PMC8411560,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8411560,faip,PROBLEM,PMC,,,,
PMC8411560,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8411560,eus characteristics,TEST,PMC,,,,
PMC8411560,the prediction model,TEST,PMC,C0451318,Mortality prediction model,SNOMEDCT_US,Intellectual Product
PMC8411560,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8411560,nil,PROBLEM,PMC,C0442734,Nil,SNOMEDCT_US,Quantitative Concept
PMC8411560,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC8411560,standard procedures,TREATMENT,PMC,C4738289,Standard operating procedures inventory,LNC,Occupational Activity
PMC8411560,other conflicts of interest,PROBLEM,PMC,,,,
PMC3641289,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC3641289,the pancreatic cancer disease impact,PROBLEM,PMC,,,,
PMC3641289,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC3641289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3641289,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC3641289,numeric rating scales,TEST,PMC,C4050142,Numeric Rating Scale,MTH,Intellectual Product
PMC3641289,the relative weights,TEST,PMC,C2983690,Water Consumption Relative to Body Weight,NCI,Activity
PMC3641289,the scores,TEST,PMC,C0237855,Test scores,MTH,Qualitative Concept
PMC3641289,the nrs,TEST,PMC,C0721919,NRS Nasal,MMSL,"Organic Chemical, Pharmacologic Substance"
PMC3641289,the pacadi score,TEST,PMC,,,,
PMC3641289,edmonton symptom assessment system,TEST,PMC,C3472649,Edmonton Symptom Assessment System,SNOMEDCT_US,Intellectual Product
PMC3641289,the pacadi score,TEST,PMC,,,,
PMC3641289,paindiscomfort,PROBLEM,PMC,,,,
PMC3641289,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC3641289,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC3641289,boweldigestive problems,PROBLEM,PMC,,,,
PMC3641289,loss of appetite,PROBLEM,PMC,C3814874,Loss of Appetite question,MTH,Intellectual Product
PMC3641289,dry mouth,PROBLEM,PMC,C0043352,Xerostomia,MTH,Disease or Syndrome
PMC3641289,itchiness,PROBLEM,PMC,C3840668,Itchiness,LNC,Finding
PMC3641289,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC3641289,the pacadi score,TEST,PMC,,,,
PMC3641289,a mean,TEST,PMC,C2348143,Sample Mean,MTH,Quantitative Concept
PMC3641289,eq5d,TEST,PMC,,,,
PMC3641289,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC3641289,the pacadi score,TEST,PMC,,,,
PMC3641289,preliminary validation,TEST,PMC,,,,
PMC3641289,construct validity,TEST,PMC,C0681897,Construct Validity,NCI,Qualitative Concept
PMC3641289,further validation,TEST,PMC,C3844494,"Yes, patient was screened with a different standardized, validated assessment and the patient meets criteria for further evaluation for depression.",LNC,Finding
PMC3641289,supplementary material,TREATMENT,PMC,C2936424,Electronic Supplementary Materials,MSH,Intellectual Product
PMC3641289,the pacadi score,TEST,PMC,,,,
PMC3641289,preliminary validation,TEST,PMC,,,,
PMC3641289,construct validity,TEST,PMC,C0681897,Construct Validity,NCI,Qualitative Concept
PMC3641289,further validation,TEST,PMC,C3844494,"Yes, patient was screened with a different standardized, validated assessment and the patient meets criteria for further evaluation for depression.",LNC,Finding
PMC8218365,acute pancreatitis,PROBLEM,PMC,C0001339,"Pancreatitis, Acute",MSH,Disease or Syndrome
PMC8218365,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,three distinct pancreatic diseases,PROBLEM,PMC,,,,
PMC8218365,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC8218365,benign and malignant disease,PROBLEM,PMC,,,,
PMC8218365,ap,PROBLEM,PMC,C0002680,ampicillin,MTH,"Organic Chemical, Antibiotic"
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,presumed idiopathic ap,PROBLEM,PMC,,,,
PMC8218365,newonset diabetes mellitus,PROBLEM,PMC,,,,
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,ap,PROBLEM,PMC,C0002680,ampicillin,MTH,"Organic Chemical, Antibiotic"
PMC8218365,additional imaging,TEST,PMC,C5667574,Additional Imaging Features/Comments,NCI,Intellectual Product
PMC8218365,endoscopic ultrasonography,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,oncogenic mutations,PROBLEM,PMC,C1711381,RET gene mutation,MDR,Cell or Molecular Dysfunction
PMC8218365,hereditary cp,PROBLEM,PMC,,,,
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,autosomal dominant hereditary cp,PROBLEM,PMC,,,,
PMC8218365,known genetic mutations,PROBLEM,PMC,C3870428,AIP gene mutation analysis limited to known familial mutations:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC8218365,surveillance,TEST,PMC,C0684245,legal surveillance,MTH,Occupational Activity
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,pancreatic inflammation,PROBLEM,PMC,C0030305,Pancreatitis,MTH,Disease or Syndrome
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,a focal massforming lesion,PROBLEM,PMC,,,,
PMC8218365,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC8218365,the ductpenetrating sign,PROBLEM,PMC,,,,
PMC8218365,the ducttoparenchyma ratio,TEST,PMC,,,,
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC8218365,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC8218365,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8218365,underlying pdac,PROBLEM,PMC,,,,
PMC8218365,presumed idiopathic ap,PROBLEM,PMC,,,,
PMC8218365,newonset dm,PROBLEM,PMC,,,,
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,additional imaging,TEST,PMC,C5667574,Additional Imaging Features/Comments,NCI,Intellectual Product
PMC8218365,pdac,PROBLEM,PMC,,,,
PMC8218365,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC8218365,imaging modality,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,hereditary cp,PROBLEM,PMC,,,,
PMC8218365,pdac,PROBLEM,PMC,,,,
PMC8218365,oncogenic mutations,PROBLEM,PMC,C1711381,RET gene mutation,MDR,Cell or Molecular Dysfunction
PMC8218365,longstanding pancreatic inflammation,PROBLEM,PMC,,,,
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,pdac,PROBLEM,PMC,,,,
PMC8218365,autosomal dominant hereditary cp,PROBLEM,PMC,,,,
PMC8218365,known mutations,PROBLEM,PMC,C3258812,mutation analysis limited to known familial mutations,LNC,Laboratory Procedure
PMC8218365,pdac,PROBLEM,PMC,,,,
PMC8218365,surveillance,TEST,PMC,C0684245,legal surveillance,MTH,Occupational Activity
PMC8218365,chronic pancreatic inflammation,PROBLEM,PMC,,,,
PMC8218365,a focal mass,PROBLEM,PMC,C2021790,magnetic resonance imaging of abdomen: focal splenic mass,MEDCIN,Finding
PMC8218365,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC8218365,specific findings,PROBLEM,PMC,C0221564,Specific X-ray Findings,AIR,Finding
PMC8218365,the ductpenetrating sign,TEST,PMC,,,,
PMC8218365,the ducttoparenchyma ratio,TEST,PMC,,,,
PMC8218365,pancreatitis,PROBLEM,PMC,C0030305,Pancreatitis,MTH,Disease or Syndrome
PMC8218365,pdac,TEST,PMC,,,,
PMC8218365,machinelearning methods,TREATMENT,PMC,,,,
PMC8218365,pdac,TEST,PMC,,,,
PMC8218365,clinically useful technique,PROBLEM,PMC,,,,
PMC8218365,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8218365,pdac,PROBLEM,PMC,,,,
PMC8218365,future pdac,PROBLEM,PMC,,,,
PMC8218365,the diagnostic process,TEST,PMC,C1608472,Diagnostic/Screening Processes or Results,CPT,Finding
PMC6507030,oxaliplatin,TREATMENT,PMC,C0069717,oxaliplatin,MTH,"Organic Chemical, Pharmacologic Substance"
PMC6507030,irinotecan,TREATMENT,PMC,C0123931,irinotecan,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC6507030,5fluorouracil,TREATMENT,PMC,C0016360,fluorouracil,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC6507030,andlleucovorin,TREATMENT,PMC,,,,
PMC6507030,the firstline treatment options,TREATMENT,PMC,,,,
PMC6507030,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6507030,grade 3 or 4 adverse events,PROBLEM,PMC,,,,
PMC6507030,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC6507030,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6507030,a modified folfirinox regimen,TREATMENT,PMC,C4763557,Modified FOLFIRINOX Regimen,NCI,Therapeutic or Preventive Procedure
PMC6507030,a firstline chemotherapy,TREATMENT,PMC,,,,
PMC6507030,metastatic pc,PROBLEM,PMC,,,,
PMC6507030,primary metastatic pancreatic adenocarcinoma,PROBLEM,PMC,,,,
PMC6507030,an,TEST,PMC,C1423519,DIAPH3 gene,MTH,Gene or Genome
PMC6507030,the modified folfirinox regimen,TREATMENT,PMC,C4763557,Modified FOLFIRINOX Regimen,NCI,Therapeutic or Preventive Procedure
PMC6507030,irinotecan,TREATMENT,PMC,C0123931,irinotecan,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC6507030,5fluorouracil,TREATMENT,PMC,C0016360,fluorouracil,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC6507030,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC6507030,progressive disease pd,PROBLEM,PMC,,,,
PMC6507030,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC6507030,symptom deterioration,PROBLEM,PMC,C1821597,Monitors symptoms of vision deterioration,NOC,Finding
PMC6507030,unacceptable adverse events,PROBLEM,PMC,C4527409,Therapy-Related Toxicity - Unacceptable to Patient,NCI,Finding
PMC6507030,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC6507030,objective response rate,TEST,PMC,C0993770,Dual chamber rate responsive implantable cardiac pacemaker,SNOMEDCT_US,Medical Device
PMC6507030,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6507030,complete response,PROBLEM,PMC,C5203034,IMWG Complete Response,MTH,Finding
PMC6507030,partial responses,PROBLEM,PMC,C1521726,partial response,MTH,Finding
PMC6507030,sd,PROBLEM,PMC,C0332147,Suspected diagnosis,MTH,Qualitative Concept
PMC6507030,the orr,TEST,PMC,C1260880,Rhinorrhea,MTH,Sign or Symptom
PMC6507030,disease control rate,TEST,PMC,,,,
PMC6507030,the study cohort,TEST,PMC,C5960458,Study Cohort Name,NCI,Intellectual Product
PMC6507030,progressionfree survival,TEST,PMC,,,,
PMC6507030,major grade 3 or 4 adverse events,PROBLEM,PMC,,,,
PMC6507030,neutropenia,PROBLEM,PMC,C0027947,Neutropenia,MTH,Disease or Syndrome
PMC6507030,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC6507030,treatmentrelated death,PROBLEM,PMC,,,,
PMC6507030,modified folfirinox,TREATMENT,PMC,C4763557,Modified FOLFIRINOX Regimen,NCI,Therapeutic or Preventive Procedure
PMC6507030,firstline therapy,TREATMENT,PMC,,,,
PMC6507030,metastatic pc,PROBLEM,PMC,,,,
PMC6507030,trial registrationclinicaltrialsgovnct02028806,TEST,PMC,,,,
PMC6507030,modified folfirinox,TREATMENT,PMC,C4763557,Modified FOLFIRINOX Regimen,NCI,Therapeutic or Preventive Procedure
PMC6507030,firstline therapy,TREATMENT,PMC,,,,
PMC6507030,metastatic pc,PROBLEM,PMC,,,,
PMC6507030,trial registrationclinicaltrialsgovnct02028806,TEST,PMC,,,,
PMC6507030,this modified folfirinox,TREATMENT,PMC,,,,
PMC6507030,the original regimen,TREATMENT,PMC,,,,
PMC6507030,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC6507030,this modified folfirinox regimen,TREATMENT,PMC,,,,
PMC6507030,a promising firstline chemotherapy option,TREATMENT,PMC,,,,
PMC6507030,metastatic pc,PROBLEM,PMC,,,,
PMC11240790,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11240790,the most aggressive cancers,PROBLEM,PMC,,,,
PMC11240790,advanced or irresectable disease,PROBLEM,PMC,,,,
PMC11240790,radiological imaging modalities,TEST,PMC,C5151288,Abdomen | {Imaging modality} | Radiology,LNC,Body Location or Region
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC11240790,an assessment,TEST,PMC,C0028708,Nutrition Assessment,MTH,Diagnostic Procedure
PMC11240790,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11240790,small tumors,PROBLEM,PMC,C0475277,Small tumor,SNOMEDCT_US,Qualitative Concept
PMC11240790,computeraided detection,TEST,PMC,,,,
PMC11240790,artificial intelligence ai techniques,TREATMENT,PMC,,,,
PMC11240790,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11240790,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11240790,a deep learningbased tumor detection framework,TREATMENT,PMC,,,,
PMC11240790,pancreatic head cancer,PROBLEM,PMC,C0149954,adenocarcinoma of head of pancreas,MEDCIN,Neoplastic Process
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,a tumor detection framework,PROBLEM,PMC,,,,
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11240790,an increased detection accuracy,PROBLEM,PMC,,,,
PMC11240790,pancreatic head tumors,PROBLEM,PMC,,,,
PMC11240790,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11240790,optimal treatment,TREATMENT,PMC,C5696347,Obtaining respiratory data needed to develop the optimal radiation treatment,CPT,Health Care Activity
PMC11240790,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11240790,a tumor detection framework,PROBLEM,PMC,,,,
PMC11240790,pancreatic head tumors,PROBLEM,PMC,,,,
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,this retrospective research study,TEST,PMC,,,,
PMC11240790,ct images,TEST,PMC,C5785262,Number of CT Images Used in Session,NCI,Quantitative Concept
PMC11240790,pancreatic head cancer,PROBLEM,PMC,C0149954,adenocarcinoma of head of pancreas,MEDCIN,Neoplastic Process
PMC11240790,a multistage 3d unetbased approach,TREATMENT,PMC,,,,
PMC11240790,pdac detection,TEST,PMC,,,,
PMC11240790,clinically significant secondary features,PROBLEM,PMC,,,,
PMC11240790,pancreatic duct,PROBLEM,PMC,C0030288,Pancreatic duct,MTH,"Body Part, Organ, or Organ Component"
PMC11240790,a local test set,TEST,PMC,,,,
PMC11240790,59,TEST,PMC,C3830128,59 (qualifier value),MTH,Quantitative Concept
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,28 pancreatic cancer,PROBLEM,PMC,,,,
PMC11240790,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11240790,a sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11240790,pancreatic head cancer,PROBLEM,PMC,C0149954,adenocarcinoma of head of pancreas,MEDCIN,Neoplastic Process
PMC11240790,the local test set,TEST,PMC,,,,
PMC11240790,the external test set,TEST,PMC,,,,
PMC11240790,a sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11240790,the tumor location,PROBLEM,PMC,C5667396,Specify Tumor Location,NCI,Intellectual Product
PMC11240790,a dice similarity coefficient,TEST,PMC,,,,
PMC11240790,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11240790,a tumor detection framework,PROBLEM,PMC,,,,
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11240790,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11240790,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11240790,a tumor detection framework,PROBLEM,PMC,,,,
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11240790,an increased sensitivity,PROBLEM,PMC,C2346484,Increased Sensitivity,MTH,Phenomenon or Process
PMC11240790,pancreatic head tumors,PROBLEM,PMC,,,,
PMC11240790,the multistage detection models,TEST,PMC,,,,
PMC11240790,detailed duct and pancreas segmentation maps,TEST,PMC,,,,
PMC11240790,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11240790,tumor presence,PROBLEM,PMC,C5785865,Bladder Tumor Antigen [Presence] in Urine,NCI,Laboratory Procedure
PMC11240790,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11240790,ai algorithms,TREATMENT,PMC,,,,
PMC11240790,early pancreatic cancer,PROBLEM,PMC,,,,
PMC11240790,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC11240790,large multicenter datasets,TREATMENT,PMC,,,,
PMC11240790,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9602008,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC9602008,a descriptive crosssectional design,TEST,PMC,,,,
PMC9602008,the convenience sampling method,TEST,PMC,,,,
PMC9602008,a structured questionnaire,TEST,PMC,C5211437,"During the past 4W, working gives me structure in my life:Find:4W:^Patient:Ord:QWLQ-CS",LNC,Clinical Attribute
PMC9602008,the collected data,TEST,PMC,C5392850,Routinely Collected Data,MSH,Intellectual Product
PMC9602008,the spss,TREATMENT,PMC,,,,
PMC9602008,amos,TREATMENT,PMC,C4277666,Antagomirs,MSH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9602008,social support intervention programs,TREATMENT,PMC,,,,
PMC9602008,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,a nursing intervention plan,TREATMENT,PMC,,,,
PMC9602008,writing evaluation,TEST,PMC,C0516518,Write trial criteria to be used during the evaluation,NIC,Health Care Activity
PMC9602008,nursing care,TREATMENT,PMC,C0028682,Nursing care (regime/therapy),MTH,Health Care Activity
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,nursing intervention strategies,TREATMENT,PMC,,,,
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9602008,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9602008,social support intervention programs,TREATMENT,PMC,,,,
PMC9602008,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC9602008,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9451139,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9451139,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9451139,a high diseasespecific burden of symptoms,PROBLEM,PMC,,,,
PMC9451139,palliative chemotherapy,TREATMENT,PMC,C5556542,Palliative Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC9451139,varying side effects,PROBLEM,PMC,,,,
PMC9451139,standard oncological treatment,TREATMENT,PMC,,,,
PMC9451139,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9451139,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9451139,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9451139,this retrospective study,TEST,PMC,,,,
PMC9451139,histopathologically verified,PROBLEM,PMC,,,,
PMC9451139,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC9451139,palliative chemotherapy,TREATMENT,PMC,C5556542,Palliative Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC9451139,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9451139,spc,TREATMENT,PMC,C1442758,SFTPC gene,MTH,Gene or Genome
PMC9451139,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9451139,the last palliative chemotherapy treatment,TREATMENT,PMC,,,,
PMC9451139,median,TREATMENT,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC9451139,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9451139,futile palliative chemotherapy,TREATMENT,PMC,,,,
PMC9451139,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9451139,enrollment,TREATMENT,PMC,C1516879,Enrollment,MTH,Health Care Activity
PMC9451139,spc,TREATMENT,PMC,C1442758,SFTPC gene,MTH,Gene or Genome
PMC9451139,this retrospective study,TEST,PMC,,,,
PMC9451139,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9451139,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9451139,futile palliative chemotherapy,TREATMENT,PMC,,,,
PMC9451139,spc,PROBLEM,PMC,C1442758,SFTPC gene,MTH,Gene or Genome
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC11978711,intractable pain,PROBLEM,PMC,C0030200,"Pain, Intractable",MSH,Sign or Symptom
PMC11978711,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC11978711,palliation,TREATMENT,PMC,C0679251,disease palliation,AOD,Finding
PMC11978711,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,consecutive national cohort study,TEST,PMC,,,,
PMC11978711,symptom distress,PROBLEM,PMC,C4084760,Symptom Distress Scale,MTH,Intellectual Product
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,pain and appetite,PROBLEM,PMC,C0510081,"Determine the effect of the pain experience on quality of life (e.g., sleep, appetite, activity, cognition, mood, relationships, job performance, and role responsibilities)",NIC,Health Care Activity
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC11978711,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC11978711,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11978711,psychologicalspiritual issues,PROBLEM,PMC,,,,
PMC11978711,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11978711,appetiterelated distress,PROBLEM,PMC,,,,
PMC11978711,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11978711,community or,TEST,PMC,C0009462,Community,MSH,Group
PMC11978711,pain distress,PROBLEM,PMC,C1821295,Pain distress level,MTH,Finding
PMC11978711,increased mild appetiterelated distress,PROBLEM,PMC,,,,
PMC11978711,decreased moderate  22,PROBLEM,PMC,,,,
PMC11978711,severe  11 distress,PROBLEM,PMC,,,,
PMC11978711,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11978711,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11978711,prevalent distress,PROBLEM,PMC,,,,
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,australian palliative care,TREATMENT,PMC,,,,
PMC11978711,optimised referrals,TREATMENT,PMC,,,,
PMC11978711,strategies,TREATMENT,PMC,C0679199,Strategy,NCI,Mental Process
PMC11978711,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11978711,appetiterelated concerns,PROBLEM,PMC,,,,
PMC11978711,improved care,TREATMENT,PMC,C4715369,Instruction to improve participation in care,NOC,Finding
PMC11978711,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11978711,prevalent distress,PROBLEM,PMC,,,,
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,australian palliative care,TREATMENT,PMC,,,,
PMC11978711,optimised referrals,TREATMENT,PMC,,,,
PMC11978711,strategies,TREATMENT,PMC,C0679199,Strategy,NCI,Mental Process
PMC11978711,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11978711,appetiterelated concerns,PROBLEM,PMC,,,,
PMC11978711,improved care,TREATMENT,PMC,C4715369,Instruction to improve participation in care,NOC,Finding
PMC11978711,our analysis,TEST,PMC,,,,
PMC11978711,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC11978711,distress levels from pain,PROBLEM,PMC,,,,
PMC11978711,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,psychological and spiritual issues,PROBLEM,PMC,,,,
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,holistic care approaches,TREATMENT,PMC,,,,
PMC11978711,pain severity,PROBLEM,PMC,C1507013,Pain severity,MTH,Clinical Attribute
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,patientcentred care,TREATMENT,PMC,,,,
PMC11978711,tailoring effective pain management interventions,TREATMENT,PMC,,,,
PMC11978711,reported pain,PROBLEM,PMC,C5934469,Reported pain intensity,NOC,Finding
PMC11978711,distress,PROBLEM,PMC,C0231303,Distress,MTH,Mental Process
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11978711,targeted strategies,TREATMENT,PMC,C0511843,Incorporate strategies to enhance self-esteem of target audience,NIC,Educational Activity
PMC11978711,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC11978711,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7403883,stage iii t4n1m0 unresectable pancreatic adenocarcinoma,PROBLEM,PMC,,,,
PMC7403883,percutaneous,TREATMENT,PMC,C0522523,Percutaneous,MTH,Spatial Concept
PMC7403883,ire,TEST,PMC,C5575096,irreversible electroporation (treatment),MTH,Therapeutic or Preventive Procedure
PMC7403883,severe abdominal pain,PROBLEM,PMC,C5784886,Severity of Abdominal Pain,NCI,Intellectual Product
PMC7403883,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC7403883,assessment,TEST,PMC,C0549070,Assessment: Coping,MTH,Health Care Activity
PMC7403883,his symptoms,PROBLEM,PMC,C4712283,"Instruct patient on how to manage his or her illness symptoms, if appropriate",NIC,Health Care Activity
PMC7403883,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC7403883,severe duodenal wall thickening,PROBLEM,PMC,,,,
PMC7403883,local inflammatory changes,PROBLEM,PMC,,,,
PMC7403883,duodenal infarction,PROBLEM,PMC,,,,
PMC7403883,imaging features,TEST,PMC,C5667574,Additional Imaging Features/Comments,NCI,Intellectual Product
PMC7403883,conservative management,TREATMENT,PMC,C0459914,Conservative Treatment,MSH,Therapeutic or Preventive Procedure
PMC7403883,better pain management,TREATMENT,PMC,,,,
PMC7403883,the clinical symptoms,PROBLEM,PMC,C3483785,Clinical sepsis symptoms present,LNC,Finding
PMC7403883,imaging features,TEST,PMC,C5667574,Additional Imaging Features/Comments,NCI,Intellectual Product
PMC7403883,severe duodenal swelling,PROBLEM,PMC,,,,
PMC7403883,ire,TEST,PMC,C5575096,irreversible electroporation (treatment),MTH,Therapeutic or Preventive Procedure
PMC7403883,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC7403883,duodenal infarction,PROBLEM,PMC,,,,
PMC7403883,appropriate clinical management,TREATMENT,PMC,,,,
PMC7403883,severe duodenal thickeningswelling,PROBLEM,PMC,,,,
PMC7403883,duodenal thickening,PROBLEM,PMC,C2021908,MRI of alimentary tract: thickening of duodenal wall,MEDCIN,Finding
PMC7403883,duodenal infarction,PROBLEM,PMC,,,,
PMC7403883,conservative management,TREATMENT,PMC,C0459914,Conservative Treatment,MSH,Therapeutic or Preventive Procedure
PMC12149456,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12149456,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC12149456,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC12149456,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC12149456,the pancan registry,TREATMENT,PMC,,,,
PMC12149456,patientreported outcomes data,TEST,PMC,,,,
PMC12149456,statistical analyses,TEST,PMC,C0015483,"Factor Analysis, Statistical",MSH,Quantitative Concept
PMC12149456,a relatively small sample size,PROBLEM,PMC,,,,
PMC12149456,participants,TREATMENT,PMC,C0679646,Participant,MTH,Population Group
PMC12149456,data analysis,TEST,PMC,C0010992,Data Analysis,MSH,Occupational Activity
PMC12149456,bivariate analysis,TEST,PMC,C0681927,bivariate analysis,AOD,Quantitative Concept
PMC12149456,the chisquare test,TEST,PMC,,,,
PMC12149456,categorical variables,TEST,PMC,C0814916,longitudinal analysis for categorical variables,AOD,Qualitative Concept
PMC12149456,withpvalues,TEST,PMC,,,,
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,the painrelated,PROBLEM,PMC,,,,
PMC12149456,the general assessment survey,TEST,PMC,C0451286,Medical outcomes study short form general health survey,SNOMEDCT_US,Intellectual Product
PMC12149456,a marginally significant,PROBLEM,PMC,,,,
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC12149456,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12149456,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC12149456,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12149456,clinical practice,TREATMENT,PMC,C2986419,Good Clinical Practice,MTH,Intellectual Product
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC12149456,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC12149456,their cancer,PROBLEM,PMC,C5707026,My Family or Friends Had to Permanently Quit Their Job to Help with My Care Needs Because of My Cancer Diagnosis or Treatment,NCI,Intellectual Product
PMC12149456,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12149456,clinical practice,TREATMENT,PMC,C2986419,Good Clinical Practice,MTH,Intellectual Product
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC12149456,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC12149456,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC12149456,their cancer,PROBLEM,PMC,C5707026,My Family or Friends Had to Permanently Quit Their Job to Help with My Care Needs Because of My Cancer Diagnosis or Treatment,NCI,Intellectual Product
PMC6722558,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6722558,a catastrophic disease,PROBLEM,PMC,,,,
PMC6722558,high recurrence,PROBLEM,PMC,C2979955,high risk of prostate cancer recurrence,MTH,Finding
PMC6722558,death rates,PROBLEM,PMC,C0205848,Death Rate,MTH,Quantitative Concept
PMC6722558,early treatment,TREATMENT,PMC,C0814494,early treatment phase,AOD,Health Care Activity
PMC6722558,many cancer types,PROBLEM,PMC,,,,
PMC6722558,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6722558,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6722558,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC6722558,early pancreatic cancermethods,PROBLEM,PMC,,,,
PMC6722558,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6722558,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC6722558,surveillance strategy,TEST,PMC,C5912527,"Use technology strategies such as pressure pads, locating devices, door alarms, surveillance, and wandering detection devices for elopement concerns",NIC,Health Care Activity
PMC6722558,the symptom group,PROBLEM,PMC,C2127007,multiple skin blisters grouped on red base,MEDCIN,Finding
PMC6722558,the imaging group,TEST,PMC,C1512630,Imaging Sciences Working Group,NCI,Professional or Occupational Group
PMC6722558,the marker group,TEST,PMC,,,,
PMC6722558,carcinoembryonic antigen,TEST,PMC,C0007082,Carcinoembryonic Antigen,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC6722558,tumor marker assessment,TEST,PMC,,,,
PMC6722558,overall,TEST,PMC,C1561607,Overall,MTH,Qualitative Concept
PMC6722558,relapsefree survival,TEST,PMC,,,,
PMC6722558,postrecurrence,PROBLEM,PMC,,,,
PMC6722558,documented recurrence,PROBLEM,PMC,C5974336,Patients with documentation of an exam performed for recurrence of melanoma,HCPCS,Finding
PMC6722558,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC6722558,our analysis,TEST,PMC,,,,
PMC6722558,the symptom group,PROBLEM,PMC,C2127007,multiple skin blisters grouped on red base,MEDCIN,Finding
PMC6722558,imaging group,TEST,PMC,C1512630,Imaging Sciences Working Group,NCI,Professional or Occupational Group
PMC6722558,surveillance,TEST,PMC,C0684245,legal surveillance,MTH,Occupational Activity
PMC6722558,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC6722558,tumor markers,TEST,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC6722558,multivariate analyses,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC6722558,significant difference,PROBLEM,PMC,,,,
PMC6722558,median,TEST,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC6722558,imaging group,TEST,PMC,C1512630,Imaging Sciences Working Group,NCI,Professional or Occupational Group
PMC6722558,median pros,TEST,PMC,,,,
PMC6722558,imaging group,TEST,PMC,C1512630,Imaging Sciences Working Group,NCI,Professional or Occupational Group
PMC6722558,multivariate analyses,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC6722558,poor eastern cooperative oncology group performance status,PROBLEM,PMC,,,,
PMC6722558,primary tumor site,PROBLEM,PMC,C0475447,Site of primary tumor,SNOMEDCT_US,Finding
PMC6722558,tumor grade,PROBLEM,PMC,C0475271,Tumor grade G3,MTH,Classification
PMC6722558,poor prognostic factors,PROBLEM,PMC,,,,
PMC6722558,regular imaging,TEST,PMC,,,,
PMC6722558,tumor marker,PROBLEM,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC6722558,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6722558,curative tumor resection,TREATMENT,PMC,,,,
PMC6722558,our study,TEST,PMC,,,,
PMC6722558,early treatment,TREATMENT,PMC,C0814494,early treatment phase,AOD,Health Care Activity
PMC6722558,recurrent pancreatic cancer,PROBLEM,PMC,C0854777,Pancreatic carcinoma recurrent,MDR,Neoplastic Process
PMC6722558,surveillance,TEST,PMC,C0684245,legal surveillance,MTH,Occupational Activity
PMC6722558,assessment,TEST,PMC,C0549070,Assessment: Coping,MTH,Health Care Activity
PMC6722558,signs and symptoms,PROBLEM,PMC,C0037088,Signs and Symptoms,MTH,Sign or Symptom
PMC6722558,recurrence,PROBLEM,PMC,C0034897,Recurrence,MTH,Phenomenon or Process
PMC6722558,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC6722558,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6722558,the standard surveillance strategy,TREATMENT,PMC,,,,
PMC6722558,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC6722558,new systemic and local treatments,TREATMENT,PMC,,,,
PMC6722558,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,elusive early symptoms,PROBLEM,PMC,,,,
PMC11504279,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC11504279,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC11504279,treatment responses,TREATMENT,PMC,C0438286,Absent response to treatment,MTH,Finding
PMC11504279,hypoxia,PROBLEM,PMC,C0242184,Hypoxia,MTH,Pathologic Function
PMC11504279,immunosuppression,TREATMENT,PMC,C4048329,Immunosuppression,MTH,Disease or Syndrome
PMC11504279,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11504279,hypoxiarelated genes,PROBLEM,PMC,,,,
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,gene expression data,TEST,PMC,,,,
PMC11504279,the cancer,TEST,PMC,C0153567,Uterine Cancer,MTH,Neoplastic Process
PMC11504279,subsequent gokegg enrichment analysis,TEST,PMC,,,,
PMC11504279,hypoxiarelated pathways,PROBLEM,PMC,,,,
PMC11504279,lasso regression,TREATMENT,PMC,,,,
PMC11504279,expression levels,TEST,PMC,C3836899,"MAAA with mRNA expression levels, 161 genes, hepatocellular carcinoma tissue, for hepatic cancer risk",MEDCIN,Laboratory Procedure
PMC11504279,plau,TEST,PMC,C1335224,PLAU gene,MTH,Gene or Genome
PMC11504279,ca9,TEST,PMC,C1413052,CA9 gene,MTH,Gene or Genome
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,the prognostic model,TEST,PMC,C1514306,Predictive Cancer Model,NCI,Experimental Model of Disease
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,the established hypoxiarelated prognostic model,PROBLEM,PMC,,,,
PMC11504279,rtqpcr,TEST,PMC,,,,
PMC11504279,notable differences,PROBLEM,PMC,,,,
PMC11504279,hypoxia pathwayrelated,PROBLEM,PMC,,,,
PMC11504279,hypoxictreated panc1 cells,PROBLEM,PMC,,,,
PMC11504279,our study,TEST,PMC,,,,
PMC11504279,the hypoxic microenvironment,PROBLEM,PMC,,,,
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,clinical application,TREATMENT,PMC,C1880106,Clinical Nanoparticle Application,NCI,Health Care Activity
PMC11504279,our study,TEST,PMC,,,,
PMC11504279,the hypoxic microenvironment,PROBLEM,PMC,,,,
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,clinical application,TREATMENT,PMC,C1880106,Clinical Nanoparticle Application,NCI,Health Care Activity
PMC11504279,hypoxia,PROBLEM,PMC,C0242184,Hypoxia,MTH,Pathologic Function
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,immune infiltration,PROBLEM,PMC,C4531202,Myocardial immune cell infiltration,HPO,Finding
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,hypoxia,PROBLEM,PMC,C0242184,Hypoxia,MTH,Pathologic Function
PMC11504279,immune infiltration,PROBLEM,PMC,C4531202,Myocardial immune cell infiltration,HPO,Finding
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11504279,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC11504279,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9459213,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC9459213,a standard firstline drug,TREATMENT,PMC,,,,
PMC9459213,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9459213,prolong survival time,TREATMENT,PMC,,,,
PMC9459213,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,a systematic review,TEST,PMC,C1955832,Systematic Review,MSH,Intellectual Product
PMC9459213,rcts,TEST,PMC,C4043509,RCT-18 fusion protein,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9459213,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC9459213,review manager,TREATMENT,PMC,C5914363,Review strategies for managing medication regimen,NIC,Health Care Activity
PMC9459213,hazard ratio,TEST,PMC,C2985465,Hazard Ratio,NCI,Quantitative Concept
PMC9459213,odds ratio,TEST,PMC,C0028873,Odds Ratio,MTH,Quantitative Concept
PMC9459213,quality assessment,TEST,PMC,C0086887,Healthcare Quality Assessment,MSH,Qualitative Concept
PMC9459213,individual study,TEST,PMC,C0681857,individual as study subject,AOD,Population Group
PMC9459213,17 studies,TEST,PMC,C0485803,Service comment 17:Imp:Pt:XXX:Nom,MTH,Clinical Attribute
PMC9459213,this analysis,TEST,PMC,,,,
PMC9459213,the pooled,TEST,PMC,C5235128,Sex Pooled Sample,MTH,Body Substance
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,progressionfree survival,PROBLEM,PMC,,,,
PMC9459213,hr,TEST,PMC,C0439227,Hour,MTH,Temporal Concept
PMC9459213,overall response rate,TEST,PMC,C5958776,Myelodysplastic Syndrome Overall Response Rate,NCI,Quantitative Concept
PMC9459213,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC9459213,subgroup analysis,TEST,PMC,,,,
PMC9459213,gem,TREATMENT,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,capecitabine,TREATMENT,PMC,C0671970,capecitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC9459213,gem plus s1,TREATMENT,PMC,,,,
PMC9459213,gem,TREATMENT,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,gem,TREATMENT,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,cisplatin,TREATMENT,PMC,C0008838,cisplatin,MTH,"Pharmacologic Substance, Inorganic Chemical"
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,aes,PROBLEM,PMC,C2699274,Scanning Auger Spectrometer,MTH,Research Device
PMC9459213,leukopenia,PROBLEM,PMC,C0023530,Leukopenia,MTH,Disease or Syndrome
PMC9459213,neutropenia,PROBLEM,PMC,C0027947,Neutropenia,MTH,Disease or Syndrome
PMC9459213,anemia,PROBLEM,PMC,C0002871,Anemia,MTH,Disease or Syndrome
PMC9459213,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC9459213,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC9459213,stomatitis,PROBLEM,PMC,C0038362,Stomatitis,MTH,Disease or Syndrome
PMC9459213,publication bias,PROBLEM,PMC,C0206086,Publication Bias,MSH,Qualitative Concept
PMC9459213,our metaanalysis,TEST,PMC,,,,
PMC9459213,our study,TEST,PMC,,,,
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,gem,TREATMENT,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,aes,PROBLEM,PMC,C2699274,Scanning Auger Spectrometer,MTH,Research Device
PMC9459213,the appropriate combination therapy,TREATMENT,PMC,,,,
PMC9459213,this metaanalysis,TEST,PMC,,,,
PMC9459213,pfs,TEST,PMC,C5890237,Piper Fatigue Scale,MTH,Intellectual Product
PMC9459213,survival,TEST,PMC,C0220921,survival aspects,MTH,Functional Concept
PMC9459213,gembased combination therapy,TREATMENT,PMC,,,,
PMC9459213,the aes,PROBLEM,PMC,C1412268,TLE5 gene,MTH,Gene or Genome
PMC9459213,subgroup analysis,TEST,PMC,,,,
PMC9459213,gem,TREATMENT,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,cap,TREATMENT,PMC,C4522312,CAP1 gene,MTH,Gene or Genome
PMC9459213,gem,TREATMENT,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,gem,TEST,PMC,C0018966,Heme,MTH,"Organic Chemical, Biologically Active Substance"
PMC9459213,cis,TEST,PMC,C5574375,Cisgender,MTH,Finding
PMC9459213,the combination therapy,TREATMENT,PMC,C0013218,Combination Drug Therapy,MTH,Therapeutic or Preventive Procedure
PMC9459213,the high rate of aes,PROBLEM,PMC,,,,
PMC9459213,latent economic problems,PROBLEM,PMC,,,,
PMC9459213,further study,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC10093482,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10093482,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC10093482,high rates of metastasis,PROBLEM,PMC,,,,
PMC10093482,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC10093482,a complex multistep process,PROBLEM,PMC,,,,
PMC10093482,many dynamic changes in cellular shape,PROBLEM,PMC,,,,
PMC10093482,adhesion,PROBLEM,PMC,C0001511,Tissue Adhesions,MTH,Pathologic Function
PMC10093482,bulk tumors,PROBLEM,PMC,C5707744,Anatomic Site of Maximum Tumor Bulk,NCI,Spatial Concept
PMC10093482,the cell biological processes,PROBLEM,PMC,,,,
PMC10093482,tumor cell invasion,PROBLEM,PMC,C1269955,Tumor Cell Invasion,MTH,Neoplastic Process
PMC10093482,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10093482,inhibiting metastasis,PROBLEM,PMC,C3813373,LINC01089 gene,MTH,Gene or Genome
PMC10093482,cancer therapy,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC10093482,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10093482,cancerrelated mortality,PROBLEM,PMC,,,,
PMC10093482,routine screening protocols,TEST,PMC,,,,
PMC10093482,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10093482,earlystage disease,PROBLEM,PMC,,,,
PMC10093482,effective treatment options,TREATMENT,PMC,,,,
PMC10093482,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10093482,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10093482,metastasis in pdac,PROBLEM,PMC,,,,
PMC10093482,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC10093482,tumor cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC10093482,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC10093482,a secondary tumor,PROBLEM,PMC,C2712918,secondary carcinoid tumor,MEDCIN,Neoplastic Process
PMC10093482,tumor cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC10093482,an enhanced ability,PROBLEM,PMC,C4062215,Expresses desire to enhance ability to set achievable goals,NANDA-I,Finding
PMC10093482,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC10093482,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC10093482,the various,PROBLEM,PMC,C3540765,various allergen extracts,MTH,"Pharmacologic Substance, Immunologic Factor"
PMC10093482,matrix proteins,PROBLEM,PMC,C0042731,Viral Matrix Proteins,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC10093482,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC10093482,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC10093482,pdac,TEST,PMC,,,,
PMC10093482,the metastatic cascade,PROBLEM,PMC,,,,
PMC10093482,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10093482,epithelialtomesenchymal transition,PROBLEM,PMC,,,,
PMC10093482,pdac,PROBLEM,PMC,,,,
PMC10093482,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC10093482,pdac cells,PROBLEM,PMC,,,,
PMC10093482,cancer cell motility,PROBLEM,PMC,C3826624,Cancer cells--Motility,LCH_NW,Cell
PMC10093482,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC10093482,these invasive processes,PROBLEM,PMC,,,,
PMC10093482,pdac,PROBLEM,PMC,,,,
PMC10093482,halting metastatic dissemination,PROBLEM,PMC,,,,
PMC10093482,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC10093482,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC10093482,emt in pdac,PROBLEM,PMC,,,,
PMC10093482,classical transcriptional emt,PROBLEM,PMC,,,,
PMC10093482,metastatic dissemination,PROBLEM,PMC,C0339399,Metastatic disseminated retinitis,SNOMEDCT_US,Disease or Syndrome
PMC10093482,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC10093482,metastatic cell biology,PROBLEM,PMC,,,,
PMC10093482,functional invadopodia,PROBLEM,PMC,,,,
PMC10093482,lamellipodia,PROBLEM,PMC,C0230628,Lamellipodia,MSH,Cell Component
PMC10093482,focal adhesions,PROBLEM,PMC,C0887870,Focal Adhesions,MTH,Cell Component
PMC10093482,pdac cells,PROBLEM,PMC,,,,
PMC10093482,invadopodia,PROBLEM,PMC,C2248020,Podosomes,MSH,Cell Component
PMC10093482,focal adhesions,PROBLEM,PMC,C0887870,Focal Adhesions,MTH,Cell Component
PMC10093482,other processes,PROBLEM,PMC,C0335587,Other metal processers,SNMI,Professional or Occupational Group
PMC10093482,the tme,TEST,PMC,C5783677,Xerna TME Panel,NCI,Laboratory Procedure
PMC10093482,matrix degradation,PROBLEM,PMC,C1517052,Extracellular Matrix Degradation,NCI,Cell Function
PMC10093482,invadopodial versus noninvadopodial ecm degradation,PROBLEM,PMC,,,,
PMC10093482,pdac metastasis,PROBLEM,PMC,,,,
PMC10093482,ecm degradation,PROBLEM,PMC,,,,
PMC10093482,the tme,TEST,PMC,C5783677,Xerna TME Panel,NCI,Laboratory Procedure
PMC10093482,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC10093482,invadopodia,PROBLEM,PMC,C2248020,Podosomes,MSH,Cell Component
PMC10093482,focal adhesions,PROBLEM,PMC,C0887870,Focal Adhesions,MTH,Cell Component
PMC10093482,early metastatic dissemination,PROBLEM,PMC,,,,
PMC10093482,future studies,TEST,PMC,,,,
PMC10093482,cancer cell migration,PROBLEM,PMC,C5551205,PCAT29 wt Allele,MTH,Gene or Genome
PMC10093482,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC10093482,unique markers,PROBLEM,PMC,,,,
PMC10093482,invadopodia,PROBLEM,PMC,C2248020,Podosomes,MSH,Cell Component
PMC10093482,focal adhesions in vivo,PROBLEM,PMC,,,,
PMC10093482,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,an aggressive malignancy,PROBLEM,PMC,C1112486,Aggressive Systemic Mastocytosis,MTH,Neoplastic Process
PMC5372906,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC5372906,its treatment,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC5372906,significant nutritional impairments,PROBLEM,PMC,,,,
PMC5372906,both exocrine and endocrine functions,PROBLEM,PMC,,,,
PMC5372906,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC5372906,pancreatic exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC5372906,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5372906,steatorrhea,PROBLEM,PMC,C0038238,Steatorrhea,MSH,Finding
PMC5372906,endocrine insufficiency,PROBLEM,PMC,C5232863,"Pancreatic endocrine insufficiency, mild",OMIM,Disease or Syndrome
PMC5372906,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC5372906,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC5372906,pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC5372906,these dysfunctions,PROBLEM,PMC,,,,
PMC5372906,nutritional and metabolic dysfunctions,PROBLEM,PMC,,,,
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,nutritional support,TREATMENT,PMC,C0242739,Nutritional Support,MTH,Therapeutic or Preventive Procedure
PMC5372906,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC5372906,nutritional support,TREATMENT,PMC,C0242739,Nutritional Support,MTH,Therapeutic or Preventive Procedure
PMC5372906,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,these investigations,TEST,PMC,,,,
PMC5372906,nutritional support,TREATMENT,PMC,C0242739,Nutritional Support,MTH,Therapeutic or Preventive Procedure
PMC5372906,pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC5372906,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC5372906,conservative perioperative strategies,TREATMENT,PMC,,,,
PMC5372906,albumin,TEST,PMC,C5966160,Albumin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC5372906,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5372906,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5372906,aggressive nutrition supplementation,TREATMENT,PMC,,,,
PMC5372906,albumin,TEST,PMC,C5966160,Albumin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC5372906,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5372906,nutrition supplementation,TREATMENT,PMC,C2698845,Nutritional Supplement Drink,MTH,Food
PMC5372906,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5372906,enteral nutrition,TREATMENT,PMC,C0014327,Enteral Nutrition,MTH,Therapeutic or Preventive Procedure
PMC5372906,a nutritional intervention,TREATMENT,PMC,C1882127,Nutritional Intervention,NCI,Health Care Activity
PMC5372906,total parenteral nutrition,TREATMENT,PMC,C2064719,infusion of total parenteral nutrition,MTH,Therapeutic or Preventive Procedure
PMC5372906,a multidisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC5372906,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5372906,endocrine and exocrine pancreatic insufficiency,PROBLEM,PMC,,,,
PMC5372906,appropriate treatment,TREATMENT,PMC,C3640049,Appropriate Treatment,NCI,Clinical Attribute
PMC5372906,postoperative care,TREATMENT,PMC,C0032786,Postoperative Care,MSH,Health Care Activity
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,benign pancreatic disease,PROBLEM,PMC,,,,
PMC5372906,several conservative recommendations,TREATMENT,PMC,,,,
PMC5372906,hypoalbuminemia,PROBLEM,PMC,C0239981,Hypoalbuminemia,MTH,Disease or Syndrome
PMC5372906,10 weight loss,PROBLEM,PMC,C4086030,Body Weight Loss Exceeding 10 Pounds,NCI,Intellectual Product
PMC5372906,these markers,TEST,PMC,,,,
PMC5372906,the preoperative nutritional optimization,TREATMENT,PMC,,,,
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,surgical complications,PROBLEM,PMC,C0221082,Surgical Complication,NCI,Pathologic Function
PMC5372906,morbidity,PROBLEM,PMC,C0220880,morbidity aspects,MTH,Intellectual Product
PMC5372906,albumin levels,TEST,PMC,C0428519,Albumin level - finding,MTH,Laboratory or Test Result
PMC5372906,greater morbidity,PROBLEM,PMC,,,,
PMC5372906,an albumin level,TEST,PMC,C0587185,Urine albumin level,MTH,Laboratory or Test Result
PMC5372906,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5372906,intense nutritional intervention,TREATMENT,PMC,,,,
PMC5372906,postoperative complications,PROBLEM,PMC,C0032787,Postoperative Complications,MSH,Pathologic Function
PMC5372906,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5372906,serum markers,TEST,PMC,C0162491,Serum Markers,MSH,Qualitative Concept
PMC5372906,functional status,TEST,PMC,C0598463,Functional Status,MTH,Finding
PMC5372906,moderately decreased albumin levels,PROBLEM,PMC,,,,
PMC5372906,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5372906,nutritional supplementation,TREATMENT,PMC,C0242297,Dietary Supplementation,MTH,Therapeutic or Preventive Procedure
PMC5372906,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5372906,undesirable patient outcomes,PROBLEM,PMC,,,,
PMC5372906,an insufficient nutritional intervention,TREATMENT,PMC,,,,
PMC5372906,fjts,TREATMENT,PMC,,,,
PMC5372906,complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC5372906,the albumin level,TEST,PMC,C0728877,Serum albumin level,MTH,Laboratory or Test Result
PMC5372906,fjts,TREATMENT,PMC,,,,
PMC5372906,preoperative hypoalbuminemia,PROBLEM,PMC,,,,
PMC5372906,an anticipated,PROBLEM,PMC,C3841702,Not anticipated,LNC,Finding
PMC5372906,oral feeding difficulty,PROBLEM,PMC,,,,
PMC5372906,other preoperative screening substances,TEST,PMC,,,,
PMC5372906,prealbumin,TEST,PMC,C0032923,Prealbumin,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5372906,creactive protein,TEST,PMC,,,,
PMC5372906,fasting blood glucose,TEST,PMC,C1261430,Fasting blood glucose level,MTH,Laboratory or Test Result
PMC5372906,hemoglobin a,TEST,PMC,C0019016,Hemoglobin A,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5372906,fecal elastase,TEST,PMC,C4748912,Low fecal elastase,OMIM,Finding
PMC5372906,such screening,TEST,PMC,C1978523,"Maternal screen for fetal abnormalities such as Open Neural Tube Defects, Trisomy 21 or Trisomy 18 panel",MTH,Laboratory Procedure
PMC5372906,appropriate enzyme supplementation,TREATMENT,PMC,,,,
PMC5372906,glucose management,TREATMENT,PMC,C1638311,Blood glucose management,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC5372906,worsening function,PROBLEM,PMC,C2024790,cardiovascular surgery result: left ventricular function worse,MEDCIN,Finding
PMC5372906,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5372906,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC5372906,hypoglycemic events,PROBLEM,PMC,C0342312,Hypoglycemic event due to diabetes,SNOMEDCT_US,Disease or Syndrome
PMC5372906,malabsorption,PROBLEM,PMC,C3714745,Malabsorption,MTH,Finding
PMC5372906,enzyme insufficiency,PROBLEM,PMC,,,,
PMC5372906,endocrine function,TEST,PMC,C0678896,Endocrine function,MTH,Physiologic Function
PMC5372906,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5372906,medication changes,TREATMENT,PMC,C2020507,stopped medication because of mental changes,MEDCIN,Finding
PMC5372906,vitamins,TREATMENT,PMC,C0042890,Vitamins,MTH,"Organic Chemical, Pharmacologic Substance, Vitamin"
PMC5372906,fatsoluble vitamins,TREATMENT,PMC,,,,
PMC5372906,vitamin b12,TREATMENT,PMC,C0042845,vitamin B12,MTH,"Organic Chemical, Pharmacologic Substance, Vitamin"
PMC5372906,micronutrients,TREATMENT,PMC,C0282575,Micronutrients,MTH,Biologically Active Substance
PMC5372906,zinc and iron,TREATMENT,PMC,C1153281,"zinc, iron permease activity",GO,Molecular Function
PMC5372906,postoperative malabsorption,PROBLEM,PMC,C0341308,Post-surgical malabsorption,SNOMEDCT_US,Disease or Syndrome
PMC5372906,supplementation,TREATMENT,PMC,C0242297,Dietary Supplementation,MTH,Therapeutic or Preventive Procedure
PMC5372906,exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC5372906,the assessment,TEST,PMC,C0028708,Nutrition Assessment,MTH,Diagnostic Procedure
PMC5372906,multiple components,TEST,PMC,C0492983,"APPLIANCE, FIXATION, NAIL/BLADE/PLATE COMBINATION, MULTIPLE COMPONENT",SPN,Medical Device
PMC5372906,fecal elastase,TEST,PMC,C4748912,Low fecal elastase,OMIM,Finding
PMC5372906,exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC5372906,integrating diarrheal symptoms,PROBLEM,PMC,,,,
PMC5372906,fecal fat levels,TEST,PMC,C0474696,Fecal fat level - finding,SNOMEDCT_US,Laboratory or Test Result
PMC5372906,fatsoluble,TREATMENT,PMC,,,,
PMC5372906,appropriate synthetic enzyme supplementation,TREATMENT,PMC,,,,
PMC5372906,a dual exocrine and endocrine gland,PROBLEM,PMC,,,,
PMC5372906,absorption of nutrients,TREATMENT,PMC,C1961155,nutrient absorption,CHV,Physiologic Function
PMC5372906,glucose metabolism,TEST,PMC,C0596620,glucose metabolism,CHV,Molecular Function
PMC5372906,pdac,TEST,PMC,,,,
PMC5372906,inflammation,PROBLEM,PMC,C0021368,Inflammation,MTH,Pathologic Function
PMC5372906,desmoplastic changes,PROBLEM,PMC,,,,
PMC5372906,mass effectobstruction,PROBLEM,PMC,,,,
PMC5372906,diabetogenic substances,PROBLEM,PMC,,,,
PMC5372906,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC5372906,gastrointestinal cancer,PROBLEM,PMC,C0685938,Malignant neoplasm of gastrointestinal tract,MTH,Neoplastic Process
PMC5372906,preoperative nutritional optimization,TREATMENT,PMC,,,,
PMC5372906,postoperative complications,PROBLEM,PMC,C0032787,Postoperative Complications,MSH,Pathologic Function
PMC5372906,pancreatic parenchyma reduction,TREATMENT,PMC,,,,
PMC5372906,anatomical alterations,PROBLEM,PMC,C2435098,"Medical and Surgical @ Anatomical Regions, General @ Alteration",ICD10PCS,Therapeutic or Preventive Procedure
PMC5372906,postoperative morbidity,PROBLEM,PMC,,,,
PMC5372906,pd,TREATMENT,PMC,C5575533,ITMIG MRECIST Progressive Disease,MTH,Classification
PMC5372906,a complication rate,PROBLEM,PMC,C0475563,Labor and delivery complicated by fetal heart rate anomaly,SNOMEDCT_US,Pathologic Function
PMC5372906,endocrine and exocrine insufficiency,PROBLEM,PMC,,,,
PMC5372906,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC5372906,altered anatomy,PROBLEM,PMC,C3867841,Insertion of temporary indwelling bladder catheter complicated by altered anatomy,CPT,Therapeutic or Preventive Procedure
PMC5372906,gastrointestinal reconstruction,TREATMENT,PMC,C1293484,Gastrointestinal tract reconstruction,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC5372906,the poor absorption of,PROBLEM,PMC,C2957425,bandage / dressing poor absorption,MEDCIN,Finding
PMC5372906,fatsoluble vitamins,TREATMENT,PMC,,,,
PMC5372906,functional impairment,PROBLEM,PMC,C4062321,Functional impairment,NANDA-I,Finding
PMC5372906,pei,TREATMENT,PMC,C0814202,Personal Experience Inventory,MTH,Intellectual Product
PMC5372906,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC5372906,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5372906,glucose metabolism,PROBLEM,PMC,C0596620,glucose metabolism,CHV,Molecular Function
PMC5372906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5372906,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC5372906,nodm,TREATMENT,PMC,C0132733,"nodM protein, Rhizobium",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC5372906,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC5372906,pancreatogenic diabetes,PROBLEM,PMC,C0860262,Pancreatogenous diabetes,MDR,Disease or Syndrome
PMC5372906,pd versus dp,TREATMENT,PMC,,,,
PMC5372906,developing diabetes,PROBLEM,PMC,C5934766,Identifies risk factors of developing type 2 diabetes,NOC,Finding
PMC5372906,malabsorption syndromes,PROBLEM,PMC,C0024523,Malabsorption Syndrome,MTH,Disease or Syndrome
PMC5372906,a pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC5372906,a multidisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC5372906,pdac,TREATMENT,PMC,,,,
PMC5372906,the preoperative optimization,TREATMENT,PMC,,,,
PMC5372906,immunonutrition,TREATMENT,PMC,C5690775,Immunonutrition,MSH,Therapeutic or Preventive Procedure
PMC5372906,postoperative infectious complications,PROBLEM,PMC,,,,
PMC5372906,postoperative early enteral feeding,TREATMENT,PMC,,,,
PMC5372906,the multidisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC5372906,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5372906,pancreatic endocrine,PROBLEM,PMC,C1328479,Pancreatic Endocrine Carcinoma,MTH,Neoplastic Process
PMC5372906,an appropriate treatment,TREATMENT,PMC,C3640049,Appropriate Treatment,NCI,Clinical Attribute
PMC6910167,metachronous pancreatic metastasis symptoms,PROBLEM,PMC,,,,
PMC6910167,medication,TREATMENT,PMC,C4284232,Medications,MTH,Intellectual Product
PMC6910167,clinical procedure,TREATMENT,PMC,C0586186,Clinical procedure report,MTH,Intellectual Product
PMC6910167,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6910167,rare disease,PROBLEM,PMC,C0678236,Rare Diseases,MSH,Disease or Syndrome
PMC6910167,pancreatic metastasis,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6910167,colorectal cancer,PROBLEM,PMC,C0009402,Colorectal Carcinoma,MTH,Neoplastic Process
PMC6910167,primary pancreatic cancer,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC6910167,advanced rectal cancer,PROBLEM,PMC,,,,
PMC6910167,multiple liver metastases,PROBLEM,PMC,,,,
PMC6910167,neoadjuvant chemotherapy,TREATMENT,PMC,C5392214,Neoadjuvant Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC6910167,radical surgery,TREATMENT,PMC,C0198868,Anesthesia for radical surgery on nose,SNMI,Therapeutic or Preventive Procedure
PMC6910167,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC6910167,hepatectomy,TREATMENT,PMC,C0019144,Hepatectomy,MSH,Therapeutic or Preventive Procedure
PMC6910167,multiple liver metastases,PROBLEM,PMC,,,,
PMC6910167,adjuvant chemotherapies,TREATMENT,PMC,C0281265,Prior Adjuvant Chemotherapy,NCI,Finding
PMC6910167,additional surgeries,TREATMENT,PMC,C1706711,Additional Surgical Procedure,NCI,Therapeutic or Preventive Procedure
PMC6910167,recurrences in the liver lung and lymph nodes,PROBLEM,PMC,,,,
PMC6910167,a diffuse hypovascular nodule in the pancreatic head,PROBLEM,PMC,,,,
PMC6910167,a solitary liver metastasis,PROBLEM,PMC,,,,
PMC6910167,the initial surgery,TREATMENT,PMC,C4285446,Initial evaluation note:Find:Pt:{Setting}:Doc:Plastic surgery,LNC,Clinical Attribute
PMC6910167,further chemotherapy,TREATMENT,PMC,,,,
PMC6910167,the pancreatic tumor,PROBLEM,PMC,C0941236,Pancreatic/biliary tumor,MTHMST,Neoplastic Process
PMC6910167,invading the pancreatic duct and biliary tract,PROBLEM,PMC,,,,
PMC6910167,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC6910167,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6910167,biliary drainage,TREATMENT,PMC,C0400745,Biliary drainage (procedure),MTH,Therapeutic or Preventive Procedure
PMC6910167,his diffuse and hypovascular tumor,PROBLEM,PMC,,,,
PMC6910167,a primary pancreatic cancer,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC6910167,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC6910167,the pancreatic tumor,PROBLEM,PMC,C0941236,Pancreatic/biliary tumor,MTHMST,Neoplastic Process
PMC6910167,hepatectomy,TREATMENT,PMC,C0019144,Hepatectomy,MSH,Therapeutic or Preventive Procedure
PMC6910167,the liver metastasis,PROBLEM,PMC,C0585483,Excision of liver metastasis,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6910167,the initial surgery,TREATMENT,PMC,C4285446,Initial evaluation note:Find:Pt:{Setting}:Doc:Plastic surgery,LNC,Clinical Attribute
PMC6910167,radiographic,TREATMENT,PMC,C0444708,Radiographic,SNOMEDCT_US,Natural Phenomenon or Process
PMC6910167,pathological examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC6910167,the surgical specimen,TEST,PMC,C5453903,^Surgical specimen,LNC,Body Substance
PMC6910167,metachronous pancreatic metastasis,PROBLEM,PMC,,,,
PMC6910167,his primary rectal cancer,PROBLEM,PMC,,,,
PMC6910167,further chemotherapy,TREATMENT,PMC,,,,
PMC6910167,his general condition,PROBLEM,PMC,,,,
PMC6910167,the initial surgery,TREATMENT,PMC,C4285446,Initial evaluation note:Find:Pt:{Setting}:Doc:Plastic surgery,LNC,Clinical Attribute
PMC6910167,best supportive care,TREATMENT,PMC,C4683871,"Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management",NCI,Finding
PMC6910167,pancreatic metastasis,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6910167,rectal cancer,PROBLEM,PMC,C0007113,Rectal Carcinoma,MTH,Neoplastic Process
PMC6910167,primary pancreatic cancer,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC6910167,multimodality treatment,TREATMENT,PMC,C0009429,Combined Modality Therapy,MTH,Therapeutic or Preventive Procedure
PMC6910167,metastatic colorectal cancer,PROBLEM,PMC,C4721579,Metastasis from malignant neoplasm of colon and/or rectum,MTH,Neoplastic Process
PMC6910167,aggressive surgeries,TREATMENT,PMC,,,,
PMC6910167,pancreatic metastasis,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC6910167,curative resection,TREATMENT,PMC,,,,
PMC6910167,metachronous pancreatic metastasis,PROBLEM,PMC,,,,
PMC6910167,rectal cancer,PROBLEM,PMC,C0007113,Rectal Carcinoma,MTH,Neoplastic Process
PMC6910167,a primary pancreatic cancer,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC6910167,a rare easily misdiagnosed metastatic tumor in the pancreas,PROBLEM,PMC,,,,
PMC6910167,aggressive surgery,TREATMENT,PMC,,,,
PMC6910167,pancreatic metastases,PROBLEM,PMC,,,,
PMC6910167,subsequent chemotherapy,TREATMENT,PMC,C5667387,Subsequent Progression Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC6910167,recurrences,PROBLEM,PMC,C2825055,Recurrence (disease attribute),MTH,Pathologic Function
PMC6910167,metastases,PROBLEM,PMC,C1513183,Metastatic Lesion,MTH,Finding
PMC6910167,radiographic,TEST,PMC,C0444708,Radiographic,SNOMEDCT_US,Natural Phenomenon or Process
PMC6910167,surgical curative resection,TREATMENT,PMC,,,,
PMC11235423,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11235423,treatment rates,TREATMENT,PMC,C3475495,Treatment Rating Overall,NCI,Intellectual Product
PMC11235423,high metastasis,PROBLEM,PMC,C2367693,high dose radiopharmaceutical therapy for metastases of thyroid carcinoma,MEDCIN,Therapeutic or Preventive Procedure
PMC11235423,mortality rates,TEST,PMC,C0026565,Mortality Vital Statistics,MTH,Quantitative Concept
PMC11235423,the median,TREATMENT,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC11235423,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11235423,small pancreatic cancers,PROBLEM,PMC,,,,
PMC11235423,early pancreatic cancer,PROBLEM,PMC,,,,
PMC11235423,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11235423,a malignant tumor of the digestive tract,PROBLEM,PMC,C0346617,Malignant tumor of digestive organ,SNOMEDCT_US,Neoplastic Process
PMC11235423,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11235423,its occult,PROBLEM,PMC,,,,
PMC11235423,atypical clinical symptoms,PROBLEM,PMC,,,,
PMC11235423,recurrent pancreatitis,PROBLEM,PMC,C4551632,Recurrent pancreatitis,MTH,Disease or Syndrome
PMC11235423,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11235423,recurrent acute pancreatitis,PROBLEM,PMC,C0267937,Acute recurrent pancreatitis,SNOMEDCT_US,Disease or Syndrome
PMC11235423,pancreatitis,PROBLEM,PMC,C0030305,Pancreatitis,MTH,Disease or Syndrome
PMC11235423,routine imaging,TEST,PMC,C5411262,"Imaging of organ, complimenting routine exam",CPT,Diagnostic Procedure
PMC11235423,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11235423,acute pancreatitis,PROBLEM,PMC,C0001339,"Pancreatitis, Acute",MSH,Disease or Syndrome
PMC11235423,endoscopic ultrasonography,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11235423,a spaceoccupying lesion,PROBLEM,PMC,,,,
PMC11235423,subsequent eus,TEST,PMC,,,,
PMC11235423,fineneedle aspiration examination,TEST,PMC,,,,
PMC11235423,atypical pancreatic gland epithelium,PROBLEM,PMC,,,,
PMC11235423,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC11235423,an intraductal papillary mucinous tumor of the pancreas,PROBLEM,PMC,,,,
PMC11235423,focal cancer,PROBLEM,PMC,C3470867,FALEC gene,MTH,Gene or Genome
PMC11235423,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11235423,recurrent pancreatitis,PROBLEM,PMC,C4551632,Recurrent pancreatitis,MTH,Disease or Syndrome
PMC11235423,early pancreatic cancer,PROBLEM,PMC,,,,
PMC11235423,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11235423,recurrent pancreatitis,PROBLEM,PMC,C4551632,Recurrent pancreatitis,MTH,Disease or Syndrome
PMC11235423,early pancreatic cancer,PROBLEM,PMC,,,,
PMC11235423,highrisk factors,PROBLEM,PMC,,,,
PMC11235423,shortterm recurrent pancreatitis,PROBLEM,PMC,,,,
PMC11235423,pancreatic cancer lesions,PROBLEM,PMC,,,,
PMC11235423,routine examinations,TEST,PMC,C2063084,routine examination,MEDCIN,Finding
PMC11235423,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11235423,this diagnostic approach,TEST,PMC,,,,
PMC11235423,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11235423,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11235423,pathological specimens,TEST,PMC,C0444061,Pathology specimen,MTH,Body Substance
PMC5893263,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5893263,a highly malignant disease,PROBLEM,PMC,,,,
PMC5893263,the fourth leading cancerrelated death,PROBLEM,PMC,,,,
PMC5893263,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC5893263,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5893263,its rapid progression,PROBLEM,PMC,,,,
PMC5893263,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC5893263,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC5893263,available chemotherapy,TREATMENT,PMC,C3844220,"Information is not available at this time, but it is expected that it will be available later (e.g., chemotherapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).",LNC,Finding
PMC5893263,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC5893263,this malignancy,PROBLEM,PMC,,,,
PMC5893263,a promising strategy,TREATMENT,PMC,C5144326,"Current level of confidence I can use a strategy (for example: humor, leaving a situation) to keep from getting upset:Find:Pt:^Patient:Ord:PROMIS",LNC,Clinical Attribute
PMC5893263,numerous translational studies,TEST,PMC,,,,
PMC5893263,body fluids,TREATMENT,PMC,C0005889,Body Fluids,MTH,Body Substance
PMC5893263,pcspecific biomarkers,PROBLEM,PMC,,,,
PMC5893263,proteomic methods,TEST,PMC,C5206111,Proteomic Quantification Method,NCI,Intellectual Product
PMC5893263,protein biomarkers,TEST,PMC,C5851918,Test for 10 protein biomarkers for bladder cancer,CPT,Laboratory Procedure
PMC5893263,different cancers,PROBLEM,PMC,C3641217,Breast Shape Difference Since Cancer Treatment,NCI,Intellectual Product
PMC5893263,a proteomic approach,TEST,PMC,,,,
PMC5893263,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5893263,protein biomarkers,TEST,PMC,C5851918,Test for 10 protein biomarkers for bladder cancer,CPT,Laboratory Procedure
PMC5893263,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC5893263,novel proteomic,PROBLEM,PMC,,,,
PMC5893263,body fluids,TREATMENT,PMC,C0005889,Body Fluids,MTH,Body Substance
PMC5893263,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5893263,the most lethal tumors,PROBLEM,PMC,,,,
PMC5893263,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC5893263,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC5893263,successful treatment,TREATMENT,PMC,C0521982,Response to treatment,MTH,Clinical Attribute
PMC5893263,specific biomarkers,TEST,PMC,,,,
PMC5893263,useful biomarkers,PROBLEM,PMC,C5972199,intracranial stereotaxis using MRgFUS for blood-brain barrier disruption using microbubble resonators to increase concentration of blood-based biomarkers,MEDCIN,Therapeutic or Preventive Procedure
PMC5893263,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC5893263,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5893263,a proteomic approach,TREATMENT,PMC,,,,
PMC5893263,novel protein biomarkers,PROBLEM,PMC,,,,
PMC5893263,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5893263,an invasive procedure,TREATMENT,PMC,C4048276,Invasive procedure,MTH,Therapeutic or Preventive Procedure
PMC5893263,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC5893263,multiple biomarkers,TEST,PMC,,,,
PMC5893263,various body fluids,TREATMENT,PMC,C0513559,"Monitor output of various body fluids (e.g., urine, nasogastric drainage, and chest tube)",NIC,Health Care Activity
PMC5893263,some studies,TEST,PMC,C3830967,"C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Since Study Start)",NCI,Intellectual Product
PMC5893263,conventional biomarkers,TEST,PMC,,,,
PMC5893263,new molecules,TREATMENT,PMC,C5920611,"Measurement of Infection, Positive Blood Culture Small Molecule Sensor Array Technology, New Technology Group 10",ICD10PCS,Therapeutic or Preventive Procedure
PMC5893263,genetic alterations,PROBLEM,PMC,C5555056,BCOR Genetic Alteration,NCI,Laboratory or Test Result
PMC5893263,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5893263,a single biomarker,TEST,PMC,C5411925,Detection of single alcohol biomarker,CPT,Laboratory Procedure
PMC5893263,proteomic studies,TEST,PMC,,,,
PMC5893263,proteome aberrations,PROBLEM,PMC,,,,
PMC5893263,therapeutic targets,TREATMENT,PMC,C4732277,"Cancer RNA gene expression profiling by whole transcriptome sequencing in fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",CPT,Laboratory Procedure
PMC5893263,largescale validation studies,TEST,PMC,,,,
PMC5893263,clinical trials,TREATMENT,PMC,C0008976,Clinical Trials,MTH,Research Activity
PMC5893263,useful biomarkers,TEST,PMC,C5972199,intracranial stereotaxis using MRgFUS for blood-brain barrier disruption using microbubble resonators to increase concentration of blood-based biomarkers,MEDCIN,Therapeutic or Preventive Procedure
PMC10879602,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10879602,the deadliest cancer,PROBLEM,PMC,,,,
PMC10879602,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10879602,microbiome studies,TEST,PMC,,,,
PMC10879602,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10879602,the human oral and gut microbiomes,PROBLEM,PMC,,,,
PMC10879602,the gut microbial antibiotic resistance,TREATMENT,PMC,,,,
PMC10879602,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10879602,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10879602,the gut microbial antibiotic resistance genes,TREATMENT,PMC,,,,
PMC10879602,the metagenomic data,TEST,PMC,,,,
PMC10879602,crosssectional comparisons,TEST,PMC,,,,
PMC10879602,two strategies,TREATMENT,PMC,,,,
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,these two approaches,TREATMENT,PMC,,,,
PMC10879602,microbeantibiotic resistance gene networks,TREATMENT,PMC,,,,
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10879602,our study,TEST,PMC,,,,
PMC10879602,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC10879602,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10879602,our study,TEST,PMC,,,,
PMC10879602,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC10879602,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10879602,an extensive evaluation,TEST,PMC,C2165421,dental services-extensive oral evaluation,MEDCIN,Therapeutic or Preventive Procedure
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,pancreatic cancer populations,PROBLEM,PMC,,,,
PMC10879602,crosssectional comparisons,TEST,PMC,,,,
PMC10879602,two strategies,TREATMENT,PMC,,,,
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,these two approaches,TREATMENT,PMC,,,,
PMC10879602,rgi prediction strategy,TEST,PMC,,,,
PMC10879602,four vancomycinresistant genes,TREATMENT,PMC,,,,
PMC10879602,one tetracyclineresistant gene,TREATMENT,PMC,,,,
PMC10879602,the pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC10879602,microbeantibiotic resistance gene networks,TREATMENT,PMC,,,,
PMC10879602,antibiotic resistance genes,TREATMENT,PMC,C5851946,Test for genitourinary pathogen antibiotic-resistance genes,CPT,Laboratory Procedure
PMC10879602,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC10879602,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10879602,new antibiotic regimens,TREATMENT,PMC,,,,
PMC10879602,dysbiotic microbiota,PROBLEM,PMC,,,,
PMC12078320,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12078320,a poor prognosis,PROBLEM,PMC,C0278252,Prognosis bad,SNOMEDCT_US,Finding
PMC12078320,limited responsiveness,PROBLEM,PMC,C2182553,limited evoked response audiometry,MEDCIN,Diagnostic Procedure
PMC12078320,conventional therapies,TREATMENT,PMC,C5442354,Conventional oxygen therapy,MDR,Therapeutic or Preventive Procedure
PMC12078320,a substantial therapeutic challenge,TREATMENT,PMC,,,,
PMC12078320,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC12078320,systemic treatment,TREATMENT,PMC,C1632806,Date 1st systemic treatment,LNC,Temporal Concept
PMC12078320,frontline therapies,TREATMENT,PMC,,,,
PMC12078320,targeted therapies,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC12078320,immunotherapies,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC12078320,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12078320,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC12078320,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12078320,novel treatment strategieswe,TREATMENT,PMC,,,,
PMC12078320,a pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC12078320,frontline,TREATMENT,PMC,C5669824,Frontline Study,NCI,Research Activity
PMC12078320,targeted therapy,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC12078320,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC12078320,the targeted agent,TREATMENT,PMC,C5235658,Targeted Therapy Agent,NCI,"Organic Chemical, Pharmacologic Substance"
PMC12078320,surufatinib,TREATMENT,PMC,C3897426,surufatinib,MSH,"Organic Chemical, Pharmacologic Substance"
PMC12078320,a tyrosine kinase inhibitor,TREATMENT,PMC,C2985521,VEGFR Tyrosine Kinase Inhibitor,NCI,Pharmacologic Substance
PMC12078320,vascular endothelial growth factor receptor,TEST,PMC,C0148199,Vascular Endothelial Growth Factor Receptor,MTH,"Amino Acid, Peptide, or Protein, Enzyme, Receptor"
PMC12078320,fibroblast growth factor receptor,TEST,PMC,C0060369,Fibroblast Growth Factor Receptors,MTH,"Amino Acid, Peptide, or Protein, Receptor"
PMC12078320,colonystimulating factor 1 receptor,TEST,PMC,,,,
PMC12078320,the immunotherapy agent,TREATMENT,PMC,C4760444,Adoptive immunotherapy agent CTL019,MTH,Cell
PMC12078320,toripalimab,TREATMENT,PMC,C4763386,toripalimab,RXNORM,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC12078320,an immune checkpoint inhibitor,TREATMENT,PMC,C4684977,Immune Checkpoint Inhibitors,MSH,"Pharmacologic Substance, Immunologic Factor"
PMC12078320,programmed cell death protein,TREATMENT,PMC,C1564881,Apoptosis Regulatory Proteins,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC12078320,this regimen,TREATMENT,PMC,,,,
PMC12078320,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC12078320,improved clinical symptoms,PROBLEM,PMC,,,,
PMC12078320,prolonged progressionfree survival,PROBLEM,PMC,,,,
PMC12078320,personalized therapy,TREATMENT,PMC,C0871063,Personal Therapy,PSY,Therapeutic or Preventive Procedure
PMC12078320,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12078320,the time,PROBLEM,PMC,C0040223,Time,MTH,Temporal Concept
PMC12078320,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC12078320,personalized strategies,TREATMENT,PMC,C5933141,Use of personal protection strategies,NOC,Finding
PMC12078320,longterm progressionfree survival,TREATMENT,PMC,,,,
PMC12078320,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12078320,the tumor immune microenvironment,PROBLEM,PMC,,,,
PMC12078320,toripalimab,TREATMENT,PMC,C4763386,toripalimab,RXNORM,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC12078320,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC12078320,surufatinib,TREATMENT,PMC,C3897426,surufatinib,MSH,"Organic Chemical, Pharmacologic Substance"
PMC12078320,refractory pc,PROBLEM,PMC,,,,
PMC12078320,future largescale cohort studies,TEST,PMC,,,,
PMC12078320,the individual treatment strategy,TREATMENT,PMC,,,,
PMC10928015,introduction computed tomography ct of the abdomen,TEST,PMC,,,,
PMC10928015,contrast stands,TEST,PMC,,,,
PMC10928015,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10928015,both staging,TEST,PMC,C2066896,"laminectomy with cordotomy both tracts, one stage, cervical",MEDCIN,Therapeutic or Preventive Procedure
PMC10928015,vascular analysis,TEST,PMC,C4512058,Breast 3-D infrared imaging/vascular analysis system,SNOMEDCT_US,Medical Device
PMC10928015,contrastenhanced ct cect scans,TEST,PMC,,,,
PMC10928015,contrast agent allergies,PROBLEM,PMC,,,,
PMC10928015,pregnancy,PROBLEM,PMC,C0032961,Pregnancy,MTH,Organism Function
PMC10928015,renal impairment,PROBLEM,PMC,C1565489,Renal Insufficiency,MTH,Disease or Syndrome
PMC10928015,radiation risks,PROBLEM,PMC,C0557999,Radiation risk assessment,SNOMEDCT_US,Health Care Activity
PMC10928015,limited tissue sampling capability,PROBLEM,PMC,,,,
PMC10928015,cect scans of the abdomen,TEST,PMC,,,,
PMC10928015,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10928015,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,cect,TEST,PMC,C0047122,3-(2-carboxyethyl)cytosine,MSH,Organic Chemical
PMC10928015,staging,TEST,PMC,C0332305,With staging,SNOMEDCT_US,Functional Concept
PMC10928015,vascular assessment,TEST,PMC,C0846601,Vascular assessment,ICD10AM,Diagnostic Procedure
PMC10928015,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10928015,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10928015,evaluations,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC10928015,both cect scans,TEST,PMC,,,,
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,staging,TEST,PMC,C0332305,With staging,SNOMEDCT_US,Functional Concept
PMC10928015,vascular invasion assessment,TEST,PMC,C4288029,Vascular Invasion Assessment,MTH,Laboratory Procedure
PMC10928015,vascular evaluation,TEST,PMC,C4298407,Initial evaluation note:Find:Pt:{Setting}:Doc:Vascular surgery,LNC,Clinical Attribute
PMC10928015,a categorization system,TEST,PMC,C2585518,Person categorized by affiliation with belief system,SNOMEDCT_US,Population Group
PMC10928015,eus findings,TEST,PMC,,,,
PMC10928015,the tumorvessel relationship,PROBLEM,PMC,,,,
PMC10928015,clear invasion,PROBLEM,PMC,C5782299,Invasive Clear Cell (Glycogen-Rich) Urothelial Carcinoma,MTH,Neoplastic Process
PMC10928015,encasement of a vessel,PROBLEM,PMC,,,,
PMC10928015,a tumor,PROBLEM,PMC,C0007095,Carcinoid Tumor,MTH,Neoplastic Process
PMC10928015,a tumor,PROBLEM,PMC,C0007095,Carcinoid Tumor,MTH,Neoplastic Process
PMC10928015,clear noninvasion,PROBLEM,PMC,,,,
PMC10928015,a tumor,PROBLEM,PMC,C0007095,Carcinoid Tumor,MTH,Neoplastic Process
PMC10928015,vascular invasion,PROBLEM,PMC,C0521157,Tumor Vascular Invasion,NCI,Finding
PMC10928015,vascular noninvasion,PROBLEM,PMC,C4303678,Invasive/noninvasive vascular ultrasound probe,SNOMEDCT_US,Medical Device
PMC10928015,cect scans,TEST,PMC,,,,
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,the ct outcomes,TEST,PMC,,,,
PMC10928015,the examination,TEST,PMC,C4321457,Examination,MTH,Activity
PMC10928015,pancreatic cancer staging,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,remarkable sensitivity,PROBLEM,PMC,,,,
PMC10928015,accuracy rates,TEST,PMC,C0548045,"Check accuracy of oxygen therapy; such as flow rate, source, etc.",PCDS,Therapeutic or Preventive Procedure
PMC10928015,the t,TEST,PMC,C1552647,ProbabilityDistributionType - T,MTH,Quantitative Concept
PMC10928015,vascular invasion assessment,TEST,PMC,C4288029,Vascular Invasion Assessment,MTH,Laboratory Procedure
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,specificity,TEST,PMC,C0037791,Specificity,MTH,Quantitative Concept
PMC10928015,venous invasion,PROBLEM,PMC,C1710625,Venous Invasion,NCI,Finding
PMC10928015,arterial invasion,PROBLEM,PMC,C1301281,Arterial (large vessel) invasion by tumor absent,SNOMEDCT_US,Finding
PMC10928015,the figures,TEST,PMC,C0451214,Hidden figures test,SNOMEDCT_US,Intellectual Product
PMC10928015,an overall accuracy,TEST,PMC,,,,
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,both staging,TEST,PMC,C2066896,"laminectomy with cordotomy both tracts, one stage, cervical",MEDCIN,Therapeutic or Preventive Procedure
PMC10928015,vascular invasion,PROBLEM,PMC,C0521157,Tumor Vascular Invasion,NCI,Finding
PMC10928015,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10928015,accuracy rates,TEST,PMC,C0548045,"Check accuracy of oxygen therapy; such as flow rate, source, etc.",PCDS,Therapeutic or Preventive Procedure
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC10928015,evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,tissue sampling capability,TEST,PMC,,,,
PMC10928015,our study,TEST,PMC,,,,
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,the staging,TEST,PMC,C0332305,With staging,SNOMEDCT_US,Functional Concept
PMC10928015,vascular invasion,PROBLEM,PMC,C0521157,Tumor Vascular Invasion,NCI,Finding
PMC10928015,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10928015,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10928015,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC10928015,the primary evaluation tool,TEST,PMC,,,,
PMC10928015,euss,TEST,PMC,,,,
PMC10928015,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC10928015,potentially,TREATMENT,PMC,C1273512,Potentially abnormal,SNOMEDCT_US,Finding
PMC10928015,harmful contrast agents,TREATMENT,PMC,,,,
PMC3756374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3756374,the most deadly solid tumors,PROBLEM,PMC,,,,
PMC3756374,a nonspecific clinical presentation,PROBLEM,PMC,,,,
PMC3756374,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC3756374,appropriate staging,TEST,PMC,C0548314,Provide appropriate treatment for each wound stage.,PCDS,Therapeutic or Preventive Procedure
PMC3756374,several imaging modalities,TEST,PMC,,,,
PMC3756374,the evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC3756374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3756374,different techniques,TREATMENT,PMC,C1610108,"Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)",CPT,Therapeutic or Preventive Procedure
PMC3756374,the diagnostic management,TREATMENT,PMC,C4716712,Role of diagnostic tests for disease management,NOC,Finding
PMC3756374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3756374,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC3756374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3756374,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC3756374,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC3756374,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC3756374,nuclear imaging,TEST,PMC,C0392286,Nuclear Imaging Kits,UMD,Medical Device
PMC3756374,endoscopy,TEST,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC3756374,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC3756374,biochemical markers,TEST,PMC,C0206015,Biochemical Marker,MSH,Qualitative Concept
PMC3756374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3756374,a challenging disease,PROBLEM,PMC,C5213406,Fabry disease | DBS | Chemistry - non-challenge,LNC,Disease or Syndrome
PMC3756374,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC3756374,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC3756374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3756374,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC3756374,tissue acquisition,TEST,PMC,C0040296,Tissue Procurement,MSH,Health Care Activity
PMC3756374,the other imaging modalities,TEST,PMC,C1518654,Other Imaging Modalities,NCI,Diagnostic Procedure
PMC3756374,a staging tool,TEST,PMC,,,,
PMC11617590,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11617590,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC11617590,sulforaphane sfn,TREATMENT,PMC,,,,
PMC11617590,anticancer effects,PROBLEM,PMC,,,,
PMC11617590,gastric and colon cancers,PROBLEM,PMC,,,,
PMC11617590,glycogen synthase kinase3,TEST,PMC,,,,
PMC11617590,a serinethreonine kinase,TREATMENT,PMC,,,,
PMC11617590,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC11617590,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC11617590,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC11617590,treatment resistance,TREATMENT,PMC,C5211838,Treatment to which genetic variant confers resistance,LNC,Finding
PMC11617590,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11617590,sfn,PROBLEM,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11617590,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11617590,sfn,TREATMENT,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,human pancreatic cancer,PROBLEM,PMC,C4286572,"IVD Panels, Human Genetics, Cancer, Familial, Pancreatic, Mutation",UMD,Medical Device
PMC11617590,sfn,PROBLEM,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11617590,gsk3 induced apoptosis,PROBLEM,PMC,,,,
PMC11617590,phosphorylating,TREATMENT,PMC,C5886951,allokinase (phosphorylating),GO,Molecular Function
PMC11617590,mutant kirsten rat sarcoma viral oncogene homologlikedependent cells,PROBLEM,PMC,,,,
PMC11617590,mia,PROBLEM,PMC,C1417154,MIA gene,MTH,Gene or Genome
PMC11617590,gsk3,TEST,PMC,,,,
PMC11617590,the catenin level,TEST,PMC,,,,
PMC11617590,sfn,PROBLEM,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,catenin,TEST,PMC,,,,
PMC11617590,cmyc,TEST,PMC,C4521289,"Myosin-Binding Protein C, Cardiac-Type, human",MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC11617590,catenin,TREATMENT,PMC,,,,
PMC11617590,sfn decreased cmyc expression,PROBLEM,PMC,,,,
PMC11617590,an increase,PROBLEM,PMC,C0442805,Increase,MTH,Functional Concept
PMC11617590,the catenin,TREATMENT,PMC,,,,
PMC11617590,nuclear factor nfb,TEST,PMC,,,,
PMC11617590,gsk3,TREATMENT,PMC,,,,
PMC11617590,cmyc,TEST,PMC,C4521289,"Myosin-Binding Protein C, Cardiac-Type, human",MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC11617590,sfn,PROBLEM,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,nfb,TEST,PMC,C0663914,IkappaB kinase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC11617590,cmyc,TEST,PMC,C4521289,"Myosin-Binding Protein C, Cardiac-Type, human",MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC11617590,sfn inhibits cell proliferation,PROBLEM,PMC,,,,
PMC11617590,the gsk3nfbcmyc pathway,TEST,PMC,,,,
PMC11617590,a decrease in bcell lymphoma,PROBLEM,PMC,,,,
PMC11617590,the antiapoptotic gene,TREATMENT,PMC,,,,
PMC11617590,sfn,TREATMENT,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,sfn,TREATMENT,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,the apoptotic regulator gene,TREATMENT,PMC,,,,
PMC11617590,sfn,TREATMENT,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,the cleaved cysteine aspartase3,TREATMENT,PMC,,,,
PMC11617590,polyadenosine diphosphate ribose polymerase,TREATMENT,PMC,C0920634,polyadenosine diphosphate ribose polymerase,CSP,"Amino Acid, Peptide, or Protein, Enzyme"
PMC11617590,sfn,PROBLEM,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11617590,sfn,PROBLEM,PMC,C1335813,SFN gene,MTH,Gene or Genome
PMC11617590,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5968243,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC5968243,a cardiotoxic agent,TREATMENT,PMC,C3161944,avoid cardiotoxic agents,MEDCIN,Health Care Activity
PMC5968243,cardiac side effects,PROBLEM,PMC,C0421188,Cardiac drug side effects,SNOMEDCT_US,Finding
PMC5968243,congestive cardiac failure,PROBLEM,PMC,C0018802,Congestive heart failure,MTH,Disease or Syndrome
PMC5968243,gemcitabine monotherapy,TREATMENT,PMC,,,,
PMC5968243,the adjuvant setting,TREATMENT,PMC,C4084850,Adjuvant Therapy Clinical Trial Setting,MTH,Functional Concept
PMC5968243,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC5968243,adjuvant chemotherapy,TREATMENT,PMC,C0085533,"Chemotherapy, Adjuvant",MTH,Therapeutic or Preventive Procedure
PMC5968243,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC5968243,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5968243,successful surgery,TREATMENT,PMC,C2024904,cardiovascular surgery successful,MEDCIN,Therapeutic or Preventive Procedure
PMC5968243,the conko001,TEST,PMC,,,,
PMC5968243,espac3 study,TEST,PMC,,,,
PMC5968243,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC5968243,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5968243,cardiac failure,PROBLEM,PMC,C0018801,Heart failure,MTH,Disease or Syndrome
PMC5968243,a drop in ejection fraction,PROBLEM,PMC,,,,
PMC5968243,echocardiography,TEST,PMC,C0013516,Echocardiography,MTH,Diagnostic Procedure
PMC5968243,conservative treatment,TREATMENT,PMC,C0459914,Conservative Treatment,MSH,Therapeutic or Preventive Procedure
PMC5968243,heart failure,PROBLEM,PMC,C0018801,Heart failure,MTH,Disease or Syndrome
PMC5968243,gemcitabine therapy,TREATMENT,PMC,,,,
PMC5968243,gemcitabine chemotherapy,TREATMENT,PMC,,,,
PMC5968243,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC5968243,cardiotoxicity,PROBLEM,PMC,C0876994,Cardiotoxicity,MSH,Injury or Poisoning
PMC5968243,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC5968243,a total dose,TREATMENT,PMC,C5239456,Steroid Total Dose,NCI,Quantitative Concept
PMC5968243,close surveillance,TEST,PMC,,,,
PMC5968243,cardiac toxicity,PROBLEM,PMC,C0876994,Cardiotoxicity,MSH,Injury or Poisoning
PMC5968243,gemcitabine treatment,TREATMENT,PMC,,,,
PMC5968243,gemcitabine treatment,TREATMENT,PMC,,,,
PMC5968243,potential cardiotoxicity,PROBLEM,PMC,,,,
PMC5968243,an echocardiogram,TEST,PMC,C0013516,Echocardiography,MTH,Diagnostic Procedure
PMC5968243,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5968243,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC5968243,previous coronary artery disease,PROBLEM,PMC,,,,
PMC5968243,gemcitabine cardiotoxicity,PROBLEM,PMC,,,,
PMC5968243,cardiotoxicity,PROBLEM,PMC,C0876994,Cardiotoxicity,MSH,Injury or Poisoning
PMC5968243,continuing surveillance,TEST,PMC,C1827655,Continuity of care surveillance,SNOMEDCT_US,Health Care Activity
PMC3522022,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC3522022,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC3522022,tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC3522022,patient care,TREATMENT,PMC,C0017313,patient care,MTH,Health Care Activity
PMC3522022,a retrospective observational study,TEST,PMC,,,,
PMC3522022,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC3522022,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3522022,tumor extent,PROBLEM,PMC,C0475289,Generic tumor extent,SNOMEDCT_US,Qualitative Concept
PMC3522022,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC3522022,an ultrasound,TEST,PMC,C1315081,Urological ultrasound,MTH,Diagnostic Procedure
PMC3522022,a ct scan,TEST,PMC,C5780258,Cranial CT scan,MDR,Diagnostic Procedure
PMC3522022,the tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC3522022,liver metastases,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3522022,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3522022,median survival,TREATMENT,PMC,C2986586,Median Survival Time,NCI,Temporal Concept
PMC3522022,the sample groups,TEST,PMC,,,,
PMC3522022,a,PROBLEM,PMC,,,,
PMC3522022,a largest tumor diameter,TEST,PMC,,,,
PMC3522022,median survival,TEST,PMC,C2986586,Median Survival Time,NCI,Temporal Concept
PMC3522022,cox regression,TEST,PMC,C0010235,Cox Proportional Hazards Models,MSH,Quantitative Concept
PMC3522022,a hazard ratio,TEST,PMC,C2985465,Hazard Ratio,NCI,Quantitative Concept
PMC3522022,tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC3522022,the gemcitabine treatment,TREATMENT,PMC,,,,
PMC3522022,liver metastasis,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3522022,stricture length,PROBLEM,PMC,,,,
PMC3522022,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC3522022,stricture,TEST,PMC,C1261287,Stenosis,MTH,Pathologic Function
PMC3522022,a kaplanmeier analysis,TEST,PMC,,,,
PMC3522022,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC3522022,the initial xray examination,TEST,PMC,,,,
PMC3522022,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3522022,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC3522022,stricture length,PROBLEM,PMC,,,,
PMC3522022,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC3522022,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC3522022,the initial xray examination,TEST,PMC,,,,
PMC3522022,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3522022,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC3522022,stricture length,PROBLEM,PMC,,,,
PMC3522022,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC3522022,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC3522022,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC3522022,the initial xray examination,TEST,PMC,,,,
PMC3522022,stricture,PROBLEM,PMC,C1261287,Stenosis,MTH,Pathologic Function
PMC3522022,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC3522022,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC12086372,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC12086372,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC12086372,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC12086372,a significant hurdle,PROBLEM,PMC,,,,
PMC12086372,its management,TREATMENT,PMC,C5204378,Manage Child's Side Effects of Cancer or its Treatment,NCI,Intellectual Product
PMC12086372,characteristic earlystage symptoms,PROBLEM,PMC,,,,
PMC12086372,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12086372,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC12086372,an advanced stage,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC12086372,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC12086372,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12086372,cancer progression,PROBLEM,PMC,C1947901,Cancer Progression,MTH,Pathologic Function
PMC12086372,cell proliferation,PROBLEM,PMC,C0596290,Cell Proliferation,MTH,Cell Function
PMC12086372,epithelialmesenchymal transition,PROBLEM,PMC,,,,
PMC12086372,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC12086372,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12086372,the proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC12086372,apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC12086372,metastasis of pancreatic cancer cells,PROBLEM,PMC,,,,
PMC12086372,chipseq,TEST,PMC,,,,
PMC12086372,the metastasis of pancreatic cancer cells,PROBLEM,PMC,,,,
PMC12086372,functional experiments,TEST,PMC,C2370916,"Experience of self and time functions, other specified",ICF,Mental Process
PMC12086372,western blot,TEST,PMC,C0949466,Western Blot,MTH,Laboratory Procedure
PMC12086372,a high level ofskilexpression,PROBLEM,PMC,,,,
PMC12086372,an unfavorable prognosis in paad,PROBLEM,PMC,,,,
PMC12086372,cell migration,PROBLEM,PMC,C1622501,"Migration, Cell",MTH,Cell Function
PMC12086372,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC12086372,chipseq analysis,TEST,PMC,,,,
PMC12086372,a nuclear protein,PROBLEM,PMC,C0949374,Nuclear Protein,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC12086372,the tgf,TEST,PMC,C0076930,Transforming Growth Factor beta Receptors,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor, Receptor"
PMC12086372,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC12086372,the tgf pathway,PROBLEM,PMC,,,,
PMC12086372,metastasis in pancreatic cancer cells,PROBLEM,PMC,,,,
PMC12086372,a novel regulatory mechanism involvingskiltspyl2,PROBLEM,PMC,,,,
PMC12086372,the tgf pathway,TREATMENT,PMC,,,,
PMC12086372,new therapeutic targets,TREATMENT,PMC,,,,
PMC12086372,paad,PROBLEM,PMC,C1538757,PYDC1 gene,MTH,Gene or Genome
PMC12086372,the elevated expression of theskilgene,PROBLEM,PMC,,,,
PMC12086372,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12086372,the tgf pathway,TEST,PMC,,,,
PMC12086372,the epithelialmesenchymal transition,PROBLEM,PMC,,,,
PMC12086372,the downregulation of ecadherin expression,PROBLEM,PMC,,,,
PMC12086372,the upregulation of vimentin and snai1 expression,PROBLEM,PMC,,,,
PMC12086372,promoting tumor metastasis,PROBLEM,PMC,,,,
PMC12086372,a novel regulatory mechanism involvingskiltspyl2,PROBLEM,PMC,,,,
PMC12086372,the tgf pathway,TREATMENT,PMC,,,,
PMC12086372,new therapeutic targets,TREATMENT,PMC,,,,
PMC12086372,paad,PROBLEM,PMC,C1538757,PYDC1 gene,MTH,Gene or Genome
PMC12086372,a,PROBLEM,PMC,,,,
PMC12086372,the tgf pathway,TEST,PMC,,,,
PMC12086372,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC12086372,metastasis in pancreatic cancer cells,PROBLEM,PMC,,,,
PMC12086372,the tgf pathway,TEST,PMC,,,,
PMC12086372,therapeutic applications,TREATMENT,PMC,C0150611,Therapeutic heat application,MTH,Therapeutic or Preventive Procedure
PMC12086372,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC12086372,smallmolecule inhibitors,TREATMENT,PMC,,,,
PMC12086372,these inhibitors,TREATMENT,PMC,,,,
PMC12086372,the tgf pathway,TREATMENT,PMC,,,,
PMC12086372,the tgf pathway,TREATMENT,PMC,,,,
PMC12086372,a therapeutic strategy,TREATMENT,PMC,C5913765,Use therapeutic communication strategies to acknowledge pain experience and convey acceptance of response to pain,NIC,Health Care Activity
PMC12086372,smallmolecule activators oftspyl2can,TREATMENT,PMC,,,,
PMC12086372,the tgf pathway,TREATMENT,PMC,,,,
PMC12086372,the emt,PROBLEM,PMC,C4699299,Advanced EMT,MSH,Professional or Occupational Group
PMC12086372,metastasis of pancreatic cancer cells,PROBLEM,PMC,,,,
PMC9225738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9225738,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9225738,asymptotic manifestations,PROBLEM,PMC,,,,
PMC9225738,tumor cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC9225738,the metastatic stage,PROBLEM,PMC,C0741680,BREAST CANCER NOS METASTATIC END STAGE,CCPSS,Neoplastic Process
PMC9225738,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9225738,pharmacotherapeutic drugs,TREATMENT,PMC,,,,
PMC9225738,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9225738,an efficient nanocarrier system,TREATMENT,PMC,,,,
PMC9225738,raloxifene,TREATMENT,PMC,C0244404,raloxifene,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9225738,pc cells,PROBLEM,PMC,C3890720,PC-3 cell line,MTH,Cell
PMC9225738,the current investigation,TEST,PMC,C2882169,"Past myocardial infarction diagnosed by ECG or other investigation, but currently presenting no symptoms",ICD10CM,Pathologic Function
PMC9225738,an effective treatment method,TREATMENT,PMC,C0683464,AODE treatment method,AOD,Finding
PMC9225738,an optimum rlx loaded phospholipidbased vesicles,TREATMENT,PMC,,,,
PMC9225738,melittin plmel,TREATMENT,PMC,,,,
PMC9225738,experimental design software,TREATMENT,PMC,,,,
PMC9225738,particle size,TEST,PMC,C0030608,Particle Size,MSH,Quantitative Concept
PMC9225738,zeta potential,TREATMENT,PMC,C0597697,Zeta Potential,NCI,Phenomenon or Process
PMC9225738,entrapment efficiency,TREATMENT,PMC,,,,
PMC9225738,anticancer,TREATMENT,PMC,C0614568,anticancer principle GCE,MSH,"Pharmacologic Substance, Biologically Active Substance"
PMC9225738,panc1 cells,PROBLEM,PMC,,,,
PMC9225738,the optimized nanovesicle parameters,TREATMENT,PMC,,,,
PMC9225738,zeta potential,TEST,PMC,C0597697,Zeta Potential,NCI,Phenomenon or Process
PMC9225738,entrapment efficiency,TEST,PMC,,,,
PMC9225738,rlxraw,TREATMENT,PMC,,,,
PMC9225738,plain formula,TREATMENT,PMC,C4550703,Core Essentials Pediatric Formula 1.2 Cal/mL Total Nutrition (Plain),GS,Food
PMC9225738,optimized rlxplmel,TREATMENT,PMC,,,,
PMC9225738,ic50concentrations,TEST,PMC,,,,
PMC9225738,cell cycle analysis,TEST,PMC,C4087005,Cell Cycle Profile,NCI,Laboratory or Test Result
PMC9225738,the nanovesicle,PROBLEM,PMC,C4722694,SapC-DOPS Nanovesicles,NCI,"Organic Chemical, Pharmacologic Substance"
PMC9225738,bax,TEST,PMC,C0812198,BAX gene,MTH,Gene or Genome
PMC9225738,bcl2 estimates,TEST,PMC,,,,
PMC9225738,optimized rlx formula,TREATMENT,PMC,,,,
PMC9225738,the highest apoptotic activity,PROBLEM,PMC,,,,
PMC9225738,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC9225738,rlx,TREATMENT,PMC,,,,
PMC9225738,plain formula,TREATMENT,PMC,C4550703,Core Essentials Pediatric Formula 1.2 Cal/mL Total Nutrition (Plain),GS,Food
PMC9225738,the optimized formula,TREATMENT,PMC,,,,
PMC9225738,a significant reduction of bcl2 and,PROBLEM,PMC,,,,
PMC9225738,nfb expression,TEST,PMC,,,,
PMC9225738,mitochondrial membrane potential mmp analysis,TEST,PMC,,,,
PMC9225738,the apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC9225738,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9225738,the optimized formula,TREATMENT,PMC,,,,
PMC9225738,the present study,TEST,PMC,C2207391,nerve conduction study anomalous innervation screen anomalous innervation present,MEDCIN,Finding
PMC9225738,the rlx,TREATMENT,PMC,C0963485,"6,7,8,9,10,12-hexahydroazepino(2,1-b)quinazolin-12-one",MSH,Organic Chemical
PMC9225738,phospholipid conjugated melittin,TREATMENT,PMC,,,,
PMC9225738,a novel treatment approach,TREATMENT,PMC,,,,
PMC9225738,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9225738,a promising nanovesicle formula,TREATMENT,PMC,,,,
PMC9225738,pc cell line,PROBLEM,PMC,C3890720,PC-3 cell line,MTH,Cell
PMC9225738,this investigation,TEST,PMC,C3842277,One of my relatives has already participated in this investigation,LNC,Finding
PMC9225738,an optimized rlxplmel,TREATMENT,PMC,,,,
PMC9225738,minimum particle size,TREATMENT,PMC,,,,
PMC9225738,maximum zeta potential,TREATMENT,PMC,,,,
PMC9225738,maximum entrapment efficiency ,TREATMENT,PMC,,,,
PMC9225738,optimized nanovesicles,TREATMENT,PMC,,,,
PMC9225738,polynomial equations,TEST,PMC,,,,
PMC9225738,various independent factors over responses,PROBLEM,PMC,,,,
PMC9225738,panc1 cells,PROBLEM,PMC,,,,
PMC9225738,optimized rlxplmel,TREATMENT,PMC,,,,
PMC9225738,rlxraw,TREATMENT,PMC,,,,
PMC9225738,plain formula,TREATMENT,PMC,C4550703,Core Essentials Pediatric Formula 1.2 Cal/mL Total Nutrition (Plain),GS,Food
PMC9225738,enhanced antipc activity,TREATMENT,PMC,,,,
PMC9225738,superior apoptosis,PROBLEM,PMC,,,,
PMC9225738,rlx,TREATMENT,PMC,,,,
PMC9225738,plain formula,TREATMENT,PMC,C4550703,Core Essentials Pediatric Formula 1.2 Cal/mL Total Nutrition (Plain),GS,Food
PMC9225738,rlxplmel,TREATMENT,PMC,,,,
PMC9225738,a novel promising treatment approach,TREATMENT,PMC,,,,
PMC9225738,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7330738,pancreatic and periampullary cancers,PROBLEM,PMC,,,,
PMC7330738,high mortality rates,PROBLEM,PMC,,,,
PMC7330738,surgical removal,TREATMENT,PMC,C1293139,Surgical extraction,MTH,Therapeutic or Preventive Procedure
PMC7330738,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC7330738,pancreatic surgery,TREATMENT,PMC,C2033062,pancreatic surgery,MEDCIN,Therapeutic or Preventive Procedure
PMC7330738,their symptoms,PROBLEM,PMC,,,,
PMC7330738,selfcare,TREATMENT,PMC,C0036592,Self-care interventions,MTH,Daily or Recreational Activity
PMC7330738,unmet supportive care needs,TREATMENT,PMC,,,,
PMC7330738,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7330738,personcentered care,TREATMENT,PMC,,,,
PMC7330738,pancreatic cancer surgery,TREATMENT,PMC,,,,
PMC7330738,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7330738,selfcare,TREATMENT,PMC,C0036592,Self-care interventions,MTH,Daily or Recreational Activity
PMC7330738,patients symptom burden,PROBLEM,PMC,C3533830,Symptom burden score:Score:Pt:^Patient:Qn:KCCQ,LNC,Clinical Attribute
PMC7330738,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC7330738,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC7330738,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC7330738,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC7330738,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC7330738,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC7330738,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7330738,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC7330738,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7330738,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7330738,alerting symptoms,PROBLEM,PMC,C4711874,Be alert to the need to treat worsening symptoms urgently,NIC,Health Care Activity
PMC7330738,reported symptoms,PROBLEM,PMC,C2186404,reported home blood sugar check during symptoms,MEDCIN,Finding
PMC7330738,descriptive statistics,TEST,PMC,C5236893,Statistical Analysis Plan Version Description,NCI,Intellectual Product
PMC7330738,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC7330738,thematic analysis,TEST,PMC,,,,
PMC7330738,symptom reporting,PROBLEM,PMC,C5979552,Symptom Impact:-:RptPeriod:^Patient:-:CMS Assessment,LNC,Clinical Attribute
PMC7330738,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC7330738,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC7330738,the most reported symptoms,PROBLEM,PMC,,,,
PMC7330738,alerting symptoms,PROBLEM,PMC,C4711874,Be alert to the need to treat worsening symptoms urgently,NIC,Health Care Activity
PMC7330738,fever,PROBLEM,PMC,C0015967,Fever,MTH,Sign or Symptom
PMC7330738,the selfcare advice,TREATMENT,PMC,,,,
PMC7330738,pancreatic enzyme supplements,TREATMENT,PMC,,,,
PMC7330738,the interviews,TEST,PMC,C0021822,Interview,MTH,Activity
PMC7330738,selfcare,TREATMENT,PMC,C0036592,Self-care interventions,MTH,Daily or Recreational Activity
PMC7330738,personcentered care,TREATMENT,PMC,,,,
PMC7330738,individual supportive care needs,TREATMENT,PMC,C5915792,Tailor care toward individual and groups with greatest needs to provide more resources and support,NIC,Health Care Activity
PMC7330738,our recent studies,TEST,PMC,,,,
PMC7330738,less symptom burden,PROBLEM,PMC,,,,
PMC7330738,higher selfcare activity levels,PROBLEM,PMC,,,,
PMC7330738,standard care,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC7330738,interaktor,TREATMENT,PMC,,,,
PMC7330738,selfcare,TREATMENT,PMC,C0036592,Self-care interventions,MTH,Daily or Recreational Activity
PMC7330738,personcentered care,TREATMENT,PMC,,,,
PMC7330738,individual supportive care needs,TREATMENT,PMC,C5915792,Tailor care toward individual and groups with greatest needs to provide more resources and support,NIC,Health Care Activity
PMC7330738,our recent studies,TEST,PMC,,,,
PMC7330738,less symptom burden,PROBLEM,PMC,,,,
PMC7330738,higher selfcare activity levels,PROBLEM,PMC,,,,
PMC7330738,standard care,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC7330738,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC7330738,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC7330738,selfcare,TREATMENT,PMC,C0036592,Self-care interventions,MTH,Daily or Recreational Activity
PMC7330738,personcentered care,TREATMENT,PMC,,,,
PMC7330738,individual supportive care needs,TREATMENT,PMC,C5915792,Tailor care toward individual and groups with greatest needs to provide more resources and support,NIC,Health Care Activity
PMC7330738,our recent studies,TEST,PMC,,,,
PMC7330738,less symptom burden,PROBLEM,PMC,,,,
PMC7330738,higher selfcare activity levels,PROBLEM,PMC,,,,
PMC7330738,standard care,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC7330738,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7330738,mhealth support systems,TREATMENT,PMC,,,,
PMC7330738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11566511,pancreatic carcinoma,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11566511,an aggressive cancer,PROBLEM,PMC,C2945759,aggressive cancer,CHV,Neoplastic Process
PMC11566511,many symptoms,PROBLEM,PMC,C0349205,Mania without psychotic symptoms,ICD10,Mental or Behavioral Dysfunction
PMC11566511,traditional treatments,TREATMENT,PMC,C3250936,discussed concerns about importance of family customs and traditions,MEDCIN,Health Care Activity
PMC11566511,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11566511,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11566511,gene therapy,TREATMENT,PMC,C0017296,gene therapy,MTH,Therapeutic or Preventive Procedure
PMC11566511,increase survival rates,TREATMENT,PMC,,,,
PMC11566511,small interfering ribonucleic acid,TREATMENT,PMC,C1099354,"RNA, Small Interfering",MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC11566511,a promising advanced therapeutic strategy,TREATMENT,PMC,,,,
PMC11566511,cancer treatment,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC11566511,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11566511,the human pancreatic carcinoma cell line,PROBLEM,PMC,,,,
PMC11566511,small interfering ribonucleic acid,TREATMENT,PMC,C1099354,"RNA, Small Interfering",MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC11566511,gold nanoparticles,TREATMENT,PMC,C3824478,response to gold nanoparticle,GO,Cell Function
PMC11566511,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11566511,25 nm sirna,TREATMENT,PMC,,,,
PMC11566511,gold nanoparticles,TREATMENT,PMC,C3824478,response to gold nanoparticle,GO,Cell Function
PMC11566511,realtime pcr analysis,TEST,PMC,,,,
PMC11566511,agarose gel electrophoresis,TEST,PMC,C0013856,"Electrophoresis, Agar Gel",MSH,Laboratory Procedure
PMC11566511,double staining,TEST,PMC,C0201404,"Fluorescent treponemal absorption test, double staining test",SNOMEDCT_US,Laboratory Procedure
PMC11566511,xcelligence realtime cell analysis,TEST,PMC,,,,
PMC11566511,proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC11566511,the pcr analysis,TEST,PMC,C2733022,Quantitative PCR analysis,SNOMEDCT_US,Laboratory Procedure
PMC11566511,crossing point,TEST,PMC,C5236085,Cross-Linked Chemical Connection Points,NCI,Chemical Viewed Structurally
PMC11566511,actin beta actb,TEST,PMC,,,,
PMC11566511,all samples,TEST,PMC,C5914950,Expel all air from syringe by holding sample upright and gently tapping,NIC,Health Care Activity
PMC11566511,the gold nanoparticlesirna complex,TREATMENT,PMC,,,,
PMC11566511,the double staining analysis,TEST,PMC,,,,
PMC11566511,gold nanoparticle,TREATMENT,PMC,C3824478,response to gold nanoparticle,GO,Cell Function
PMC11566511,the wst1 technique,TEST,PMC,,,,
PMC11566511,sirnaaupei cells,TREATMENT,PMC,,,,
PMC11566511,a viability rate,TEST,PMC,,,,
PMC11566511,toxicity,PROBLEM,PMC,C0040539,Toxicity aspects,MTH,Qualitative Concept
PMC11566511,side effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC11566511,the xcelligence rtca,TEST,PMC,,,,
PMC11566511,a significant difference in proliferation,PROBLEM,PMC,,,,
PMC11566511,the 05 mgml peiaunpsirna,TREATMENT,PMC,,,,
PMC11566511,sirna groups,TREATMENT,PMC,,,,
PMC11566511,sirna groups,TREATMENT,PMC,,,,
PMC11566511,proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC11566511,this analysis,TEST,PMC,,,,
PMC11566511,the aupeisirna complex,TREATMENT,PMC,,,,
PMC11566511,more studies,TEST,PMC,C3510339,"Nerve conduction, 13 or more studies",CPT,Diagnostic Procedure
PMC11566511,this analysis,TEST,PMC,,,,
PMC11566511,the aupeisirna complex,TREATMENT,PMC,,,,
PMC11566511,more studies,TEST,PMC,C3510339,"Nerve conduction, 13 or more studies",CPT,Diagnostic Procedure
PMC11566511,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11566511,sirnamediated gene silencing,TREATMENT,PMC,,,,
PMC11566511,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC11566511,the gold nanoparticlesikras complex,TREATMENT,PMC,,,,
PMC11566511,pei,TREATMENT,PMC,C0814202,Personal Experience Inventory,MTH,Intellectual Product
PMC11566511,capan1,TEST,PMC,,,,
PMC11566511,the kras protein,TEST,PMC,C2353283,"Kras protein, rat",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC11566511,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11566511,new therapies,TREATMENT,PMC,C3242274,new therapy,HL7V3.0,Finding
PMC11566511,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9652687,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9652687,any symptoms,PROBLEM,PMC,C5706833,PRO-CTCAE V1.0 - Any Other Symptoms Reported,NCI,Intellectual Product
PMC9652687,metastatic process,PROBLEM,PMC,C1504701,"NME1 protein, human",MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC9652687,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9652687,novel treatment strategies,TREATMENT,PMC,,,,
PMC9652687,antiinvasive and antimetastatic strategies,TREATMENT,PMC,,,,
PMC9652687,the cytotoxic,TREATMENT,PMC,C1511636,cytotoxic,MTH,Functional Concept
PMC9652687,juglone,TREATMENT,PMC,C0064170,juglone,MSH,"Organic Chemical, Pharmacologic Substance"
PMC9652687,various cancer cells,PROBLEM,PMC,,,,
PMC9652687,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9652687,juglone,TREATMENT,PMC,C0064170,juglone,MSH,"Organic Chemical, Pharmacologic Substance"
PMC9652687,selenium,TREATMENT,PMC,C0036581,selenium,MTH,"Pharmacologic Substance, Biologically Active Substance, Element, Ion, or Isotope"
PMC9652687,panc1,PROBLEM,PMC,C2987413,siG12D LODER,DRUGBANK,"Organic Chemical, Pharmacologic Substance"
PMC9652687,bxpc3 pancreatic cancer cells,PROBLEM,PMC,,,,
PMC9652687,juglonenase,TREATMENT,PMC,,,,
PMC9652687,adhesion and invasion assays,TEST,PMC,,,,
PMC9652687,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9652687,protein expressions,TEST,PMC,C1171362,protein expression,MTH,Genetic Function
PMC9652687,expression analysis,TEST,PMC,C1882495,Protein Expression Analysis,NCI,Laboratory Procedure
PMC9652687,the cdh1,TEST,PMC,C0694872,CDH1 gene,MTH,Gene or Genome
PMC9652687,3 integrin,TREATMENT,PMC,,,,
PMC9652687,tumstatin,TREATMENT,PMC,C4316931,"Tumstatin, human",MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC9652687,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC9652687,angiogenesis processes,PROBLEM,PMC,,,,
PMC9652687,qpcr,TEST,PMC,C1709846,Real-Time Polymerase Chain Reaction,MTH,Molecular Biology Research Technique
PMC9652687,immunohistochemical analysis,TEST,PMC,C2828147,p16 Immunohistochemical Expression Analysis,NCI,Laboratory Procedure
PMC9652687,study findings,TEST,PMC,C0683954,Study Results,NCI,Finding
PMC9652687,a cytotoxic and dose dependent,TREATMENT,PMC,,,,
PMC9652687,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC9652687,metastasis in panc1,PROBLEM,PMC,,,,
PMC9652687,the juglonenase,TREATMENT,PMC,,,,
PMC9652687,a promising agent,TREATMENT,PMC,,,,
PMC9652687,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC9652687,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC9652687,pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC9652687,depth studies,TEST,PMC,C0802606,Insertion depth:Len:Stdy:Gastrointestinal tract.upper:Qn:EGD,LNC,Clinical Attribute
PMC9652687,jugloneselenium,TREATMENT,PMC,,,,
PMC9652687,the juglonenase,TREATMENT,PMC,,,,
PMC9652687,a promising agent,TREATMENT,PMC,,,,
PMC9652687,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC9652687,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC9652687,pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC9652687,depth studies,TEST,PMC,C0802606,Insertion depth:Len:Stdy:Gastrointestinal tract.upper:Qn:EGD,LNC,Clinical Attribute
PMC9652687,jugloneselenium,TREATMENT,PMC,,,,
PMC11442445,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11442445,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11442445,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC11442445,available,TEST,PMC,C0470187,Availability of,SNOMEDCT_US,Functional Concept
PMC11442445,comprehensive serum mirna sequencing,TEST,PMC,,,,
PMC11442445,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11442445,the pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC11442445,a training,TEST,PMC,C0220931,Training,MTH,Educational Activity
PMC11442445,a validation cohort,TEST,PMC,,,,
PMC11442445,ensemble,TEST,PMC,C5940529,Ensemble Learning,MSH,Machine Activity
PMC11442445,automated,TREATMENT,PMC,C0205554,Automated (qualifier value),MTH,Functional Concept
PMC11442445,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11442445,the diagnostic model,TEST,PMC,C0204139,Diagnostic model construction,SNMI,Diagnostic Procedure
PMC11442445,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11442445,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11442445,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11442445,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11442445,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11442445,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11442445,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7156736,mutations inkrasresult,PROBLEM,PMC,,,,
PMC7156736,a constitutively activated mapk pathway,PROBLEM,PMC,,,,
PMC7156736,inkrasmutant tumours,PROBLEM,PMC,,,,
PMC7156736,existing treatment options,TREATMENT,PMC,,,,
PMC7156736,mek inhibition,TREATMENT,PMC,C2347168,Mitogen-Activated Protein Kinase Kinase Inhibitor,MTH,Pharmacologic Substance
PMC7156736,epidermal growth factor receptors,TREATMENT,PMC,C0034802,Epidermal Growth Factor Receptor,MTH,"Amino Acid, Peptide, or Protein, Enzyme, Receptor"
PMC7156736,this phase 1 study,TEST,PMC,,,,
PMC7156736,the panher inhibitor dacomitinib,TREATMENT,PMC,,,,
PMC7156736,the mek12 inhibitor pd0325901,TREATMENT,PMC,,,,
PMC7156736,pancreatic and nonsmallcell lung cancer,PROBLEM,PMC,,,,
PMC7156736,escalating oral doses,TREATMENT,PMC,,,,
PMC7156736,dacomitinib,TREATMENT,PMC,C2987430,dacomitinib,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7156736,11 nsclc,PROBLEM,PMC,,,,
PMC7156736,3 pancreatic cancer,PROBLEM,PMC,C3150547,"PANCREATIC CANCER, SUSCEPTIBILITY TO, 3",MTH,Finding
PMC7156736,doselimiting toxicities,PROBLEM,PMC,,,,
PMC7156736,the rp2d,TREATMENT,PMC,,,,
PMC7156736,continuous dacomitinib dosing,TREATMENT,PMC,,,,
PMC7156736,dacomitinib,TREATMENT,PMC,C2987430,dacomitinib,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7156736,pd0325901,TREATMENT,PMC,C1675748,PD-0325901,DRUGBANK,"Organic Chemical, Pharmacologic Substance"
PMC7156736,major toxicity,PROBLEM,PMC,,,,
PMC7156736,rash,PROBLEM,PMC,C5779628,Skin rash,MTH,Sign or Symptom
PMC7156736,diarrhoea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC7156736,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC7156736,longterm treatment,TREATMENT,PMC,C5389516,placement of longterm midline catheter with fluoroscopic angiography guidance,MEDCIN,Therapeutic or Preventive Procedure
PMC7156736,other intermittent schedules,TREATMENT,PMC,,,,
PMC7156736,slightly improved toxicity,PROBLEM,PMC,,,,
PMC7156736,tumour regression,PROBLEM,PMC,C1300743,Tumor regression finding,SNOMEDCT_US,Finding
PMC7156736,the longest treatment,TREATMENT,PMC,C0801703,Longest period of sobriety:Time:Pt:^Patient:Qn,LNC,Clinical Attribute
PMC7156736,nsclc,PROBLEM,PMC,C0007131,Non-Small Cell Lung Carcinoma,MTH,Neoplastic Process
PMC7156736,antitumour activity in nsclc,PROBLEM,PMC,,,,
PMC7156736,further exploration,TEST,PMC,,,,
PMC7156736,this combination inkrasmutant patients,TREATMENT,PMC,,,,
PMC7156736,antitumour activity in nsclc,PROBLEM,PMC,,,,
PMC7156736,further exploration,TEST,PMC,,,,
PMC7156736,this combination inkrasmutant patients,TREATMENT,PMC,,,,
PMC8112949,sleep disturbances,PROBLEM,PMC,C0037317,Sleep disturbances,MTH,Finding
PMC8112949,such disturbances,PROBLEM,PMC,C5676356,"Vascular dementia, mild, with behavioral disturbances such as sleep disturbance, social disinhibition, or sexual disinhibition",ICD10CM,Disease or Syndrome
PMC8112949,our study,TEST,PMC,,,,
PMC8112949,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC8112949,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8112949,recent pancreaticoduodenectomy,TREATMENT,PMC,,,,
PMC8112949,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8112949,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC8112949,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC8112949,the pittsburgh,TEST,PMC,C4015819,PI PITTSBURGH PHENOTYPE,MTH,Finding
PMC8112949,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC8112949,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC8112949,these symptoms,PROBLEM,PMC,C3175527,How long did these symptoms last,LNC,Intellectual Product
PMC8112949,the insomnia severity index,PROBLEM,PMC,C4520529,Insomnia severity index,MTH,Intellectual Product
PMC8112949,mild insomnia,PROBLEM,PMC,,,,
PMC8112949,moderate to severe insomnia,PROBLEM,PMC,,,,
PMC8112949,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8112949,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC8112949,their sleep disturbances,PROBLEM,PMC,,,,
PMC8112949,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC8112949,mild insomnia,PROBLEM,PMC,,,,
PMC8112949,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC8112949,moderate to severe insomnia,PROBLEM,PMC,,,,
PMC8112949,the mean isi score,TEST,PMC,,,,
PMC8112949,the mean psqi score,TEST,PMC,,,,
PMC8112949,isi,TEST,PMC,C4520529,Insomnia severity index,MTH,Intellectual Product
PMC8112949,psqi,TEST,PMC,C3697468,Pittsburgh sleep quality index,SNOMEDCT_US,Intellectual Product
PMC8112949,a strong positive correlation,PROBLEM,PMC,,,,
PMC8112949,sleep disturbances,PROBLEM,PMC,C0037317,Sleep disturbances,MTH,Finding
PMC8112949,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC8112949,pancreatic cancer surgery,TREATMENT,PMC,,,,
PMC8112949,sleep disorders,PROBLEM,PMC,C0851578,Sleep Disorders,MTH,Mental or Behavioral Dysfunction
PMC8112949,sleep disturbances,PROBLEM,PMC,C0037317,Sleep disturbances,MTH,Finding
PMC8112949,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC8112949,pancreatic cancer surgery,TREATMENT,PMC,,,,
PMC8112949,sleep disorders,PROBLEM,PMC,C0851578,Sleep Disorders,MTH,Mental or Behavioral Dysfunction
PMC9090359,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,crosssectional study,TEST,PMC,,,,
PMC9090359,incident pancreatic cancer,PROBLEM,PMC,,,,
PMC9090359,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9090359,general practice,TREATMENT,PMC,C0086343,general practice (field),MTH,Biomedical Occupation or Discipline
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,serious illness,PROBLEM,PMC,C2020635,stress associated with serious illness,MEDCIN,Finding
PMC9090359,high comorbidity,PROBLEM,PMC,,,,
PMC9090359,a cpp referral,TREATMENT,PMC,,,,
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,presenting symptoms,PROBLEM,PMC,C3177142,Main presenting symptom,LNC,Sign or Symptom
PMC9090359,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9090359,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9090359,other serious illness,PROBLEM,PMC,C3172704,Have you ever continued to drink when you knew you had any other serious physical illness or condition that might be made worse by drinking,LNC,Intellectual Product
PMC9090359,high comorbidity,PROBLEM,PMC,,,,
PMC9090359,low education,PROBLEM,PMC,C0418844,Low fat diet education,SNOMEDCT_US,Health Care Activity
PMC9090359,a cpp,TEST,PMC,C0293505,CPP 200,MSH,Organic Chemical
PMC6749961,supplemental digital content,TREATMENT,PMC,,,,
PMC6749961,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6749961,its treatments,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC6749961,pancreatic exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC6749961,pancreatic enzyme replacement therapy,TREATMENT,PMC,C4523842,Pancreatic enzyme replacement therapy,MDR,Therapeutic or Preventive Procedure
PMC6749961,appropriate pert usage,TREATMENT,PMC,,,,
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,symptom alleviation,PROBLEM,PMC,C1274136,Symptom control (regime/therapy),MTH,Therapeutic or Preventive Procedure
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,indigestion,PROBLEM,PMC,C0235309,Upset stomach,MTH,Sign or Symptom
PMC6749961,significantly decreased,PROBLEM,PMC,C3151891,Significantly decreased axial length,OMIM,Finding
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,weight gain,PROBLEM,PMC,C0043094,Weight Gain,MTH,Finding
PMC6749961,less weight loss,PROBLEM,PMC,C4086031,Body Weight Loss Less Than 10 Pounds,NCI,Intellectual Product
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,pert administration guidelines,TREATMENT,PMC,,,,
PMC6749961,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,appropriate pert usage,TREATMENT,PMC,,,,
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,pert administration guidelines,TREATMENT,PMC,,,,
PMC6749961,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6749961,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6749961,appropriate pert usage,TREATMENT,PMC,,,,
PMC7236181,n6methyladenosine m6a,TREATMENT,PMC,,,,
PMC7236181,tumourigenesis,PROBLEM,PMC,,,,
PMC7236181,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7236181,the m6a demethylase alkbh5,TREATMENT,PMC,,,,
PMC7236181,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7236181,alkbh5,PROBLEM,PMC,C1823178,ALKBH5 gene,MTH,Gene or Genome
PMC7236181,pc cohorts,TEST,PMC,,,,
PMC7236181,alkbh5,PROBLEM,PMC,C1823178,ALKBH5 gene,MTH,Gene or Genome
PMC7236181,pc cells,PROBLEM,PMC,C3890720,PC-3 cell line,MTH,Cell
PMC7236181,lossoffunction analyses,TEST,PMC,,,,
PMC7236181,subcutaneous and orthotopic models,TEST,PMC,,,,
PMC7236181,tumour growth,PROBLEM,PMC,C0201601,Tumor growth factor assay,SNOMEDCT_US,Laboratory Procedure
PMC7236181,mrna and m6a sequencing,TEST,PMC,,,,
PMC7236181,assays,TEST,PMC,C2717977,Enzyme Assays,MSH,Laboratory Procedure
PMC7236181,m6a methylated rna immunoprecipitationqpcr,TEST,PMC,,,,
PMC7236181,p53binding sites,PROBLEM,PMC,,,,
PMC7236181,chip,TEST,PMC,C0600596,DNA Microarray Chip,MTH,Research Device
PMC7236181,alkbh5,TREATMENT,PMC,C1823178,ALKBH5 gene,MTH,Gene or Genome
PMC7236181,alkbh5 loss,PROBLEM,PMC,,,,
PMC7236181,poor clinicopathological manifestations,PROBLEM,PMC,,,,
PMC7236181,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7236181,alkbh5,TREATMENT,PMC,C1823178,ALKBH5 gene,MTH,Gene or Genome
PMC7236181,tumoural proliferative,PROBLEM,PMC,C0334494,Proliferating Brenner Tumor,MTH,Neoplastic Process
PMC7236181,alkbh5 knockdown,TREATMENT,PMC,,,,
PMC7236181,pc progression,PROBLEM,PMC,,,,
PMC7236181,m6a demethylation,TREATMENT,PMC,,,,
PMC7236181,an m6aythdf2dependent manner,TREATMENT,PMC,,,,
PMC7236181,per1 upregulation,PROBLEM,PMC,,,,
PMC7236181,atmchk2p53cdc25c signalling,TREATMENT,PMC,,,,
PMC7236181,cell growth,PROBLEM,PMC,C0007595,Cell Growth,MTH,Cell Function
PMC7236181,a feedback loop,TREATMENT,PMC,C0682724,CNS loop,AOD,"Body Part, Organ, or Organ Component"
PMC7236181,the m6a,TREATMENT,PMC,C0067228,N-methyladenosine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC7236181,a pc suppressor,TREATMENT,PMC,,,,
PMC7236181,a demethylationbased approach,TREATMENT,PMC,,,,
PMC7236181,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC7236181,a pc suppressor,TREATMENT,PMC,,,,
PMC7236181,a demethylationbased approach,TREATMENT,PMC,,,,
PMC7236181,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC6378466,advanced adenocarcinoma of the pancreas,PROBLEM,PMC,,,,
PMC6378466,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6378466,pancreatic exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC6378466,a malabsorption syndrome,PROBLEM,PMC,C0024523,Malabsorption Syndrome,MTH,Disease or Syndrome
PMC6378466,subsequent digestive symptoms,PROBLEM,PMC,,,,
PMC6378466,pei,PROBLEM,PMC,C0814202,Personal Experience Inventory,MTH,Intellectual Product
PMC6378466,malabsorption in pc,PROBLEM,PMC,,,,
PMC6378466,pancreatic enzyme replacement therapy,TREATMENT,PMC,C4523842,Pancreatic enzyme replacement therapy,MDR,Therapeutic or Preventive Procedure
PMC6378466,this pilot study,TEST,PMC,,,,
PMC6378466,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6378466,improving symptoms,PROBLEM,PMC,C5852836,Until symptoms improve,SNOMEDCT_US,Temporal Concept
PMC6378466,metastatic pc,PROBLEM,PMC,,,,
PMC6378466,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC6378466,advanced pc,PROBLEM,PMC,,,,
PMC6378466,an initial assessment,TEST,PMC,C0419941,Urinary: initial assessment,SNOMEDCT_US,Health Care Activity
PMC6378466,pancrealipase,TREATMENT,PMC,C0770343,pancrelipase,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Enzyme"
PMC6378466,supplementation,TREATMENT,PMC,C0242297,Dietary Supplementation,MTH,Therapeutic or Preventive Procedure
PMC6378466,these assessments,TEST,PMC,,,,
PMC6378466,malabsorption symptom checklist,PROBLEM,PMC,,,,
PMC6378466,cancer qlqc30,TEST,PMC,,,,
PMC6378466,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6378466,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6378466,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6378466,pert initiation,TREATMENT,PMC,C2364087,Loss of initiative,MTH,Finding
PMC6378466,a reduction in diarrhoea scores,PROBLEM,PMC,,,,
PMC6378466,pancreatic and hepatic pain,PROBLEM,PMC,,,,
PMC6378466,pancreatic pain,PROBLEM,PMC,C0522071,Pancreatic pain,SNOMEDCT_US,Sign or Symptom
PMC6378466,bloatinggas,PROBLEM,PMC,,,,
PMC6378466,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6378466,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6378466,malabsorption,PROBLEM,PMC,C3714745,Malabsorption,MTH,Finding
PMC6378466,metastatic pc,PROBLEM,PMC,,,,
PMC6378466,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6378466,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC6378466,a safe therapy,TREATMENT,PMC,C0589275,Safe swallow technique,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6378466,malabsorption symptoms,PROBLEM,PMC,,,,
PMC6378466,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6378466,a positive impact on symptoms,PROBLEM,PMC,,,,
PMC6378466,international guidelines,TREATMENT,PMC,C5786776,"Childhood Malignant Kidney Neoplasm Excluding Renal Cell Carcinoma by Toronto Guidelines v2 Stage, International Society of Pediatric Oncology (SIOP) Protocol",NCI,Classification
PMC8362519,pylephlebitis,PROBLEM,PMC,C0034192,Phlebitis of portal vein,MTH,Disease or Syndrome
PMC8362519,a rare condition,PROBLEM,PMC,,,,
PMC8362519,a pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC8362519,a fish bone,PROBLEM,PMC,C0016153,Fish bone,SNOMEDCT_US,Food
PMC8362519,fever,PROBLEM,PMC,C0015967,Fever,MTH,Sign or Symptom
PMC8362519,loss of appetite,PROBLEM,PMC,C3814874,Loss of Appetite question,MTH,Intellectual Product
PMC8362519,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC8362519,tenderness in the right upper quadrant,PROBLEM,PMC,C3164070,Tenderness of right upper quadrant of abdomen,SNOMEDCT_US,Sign or Symptom
PMC8362519,inflammation marker,TEST,PMC,C5698558,True Marker Inflammation Test,GS,Medical Device
PMC8362519,a computed tomography ct scan,TEST,PMC,C5202483,CT scan for biomechanical computed tomography analysis,CPT,Diagnostic Procedure
PMC8362519,gallstones,PROBLEM,PMC,C0947622,Cholecystolithiasis,MTH,Disease or Syndrome
PMC8362519,acute pancreatitis,PROBLEM,PMC,C0001339,"Pancreatitis, Acute",MSH,Disease or Syndrome
PMC8362519,her condition,PROBLEM,PMC,C4533004,I am able to help this person maintain lifestyle changes (like eating right or exercising) for her or his condition,LNC,Intellectual Product
PMC8362519,a magnetic resonance,TEST,PMC,C0917874,Magnetic Resonance,MTH,Natural Phenomenon or Process
PMC8362519,multifocal liver lesions,PROBLEM,PMC,,,,
PMC8362519,a cholangiopancreatography,TEST,PMC,C5545559,Cholangiopancreatography catheter,SNOMEDCT_US,Medical Device
PMC8362519,an endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC8362519,specific treatment,TREATMENT,PMC,C4716648,Specific treatment regimen,NOC,Finding
PMC8362519,pylephlebitis,PROBLEM,PMC,C0034192,Phlebitis of portal vein,MTH,Disease or Syndrome
PMC8362519,a fish bone,PROBLEM,PMC,C0016153,Fish bone,SNOMEDCT_US,Food
PMC8362519,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC8362519,traditional imaging studies,TEST,PMC,,,,
PMC8362519,transabdominal us,TEST,PMC,C1633471,Multisection transabdominal:Find:Pt:Pelvis:Nar:US,LNC,Clinical Attribute
PMC8362519,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC8362519,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC8362519,pylephlebitis,PROBLEM,PMC,C0034192,Phlebitis of portal vein,MTH,Disease or Syndrome
PMC8362519,a fish bone,PROBLEM,PMC,C0016153,Fish bone,SNOMEDCT_US,Food
PMC8362519,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC8362519,traditional imaging studies,TEST,PMC,,,,
PMC8362519,transabdominal us,TEST,PMC,C1633471,Multisection transabdominal:Find:Pt:Pelvis:Nar:US,LNC,Clinical Attribute
PMC8362519,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC8362519,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC8362519,dangerous complication,PROBLEM,PMC,,,,
PMC8362519,pylephlebitis,PROBLEM,PMC,C0034192,Phlebitis of portal vein,MTH,Disease or Syndrome
PMC8362519,early treatment,TREATMENT,PMC,C0814494,early treatment phase,AOD,Health Care Activity
PMC8362519,broadspectrum antibiotic therapy,TREATMENT,PMC,,,,
PMC8362519,anticoagulation,TREATMENT,PMC,C0003281,Anticoagulation Therapy,MTH,Therapeutic or Preventive Procedure
PMC8362519,unexplained fever,PROBLEM,PMC,C1844662,Unexplained fevers,HPO,Finding
PMC8362519,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC8362519,pylephlebitis,PROBLEM,PMC,C0034192,Phlebitis of portal vein,MTH,Disease or Syndrome
PMC8362519,a fish bone,PROBLEM,PMC,C0016153,Fish bone,SNOMEDCT_US,Food
PMC8362519,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC8362519,clinical findings,TEST,PMC,C0037088,Signs and Symptoms,MTH,Sign or Symptom
PMC8362519,traditional imaging studies,TEST,PMC,,,,
PMC8362519,transabdominal us,TEST,PMC,C1633471,Multisection transabdominal:Find:Pt:Pelvis:Nar:US,LNC,Clinical Attribute
PMC8362519,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC8362519,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC8362519,an alternative instrument,TREATMENT,PMC,,,,
PMC8362519,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC10214075,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10214075,its treatment,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC10214075,cardiorespiratory fitness,PROBLEM,PMC,C2981722,Cardiorespiratory Fitness,MSH,Organism Function
PMC10214075,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10214075,borderline resectable pancreatic cancer,PROBLEM,PMC,C4763562,Borderline Resectable Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC10214075,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10214075,folfirinox neoadjuvant chemotherapy,TREATMENT,PMC,,,,
PMC10214075,a whipple procedure,TREATMENT,PMC,C4038811,History of Whipple procedure,SNOMEDCT_US,Finding
PMC10214075,a right hemicolectomy,TREATMENT,PMC,C0192861,Right colectomy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10214075,venous segment resection,TREATMENT,PMC,,,,
PMC10214075,adjuvant folfirinox chemotherapy,TREATMENT,PMC,,,,
PMC10214075,moderate to vigorous physical activity,PROBLEM,PMC,C4034481,Days per week of moderate to vigorous physical activity,MTH,Finding
PMC10214075,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10214075,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10214075,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10214075,adjuvant chemotherapy,TREATMENT,PMC,C0085533,"Chemotherapy, Adjuvant",MTH,Therapeutic or Preventive Procedure
PMC10214075,estimated vo2max,TEST,PMC,,,,
PMC10214075,neoadjuvant chemotherapy,TREATMENT,PMC,C5392214,Neoadjuvant Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC10214075,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10214075,heart rate,TEST,PMC,C0018810,heart rate,MTH,Clinical Attribute
PMC10214075,heart rate variability,TEST,PMC,C4761043,Heart rate variability test,MDR,Diagnostic Procedure
PMC10214075,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10214075,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10214075,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10214075,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10214075,its treatment,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC10214075,the last chemotherapy recovery,TREATMENT,PMC,,,,
PMC10214075,telemonitoring,TEST,PMC,C3898905,Health Telemonitoring,NCI,Health Care Activity
PMC10214075,wearable heath data,TREATMENT,PMC,,,,
PMC10214075,telemonitoring,TREATMENT,PMC,C3898905,Health Telemonitoring,NCI,Health Care Activity
PMC10214075,cancer treatment,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC10214075,disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10214075,continuous monitoring,TEST,PMC,C0420200,Continuous ECG monitoring,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10214075,various complex underlying processes,PROBLEM,PMC,,,,
PMC7769744,total pancreatectomy,TREATMENT,PMC,C0040511,Total pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC7769744,a therapeutic option,TREATMENT,PMC,,,,
PMC7769744,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7769744,whipple surgery,TREATMENT,PMC,C0747191,PANCREAS SURGERY WHIPPLE PROCEDURE,CCPSS,Therapeutic or Preventive Procedure
PMC7769744,distal pancreatectomy,TREATMENT,PMC,C0176940,Distal subtotal pancreatectomy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC7769744,brittle diabetes,PROBLEM,PMC,C0342302,Brittle diabetes,MTH,Disease or Syndrome
PMC7769744,poor quality of,PROBLEM,PMC,C1262141,Poor quality sleep,MDR,Pathologic Function
PMC7769744,tp,TREATMENT,PMC,C1333327,TYMP gene,MTH,Gene or Genome
PMC7769744,severe hypoglycemia,PROBLEM,PMC,C4728082,Severe hypoglycaemia,MDR,Disease or Syndrome
PMC7769744,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7769744,the pancreatic head and proximal body,PROBLEM,PMC,,,,
PMC7769744,invasion to the pancreatic tail,PROBLEM,PMC,,,,
PMC7769744,partial pancreatic tail preserving subtotal pancreatectomy,TREATMENT,PMC,,,,
PMC7769744,postoperative glycemic control,TREATMENT,PMC,,,,
PMC7769744,compromising oncological outcomes,PROBLEM,PMC,,,,
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7769744,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,oncological outcomes,TREATMENT,PMC,,,,
PMC7769744,postoperative glycemic control,TREATMENT,PMC,,,,
PMC7769744,cancer,TREATMENT,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC7769744,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC7769744,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7769744,perioperative outcomes,TREATMENT,PMC,C5569287,Perioperative nursing data set outcomes panel,LNC,Intellectual Product
PMC7769744,recurrencefree survival,TREATMENT,PMC,,,,
PMC7769744,overall,TEST,PMC,C1561607,Overall,MTH,Qualitative Concept
PMC7769744,cancer recurrence in the pancreatic tail stump,PROBLEM,PMC,,,,
PMC7769744,splenic hilum,PROBLEM,PMC,C0229685,Structure of hilum of spleen,MTH,"Body Part, Organ, or Organ Component"
PMC7769744,a clinical pancreatic fistula,PROBLEM,PMC,,,,
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,insulinindependence,TREATMENT,PMC,,,,
PMC7769744,lower,TEST,PMC,C2003888,Lower (action),MTH,Activity
PMC7769744,lower daily insulin dosage,TREATMENT,PMC,,,,
PMC7769744,less frequent hypoglycemic episodes,PROBLEM,PMC,,,,
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,milder symptoms,PROBLEM,PMC,,,,
PMC7769744,less,PROBLEM,PMC,C0439092,Less Than,MTH,Quantitative Concept
PMC7769744,severe diet restriction,TREATMENT,PMC,,,,
PMC7769744,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,perioperative and oncological outcomes,TREATMENT,PMC,,,,
PMC7769744,longterm glycemic control,TREATMENT,PMC,,,,
PMC7769744,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,perioperative and oncological outcomes,TREATMENT,PMC,,,,
PMC7769744,longterm glycemic control,TREATMENT,PMC,,,,
PMC7769744,treating pancreatic cancer,PROBLEM,PMC,C1880059,Regimen Used to Treat Pancreatic Carcinoma,NCI,Therapeutic or Preventive Procedure
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,perioperative and oncological outcomes,TREATMENT,PMC,,,,
PMC7769744,longterm glycemic control,TREATMENT,PMC,,,,
PMC7769744,pptpsp,TREATMENT,PMC,,,,
PMC7769744,cancer recurrence in the remnant pancreas,PROBLEM,PMC,,,,
PMC7769744,splenic hilum,PROBLEM,PMC,C0229685,Structure of hilum of spleen,MTH,"Body Part, Organ, or Organ Component"
PMC7769744,a clinical pancreatic fistula,PROBLEM,PMC,,,,
PMC7769744,gastric bleeding,PROBLEM,PMC,C0235325,Gastric hemorrhage,MTH,Pathologic Function
PMC7769744,multicenter and,TEST,PMC,C1096776,Multicenter Study,MTH,Research Activity
PMC7769744,prospective studies,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC7769744,this procedure,TREATMENT,PMC,C2598204,Procedure this admission,LNC,Finding
PMC7888169,clinical management,TREATMENT,PMC,C1516615,Clinical Management,NCI,Health Care Activity
PMC7888169,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7888169,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC7888169,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7888169,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC7888169,tissue samples,TEST,PMC,C0475358,Tumor tissue sample,MTH,Tissue
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,minimal invasiveness,PROBLEM,PMC,C1881856,Minimally Invasive Lesion,NCI,Finding
PMC7888169,repeated sampling,TEST,PMC,C0430139,Repeated sampling for hormone pulsatility,SNOMEDCT_US,Laboratory Procedure
PMC7888169,multisite tumor bulks,PROBLEM,PMC,,,,
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7888169,many studies,TEST,PMC,C3171825,How many Y were you regularly exposed to this material:Time:Pt:^Patient:Qn:ACSCP Study II,LNC,Clinical Attribute
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7888169,residual disease,PROBLEM,PMC,C0543478,Residual Tumor,MTH,Neoplastic Process
PMC7888169,recurrence,PROBLEM,PMC,C0034897,Recurrence,MTH,Phenomenon or Process
PMC7888169,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,different studies,TEST,PMC,C5696439,Nuclear medicine study of bone taken at different times,CPT,Diagnostic Procedure
PMC7888169,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,integrated biomarkers,TEST,PMC,,,,
PMC7888169,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC7888169,dna extracellular vesicles,PROBLEM,PMC,,,,
PMC7888169,circulating dna,TEST,PMC,C4289789,Cell-Free DNA,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC7888169,cell free dna,TEST,PMC,C4289789,Cell-Free DNA,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC7888169,proteins,TEST,PMC,C0033684,Proteins,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,liquid,TREATMENT,PMC,C0301571,Liquid diet,MTH,Therapeutic or Preventive Procedure
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC7888169,clinical biomarkers,TEST,PMC,C2986107,Performed Clinical Result Biomarker Indicator,NCI,Qualitative Concept
PMC7888169,these tests,TEST,PMC,,,,
PMC8529923,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8529923,cancer mortality,PROBLEM,PMC,C1516192,Cancer Death Rate,NCI,Quantitative Concept
PMC8529923,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC8529923,specific biomarkers,PROBLEM,PMC,,,,
PMC8529923,available chemotherapies,TREATMENT,PMC,,,,
PMC8529923,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC8529923,cancer interception,PROBLEM,PMC,,,,
PMC8529923,a fullblown advanced tumor,PROBLEM,PMC,,,,
PMC8529923,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8529923,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC8529923,tissue biopsies,TEST,PMC,C4716580,Required tissue biopsies,NOC,Finding
PMC8529923,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8529923,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8529923,individually tailored treatments,TREATMENT,PMC,,,,
PMC8529923,carbohydrates proteins,TREATMENT,PMC,C1874717,CARBOHYDRATES/FATS/PROTEINS,VANDF,Pharmacologic Substance
PMC8529923,cellfree nucleic acids,TREATMENT,PMC,,,,
PMC8529923,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC8529923,metabolome compounds,PROBLEM,PMC,,,,
PMC8529923,exosomes,TEST,PMC,C2350332,Exosomes,MSH,Cell Component
PMC8529923,platelets,TEST,PMC,C0005821,Blood Platelets,MTH,Cell
PMC8529923,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8529923,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8529923,the screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC8529923,treatment guidance,TREATMENT,PMC,C4318551,Guidance for treatment,LNC,Therapeutic or Preventive Procedure
PMC8529923,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC8529923,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8529923,lesions,PROBLEM,PMC,C0221198,Lesion,MTH,Finding
PMC8529923,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC8529923,a wide time window,TREATMENT,PMC,,,,
PMC8529923,preventative interventions,TREATMENT,PMC,C1882456,Preventative Dietary Intervention,NCI,Therapeutic or Preventive Procedure
PMC8529923,the liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8529923,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8529923,relapse,PROBLEM,PMC,C0035020,Relapse,MTH,Phenomenon or Process
PMC8529923,metastatic progression,PROBLEM,PMC,C1620998,"Oncology; disease status; limited to non-small cell lung cancer; stage iii b- iv at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC8529923,futile treatments,TREATMENT,PMC,C0242650,Futile Treatment,MSH,Health Care Activity
PMC8529923,an inadequate sensitivity,PROBLEM,PMC,,,,
PMC8529923,a low concentration of biosources,PROBLEM,PMC,,,,
PMC8529923,cfdna,TEST,PMC,C4289789,Cell-Free DNA,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC8529923,ctcs,TEST,PMC,C0308749,CTC 70,SNMI,"Organic Chemical, Pharmacologic Substance"
PMC8529923,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8529923,liquid biopsy evaluation,TEST,PMC,,,,
PMC8529923,different isolation methodologies,TEST,PMC,,,,
PMC8529923,sensitivity values,TEST,PMC,C0332324,Sensitive,MTH,Functional Concept
PMC8529923,a pooled sensitivity,TEST,PMC,C3871188,aPTT.lupus sensitive with 1:1 Pooled Normal Plasma actual,LNC,Laboratory or Test Result
PMC8529923,sample collection,TEST,PMC,C0200345,Specimen Collection,MSH,Health Care Activity
PMC8529923,centrifugation parameters,TREATMENT,PMC,,,,
PMC8529923,sample handling conditions,TREATMENT,PMC,,,,
PMC8529923,molecular signatures,PROBLEM,PMC,C1704864,Molecular Signature,MTH,Functional Concept
PMC8529923,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC11981310,pancreatic cancer metastasis to the cerebellopontine angle,PROBLEM,PMC,,,,
PMC11981310,this uncommon condition,PROBLEM,PMC,,,,
PMC11981310,recurrent headaches,PROBLEM,PMC,C1168188,Intermittent headache,MTH,Sign or Symptom
PMC11981310,dizziness,PROBLEM,PMC,C0012833,Dizziness,MTH,Sign or Symptom
PMC11981310,gait disturbances,PROBLEM,PMC,C0575081,Gait abnormality,MTH,Finding
PMC11981310,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC11981310,pancreatic head adenocarcinoma,PROBLEM,PMC,C4304515,Primary adenocarcinoma of head of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11981310,preoperative imaging,TEST,PMC,C2014645,computer-assisted navigational orthopedic procedure using preoperative images,MEDCIN,Therapeutic or Preventive Procedure
PMC11981310,a right cpa meningioma,PROBLEM,PMC,,,,
PMC11981310,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC11981310,the cpa tumor,PROBLEM,PMC,,,,
PMC11981310,general anesthesia,TREATMENT,PMC,C0002915,General Anesthesia,MTH,Therapeutic or Preventive Procedure
PMC11981310,postoperative pathology,TEST,PMC,C4087283,Postoperative pathological diuresis,MDR,Pathologic Function
PMC11981310,a metastatic pancreatic adenocarcinoma,PROBLEM,PMC,C5238966,Refractory Metastatic Pancreatic Adenocarcinoma,NCI,Neoplastic Process
PMC11981310,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11981310,adjuvant chemotherapy,TREATMENT,PMC,C0085533,"Chemotherapy, Adjuvant",MTH,Therapeutic or Preventive Procedure
PMC11981310,widespread metastatic disease,PROBLEM,PMC,C5787708,Chorea due to widespread metastatic malignant neoplastic disease,SNOMEDCT_US,Disease or Syndrome
PMC11981310,the cpa tumor resection,TREATMENT,PMC,,,,
PMC11981310,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11981310,diagnostic,PROBLEM,PMC,C0348026,Diagnostic,MTH,Functional Concept
PMC11981310,meningioma,PROBLEM,PMC,C0025286,Meningioma,MTH,Neoplastic Process
PMC11981310,benign conditions,PROBLEM,PMC,C1635030,Benign breast condition,SNOMEDCT_US,Disease or Syndrome
PMC11981310,appropriate management,TREATMENT,PMC,C0811031,Discuss age-appropriate behavior management strategies,NIC,Health Care Activity
PMC11981310,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC11981310,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC11981310,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11981310,more common cpa lesions,PROBLEM,PMC,,,,
PMC11981310,vigilant monitoring,TEST,PMC,,,,
PMC11981310,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11981310,neurological symptoms,PROBLEM,PMC,C0235031,Neurologic Symptoms,MSH,Sign or Symptom
PMC11981310,metastatic spread to uncommon sites,PROBLEM,PMC,,,,
PMC11981310,the cpa,PROBLEM,PMC,C0625548,CPA-P1,MSH,Organic Chemical
PMC11981310,surgical intervention,TREATMENT,PMC,C0549433,Surgical intervention (finding),MTH,Finding
PMC11981310,widespread metastasis,PROBLEM,PMC,C5206721,Widespread Metastasis,NCI,Finding
PMC11981310,poor outcomes,PROBLEM,PMC,C3841289,Previous poor pregnancy outcome,LNC,Finding
PMC11981310,optimal management,TREATMENT,PMC,C5912150,"Optimize local wound environment through cleansing, debriding, managing bacterial balance and managing moisture balance, as appropriate",NIC,Health Care Activity
PMC11981310,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11981310,disease diagnosis,PROBLEM,PMC,C0338067,Disease/diagnosis,PDQ,Disease or Syndrome
PMC11981310,imaging features,TEST,PMC,C5667574,Additional Imaging Features/Comments,NCI,Intellectual Product
PMC11981310,pathological examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC11981310,cpa metastasis,PROBLEM,PMC,,,,
PMC11981310,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11147847,pancreatic enzyme replacement therapy,TREATMENT,PMC,C4523842,Pancreatic enzyme replacement therapy,MDR,Therapeutic or Preventive Procedure
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,a crosssectional survey study,TEST,PMC,,,,
PMC11147847,a mixedmedia campaign,TREATMENT,PMC,,,,
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,the questionnaire,TEST,PMC,C0451277,Master questionnaire,SNOMEDCT_US,Intellectual Product
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,prescribing practices,TREATMENT,PMC,C1269817,Prescription of drug within scope of practice,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11147847,enzyme replacement,TREATMENT,PMC,C0598391,Enzyme Replacement Therapy,MSH,Therapeutic or Preventive Procedure
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,PROBLEM,PMC,C0599890,pert,CHV,Hormone
PMC11147847,dosing regimens,TREATMENT,PMC,C2348331,Dose Regimen,NCI,Therapeutic or Preventive Procedure
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,pert commencement,TREATMENT,PMC,,,,
PMC11147847,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11147847,malabsorption,PROBLEM,PMC,C3714745,Malabsorption,MTH,Finding
PMC11147847,all symptoms,PROBLEM,PMC,C5979652,"Not at all - symptom does not affect the patient, including symptoms well-controlled with current treatment",LNC,Finding
PMC11147847,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11147847,their medication,TREATMENT,PMC,C5447622,Palliative Care Can Help People Manage Side Effects of Their Medical Treatments,NCI,Intellectual Product
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,standard therapy,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC11147847,enzyme replacement,TREATMENT,PMC,C0598391,Enzyme Replacement Therapy,MSH,Therapeutic or Preventive Procedure
PMC11147847,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11147847,malabsorption,PROBLEM,PMC,C3714745,Malabsorption,MTH,Finding
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,standard therapy,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC11147847,enzyme replacement,TREATMENT,PMC,C0598391,Enzyme Replacement Therapy,MSH,Therapeutic or Preventive Procedure
PMC11147847,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11147847,malabsorption,PROBLEM,PMC,C3714745,Malabsorption,MTH,Finding
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pei,PROBLEM,PMC,C0814202,Personal Experience Inventory,MTH,Intellectual Product
PMC11147847,malabsorption,PROBLEM,PMC,C3714745,Malabsorption,MTH,Finding
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,effective treatment,TREATMENT,PMC,C0510269,Discuss effective and ineffective methods of prior treatment,NIC,Health Care Activity
PMC11147847,pei,PROBLEM,PMC,C0814202,Personal Experience Inventory,MTH,Intellectual Product
PMC11147847,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,clinician education,TREATMENT,PMC,,,,
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,a standard of care,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC11147847,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC11147847,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10605673,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10605673,poor survival,PROBLEM,PMC,C4288383,Poor Survival after Reirradiation,NCI,Finding
PMC10605673,anticancer treatment,TREATMENT,PMC,C3176985,"Do you take cortisone, predniSONE, other steroids, or anticancer drugs, or have you had radiation treatments",LNC,Intellectual Product
PMC10605673,the treatment goal,TREATMENT,PMC,C2095149,ENT goal to eliminate tumor,MTH,Idea or Concept
PMC10605673,prolongation of survival,TREATMENT,PMC,,,,
PMC10605673,integrative therapeutic approaches,TREATMENT,PMC,C5912363,"Use established therapeutic approach to guide counseling sessions (e.g., psychodynamic, behavioral, cognitive, humanistic, integrative-holistic)",NIC,Health Care Activity
PMC10605673,integrative therapies,TREATMENT,PMC,C0582728,Integrative psychotherapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10605673,conventional treatment,TREATMENT,PMC,C2945704,Conventional Treatment,MTH,Therapeutic or Preventive Procedure
PMC10605673,symptom alleviation,PROBLEM,PMC,C1274136,Symptom control (regime/therapy),MTH,Therapeutic or Preventive Procedure
PMC10605673,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10605673,integrative therapies,TREATMENT,PMC,C0582728,Integrative psychotherapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10605673,a conclusive assessment,TEST,PMC,C1830767,Why conclusions are not supported by the evidence in file:Imp:Pt:^Patient:Nar:RFC assessment,LNC,Clinical Attribute
PMC10605673,advanced or metastatic pancreatic cancer,PROBLEM,PMC,,,,
PMC10605673,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC10605673,conventional therapy,TREATMENT,PMC,C2945704,Conventional Treatment,MTH,Therapeutic or Preventive Procedure
PMC10605673,additional complementary integrative mistletoe,TREATMENT,PMC,,,,
PMC10605673,hyperthermia,TREATMENT,PMC,C5232927,Hyperthermia,MTH,Finding
PMC10605673,this retrospective analysis,TEST,PMC,,,,
PMC10605673,integrative therapies,TREATMENT,PMC,C0582728,Integrative psychotherapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10605673,palliative chemotherapy,TREATMENT,PMC,C5556542,Palliative Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC10605673,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10605673,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC10605673,palliative chemotherapy,TREATMENT,PMC,C5556542,Palliative Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC10605673,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC10605673,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC10605673,integrative care,TREATMENT,PMC,C0282599,Integrated Health Care Systems,MSH,Health Care Related Organization
PMC10605673,integrative therapies,TREATMENT,PMC,C0582728,Integrative psychotherapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10605673,conventional chemotherapy,TREATMENT,PMC,,,,
PMC10605673,mistletoe,TREATMENT,PMC,C0042785,Mistletoe,MTH,Plant
PMC10605673,hyperthermia,PROBLEM,PMC,C5232927,Hyperthermia,MTH,Finding
PMC10605673,integrative mistletoe,TREATMENT,PMC,,,,
PMC10605673,hyperthermia,PROBLEM,PMC,C5232927,Hyperthermia,MTH,Finding
PMC10605673,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10605673,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10605673,mistletoe therapy,TREATMENT,PMC,,,,
PMC10605673,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10605673,mistletoe,TREATMENT,PMC,C0042785,Mistletoe,MTH,Plant
PMC10605673,hyperthermia,TREATMENT,PMC,C5232927,Hyperthermia,MTH,Finding
PMC10605673,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10605673,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10605673,pivotal phaseiii studies,TEST,PMC,,,,
PMC10605673,additional mistletoe,TREATMENT,PMC,,,,
PMC10605673,hyperthermia,TREATMENT,PMC,C5232927,Hyperthermia,MTH,Finding
PMC10605673,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10605673,poor outcome,PROBLEM,PMC,C3841289,Previous poor pregnancy outcome,LNC,
PMC10605673,integrative therapies,TREATMENT,PMC,C0582728,Integrative psychotherapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10605673,treatment success,TREATMENT,PMC,C0679864,treatment success,CHV,Qualitative Concept
PMC10605673,survival data,TEST,PMC,,,,
PMC10605673,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10605673,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10605673,pivotal phaseiii studies,TEST,PMC,,,,
PMC10605673,additional mistletoe,TREATMENT,PMC,,,,
PMC10605673,hyperthermia,PROBLEM,PMC,C5232927,Hyperthermia,MTH,Finding
PMC4780462,concurrent chemoradiotherapy,TREATMENT,PMC,C3178775,Concurrent Chemoradiotherapy,MSH,Therapeutic or Preventive Procedure
PMC4780462,the treatment option,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC4780462,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4780462,accompanying gastrointestinal toxicities,PROBLEM,PMC,,,,
PMC4780462,the most common complication,PROBLEM,PMC,C4086602,Most Common Complication After Surgery for Prostate Cancer,NCI,Intellectual Product
PMC4780462,threedimensional conformal radiotherapy,TREATMENT,PMC,,,,
PMC4780462,intensitymodulated radiotherapy,TREATMENT,PMC,,,,
PMC4780462,ccrtrelated adverse events,PROBLEM,PMC,,,,
PMC4780462,radiation modalities,TREATMENT,PMC,C5785293,Radiation Modality Technique,NCI,Health Care Activity
PMC4780462,gastrointestinal toxicities,PROBLEM,PMC,C1142499,Gastrointestinal toxicity,MDR,Injury or Poisoning
PMC4780462,3d crt,TREATMENT,PMC,C0600521,"Radiotherapy, Conformal",MSH,Therapeutic or Preventive Procedure
PMC4780462,imrt,TREATMENT,PMC,C1512814,"Radiotherapy, Intensity-Modulated",MSH,Therapeutic or Preventive Procedure
PMC4780462,ccrt,TREATMENT,PMC,,,,
PMC4780462,upper endoscopy,TEST,PMC,C2065650,anesthesia for upper endoscopy,MEDCIN,Therapeutic or Preventive Procedure
PMC4780462,ccrt,TREATMENT,PMC,,,,
PMC4780462,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC4780462,the radiotherapy modalities,TREATMENT,PMC,C5854951,mCode Radiotherapy Modality Value Set,NCI,Intellectual Product
PMC4780462,3dcrt,TREATMENT,PMC,,,,
PMC4780462,imrt,TREATMENT,PMC,C1512814,"Radiotherapy, Intensity-Modulated",MSH,Therapeutic or Preventive Procedure
PMC4780462,ccrt,TREATMENT,PMC,,,,
PMC4780462,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC4780462,dyspepsia,PROBLEM,PMC,C0013395,Dyspepsia,MTH,Sign or Symptom
PMC4780462,nauseavomiting,PROBLEM,PMC,,,,
PMC4780462,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC4780462,upper endoscopy,TEST,PMC,C2065650,anesthesia for upper endoscopy,MEDCIN,Therapeutic or Preventive Procedure
PMC4780462,significantly more gastroduodenal ulcers,PROBLEM,PMC,,,,
PMC4780462,the 3d crt group,TREATMENT,PMC,,,,
PMC4780462,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC4780462,odds ratio,TEST,PMC,C0028873,Odds Ratio,MTH,Quantitative Concept
PMC4780462,tumor location,PROBLEM,PMC,C5667396,Specify Tumor Location,NCI,Intellectual Product
PMC4780462,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC4780462,gastrointestinal toxicities,PROBLEM,PMC,C1142499,Gastrointestinal toxicity,MDR,Injury or Poisoning
PMC4780462,imrt,TREATMENT,PMC,C1512814,"Radiotherapy, Intensity-Modulated",MSH,Therapeutic or Preventive Procedure
PMC4780462,significantly fewer gastroduodenal injuries,PROBLEM,PMC,,,,
PMC4780462,ccrt,TREATMENT,PMC,,,,
PMC4780462,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4780462,imrt,TREATMENT,PMC,C1512814,"Radiotherapy, Intensity-Modulated",MSH,Therapeutic or Preventive Procedure
PMC4780462,significantly fewer gastroduodenal injuries,PROBLEM,PMC,,,,
PMC4780462,ccrt,TREATMENT,PMC,,,,
PMC4780462,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6803577,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6803577,its treatments,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC6803577,patients symptoms,PROBLEM,PMC,C1317600,patient symptoms,CHV,Finding
PMC6803577,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6803577,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6803577,pro,TREATMENT,PMC,C0033382,proline,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC6803577,qualitative literature,TEST,PMC,,,,
PMC6803577,pro instruments,TEST,PMC,,,,
PMC6803577,gaps in measurement,PROBLEM,PMC,C0201889,Anion gap measurement,MTH,Laboratory Procedure
PMC6803577,cognitive debriefing,TEST,PMC,C4684609,Cognitive Debriefing,NCI,Research Activity
PMC6803577,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6803577,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC6803577,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6803577,radiation,TREATMENT,PMC,C0851346,Radiation,MTH,Natural Phenomenon or Process
PMC6803577,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6803577,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC6803577,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6803577,acute pain,PROBLEM,PMC,C0184567,Acute onset pain,MTH,Sign or Symptom
PMC6803577,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6803577,chemotherapychemoradiation,TREATMENT,PMC,,,,
PMC6803577,fatiguetiredness,PROBLEM,PMC,,,,
PMC6803577,appetite loss,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC6803577,bowel problems,PROBLEM,PMC,C0579086,Bowel problem,MTH,Finding
PMC6803577,nauseavomiting,PROBLEM,PMC,,,,
PMC6803577,impaired,PROBLEM,PMC,C0221099,Impaired,MTH,Functional Concept
PMC6803577,the literature review,TEST,PMC,C0282441,Review Literature,MTH,Intellectual Product
PMC6803577,the eortc qlqc30pan26,TEST,PMC,,,,
PMC6803577,the eortc qlqc30pan26,TEST,PMC,,,,
PMC6803577,neuropathic side effects,PROBLEM,PMC,,,,
PMC6803577,the first study,TEST,PMC,C4684677,First-in-Human Study,NCI,Research Activity
PMC6803577,metastaticrecurrent pancreatic cancer,PROBLEM,PMC,,,,
PMC6803577,the eortc,TEST,PMC,C1958399,EORTC GIMEMA AML-10 protocol,MSH,Therapeutic or Preventive Procedure
PMC6803577,therapeutic advances,TREATMENT,PMC,C4059223,Ensure Enlive advanced therapeutic nutrition (Vanilla),GS,Food
PMC6803577,the eortc qlqc30pan26,TEST,PMC,,,,
PMC6803577,neuropathic side effects,PROBLEM,PMC,,,,
PMC6803577,a recall,TEST,PMC,C0034770,Mental Recall,MTH,Mental Process
PMC6803577,supplementary material,TREATMENT,PMC,C2936424,Electronic Supplementary Materials,MSH,Intellectual Product
PMC6803577,the first study,TEST,PMC,C4684677,First-in-Human Study,NCI,Research Activity
PMC6803577,metastaticrecurrent pancreatic cancer,PROBLEM,PMC,,,,
PMC6803577,the eortc,TEST,PMC,C1958399,EORTC GIMEMA AML-10 protocol,MSH,Therapeutic or Preventive Procedure
PMC6803577,therapeutic advances,TREATMENT,PMC,C4059223,Ensure Enlive advanced therapeutic nutrition (Vanilla),GS,Food
PMC6803577,the eortc qlqc30pan26,TEST,PMC,,,,
PMC6803577,neuropathic side effects,PROBLEM,PMC,,,,
PMC6803577,a recall,TEST,PMC,C0034770,Mental Recall,MTH,Mental Process
PMC6803577,this qualitative interview study,TEST,PMC,,,,
PMC6803577,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6803577,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6803577,the eortc qlqc30,TEST,PMC,,,,
PMC6803577,a stage iiiiv pancreatic cancer population,PROBLEM,PMC,,,,
PMC6803577,neuropathic treatmentrelated side effects,PROBLEM,PMC,,,,
PMC6803577,the eortc qlqc30pan26,TEST,PMC,,,,
PMC6803577,minor revisions,TREATMENT,PMC,C2066367,minor revision of rhinoplasty,MEDCIN,Therapeutic or Preventive Procedure
PMC6803577,our study,TEST,PMC,,,,
PMC6803577,the eortc qlqc30,TEST,PMC,,,,
PMC6803577,a clear assessment,TEST,PMC,C2234307,assessment of implant site discharge clear,MEDCIN,Finding
PMC6803577,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC7436982,leftsided portal hypertension,PROBLEM,PMC,,,,
PMC7436982,an extremely rare clinical syndrome,PROBLEM,PMC,,,,
PMC7436982,curable portal hypertension,PROBLEM,PMC,,,,
PMC7436982,pancreatic disease,PROBLEM,PMC,C0030286,Pancreatic Diseases,MTH,Disease or Syndrome
PMC7436982,complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC7436982,spleen vein compression,PROBLEM,PMC,,,,
PMC7436982,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC7436982,splenectomy,TREATMENT,PMC,C0037995,Splenectomy,MSH,Therapeutic or Preventive Procedure
PMC7436982,the main treatment,TREATMENT,PMC,C0814495,main treatment phase,AOD,Health Care Activity
PMC7436982,variceal bleeding,PROBLEM,PMC,C0267092,Esophageal varices without bleeding,SNOMEDCT_US,Disease or Syndrome
PMC7436982,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7436982,the primary disease,PROBLEM,PMC,C5204035,Primary Site of Disease,MTH,Finding
PMC7436982,repeated hematemesis,PROBLEM,PMC,,,,
PMC7436982,black stool,PROBLEM,PMC,C0474585,Feces color: tarry,MTH,Sign or Symptom
PMC7436982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7436982,combined imaging,TEST,PMC,C3504307,"Software, Magnetic Resonance Imaging/Positron Emission Tomography",UMD,Intellectual Product
PMC7436982,endoscopic examination,TEST,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC7436982,varicose gastric fundus veins,PROBLEM,PMC,,,,
PMC7436982,a pancreatic mass,PROBLEM,PMC,C0877425,Mass of pancreas,SNOMEDCT_US,Finding
PMC7436982,enlarged peripancreatic lymph nodes,PROBLEM,PMC,,,,
PMC7436982,laboratory investigations,TEST,PMC,C5400392,Manufacturing laboratory analytical testing not investigated due to pandemic,MDR,Finding
PMC7436982,reduced erythrocyte,PROBLEM,PMC,C2675907,Reduced erythrocyte Gs activity,OMIM,Finding
PMC7436982,platelet,TEST,PMC,C0005821,Blood Platelets,MTH,Cell
PMC7436982,the interferon gamma release assay,TEST,PMC,C3544352,Interferon gamma release assay positive,MDR,Laboratory or Test Result
PMC7436982,liver function,TEST,PMC,C0232741,Liver function,SNOMEDCT_US,Organ or Tissue Function
PMC7436982,abdominal exploration,TEST,PMC,C0085704,Exploratory laparotomy,MTH,Diagnostic Procedure
PMC7436982,splenectomy,TREATMENT,PMC,C0037995,Splenectomy,MSH,Therapeutic or Preventive Procedure
PMC7436982,varicose vein dissection,TREATMENT,PMC,,,,
PMC7436982,lesion resection,TREATMENT,PMC,C0396486,Bronchoscopic resection of lesion,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC7436982,laparotomy,TREATMENT,PMC,C0023038,Laparotomy,MTH,Therapeutic or Preventive Procedure
PMC7436982,postoperative biopsy analysis,TEST,PMC,,,,
PMC7436982,lymph node tuberculosis,PROBLEM,PMC,C0041316,Lymph Node Tuberculosis,MTH,Disease or Syndrome
PMC7436982,lsph,PROBLEM,PMC,,,,
PMC7436982,peripancreatic lymph node tuberculosis,PROBLEM,PMC,,,,
PMC7436982,lsph,PROBLEM,PMC,,,,
PMC7436982,peripancreatic lymph node tuberculosis,PROBLEM,PMC,,,,
PMC7436982,left portal hypertension,PROBLEM,PMC,C5690830,Sinistral Portal Hypertension,MSH,Disease or Syndrome
PMC7436982,peripancreatic lymph node tuberculosis,PROBLEM,PMC,,,,
PMC7436982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7436982,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC7436982,pancreas masses,PROBLEM,PMC,C0747181,PANCREAS HEAD MASS,CCPSS,Finding
PMC7436982,advantageous therapy,TREATMENT,PMC,,,,
PMC7436982,lsph,PROBLEM,PMC,,,,
PMC7436982,mechanical compression,TREATMENT,PMC,C0563291,Mechanical compression,SNOMEDCT_US,Phenomenon or Process
PMC7436982,lsph,PROBLEM,PMC,,,,
PMC7436982,peripancreatic lymph node tuberculosis,PROBLEM,PMC,,,,
PMC7436982,left portal hypertension,PROBLEM,PMC,C5690830,Sinistral Portal Hypertension,MSH,Disease or Syndrome
PMC7436982,peripancreatic lymph node tuberculosis,PROBLEM,PMC,,,,
PMC7436982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7436982,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC7436982,pancreas masses,PROBLEM,PMC,C0747181,PANCREAS HEAD MASS,CCPSS,Finding
PMC7436982,advantageous therapy,TREATMENT,PMC,,,,
PMC7436982,lsph,PROBLEM,PMC,,,,
PMC7436982,mechanical compression,TREATMENT,PMC,C0563291,Mechanical compression,SNOMEDCT_US,Phenomenon or Process
PMC4233091,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC4233091,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC4233091,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC4233091,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC4233091,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC4233091,other symptoms,PROBLEM,PMC,C3257980,Other Symptom,NCI,Sign or Symptom
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,the examination,TEST,PMC,C4321457,Examination,MTH,Activity
PMC4233091,combined tumor markers,TEST,PMC,,,,
PMC4233091,twelve tumor markers,TEST,PMC,,,,
PMC4233091,afp,TEST,PMC,C1367597,AFP gene,MTH,Gene or Genome
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,ca153,TEST,PMC,C0201547,CA 15-3 measurement,MTH,Laboratory Procedure
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,psa,TEST,PMC,C3272395,NPEPPS wt Allele,MTH,Gene or Genome
PMC4233091,fpsa,TEST,PMC,C1541546,fowlpox-PSA-TRICOM vaccine/sargramostim,PDQ,Therapeutic or Preventive Procedure
PMC4233091,fer,TEST,PMC,C0812288,FER gene,MTH,Gene or Genome
PMC4233091,hcg,TEST,PMC,,,,
PMC4233091,hgh,TEST,PMC,C3714500,Human Growth Hormone,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC4233091,the protein biochip detection,TEST,PMC,,,,
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,benign pancreatic disease,PROBLEM,PMC,,,,
PMC4233091,tumor markers,TEST,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,fer,TEST,PMC,C0812288,FER gene,MTH,Gene or Genome
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,ca153,TEST,PMC,C0201547,CA 15-3 measurement,MTH,Laboratory Procedure
PMC4233091,hcg,TEST,PMC,,,,
PMC4233091,afp,TEST,PMC,C1367597,AFP gene,MTH,Gene or Genome
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,psa,TEST,PMC,C3272395,NPEPPS wt Allele,MTH,Gene or Genome
PMC4233091,fpsa,TEST,PMC,C1541546,fowlpox-PSA-TRICOM vaccine/sargramostim,PDQ,Therapeutic or Preventive Procedure
PMC4233091,hgh,TEST,PMC,C3714500,Human Growth Hormone,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC4233091,significant difference,PROBLEM,PMC,,,,
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,multitumor marker protein biochip detection,TEST,PMC,,,,
PMC4233091,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC4233091,benign disease,PROBLEM,PMC,C0155587,Benign hypertensive heart disease,SNOMEDCT_US,Disease or Syndrome
PMC4233091,the positive rate,TEST,PMC,C2265594,positive regulation of heart rate,GO,Organism Function
PMC4233091,5 tumor markers,TEST,PMC,C2975100,"GPR124 protein, mouse",MSH,"Amino Acid, Peptide, or Protein, Receptor"
PMC4233091,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,the multitumor marker protein biochip system,TEST,PMC,,,,
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,the multitumor marker protein biochip system,TEST,PMC,,,,
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,the biosensor system,TREATMENT,PMC,,,,
PMC4233091,the measurement,TEST,PMC,C0242485,Measurement,MTH,Functional Concept
PMC4233091,a,TEST,PMC,,,,
PMC4233091,the serum levels,TEST,PMC,C1318357,Serum lipoprotein levels,MTH,Laboratory or Test Result
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,fer,TEST,PMC,C0812288,FER gene,MTH,Gene or Genome
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,ca153,TEST,PMC,C0201547,CA 15-3 measurement,MTH,Laboratory Procedure
PMC4233091,hcg,TEST,PMC,,,,
PMC4233091,afp,TEST,PMC,C1367597,AFP gene,MTH,Gene or Genome
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,psa,TEST,PMC,C3272395,NPEPPS wt Allele,MTH,Gene or Genome
PMC4233091,fpsa,TEST,PMC,C1541546,fowlpox-PSA-TRICOM vaccine/sargramostim,PDQ,Therapeutic or Preventive Procedure
PMC4233091,hgh,TEST,PMC,C3714500,Human Growth Hormone,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,simultaneous analysis,TEST,PMC,C0200138,"Polysomnograph recording, analysis and interpretation of the multiple simultaneous physiologic measurements of sleep",SNMI,Diagnostic Procedure
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4233091,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4233091,nse,TEST,PMC,C1880904,Gamma-Enolase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4233091,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC4233091,ca242,TEST,PMC,C5555170,CA242 Antigen,NCI,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4233091,ca125,TEST,PMC,C0006610,CA-125 Antigen,MTH,"Organic Chemical, Immunologic Factor"
PMC4233091,the multitumor markers protein biochip system,TEST,PMC,,,,
PMC4233091,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4233091,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC4233091,study participation,TEST,PMC,C5418626,Study Participation,NCI,Functional Concept
PMC7677881,head pancreatic cancers,PROBLEM,PMC,C0149954,adenocarcinoma of head of pancreas,MEDCIN,Neoplastic Process
PMC7677881,clinical challenges,PROBLEM,PMC,C0374404,Ingestion Challenge Allergy and Clinical Immunology Testing Procedures,CPT,Diagnostic Procedure
PMC7677881,biliary drainage,TREATMENT,PMC,C0400745,Biliary drainage (procedure),MTH,Therapeutic or Preventive Procedure
PMC7677881,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7677881,palliative scope,TREATMENT,PMC,,,,
PMC7677881,usual endoscopic modalities,TREATMENT,PMC,,,,
PMC7677881,percutaneous approach,TREATMENT,PMC,C0522523,Percutaneous,MTH,Spatial Concept
PMC7677881,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7677881,biliary drainage,TREATMENT,PMC,C0400745,Biliary drainage (procedure),MTH,Therapeutic or Preventive Procedure
PMC7677881,eusguided gallbladder drainage,TREATMENT,PMC,,,,
PMC7677881,acute severe cholangitis,PROBLEM,PMC,,,,
PMC7677881,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC7677881,a previous eusbiopsy,TEST,PMC,,,,
PMC7677881,head pancreatic cancer,PROBLEM,PMC,C0149954,adenocarcinoma of head of pancreas,MEDCIN,Neoplastic Process
PMC7677881,acute cholangitis,PROBLEM,PMC,C0267917,Acute cholangitis,MTH,Disease or Syndrome
PMC7677881,a biliary and duodenal stent,TREATMENT,PMC,,,,
PMC7677881,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC7677881,an initial duodenal substenosis,PROBLEM,PMC,,,,
PMC7677881,an abdominal computed tomography scan,TEST,PMC,C2207133,computed tomography of abdomen with intravenous contrast,MEDCIN,Diagnostic Procedure
PMC7677881,proximal biliary stent occlusion,PROBLEM,PMC,,,,
PMC7677881,neoplastic progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC7677881,endoscopic retrograde cholangiopancreatography,TEST,PMC,C0008310,Endoscopic Retrograde Cholangiopancreatography,MTH,Diagnostic Procedure
PMC7677881,worsening duodenal stenosis,PROBLEM,PMC,,,,
PMC7677881,eusguided choledocoduodenostomy,TREATMENT,PMC,,,,
PMC7677881,the cystic duct,PROBLEM,PMC,C1280323,Entire cystic duct,MTH,"Body Part, Organ, or Organ Component"
PMC7677881,neoplastic infiltration,PROBLEM,PMC,C0751425,Peripheral Nerve Neoplastic Infiltration,MSH,Neoplastic Process
PMC7677881,an eusgbd,TEST,PMC,,,,
PMC7677881,an axios stent,TREATMENT,PMC,,,,
PMC7677881,cholangitis,PROBLEM,PMC,C0008311,Cholangitis,MTH,Disease or Syndrome
PMC7677881,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7677881,axios stent occlusiondysfunction,PROBLEM,PMC,,,,
PMC7677881,her,PROBLEM,PMC,C0574443,Herero language,SNOMEDCT_US,Language
PMC7677881,underlying disease,PROBLEM,PMC,C1304391,Alopecia due to underlying disease,SNOMEDCT_US,Disease or Syndrome
PMC7677881,different eus therapeutic approaches,TREATMENT,PMC,,,,
PMC7677881,different eus therapeutic approaches,TREATMENT,PMC,,,,
PMC7677881,eusgbd,TEST,PMC,,,,
PMC7677881,an effective biliary drainage,TREATMENT,PMC,,,,
PMC7677881,conventional ercp,TEST,PMC,,,,
PMC7677881,eusguided choledocoduodenostomy,TREATMENT,PMC,,,,
PMC11671877,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC11671877,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC11671877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11671877,nutritional decline,PROBLEM,PMC,C5396249,Nutrition counseling declined,SNOMEDCT_US,Finding
PMC11671877,percutaneous endoscopic gastrostomy,TREATMENT,PMC,C0176751,Percutaneous endoscopic gastrostomy,MTH,Therapeutic or Preventive Procedure
PMC11671877,a jejunal extension tube,TREATMENT,PMC,,,,
PMC11671877,supplementary nutrition,TREATMENT,PMC,C0357170,Supplementary preparations for parenteral nutrition,RCD,Pharmacologic Substance
PMC11671877,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11671877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11671877,intensive nutrition intervention,TREATMENT,PMC,,,,
PMC11671877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11671877,qualitative semistructured interviews,TEST,PMC,,,,
PMC11671877,deductive thematic analysis,TEST,PMC,,,,
PMC11671877,the framework model,TREATMENT,PMC,,,,
PMC11671877,deterioration in physical and mental wellbeing,PROBLEM,PMC,,,,
PMC11671877,debilitating nutrition impact symptoms,PROBLEM,PMC,,,,
PMC11671877,nutritional deterioration,PROBLEM,PMC,,,,
PMC11671877,adequate dietetic support,TREATMENT,PMC,,,,
PMC11671877,a percutaneous endoscopic gastrostomy,TREATMENT,PMC,C0176751,Percutaneous endoscopic gastrostomy,MTH,Therapeutic or Preventive Procedure
PMC11671877,jejunal extension feeding tube,TREATMENT,PMC,,,,
PMC11671877,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC11671877,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11671877,their,TREATMENT,PMC,C4284800,Can pronounce their,LNC,Finding
PMC11671877,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11671877,regular and ad hoc support,TREATMENT,PMC,,,,
PMC11671877,individual nutritional deterioration,PROBLEM,PMC,,,,
PMC11671877,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC11671877,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11671877,their,TREATMENT,PMC,C4284800,Can pronounce their,LNC,Finding
PMC11671877,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11671877,regular and ad hoc support,TREATMENT,PMC,,,,
PMC11671877,individual nutritional deterioration,PROBLEM,PMC,,,,
PMC11671877,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11671877,intensive nutrition intervention,TREATMENT,PMC,,,,
PMC11671877,supplementary enteral feeding,TREATMENT,PMC,,,,
PMC11671877,pegj tube,TREATMENT,PMC,,,,
PMC11671877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11671877,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC11671877,low levels of burden,PROBLEM,PMC,,,,
PMC11671877,diseaserelated symptom severity,PROBLEM,PMC,,,,
PMC11671877,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC11671877,future studies,TEST,PMC,,,,
PMC11671877,home enteral nutrition,TREATMENT,PMC,C2046815,home care visit for enteral nutrition,MEDCIN,Health Care Activity
PMC11671877,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC11671877,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11671877,intervention delivery,TREATMENT,PMC,C0269805,indication for care or intervention related to labor and delivery,MEDCIN,Finding
PMC10393853,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10393853,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10393853,this observational study,TEST,PMC,,,,
PMC10393853,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10393853,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC10393853,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10393853,multivariable logistic regression analyses,TEST,PMC,,,,
PMC10393853,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC10393853,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC10393853,high fatigue,PROBLEM,PMC,C0231525,High frequency muscle fatigue,SNOMEDCT_US,Sign or Symptom
PMC10393853,appetiterelated distress,PROBLEM,PMC,,,,
PMC10393853,lower symptom burden,PROBLEM,PMC,,,,
PMC10393853,significant differences,PROBLEM,PMC,,,,
PMC10393853,symptom burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC10393853,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC10393853,high familycarer problems,PROBLEM,PMC,,,,
PMC10393853,high symptom burden,PROBLEM,PMC,,,,
PMC10393853,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10393853,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10393853,a deteriorating phase,PROBLEM,PMC,,,,
PMC10393853,culturally,TREATMENT,PMC,C0010453,Culture (Anthropological),MTH,Idea or Concept
PMC10393853,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC10393853,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10393853,a deteriorating phase,PROBLEM,PMC,,,,
PMC10393853,culturally,TREATMENT,PMC,C0010453,Culture (Anthropological),MTH,Idea or Concept
PMC10393853,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC10393853,firsttime pc episodes,PROBLEM,PMC,,,,
PMC10393853,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10393853,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC10393853,high symptom distress,PROBLEM,PMC,,,,
PMC10393853,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC10393853,high symptom distress,PROBLEM,PMC,,,,
PMC10393853,further interrogation,TEST,PMC,,,,
PMC10393853,pc,TREATMENT,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC10393853,higher familycarer problems scores,PROBLEM,PMC,,,,
PMC10393853,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC8603447,chemotherapeutic regimens,TREATMENT,PMC,C2045827,oral chemotherapeutics regimen,MEDCIN,Therapeutic or Preventive Procedure
PMC8603447,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8603447,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8603447,a refractory disease,PROBLEM,PMC,C1514815,Refractory Disease,NCI,Finding
PMC8603447,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC8603447,symptom resolution,PROBLEM,PMC,C5555375,Symptom Resolution Date,NCI,Temporal Concept
PMC8603447,an expanded spectrum of,TREATMENT,PMC,,,,
PMC8603447,anticancer drugs,TREATMENT,PMC,C1548818,Anticancer Drugs - Consent type,MTH,Health Care Activity
PMC8603447,reduced susceptibility,PROBLEM,PMC,,,,
PMC8603447,conventional chemotherapies,TREATMENT,PMC,,,,
PMC8603447,breast cancer susceptibility gene brca mutations,PROBLEM,PMC,,,,
PMC8603447,a new perspective,TREATMENT,PMC,,,,
PMC8603447,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8603447,increased genome instability,PROBLEM,PMC,,,,
PMC8603447,poly adpribose polymerase,TREATMENT,PMC,C0032405,Poly(ADP-ribose) Polymerases,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8603447,an enzyme,TEST,PMC,C0014442,Enzymes,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8603447,dna damage,PROBLEM,PMC,C0012860,DNA Damage,MSH,Cell or Molecular Dysfunction
PMC8603447,germline mutations in brcas,PROBLEM,PMC,C4708088,"Germline BRCA-mutated, HER2-negative metastatic breast cancer",SNOMEDCT_US,Neoplastic Process
PMC8603447,homologous,PROBLEM,PMC,C1334043,Homologous Gene,MTH,Gene or Genome
PMC8603447,dna damage,PROBLEM,PMC,C0012860,DNA Damage,MSH,Cell or Molecular Dysfunction
PMC8603447,dna damage response,PROBLEM,PMC,C1155291,DNA Damage Response,MSH,Cell Function
PMC8603447,parp1,TREATMENT,PMC,C1538577,PARP1 gene,MTH,Gene or Genome
PMC8603447,the genome instability,PROBLEM,PMC,C0919532,Genomic Instability,MSH,Cell or Molecular Dysfunction
PMC8603447,genomic instability,PROBLEM,PMC,C0919532,Genomic Instability,MSH,Cell or Molecular Dysfunction
PMC8603447,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8603447,the brcaness phenotype,PROBLEM,PMC,,,,
PMC8603447,clinical,TREATMENT,PMC,C0205210,Clinical,MTH,Qualitative Concept
PMC8603447,parp1 inhibitors,TREATMENT,PMC,C5959207,PARP1 Inhibitor SNV1521,NCI,"Organic Chemical, Pharmacologic Substance"
PMC8603447,targeting parp1 activity,TREATMENT,PMC,,,,
PMC8603447,parp1 inhibitors,TREATMENT,PMC,C5959207,PARP1 Inhibitor SNV1521,NCI,"Organic Chemical, Pharmacologic Substance"
PMC8603447,targeting pancreatic cancer,PROBLEM,PMC,,,,
PMC8603447,the brcaness phenotype,PROBLEM,PMC,,,,
PMC8603447,parp inhibitors,TREATMENT,PMC,C1882413,Poly(ADP-ribose) Polymerase Inhibitors,MTH,Pharmacologic Substance
PMC8603447,a major therapeutic strategy,TREATMENT,PMC,,,,
PMC8603447,a single therapeutic agent,TREATMENT,PMC,C5205681,Single-agent Therapeutic Regimens,NCI,Therapeutic or Preventive Procedure
PMC8603447,existing dna damage agents,TREATMENT,PMC,,,,
PMC4352626,slowly progressing altered mental status,PROBLEM,PMC,,,,
PMC4352626,gait disturbance,PROBLEM,PMC,C0575081,Gait abnormality,MTH,Finding
PMC4352626,magnetic resonance imaging,TEST,PMC,C0024485,Magnetic Resonance Imaging,MTH,Diagnostic Procedure
PMC4352626,abdominal computed tomography,TEST,PMC,C5151313,Abdominal Aorta | Computed tomography | Radiology,LNC,"Body Part, Organ, or Organ Component"
PMC4352626,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4352626,brain and paraaortic lymph node metastases,PROBLEM,PMC,,,,
PMC4352626,gross total resection,TREATMENT,PMC,C4330055,Gross Total Resection,MTH,Therapeutic or Preventive Procedure
PMC4352626,the brain metastatic tumor,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC4352626,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC4352626,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC4352626,brain metastasis,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC4352626,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC4352626,brain metastasis,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC4352626,the primary pc,PROBLEM,PMC,C5832561,The Primary Care PTSD Screen for DSM-5:-:Pt:^Patient:-:PC-PTSD-5,LNC,Clinical Attribute
PMC4352626,particular oncocytictype tumors,PROBLEM,PMC,,,,
PMC4352626,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC4352626,brain metastasis,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC4352626,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC4352626,brain metastasis,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC4352626,the primary pc,PROBLEM,PMC,C5832561,The Primary Care PTSD Screen for DSM-5:-:Pt:^Patient:-:PC-PTSD-5,LNC,Clinical Attribute
PMC4352626,particular oncocytictype tumors,PROBLEM,PMC,,,,
PMC4352626,ipmnderived pc,PROBLEM,PMC,,,,
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,the most malignant solid tumours,PROBLEM,PMC,,,,
PMC10741570,the diseases,PROBLEM,PMC,C0040128,Thyroid Diseases,MTH,Disease or Syndrome
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,great distress,PROBLEM,PMC,,,,
PMC10741570,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10741570,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10741570,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC10741570,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC10741570,cancerrelated fatigue,PROBLEM,PMC,,,,
PMC10741570,exercise interventions,TREATMENT,PMC,C1831738,Exercise Intervention,NCI,Therapeutic or Preventive Procedure
PMC10741570,a supportive strategy,TREATMENT,PMC,C4717614,Uses personal support systems to follow risk strategies,NOC,Finding
PMC10741570,these and other symptoms,PROBLEM,PMC,C3175525,"Have these symptoms interfered with your ability to work, to be with others, or to function in other areas of life",LNC,Intellectual Product
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,this scoping review,TEST,PMC,,,,
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC10741570,further randomizedcontrolled trials,TREATMENT,PMC,,,,
PMC10741570,common cancer entities,PROBLEM,PMC,,,,
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,this scoping review,TEST,PMC,,,,
PMC10741570,exercise training,TREATMENT,PMC,C4279936,Exercise Training,MSH,Daily or Recreational Activity
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,methods,TEST,PMC,C0025663,Methods,MTH,Functional Concept
PMC10741570,a literature search,TEST,PMC,,,,
PMC10741570,structured exercise interventions,TREATMENT,PMC,,,,
PMC10741570,pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC10741570,aerobic or resistance training,TREATMENT,PMC,,,,
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,cancerrelated fatigue,PROBLEM,PMC,,,,
PMC10741570,muscle strength,PROBLEM,PMC,C0517349,Muscle Strength,MTH,Organ or Tissue Function
PMC10741570,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10741570,exercise interventions,TREATMENT,PMC,C1831738,Exercise Intervention,NCI,Therapeutic or Preventive Procedure
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,cancerrelated fatigue,PROBLEM,PMC,,,,
PMC10741570,muscle strength,PROBLEM,PMC,C0517349,Muscle Strength,MTH,Organ or Tissue Function
PMC10741570,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC10741570,larger sample sizes,TEST,PMC,,,,
PMC10741570,exercise,PROBLEM,PMC,C0015259,Exercise,MTH,Daily or Recreational Activity
PMC10741570,advanced stages,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC10741570,this scoping review,TEST,PMC,,,,
PMC10741570,exercise interventions,TREATMENT,PMC,C1831738,Exercise Intervention,NCI,Therapeutic or Preventive Procedure
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,exercise,TREATMENT,PMC,C0015259,Exercise,MTH,Daily or Recreational Activity
PMC10741570,cancerrelated fatigue,PROBLEM,PMC,,,,
PMC10741570,muscle strength,PROBLEM,PMC,C0517349,Muscle Strength,MTH,Organ or Tissue Function
PMC10741570,a few,TEST,PMC,C0205388,Few,SNOMEDCT_US,Quantitative Concept
PMC10741570,small sample sizes,PROBLEM,PMC,,,,
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10741570,cancerrelated cachexia,PROBLEM,PMC,,,,
PMC10741570,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC10741570,further rcts,TEST,PMC,,,,
PMC10741570,larger,TREATMENT,PMC,C0549177,Large,MTH,Quantitative Concept
PMC10741570,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10741570,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC10741570,the measurement,TEST,PMC,C0242485,Measurement,MTH,Functional Concept
PMC4568900,supplemental digital content,TREATMENT,PMC,,,,
PMC4568900,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4568900,a complex and heterogeneous disease,PROBLEM,PMC,,,,
PMC4568900,diseasespecific symptoms,PROBLEM,PMC,,,,
PMC4568900,the malignancy,PROBLEM,PMC,C0346429,Multiple malignancy,SNOMEDCT_US,Neoplastic Process
PMC4568900,cancerrelated death,PROBLEM,PMC,,,,
PMC4568900,advanced stages,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC4568900,targeting,PROBLEM,PMC,C1521840,Target,MTH,Functional Concept
PMC4568900,stromal components,PROBLEM,PMC,C3158623,extrinsic component of stromal side of plastid inner membrane,GO,Cell Component
PMC4568900,stromal depletion,PROBLEM,PMC,,,,
PMC4568900,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4568900,a glycoprotein,TEST,PMC,C0017968,Glycoproteins,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC4568900,sparc in carcinogenesis,PROBLEM,PMC,,,,
PMC4568900,sparc signaling,TEST,PMC,,,,
PMC4568900,sparc,TEST,PMC,C1420342,SPARC gene,MTH,Gene or Genome
PMC4568900,the tumor stroma,PROBLEM,PMC,C1276696,Tumor invasion into stroma,SNOMEDCT_US,Finding
PMC4568900,peritumoral fibroblasts,PROBLEM,PMC,,,,
PMC4568900,the overexpression of sparc in this,PROBLEM,PMC,,,,
PMC4568900,sparc,PROBLEM,PMC,C1420342,SPARC gene,MTH,Gene or Genome
PMC4568900,the tumor stroma,PROBLEM,PMC,C1276696,Tumor invasion into stroma,SNOMEDCT_US,Finding
PMC4568900,albuminbound paclitaxel,TREATMENT,PMC,,,,
PMC4568900,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4568900,paclitaxel,TREATMENT,PMC,C0144576,paclitaxel,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4568900,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4568900,future therapies,TREATMENT,PMC,,,,
PMC4568900,pdac,PROBLEM,PMC,,,,
PMC4568900,hypermethylated,PROBLEM,PMC,C4528593,MGMT Gene Promoter Hypermethylation,NCI,Finding
PMC4568900,premalignant lesions,PROBLEM,PMC,C0850639,Premalignant Lesion,NCI,Neoplastic Process
PMC4568900,tumor initiation,PROBLEM,PMC,C0598935,Tumor Initiation,NCI,Neoplastic Process
PMC4568900,a tumor,PROBLEM,PMC,C0007095,Carcinoid Tumor,MTH,Neoplastic Process
PMC4568900,pdac tumor cells,PROBLEM,PMC,,,,
PMC4568900,sparc in peritumoral fibroblast,PROBLEM,PMC,,,,
PMC4568900,devastating effects,PROBLEM,PMC,C3533033,Criticism had a devastating effect on me in last W,LNC,Finding
PMC4568900,pdac cells,PROBLEM,PMC,,,,
PMC4568900,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC4568900,sparc overexpression in stromal cells,PROBLEM,PMC,,,,
PMC4568900,this,PROBLEM,PMC,C1080058,This <Coelopellini>,MTH,Eukaryote
PMC4568900,serum sparc levels,TEST,PMC,,,,
PMC4568900,a,PROBLEM,PMC,,,,
PMC4568900,increased sparc levels in serum,PROBLEM,PMC,,,,
PMC4568900,pancreatic juice,PROBLEM,PMC,C0030296,pancreatic juice,MTH,Body Substance
PMC4568900,ascites,PROBLEM,PMC,C0003962,Ascites,MTH,Disease or Syndrome
PMC4568900,nabpaclitaxelcontaining regimens,TREATMENT,PMC,,,,
PMC4568900,methylation panels,TEST,PMC,C4287459,Gene Methylation Panel Reagents,UMD,"Indicator, Reagent, or Diagnostic Aid"
PMC4568900,sparc,TEST,PMC,C1420342,SPARC gene,MTH,Gene or Genome
PMC4568900,early detection,TEST,PMC,C0596473,Early Diagnosis,MSH,Diagnostic Procedure
PMC4568900,nabpaclitaxel,TREATMENT,PMC,,,,
PMC4568900,sparc,TREATMENT,PMC,C1420342,SPARC gene,MTH,Gene or Genome
PMC4568900,stromal depletion,PROBLEM,PMC,,,,
PMC4568900,nabpaclitaxel treatment,TREATMENT,PMC,,,,
PMC4568900,sparc,TEST,PMC,C1420342,SPARC gene,MTH,Gene or Genome
PMC4568900,murine studies,TEST,PMC,,,,
PMC4568900,nabpaclitaxel,TREATMENT,PMC,,,,
PMC4568900,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4568900,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4568900,pdac,PROBLEM,PMC,,,,
PMC4568900,novel compounds,TREATMENT,PMC,,,,
PMC4568900,albumin,TEST,PMC,C5966160,Albumin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC4568900,nab technology,TREATMENT,PMC,,,,
PMC4568900,other chemotherapeutic agents128the,TREATMENT,PMC,,,,
PMC4568900,nanoparticles,TREATMENT,PMC,C1450054,Artificial nanoparticles,MTH,Manufactured Object
PMC4568900,drug delivery,TREATMENT,PMC,C0085104,Drug Delivery Systems,MTH,Medical Device
PMC4568900,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC4568900,pdac,TREATMENT,PMC,,,,
PMC5728835,heterotaxy,PROBLEM,PMC,C0266642,Situs ambiguus,MTH,Congenital Abnormality
PMC5728835,polysplenia,PROBLEM,PMC,C1856659,Polysplenia,MTH,Congenital Abnormality
PMC5728835,an extremely rare congenital condition,PROBLEM,PMC,,,,
PMC5728835,abnormal arrangement of organs in the abdominal and thoracic cavities,PROBLEM,PMC,,,,
PMC5728835,a malignancy,PROBLEM,PMC,C0346429,Multiple malignancy,SNOMEDCT_US,Neoplastic Process
PMC5728835,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5728835,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC5728835,successful pancreatic cancer resection,TREATMENT,PMC,,,,
PMC5728835,mild right upper quadrant pain,PROBLEM,PMC,,,,
PMC5728835,physical examination,TEST,PMC,C0031809,Physical Examination,MTH,Health Care Activity
PMC5728835,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC5728835,scleral icterus,PROBLEM,PMC,C0240962,Scleral icterus,SNOMEDCT_US,Finding
PMC5728835,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC5728835,radiographic imaging,TEST,PMC,C0457276,Radiographic imaging - action,SNOMEDCT_US,Diagnostic Procedure
PMC5728835,hepatic duct dilation,PROBLEM,PMC,C5429887,dilation of hepatic duct,MEDCIN,Therapeutic or Preventive Procedure
PMC5728835,several anatomic anomalies,PROBLEM,PMC,,,,
PMC5728835,small bowel location,PROBLEM,PMC,,,,
PMC5728835,reversed superior mesenteric artery and superior mesenteric vein positions,PROBLEM,PMC,,,,
PMC5728835,rightsided duodenaljejunal flexture,TREATMENT,PMC,,,,
PMC5728835,an entirely rightsided pancreas and left lower pelvis,PROBLEM,PMC,,,,
PMC5728835,6 separate splenules,PROBLEM,PMC,,,,
PMC5728835,heterotaxy syndrome,PROBLEM,PMC,C3178805,Heterotaxy Syndrome,MTH,Disease or Syndrome
PMC5728835,polysplenia,PROBLEM,PMC,C1856659,Polysplenia,MTH,Congenital Abnormality
PMC5728835,careful preoperative planning,TREATMENT,PMC,,,,
PMC5728835,total pancreatectomy,TREATMENT,PMC,C0040511,Total pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC5728835,complication,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC5728835,pathologic examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC5728835,the pancreatic mass,PROBLEM,PMC,C2220607,computed tomography of abdomen: pancreatic mass,MEDCIN,Finding
PMC5728835,moderatelypoorly differentiated invasive pancreatic duct adenocarcinoma,PROBLEM,PMC,,,,
PMC5728835,recurrent disease,PROBLEM,PMC,C0277556,Recurrent disease,MTH,Disease or Syndrome
PMC5728835,anatomical variants,PROBLEM,PMC,C1254472,Anatomic Variant,CPM,Organism Attribute
PMC5728835,heterotaxy syndrome,PROBLEM,PMC,C3178805,Heterotaxy Syndrome,MTH,Disease or Syndrome
PMC5728835,a thorough radiologic assessment,TEST,PMC,,,,
PMC5728835,any surgical procedure,TREATMENT,PMC,C3248074,"Thoracoscopy, surgical; with resection-plication of bullae, includes any pleural procedure when performed",CPT,Diagnostic Procedure
PMC5728835,the various anatomic anomalies,PROBLEM,PMC,,,,
PMC5728835,the short and vertically oriented pancreas,PROBLEM,PMC,,,,
PMC5728835,the nonrotation of the intestines,PROBLEM,PMC,C0341408,Malrotation of the intestine type IA,SNOMEDCT_US,Congenital Abnormality
PMC5728835,the anomalous origin of the right hepatic artery,PROBLEM,PMC,,,,
PMC5728835,a safe and uncomplicated total pancreatectomy,TREATMENT,PMC,,,,
PMC5728835,heterotaxy syndromes,PROBLEM,PMC,C3178805,Heterotaxy Syndrome,MTH,Disease or Syndrome
PMC5728835,numerous anatomical abnormalities,PROBLEM,PMC,,,,
PMC5728835,multiple organ systems,PROBLEM,PMC,C0026766,Multiple Organ Failure,MTH,Disease or Syndrome
PMC5728835,any surgical intervention,TREATMENT,PMC,,,,
PMC5728835,the anatomic aberrancies,PROBLEM,PMC,,,,
PMC5728835,successful resection,TREATMENT,PMC,C0940905,Successful mucosal resection,MTHMST,Qualitative Concept
PMC5728835,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC5728835,preoperative preparation,TREATMENT,PMC,C0204800,Preoperative preparation of skin,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC5728835,medical clearance,TREATMENT,PMC,C4553055,Medical Clearance,MTH,Intellectual Product
PMC5728835,a thorough cardiopulmonary evaluation,TEST,PMC,,,,
PMC5728835,cardiac and pulmonary complications,PROBLEM,PMC,C2007457,cardiac catheterization complicated by pulmonary emboli,MEDCIN,Finding
PMC5728835,congenital pancreatic anomalies,PROBLEM,PMC,C0158684,Anomalies of pancreas,SNOMEDCT_US,Congenital Abnormality
PMC5728835,heterotaxic syndromes,PROBLEM,PMC,,,,
PMC5728835,standard evaluation,TEST,PMC,C4717855,Obtains standardized bone mineral density evaluation,NOC,Finding
PMC5728835,a pancreatic adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC5728835,dorsal pancreatic agenesis,PROBLEM,PMC,,,,
PMC5728835,a short pancreas,PROBLEM,PMC,,,,
PMC5728835,a total pancreatectomy,TREATMENT,PMC,C0040511,Total pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC5728835,a pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC5728835,anatomical variants,PROBLEM,PMC,C1254472,Anatomic Variant,CPM,Organism Attribute
PMC5728835,heterotaxy syndrome,PROBLEM,PMC,C3178805,Heterotaxy Syndrome,MTH,Disease or Syndrome
PMC5728835,a thorough radiologic assessment,TEST,PMC,,,,
PMC5728835,any surgical procedure,TREATMENT,PMC,C3248074,"Thoracoscopy, surgical; with resection-plication of bullae, includes any pleural procedure when performed",CPT,Diagnostic Procedure
PMC5728835,the various anatomic anomalies,PROBLEM,PMC,,,,
PMC5728835,the short and vertically oriented pancreas,PROBLEM,PMC,,,,
PMC5728835,the nonrotation of the intestines,PROBLEM,PMC,C0341408,Malrotation of the intestine type IA,SNOMEDCT_US,Congenital Abnormality
PMC5728835,the anomalous origin of the right hepatic artery,PROBLEM,PMC,,,,
PMC5728835,a safe and uncomplicated total pancreatectomy,TREATMENT,PMC,,,,
PMC5049564,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC5049564,devastating symptom,PROBLEM,PMC,,,,
PMC5049564,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC5049564,proven treatment,TREATMENT,PMC,,,,
PMC5049564,methylphenidate,TREATMENT,PMC,C0025810,methylphenidate,MTH,"Organic Chemical, Pharmacologic Substance"
PMC5049564,other cancer,PROBLEM,PMC,C1707251,Cancer Other,NCI,Neoplastic Process
PMC5049564,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC5049564,a retrospective study,TEST,PMC,C0035363,Retrospective Studies,MTH,Research Activity
PMC5049564,ameliorating fatigue,PROBLEM,PMC,,,,
PMC5049564,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC5049564,visual analog fatigue scale,TEST,PMC,C3826867,Visual Analogue Fatigue Scale,NCI,Intellectual Product
PMC5049564,ctcae,TEST,PMC,C4552835,"Belching, CTCAE",MTH,Finding
PMC5049564,mph,TREATMENT,PMC,C0439495,Miles per hour,MTH,Quantitative Concept
PMC5049564,fatigue grade,PROBLEM,PMC,C1556362,"Grade 1 Fatigue, CTCAE",NCI,Finding
PMC5049564,mph,TREATMENT,PMC,C0439495,Miles per hour,MTH,Quantitative Concept
PMC5049564,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC5049564,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC5049564,maintenance chemotherapy intensity,TREATMENT,PMC,,,,
PMC5049564,adverse effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC5049564,concomitant chemotherapy,TREATMENT,PMC,,,,
PMC5049564,doublet,TREATMENT,PMC,C5206469,Platinum Doublet,NCI,Pharmacologic Substance
PMC5049564,singleagent chemotherapy,TREATMENT,PMC,,,,
PMC5049564,mean baseline vafs,TEST,PMC,,,,
PMC5049564,mph,TREATMENT,PMC,C0439495,Miles per hour,MTH,Quantitative Concept
PMC5049564,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC5049564,chemotherapy intensity,TREATMENT,PMC,C5783968,Intensive Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC5049564,less depression,PROBLEM,PMC,C5142304,Smoking makes me less depressed,LNC,Intellectual Product
PMC5049564,improved appetite,PROBLEM,PMC,,,,
PMC5049564,mph,TREATMENT,PMC,C0439495,Miles per hour,MTH,Quantitative Concept
PMC5049564,side effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC5049564,rare grade 3 or 4 adverse events,PROBLEM,PMC,,,,
PMC5049564,insomnia,PROBLEM,PMC,C1950154,Insomnia homeopathic medication,MTH,Pharmacologic Substance
PMC5049564,restlessness,PROBLEM,PMC,C3887611,Restlessness,MTH,Sign or Symptom
PMC5049564,palpitations,PROBLEM,PMC,C0030252,Palpitations,MTH,Finding
PMC5049564,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC5049564,lowdose mph benefits apc,TREATMENT,PMC,,,,
PMC5049564,improved fatigue,PROBLEM,PMC,,,,
PMC5049564,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC5049564,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC5049564,a large randomized clinical trial,TREATMENT,PMC,,,,
PMC5049564,lowdose mph benefits apc,TREATMENT,PMC,,,,
PMC5049564,improved fatigue,PROBLEM,PMC,,,,
PMC5049564,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC5049564,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC5049564,a large randomized clinical trial,TREATMENT,PMC,,,,
PMC3884621,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC3884621,patient care,TREATMENT,PMC,C0017313,patient care,MTH,Health Care Activity
PMC3884621,an observational retrospective study,TEST,PMC,,,,
PMC3884621,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC3884621,the initial radiographs,TEST,PMC,C5407766,"Open transluminal balloon angioplasty using imaging with radiographic supervision and interpretation, initial vein",CPT,Therapeutic or Preventive Procedure
PMC3884621,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3884621,the primary tumour,PROBLEM,PMC,C0475447,Site of primary tumor,SNOMEDCT_US,Finding
PMC3884621,liver metastases,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3884621,performance status,PROBLEM,PMC,C1518965,Performance Status,NCI,Finding
PMC3884621,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3884621,the regression analysis,TEST,PMC,C0034980,Regression Analysis,MSH,Intellectual Product
PMC3884621,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC3884621,statistical analyses,TEST,PMC,C0015483,"Factor Analysis, Statistical",MSH,Quantitative Concept
PMC3884621,kaplanmeier analysis,TEST,PMC,,,,
PMC3884621,logrank test,TEST,PMC,,,,
PMC3884621,cox regression,TREATMENT,PMC,C0010235,Cox Proportional Hazards Models,MSH,Quantitative Concept
PMC3884621,tumour diameter,PROBLEM,PMC,C0843406,Resection of carotid artery tumor <= 4cm in diameter,ICD10AMAE,Therapeutic or Preventive Procedure
PMC3884621,liver metastases,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3884621,chemotherapy treatment,TREATMENT,PMC,C5239596,Prephase Chemotherapy Treatment,NCI,Therapeutic or Preventive Procedure
PMC3884621,log h0357,TEST,PMC,,,,
PMC3884621,tumour size1181,TEST,PMC,,,,
PMC3884621,liver metastases0989,PROBLEM,PMC,,,,
PMC3884621,a lowrisk group,PROBLEM,PMC,,,,
PMC3884621,a mediumrisk group,PROBLEM,PMC,,,,
PMC3884621,a highrisk group,PROBLEM,PMC,,,,
PMC3884621,the primary tumour,PROBLEM,PMC,C0475447,Site of primary tumor,SNOMEDCT_US,Finding
PMC3884621,liver metastases,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3884621,the xray examination,TEST,PMC,,,,
PMC3884621,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3884621,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3884621,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC3884621,an easytouse model,TREATMENT,PMC,,,,
PMC3884621,the primary tumour,PROBLEM,PMC,C0475447,Site of primary tumor,SNOMEDCT_US,Finding
PMC3884621,liver metastases,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3884621,the xray examination,TEST,PMC,,,,
PMC3884621,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3884621,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3884621,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC3884621,an easytouse model,TREATMENT,PMC,,,,
PMC3884621,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC3884621,the primary tumour,PROBLEM,PMC,C0475447,Site of primary tumor,SNOMEDCT_US,Finding
PMC3884621,liver metastases,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC3884621,initial radiological examination,TEST,PMC,,,,
PMC3884621,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3884621,optimal patient care,TREATMENT,PMC,C5974370,Optimal care for patients with urologic conditions mips value pathway,HCPCS,Health Care Activity
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,all major cancers,PROBLEM,PMC,,,,
PMC9806441,early warning signs,PROBLEM,PMC,C2114019,prenatal education at initial visit about warning signs in early pregnancy,MEDCIN,Educational Activity
PMC9806441,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,vague,PROBLEM,PMC,C0205408,Vague,SNOMEDCT_US,Qualitative Concept
PMC9806441,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9806441,inoperable pancreatic cancer,PROBLEM,PMC,,,,
PMC9806441,current conventional treatment modalities,TREATMENT,PMC,,,,
PMC9806441,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9806441,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC9806441,tumor progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC9806441,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC9806441,peripheral blood vessels,PROBLEM,PMC,C0150936,Peripheral Blood Vessel,NCI,"Body Part, Organ, or Organ Component"
PMC9806441,bone marrowderived inflammatory cells,PROBLEM,PMC,,,,
PMC9806441,fibroblasts,PROBLEM,PMC,C0016030,Fibroblasts,MTH,Cell
PMC9806441,immune cells,PROBLEM,PMC,C4329351,Antineoplastic Immune Cell,NCI,Cell
PMC9806441,signaling molecules,TEST,PMC,C1519315,Signaling Molecule,MTH,Biologically Active Substance
PMC9806441,extracellular matrix,TREATMENT,PMC,C0015350,Extracellular Matrix,MTH,Tissue
PMC9806441,tumor cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC9806441,peripheral immune tolerance,PROBLEM,PMC,,,,
PMC9806441,promoting tumor angiogenesis,PROBLEM,PMC,,,,
PMC9806441,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC9806441,proliferation of cancer cells,PROBLEM,PMC,C3889757,SLC25A25-AS1 gene,MTH,Gene or Genome
PMC9806441,myeloidderived suppressor cells,TREATMENT,PMC,,,,
PMC9806441,key cellular components,PROBLEM,PMC,,,,
PMC9806441,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC9806441,immunosuppressive functions,TREATMENT,PMC,,,,
PMC9806441,recognizing other immune cells,PROBLEM,PMC,,,,
PMC9806441,promoting tumor growth,PROBLEM,PMC,,,,
PMC9806441,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC9806441,myeloidderived suppressor cells,TREATMENT,PMC,,,,
PMC9806441,the tumor immune response,PROBLEM,PMC,C2256218,inhibition of immune response to tumor cell,GO,Organism Function
PMC9806441,tumor treatments,TREATMENT,PMC,C2066011,destruction of rectal tumor (treatment),MTH,Therapeutic or Preventive Procedure
PMC9806441,rt,TREATMENT,PMC,C1418752,POMT1 gene,MTH,Gene or Genome
PMC9806441,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,mdscs generation,PROBLEM,PMC,,,,
PMC9806441,current therapies,TREATMENT,PMC,C2827774,Current Therapy,NCI,Therapeutic or Preventive Procedure
PMC9806441,new targetbased therapies,TREATMENT,PMC,,,,
PMC9806441,myeloidderived suppressor cells,TREATMENT,PMC,,,,
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,its treatment application,TREATMENT,PMC,,,,
PMC9806441,preclinical and clinical studies,TEST,PMC,,,,
PMC9806441,immune cells,PROBLEM,PMC,C4329351,Antineoplastic Immune Cell,NCI,Cell
PMC9806441,cytokineschemokines,TEST,PMC,,,,
PMC9806441,signaling pathways,TEST,PMC,C0037080,Signal Pathways,MSH,Molecular Function
PMC9806441,mdscs,TREATMENT,PMC,C4277543,Myeloid-Derived Suppressor Cells,MSH,Cell
PMC9806441,mdscs,PROBLEM,PMC,C4277543,Myeloid-Derived Suppressor Cells,MSH,Cell
PMC9806441,the progression,PROBLEM,PMC,C0449258,Progression,MTH,Functional Concept
PMC9806441,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC9806441,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,mouse pancreatic tumor models,PROBLEM,PMC,,,,
PMC9806441,mdscs,PROBLEM,PMC,C4277543,Myeloid-Derived Suppressor Cells,MSH,Cell
PMC9806441,the antitumor immune,TREATMENT,PMC,,,,
PMC9806441,therapeutic drugs,TREATMENT,PMC,C0580398,Drug level therapeutic,MDR,Laboratory or Test Result
PMC9806441,mdscs,TEST,PMC,C4277543,Myeloid-Derived Suppressor Cells,MSH,Cell
PMC9806441,a potential biomarker,TEST,PMC,,,,
PMC9806441,tumor progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC9806441,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC9806441,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9806441,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9806441,targeting mdscs,PROBLEM,PMC,,,,
PMC9806441,standard chemotherapy,TREATMENT,PMC,C5909315,Treatment Arm for COG ACNS0331 Comparison of Radiation Therapy Regimens in Combination with Chemotherapy in Treating Young Patients with Newly Diagnosed Standard-Risk Medulloblastoma,NCI,Research Activity
PMC9806441,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC9806441,new interventions,TREATMENT,PMC,,,,
PMC9806441,mdscs,PROBLEM,PMC,C4277543,Myeloid-Derived Suppressor Cells,MSH,Cell
PMC9806441,their immunosuppressive activity,TREATMENT,PMC,,,,
PMC9806441,cancer treatment,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC6584982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6584982,any malignancy,PROBLEM,PMC,C2349333,"Malignant poorly differentiated neuroendocrine carcinoma, any site",ICD9CM,Neoplastic Process
PMC6584982,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC6584982,psychosocial and palliative care services,TREATMENT,PMC,,,,
PMC6584982,standardized approaches,TREATMENT,PMC,C4699735,"Relaxation: Standardized, programmatic, complementary exercise approaches",LNC,Therapeutic or Preventive Procedure
PMC6584982,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6584982,an interdisciplinary group psychoeducational intervention,TREATMENT,PMC,,,,
PMC6584982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6584982,a subsequent feasibility study,TEST,PMC,,,,
PMC6584982,cancer care,TREATMENT,PMC,C0920687,cancer care,CHV,Therapeutic or Preventive Procedure
PMC6584982,the intervention content,TREATMENT,PMC,C3710407,Intervention for presence of leak of endoluminal contents through an anastomosis required,HCPCS,Finding
PMC6584982,the implementation process,TREATMENT,PMC,C5558495,Implements surgical debriefing process,PNDS,Health Care Activity
PMC6584982,the formative evaluation,TEST,PMC,C0681838,formative evaluation,AOD,Research Activity
PMC6584982,the intervention content,TREATMENT,PMC,C3710407,Intervention for presence of leak of endoluminal contents through an anastomosis required,HCPCS,Finding
PMC6584982,implementation science,TREATMENT,PMC,C4704785,Implementation Science,MSH,Occupation or Discipline
PMC6584982,the final intervention prototype,TREATMENT,PMC,,,,
PMC6584982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6584982,nutrition guidelines,TREATMENT,PMC,C3658297,Nutrition Guidelines,MSH,Intellectual Product
PMC6584982,disease,TREATMENT,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6584982,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC6584982,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6584982,palliative and supportive care services,TREATMENT,PMC,,,,
PMC6584982,a group psychoeducational intervention,TREATMENT,PMC,,,,
PMC6584982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6584982,implementation science,TREATMENT,PMC,C4704785,Implementation Science,MSH,Occupation or Discipline
PMC6584982,intervention development efforts,TREATMENT,PMC,,,,
PMC6584982,similar initiatives,TREATMENT,PMC,C2879404,"Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter",ICD10CM,Injury or Poisoning
PMC6584982,diseases,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6584982,limited prognoses,PROBLEM,PMC,,,,
PMC6584982,supplementary,TREATMENT,PMC,C5969725,Supplementary,SNOMEDCT_US,Qualitative Concept
PMC6584982,a group psychoeducational intervention,TREATMENT,PMC,,,,
PMC6584982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6584982,implementation science,TREATMENT,PMC,C4704785,Implementation Science,MSH,Occupation or Discipline
PMC6584982,intervention development efforts,TREATMENT,PMC,,,,
PMC6584982,similar initiatives,TREATMENT,PMC,C2879404,"Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter",ICD10CM,Injury or Poisoning
PMC6584982,diseases,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6584982,limited prognoses,PROBLEM,PMC,,,,
PMC6584982,the present study,TEST,PMC,C2207391,nerve conduction study anomalous innervation screen anomalous innervation present,MEDCIN,Finding
PMC6584982,an interdisciplinaryled intervention,TREATMENT,PMC,,,,
PMC6584982,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6584982,implementation science principles,TREATMENT,PMC,,,,
PMC6584982,intervention development,TREATMENT,PMC,C1514724,Rapid Access to Intervention Development,NCI,Governmental or Regulatory Activity
PMC6584982,similar initiatives,TREATMENT,PMC,C2879404,"Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter",ICD10CM,Injury or Poisoning
PMC6584982,other diseases,PROBLEM,PMC,C0156194,other diseases of liver,MEDCIN,Disease or Syndrome
PMC6584982,limited prognoses,PROBLEM,PMC,,,,
PMC3932002,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3932002,prediagnostic signs and symptoms,PROBLEM,PMC,,,,
PMC3932002,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3932002,thematic analysis,TEST,PMC,,,,
PMC3932002,prediagnostic symptom descriptions,PROBLEM,PMC,,,,
PMC3932002,a qualitative,TEST,PMC,C0205556,Qualitative,SNOMEDCT_US,Qualitative Concept
PMC3932002,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3932002,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3932002,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC3932002,the symptom,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3932002,such symptoms,PROBLEM,PMC,C5211393,"Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as backaches",LNC,Intellectual Product
PMC3932002,symptom episodes,PROBLEM,PMC,C2106794,completely free of symptoms between episodes,MEDCIN,Sign or Symptom
PMC3932002,the intermittent symptoms,PROBLEM,PMC,C1282310,Intermittent pain,SNOMEDCT_US,Sign or Symptom
PMC3932002,additional symptoms,PROBLEM,PMC,C2050586,past medical history reviewed with no additions since (date),MEDCIN,Finding
PMC3932002,consultation behaviour,PROBLEM,PMC,,,,
PMC3932002,our studythe,TEST,PMC,,,,
PMC3932002,pancreatic cancerreports,PROBLEM,PMC,,,,
PMC3932002,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3932002,a pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC3932002,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3932002,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3932002,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC3932002,intermittent gastrointestinal symptoms,PROBLEM,PMC,,,,
PMC3932002,intermittent pancreatitislike symptoms,PROBLEM,PMC,,,,
PMC3932002,our studythe,TEST,PMC,,,,
PMC3932002,pancreatic cancerreports,PROBLEM,PMC,,,,
PMC3932002,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3932002,a pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC3932002,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3932002,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3932002,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC3932002,intermittent gastrointestinal symptoms,PROBLEM,PMC,,,,
PMC3932002,intermittent pancreatitislike symptoms,PROBLEM,PMC,,,,
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,unfavorable,TREATMENT,PMC,C3640815,Unfavorable,NCI,Qualitative Concept
PMC11201547,the existing screening methods,TEST,PMC,,,,
PMC11201547,conventional treatments,TREATMENT,PMC,C2945704,Conventional Treatment,MTH,Therapeutic or Preventive Procedure
PMC11201547,limited efficacy,PROBLEM,PMC,,,,
PMC11201547,recent studies,TEST,PMC,C3642031,C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date,NCI,Intellectual Product
PMC11201547,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC11201547,extracellular vesicles,PROBLEM,PMC,C3894683,Extracellular Vesicles,MSH,Cell Component
PMC11201547,these,PROBLEM,PMC,C0039828,Theses,MTH,Intellectual Product
PMC11201547,mrnas,TREATMENT,PMC,C2754188,nuclear mRNA surveillance of mRNP export,GO,Genetic Function
PMC11201547,lipids,TREATMENT,PMC,C0023779,Lipids,MTH,Organic Chemical
PMC11201547,cancer growth,PROBLEM,PMC,C1516170,Cancer Cell Growth,NCI,Neoplastic Process
PMC11201547,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC11201547,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11201547,this intercellular communication among cells,PROBLEM,PMC,,,,
PMC11201547,novel therapeutic strategies,TREATMENT,PMC,,,,
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,a prevalent lethal gastrointestinal cancer,PROBLEM,PMC,,,,
PMC11201547,any symptoms,PROBLEM,PMC,C5706833,PRO-CTCAE V1.0 - Any Other Symptoms Reported,NCI,Intellectual Product
PMC11201547,a high mortality rate,PROBLEM,PMC,,,,
PMC11201547,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC11201547,screening protocol,TEST,PMC,C3656617,CCHD newborn screening protocol used,LNC,Finding
PMC11201547,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11201547,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,innovative therapeutic strategies,TREATMENT,PMC,,,,
PMC11201547,recent studies,TEST,PMC,C3642031,C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date,NCI,Intellectual Product
PMC11201547,the complex interaction,PROBLEM,PMC,C1373115,Synaptic Fusion Complex Interactions,MED-RT,Cell Function
PMC11201547,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC11201547,the extracellular matrix,PROBLEM,PMC,C0015350,Extracellular Matrix,MTH,Tissue
PMC11201547,cancerassociated cells,PROBLEM,PMC,,,,
PMC11201547,diverse immune cells,PROBLEM,PMC,,,,
PMC11201547,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11201547,heterogeneous cell subpopulations,PROBLEM,PMC,,,,
PMC11201547,pancreatic cancer pathogenesis,PROBLEM,PMC,,,,
PMC11201547,proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC11201547,angiogenesis,PROBLEM,PMC,C0302600,Angiogenic Process,MTH,Organ or Tissue Function
PMC11201547,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC11201547,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11201547,evassociated mirnas,PROBLEM,PMC,,,,
PMC11201547,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC11201547,drug resistance,PROBLEM,PMC,C0013203,Drug resistance,MTH,Biologic Function
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,drugdelivery mechanisms,TREATMENT,PMC,,,,
PMC11201547,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,high mortality among cancer,PROBLEM,PMC,,,,
PMC11201547,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11201547,therapeutic approaches,TREATMENT,PMC,C2453172,"Introduction of Other Therapeutic Substance into Heart, Open Approach",ICD10PCS,Therapeutic or Preventive Procedure
PMC11201547,lipidbound structures,PROBLEM,PMC,,,,
PMC11201547,bioactive molecules,PROBLEM,PMC,,,,
PMC11201547,intercellular communication,TREATMENT,PMC,C1154413,Intercellular Communication Process,NCI,Cell Function
PMC11201547,exosomes carrying mirnas,TREATMENT,PMC,,,,
PMC11201547,pdac progression,PROBLEM,PMC,,,,
PMC11201547,influencing angiogenesis,PROBLEM,PMC,,,,
PMC11201547,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC11201547,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC11201547,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC11201547,the wnt pathway,TEST,PMC,C1520113,Wnt Signaling Pathway,MTH,Molecular Function
PMC11201547,jakstat,TEST,PMC,,,,
PMC11201547,heightening cancer cell aggressiveness,PROBLEM,PMC,,,,
PMC11201547,combating pancreatic cancer metastasis,PROBLEM,PMC,,,,
PMC11201547,improving patient outcomes,PROBLEM,PMC,C0677282,Assist patients in making lifestyle changes to improve health outcomes,PPAC,Health Care Activity
PMC11201547,exosomal mirna profiles,TEST,PMC,,,,
PMC11201547,pdac,PROBLEM,PMC,,,,
PMC11201547,various mirnas,PROBLEM,PMC,,,,
PMC11201547,effective drugs,TREATMENT,PMC,C5914580,"Provide effective antiemetic drugs to prevent nausea when possible (i.e., avoid nausea related to pregnancy)",NIC,Health Care Activity
PMC11201547,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11201547,cisplatin,TREATMENT,PMC,C0008838,cisplatin,MTH,"Pharmacologic Substance, Inorganic Chemical"
PMC11201547,doxorubicin,TREATMENT,PMC,C0013089,doxorubicin,MTH,"Organic Chemical, Antibiotic"
PMC11201547,5fluorouracil,TREATMENT,PMC,C0016360,fluorouracil,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11201547,apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC11201547,drug metabolism,PROBLEM,PMC,C0683140,Drug Metabolism,NCI,Molecular Function
PMC11201547,this,PROBLEM,PMC,C1080058,This <Coelopellini>,MTH,Eukaryote
PMC11201547,effective therapeutic strategies,TREATMENT,PMC,,,,
PMC11201547,drug resistance,PROBLEM,PMC,C0013203,Drug resistance,MTH,Biologic Function
PMC11201547,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11201547,evs,TREATMENT,PMC,C0560135,electronvolt,MTH,Quantitative Concept
PMC11201547,therapeutic agents,TREATMENT,PMC,C0304231,Therapeutic agent,MTH,Manufactured Object
PMC11201547,delivery systems,TREATMENT,PMC,C0449914,Delivery system,SNOMEDCT_US,Functional Concept
PMC11201547,various studies,TEST,PMC,,,,
PMC11201547,clinical trials,TREATMENT,PMC,C0008976,Clinical Trials,MTH,Research Activity
PMC12049877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12049877,an aggressive cancer,PROBLEM,PMC,C2945759,aggressive cancer,CHV,Neoplastic Process
PMC12049877,unspecific symptoms,PROBLEM,PMC,,,,
PMC12049877,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC12049877,surveillance programmes,TEST,PMC,C0206214,Hazard Surveillance Program,MSH,Occupational Activity
PMC12049877,highrisk individuals,PROBLEM,PMC,,,,
PMC12049877,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12049877,a pancreatic cancer surveillance programme,TREATMENT,PMC,,,,
PMC12049877,the psychological burden,PROBLEM,PMC,C0510112,Determine the psychological burden of prognosis for family,NIC,Health Care Activity
PMC12049877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12049877,this singlecentre crosssectional study,TEST,PMC,,,,
PMC12049877,cancer worry,PROBLEM,PMC,C5444059,Cancer Worry Scale,MTH,Intellectual Product
PMC12049877,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC12049877,a digital questionnaire,TEST,PMC,,,,
PMC12049877,cancer worry scale,PROBLEM,PMC,C5444059,Cancer Worry Scale,MTH,Intellectual Product
PMC12049877,statetrait anxiety inventory,TEST,PMC,,,,
PMC12049877,shortform survey,TEST,PMC,,,,
PMC12049877,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12049877,a pancreatic cancer surveillance programme,TREATMENT,PMC,,,,
PMC12049877,high cancer worry,PROBLEM,PMC,,,,
PMC12049877,high scores,PROBLEM,PMC,C5387520,HEART score: MACE risk high,MEDCIN,Finding
PMC12049877,cws,TEST,PMC,C5444059,Cancer Worry Scale,MTH,Intellectual Product
PMC12049877,high cancer worry,PROBLEM,PMC,,,,
PMC12049877,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC12049877,stais,TEST,PMC,C0723445,Stay Alert,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC12049877,higher cancer worry,PROBLEM,PMC,,,,
PMC12049877,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC12049877,outcomes,PROBLEM,PMC,C0085415,Treatment outcome,MTH,Qualitative Concept
PMC12049877,coping,PROBLEM,PMC,C0009967,Coping Behavior,MTH,Individual Behavior
PMC12049877,cancer worry,PROBLEM,PMC,C5444059,Cancer Worry Scale,MTH,Intellectual Product
PMC12049877,psychological burden,PROBLEM,PMC,C0510112,Determine the psychological burden of prognosis for family,NIC,Health Care Activity
PMC12049877,cancer worry,PROBLEM,PMC,C5444059,Cancer Worry Scale,MTH,Intellectual Product
PMC12049877,psychological burden,PROBLEM,PMC,C0510112,Determine the psychological burden of prognosis for family,NIC,Health Care Activity
PMC12049877,cancer worry,PROBLEM,PMC,C5444059,Cancer Worry Scale,MTH,Intellectual Product
PMC12049877,pdac surveillance,TEST,PMC,,,,
PMC12049877,other studies,TEST,PMC,C2015796,other imaging studies,MEDCIN,Diagnostic Procedure
PMC12049877,other cancer types,PROBLEM,PMC,C5225787,Breast cancer - all other types,CCSR_ICD10CM,Neoplastic Process
PMC12049877,significantly more cancer worry,PROBLEM,PMC,,,,
PMC12049877,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC12049877,anxiety levels,TEST,PMC,C0564474,Level of anxiety,SNOMEDCT_US,Finding
PMC12049877,the total study population,TEST,PMC,,,,
PMC12049877,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6441154,all the deadly cancers,PROBLEM,PMC,,,,
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,any grave symptoms,PROBLEM,PMC,,,,
PMC6441154,diagnostic markers,TEST,PMC,C1511876,Diagnostic Factor,NCI,Clinical Attribute
PMC6441154,the disease incurable,PROBLEM,PMC,C0175969,incurable diseases,CHV,Disease or Syndrome
PMC6441154,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6441154,the early disease diagnosis,PROBLEM,PMC,C2367228,early lyme disease,MEDCIN,Disease or Syndrome
PMC6441154,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC6441154,the prime option,TREATMENT,PMC,,,,
PMC6441154,curative local disease,PROBLEM,PMC,,,,
PMC6441154,advanced cancer,PROBLEM,PMC,C0877373,Advanced cancer,MDR,Neoplastic Process
PMC6441154,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6441154,the standard treatment modality,TREATMENT,PMC,,,,
PMC6441154,drug resistance,PROBLEM,PMC,C0013203,Drug resistance,MTH,Biologic Function
PMC6441154,severe side effects,PROBLEM,PMC,C1829911,Severity of side effect to human immunodeficiency virus Rx,MTH,Finding
PMC6441154,desmoplasia,PROBLEM,PMC,C5671213,Desmoplasia,MTH,Pathologic Function
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,a thick scar tissue,PROBLEM,PMC,,,,
PMC6441154,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC6441154,different cell populations,PROBLEM,PMC,,,,
PMC6441154,this heterogenous population,PROBLEM,PMC,,,,
PMC6441154,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC6441154,sustained tumor growth,PROBLEM,PMC,,,,
PMC6441154,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC6441154,the tumorassociated macrophages,PROBLEM,PMC,,,,
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,tumor hallmarks,PROBLEM,PMC,,,,
PMC6441154,chemoresistance,TREATMENT,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC6441154,the therapeutic interventions,TREATMENT,PMC,C0869947,Therapeutic Interventions: Other Therapeutic Interventions,ICD10AM,Therapeutic or Preventive Procedure
PMC6441154,reduced tumor burden,PROBLEM,PMC,,,,
PMC6441154,pdac,PROBLEM,PMC,,,,
PMC6441154,effective therapeutic strategies,TREATMENT,PMC,,,,
PMC6441154,the cancer,PROBLEM,PMC,C0153567,Uterine Cancer,MTH,Neoplastic Process
PMC6441154,tumorassociated macrophages,PROBLEM,PMC,,,,
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,the various strategies,TREATMENT,PMC,,,,
PMC6441154,novel therapeutic interventions,TREATMENT,PMC,,,,
PMC6441154,pdac,TREATMENT,PMC,,,,
PMC6441154,cell signaling,PROBLEM,PMC,C0037083,Signal Transduction,MTH,Cell Function
PMC6441154,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC6441154,m2 tams,PROBLEM,PMC,,,,
PMC6441154,yap1 signaling,PROBLEM,PMC,,,,
PMC6441154,tumorigenesis,PROBLEM,PMC,C0596263,Carcinogenesis,MTH,Neoplastic Process
PMC6441154,several cancer types,PROBLEM,PMC,,,,
PMC6441154,recent studies,TEST,PMC,C3642031,C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date,NCI,Intellectual Product
PMC6441154,yap1hif pathway,PROBLEM,PMC,,,,
PMC6441154,promoting cancer stem cells,PROBLEM,PMC,,,,
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,the mtor signaling pathway,TEST,PMC,C2984436,mTOR Signaling Pathway PID,MTH,Molecular Function
PMC6441154,tams,PROBLEM,PMC,C0755473,Tams1 antigen,MSH,Immunologic Factor
PMC6441154,the cellular metabolism in tams,PROBLEM,PMC,,,,
PMC6441154,the mtor inhibitor redd1,TREATMENT,PMC,,,,
PMC6441154,redd1deficient tams,PROBLEM,PMC,,,,
PMC6441154,glycolysis,TEST,PMC,C0017952,Glycolysis,MSH,Molecular Function
PMC6441154,tam populations in tumor stroma,PROBLEM,PMC,,,,
PMC6441154,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC6441154,notch signaling,PROBLEM,PMC,C1155452,Notch Signaling Pathway,NCI,Molecular Function
PMC6441154,monocyte differentiation into tams,PROBLEM,PMC,,,,
PMC6441154,tams from monocytes,PROBLEM,PMC,,,,
PMC6441154,dna damage,PROBLEM,PMC,C0012860,DNA Damage,MSH,Cell or Molecular Dysfunction
PMC6441154,tams,PROBLEM,PMC,C0755473,Tams1 antigen,MSH,Immunologic Factor
PMC6441154,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC6441154,genomic instability,PROBLEM,PMC,C0919532,Genomic Instability,MSH,Cell or Molecular Dysfunction
PMC6441154,inflammation,PROBLEM,PMC,C0021368,Inflammation,MTH,Pathologic Function
PMC6441154,the activationinduced cytidinedeaminase,TEST,PMC,,,,
PMC6441154,em transition,TREATMENT,PMC,,,,
PMC6441154,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6441154,pd1 therapy,TREATMENT,PMC,,,,
PMC6441154,this suppression,PROBLEM,PMC,C0373508,Insulin-induced C-peptide suppression panel This panel must include the following: Insulin (83525) C-peptide (84681 x 5) Glucose (82947 x 5),CPT,Laboratory Procedure
PMC6441154,meaningful combinatorial studies,TEST,PMC,,,,
PMC6441154,m2 polarisation,PROBLEM,PMC,C5239833,NR4A1AS gene,MTH,Gene or Genome
PMC6441154,increased t cell response,PROBLEM,PMC,,,,
PMC6441154,induced cytotoxicity,PROBLEM,PMC,C1516454,Chemically Induced Cytotoxicity,NCI,Injury or Poisoning
PMC6441154,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC6441154,this epidemiological crisis,PROBLEM,PMC,,,,
PMC11843702,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11843702,a frequently fatal disease,PROBLEM,PMC,,,,
PMC11843702,severe symptoms,PROBLEM,PMC,C0436345,Symptom severe,SNOMEDCT_US,Finding
PMC11843702,highintensity endoflife hieol care,TREATMENT,PMC,,,,
PMC11843702,the examination,TEST,PMC,C4321457,Examination,MTH,Activity
PMC11843702,hieol care,TREATMENT,PMC,,,,
PMC11843702,tailored interventions,TREATMENT,PMC,C2986593,Tailored Intervention,NCI,Health Care Activity
PMC11843702,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC11843702,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11843702,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11843702,endoflife eol care,TREATMENT,PMC,,,,
PMC11843702,a retrospective study,TEST,PMC,C0035363,Retrospective Studies,MTH,Research Activity
PMC11843702,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11843702,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC11843702,the evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC11843702,hieol care,TREATMENT,PMC,,,,
PMC11843702,chemotherapy administration,TREATMENT,PMC,C3665478,chemotherapy administration,MEDCIN,Health Care Activity
PMC11843702,mostintensive eol,TREATMENT,PMC,,,,
PMC11843702,invasive procedures,TREATMENT,PMC,C0038895,Surgical aspects,MTH,Functional Concept
PMC11843702,univariate and multivariate logistic regression analyses,TEST,PMC,,,,
PMC11843702,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11843702,hieol,PROBLEM,PMC,,,,
PMC11843702,mieol care,TREATMENT,PMC,,,,
PMC11843702,ips,TREATMENT,PMC,C1019118,Ips <Scolytinae>,MTH,Eukaryote
PMC11843702,the multivariate analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC11843702,hieol,PROBLEM,PMC,,,,
PMC11843702,palliative,TREATMENT,PMC,C1285530,Palliative,MTH,Qualitative Concept
PMC11843702,palliative care involvement,PROBLEM,PMC,,,,
PMC11843702,mieol care,TREATMENT,PMC,,,,
PMC11843702,ips,TREATMENT,PMC,C1019118,Ips <Scolytinae>,MTH,Eukaryote
PMC11843702,palliative care integration,TREATMENT,PMC,C4305044,Integrated Palliative care Outcome Scale Patient Version (3 day recall period),SNOMEDCT_US,Intellectual Product
PMC11843702,individualized approaches,TREATMENT,PMC,C0683493,individual-focused prevention,AOD,Intellectual Product
PMC11843702,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11843702,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11843702,clear palliative care intervention,TREATMENT,PMC,,,,
PMC11843702,hieol care,TREATMENT,PMC,,,,
PMC11843702,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11843702,equitable eol support,TREATMENT,PMC,,,,
PMC11843702,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC3388562,new pancreatic cancers,PROBLEM,PMC,,,,
PMC3388562,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3388562,a casecontrol study,TEST,PMC,,,,
PMC3388562,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3388562,primary pancreatic cancer,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC3388562,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3388562,odds ratios,TEST,PMC,C0028873,Odds Ratio,MTH,Quantitative Concept
PMC3388562,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC3388562,conditional logistic regression,TEST,PMC,,,,
PMC3388562,positive,TEST,PMC,C1446409,Positive,MTH,Finding
PMC3388562,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3388562,back painp0004,PROBLEM,PMC,,,,
PMC3388562,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC3388562,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC3388562,nauseavomiting,PROBLEM,PMC,,,,
PMC3388562,back pain,PROBLEM,PMC,C0004604,Back Pain,MTH,Sign or Symptom
PMC3388562,constipation,PROBLEM,PMC,C0009806,Constipation,MTH,Sign or Symptom
PMC3388562,diarrhoea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC3388562,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC3388562,malaise,PROBLEM,PMC,C0231218,Malaise,MTH,Sign or Symptom
PMC3388562,newonset diabetes,PROBLEM,PMC,,,,
PMC3388562,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC3388562,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3388562,ppvs,TEST,PMC,C0265915,Congenital stenosis of pulmonary veins,SNOMEDCT_US,Congenital Abnormality
PMC3388562,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3388562,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3388562,predictive values,TEST,PMC,C1514307,Predictive Value,NCI,Qualitative Concept
PMC3388562,small ,PROBLEM,PMC,C0700321,Small,MTH,Quantitative Concept
PMC3388562,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC3388562,investigation,TEST,PMC,C1552578,Act Class - investigation,MTH,Intellectual Product
PMC3388562,multiple symptoms,PROBLEM,PMC,C0231217,Multiple symptoms,SNOMEDCT_US,Sign or Symptom
PMC3388562,current mortality,PROBLEM,PMC,C0479494,Exposure to unspecified electric current as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC3388562,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3388562,the cancer,PROBLEM,PMC,C0153567,Uterine Cancer,MTH,Neoplastic Process
PMC3388562,urgent investigation,TEST,PMC,,,,
PMC3388562,new major findings,PROBLEM,PMC,,,,
PMC3388562,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5588944,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5588944,poor survival rates,PROBLEM,PMC,,,,
PMC5588944,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC5588944,their symptoms,PROBLEM,PMC,,,,
PMC5588944,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5588944,symptom appraisal,PROBLEM,PMC,,,,
PMC5588944,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5588944,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5588944,qualitative analysis,TEST,PMC,C0681942,qualitative data analysis,AOD,Research Activity
PMC5588944,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5588944,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5588944,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5588944,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5588944,a cohort study,TEST,PMC,C0009247,Cohort Studies,MTH,Quantitative Concept
PMC5588944,interviews,TEST,PMC,C0021822,Interview,MTH,Activity
PMC5588944,noncancer conditions,PROBLEM,PMC,,,,
PMC5588944,first symptoms,PROBLEM,PMC,C0425967,Date symptom of pregnancy first noted,MTH,Finding
PMC5588944,three main themes,PROBLEM,PMC,,,,
PMC5588944,initial,PROBLEM,PMC,C0205265,Initially,MTH,Temporal Concept
PMC5588944,intermittent nonspecific symptoms,PROBLEM,PMC,,,,
PMC5588944,tiredness,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC5588944,appetite changes,PROBLEM,PMC,C0426587,Altered appetite,SNOMEDCT_US,Finding
PMC5588944,existing gastrointestinal conditions,PROBLEM,PMC,,,,
PMC5588944,medication,TREATMENT,PMC,C4284232,Medications,MTH,Intellectual Product
PMC5588944,initial symptom appraisal,TEST,PMC,,,,
PMC5588944,selfmedication,TREATMENT,PMC,,,,
PMC5588944,symptom changes,PROBLEM,PMC,C0421292,Skin symptom change,MTH,Finding
PMC5588944,alterations in appetite,PROBLEM,PMC,C0426587,Altered appetite,SNOMEDCT_US,Finding
PMC5588944,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC5588944,further appraisal,TEST,PMC,,,,
PMC5588944,a change,PROBLEM,PMC,C0392747,Changing,MTH,Functional Concept
PMC5588944,worsening of symptoms,PROBLEM,PMC,C5933149,Recognized worsening symptoms,NOC,Finding
PMC5588944,particularly pain,PROBLEM,PMC,C5775573,"Joint pain, particularly of hips and knees",OMIM,Finding
PMC5588944,helpseeking,TREATMENT,PMC,,,,
PMC5588944,symptom appraisal,PROBLEM,PMC,,,,
PMC5588944,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC5588944,other conditions,PROBLEM,PMC,C2707304,Other health conditions,MTH,Finding
PMC5588944,subtle and intermittent symptoms,PROBLEM,PMC,,,,
PMC5588944,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5588944,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5588944,subtle and intermittent symptoms,PROBLEM,PMC,,,,
PMC5588944,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC5588944,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10518105,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10518105,cancer death,PROBLEM,PMC,C4722463,Cancer-Related Death,MTH,Finding
PMC10518105,chemotherapies,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10518105,a high mortality rate,PROBLEM,PMC,,,,
PMC10518105,more effective therapies,TREATMENT,PMC,C3494935,More effective medication therapy available,SNOMEDCT_US,Finding
PMC10518105,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC10518105,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10518105,usnic acid,TREATMENT,PMC,C0042118,usnic acid,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10518105,modest antiproliferative activity,PROBLEM,PMC,,,,
PMC10518105,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC10518105,a ua pyrazole derivative,TREATMENT,PMC,,,,
PMC10518105,cervical cancer cells,PROBLEM,PMC,C0279671,Cervical Squamous Cell Carcinoma,MTH,Neoplastic Process
PMC10518105,other cancer cells,PROBLEM,PMC,C3829832,Has Cancer Other than Basal Cell Skin Cancer,NCI,Intellectual Product
PMC10518105,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC10518105,ua,PROBLEM,PMC,C0042014,Urinalysis,MTH,Laboratory Procedure
PMC10518105,cell,TEST,PMC,C0007634,Cells,MTH,Cell
PMC10518105,cell cycle,TEST,PMC,C0007586,Cell Cycle,MTH,Cell Function
PMC10518105,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC10518105,the mtt test,TEST,PMC,C0431034,McCormick toy test,SNOMEDCT_US,Diagnostic Procedure
PMC10518105,electron microscopy,TEST,PMC,C0026019,Electron Microscopy,MTH,Laboratory Procedure
PMC10518105,flow cytometry,TEST,PMC,C0016263,Flow Cytometry,MSH,Laboratory Procedure
PMC10518105,immunoblotting,TEST,PMC,C0020985,Immunoblotting,MTH,Laboratory Procedure
PMC10518105,the calcium ions level,TEST,PMC,C4236611,calcium ion binding involved in regulation of presynaptic cytosolic calcium ion concentration,GO,Molecular Function
PMC10518105,a murine xenograft model,TREATMENT,PMC,,,,
PMC10518105,different cancer cells,PROBLEM,PMC,,,,
PMC10518105,noncancerous cells,PROBLEM,PMC,C1412939,TPX2 gene,MTH,Gene or Genome
PMC10518105,calcium ions,TEST,PMC,C0596235,calcium ion,MTH,"Pharmacologic Substance, Element, Ion, or Isotope"
PMC10518105,er stress,PROBLEM,PMC,C3178870,Endoplasmic Reticulum Stress,MSH,Cell or Molecular Dysfunction
PMC10518105,cell vacuolization,PROBLEM,PMC,C4746780,Epidermal cell vacuolization,OMIM,Finding
PMC10518105,g0g1 cell cycle arrest,PROBLEM,PMC,,,,
PMC10518105,cell death,PROBLEM,PMC,C0007587,Cell Death Process,MTH,Cell Function
PMC10518105,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC10518105,xenografted pancreatic cancer cells5inhibited,PROBLEM,PMC,,,,
PMC10518105,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC10518105,kidney or liver toxicity,PROBLEM,PMC,,,,
PMC10518105,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC10518105,er stress exaggeration,PROBLEM,PMC,,,,
PMC10518105,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC10518105,er stress exaggeration,PROBLEM,PMC,,,,
PMC10518105,ua,TREATMENT,PMC,C0042014,Urinalysis,MTH,Laboratory Procedure
PMC10518105,er,TREATMENT,PMC,C1706324,EREG wt Allele,MTH,Gene or Genome
PMC10518105,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC10518105,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC10518105,adverse effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC10518105,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC10518105,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,a debilitating symptom,PROBLEM,PMC,,,,
PMC10932679,effective treatment options,TREATMENT,PMC,,,,
PMC10932679,this phenomenon,PROBLEM,PMC,,,,
PMC10932679,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,the intrapancreatic injection,TREATMENT,PMC,,,,
PMC10932679,mpakpcluc cells,TREATMENT,PMC,,,,
PMC10932679,abdominal mechanical hyperalgesia,PROBLEM,PMC,,,,
PMC10932679,hunch score,TEST,PMC,,,,
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,thein vitroelectrophysiological patchclamp technique,TREATMENT,PMC,,,,
PMC10932679,the electrophysiological,TEST,PMC,C0850293,electrophysiological studies,CHV,Diagnostic Procedure
PMC10932679,gabaergic neurons,PROBLEM,PMC,C0815002,GABAergic Neurons,MSH,Cell
PMC10932679,specific neuron ablation,TREATMENT,PMC,,,,
PMC10932679,chemogenetics methods,TREATMENT,PMC,,,,
PMC10932679,gabaergic neurons,PROBLEM,PMC,C0815002,GABAergic Neurons,MSH,Cell
PMC10932679,pancreatic cancerinduced,PROBLEM,PMC,,,,
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,the firing frequency,TEST,PMC,,,,
PMC10932679,gabaergic neurons,PROBLEM,PMC,C0815002,GABAergic Neurons,MSH,Cell
PMC10932679,specific destruction of gabaergic neurons,PROBLEM,PMC,,,,
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,chemogenetics,PROBLEM,PMC,C5940580,Chemogenetics,MSH,Molecular Biology Research Technique
PMC10932679,gabaergic neurons,PROBLEM,PMC,C0815002,GABAergic Neurons,MSH,Cell
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,gabaergic neurons,PROBLEM,PMC,C0815002,GABAergic Neurons,MSH,Cell
PMC10932679,pancreatic cancer in mice,PROBLEM,PMC,,,,
PMC10932679,pancreatic cancerrelated,PROBLEM,PMC,,,,
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,gabaergic neurons,PROBLEM,PMC,C0815002,GABAergic Neurons,MSH,Cell
PMC10932679,pancreatic cancer in mice,PROBLEM,PMC,,,,
PMC10932679,pancreatic cancerrelated,PROBLEM,PMC,,,,
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,the inhibition of gabaergic neurons in pvn,PROBLEM,PMC,,,,
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,pancreatic cancer in mice,PROBLEM,PMC,,,,
PMC10932679,chemogenetics,TREATMENT,PMC,C5940580,Chemogenetics,MSH,Molecular Biology Research Technique
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC10932679,innovative intervention agents,TREATMENT,PMC,,,,
PMC10932679,managing,PROBLEM,PMC,C1273870,Management procedure,MTH,Occupational Activity
PMC10932679,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10932679,visceral pain,PROBLEM,PMC,C0234245,Visceral Pain,MSH,Sign or Symptom
PMC12000257,this scoping review,TEST,PMC,,,,
PMC12000257,a comprehensive literature,TEST,PMC,,,,
PMC12000257,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC12000257,related interventions,TREATMENT,PMC,C1705910,Possibly Related to Intervention,MTH,Qualitative Concept
PMC12000257,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12000257,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC12000257,the supportive care framework,TREATMENT,PMC,,,,
PMC12000257,the review,TEST,PMC,C0030768,Peer Review,MSH,Health Care Activity
PMC12000257,the 33 descriptive studiesinformational,TEST,PMC,,,,
PMC12000257,psychoeducational interventions,TREATMENT,PMC,,,,
PMC12000257,painsymptom management interventions,TREATMENT,PMC,,,,
PMC12000257,four studies,TEST,PMC,,,,
PMC12000257,statistically significant,PROBLEM,PMC,C0237881,Statistical Significance,MTH,Quantitative Concept
PMC12000257,intervention groups,TREATMENT,PMC,C2985783,Intervention Group Quantity,NCI,Quantitative Concept
PMC12000257,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12000257,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC12000257,intervention strategies,TREATMENT,PMC,C0184661,Interventional procedure,MTH,Therapeutic or Preventive Procedure
PMC12000257,their supportive care,TREATMENT,PMC,C4710429,Assist in the introduction and passage of health care legislation by finding sponsors and persuading potential cosponsors to sign on with their support,NIC,Health Care Activity
PMC12000257,a few studies,TEST,PMC,C5413802,"Antimicrobial agent susceptibility study using disk method, per plate, 12 or fewer agents",CPT,Laboratory Procedure
PMC12000257,statistically significant improvements,PROBLEM,PMC,,,,
PMC12000257,the supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC12000257,related,TREATMENT,PMC,C0445223,Related (finding),MTH,Finding
PMC12000257,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12000257,targeted interventions,TREATMENT,PMC,C0237094,Other Intervention Target,MTH,Finding
PMC12000257,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12000257,supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC12000257,intervention strategies,TREATMENT,PMC,C0184661,Interventional procedure,MTH,Therapeutic or Preventive Procedure
PMC12000257,their supportive care,TREATMENT,PMC,C4710429,Assist in the introduction and passage of health care legislation by finding sponsors and persuading potential cosponsors to sign on with their support,NIC,Health Care Activity
PMC12000257,a few studies,TEST,PMC,C5413802,"Antimicrobial agent susceptibility study using disk method, per plate, 12 or fewer agents",CPT,Laboratory Procedure
PMC12000257,statistically significant improvements,PROBLEM,PMC,,,,
PMC12000257,the supportive care needs,TREATMENT,PMC,C5447463,Supportive Care Needs Survey-Short Form 34,NCI,Intellectual Product
PMC12000257,related,TREATMENT,PMC,C0445223,Related (finding),MTH,Finding
PMC12000257,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12000257,targeted interventions,TREATMENT,PMC,C0237094,Other Intervention Target,MTH,Finding
PMC11487006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11487006,a highly lethal disease,PROBLEM,PMC,,,,
PMC11487006,cancerrelated mortality,PROBLEM,PMC,,,,
PMC11487006,the staging,TEST,PMC,C0332305,With staging,SNOMEDCT_US,Functional Concept
PMC11487006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11487006,resectable cancers,PROBLEM,PMC,C0742559,colon cancer resection,CHV,Therapeutic or Preventive Procedure
PMC11487006,locally advanced or borderline resectable cancers,PROBLEM,PMC,,,,
PMC11487006,metastatic cancers,PROBLEM,PMC,C0854963,Metastatic Penile Cancer,MTH,Neoplastic Process
PMC11487006,endoscopy,TREATMENT,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC11487006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11487006,the palliation,TREATMENT,PMC,C0679251,disease palliation,AOD,Finding
PMC11487006,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11487006,biliary andor gastric outlet obstructions,PROBLEM,PMC,,,,
PMC11487006,the palliative ablation,TREATMENT,PMC,,,,
PMC11487006,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC11487006,the endoscopic evaluation,TEST,PMC,C3888833,Endoscopic swallowing evaluation,MDR,Diagnostic Procedure
PMC11487006,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC11487006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11487006,the diagnostic approach,TEST,PMC,C2406624,"Drainage of Anus, External Approach, Diagnostic",ICD10PCS,Diagnostic Procedure
PMC11487006,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11487006,palliative interventions,TREATMENT,PMC,,,,
PMC11487006,endoscopic retrograde cholangiopancreatography,TEST,PMC,C0008310,Endoscopic Retrograde Cholangiopancreatography,MTH,Diagnostic Procedure
PMC11487006,tumor debulking,TREATMENT,PMC,C0439805,Tumor Debulking,MTH,Therapeutic or Preventive Procedure
PMC11487006,radiofrequency ablation,TREATMENT,PMC,C0850292,Radiofrequency Ablation,MTH,Therapeutic or Preventive Procedure
PMC11487006,endoscopy,TEST,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC11487006,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11487006,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11487006,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC11487006,surgical intervention,TREATMENT,PMC,C0549433,Surgical intervention (finding),MTH,Finding
PMC11487006,the primary treatment,TREATMENT,PMC,C2008107,"cardiac catheterization lesion #1, primary treatment device",MEDCIN,Finding
PMC11487006,endoscopy,TEST,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC11487006,chemotherapy treatment,TREATMENT,PMC,C5239596,Prephase Chemotherapy Treatment,NCI,Therapeutic or Preventive Procedure
PMC11487006,histological confirmation,TEST,PMC,C1389238,with bacteriological and histological confirmation; epituberculosis,ICPC2ICD10ENG,Disease or Syndrome
PMC11487006,tissue samples,TEST,PMC,C0475358,Tumor tissue sample,MTH,Tissue
PMC11487006,appropriate treatment decisions,TREATMENT,PMC,C5430055,"new outpatient, medically appropriate H&P, straightforward decision making, 15+ minutes",MEDCIN,Health Care Activity
PMC11487006,the palliative care setting,TREATMENT,PMC,C3699590,interRAI palliative care:Find:Pt:{Setting}:Doc:{Role},LNC,Clinical Attribute
PMC11487006,endoscopy,TREATMENT,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC11487006,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC11487006,endoscopy,TREATMENT,PMC,C0014245,Endoscopy (procedure),MTH,Diagnostic Procedure
PMC11487006,effective palliation,TREATMENT,PMC,,,,
PMC11487006,biliary and enteric strictures,PROBLEM,PMC,C1282280,Stricture of biliary-enteric anastomosis,SNOMEDCT_US,Disease or Syndrome
PMC11487006,minimally invasive approaches,TREATMENT,PMC,C2170381,repair of pectus carinatum via minimally invasive approach,MEDCIN,Therapeutic or Preventive Procedure
PMC11487006,relieving symptoms,PROBLEM,PMC,C0436325,Food relieves symptom,SNOMEDCT_US,Finding
PMC11487006,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC11487006,obstruction,PROBLEM,PMC,C0028778,Obstruction,MTH,Finding
PMC11487006,ablative treatments,TREATMENT,PMC,C4537818,ablative laser treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC11487006,the tumor mass,PROBLEM,PMC,C3273930,Tumor Mass,MTH,Finding
PMC11487006,minimally invasive procedures,TREATMENT,PMC,C2711297,Minimally invasive procedure,SNOMEDCT_US,Functional Concept
PMC11487006,techniques,TREATMENT,PMC,C0449851,Techniques,MTH,Functional Concept
PMC11487006,intraductal radiofrequency ablation,TREATMENT,PMC,,,,
PMC11487006,endoscopic debulking of,TREATMENT,PMC,,,,
PMC11487006,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC11487006,targeted energy,TREATMENT,PMC,,,,
PMC11487006,managing pancreatic tumors,PROBLEM,PMC,,,,
PMC11487006,slowing their progression,PROBLEM,PMC,,,,
PMC6843405,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6843405,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC6843405,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC6843405,osteoporosis,PROBLEM,PMC,C0029456,Osteoporosis,MTH,Disease or Syndrome
PMC6843405,different mechanisms,PROBLEM,PMC,,,,
PMC6843405,body weight,TEST,PMC,C0005910,Body Weight,MTH,Organism Attribute
PMC6843405,these metabolic changes,PROBLEM,PMC,,,,
PMC6843405,treatment outcomes,TREATMENT,PMC,C0085415,Treatment outcome,MTH,Qualitative Concept
PMC6843405,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6843405,radiological changes in body composition,PROBLEM,PMC,,,,
PMC6843405,exocrine and endocrine pancreatic insufficiency,PROBLEM,PMC,,,,
PMC6843405,body mass,PROBLEM,PMC,C0518010,body mass,CHV,Finding
PMC6843405,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC6843405,pdacmaterials,PROBLEM,PMC,,,,
PMC6843405,diagnosed cp,PROBLEM,PMC,,,,
PMC6843405,pdac,PROBLEM,PMC,,,,
PMC6843405,analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC6843405,dualenergy xray absorptiometry,TEST,PMC,,,,
PMC6843405,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC6843405,magnetic resonance imaging,TEST,PMC,C0024485,Magnetic Resonance Imaging,MTH,Diagnostic Procedure
PMC6843405,cancer,TREATMENT,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6843405,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC6843405,changes in fecal elastase1,PROBLEM,PMC,,,,
PMC6843405,significant difference in skeletal muscle mass,PROBLEM,PMC,,,,
PMC6843405,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC6843405,pdac,TEST,PMC,,,,
PMC6843405,low smm,PROBLEM,PMC,,,,
PMC6843405,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC6843405,more pronounced pancreatic fibrosis pf,PROBLEM,PMC,,,,
PMC6843405,a high degree of pf,PROBLEM,PMC,,,,
PMC6843405,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC6843405,low fecal elastase1 levels,PROBLEM,PMC,,,,
PMC6843405,a statistically significant lower qol,PROBLEM,PMC,,,,
PMC6843405,pf,TEST,PMC,,,,
PMC6843405,osteoporosisosteopenia,PROBLEM,PMC,,,,
PMC6843405,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6843405,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6843405,ct and mribased assessment,TEST,PMC,,,,
PMC6843405,body composition,TEST,PMC,C0005885,Body Composition,MSH,Organism Attribute
PMC6843405,pancreatic fibrosis,PROBLEM,PMC,C0267952,Fibrosis of pancreas,SNOMEDCT_US,Disease or Syndrome
PMC6843405,these significant metabolic changes,PROBLEM,PMC,,,,
PMC6843405,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC6843405,osteopenia,PROBLEM,PMC,C0029453,Osteopenia,MTH,Disease or Syndrome
PMC6843405,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6843405,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6843405,the main disease,PROBLEM,PMC,C0856739,Left main stem disease,MTH,Disease or Syndrome
PMC6843405,body weight,TEST,PMC,C0005910,Body Weight,MTH,Organism Attribute
PMC6843405,pancreatic fibrosis,PROBLEM,PMC,C0267952,Fibrosis of pancreas,SNOMEDCT_US,Disease or Syndrome
PMC6843405,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC6843405,pf,PROBLEM,PMC,,,,
PMC6843405,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC6843405,low fecal elastase1 levels,PROBLEM,PMC,,,,
PMC6843405,pancreatic exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC6843405,fecal elastase1,TEST,PMC,,,,
PMC6843405,abnormal bone density,PROBLEM,PMC,C4021657,Abnormality of bone mineral density,HPO,Anatomical Abnormality
PMC6843405,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC6843405,a moderate overall accuracy,PROBLEM,PMC,,,,
PMC6843405,exocrine insufficiency,PROBLEM,PMC,C0267963,Exocrine pancreatic insufficiency,MTH,Disease or Syndrome
PMC6843405,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC6843405,evaluation of pf,TEST,PMC,,,,
PMC6843405,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC6843405,body composition,TEST,PMC,C0005885,Body Composition,MSH,Organism Attribute
PMC6843405,metabolic disorders,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6843405,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6843405,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6843405,routine assessment,TEST,PMC,C5671166,Routine prenatal assessment panel,MTH,Health Care Activity
PMC6843405,treatment planning,TREATMENT,PMC,C5202876,Treatment Planning,MTH,Health Care Activity
PMC6843405,dxa,TEST,PMC,C1510486,Dual-Energy X-Ray Absorptiometry,MTH,Diagnostic Procedure
PMC6843405,the evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC6843405,bone density status,PROBLEM,PMC,,,,
PMC6843405,pancreatic disease,PROBLEM,PMC,C0030286,Pancreatic Diseases,MTH,Disease or Syndrome
PMC6843405,osteopenia,PROBLEM,PMC,C0029453,Osteopenia,MTH,Disease or Syndrome
PMC6843405,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC6843405,our study,TEST,PMC,,,,
PMC6843405,the study population,TEST,PMC,C2348150,Sample Study Population,NCI,Population Group
PMC6843405,both pancreatic cancer,PROBLEM,PMC,,,,
PMC6843405,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6843405,other illnesses,PROBLEM,PMC,C3173481,Other chest illnesses you had,LNC,Intellectual Product
PMC6843405,the comorbidities,PROBLEM,PMC,C5933942,Potential comorbidities,NOC,Finding
PMC6843405,histological tissue examination,TEST,PMC,C4315894,Histologic examination of tumor tissue shows mixed smooth muscle hamartoma and lipoma,OMIM,Finding
PMC6843405,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6843405,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC6843405,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC6843405,clinical examination,TEST,PMC,C0031809,Physical Examination,MTH,Health Care Activity
PMC6843405,the clinical conditions,PROBLEM,PMC,C5421238,CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology,NCI,Intellectual Product
PMC6843405,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6843405,a lesion in the pancreas,PROBLEM,PMC,C0400481,Drainage of lesion of pancreas,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC6843405,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC6843405,our study,TEST,PMC,,,,
PMC6843405,diagnosed pancreatic pathology,PROBLEM,PMC,,,,
PMC6843405,sarcopenia,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC6843405,a multicentric study,TEST,PMC,C0282439,Multicenter Studies as Topic,MTH,Intellectual Product
PMC6843405,clinical value,TEST,PMC,C0205210,Clinical,MTH,Qualitative Concept
PMC9433056,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC9433056,an extremely aggressive cancer,PROBLEM,PMC,,,,
PMC9433056,a low survival rate,PROBLEM,PMC,,,,
PMC9433056,common sites,PROBLEM,PMC,C1268421,"Ureter and common iliac artery, CS",SNOMEDCT_US,Body Location or Region
PMC9433056,metastases include the liver and lungs,PROBLEM,PMC,,,,
PMC9433056,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9433056,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9433056,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9433056,gross tumor resection,TREATMENT,PMC,C3526360,Surgical pathology with gross and microscopic examination of specimen from resection of brain for tumor,CPT,Diagnostic Procedure
PMC9433056,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9433056,stereotactic radiosurgery,TREATMENT,PMC,C3846112,"Radiosurgery, Stereotactic",MTH,Therapeutic or Preventive Procedure
PMC9433056,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC9433056,her neurological symptoms,PROBLEM,PMC,,,,
PMC9433056,generalized tonicclonic seizures,PROBLEM,PMC,,,,
PMC9433056,leptomeningeal carcinomatosis,PROBLEM,PMC,C0220654,Meningeal Carcinomatosis,MTH,Neoplastic Process
PMC9433056,tumor resection,TREATMENT,PMC,C4761063,Tumor resection,MDR,Therapeutic or Preventive Procedure
PMC9433056,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9433056,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9433056,treatment strategies,TREATMENT,PMC,C4535966,intervention using focused treatment strategies,MEDCIN,Therapeutic or Preventive Procedure
PMC9433056,similar presentations,PROBLEM,PMC,C2368538,Advance care plan or similar legal document present in the medical record (COA),CPT,Health Care Activity
PMC9433056,a gross total resection,TREATMENT,PMC,C4330055,Gross Total Resection,MTH,Therapeutic or Preventive Procedure
PMC9433056,adjuvant radiosurgery,TREATMENT,PMC,,,,
PMC9433056,two bilateral frontal area metastases,PROBLEM,PMC,,,,
PMC9433056,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9433056,her neurological symptoms,PROBLEM,PMC,,,,
PMC9433056,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9433056,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9433056,treatment strategies,TREATMENT,PMC,C4535966,intervention using focused treatment strategies,MEDCIN,Therapeutic or Preventive Procedure
PMC9433056,similar presentations,PROBLEM,PMC,C2368538,Advance care plan or similar legal document present in the medical record (COA),CPT,Health Care Activity
PMC6299603,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6299603,cancer related deaths,PROBLEM,PMC,C4722463,Cancer-Related Death,MTH,Finding
PMC6299603,generic symptoms,PROBLEM,PMC,C0159028,General symptom,MDR,Sign or Symptom
PMC6299603,effective screening strategies,TREATMENT,PMC,,,,
PMC6299603,chemo,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6299603,radiotherapies,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC6299603,the risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC6299603,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6299603,several metabolic disorders,PROBLEM,PMC,C3809719,"Severe dermatitis, multiple allergies, metabolic wasting syndrome",MTH,Disease or Syndrome
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,insulin resistance,PROBLEM,PMC,C0021655,Insulin Resistance,MTH,Pathologic Function
PMC6299603,type 2 diabetes mellitus,PROBLEM,PMC,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",MTH,Disease or Syndrome
PMC6299603,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,t2dm,PROBLEM,PMC,,,,
PMC6299603,pc pathogenesis,PROBLEM,PMC,,,,
PMC6299603,several biochemical and physiological factors,PROBLEM,PMC,,,,
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,t2dm,PROBLEM,PMC,,,,
PMC6299603,adipokines,PROBLEM,PMC,C1955907,Adipokines,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC6299603,inflammatory mediators,PROBLEM,PMC,C5543552,Increased levels of inflammatory mediators and cytokines,OMIM,Finding
PMC6299603,altered microbiome,PROBLEM,PMC,,,,
PMC6299603,pc progression,PROBLEM,PMC,,,,
PMC6299603,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC6299603,these factors,PROBLEM,PMC,,,,
PMC6299603,altered signaling pathways,PROBLEM,PMC,C5908160,EGFR Signaling Pathway Alteration Positive,NCI,Laboratory or Test Result
PMC6299603,disease complexity,PROBLEM,PMC,C1449809,Bovine Respiratory Disease Complex,MTH,Disease or Syndrome
PMC6299603,novel therapies,TREATMENT,PMC,,,,
PMC6299603,gut microbiota,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC6299603,adrenomedullin hyaluronan vanin,TREATMENT,PMC,,,,
PMC6299603,matrix metalloproteinase,TREATMENT,PMC,C0623362,Matrix Metalloproteinases,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6299603,metabolic alteration,PROBLEM,PMC,C1372744,Metabolic Activity Alteration,MED-RT,Physiologic Function
PMC6299603,pancreatic tumor progression,PROBLEM,PMC,,,,
PMC6299603,metabolic diseases,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,t2dm,PROBLEM,PMC,,,,
PMC6299603,pc development,PROBLEM,PMC,,,,
PMC6299603,altered metabolic pathways,PROBLEM,PMC,,,,
PMC6299603,oncogenic development in pancreas,PROBLEM,PMC,,,,
PMC6299603,metabolic disorder,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6299603,a beneficial strategy,TREATMENT,PMC,,,,
PMC6299603,combat cancers,PROBLEM,PMC,C0042958,Voluntary Health Agencies,MSH,Health Care Activity
PMC6299603,metabolic diseases,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6299603,metabolic diseases,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,t2dm,PROBLEM,PMC,,,,
PMC6299603,pc development,PROBLEM,PMC,,,,
PMC6299603,altered metabolic pathways,PROBLEM,PMC,,,,
PMC6299603,oncogenic development in pancreas,PROBLEM,PMC,,,,
PMC6299603,metabolic disorder,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6299603,a beneficial strategy,TREATMENT,PMC,,,,
PMC6299603,combat cancers,PROBLEM,PMC,C0042958,Voluntary Health Agencies,MSH,Health Care Activity
PMC6299603,metabolic diseases,PROBLEM,PMC,C0025517,Metabolic Diseases,MSH,Disease or Syndrome
PMC6299603,several studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,t2dm,PROBLEM,PMC,,,,
PMC6299603,pc development,PROBLEM,PMC,,,,
PMC6299603,its pathogenesis,PROBLEM,PMC,,,,
PMC6299603,pancreatic tumor,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC6299603,recent studies,TEST,PMC,C3642031,C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date,NCI,Intellectual Product
PMC6299603,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC6299603,adipocytokines,TEST,PMC,C1955907,Adipokines,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC6299603,gut microbiota,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC6299603,adrenomedullin hyaluronan vanin,TREATMENT,PMC,,,,
PMC6299603,pcdm,PROBLEM,PMC,,,,
PMC6299603,promoting obesityand,PROBLEM,PMC,,,,
PMC6299603,diabetesassociated pancreatic cancer,PROBLEM,PMC,,,,
PMC6299603,therapeutic targeting,TREATMENT,PMC,C4329355,Apoptotic Pathway-targeting Antineoplastic Agent,NCI,Pharmacologic Substance
PMC6299603,literature survey,TEST,PMC,C0178732,literature survey,CSP,Intellectual Product
PMC6299603,the obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6299603,t2dm,PROBLEM,PMC,,,,
PMC6299603,pc development,PROBLEM,PMC,,,,
PMC6299603,this highly lethal malignancy,PROBLEM,PMC,,,,
PMC11416195,background pancreatic duct pd disruption,PROBLEM,PMC,,,,
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,therapeutic interventions,TREATMENT,PMC,C0808232,Therapeutic Intervention,MTH,Therapeutic or Preventive Procedure
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,pancreatic cancer prognosis,PROBLEM,PMC,,,,
PMC11416195,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11416195,the therapeutic modalities,TREATMENT,PMC,C3881343,"Multi-modality therapeutic radiation phantom, test object",SNOMEDCT_US,Medical Device
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,this retrospective study,TEST,PMC,,,,
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,an endoscopic intervention,TREATMENT,PMC,C0940709,Type of previous endoscopic intervention of the papilla major,MTHMST,Intellectual Product
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,endoscopic pancreatic stenting,TREATMENT,PMC,C0400526,Endoscopic change of pancreatic stent,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11416195,endoscopic ultrasonographyguided,TEST,PMC,,,,
PMC11416195,stent placement,TREATMENT,PMC,C2348535,Stenting,MTH,Therapeutic or Preventive Procedure
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic juice leakage,PROBLEM,PMC,,,,
PMC11416195,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11416195,pancreatic pseudocyst,PROBLEM,PMC,C0030299,Pancreatic Pseudocyst,MSH,Disease or Syndrome
PMC11416195,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC11416195,ppc,PROBLEM,PMC,C0334361,Extraovarian primary peritoneal carcinoma,MTH,Neoplastic Process
PMC11416195,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC11416195,eps,TEST,PMC,C0221271,Elastosis perforans serpiginosa,MTH,Disease or Syndrome
PMC11416195,euspfd,TEST,PMC,,,,
PMC11416195,lumenapposing metal stent placement,TREATMENT,PMC,,,,
PMC11416195,complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,carcinoma in situ,PROBLEM,PMC,C0007099,Carcinoma in Situ,MTH,Neoplastic Process
PMC11416195,the metastatic phase,TEST,PMC,,,,
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC11416195,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11416195,obvious recurrence of peritoneal sowing,PROBLEM,PMC,,,,
PMC11416195,the median overall survival,TREATMENT,PMC,,,,
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,endoscopic intervention,TREATMENT,PMC,C0940709,Type of previous endoscopic intervention of the papilla major,MTHMST,Intellectual Product
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,survival rates,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC11416195,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11416195,endoscopic treatment,TREATMENT,PMC,C2169949,Endoscopic cyclophotocoagulation,CPT,Therapeutic or Preventive Procedure
PMC11416195,pancreatic cancerassociated,PROBLEM,PMC,,,,
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,cyst infection,PROBLEM,PMC,C0948141,Hepatic cyst infection,MDR,Disease or Syndrome
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,appropriate management,TREATMENT,PMC,C0811031,Discuss age-appropriate behavior management strategies,NIC,Health Care Activity
PMC11416195,endoscopic therapy,TREATMENT,PMC,C2064938,endoscopic laser therapy,MEDCIN,Therapeutic or Preventive Procedure
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pd disruption,PROBLEM,PMC,C4288532,PDCD-1 Knockout Autologous T-lymphocytes,NCI,Cell
PMC11416195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416195,pd failure,PROBLEM,PMC,C3841810,Following hemodialysis (HD) or peritoneal dialysis (PD) access failure,LNC,Finding
PMC11416195,cytological diagnosis,TEST,PMC,C0332141,Cytology diagnosis,MTH,Diagnostic Procedure
PMC11416195,imaging studies,TEST,PMC,C1881134,imaging studies,MEDCIN,Diagnostic Procedure
PMC11416195,coexisting pancreatic cancer,PROBLEM,PMC,,,,
PMC5708962,malignant ascites,PROBLEM,PMC,C0220656,Malignant ascites,SNOMEDCT_US,Neoplastic Process
PMC5708962,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC5708962,serious symptoms,PROBLEM,PMC,C2048447,impulsive behavior with serious assault or property damage,MEDCIN,Individual Behavior
PMC5708962,standard method,TREATMENT,PMC,C3516472,"Transplant antibody measurement, standard method",CPT,Laboratory Procedure
PMC5708962,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC5708962,pancreatic cancermediated,PROBLEM,PMC,,,,
PMC5708962,apatinib,TREATMENT,PMC,C2346836,apatinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC5708962,a novel,TREATMENT,PMC,C4042926,Graphic Novel,MSH,Intellectual Product
PMC5708962,vascular endothelial growth factor receptor2,TREATMENT,PMC,,,,
PMC5708962,concurrent apatinib,TREATMENT,PMC,,,,
PMC5708962,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC5708962,pancreatic cancermediated,PROBLEM,PMC,,,,
PMC5708962,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC5708962,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5708962,his first symptom,PROBLEM,PMC,,,,
PMC5708962,tube drainage,TREATMENT,PMC,C0184114,Tube drain,SNOMEDCT_US,Medical Device
PMC5708962,gemcitabine therapy,TREATMENT,PMC,,,,
PMC5708962,gemcitabine combined apatinib orally,TREATMENT,PMC,,,,
PMC5708962,paracentesis,TREATMENT,PMC,C0034115,Paracentesis,MTH,Therapeutic or Preventive Procedure
PMC5708962,the cea,TEST,PMC,C3463961,Cea <Ceinae>,MTH,Eukaryote
PMC5708962,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC5708962,the treatment process,TREATMENT,PMC,C0186072,closed treatment of vertebral process fracture,MEDCIN,Therapeutic or Preventive Procedure
PMC5708962,apatinib administration,TREATMENT,PMC,,,,
PMC5708962,a progressionfree survival,TREATMENT,PMC,,,,
PMC5708962,hypertension,PROBLEM,PMC,C0020538,Hypertensive disease,MTH,Disease or Syndrome
PMC5708962,handfoot syndrome,PROBLEM,PMC,,,,
PMC5708962,proteinuria,PROBLEM,PMC,C0033687,Proteinuria,MTH,Finding
PMC5708962,apatinib concurrent gemcitabine,TREATMENT,PMC,,,,
PMC5708962,pancreatic cancermediated,PROBLEM,PMC,,,,
PMC5708962,further clinical trials,TREATMENT,PMC,,,,
PMC5708962,apatinib concurrent gemcitabine,TREATMENT,PMC,,,,
PMC5708962,an additional option,TREATMENT,PMC,C5142702,Optional additional questions,LNC,Intellectual Product
PMC5708962,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC5708962,pancreatic cancermediated,PROBLEM,PMC,,,,
PMC5708962,further largescale clinical trials,TREATMENT,PMC,,,,
PMC8128017,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC8128017,a debilitating symptom,PROBLEM,PMC,,,,
PMC8128017,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8128017,pancreatic duct pd decompression,TREATMENT,PMC,,,,
PMC8128017,this pain,PROBLEM,PMC,C3259363,Have you ever seen a doctor about this pain,LNC,Intellectual Product
PMC8128017,endoscopic pd decompression,TREATMENT,PMC,,,,
PMC8128017,palliation,TREATMENT,PMC,C0679251,disease palliation,AOD,Finding
PMC8128017,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8128017,a systematic review,TEST,PMC,C1955832,Systematic Review,MSH,Intellectual Product
PMC8128017,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC8128017,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8128017,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC8128017,pd decompression,TREATMENT,PMC,,,,
PMC8128017,plastic stents,TREATMENT,PMC,C0441289,Plastic stent,SNOMEDCT_US,Medical Device
PMC8128017,all included studies,TEST,PMC,,,,
PMC8128017,pain levels,PROBLEM,PMC,C1821295,Pain distress level,MTH,Finding
PMC8128017,pd stenting,TREATMENT,PMC,,,,
PMC8128017,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC8128017,endoscopic retrograde cholangiopancreatography,TEST,PMC,C0008310,Endoscopic Retrograde Cholangiopancreatography,MTH,Diagnostic Procedure
PMC8128017,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC8128017,hemosuccus pancreaticus,PROBLEM,PMC,,,,
PMC8128017,aes,PROBLEM,PMC,C2699274,Scanning Auger Spectrometer,MTH,Research Device
PMC8128017,endoscopic ultrasoundguided,TEST,PMC,,,,
PMC8128017,the stentmigration,TREATMENT,PMC,C4087543,Stent migration,MDR,Pathologic Function
PMC8128017,stentocclusion rates,TEST,PMC,,,,
PMC8128017,aerelated mortality,PROBLEM,PMC,,,,
PMC8128017,the methodological quality assessment,TEST,PMC,,,,
PMC8128017,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC8128017,this exploratory analysis,TEST,PMC,,,,
PMC8128017,endoscopic pd drainage,TREATMENT,PMC,,,,
PMC8128017,safe option,TREATMENT,PMC,C5934745,Seeks current information on safe housing options,NOC,Finding
PMC8128017,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC8128017,obstructivetype pc pain,PROBLEM,PMC,,,,
PMC8128017,a randomizedcontrolled trial,TREATMENT,PMC,,,,
PMC8128017,this invasive practice,TREATMENT,PMC,,,,
PMC8128017,this exploratory analysis,TEST,PMC,,,,
PMC8128017,endoscopic pd drainage,TREATMENT,PMC,,,,
PMC8128017,safe option,TREATMENT,PMC,C5934745,Seeks current information on safe housing options,NOC,Finding
PMC8128017,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC8128017,obstructivetype pc pain,PROBLEM,PMC,,,,
PMC8128017,a randomizedcontrolled trial,TREATMENT,PMC,,,,
PMC8128017,this invasive practice,TREATMENT,PMC,,,,
PMC4122139,traditional chinese medicine,TREATMENT,PMC,C0025124,Traditional Chinese Medicine,MTH,Biomedical Occupation or Discipline
PMC4122139,prescriptions,TREATMENT,PMC,C0033080,Prescription (procedure),MTH,Health Care Activity
PMC4122139,the signs and symptoms,PROBLEM,PMC,C0037088,Signs and Symptoms,MTH,Sign or Symptom
PMC4122139,syndrome differentiation,PROBLEM,PMC,C4324295,IDH differentiation syndrome,MDR,Disease or Syndrome
PMC4122139,inspection,TEST,PMC,C0199219,Inspection (procedure),MTH,Health Care Activity
PMC4122139,auscultation,TEST,PMC,C0004339,Auscultation,MTH,Diagnostic Procedure
PMC4122139,olfaction,TEST,PMC,C0037361,Smell Perception,MTH,Organism Function
PMC4122139,palpation,TEST,PMC,C0030247,Palpation,MTH,Diagnostic Procedure
PMC4122139,the zheng,PROBLEM,PMC,C2986502,Zheng,NCI,Therapeutic or Preventive Procedure
PMC4122139,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4122139,384 cancerrelated mirnas,PROBLEM,PMC,,,,
PMC4122139,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4122139,mirna polymerase chain reaction,TEST,PMC,,,,
PMC4122139,the different expression,PROBLEM,PMC,C4712253,Encourage free expression of different opinions and ideas,NIC,Health Care Activity
PMC4122139,realtime quantitative pcr,TEST,PMC,C5979797,"Oncology (urothelial), dna, quantitative methylated realtime pcr of trna-cys, sim2, and nkx1-1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (utuc)",HCPT,Laboratory Procedure
PMC4122139,some mirnas,TEST,PMC,,,,
PMC4122139,mir17,TEST,PMC,C1537713,MIR17 gene,MTH,Gene or Genome
PMC4122139,mir21,TEST,PMC,C1537719,MIR21 gene,MTH,Gene or Genome
PMC4122139,mir181b,TEST,PMC,C4319735,MicroRNA 181b,MTH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC4122139,mir196a,TEST,PMC,,,,
PMC4122139,these mirnas,PROBLEM,PMC,,,,
PMC4122139,different zheng condition,PROBLEM,PMC,,,,
PMC4122139,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4122139,tcm zheng,PROBLEM,PMC,C2355396,fu zheng yang yin,MSH,Pharmacologic Substance
PMC4122139,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4122139,mirnas in salivary supernatant,TEST,PMC,,,,
PMC4122139,4 mirnas,TEST,PMC,,,,
PMC4122139,mir17,TEST,PMC,C1537713,MIR17 gene,MTH,Gene or Genome
PMC4122139,mir21,TEST,PMC,C1537719,MIR21 gene,MTH,Gene or Genome
PMC4122139,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC4122139,syndrome differentiation,PROBLEM,PMC,C4324295,IDH differentiation syndrome,MDR,Disease or Syndrome
PMC4122139,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4122139,further study,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC4122139,larger,TREATMENT,PMC,C0549177,Large,MTH,Quantitative Concept
PMC4122139,salivary supernatant,TEST,PMC,,,,
PMC4122139,gene profiling analysis,TEST,PMC,C5413260,"Gene analysis of breast tumor tissue, profiling by hybrid capture of 58 genes",CPT,Laboratory Procedure
PMC4122139,oral foreign body,PROBLEM,PMC,C0161018,Foreign body in mouth,SNOMEDCT_US,Injury or Poisoning
PMC4122139,food debris,PROBLEM,PMC,,,,
PMC4122139,mirna expression in cancer,PROBLEM,PMC,,,,
PMC4122139,these 4 mirnas,TEST,PMC,,,,
PMC4122139,pc progression,PROBLEM,PMC,,,,
PMC4122139,further in vitro and in vivo studies,TEST,PMC,,,,
PMC4122139,these 4 mirnas,TEST,PMC,,,,
PMC4122139,zheng differentiation,PROBLEM,PMC,,,,
PMC5868586,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5868586,cancerrelated death,PROBLEM,PMC,,,,
PMC5868586,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC5868586,effective therapies,TREATMENT,PMC,C1264021,Effects of immunosuppressant therapy,SNOMEDCT_US,Pathologic Function
PMC5868586,pancreatic cancer therapy,TREATMENT,PMC,,,,
PMC5868586,smallmolecule inhibitors,TREATMENT,PMC,,,,
PMC5868586,bioassay screening,TEST,PMC,,,,
PMC5868586,molecular docking,TEST,PMC,C5392994,Molecular Docking,MSH,Molecular Biology Research Technique
PMC5868586,a small molecule l61h46,PROBLEM,PMC,,,,
PMC5868586,kill human pancreatic cancer cells,PROBLEM,PMC,,,,
PMC5868586,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC5868586,halfmaximal inhibitory concentration,TEST,PMC,,,,
PMC5868586,l61h46,PROBLEM,PMC,,,,
PMC5868586,stat3 phosphorylation,TEST,PMC,C5960313,STAT3 Dual Phosphorylation Site Inhibitor YY201,NCI,"Organic Chemical, Pharmacologic Substance"
PMC5868586,the subsequent nucleus translocation,PROBLEM,PMC,,,,
PMC5868586,stat1 phosphorylation,TEST,PMC,C1155535,tyrosine phosphorylation of Stat1 protein,GO,Molecular Function
PMC5868586,a potent activity,PROBLEM,PMC,,,,
PMC5868586,suppressing pancreatic tumor growth,PROBLEM,PMC,,,,
PMC5868586,bxpc3 xenograft model,TREATMENT,PMC,,,,
PMC5868586,l61h46,TEST,PMC,,,,
PMC5868586,adverse effects on liver heart and kidney cells,PROBLEM,PMC,,,,
PMC5868586,l61h46,PROBLEM,PMC,,,,
PMC5868586,a highly potent stat3 inhibitor,TREATMENT,PMC,,,,
PMC5868586,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC5868586,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5868586,l61h46,PROBLEM,PMC,,,,
PMC5868586,a highly potent stat3 inhibitor,TREATMENT,PMC,,,,
PMC5868586,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC5868586,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5868586,our data,TEST,PMC,,,,
PMC5868586,a selective stat3 inhibitor,TREATMENT,PMC,,,,
PMC5868586,highly potent antitumor activity,PROBLEM,PMC,,,,
PMC5868586,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC5868586,l61h46,PROBLEM,PMC,,,,
PMC5868586,a promising stat3 inhibitor,TREATMENT,PMC,,,,
PMC5868586,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6895569,an alleviative treatment,TREATMENT,PMC,C2012266,general goal to alleviate pain,MEDCIN,Idea or Concept
PMC6895569,unresectable advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6895569,radiofrequency ablation,TREATMENT,PMC,C0850292,Radiofrequency Ablation,MTH,Therapeutic or Preventive Procedure
PMC6895569,clinical,TEST,PMC,C0205210,Clinical,MTH,Qualitative Concept
PMC6895569,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6895569,rfa,TREATMENT,PMC,C1718255,Reason for assessment,MTH,Finding
PMC6895569,perioperative periphery carcinoma,PROBLEM,PMC,,,,
PMC6895569,clinical data,TEST,PMC,C1516606,Clinical Data,MTH,Intellectual Product
PMC6895569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6895569,rfa surgery,TREATMENT,PMC,,,,
PMC6895569,pain degree,PROBLEM,PMC,C4086940,Usually in Some Degree of Pain,NCI,Intellectual Product
PMC6895569,the changes,PROBLEM,PMC,C0234909,Nail changes,MTH,Finding
PMC6895569,serum tumor markers,TEST,PMC,C2217648,malignant neoplasm of testis staging serum tumor markers (S),MEDCIN,Neoplastic Process
PMC6895569,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC6895569,ca,TEST,PMC,C0006675,calcium,MTH,"Pharmacologic Substance, Biologically Active Substance, Element, Ion, or Isotope"
PMC6895569,surgeryex,TREATMENT,PMC,,,,
PMC6895569,human,TREATMENT,PMC,C0086418,Homo sapiens,MTH,Human
PMC6895569,panc1 heat treatment,TREATMENT,PMC,,,,
PMC6895569,the heat exposure condition periphery carcinoma,PROBLEM,PMC,,,,
PMC6895569,rfa surgery,TREATMENT,PMC,,,,
PMC6895569,the proliferation rate,TEST,PMC,C0812425,S-Phase Fraction,MTH,Finding
PMC6895569,hsp70 expression change,PROBLEM,PMC,,,,
PMC6895569,upper gastrointestinal hemorrhage,PROBLEM,PMC,C0041909,Upper gastrointestinal hemorrhage,MTH,Pathologic Function
PMC6895569,the average ca199,TEST,PMC,,,,
PMC6895569,ca 242 levels,TEST,PMC,,,,
PMC6895569,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6895569,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC6895569,the increased hsp70 expression,PROBLEM,PMC,,,,
PMC6895569,hsp70 inhibitor,TREATMENT,PMC,,,,
PMC6895569,heat therapy,TREATMENT,PMC,C0020548,Induced Hyperthermia,MTH,Therapeutic or Preventive Procedure
PMC6895569,rfa,TREATMENT,PMC,C1718255,Reason for assessment,MTH,Finding
PMC6895569,unresectable advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6895569,the pain,PROBLEM,PMC,C0008031,Chest Pain,MTH,Sign or Symptom
PMC6895569,decline jaundice,PROBLEM,PMC,,,,
PMC6895569,deduce tumor,PROBLEM,PMC,,,,
PMC6895569,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6895569,a higher proliferative rate,PROBLEM,PMC,,,,
PMC6895569,a higher hsp70 expression level,PROBLEM,PMC,,,,
PMC6895569,pancreatic carcinoma cells,PROBLEM,PMC,C1328479,Pancreatic Endocrine Carcinoma,MTH,Neoplastic Process
PMC6895569,heat treatment,TREATMENT,PMC,C0203597,hyperthermia treatment,MTH,Therapeutic or Preventive Procedure
PMC6895569,hsp70 inhibitor,TREATMENT,PMC,,,,
PMC6895569,the heat exposure,PROBLEM,PMC,C0239930,Heat exposure,SNOMEDCT_US,Injury or Poisoning
PMC6895569,periphery carcinoma,PROBLEM,PMC,,,,
PMC6895569,rfa surgery,TREATMENT,PMC,,,,
PMC6895569,rfa,TREATMENT,PMC,C1718255,Reason for assessment,MTH,Finding
PMC6895569,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6895569,pancreatic cancerhigher,PROBLEM,PMC,,,,
PMC6895569,proliferation in panc1heat,PROBLEM,PMC,,,,
PMC6895569,rfa,TREATMENT,PMC,C1718255,Reason for assessment,MTH,Finding
PMC6895569,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6895569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6895569,higher hsp70 expression,PROBLEM,PMC,,,,
PMC6895569,heat expose impact pancreatic cells,PROBLEM,PMC,,,,
PMC6895569,rfa,TREATMENT,PMC,C1718255,Reason for assessment,MTH,Finding
PMC6895569,unresectable advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6895569,the pain,PROBLEM,PMC,C0008031,Chest Pain,MTH,Sign or Symptom
PMC6895569,decline jaundice,PROBLEM,PMC,,,,
PMC6895569,deduce tumor,PROBLEM,PMC,,,,
PMC6895569,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6895569,a higher proliferative rate,PROBLEM,PMC,,,,
PMC6895569,a higher hsp70 expression level,PROBLEM,PMC,,,,
PMC6895569,pancreatic carcinoma cells,PROBLEM,PMC,C1328479,Pancreatic Endocrine Carcinoma,MTH,Neoplastic Process
PMC6895569,heat treatment,TREATMENT,PMC,C0203597,hyperthermia treatment,MTH,Therapeutic or Preventive Procedure
PMC6895569,hsp70 inhibitor,TREATMENT,PMC,,,,
PMC6895569,the heat exposure,PROBLEM,PMC,C0239930,Heat exposure,SNOMEDCT_US,Injury or Poisoning
PMC6895569,periphery carcinoma,PROBLEM,PMC,,,,
PMC6895569,rfa surgery,TREATMENT,PMC,,,,
PMC7066303,a onesession psychological intervention,TREATMENT,PMC,,,,
PMC7066303,anxiety symptoms,PROBLEM,PMC,C0860603,Anxiety symptoms,MTH,Sign or Symptom
PMC7066303,major pancreatic cancer surgery,TREATMENT,PMC,,,,
PMC7066303,parallel assignment rct,TREATMENT,PMC,,,,
PMC7066303,pancreatic major surgery,TREATMENT,PMC,,,,
PMC7066303,a psychological intervention,TREATMENT,PMC,C5392103,Psychosocial Intervention,MSH,Therapeutic or Preventive Procedure
PMC7066303,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7066303,the psychological intervention,TREATMENT,PMC,C5392103,Psychosocial Intervention,MSH,Therapeutic or Preventive Procedure
PMC7066303,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC7066303,learning mindfulness based techniques,TREATMENT,PMC,,,,
PMC7066303,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC7066303,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7066303,usual care group,TREATMENT,PMC,,,,
PMC7066303,postintervention measures,TREATMENT,PMC,,,,
PMC7066303,the dropout rate,TEST,PMC,,,,
PMC7066303,presurgery intervention,TREATMENT,PMC,,,,
PMC7066303,several management,TREATMENT,PMC,C0231376,"Impaired home maintenance management, severe",SNOMEDCT_US,Finding
PMC7066303,managing anxiety,PROBLEM,PMC,C0871652,Management of anxiety,SNOMEDCT_US,Individual Behavior
PMC7066303,a significant increase,PROBLEM,PMC,C4062396,Significant increase in respiratory rate above baseline,NANDA-I,Finding
PMC7066303,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC7066303,a reduction in state anxiety,PROBLEM,PMC,,,,
PMC7066303,the intervention group,TREATMENT,PMC,C5224194,"health behavior intervention, group",MEDCIN,Health Care Activity
PMC7066303,lower emotional pain,PROBLEM,PMC,,,,
PMC7066303,a power analysis,TEST,PMC,,,,
PMC7066303,a definitive rct,TEST,PMC,,,,
PMC7066303,pancreatic surgery,TREATMENT,PMC,C2033062,pancreatic surgery,MEDCIN,Therapeutic or Preventive Procedure
PMC7066303,a brief psychological intervention,TREATMENT,PMC,,,,
PMC7066303,a significant reduction in,PROBLEM,PMC,C4747586,Significant reduction of medullary space,OMIM,Finding
PMC7066303,preoperative emotional distress,PROBLEM,PMC,,,,
PMC7066303,less emotional pain perception,PROBLEM,PMC,,,,
PMC7066303,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7066303,caution,TREATMENT,PMC,C4296874,Use caution,LNC,Finding
PMC7066303,the high attrition rate,PROBLEM,PMC,,,,
PMC7066303,our psychological intervention,TREATMENT,PMC,,,,
PMC7066303,the full protocol,TREATMENT,PMC,,,,
PMC7066303,pancreatic surgery,TREATMENT,PMC,C2033062,pancreatic surgery,MEDCIN,Therapeutic or Preventive Procedure
PMC7066303,a brief psychological intervention,TREATMENT,PMC,,,,
PMC7066303,a significant reduction in,PROBLEM,PMC,C4747586,Significant reduction of medullary space,OMIM,Finding
PMC7066303,preoperative emotional distress,PROBLEM,PMC,,,,
PMC7066303,less emotional pain perception,PROBLEM,PMC,,,,
PMC7066303,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7066303,caution,TREATMENT,PMC,C4296874,Use caution,LNC,Finding
PMC7066303,the high attrition rate,PROBLEM,PMC,,,,
PMC7066303,our psychological intervention,TREATMENT,PMC,,,,
PMC4627359,chemoradiation therapy,TREATMENT,PMC,C3468348,chemoradiation therapy,MEDCIN,Therapeutic or Preventive Procedure
PMC4627359,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4627359,survival,TREATMENT,PMC,C0220921,survival aspects,MTH,Functional Concept
PMC4627359,considerable toxicity,PROBLEM,PMC,,,,
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,hrql data,TEST,PMC,,,,
PMC4627359,the selective chemoradiation,TREATMENT,PMC,,,,
PMC4627359,advanced localised pancreatic cancer,PROBLEM,PMC,,,,
PMC4627359,the qlqpan26 tool,TEST,PMC,,,,
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,locally advanced inoperable nonmetastatic carcinoma of the pancreas,PROBLEM,PMC,,,,
PMC4627359,induction gemcitabine,TREATMENT,PMC,,,,
PMC4627359,capecitabine,TREATMENT,PMC,C0671970,capecitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4627359,stable and responding disease,PROBLEM,PMC,,,,
PMC4627359,gemcap,TREATMENT,PMC,,,,
PMC4627359,capecitabine,TREATMENT,PMC,C0671970,capecitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4627359,gemcitabinebased crt,TREATMENT,PMC,,,,
PMC4627359,cancer,TREATMENT,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC4627359,hrql scales,TREATMENT,PMC,,,,
PMC4627359,induction chemotherapy,TREATMENT,PMC,C3179010,Induction Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC4627359,significant deterioration in fatigue,PROBLEM,PMC,,,,
PMC4627359,appetite loss,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC4627359,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,capecitabine therapy,TREATMENT,PMC,,,,
PMC4627359,pan26 scales,TEST,PMC,,,,
PMC4627359,toxicity,PROBLEM,PMC,C0040539,Toxicity aspects,MTH,Qualitative Concept
PMC4627359,deterioration in hrql,PROBLEM,PMC,,,,
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,hrql data,TEST,PMC,,,,
PMC4627359,capecitabine,TREATMENT,PMC,C0671970,capecitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4627359,gemcitabinebased chemoradiation,TREATMENT,PMC,,,,
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,deterioration in hrql,PROBLEM,PMC,,,,
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,hrql data,TEST,PMC,,,,
PMC4627359,capecitabine,TREATMENT,PMC,C0671970,capecitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4627359,gemcitabinebased chemoradiation,TREATMENT,PMC,,,,
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,induction chemotherapy,TREATMENT,PMC,C3179010,Induction Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC4627359,consolidation crt,TREATMENT,PMC,,,,
PMC4627359,lapc,TREATMENT,PMC,,,,
PMC4627359,capecitabine,TREATMENT,PMC,C0671970,capecitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4627359,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4627359,the concomitant cytotoxic,TREATMENT,PMC,,,,
PMC4627359,our,TEST,PMC,C4296191,Can pronounce our,LNC,Finding
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,a toxic treatment,TREATMENT,PMC,C2028341,hair treatment toxicity,MEDCIN,Injury or Poisoning
PMC4627359,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC4627359,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC4627359,lapc,TREATMENT,PMC,,,,
PMC4627359,hrql end points,TEST,PMC,,,,
PMC11416134,focal autoimmune pancreatitis symptoms,PROBLEM,PMC,,,,
PMC11416134,painless obstructive jaundice,PROBLEM,PMC,,,,
PMC11416134,clinical procedure,TREATMENT,PMC,C0586186,Clinical procedure report,MTH,Intellectual Product
PMC11416134,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC11416134,autoimmune pancreatitis,PROBLEM,PMC,C2609129,Autoimmune Pancreatitis,MTH,Disease or Syndrome
PMC11416134,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC11416134,autoimmune system dysfunction,PROBLEM,PMC,,,,
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,aip type,PROBLEM,PMC,C4302243,Type 1 Autoimmune Pancreatitis,MSH,Disease or Syndrome
PMC11416134,aip type,PROBLEM,PMC,C4302243,Type 1 Autoimmune Pancreatitis,MSH,Disease or Syndrome
PMC11416134,corticosteroids,TREATMENT,PMC,C3540725,Corticosteroid otologicals,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11416134,painless obstructive jaundice,PROBLEM,PMC,,,,
PMC11416134,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11416134,hyperdense gallbladder material,PROBLEM,PMC,,,,
PMC11416134,further dilatation of intrahepatic bile ducts,PROBLEM,PMC,,,,
PMC11416134,distention of the bile duct,PROBLEM,PMC,,,,
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416134,whipple surgery,TREATMENT,PMC,C0747191,PANCREAS SURGERY WHIPPLE PROCEDURE,CCPSS,Therapeutic or Preventive Procedure
PMC11416134,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC11416134,the consequent histopathological report,TEST,PMC,,,,
PMC11416134,pancreatic parenchyma,PROBLEM,PMC,C1179571,Parenchyma of pancreas,FMA,"Body Part, Organ, or Organ Component"
PMC11416134,fibrous connective tissue development,PROBLEM,PMC,,,,
PMC11416134,dense inflammatory cell infiltration,PROBLEM,PMC,,,,
PMC11416134,lymphocytes,PROBLEM,PMC,C0024264,Lymphocyte,MTH,Cell
PMC11416134,plasmacytes,PROBLEM,PMC,C0032112,Plasma Cells,MTH,Cell
PMC11416134,igg4 positivity,TEST,PMC,C5539730,IgG4 autoimmune antibody positivity,HPO,Laboratory or Test Result
PMC11416134,aip type 1,PROBLEM,PMC,C4302243,Type 1 Autoimmune Pancreatitis,MSH,Disease or Syndrome
PMC11416134,further treatment,TREATMENT,PMC,C5239246,Subject/Guardian Refused Further Treatment,NCI,Finding
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,preoperative histological examination,TEST,PMC,,,,
PMC11416134,evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC11416134,the radiological and serological features,TEST,PMC,,,,
PMC11416134,aip type 1 pancreatitis,PROBLEM,PMC,,,,
PMC11416134,the unique abnormality,PROBLEM,PMC,C1844678,Progressive hearing loss stapes fixation,MTH,Disease or Syndrome
PMC11416134,the aforementioned conditions,PROBLEM,PMC,,,,
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,a canonical ailment,PROBLEM,PMC,,,,
PMC11416134,an unnecessary surgery,TREATMENT,PMC,C0376707,Unnecessary Surgery,MSH,Therapeutic or Preventive Procedure
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,an uncommon disease,PROBLEM,PMC,,,,
PMC11416134,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416134,a common malignancy,PROBLEM,PMC,C1301009,Surgical common bile duct margin involved by malignant neoplasm,SNOMEDCT_US,Laboratory or Test Result
PMC11416134,high mortality,PROBLEM,PMC,C0479563,Exposure to high and low air pressure and changes in air pressure as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,steroid treatment,TREATMENT,PMC,C0149783,Steroid therapy,MTH,Therapeutic or Preventive Procedure
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416134,technically difficult surgery,TREATMENT,PMC,,,,
PMC11416134,autoimmune pancreatitis,PROBLEM,PMC,C2609129,Autoimmune Pancreatitis,MTH,Disease or Syndrome
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416134,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC11416134,laboratory findings,TEST,PMC,C0587081,Laboratory test finding,MTH,Laboratory or Test Result
PMC11416134,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC11416134,histopathological examination,TEST,PMC,C5578069,Histopathology examination,MDR,Laboratory Procedure
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,lymphoplasmacytic infiltration,PROBLEM,PMC,C1334467,Lymphoplasmacytic Infiltrate,MTH,Finding
PMC11416134,obliterative phlebitis,PROBLEM,PMC,,,,
PMC11416134,postoperative risks,PROBLEM,PMC,C4692384,At increased risk for postoperative nausea and vomiting,PNDS,Finding
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416134,assessment,TEST,PMC,C0549070,Assessment: Coping,MTH,Health Care Activity
PMC11416134,basic aip biomarkers,TEST,PMC,,,,
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11416134,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC11416134,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12031639,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12031639,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC12031639,the nonspecific clinical symptoms,PROBLEM,PMC,,,,
PMC12031639,ultrasensitive nanobiosensors,TREATMENT,PMC,,,,
PMC12031639,proteasearginase detection,TEST,PMC,,,,
PMC12031639,fefe3o4nanoparticles,TREATMENT,PMC,,,,
PMC12031639,cyanine,TREATMENT,PMC,C0596395,cyanine,CSP,Organic Chemical
PMC12031639,designer peptide sequences,TREATMENT,PMC,,,,
PMC12031639,initial data,TEST,PMC,C0204489,Initial psychiatric interview with data recording by aide or social worker,SNOMEDCT_US,Diagnostic Procedure
PMC12031639,both gene expression analysis,TEST,PMC,,,,
PMC12031639,proteasearginase activity detection,TEST,PMC,,,,
PMC12031639,early pancreatic cancer detection,PROBLEM,PMC,,,,
PMC12031639,several matrix metalloproteinases,TEST,PMC,,,,
PMC12031639,cathepsins,TEST,PMC,C0007428,Cathepsins,MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC12031639,neutrophil elastase,TEST,PMC,C4551701,"Neutrophil Elastase, human",MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC12031639,urokinase plaminogen activator,TREATMENT,PMC,,,,
PMC12031639,proximal biomarkers,TEST,PMC,,,,
PMC12031639,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12031639,serum sample analysis assays,TEST,PMC,,,,
PMC12031639,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC12031639,pancreatitis,PROBLEM,PMC,C0030305,Pancreatitis,MTH,Disease or Syndrome
PMC12031639,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC12031639,ultrasensitive protease,TEST,PMC,,,,
PMC12031639,arginase activity measurements,TEST,PMC,,,,
PMC12031639,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12031639,a multiclass classification problem,PROBLEM,PMC,,,,
PMC12031639,this methodology,TEST,PMC,,,,
PMC12031639,localized pancreatic cancers,PROBLEM,PMC,C5201974,"PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis",CPT,Laboratory Procedure
PMC12031639,serum analyses,TEST,PMC,C0879211,Serum Analyzers,UMD,Medical Device
PMC12031639,the conventional statistical,TREATMENT,PMC,,,,
PMC12031639,aibased decisionmaking algorithms,TREATMENT,PMC,,,,
PMC12031639,confidence levels,TEST,PMC,C0518578,Confidence level (self-esteem),MTH,Finding
PMC12031639,early pancreatic cancer,PROBLEM,PMC,,,,
PMC12031639,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC12031639,the traditional multiclass classification approaches,TREATMENT,PMC,,,,
PMC12031639,a maximum classification accuracy,TEST,PMC,,,,
PMC12031639,standard multiclass classification approaches,TREATMENT,PMC,,,,
PMC12031639,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12031639,a decision support tool,TREATMENT,PMC,C0870393,Decision support tool,SNOMEDCT_US,"Manufactured Object, Intellectual Product"
PMC12031639,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC12031639,proteasearginase sensing in serum,TEST,PMC,,,,
PMC12031639,early pancreatic cancer,PROBLEM,PMC,,,,
PMC12031639,genetic tests,TEST,PMC,C0679560,Genetic screening method,MTH,Laboratory Procedure
PMC12031639,clinical plate readers,TREATMENT,PMC,,,,
PMC7689756,intraperitoneal chemotherapy,TREATMENT,PMC,C0281548,Intraperitoneal chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7689756,paclitaxel,TREATMENT,PMC,C0144576,paclitaxel,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7689756,an experimental approach,TREATMENT,PMC,,,,
PMC7689756,peritoneal carcinomatosis,PROBLEM,PMC,C0346990,Carcinomatosis of peritoneal cavity,MTH,Neoplastic Process
PMC7689756,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7689756,intravenous gemcitabine,TREATMENT,PMC,C4048661,gemcitabine 200 MG Injection,MTH,Clinical Drug
PMC7689756,intravenous nabpaclitaxel,TREATMENT,PMC,,,,
PMC7689756,intraperitoneal paclitaxel,TREATMENT,PMC,C5958969,Intraperitoneal Carboplatin/Paclitaxel Regimen,NCI,Therapeutic or Preventive Procedure
PMC7689756,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7689756,peritoneal metastasis,PROBLEM,PMC,C4733286,peritoneal cavity metastasis,PDQ,Neoplastic Process
PMC7689756,doselimiting toxicities,PROBLEM,PMC,,,,
PMC7689756,the phase ii analysis,TEST,PMC,,,,
PMC7689756,secondary endpoints,TEST,PMC,C4528314,Secondary Endpoint,NCI,Temporal Concept
PMC7689756,antitumour effects,PROBLEM,PMC,,,,
PMC7689756,symptomrelieving effects,PROBLEM,PMC,,,,
PMC7689756,overall survival,TREATMENT,PMC,C4086681,Overall Survival,NCI,Quantitative Concept
PMC7689756,intravenous gemcitabine,TREATMENT,PMC,C4048661,gemcitabine 200 MG Injection,MTH,Clinical Drug
PMC7689756,intravenous nabpaclitaxel,TREATMENT,PMC,,,,
PMC7689756,intraperitoneal paclitaxel,TREATMENT,PMC,C5958969,Intraperitoneal Carboplatin/Paclitaxel Regimen,NCI,Therapeutic or Preventive Procedure
PMC7689756,treatment failure,PROBLEM,PMC,C0162643,treatment failure,MTH,Finding
PMC7689756,the response,TEST,PMC,C0020964,Immune response,MTH,Organ or Tissue Function
PMC7689756,disease control rates,TEST,PMC,,,,
PMC7689756,ascites,PROBLEM,PMC,C0003962,Ascites,MTH,Disease or Syndrome
PMC7689756,cytology,TEST,PMC,C0010819,Cytology,MTH,Biomedical Occupation or Discipline
PMC7689756,conversion surgery,TREATMENT,PMC,C3494226,Conversion to Open Surgery,MSH,Therapeutic or Preventive Procedure
PMC7689756,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC7689756,grade 34 haematological toxicities,PROBLEM,PMC,,,,
PMC7689756,nonhaematological adverse events,PROBLEM,PMC,,,,
PMC7689756,intraperitoneal paclitaxel,TREATMENT,PMC,C5958969,Intraperitoneal Carboplatin/Paclitaxel Regimen,NCI,Therapeutic or Preventive Procedure
PMC7689756,this multicentre phase iii study,TEST,PMC,,,,
PMC7689756,intravenous gemcitabine,TREATMENT,PMC,C4048661,gemcitabine 200 MG Injection,MTH,Clinical Drug
PMC7689756,intravenous nabpaclitaxel,TREATMENT,PMC,,,,
PMC7689756,intraperitoneal paclitaxel,TREATMENT,PMC,C5958969,Intraperitoneal Carboplatin/Paclitaxel Regimen,NCI,Therapeutic or Preventive Procedure
PMC7689756,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC7689756,peritoneal metastasis,PROBLEM,PMC,C4733286,peritoneal cavity metastasis,PDQ,Neoplastic Process
PMC7689756,this regimen,TREATMENT,PMC,,,,
PMC7689756,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7689756,intraperitoneal paclitaxel,TREATMENT,PMC,C5958969,Intraperitoneal Carboplatin/Paclitaxel Regimen,NCI,Therapeutic or Preventive Procedure
PMC10422698,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10422698,a poor prognosis,PROBLEM,PMC,C0278252,Prognosis bad,SNOMEDCT_US,Finding
PMC10422698,cancerrelated symptoms,PROBLEM,PMC,,,,
PMC10422698,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC10422698,anticancer drugs,TREATMENT,PMC,C1548818,Anticancer Drugs - Consent type,MTH,Health Care Activity
PMC10422698,this systematic review,TEST,PMC,,,,
PMC10422698,tad,TREATMENT,PMC,C4082312,TAD brand of glutathione,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC10422698,supportive care,TREATMENT,PMC,C0344211,Supportive care,MTH,Health Care Activity
PMC10422698,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10422698,embase,TEST,PMC,,,,
PMC10422698,epistemonikos,TREATMENT,PMC,,,,
PMC10422698,data extraction,TEST,PMC,C1707635,Data Extraction,NCI,Research Activity
PMC10422698,bias assessment,TEST,PMC,C0589096,Computerized Assessment of Response Bias,SNOMEDCT_US,Intellectual Product
PMC10422698,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC10422698,14 randomised controlled trials,TREATMENT,PMC,,,,
PMC10422698,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10422698,a slight increase in overall survival,PROBLEM,PMC,,,,
PMC10422698,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10422698,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC10422698,targetedbiological therapy,TREATMENT,PMC,,,,
PMC10422698,a slight increment,PROBLEM,PMC,,,,
PMC10422698,more adverse events,PROBLEM,PMC,,,,
PMC10422698,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC10422698,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10422698,anticancer drugs,TREATMENT,PMC,C1548818,Anticancer Drugs - Consent type,MTH,Health Care Activity
PMC10422698,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10422698,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC10422698,a second line of chemotherapy,TREATMENT,PMC,,,,
PMC10422698,future studies,TEST,PMC,,,,
PMC10422698,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10422698,anticancer drugs,TREATMENT,PMC,C1548818,Anticancer Drugs - Consent type,MTH,Health Care Activity
PMC10422698,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10422698,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC10422698,a second line of chemotherapy,TREATMENT,PMC,,,,
PMC10422698,future studies,TEST,PMC,,,,
PMC10422698,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC10422698,advanced pc,PROBLEM,PMC,,,,
PMC10422698,the first chemotherapy lines,TREATMENT,PMC,C5974358,Currently on first-line immune checkpoint inhibitors without chemotherapy,HCPCS,Finding
PMC10422698,further tads,TREATMENT,PMC,,,,
PMC10422698,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10422698,tads,TREATMENT,PMC,C0391816,Tietz syndrome,MSH,Disease or Syndrome
PMC9730569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9730569,fatal disease,PROBLEM,PMC,C2924592,Type of fatal coronary heart disease,MTH,Finding
PMC9730569,advanced disease,PROBLEM,PMC,C0679246,advanced disease,AOD,Finding
PMC9730569,typical symptoms,PROBLEM,PMC,C3272268,Typical Coronary Artery Disease Symptom,NCI,Sign or Symptom
PMC9730569,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC9730569,the pancreatic tumor,PROBLEM,PMC,C0941236,Pancreatic/biliary tumor,MTHMST,Neoplastic Process
PMC9730569,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9730569,preoperative methods,TREATMENT,PMC,C3248609,Clinician diagnosed breast cancer preoperatively by a minimally invasive biopsy method,HCPCS,Finding
PMC9730569,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC9730569,the staging modality,TEST,PMC,,,,
PMC9730569,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC9730569,the complicated surgeries,TREATMENT,PMC,C1301512,Complicated cataract surgery,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC9730569,potential morbidity,PROBLEM,PMC,,,,
PMC9730569,the minimally invasive pancreatic resections,TREATMENT,PMC,,,,
PMC9730569,laparoscopic,TREATMENT,PMC,C0031150,Laparoscopy,MTH,Diagnostic Procedure
PMC9730569,standard surgical practice,TREATMENT,PMC,,,,
PMC9730569,adjuvant chemotherapy,TREATMENT,PMC,C0085533,"Chemotherapy, Adjuvant",MTH,Therapeutic or Preventive Procedure
PMC9730569,the systemic conservative treatment,TREATMENT,PMC,,,,
PMC9730569,targeted agents,TREATMENT,PMC,C5235658,Targeted Therapy Agent,NCI,"Organic Chemical, Pharmacologic Substance"
PMC9730569,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9730569,advanced disease,PROBLEM,PMC,C0679246,advanced disease,AOD,Finding
PMC9730569,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC9730569,the pancreatic tumor microenvironment,PROBLEM,PMC,,,,
PMC9730569,the immunotherapeutic strategies,TREATMENT,PMC,,,,
PMC9730569,preoperative therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC9730569,the novel surgical strategy,TREATMENT,PMC,,,,
PMC9730569,individualized systemic treatment,TREATMENT,PMC,,,,
PMC9730569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9730569,the randomized controlled studies,TEST,PMC,C5890802,Results of a randomized controlled trial will be more reliable if a larger number of people are in the study,MTH,Finding
PMC9730569,the neoadjuvant and surgical management,TREATMENT,PMC,,,,
PMC9730569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9730569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9730569,a devastating malignancy disease,PROBLEM,PMC,,,,
PMC9730569,a restricted approach,TREATMENT,PMC,C2409969,"Restriction of Anus, Open Approach",ICD10PCS,Therapeutic or Preventive Procedure
PMC9730569,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9730569,treatment outcomes,TREATMENT,PMC,C0085415,Treatment outcome,MTH,Qualitative Concept
PMC9730569,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC9730569,surgical procedures,TREATMENT,PMC,C0543467,Operative Surgical Procedures,MTH,Therapeutic or Preventive Procedure
PMC9730569,radiation,TREATMENT,PMC,C0851346,Radiation,MTH,Natural Phenomenon or Process
PMC9730569,personalized therapies,TREATMENT,PMC,C0871063,Personal Therapy,PSY,Therapeutic or Preventive Procedure
PMC9730569,pdac,PROBLEM,PMC,,,,
PMC9730569,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC9730569,inflammatory microenvironment,PROBLEM,PMC,,,,
PMC9730569,further exploration,TEST,PMC,,,,
PMC9730569,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC9730569,inflammatory microenvironment,PROBLEM,PMC,,,,
PMC9730569,immunosuppressive cells,PROBLEM,PMC,C5447615,Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation,NCI,Therapeutic or Preventive Procedure
PMC9730569,a highly fibrotic stroma,PROBLEM,PMC,,,,
PMC9730569,infiltration of immune effector cells,PROBLEM,PMC,,,,
PMC9730569,the ablative techniques,TREATMENT,PMC,C2350239,Ablation Techniques,MSH,Therapeutic or Preventive Procedure
PMC9730569,these factors,PROBLEM,PMC,,,,
PMC9730569,ablation,TREATMENT,PMC,C0547070,Ablation,MTH,Therapeutic or Preventive Procedure
PMC9730569,antitumor immune responses,TREATMENT,PMC,,,,
PMC9730569,tumorspecific neoantigens,PROBLEM,PMC,,,,
PMC9730569,an inflammatory context,PROBLEM,PMC,,,,
PMC9730569,numerous preclinical studies,TEST,PMC,,,,
PMC9730569,radiation therapy,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC9730569,thermal ablation,TREATMENT,PMC,C0677798,Thermal ablation,MDR,Therapeutic or Preventive Procedure
PMC9730569,ire,TREATMENT,PMC,C5575096,irreversible electroporation (treatment),MTH,Therapeutic or Preventive Procedure
PMC9730569,systemic antitumor immune responses,TREATMENT,PMC,,,,
PMC9730569,multiple tumor types,PROBLEM,PMC,C4229901,"Brain tumors, multiple types",OMIM,Finding
PMC9730569,the current data,TEST,PMC,C1716609,Can recall current season:Find:Pt:^Patient:Ord:MDS,LNC,Clinical Attribute
PMC9730569,the postoperative therapies,TREATMENT,PMC,C3162255,postoperative radiation therapy,MEDCIN,Therapeutic or Preventive Procedure
PMC9730569,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9730569,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC9730569,postoperative treatment,TREATMENT,PMC,C5443905,Postoperative complication treatment needed,MTH,Finding
PMC9730569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9730569,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC9730569,tumor biology,PROBLEM,PMC,C1519672,Tumor Biology,NCI,Research Activity
PMC9730569,novel therapeutic targets,TREATMENT,PMC,,,,
PMC9730569,innovative clinical trial designs,TREATMENT,PMC,,,,
PMC9730569,protocols,TREATMENT,PMC,C0677568,Protocols: Metabolism,MTH,Intellectual Product
PMC9730569,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC9730569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,an eightweek didactic course,TREATMENT,PMC,,,,
PMC11286297,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC11286297,significant bilateral pulmonary artery clotting,PROBLEM,PMC,,,,
PMC11286297,a saddle embolism,PROBLEM,PMC,C2921509,saddle embolism of pulmonary artery,MEDCIN,Pathologic Function
PMC11286297,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC11286297,sudden pulmonary failure,PROBLEM,PMC,,,,
PMC11286297,malignant tumors,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC11286297,hypercoagulable states,PROBLEM,PMC,C0398623,Thrombophilia,MTH,Disease or Syndrome
PMC11286297,thromboembolism,PROBLEM,PMC,C0040038,Thromboembolism,MTH,Pathologic Function
PMC11286297,the clots,PROBLEM,PMC,C5780321,Menstrual clots,MDR,Finding
PMC11286297,this hypercoagulable state,PROBLEM,PMC,,,,
PMC11286297,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC11286297,pancreatic carcinoma,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,pulmonary saddle embolism,PROBLEM,PMC,C2921509,saddle embolism of pulmonary artery,MEDCIN,Pathologic Function
PMC11286297,the fatal event,PROBLEM,PMC,,,,
PMC11286297,underlying pancreatic cancer,PROBLEM,PMC,,,,
PMC11286297,the extensive clotting,PROBLEM,PMC,,,,
PMC11286297,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,thromboembolic events,PROBLEM,PMC,C0040038,Thromboembolism,MTH,Pathologic Function
PMC11286297,pulmonary failure,PROBLEM,PMC,C0948755,Pulmonary failure,MDR,Disease or Syndrome
PMC11286297,sudden death,PROBLEM,PMC,C0011071,Sudden death,MTH,Pathologic Function
PMC11286297,pulmonary saddle embolism,PROBLEM,PMC,C2921509,saddle embolism of pulmonary artery,MEDCIN,Pathologic Function
PMC11286297,underlying visceral neoplasms,PROBLEM,PMC,,,,
PMC11286297,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC11286297,pulmonary failure,PROBLEM,PMC,C0948755,Pulmonary failure,MDR,Disease or Syndrome
PMC11286297,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC11286297,a saddle embolism,PROBLEM,PMC,C2921509,saddle embolism of pulmonary artery,MEDCIN,Pathologic Function
PMC11286297,hypercoagulability,PROBLEM,PMC,C0398623,Thrombophilia,MTH,Disease or Syndrome
PMC11286297,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11286297,autolysis in the pancreas,PROBLEM,PMC,,,,
PMC11286297,lymph node metastases,PROBLEM,PMC,C0686619,Lymph Node Metastasis,MTH,Neoplastic Process
PMC11286297,distension,PROBLEM,PMC,C3714614,Distention,MTH,Finding
PMC11286297,clotting,PROBLEM,PMC,C0005778,Blood coagulation,MTH,Organ or Tissue Function
PMC11286297,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,pulmonary emboli,PROBLEM,PMC,C0034065,Pulmonary Embolism,MTH,Pathologic Function
PMC11286297,other cancer types,PROBLEM,PMC,C5225787,Breast cancer - all other types,CCSR_ICD10CM,Neoplastic Process
PMC11286297,his death,PROBLEM,PMC,,,,
PMC11286297,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11286297,their coagulability,TEST,PMC,,,,
PMC11286297,catastrophic events,PROBLEM,PMC,C0919213,Resuscitation bag (for use by patient on artificial respiration during power failure or other catastrophic event),HCPCS,Medical Device
PMC11286297,major embolisms,PROBLEM,PMC,C0472586,Transluminal embolization of major aortopulmonary collateral artery,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11877337,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11877337,gastrointestinal cancerrelated,PROBLEM,PMC,,,,
PMC11877337,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11877337,advanced disease,PROBLEM,PMC,C0679246,advanced disease,AOD,Finding
PMC11877337,curative resection,TREATMENT,PMC,,,,
PMC11877337,malignant biliary obstruction,PROBLEM,PMC,C3898473,Malignant biliary obstruction,MDR,Disease or Syndrome
PMC11877337,gastric outlet obstruction,PROBLEM,PMC,C0162651,Gastric outlet obstruction,MTH,Disease or Syndrome
PMC11877337,palliative management,TREATMENT,PMC,C4683871,"Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management",NCI,Finding
PMC11877337,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11877337,subsequent chemotherapy,TREATMENT,PMC,C5667387,Subsequent Progression Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC11877337,neoadjuvant chemotherapy,TREATMENT,PMC,C5392214,Neoadjuvant Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC11877337,both,PROBLEM,PMC,C1706086,Both,MTH,Qualitative Concept
PMC11877337,borderline resectable and resectable pancreatic cancer,PROBLEM,PMC,C4763562,Borderline Resectable Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC11877337,effective biliary and gastrointestinal drainage,TREATMENT,PMC,,,,
PMC11877337,surgical bypass,TREATMENT,PMC,C2461341,Medical and Surgical @ Eye @ Bypass,ICD10PCS,Therapeutic or Preventive Procedure
PMC11877337,a minimally invasive,TREATMENT,PMC,C1881856,Minimally Invasive Lesion,NCI,Finding
PMC11877337,open approach,TREATMENT,PMC,C0348025,Open approach,MTH,Spatial Concept
PMC11877337,developing endoscopic techniques,TREATMENT,PMC,,,,
PMC11877337,endoscopic retrograde cholangiopancreatography,TEST,PMC,C0008310,Endoscopic Retrograde Cholangiopancreatography,MTH,Diagnostic Procedure
PMC11877337,mbo,PROBLEM,PMC,C0683736,management by objective,MTH,Intellectual Product
PMC11877337,endoscopic enteral stenting,TREATMENT,PMC,C2316601,Endoscopic insertion of bowel stent using fluoroscopic guidance,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11877337,goo,PROBLEM,PMC,C3643642,Booty Goo,RXNORM,"Pharmacologic Substance, Inorganic Chemical"
PMC11877337,these procedures,TREATMENT,PMC,,,,
PMC11877337,rapid,TREATMENT,PMC,C0456962,Rapid,MTH,Qualitative Concept
PMC11877337,higher stent dysfunction rates,PROBLEM,PMC,,,,
PMC11877337,frequent reintervention needs,TREATMENT,PMC,,,,
PMC11877337,ercp,TREATMENT,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11877337,percutaneous transhepatic biliary drainage,TREATMENT,PMC,C1504490,Percutaneous transhepatic cholangiodrainage,MTH,Therapeutic or Preventive Procedure
PMC11877337,mbo,PROBLEM,PMC,C0683736,management by objective,MTH,Intellectual Product
PMC11877337,endoscopic ultrasound,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11877337,eusguided,TEST,PMC,,,,
PMC11877337,eusguided gastroenterostomy,TREATMENT,PMC,,,,
PMC11877337,firstline palliative treatment,TREATMENT,PMC,,,,
PMC11877337,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC11877337,managing mbo,TREATMENT,PMC,,,,
PMC11877337,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11877337,the palliative management,TREATMENT,PMC,C4683871,"Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management",NCI,Finding
PMC11877337,goo,TREATMENT,PMC,C3643642,Booty Goo,RXNORM,"Pharmacologic Substance, Inorganic Chemical"
PMC11877337,mbo,TREATMENT,PMC,C0683736,management by objective,MTH,Intellectual Product
PMC11877337,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11877337,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC11877337,surgical,TREATMENT,PMC,C0587668,Surgical service,MTH,Health Care Activity
PMC11877337,endoscopic approaches,TREATMENT,PMC,C0442418,Endoscopic approach - access,MTH,Spatial Concept
PMC11877337,disease stage,PROBLEM,PMC,C0699749,disease stage,MTH,Clinical Attribute
PMC11877337,resectable or borderline resectable pancreatic cancer,PROBLEM,PMC,C4763562,Borderline Resectable Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC11877337,surgical candidates,TREATMENT,PMC,,,,
PMC11877337,biliary drainage,TREATMENT,PMC,C0400745,Biliary drainage (procedure),MTH,Therapeutic or Preventive Procedure
PMC11877337,mbo cases,PROBLEM,PMC,,,,
PMC11877337,cholangitis,PROBLEM,PMC,C0008311,Cholangitis,MTH,Disease or Syndrome
PMC11877337,delayed surgery,TREATMENT,PMC,C4683650,Postoperative Delayed Gastric Emptying,NCI,Finding
PMC11877337,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC11877337,neoadjuvant chemotherapy,TREATMENT,PMC,C5392214,Neoadjuvant Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC11877337,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11877337,ptbd,TREATMENT,PMC,C0657162,"perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane)",MSH,Organic Chemical
PMC11877337,internal stenting,TREATMENT,PMC,C2053008,Percutaneous removal of internally dwelling ureteral stent,CPT,Therapeutic or Preventive Procedure
PMC11877337,eusbd,TREATMENT,PMC,,,,
PMC11877337,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC11877337,preoperative treatment,TREATMENT,PMC,C1535921,Preoperative hormone treatment,MDR,Therapeutic or Preventive Procedure
PMC11877337,minimally invasive sgj,TREATMENT,PMC,,,,
PMC11877337,poor performance status,PROBLEM,PMC,C1831741,Poor Performance Status,NCI,Finding
PMC11877337,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC11877337,mbo,PROBLEM,PMC,C0683736,management by objective,MTH,Intellectual Product
PMC11877337,both ercp,TEST,PMC,,,,
PMC11877337,eusbd,TEST,PMC,,,,
PMC11877337,these procedures,TREATMENT,PMC,,,,
PMC11877337,eusbd,TEST,PMC,,,,
PMC11877337,euscds,TEST,PMC,,,,
PMC11877337,eushgs,TEST,PMC,,,,
PMC11877337,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11877337,surgically alerted anatomy,PROBLEM,PMC,,,,
PMC11877337,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11877337,unresectable goo,PROBLEM,PMC,,,,
PMC11877337,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11877337,eusge,TEST,PMC,,,,
PMC11877337,significant comorbidities,PROBLEM,PMC,C4540934,Significant medical comorbidity,NANDA-I,Finding
PMC11877337,concurrent mbo,PROBLEM,PMC,,,,
PMC11877337,sgj,TREATMENT,PMC,,,,
PMC11877337,recurrent goo,PROBLEM,PMC,,,,
PMC11877337,unsuccessful stenting,TREATMENT,PMC,C2024080,cardiac catheterization stent placement conclusions: unsuccessful,MEDCIN,Finding
PMC11877337,unresectable,PROBLEM,PMC,C1519810,Unresectable,NCI,Clinical Attribute
PMC11877337,curativeintent surgery,TREATMENT,PMC,,,,
PMC11877337,surgical bypass,TREATMENT,PMC,C2461341,Medical and Surgical @ Eye @ Bypass,ICD10PCS,Therapeutic or Preventive Procedure
PMC11877337,symptomatic,PROBLEM,PMC,C0231220,Symptomatic,MTH,Functional Concept
PMC11877337,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC11877337,each treatment approach,TREATMENT,PMC,C2138185,"corticosteroid injection into sacral joint by transforaminal approach, each additional level",MEDCIN,Therapeutic or Preventive Procedure
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,some studies,TEST,PMC,C3830967,"C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Since Study Start)",NCI,Intellectual Product
PMC11319747,psychological complications,PROBLEM,PMC,C2909771,Psychological abuse complicating pregnancy,SNOMEDCT_US,Pathologic Function
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,the pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC11319747,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,the structured clinical interview,TEST,PMC,C0935589,Structured Clinical Interview,PSY,Diagnostic Procedure
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11319747,binary logistic regression,TEST,PMC,,,,
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,newonset psychiatric complications,PROBLEM,PMC,,,,
PMC11319747,sadness,PROBLEM,PMC,C3536794,Sad mood,MTH,Mental Process
PMC11319747,anderson symptom inventory,TEST,PMC,C3826983,MD Anderson Symptom Inventory - Core,NCI,Intellectual Product
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,mdasi score,TEST,PMC,C3897629,Severity of Symptom Score 2,MTH,Finding
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,psychiatric complications,PROBLEM,PMC,C0852240,Neurological and psychiatric procedural complications,MDR,Injury or Poisoning
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,sadness,PROBLEM,PMC,C3536794,Sad mood,MTH,Mental Process
PMC11319747,mdasi score,TEST,PMC,C3897629,Severity of Symptom Score 2,MTH,Finding
PMC11319747,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11319747,higher sadness score,PROBLEM,PMC,,,,
PMC11319747,effective measures,TREATMENT,PMC,C5939160,Medication total daily effective dose:Dosage:Pt:Medication:Qn,LNC,Clinical Attribute
PMC11319747,rational psychological interventions,TREATMENT,PMC,,,,
PMC11319747,the complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC6502190,the most frequent pancreatic cancer,PROBLEM,PMC,,,,
PMC6502190,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC6502190,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6502190,this tumor,PROBLEM,PMC,C5203893,Number of Primary Tumors in this Location,NCI,Intellectual Product
PMC6502190,its neoplastic precursor,PROBLEM,PMC,,,,
PMC6502190,epidemiological data,TEST,PMC,C5912262,"Identify post-disaster needs (e.g., ongoing disaster-related health care needs, collection of epidemiological data, assessment of cause of disaster, steps for prevention of reoccurrence)",NIC,Health Care Activity
PMC6502190,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6502190,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC6502190,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC6502190,hereditary risk factors,PROBLEM,PMC,,,,
PMC6502190,genetic,PROBLEM,PMC,C0314603,Genetic,MTH,Functional Concept
PMC6502190,hboc,PROBLEM,PMC,C0961909,HBOC 301,MSH,"Amino Acid, Peptide, or Protein"
PMC6502190,hnpcc,PROBLEM,PMC,C0879290,MSH2 gene,MTH,Gene or Genome
PMC6502190,fap,PROBLEM,PMC,C1622401,"FAP protein, human",MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6502190,pjs,PROBLEM,PMC,C0031269,Peutz-Jeghers Syndrome,MTH,Disease or Syndrome
PMC6502190,fammm,PROBLEM,PMC,C0205747,Familial Atypical Multiple Mole-Melanoma,MSH,Neoplastic Process
PMC6502190,hp,PROBLEM,PMC,C1415692,HP gene,MTH,Gene or Genome
PMC6502190,cf,PROBLEM,PMC,C1413365,CFTR gene,MTH,Gene or Genome
PMC6502190,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6502190,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6502190,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC6502190,this narrative review,TEST,PMC,,,,
PMC6502190,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6502190,associated risk factors,PROBLEM,PMC,C1269826,Assessment of hypovolemia risk factors,SNOMEDCT_US,Health Care Activity
PMC6502190,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6502190,a nonmarginal healthy problem,PROBLEM,PMC,,,,
PMC6502190,certain risk factors,PROBLEM,PMC,C5916492,"Instruct on risk factors for heat-related illness (e.g., high environmental temperature, high humidity, dehydration, physical exertion, obesity, extremes of age, certain drugs, heart disease)",NIC,Educational Activity
PMC6502190,the hereditary ones,PROBLEM,PMC,C1837593,"Prostate Cancer, Hereditary, 4",MSH,Neoplastic Process
PMC6502190,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6502190,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6502190,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6502190,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC10051263,opioid analgesics,TREATMENT,PMC,C0002772,"Analgesics, Opioid",MTH,"Organic Chemical, Pharmacologic Substance"
PMC10051263,cancerrelated pain management,TREATMENT,PMC,,,,
PMC10051263,opioidinduced constipation,PROBLEM,PMC,,,,
PMC10051263,naldemedine,TREATMENT,PMC,C4325235,naldemedine,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10051263,a peripheral opioid receptor antagonist,TREATMENT,PMC,C3653546,Peripheral opioid receptor antagonists,ATC,Pharmacologic Substance
PMC10051263,an oicmodifying agent,TREATMENT,PMC,,,,
PMC10051263,safety analysis,TEST,PMC,C3658272,Hazard Analysis and Critical Control Points,MSH,Health Care Activity
PMC10051263,hepatobiliary pancreatic cancers,PROBLEM,PMC,,,,
PMC10051263,a multiinstitutional study,TEST,PMC,,,,
PMC10051263,naldemedine,TREATMENT,PMC,C4325235,naldemedine,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10051263,hepatobiliary pancreatic cancer,PROBLEM,PMC,,,,
PMC10051263,opioids,TREATMENT,PMC,C0242402,Opioids,MTH,"Organic Chemical, Pharmacologic Substance, Hazardous or Poisonous Substance"
PMC10051263,hepatobiliary pancreatic cancer,PROBLEM,PMC,,,,
PMC10051263,liver biliary tract,PROBLEM,PMC,C0745763,liver or biliary tract,CHV,Body System
PMC10051263,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC10051263,opioids,TREATMENT,PMC,C0242402,Opioids,MTH,"Organic Chemical, Pharmacologic Substance, Hazardous or Poisonous Substance"
PMC10051263,naldemedine,TREATMENT,PMC,C4325235,naldemedine,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10051263,naldemedine therapy,TREATMENT,PMC,,,,
PMC10051263,naldemedine administrationresults,TREATMENT,PMC,,,,
PMC10051263,naldemedine,TREATMENT,PMC,C4325235,naldemedine,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10051263,bowel movements,PROBLEM,PMC,C0011135,Defecation,MTH,Organism Function
PMC10051263,the response rate,TEST,PMC,C5963169,Continued Response Rate,NCI,Quantitative Concept
PMC10051263,naldemedine treatment,TREATMENT,PMC,,,,
PMC10051263,naldemedine administration,TREATMENT,PMC,,,,
PMC10051263,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC10051263,the predominant gastrointestinal symptom,PROBLEM,PMC,,,,
PMC10051263,grade,PROBLEM,PMC,C0441800,Grade,MTH,Classification
PMC10051263,grade 2,PROBLEM,PMC,C4284293,Simpson Grade 2,MTH,Intellectual Product
PMC10051263,grade 3 adverse events,PROBLEM,PMC,C1519275,Grade 3 Severe Adverse Event,MTH,Finding
PMC10051263,other adverse event,PROBLEM,PMC,C5238991,Specify Other Adverse Event,NCI,Functional Concept
PMC10051263,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC10051263,grade 24 adverse events,PROBLEM,PMC,,,,
PMC10051263,naldemedine,TREATMENT,PMC,C4325235,naldemedine,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10051263,hepatobiliary pancreatic cancer,PROBLEM,PMC,,,,
PMC10051263,opioid analgesics,TREATMENT,PMC,C0002772,"Analgesics, Opioid",MTH,"Organic Chemical, Pharmacologic Substance"
PMC10051263,the current study,TEST,PMC,C2135635,currently in third year of postgraduate studies,MEDCIN,Finding
PMC10051263,naldemedine treatment,TREATMENT,PMC,,,,
PMC10051263,hepatobiliary pancreatic cancer,PROBLEM,PMC,,,,
PMC10051263,this drug,TREATMENT,PMC,C3843957,Have strong desire or craving for this drug,LNC,Finding
PMC10051263,poor ps,PROBLEM,PMC,,,,
PMC10051263,naldemedine,TREATMENT,PMC,C4325235,naldemedine,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC10051263,oic,TREATMENT,PMC,C3160897,Opioid-Induced Constipation,MTH,Sign or Symptom
PMC10051263,most hepatobiliary pancreatic cancer,PROBLEM,PMC,,,,
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,gastrointestinal malignancies,PROBLEM,PMC,C0852202,Gastrointestinal neoplasms malignant NEC,MDR,Neoplastic Process
PMC10047484,this cancer,PROBLEM,PMC,C4697846,Evidence of this Cancer,LNC,Finding
PMC10047484,high mortality,PROBLEM,PMC,C0479563,Exposure to high and low air pressure and changes in air pressure as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC10047484,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC10047484,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10047484,highly specialized treatment,TREATMENT,PMC,,,,
PMC10047484,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10047484,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10047484,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC10047484,a significant problem,PROBLEM,PMC,C5915220,Identify significant health needs or problems,NIC,Health Care Activity
PMC10047484,limited system resources,PROBLEM,PMC,,,,
PMC10047484,the loss of potential gdp,PROBLEM,PMC,,,,
PMC10047484,the progressive aging of the population,PROBLEM,PMC,,,,
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,the cancer,PROBLEM,PMC,C0153567,Uterine Cancer,MTH,Neoplastic Process
PMC10047484,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10047484,inpatient chemotherapy,TREATMENT,PMC,,,,
PMC10047484,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10047484,a literature review,TEST,PMC,C0282441,Review Literature,MTH,Intellectual Product
PMC10047484,the rapid review methodology,TEST,PMC,,,,
PMC10047484,the snowball search,TEST,PMC,,,,
PMC10047484,qualitative assessment,TEST,PMC,C3526443,Qualitative assessment of leukocytes in feces,CPT,Laboratory Procedure
PMC10047484,amstar2 modified scheme,TREATMENT,PMC,,,,
PMC10047484,the adopted treatment regimen,TREATMENT,PMC,,,,
PMC10047484,drug therapies,TREATMENT,PMC,C0013216,Pharmacotherapy,MTH,Therapeutic or Preventive Procedure
PMC10047484,palliative treatment,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,sickness absence,PROBLEM,PMC,C0557437,Requesting sick leave,SNOMEDCT_US,Finding
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,indirect costs,PROBLEM,PMC,C1517106,Facilities and Administrative Costs,NCI,Quantitative Concept
PMC10047484,hospitalization,TREATMENT,PMC,C0019993,Hospitalization,MTH,Health Care Activity
PMC10047484,direct costs,PROBLEM,PMC,C1511972,Direct Costs,NCI,Quantitative Concept
PMC10047484,the inpatient treatment regimen,TREATMENT,PMC,C3845360,The ostomy was related to an inpatient stay or did necessitate change in medical or treatment regimen.,LNC,Finding
PMC10047484,side effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,gastrointestinal cancers,PROBLEM,PMC,C0685938,Malignant neoplasm of gastrointestinal tract,MTH,Neoplastic Process
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,the dominant colorectal cancer,PROBLEM,PMC,,,,
PMC10047484,this cancer,PROBLEM,PMC,C4697846,Evidence of this Cancer,LNC,Finding
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,neoplastic diseases,PROBLEM,PMC,C1285432,Sequelae of neoplastic diseases,SNOMEDCT_US,Pathologic Function
PMC10047484,diagnostic difficulties,PROBLEM,PMC,,,,
PMC10047484,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,an additional increase in costs,PROBLEM,PMC,,,,
PMC10047484,palliative treatment,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10047484,particular pain therapy,TREATMENT,PMC,,,,
PMC10047484,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10047484,a common problem,PROBLEM,PMC,C1821043,Management of common health problems,NOC,Finding
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,the inpatient treatment regimen,TREATMENT,PMC,C3845360,The ostomy was related to an inpatient stay or did necessitate change in medical or treatment regimen.,LNC,Finding
PMC10047484,side effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,gastrointestinal cancers,PROBLEM,PMC,C0685938,Malignant neoplasm of gastrointestinal tract,MTH,Neoplastic Process
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,colorectal cancer,PROBLEM,PMC,C0009402,Colorectal Carcinoma,MTH,Neoplastic Process
PMC10047484,this cancer,PROBLEM,PMC,C4697846,Evidence of this Cancer,LNC,Finding
PMC10047484,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10047484,long sickness absence,PROBLEM,PMC,,,,
PMC10047484,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC10047484,the progressive aging of the population,PROBLEM,PMC,,,,
PMC9778676,this retrospective cohort study,TEST,PMC,,,,
PMC9778676,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC9778676,appetite loss,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC9778676,advanced unresectable pancreatic cancer,PROBLEM,PMC,,,,
PMC9778676,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9778676,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9778676,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9778676,appetite loss,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC9778676,cumulative eventfree survival rates,TEST,PMC,,,,
PMC9778676,the kaplanmeier method,TEST,PMC,,,,
PMC9778676,the logrank test,TEST,PMC,,,,
PMC9778676,statistically significant betweengroup differences,PROBLEM,PMC,,,,
PMC9778676,significant betweengroup differences,PROBLEM,PMC,,,,
PMC9778676,albumin concentration,TEST,PMC,C0486291,albumin concentration,CHV,Laboratory or Test Result
PMC9778676,survival,TEST,PMC,C0220921,survival aspects,MTH,Functional Concept
PMC9778676,kaplanmeier curves,TEST,PMC,,,,
PMC9778676,a significant betweengroup difference,PROBLEM,PMC,,,,
PMC9778676,survival probability,TEST,PMC,C5431869,TRISS probability of survival - blunt,MEDCIN,Finding
PMC9778676,survival duration,PROBLEM,PMC,C2919551,Duration of recurrence-free survival,SNOMEDCT_US,Clinical Attribute
PMC9778676,albumin level,TEST,PMC,C0428519,Albumin level - finding,MTH,Laboratory or Test Result
PMC9778676,appetite loss,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC9778676,a useful symptom,PROBLEM,PMC,C0518686,Uses symptom relief measures,NOC,Finding
PMC9778676,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC9778676,hypoalbuminemia,PROBLEM,PMC,C0239981,Hypoalbuminemia,MTH,Disease or Syndrome
PMC9778676,deterioration in their conditions,PROBLEM,PMC,,,,
PMC9778676,subjective appetite loss,PROBLEM,PMC,,,,
PMC9778676,appetite loss,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC9778676,a useful symptom,PROBLEM,PMC,C0518686,Uses symptom relief measures,NOC,Finding
PMC9778676,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC9778676,hypoalbuminemia,PROBLEM,PMC,C0239981,Hypoalbuminemia,MTH,Disease or Syndrome
PMC9778676,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9778676,subjective appetite loss,PROBLEM,PMC,,,,
PMC9778676,loss of appetite,PROBLEM,PMC,C3814874,Loss of Appetite question,MTH,Intellectual Product
PMC9778676,advanced directives,TREATMENT,PMC,C0001683,Advance Directives,MTH,Intellectual Product
PMC10406543,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,constitutional symptoms,PROBLEM,PMC,C0009812,Constitutional Symptom,MTH,Sign or Symptom
PMC10406543,sexual dysfunction,PROBLEM,PMC,C0549622,Sexual Dysfunction,MTH,Mental or Behavioral Dysfunction
PMC10406543,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10406543,a pancreatic mass,PROBLEM,PMC,C0877425,Mass of pancreas,SNOMEDCT_US,Finding
PMC10406543,an available testosterone level,TEST,PMC,,,,
PMC10406543,a separate analysis,TEST,PMC,C2732731,Analysis using mutagenically separated PCR,SNOMEDCT_US,Laboratory Procedure
PMC10406543,total,TEST,PMC,C0439810,Total,MTH,Qualitative Concept
PMC10406543,serum samples,TEST,PMC,C1550100,Serum specimen,MTH,Body Substance
PMC10406543,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10406543,low serum testosterone,PROBLEM,PMC,C4479756,Low serum testosterone,OMIM,Finding
PMC10406543,a pancreatic mass,PROBLEM,PMC,C0877425,Mass of pancreas,SNOMEDCT_US,Finding
PMC10406543,a testosterone level,TEST,PMC,C0428412,Testosterone level,MTH,Laboratory or Test Result
PMC10406543,our analysis cohort,TEST,PMC,,,,
PMC10406543,low serum testosterone,PROBLEM,PMC,C4479756,Low serum testosterone,OMIM,Finding
PMC10406543,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC10406543,testosterone level,TEST,PMC,C0428412,Testosterone level,MTH,Laboratory or Test Result
PMC10406543,progressionfree survival,PROBLEM,PMC,,,,
PMC10406543,overall,TEST,PMC,C1561607,Overall,MTH,Qualitative Concept
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10406543,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC10406543,testosterone supplementation,TREATMENT,PMC,,,,
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10406543,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC10406543,testosterone supplementation,TREATMENT,PMC,,,,
PMC10406543,tumors of the pancreas,PROBLEM,PMC,C0347284,Benign tumor of pancreas,MTH,Neoplastic Process
PMC10406543,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10406543,testosterone deficiency,PROBLEM,PMC,C1963961,Testosterone deficiency,MTH,Disease or Syndrome
PMC10406543,low testosterone,PROBLEM,PMC,C1295654,Testosterone level below reference range,SNOMEDCT_US,Finding
PMC10406543,further prospective studies,TEST,PMC,,,,
PMC10406543,testosterone supplementation,TREATMENT,PMC,,,,
PMC10406543,pdac treatment,TREATMENT,PMC,,,,
PMC10661893,abdominal and back pain,PROBLEM,PMC,C0238548,abdominal pain radiating to back,CHV,Finding
PMC10661893,the most frequent symptom,PROBLEM,PMC,,,,
PMC10661893,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10661893,pain management,TREATMENT,PMC,C0002766,Pain management (procedure),MTH,Therapeutic or Preventive Procedure
PMC10661893,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10661893,pain control,TREATMENT,PMC,C1304888,Pain control,MTH,Therapeutic or Preventive Procedure
PMC10661893,opioid consumption,TREATMENT,PMC,,,,
PMC10661893,a retrospective analysis,TEST,PMC,,,,
PMC10661893,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10661893,cpn,TREATMENT,PMC,C1413673,CPN1 gene,MTH,Gene or Genome
PMC10661893,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10661893,persistent refractory pain,PROBLEM,PMC,,,,
PMC10661893,refractory cancer pain,PROBLEM,PMC,,,,
PMC10661893,baseline pain conditions,PROBLEM,PMC,,,,
PMC10661893,the numeric rating scale,TEST,PMC,C4050142,Numeric Rating Scale,MTH,Intellectual Product
PMC10661893,the pain scores,PROBLEM,PMC,C0582148,Pain score,SNOMEDCT_US,Finding
PMC10661893,early cpn,TREATMENT,PMC,,,,
PMC10661893,significantly lower scores,PROBLEM,PMC,,,,
PMC10661893,the opioid consumption,TREATMENT,PMC,,,,
PMC10661893,the total pain interference,PROBLEM,PMC,,,,
PMC10661893,early cpn,TREATMENT,PMC,,,,
PMC10661893,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC10661893,ctguided cpn,TREATMENT,PMC,,,,
PMC10661893,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10661893,pain exacerbation,PROBLEM,PMC,C1507007,Pain exacerbating factors,LNC,Finding
PMC10661893,opioids consumption,TREATMENT,PMC,,,,
PMC10661893,ctguided cpn,TREATMENT,PMC,,,,
PMC10661893,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10661893,pain exacerbation,PROBLEM,PMC,C1507007,Pain exacerbating factors,LNC,Finding
PMC10661893,opioids consumption,TREATMENT,PMC,,,,
PMC10661893,this retrospective cohort study,TEST,PMC,,,,
PMC10661893,ctguided cpn,TREATMENT,PMC,,,,
PMC10661893,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10661893,reduced exacerbation of pain,PROBLEM,PMC,,,,
PMC10661893,reduced opioids consumption,TREATMENT,PMC,,,,
PMC10661893,improved paininterfered qol,PROBLEM,PMC,,,,
PMC10661893,the optimal procedure timing,TREATMENT,PMC,C0547666,"Assure optimal timing of medication administration in relation to other medications, procedures, and activities.",PCDS,Therapeutic or Preventive Procedure
PMC10661893,a further largescale randomizedcontrolled trial,TREATMENT,PMC,,,,
PMC4849685,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4849685,the most lethal cancers,PROBLEM,PMC,,,,
PMC4849685,multiple symptoms,PROBLEM,PMC,C0231217,Multiple symptoms,SNOMEDCT_US,Sign or Symptom
PMC4849685,integrated supportive care,TREATMENT,PMC,,,,
PMC4849685,fluorouracilbased chemotherapy,TREATMENT,PMC,,,,
PMC4849685,a 1997 study,TEST,PMC,,,,
PMC4849685,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4849685,fluorouracil treatment,TREATMENT,PMC,C0915342,Folfox protocol,MTH,Therapeutic or Preventive Procedure
PMC4849685,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4849685,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4849685,multiple randomized studies,TEST,PMC,,,,
PMC4849685,singleagent gemcitabine,TREATMENT,PMC,,,,
PMC4849685,combination chemotherapy,TREATMENT,PMC,C1521750,Combination Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC4849685,erlotinib,TREATMENT,PMC,C1135135,erlotinib,MTH,"Organic Chemical, Pharmacologic Substance"
PMC4849685,an epidermal growth factor receptor egfr inhibitor,TREATMENT,PMC,C5574906,Epidermal growth factor receptor inhibitor,MTH,Pharmacologic Substance
PMC4849685,this regimen,TREATMENT,PMC,,,,
PMC4849685,added toxicity,PROBLEM,PMC,,,,
PMC4849685,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4849685,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC4849685,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4849685,median survival,TREATMENT,PMC,C2986586,Median Survival Time,NCI,Temporal Concept
PMC4849685,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4849685,nabpaclitaxel,TREATMENT,PMC,,,,
PMC4849685,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC4849685,these regimens,TREATMENT,PMC,,,,
PMC4849685,standard treatment,TREATMENT,PMC,C4684780,Standard Treatment,NCI,Health Care Activity
PMC4849685,multiple clinical trials,TREATMENT,PMC,,,,
PMC4849685,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4849685,the most difficult cancers,PROBLEM,PMC,,,,
PMC4849685,conventional chemotherapy,TREATMENT,PMC,,,,
PMC4849685,its aggressive characteristics,PROBLEM,PMC,,,,
PMC4849685,recent clinical trials,TREATMENT,PMC,,,,
PMC4849685,newly combined chemotherapies,TREATMENT,PMC,C5909315,Treatment Arm for COG ACNS0331 Comparison of Radiation Therapy Regimens in Combination with Chemotherapy in Treating Young Patients with Newly Diagnosed Standard-Risk Medulloblastoma,NCI,Research Activity
PMC4849685,advanced pancreatic cancer351these,PROBLEM,PMC,,,,
PMC4849685,conventional chemotherapy,TREATMENT,PMC,,,,
PMC4849685,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4849685,novel therapeutic approachesincluding,TREATMENT,PMC,,,,
PMC4849685,signal transduction inhibitors,TREATMENT,PMC,C1519313,Signal Transduction Inhibitor,NCI,Pharmacologic Substance
PMC4849685,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC4849685,stromal depleting agents,TREATMENT,PMC,,,,
PMC4849685,epigenetic therapyare,TREATMENT,PMC,,,,
PMC4849685,several studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC4849685,phase iii studies,TEST,PMC,C0282461,Phase 3 Clinical Trials,MTH,Research Activity
PMC4849685,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4849685,new chemotherapeutic regimens,TREATMENT,PMC,,,,
PMC7281628,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC7281628,cancerrelated death,PROBLEM,PMC,,,,
PMC7281628,this high mortality rate,PROBLEM,PMC,,,,
PMC7281628,the diseases,PROBLEM,PMC,C0040128,Thyroid Diseases,MTH,Disease or Syndrome
PMC7281628,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7281628,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC7281628,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC7281628,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7281628,new research models,TREATMENT,PMC,,,,
PMC7281628,novel approaches,TREATMENT,PMC,,,,
PMC7281628,pdac biomarkers,TEST,PMC,,,,
PMC7281628,the hereditary and somatic,PROBLEM,PMC,C1860909,"COLON CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6, SOMATIC",OMIM,Neoplastic Process
PMC7281628,pdac,PROBLEM,PMC,,,,
PMC7281628,the recent genome wide association studies,TEST,PMC,,,,
PMC7281628,pathway analysis studies,TEST,PMC,,,,
PMC7281628,pdac,TEST,PMC,,,,
PMC7281628,primary cell lines,TREATMENT,PMC,,,,
PMC7281628,patientderived xenografts,TREATMENT,PMC,,,,
PMC7281628,newer models,TREATMENT,PMC,,,,
PMC7281628,organoids,TREATMENT,PMC,C0029250,Organoids,MSH,Tissue
PMC7281628,organonchip,TREATMENT,PMC,,,,
PMC7281628,pdac,PROBLEM,PMC,,,,
PMC7281628,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC7281628,hereditary disease variants,PROBLEM,PMC,,,,
PMC7281628,pdac,PROBLEM,PMC,,,,
PMC7281628,driver and passenger somatic mutations,PROBLEM,PMC,,,,
PMC7281628,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC7281628,overall survival,TREATMENT,PMC,C4086681,Overall Survival,NCI,Quantitative Concept
PMC7281628,genomic variants,PROBLEM,PMC,C2717924,Genomic Structural Variation,MTH,Genetic Function
PMC7281628,gwas,TEST,PMC,C2350277,Genome-Wide Association Study,MSH,Molecular Biology Research Technique
PMC7281628,pathway analysis studies,TEST,PMC,,,,
PMC7281628,developing pdac,PROBLEM,PMC,,,,
PMC7281628,primary cell lines,TREATMENT,PMC,,,,
PMC7281628,pdx,TREATMENT,PMC,C1418724,PODXL gene,MTH,Gene or Genome
PMC7281628,gemm,TREATMENT,PMC,C0201611,Colony forming unit-granulocyte-monocyte-erythroid-megakaryocyte assay,SNOMEDCT_US,Laboratory Procedure
PMC7281628,study cancer,PROBLEM,PMC,C1514508,Prostate Cancer Outcomes Study,MTH,Research Activity
PMC7281628,organoids,TREATMENT,PMC,C0029250,Organoids,MSH,Tissue
PMC7281628,personalised treatment,TREATMENT,PMC,C5927802,"personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation",MEDCIN,Therapeutic or Preventive Procedure
PMC7281628,a novel organoid model,TREATMENT,PMC,,,,
PMC7281628,an organoid model,TREATMENT,PMC,C5708273,Organoid Model Name,NCI,Intellectual Product
PMC7281628,pdac research,TREATMENT,PMC,,,,
PMC7281628,genomic variants,PROBLEM,PMC,C2717924,Genomic Structural Variation,MTH,Genetic Function
PMC7281628,disease development,PROBLEM,PMC,C0494698,Dental Developmental Disorder,MTH,Disease or Syndrome
PMC7281628,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC7281628,disease appropriate models,TREATMENT,PMC,,,,
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,vague nonspecific symptoms,PROBLEM,PMC,,,,
PMC12162384,painless jaundice,PROBLEM,PMC,C0745472,painless jaundice,MEDCIN,Finding
PMC12162384,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC12162384,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC12162384,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,a detectable mass,PROBLEM,PMC,C4729148,MASS Syndrome Gene Anomaly Detection Reagents,UMD,"Indicator, Reagent, or Diagnostic Aid"
PMC12162384,autoimmune pancreatitis,PROBLEM,PMC,C2609129,Autoimmune Pancreatitis,MTH,Disease or Syndrome
PMC12162384,supraclavicular lymph node metastasis,PROBLEM,PMC,C0686637,Metastatic malignant neoplasm to supraclavicular lymph nodes,SNOMEDCT_US,Neoplastic Process
PMC12162384,breast lung gastric and esophageal cancers,PROBLEM,PMC,,,,
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,an isolated virchows node,PROBLEM,PMC,,,,
PMC12162384,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC12162384,an isolated enlarged left supraclavicular lymph node,PROBLEM,PMC,,,,
PMC12162384,a pancreatic mass,PROBLEM,PMC,C0877425,Mass of pancreas,SNOMEDCT_US,Finding
PMC12162384,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,a visible mass,PROBLEM,PMC,C0577129,Visible abdominal mass,SNOMEDCT_US,Finding
PMC12162384,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC12162384,the supraclavicular lymph node,PROBLEM,PMC,C1280309,Entire supraclavicular lymph node,MTH,"Body Part, Organ, or Organ Component"
PMC12162384,unremarkable labs,PROBLEM,PMC,,,,
PMC12162384,subtle imaging findings,PROBLEM,PMC,,,,
PMC12162384,a careful diagnostic approach,TEST,PMC,,,,
PMC12162384,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC12162384,biopsy,TEST,PMC,C0005558,Biopsy,MTH,Diagnostic Procedure
PMC12162384,these atypical presentations,PROBLEM,PMC,,,,
PMC12162384,appropriate treatment,TREATMENT,PMC,C3640049,Appropriate Treatment,NCI,Clinical Attribute
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,igg4related disease,PROBLEM,PMC,,,,
PMC12162384,elevated igg4,PROBLEM,PMC,,,,
PMC12162384,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12162384,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC12162384,coreneedle biopsy,TEST,PMC,,,,
PMC12162384,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC12162384,supraclavicular virchows node involvement,PROBLEM,PMC,,,,
PMC12162384,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC12162384,vague abdominal pain,PROBLEM,PMC,,,,
PMC12162384,atypical imaging,TEST,PMC,C5667569,Are Atypical DIPG Imaging Features Observed,NCI,Intellectual Product
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,the most lethal digestive malignancies,PROBLEM,PMC,,,,
PMC11909682,a steadily increasing incidence,PROBLEM,PMC,,,,
PMC11909682,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11909682,limited therapeutic options,TREATMENT,PMC,,,,
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,alterations in gut microbial composition,PROBLEM,PMC,,,,
PMC11909682,tumor initiation,TREATMENT,PMC,C0598935,Tumor Initiation,NCI,Neoplastic Process
PMC11909682,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11909682,an indepth examination,TEST,PMC,,,,
PMC11909682,the gut microbiome,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,diagnostic biomarkers,TEST,PMC,C5856751,Diagnostic Biomarker,NCI,Clinical Attribute
PMC11909682,microbiometargeted therapeutic strategies,TREATMENT,PMC,,,,
PMC11909682,gut bacteria,PROBLEM,PMC,,,,
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,a deadly disease,PROBLEM,PMC,,,,
PMC11909682,few early symptoms,PROBLEM,PMC,,,,
PMC11909682,limited treatment options,TREATMENT,PMC,C5913286,"Provide information about risks, benefits, and limitations of treatment or management options, as well as options for dealing with recurrence risk",NIC,Health Care Activity
PMC11909682,the bacteria,PROBLEM,PMC,C0939939,staph bacteria,CHV,"Organic Chemical, Pharmacologic Substance"
PMC11909682,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,changes in gut microbiota,PROBLEM,PMC,,,,
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,gut bacteria,PROBLEM,PMC,,,,
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC11909682,gut microbiota,PROBLEM,PMC,C2985398,Intestinal Microbiome,MTH,Organism
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,new strategies,TREATMENT,PMC,C1518320,New Prevention Strategies Against Disease,NCI,Research Activity
PMC11909682,increase survival rates,TREATMENT,PMC,,,,
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,a highly malignant digestive system tumor,PROBLEM,PMC,,,,
PMC11909682,treatment methods,TREATMENT,PMC,C0237934,Physical Treatment Methods,MTH,Therapeutic or Preventive Procedure
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,inflammatory states,PROBLEM,PMC,,,,
PMC11909682,immune responses,PROBLEM,PMC,C0020964,Immune response,MTH,Organ or Tissue Function
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,its disease risk,PROBLEM,PMC,,,,
PMC11909682,microbiota analysis,TEST,PMC,,,,
PMC11909682,a new approach,TREATMENT,PMC,C5674710,"Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7",ICD10PCS,Therapeutic or Preventive Procedure
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,fmt,TREATMENT,PMC,C2242628,Fecal Microbiota Transplantation,MTH,Therapeutic or Preventive Procedure
PMC11909682,probiotics,TREATMENT,PMC,C0525033,Probiotics,MSH,Bacterium
PMC11909682,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11909682,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,changes in the,PROBLEM,PMC,C0392747,Changing,MTH,Functional Concept
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11909682,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC11909682,the cure rate,TREATMENT,PMC,,,,
PMC11909682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12090895,the anatomically resectable pancreatic ductal adenocarcinoma,PROBLEM,PMC,,,,
PMC12090895,heterogeneity in patient characteristics,PROBLEM,PMC,,,,
PMC12090895,literature discrepancies,PROBLEM,PMC,,,,
PMC12090895,a biologically borderline resectable pancreatic ductal adenocarcinoma category,PROBLEM,PMC,,,,
PMC12090895,institutional criteria,TEST,PMC,C1516728,National Cancer Institute common terminology criteria for adverse events,MTH,Intellectual Product
PMC12090895,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12090895,biologically borderline resectable pancreatic ductal adenocarcinoma,PROBLEM,PMC,,,,
PMC12090895,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC12090895,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC12090895,biologically borderline resectable disease,PROBLEM,PMC,,,,
PMC12090895,carbohydrate antigen,TEST,PMC,C0443758,Carbohydrate antigen,SNOMEDCT_US,"Organic Chemical, Immunologic Factor"
PMC12090895,cancerrelated symptoms,PROBLEM,PMC,,,,
PMC12090895,regional lymph node metastases,PROBLEM,PMC,C1718268,Regional lymph nodes containing metastases,LNC,Clinical Attribute
PMC12090895,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC12090895,anatomically borderline,PROBLEM,PMC,C0154941,Anatomical narrow angle borderline glaucoma,MTH,Disease or Syndrome
PMC12090895,anatomically resectable,PROBLEM,PMC,C3520391,Thoracotomy with diagnostic wedge resection and anatomic lung resection,CPT,Health Care Activity
PMC12090895,biologically borderline resectable,PROBLEM,PMC,,,,
PMC12090895,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC12090895,a median followup,TEST,PMC,,,,
PMC12090895,the median diseasespecific,PROBLEM,PMC,,,,
PMC12090895,the biologically borderline resectable group,PROBLEM,PMC,,,,
PMC12090895,the upfront surgery,TREATMENT,PMC,,,,
PMC12090895,the median diseasespecific survival,TREATMENT,PMC,,,,
PMC12090895,biologically borderline resectable patients,PROBLEM,PMC,,,,
PMC12090895,biologically borderline resectable,PROBLEM,PMC,,,,
PMC12090895,worse diseasespecific survival,PROBLEM,PMC,,,,
PMC12090895,tumour size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC12090895,anatomically borderline resectable,PROBLEM,PMC,,,,
PMC12090895,worse eventfree survival,PROBLEM,PMC,,,,
PMC12090895,resectable and biologically borderline resectable pancreatic ductal adenocarcinoma,PROBLEM,PMC,,,,
PMC12090895,separate evaluation,TEST,PMC,C5414225,"Cytohistologic evaluation of fine needle aspirate to determine adequacy for diagnosis, each separate additional evaluation episode, same site",CPT,Laboratory Procedure
PMC12090895,different treatment approaches,TREATMENT,PMC,,,,
PMC12090895,biologically borderline resectable pancreatic canceran,PROBLEM,PMC,,,,
PMC12090895,carbohydrate antigen,TEST,PMC,C0443758,Carbohydrate antigen,SNOMEDCT_US,"Organic Chemical, Immunologic Factor"
PMC12090895,lymphadenopathy,PROBLEM,PMC,C0497156,Lymphadenopathy,MTH,Disease or Syndrome
PMC12090895,longlasting symptomshave,PROBLEM,PMC,,,,
PMC12090895,resectable disease,PROBLEM,PMC,C0844745,"Resection of large intestine or rectum for Hirschsprung's disease, with stoma formation",ICD10AM,Therapeutic or Preventive Procedure
PMC12090895,resectable and biologically borderline resectable pancreatic ductal adenocarcinoma,PROBLEM,PMC,,,,
PMC12090895,separate evaluation,TEST,PMC,C5414225,"Cytohistologic evaluation of fine needle aspirate to determine adequacy for diagnosis, each separate additional evaluation episode, same site",CPT,Laboratory Procedure
PMC12090895,different treatment approaches,TREATMENT,PMC,,,,
PMC6357627,the most common symptoms,PROBLEM,PMC,,,,
PMC6357627,crf,PROBLEM,PMC,C1366488,CRH gene,MTH,Gene or Genome
PMC6357627,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6357627,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6357627,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6357627,the brief fatigue,TEST,PMC,C2698562,Brief Fatigue Inventory,MTH,Intellectual Product
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,more fatigue,PROBLEM,PMC,C3897796,"RPQ - Fatigue, Tiring More Easily",NCI,Intellectual Product
PMC6357627,anemia,PROBLEM,PMC,C0002871,Anemia,MTH,Disease or Syndrome
PMC6357627,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6357627,a weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,high global score,PROBLEM,PMC,,,,
PMC6357627,our study,TEST,PMC,,,,
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,a frequent symptom,PROBLEM,PMC,C2008807,frequent heartburn,MEDCIN,Sign or Symptom
PMC6357627,regular evaluation,TEST,PMC,C1822457,Regular mass casualty drills with evaluation,NOC,Finding
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,all those pharmacological,TREATMENT,PMC,,,,
PMC6357627,nonpharmacological interventions,TREATMENT,PMC,C4050510,Nonpharmacologic intervention for pain,MTH,Therapeutic or Preventive Procedure
PMC6357627,this symptom,PROBLEM,PMC,C5211389,"Are you feeling bothered, upset, or worried at this point in your pregnancy about physical symptoms of pregnancy such as vomiting",LNC,Intellectual Product
PMC6357627,mild and moderate fatigue,PROBLEM,PMC,,,,
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6357627,important weight loss,PROBLEM,PMC,,,,
PMC6357627,anemia,PROBLEM,PMC,C0002871,Anemia,MTH,Disease or Syndrome
PMC6357627,these data,TEST,PMC,,,,
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6357627,its treatments,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC6357627,crf diagnosis,TEST,PMC,,,,
PMC6357627,all those pharmacological,TREATMENT,PMC,,,,
PMC6357627,nonpharmacological interventions,TREATMENT,PMC,C4050510,Nonpharmacologic intervention for pain,MTH,Therapeutic or Preventive Procedure
PMC6357627,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6357627,bfii administration,TREATMENT,PMC,,,,
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,sleep disorders,PROBLEM,PMC,C0851578,Sleep Disorders,MTH,Mental or Behavioral Dysfunction
PMC6357627,clinical stage of cancer,PROBLEM,PMC,C4521751,Clinical Stage 0 Gastric Cancer AJCC v8,MTH,Neoplastic Process
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,a multidimensional symptom,PROBLEM,PMC,C5420443,Multidimensional Fatigue Symptom Inventory-Short Form,NCI,Intellectual Product
PMC6357627,constitutional and clinical factors,PROBLEM,PMC,,,,
PMC6357627,debilitating conditions,PROBLEM,PMC,C5915579,"Identify presence of at-risk conditions (e.g., age, debilitated and immunocompromised persons, recent illness, trauma, invasive procedures, chronic conditions, change in cognition and affect)",NIC,Health Care Activity
PMC6357627,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6357627,a holistic therapeutic approach,TREATMENT,PMC,C5912363,"Use established therapeutic approach to guide counseling sessions (e.g., psychodynamic, behavioral, cognitive, humanistic, integrative-holistic)",NIC,Health Care Activity
PMC6357627,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6357627,potential fatigueinducing treatments,TREATMENT,PMC,,,,
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,the treatment implementation,TREATMENT,PMC,C0815140,prevention or treatment implementation fidelity,AOD,Therapeutic or Preventive Procedure
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,disease progression,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC6357627,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC6357627,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC6357627,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6357627,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10954243,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10954243,cancer death,PROBLEM,PMC,C4722463,Cancer-Related Death,MTH,Finding
PMC10954243,the burden,PROBLEM,PMC,C2828008,Burden,NCI,Idea or Concept
PMC10954243,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10954243,this qualitative descriptive study,TEST,PMC,,,,
PMC10954243,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10954243,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10954243,the thematic analysis method,TEST,PMC,,,,
PMC10954243,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC10954243,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10954243,symptoms management,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10954243,several symptoms,PROBLEM,PMC,C0436345,Symptom severe,SNOMEDCT_US,Finding
PMC10954243,psychological support,TREATMENT,PMC,C0600015,Emotional support,MTH,Health Care Activity
PMC10954243,palliative care structures,TREATMENT,PMC,,,,
PMC10954243,an interdisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC10954243,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10954243,patient support,TREATMENT,PMC,C0679879,patient support services,AOD,Health Care Activity
PMC10954243,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10954243,patient support,TREATMENT,PMC,C0679879,patient support services,AOD,Health Care Activity
PMC10954243,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10954243,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10954243,previous studies,TEST,PMC,C5962734,Previous Study Subject Noncompliance,NCI,Individual Behavior
PMC10954243,effective treatments,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC10954243,pain relief,PROBLEM,PMC,C0451615,Pain relief,MTH,Therapeutic or Preventive Procedure
PMC10954243,human care,TREATMENT,PMC,C1829766,human immunodeficiency virus care & family status section,MTH,Intellectual Product
PMC10954243,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10954243,multidisciplinary teams,TREATMENT,PMC,C1319406,Specialist multidisciplinary team,SNOMEDCT_US,Professional or Occupational Group
PMC10954243,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8657010,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8657010,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC8657010,devastatingly low survival rates,PROBLEM,PMC,,,,
PMC8657010,high treatment resistance profiles,PROBLEM,PMC,,,,
PMC8657010,tissue engineering,TREATMENT,PMC,C0596171,Tissue Engineering,MSH,Therapeutic or Preventive Procedure
PMC8657010,animal free tissue biomimicry,TREATMENT,PMC,,,,
PMC8657010,tumour tissue,PROBLEM,PMC,C0475358,Tumor tissue sample,MTH,Tissue
PMC8657010,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8657010,modern treatments,TREATMENT,PMC,,,,
PMC8657010,a low oxygen hypoxic 3d polyurethane scaffold system,TREATMENT,PMC,,,,
PMC8657010,longterm analysis,TEST,PMC,,,,
PMC8657010,radiation responses,TEST,PMC,C1514304,Prediction of Radiation Response,NCI,Functional Concept
PMC8657010,tumour hypoxia,PROBLEM,PMC,,,,
PMC8657010,a treatmentlimiting feature,TREATMENT,PMC,,,,
PMC8657010,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC8657010,clinical testing,TEST,PMC,C1516634,research clinical testing,MTH,Research Activity
PMC8657010,tissue engineering,TREATMENT,PMC,C0596171,Tissue Engineering,MSH,Therapeutic or Preventive Procedure
PMC8657010,tumour microenvironments,PROBLEM,PMC,,,,
PMC8657010,cancerous tissues,PROBLEM,PMC,C0027656,"Neoplasms, Connective Tissue",MSH,Neoplastic Process
PMC8657010,such advanced cancer tissue models,PROBLEM,PMC,,,,
PMC8657010,accurate preclinical assessment,TEST,PMC,,,,
PMC8657010,treatment strategies,TREATMENT,PMC,C4535966,intervention using focused treatment strategies,MEDCIN,Therapeutic or Preventive Procedure
PMC8657010,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8657010,a dangerous disease,PROBLEM,PMC,,,,
PMC8657010,high,TREATMENT,PMC,C0205250,High,MTH,Qualitative Concept
PMC8657010,a highly complex tme,PROBLEM,PMC,,,,
PMC8657010,the pancreatic cancer tme,PROBLEM,PMC,,,,
PMC8657010,complex structure,PROBLEM,PMC,C5881277,Subtalar joint complex structure,SNOMEDCT_US,Body Space or Junction
PMC8657010,complex extracellular matrix ecm protein composition,PROBLEM,PMC,,,,
PMC8657010,diverse cell populations,PROBLEM,PMC,,,,
PMC8657010,stellate cells,PROBLEM,PMC,C0598117,stellate cell,CHV,Cell
PMC8657010,cancer associated fibroblasts,PROBLEM,PMC,C4277548,Cancer-Associated Fibroblasts,MTH,Cell
PMC8657010,endothelial cells,PROBLEM,PMC,C0225336,Endothelial Cells,MSH,Cell
PMC8657010,the cancer cells,PROBLEM,PMC,C1956422,Cancer Stem Cells,MSH,Cell
PMC8657010,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8657010,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC8657010,accumulation of high amounts of ecm,PROBLEM,PMC,,,,
PMC8657010,a fibroticdesmoplastic reaction,PROBLEM,PMC,,,,
PMC8657010,the tumour,PROBLEM,PMC,C2362754,Tumour staging,MTH,Laboratory Procedure
PMC8657010,heterogeneous environmental gradients,PROBLEM,PMC,,,,
PMC8657010,hypoxia,PROBLEM,PMC,C0242184,Hypoxia,MTH,Pathologic Function
PMC8657010,vessel collapse,PROBLEM,PMC,,,,
PMC8657010,stiffness increase,PROBLEM,PMC,C3178782,Aortic Stiffness,MSH,Disease or Syndrome
PMC8657010,the fibroticdesmoplastic area,PROBLEM,PMC,,,,
PMC8657010,the tme,TEST,PMC,C5783677,Xerna TME Panel,NCI,Laboratory Procedure
PMC8657010,radiotherapeutic resistance,TREATMENT,PMC,,,,
PMC8657010,in,PROBLEM,PMC,C0332285,Within,MTH,Spatial Concept
PMC8657010,vitro hypoxia,PROBLEM,PMC,,,,
PMC8657010,the radiotherapy treatment,TREATMENT,PMC,C5769145,Radiotherapy treatment plan,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC8657010,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC8657010,a novel polymer polyurethane,TREATMENT,PMC,,,,
PMC8657010,highly macroporous scaffold,TREATMENT,PMC,,,,
PMC8657010,proteins,TREATMENT,PMC,C0033684,Proteins,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8657010,ecm mimicry,PROBLEM,PMC,,,,
PMC8657010,panc1 cells,PROBLEM,PMC,,,,
PMC8657010,fibronectin coated macroporous scaffolds,TREATMENT,PMC,,,,
PMC8657010,vitro normoxia,TREATMENT,PMC,,,,
PMC8657010,in,TREATMENT,PMC,C0332285,Within,MTH,Spatial Concept
PMC8657010,vitro hypoxia,TREATMENT,PMC,,,,
PMC8657010,vitro normoxia,TREATMENT,PMC,,,,
PMC8657010,the 3d cell cultures,TEST,PMC,C5690715,Scaffold Cell Culture Techniques,MSH,Laboratory Procedure
PMC8657010,apoptotic profiles,TEST,PMC,,,,
PMC8657010,hif1a secretion,PROBLEM,PMC,,,,
PMC8657010,the cancer cells,PROBLEM,PMC,C1956422,Cancer Stem Cells,MSH,Cell
PMC8657010,increased postradiation viability,PROBLEM,PMC,,,,
PMC8657010,reduced apoptosis,PROBLEM,PMC,C5539476,Reduced CD95-induced lymphocyte apoptosis,HPO,Finding
PMC8657010,increased collageni and hif1a secretion,PROBLEM,PMC,,,,
PMC8657010,vitro hypoxia,PROBLEM,PMC,,,,
PMC8657010,normoxic cultures,TEST,PMC,,,,
PMC8657010,hypoxiainduced radioprotection,PROBLEM,PMC,,,,
PMC8657010,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8657010,a low cost animal free model,TREATMENT,PMC,,,,
PMC8657010,longterm in vitro hypoxic 3d cell culture,TREATMENT,PMC,,,,
PMC8657010,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8657010,vitro hypoxia,PROBLEM,PMC,,,,
PMC8657010,pdac radioprotection development,TREATMENT,PMC,,,,
PMC8657010,our novel platform,TREATMENT,PMC,,,,
PMC8657010,radiation treatment screening,TREATMENT,PMC,C3693614,radiation therapy screening prior to procedure,MEDCIN,Therapeutic or Preventive Procedure
PMC8657010,longterm in vitro posttreatment observations,TREATMENT,PMC,,,,
PMC8657010,fractionated radiotherapy treatment,TREATMENT,PMC,C5880983,Fractionated dose radiotherapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC8657010,vitro hypoxic radiation treatment screening,TREATMENT,PMC,,,,
PMC8657010,vitro normoxia,TREATMENT,PMC,,,,
PMC8657010,in,TREATMENT,PMC,C0332285,Within,MTH,Spatial Concept
PMC8657010,vitro hypoxia,TREATMENT,PMC,,,,
PMC8657010,radiation treatment,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC8657010,the 3d cell cultures,TEST,PMC,C5690715,Scaffold Cell Culture Techniques,MSH,Laboratory Procedure
PMC8657010,hif1a secretion,PROBLEM,PMC,,,,
PMC8657010,the cancer cells,PROBLEM,PMC,C1956422,Cancer Stem Cells,MSH,Cell
PMC8657010,apoptotic,TEST,PMC,C1516044,Apoptotic,NCI,Qualitative Concept
PMC8657010,ecm collageni secretion,PROBLEM,PMC,,,,
PMC8657010,the cancer cells,PROBLEM,PMC,C1956422,Cancer Stem Cells,MSH,Cell
PMC8657010,our analysis,TEST,PMC,,,,
PMC8657010,increased levels of hif1a,PROBLEM,PMC,,,,
PMC8657010,increased cell viability,PROBLEM,PMC,,,,
PMC8657010,decreases in cell apoptosis,PROBLEM,PMC,,,,
PMC8657010,hif1a,PROBLEM,PMC,C1333897,HIF1A gene,MTH,Gene or Genome
PMC8657010,increases in hif1a,PROBLEM,PMC,,,,
PMC8657010,higher collageni deposition,PROBLEM,PMC,,,,
PMC8657010,vitro hypoxic cultures,TEST,PMC,,,,
PMC8657010,less collageni disruption,PROBLEM,PMC,,,,
PMC8657010,vitro hypoxic radiation treatment,TREATMENT,PMC,,,,
PMC8657010,the first study,TEST,PMC,C4684677,First-in-Human Study,NCI,Research Activity
PMC8657010,an in vitro hypoxic pdac,PROBLEM,PMC,,,,
PMC8657010,scaffold culture,TEST,PMC,C5690715,Scaffold Cell Culture Techniques,MSH,Laboratory Procedure
PMC8657010,radiation response studies,TEST,PMC,,,,
PMC8657010,hif1a,PROBLEM,PMC,C1333897,HIF1A gene,MTH,Gene or Genome
PMC8657010,increased collagen deposition,PROBLEM,PMC,C5393152,Increased collagen deposits in cardiac tissue,OMIM,Finding
PMC8657010,a 3d pdac model,TREATMENT,PMC,,,,
PMC8657010,hypoxia,PROBLEM,PMC,C0242184,Hypoxia,MTH,Pathologic Function
PMC8657010,an animal free alternative,TREATMENT,PMC,,,,
PMC8657010,predictive radiation research,TREATMENT,PMC,,,,
PMC8657010,in,PROBLEM,PMC,C0332285,Within,MTH,Spatial Concept
PMC8657010,vitro hypoxia,PROBLEM,PMC,,,,
PMC8657010,the pdac cellular,TREATMENT,PMC,,,,
PMC8657010,advanced radiotherapy modalities,TREATMENT,PMC,,,,
PMC8657010,proton therapy,TREATMENT,PMC,C0436226,Proton Therapy,MTH,Therapeutic or Preventive Procedure
PMC8657010,image guided radiotherapy,TREATMENT,PMC,C3896654,Image-Guided Adaptive Radiation Therapy,NCI,Therapeutic or Preventive Procedure
PMC8657010,mrlinacs,TREATMENT,PMC,,,,
PMC8657010,our complex multicellular scaffolds,TREATMENT,PMC,,,,
PMC8657010,lower partial pressures of oxygen,TREATMENT,PMC,,,,
PMC8657010,vitro hypoxia,PROBLEM,PMC,,,,
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,subtle clinical manifestations,PROBLEM,PMC,,,,
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,the pancreatic cancer stage,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC9793126,pancreatic cancer screening,PROBLEM,PMC,,,,
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,several screening modalities,TEST,PMC,,,,
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,pancreatic screening cancer protocol,TREATMENT,PMC,,,,
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC9793126,asymptomatic individualsseveral,PROBLEM,PMC,,,,
PMC9793126,pancreatic cancer screening protocol,TREATMENT,PMC,,,,
PMC9793126,high risk individual,PROBLEM,PMC,C0510517,Educate high-risk individuals and groups about environmental hazards,NIC,Educational Activity
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,pancreatic cancer screening,PROBLEM,PMC,,,,
PMC9793126,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC9793126,asymptomatic individuals,PROBLEM,PMC,C2977627,Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.,ICD10CM,Finding
PMC9793126,pancreatic cancer screening protocol,TREATMENT,PMC,,,,
PMC9793126,high risk individual,PROBLEM,PMC,C0510517,Educate high-risk individuals and groups about environmental hazards,NIC,Educational Activity
PMC9793126,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9793126,low survival rates,PROBLEM,PMC,,,,
PMC9793126,early management,TREATMENT,PMC,C2673554,"Cataracts, formation may be reversible with early dietary management",OMIM,Finding
PMC9793126,precursor lesions,PROBLEM,PMC,C5787479,Myeloid precursor lesion,SNOMEDCT_US,Neoplastic Process
PMC9793126,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9793126,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC9793126,asymptomatic individuals,PROBLEM,PMC,C2977627,Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.,ICD10CM,Finding
PMC9793126,highrisk pancreatic cancer individuals,PROBLEM,PMC,,,,
PMC9793126,appropriate,TREATMENT,PMC,C1548787,Appropriate,HL7V2.5,Qualitative Concept
PMC7434629,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7434629,a highly malignant tumor of the digestive system,PROBLEM,PMC,,,,
PMC7434629,early pancreatic cancer,PROBLEM,PMC,,,,
PMC7434629,its atypical clinical symptoms,PROBLEM,PMC,,,,
PMC7434629,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7434629,radical surgical tumor resection,TREATMENT,PMC,C0374080,Level V surgical pathology with gross and microscopic examination,MTH,Laboratory Procedure
PMC7434629,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC7434629,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7434629,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7434629,a peptide targeting pancreatic cancer cells,PROBLEM,PMC,,,,
PMC7434629,phage display technology,TEST,PMC,,,,
PMC7434629,panc1 cells,TEST,PMC,,,,
PMC7434629,fluorescence imaging,TEST,PMC,C0430876,Fluorescence Imaging,MSH,Diagnostic Procedure
PMC7434629,flow cytometry,TEST,PMC,C0016263,Flow Cytometry,MSH,Laboratory Procedure
PMC7434629,the targeting peptide,TREATMENT,PMC,C4549215,E5 CXCR4-targeting peptide,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7434629,the proapoptotic klaklakklaklak,TREATMENT,PMC,,,,
PMC7434629,the fusion peptide,TREATMENT,PMC,C4308576,5rolGLP-HV fusion peptide,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7434629,pancreatic tumor cells,PROBLEM,PMC,C5848150,Pancreatic Insulin-Producing Neuroendocrine Tumor,MTH,Neoplastic Process
PMC7434629,fluorescence imaging,TEST,PMC,C0430876,Fluorescence Imaging,MSH,Diagnostic Procedure
PMC7434629,in,TEST,PMC,C0332285,Within,MTH,Spatial Concept
PMC7434629,vivo imaging system,TEST,PMC,,,,
PMC7434629,flow cytometry,TEST,PMC,C0016263,Flow Cytometry,MSH,Laboratory Procedure
PMC7434629,mitochondrial membrane potential evaluation,TEST,PMC,,,,
PMC7434629,western blot,TEST,PMC,C0949466,Western Blot,MTH,Laboratory Procedure
PMC7434629,pancreatic tumor growth,PROBLEM,PMC,C0122629,human pancreatic tumor growth hormone releasing factor,MSH,"Amino Acid, Peptide, or Protein"
PMC7434629,toxic effects,PROBLEM,PMC,C0412962,Solvents -toxic effects,SNOMEDCT_US,Injury or Poisoning
PMC7434629,animal experiment,TEST,PMC,C0205664,Animal Experiments,MSH,Research Activity
PMC7434629,the targeting peptide,TREATMENT,PMC,C4549215,E5 CXCR4-targeting peptide,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7434629,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7434629,destroyed mitochondria,PROBLEM,PMC,,,,
PMC7434629,induced apoptosis,PROBLEM,PMC,C3893317,hydrogen peroxide-induced apoptosis,GO,Cell Function
PMC7434629,the fusion peptide,TREATMENT,PMC,C4308576,5rolGLP-HV fusion peptide,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7434629,pancreatic tumor cells,PROBLEM,PMC,C5848150,Pancreatic Insulin-Producing Neuroendocrine Tumor,MTH,Neoplastic Process
PMC7434629,a significant inhibitory effect,PROBLEM,PMC,,,,
PMC7434629,pancreatic tumor growth,PROBLEM,PMC,C0122629,human pancreatic tumor growth hormone releasing factor,MSH,"Amino Acid, Peptide, or Protein"
PMC7434629,reduced toxic effects,PROBLEM,PMC,,,,
PMC7434629,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7434629,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7434629,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7434629,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7434629,a peptide targeting pancreatic cancer cells,PROBLEM,PMC,,,,
PMC7434629,kla,TREATMENT,PMC,C1416656,KL gene,MTH,Gene or Genome
PMC7434629,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7434629,minimal adverse effects,PROBLEM,PMC,C5914704,Check medications and alter where possible to minimize adverse effects,NIC,Health Care Activity
PMC7434629,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7434629,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6617267,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6617267,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6617267,the cancers of the digestive tract,PROBLEM,PMC,,,,
PMC6617267,clinical symptoms,PROBLEM,PMC,C3483785,Clinical sepsis symptoms present,LNC,Finding
PMC6617267,early detection,TEST,PMC,C0596473,Early Diagnosis,MSH,Diagnostic Procedure
PMC6617267,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6617267,the tumors metastasize,PROBLEM,PMC,C0445092,No metastases,SNOMEDCT_US,Finding
PMC6617267,screening highrisk groups,PROBLEM,PMC,,,,
PMC6617267,pancreatic cancer therapy,TREATMENT,PMC,,,,
PMC6617267,genetic and epigenetic alterations,PROBLEM,PMC,,,,
PMC6617267,pancreatic tumorigenesis,PROBLEM,PMC,,,,
PMC6617267,the epigenetic alterations,PROBLEM,PMC,,,,
PMC6617267,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6617267,potential synthetic lethal strategies,TREATMENT,PMC,,,,
PMC6617267,these genetic defects,PROBLEM,PMC,,,,
PMC6617267,this deadly disease,PROBLEM,PMC,,,,
PMC6617267,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC6617267,epigenetic,TREATMENT,PMC,C1655731,study of epigenetics,MTH,Biomedical Occupation or Discipline
PMC6617267,gi cancersin,PROBLEM,PMC,,,,
PMC6617267,pancreatic cancerand,PROBLEM,PMC,,,,
PMC6617267,the screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC6617267,tumor cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC6617267,sirnas,TREATMENT,PMC,C4305867,Sirna-027,DRUGBANK,Pharmacologic Substance
PMC6617267,shrnas,TREATMENT,PMC,C2930586,Short Hairpin RNA,MSH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC6617267,epigenetic regulatormutated cancers,PROBLEM,PMC,,,,
PMC6617267,the context dependency,PROBLEM,PMC,C0455706,Context-dependent type,SNOMEDCT_US,Intellectual Product
PMC6617267,each neoplasia,PROBLEM,PMC,,,,
PMC6617267,further examination,TEST,PMC,,,,
PMC6617267,broadspectrum application,TREATMENT,PMC,,,,
PMC6617267,the therapeutics,TREATMENT,PMC,C5552741,Beam Therapeutics,MTH,Organization
PMC6617267,multiple tumor types,PROBLEM,PMC,C4229901,"Brain tumors, multiple types",OMIM,Finding
PMC6617267,the screening strategy,TEST,PMC,,,,
PMC6617267,multiple cancer types,PROBLEM,PMC,,,,
PMC6617267,a mutation,PROBLEM,PMC,C0026882,Mutation,MTH,Genetic Function
PMC6617267,the arid1a mutation in ovarian and colon tumors,PROBLEM,PMC,,,,
PMC6617267,therapeutics,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC6617267,this strategy,TREATMENT,PMC,,,,
PMC6617267,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC6617267,epigenetic regulatormutated cancers,PROBLEM,PMC,,,,
PMC9885735,nanoliposomal irinotecan,TREATMENT,PMC,C4057931,irinotecan liposomal,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC9885735,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC9885735,disease progression,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC9885735,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9885735,naliri safety profile,TREATMENT,PMC,,,,
PMC9885735,conventional irinotecan,TREATMENT,PMC,C4048963,irinotecan hydrochloride 20 MG/ML Injection,MTH,Clinical Drug
PMC9885735,the naliri safety,TREATMENT,PMC,,,,
PMC9885735,japanese phase 2 study,TEST,PMC,,,,
PMC9885735,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC9885735,other selected toxicities,PROBLEM,PMC,,,,
PMC9885735,the naliri combination,TREATMENT,PMC,,,,
PMC9885735,leukopenianeutropenia,PROBLEM,PMC,,,,
PMC9885735,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC9885735,hepatic dysfunction,PROBLEM,PMC,C0086565,Liver Dysfunction,MSH,Finding
PMC9885735,treatmentemergent adverse events,PROBLEM,PMC,,,,
PMC9885735,grade  3 diarrhea,PROBLEM,PMC,C5820574,grade 3 diarrhea,MEDCIN,Finding
PMC9885735,their symptoms,PROBLEM,PMC,,,,
PMC9885735,drug withdrawal,PROBLEM,PMC,C0152128,Drug withdrawal syndrome,MTH,Disease or Syndrome
PMC9885735,grade  3 and,PROBLEM,PMC,C0450094,Grade three rank,MTH,Finding
PMC9885735,grade  2 diarrhea,PROBLEM,PMC,C5820573,grade 2 diarrhea,MEDCIN,Finding
PMC9885735,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC9885735,naliri combination regimen,TREATMENT,PMC,,,,
PMC9885735,japanese unresectable pancreatic cancer,PROBLEM,PMC,,,,
PMC9885735,the treatmentemergent adverse events,PROBLEM,PMC,,,,
PMC9885735,prolonged toxicities,PROBLEM,PMC,C0547884,Monitor for signs and symptoms of drug toxicity due to prolongation of action.,PCDS,Therapeutic or Preventive Procedure
PMC9885735,dose modifications,TREATMENT,PMC,C1707811,Dose Modification,NCI,Research Activity
PMC9885735,liposomal irinotecan,TREATMENT,PMC,C4057931,irinotecan liposomal,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC9885735,the adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC9885735,naliri combination chemotherapy,TREATMENT,PMC,,,,
PMC9885735,gastrointestinal toxicities,PROBLEM,PMC,C1142499,Gastrointestinal toxicity,MDR,Injury or Poisoning
PMC9885735,careful management,TREATMENT,PMC,C2735310,Care management,MTH,Health Care Activity
PMC9885735,naliri combination regimen,TREATMENT,PMC,,,,
PMC9885735,japanese unresectable pancreatic cancer,PROBLEM,PMC,,,,
PMC9885735,the treatmentemergent adverse events,PROBLEM,PMC,,,,
PMC9885735,prolonged toxicities,PROBLEM,PMC,C0547884,Monitor for signs and symptoms of drug toxicity due to prolongation of action.,PCDS,Therapeutic or Preventive Procedure
PMC9885735,this analysis,TEST,PMC,,,,
PMC9885735,the naliri,TREATMENT,PMC,,,,
PMC9885735,5fullv regimen,TREATMENT,PMC,,,,
PMC9885735,japanese mpac,TREATMENT,PMC,,,,
PMC9885735,systemic chemotherapy,TREATMENT,PMC,C1883256,Systemic Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC9885735,the teaes,PROBLEM,PMC,C0598733,TEAE chromatography (triethylaminoethyl cellulose),CSP,Laboratory Procedure
PMC9885735,naliri,TREATMENT,PMC,,,,
PMC9885735,5fullv,TREATMENT,PMC,,,,
PMC9885735,ae management strategies,TREATMENT,PMC,,,,
PMC9885735,some adverse events,PROBLEM,PMC,,,,
PMC9885735,prolonged toxicities,PROBLEM,PMC,C0547884,Monitor for signs and symptoms of drug toxicity due to prolongation of action.,PCDS,Therapeutic or Preventive Procedure
PMC9885735,diarrhea,PROBLEM,PMC,C0011991,Diarrhea,MTH,Sign or Symptom
PMC9885735,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC7876378,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC7876378,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC7876378,both multifactorial diseases,PROBLEM,PMC,,,,
PMC7876378,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC7876378,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC7876378,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7876378,certain diabetes treatment,TREATMENT,PMC,,,,
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7876378,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,a novel glucagonlike peptide1 glp1 analog,TREATMENT,PMC,,,,
PMC7876378,a type 2 diabetes,PROBLEM,PMC,C4015183,TYPE 2 DIABETES 5,OMIM,Disease or Syndrome
PMC7876378,discomfort in the left upper quadrant of abdomen,PROBLEM,PMC,,,,
PMC7876378,the patients vital signs,TEST,PMC,C0150404,Taking vital signs,MTH,Health Care Activity
PMC7876378,laboratory findings,TEST,PMC,C0587081,Laboratory test finding,MTH,Laboratory or Test Result
PMC7876378,the elevated level of carbohydrate antigen,PROBLEM,PMC,,,,
PMC7876378,the upper abdomen routine enhanced computed tomography ct scan,TEST,PMC,,,,
PMC7876378,low density of the pancreatic body and tail,PROBLEM,PMC,,,,
PMC7876378,the pancreatic biopsy samples,TEST,PMC,,,,
PMC7876378,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC7876378,regional lymph node metastasis,PROBLEM,PMC,C1275854,Regional lymph node metastasis present,SNOMEDCT_US,Finding
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,his hypoglycemic treatment regimen,TREATMENT,PMC,,,,
PMC7876378,tumor biomarkers,TEST,PMC,C0041366,"Biomarkers, Tumor",MSH,Biologically Active Substance
PMC7876378,upper abdomen routine ct,TEST,PMC,,,,
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,further longerterm followup trials,TREATMENT,PMC,,,,
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,further longerterm followup trials,TREATMENT,PMC,,,,
PMC7876378,liraglutide,TREATMENT,PMC,C1456408,liraglutide,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC7876378,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC9080991,treatment tolerance,TREATMENT,PMC,C2922780,RNAx evaluate bowel tolerance,MEDCIN,Health Care Activity
PMC9080991,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC9080991,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9080991,traditional chemotherapeutics,TREATMENT,PMC,,,,
PMC9080991,concurrent palliative care,TREATMENT,PMC,,,,
PMC9080991,aggressive symptom management,TREATMENT,PMC,,,,
PMC9080991,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9080991,a concurrent palliative care intervention,TREATMENT,PMC,,,,
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,phase i clinical trials,TREATMENT,PMC,C0920321,Phase I Clinical Trials,MTH,Research Activity
PMC9080991,an advanced practice nurse,TREATMENT,PMC,C1510818,Advanced Practice Nurse,MTH,Professional or Occupational Group
PMC9080991,palliative care intervention,TREATMENT,PMC,,,,
PMC9080991,solid tumor,PROBLEM,PMC,C0280100,Solid Neoplasm,MTH,Neoplastic Process
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC9080991,the functional assessment,TEST,PMC,C0278372,Functional assessment,SNOMEDCT_US,Diagnostic Procedure
PMC9080991,cancer therapygeneral,TREATMENT,PMC,,,,
PMC9080991,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC9080991,the psychological distress,PROBLEM,PMC,C0815107,Psychological Distress,MTH,Mental or Behavioral Dysfunction
PMC9080991,repeated measures analysis,TEST,PMC,C4265026,FMR1 gene CGG repeat analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC9080991,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,psychological distress,PROBLEM,PMC,C0815107,Psychological Distress,MTH,Mental or Behavioral Dysfunction
PMC9080991,the intervention arm,TREATMENT,PMC,C5420679,No Intervention Arm,NCI,Research Activity
PMC9080991,moderate severity,PROBLEM,PMC,C0205081,Moderate (severity modifier),MTH,Qualitative Concept
PMC9080991,this secondary analysis,TEST,PMC,,,,
PMC9080991,a nurseled palliative care intervention,TREATMENT,PMC,,,,
PMC9080991,psychological distress,PROBLEM,PMC,C0815107,Psychological Distress,MTH,Mental or Behavioral Dysfunction
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,a phase iii trial,TREATMENT,PMC,C5787032,Phase I/III Trial,NCI,Research Activity
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,the intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC9080991,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,a palliative care intervention,TREATMENT,PMC,,,,
PMC9080991,qol measures,TREATMENT,PMC,C3261495,Neuro-Qol short form - stigma - version 1.0:-:Pt:^Patient:-:NeuroQol,MTH,Clinical Attribute
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,temel,TREATMENT,PMC,C0881598,Basic metabolic 1998 panel:-:Pt:Ser/Plas:Qn,MTH,Clinical Attribute
PMC9080991,lung cancer,PROBLEM,PMC,C0684249,Carcinoma of lung,MTH,Neoplastic Process
PMC9080991,early palliative care21factl,TREATMENT,PMC,,,,
PMC9080991,the temel study,TEST,PMC,,,,
PMC9080991,the intervention arm,TREATMENT,PMC,C5420679,No Intervention Arm,NCI,Research Activity
PMC9080991,improved qol,PROBLEM,PMC,,,,
PMC9080991,two other recent studies,TEST,PMC,,,,
PMC9080991,fixing symptoms,PROBLEM,PMC,C4029257,fixed breast lump,MEDCIN,Sign or Symptom
PMC9080991,advanced cancer,PROBLEM,PMC,C0877373,Advanced cancer,MDR,Neoplastic Process
PMC9080991,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9080991,early palliative care,TREATMENT,PMC,,,,
PMC9080991,a primary palliative care intervention,TREATMENT,PMC,,,,
PMC9080991,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC9080991,swog,TEST,PMC,C1519429,SWOG,MTH,Health Care Related Organization
PMC9080991,ncorp,TREATMENT,PMC,C4330791,National Cancer Institute Community Oncology Research Program,NCI,Health Care Related Organization
PMC9080991,palliative care physicians,TREATMENT,PMC,C0586875,Palliative care physician,MTH,Professional or Occupational Group
PMC9080991,a scalable approach,TREATMENT,PMC,,,,
PMC9080991,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC9080991,interventions,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC7440208,potentially serious illnesses,PROBLEM,PMC,,,,
PMC7440208,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7440208,this retrospective study,TEST,PMC,,,,
PMC7440208,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7440208,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC7440208,presenting symptoms,PROBLEM,PMC,C3177142,Main presenting symptom,LNC,Sign or Symptom
PMC7440208,signs,PROBLEM,PMC,C0220912,Aspects of signs,MTH,Functional Concept
PMC7440208,risk and prognostic factors,PROBLEM,PMC,C5851965,"Image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality",CPT,Laboratory Procedure
PMC7440208,the diagnostic assessment,TEST,PMC,C0431080,Diagnostic assessment,SNOMEDCT_US,Diagnostic Procedure
PMC7440208,a microcosting method,TREATMENT,PMC,,,,
PMC7440208,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC7440208,asthenia,PROBLEM,PMC,C0004093,Asthenia,MTH,Sign or Symptom
PMC7440208,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC7440208,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC7440208,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC7440208,palpable hepatomegaly,PROBLEM,PMC,,,,
PMC7440208,a tumor on the head of the pancreas,PROBLEM,PMC,C0345921,Neoplasm of head of pancreas,SNOMEDCT_US,Neoplastic Process
PMC7440208,a tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC7440208,a more advanced nodal stage,PROBLEM,PMC,,,,
PMC7440208,a poorer histological differentiation,PROBLEM,PMC,,,,
PMC7440208,metastatic,PROBLEM,PMC,C0036525,Metastatic to,MTH,Functional Concept
PMC7440208,surgical resections,TREATMENT,PMC,C0749561,TOE SURGICAL RESECTION,CCPSS,Therapeutic or Preventive Procedure
PMC7440208,microcosting,TREATMENT,PMC,,,,
PMC7440208,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7440208,an ambulatory diagnostic assessment,TEST,PMC,,,,
PMC7440208,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7440208,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC7440208,an inpatient diagnostic evaluation,TEST,PMC,,,,
PMC7440208,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,complementary and alternative medicine,TREATMENT,PMC,C1148475,Complementary and alternative medicine,MTH,Biomedical Occupation or Discipline
PMC12071172,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,psychological factors,PROBLEM,PMC,C0033898,Psychological Factors,MSH,Mental Process
PMC12071172,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC12071172,unconventional treatments,TREATMENT,PMC,C2986421,Unconventional Cancer Treatment,NCI,Therapeutic or Preventive Procedure
PMC12071172,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC12071172,standard therapies,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC12071172,unconventional treatments,TREATMENT,PMC,C2986421,Unconventional Cancer Treatment,NCI,Therapeutic or Preventive Procedure
PMC12071172,this systematic review,TEST,PMC,,,,
PMC12071172,various cam therapies,TREATMENT,PMC,,,,
PMC12071172,curcumin,TREATMENT,PMC,C0010467,curcumin,MTH,"Organic Chemical, Pharmacologic Substance, Indicator, Reagent, or Diagnostic Aid"
PMC12071172,mistletoe extract,TREATMENT,PMC,C1166209,Viscum album preparation,MTH,"Organic Chemical, Pharmacologic Substance"
PMC12071172,chinese herbal medicine,TREATMENT,PMC,C1273412,Chinese herbal medicine,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC12071172,electroacupuncture,TREATMENT,PMC,C0013794,Electroacupuncture,MSH,Therapeutic or Preventive Procedure
PMC12071172,complementary treatments,TREATMENT,PMC,C5934221,Alternative complementary treatments,NOC,Finding
PMC12071172,integrative oncology,TREATMENT,PMC,C4505053,Integrative Oncology,MSH,Therapeutic or Preventive Procedure
PMC12071172,rigorous,TREATMENT,PMC,C0035624,Rigor Mortis,MSH,Pathologic Function
PMC12071172,standard cancer care,TREATMENT,PMC,,,,
PMC12071172,cam,TREATMENT,PMC,C5234969,Cam,MTH,"Organic Chemical, Pharmacologic Substance"
PMC12071172,ethical principles,TREATMENT,PMC,C0562404,Lacks ethical principles,SNOMEDCT_US,Finding
PMC12071172,highquality studies,TEST,PMC,,,,
PMC12071172,these treatments,TREATMENT,PMC,C3166766,Which of these water treatment devices are now used in your home,LNC,Intellectual Product
PMC12071172,holistic patient care,TREATMENT,PMC,,,,
PMC12071172,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12071172,unconventional treatments,TREATMENT,PMC,C2986421,Unconventional Cancer Treatment,NCI,Therapeutic or Preventive Procedure
PMC12071172,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,natural products,TREATMENT,PMC,C1566558,Natural Products,MSH,Biologically Active Substance
PMC12071172,dietary supplements,TREATMENT,PMC,C0242295,Dietary Supplements,MTH,Food
PMC12071172,probiotics,TREATMENT,PMC,C0525033,Probiotics,MSH,Bacterium
PMC12071172,whole medical systems,TREATMENT,PMC,,,,
PMC12071172,bodybased therapies,TREATMENT,PMC,,,,
PMC12071172,an electronic,TEST,PMC,C0013850,Electronic,MTH,Idea or Concept
PMC12071172,randomized controlled trials,TREATMENT,PMC,C0282440,Randomized Controlled Trials as Topic,MTH,Intellectual Product
PMC12071172,prospective and retrospective studies,TEST,PMC,C0681849,retrospective study and prospective study,AOD,Research Activity
PMC12071172,unconventional treatments,TREATMENT,PMC,C2986421,Unconventional Cancer Treatment,NCI,Therapeutic or Preventive Procedure
PMC12071172,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,treatment tolerability,TREATMENT,PMC,C1319899,Treatment not tolerated,SNOMEDCT_US,Finding
PMC12071172,a total of,TEST,PMC,C0439810,Total,MTH,Qualitative Concept
PMC12071172,21 studies,TEST,PMC,C2074607,chromosome studies trisomy 21 Denver,MEDCIN,Laboratory Procedure
PMC12071172,unconventional treatments,TREATMENT,PMC,C2986421,Unconventional Cancer Treatment,NCI,Therapeutic or Preventive Procedure
PMC12071172,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,chinese herbal medicine,TREATMENT,PMC,C1273412,Chinese herbal medicine,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC12071172,mistletoe extract,TREATMENT,PMC,C1166209,Viscum album preparation,MTH,"Organic Chemical, Pharmacologic Substance"
PMC12071172,curcumin,TREATMENT,PMC,C0010467,curcumin,MTH,"Organic Chemical, Pharmacologic Substance, Indicator, Reagent, or Diagnostic Aid"
PMC12071172,electroacupuncture,TREATMENT,PMC,C0013794,Electroacupuncture,MSH,Therapeutic or Preventive Procedure
PMC12071172,chm,TREATMENT,PMC,C1413394,CHM gene,MTH,Gene or Genome
PMC12071172,curcumin,TREATMENT,PMC,C0010467,curcumin,MTH,"Organic Chemical, Pharmacologic Substance, Indicator, Reagent, or Diagnostic Aid"
PMC12071172,standard therapy,TREATMENT,PMC,C2936643,Standard of Care,MSH,Health Care Activity
PMC12071172,electroacupuncture,TREATMENT,PMC,C0013794,Electroacupuncture,MSH,Therapeutic or Preventive Procedure
PMC12071172,pancreatic cancer pain intensity,PROBLEM,PMC,,,,
PMC12071172,the data on me,TEST,PMC,C1714877,Institution data source NPI:ID:Pt:Registry message:Nom,LNC,Clinical Attribute
PMC12071172,some unconventional treatments,TREATMENT,PMC,,,,
PMC12071172,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,an integrative oncology setting,TREATMENT,PMC,,,,
PMC12071172,further highquality studies,TEST,PMC,,,,
PMC12071172,a holistic approach,TREATMENT,PMC,C0683249,holistic approach,CHV,Idea or Concept
PMC12071172,cancer treatment,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC12071172,nonconventional therapies,TREATMENT,PMC,,,,
PMC12071172,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12071172,standalone therapies,TREATMENT,PMC,,,,
PMC12071172,standard treatments,TREATMENT,PMC,C4684780,Standard Treatment,NCI,Health Care Activity
PMC12071172,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC12071172,nonconventional treatments,TREATMENT,PMC,,,,
PMC12071172,such investigations,TEST,PMC,,,,
PMC12071172,established treatment regimens,TREATMENT,PMC,C3534659,"Treatment planning and care coordination management for cancer, established patient with a change of regimen",HCPCS,Therapeutic or Preventive Procedure
PMC12071172,the underlying pathology,PROBLEM,PMC,,,,
PMC12071172,a holistic approach,TREATMENT,PMC,C0683249,holistic approach,CHV,Idea or Concept
PMC12071172,pancreatic cancer care,TREATMENT,PMC,,,,
PMC12071172,evidencebased clinical practices,TREATMENT,PMC,,,,
PMC12071172,clinical guidelines,TREATMENT,PMC,C0282451,Clinical Practice Guideline,MSH,Intellectual Product
PMC12071172,comprehensive and patientcentered management,TREATMENT,PMC,,,,
PMC7072019,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7072019,a nomogram,TEST,PMC,C1450294,Nomograms,MSH,Intellectual Product
PMC7072019,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7072019,pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC7072019,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC7072019,preoperatively detectable clinical parameters,PROBLEM,PMC,,,,
PMC7072019,extended pancreatectomy,TREATMENT,PMC,,,,
PMC7072019,complete tumor removal,TREATMENT,PMC,C2064986,craniotomy with complete removal of tumor,MEDCIN,Therapeutic or Preventive Procedure
PMC7072019,borderline resectable,PROBLEM,PMC,C4763597,Borderline Operable,NCI,Finding
PMC7072019,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC7072019,postoperative morbidity,PROBLEM,PMC,,,,
PMC7072019,mortality rates,PROBLEM,PMC,C0026565,Mortality Vital Statistics,MTH,Quantitative Concept
PMC7072019,longterm survival,TREATMENT,PMC,,,,
PMC7072019,pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC7072019,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC7072019,external validation,TEST,PMC,,,,
PMC7072019,a,TEST,PMC,,,,
PMC7072019,symptom,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7072019,tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC7072019,preoperative serum carbohydrate antigen,TEST,PMC,,,,
PMC7072019,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC7072019,planned surgery,TREATMENT,PMC,C0515633,Review planned surgery,NIC,Health Care Activity
PMC7072019,model performance,TEST,PMC,,,,
PMC7072019,discrimination,TEST,PMC,C2987623,Discrimination,MTH,Social Behavior
PMC7072019,calibration,TEST,PMC,C0006751,Calibration,MSH,Quantitative Concept
PMC7072019,the calibration plot,TEST,PMC,,,,
PMC7072019,external validation,TEST,PMC,,,,
PMC7072019,actual diseasespecific survival,PROBLEM,PMC,,,,
PMC7072019,significance differences,PROBLEM,PMC,,,,
PMC7072019,the developed nomogram,TEST,PMC,,,,
PMC7072019,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC7072019,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7072019,the developed nomogram,TEST,PMC,,,,
PMC7072019,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC7072019,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7072019,the nomogram,TEST,PMC,C1450294,Nomograms,MSH,Intellectual Product
PMC7072019,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7072019,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7072019,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC7072019,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC7072019,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,irinotecan infusion symptoms,TREATMENT,PMC,,,,
PMC7347036,slurred,TREATMENT,PMC,C0234518,Slurred speech,MTH,Finding
PMC7347036,clinical procedure,TREATMENT,PMC,C0586186,Clinical procedure report,MTH,Intellectual Product
PMC7347036,rare,PROBLEM,PMC,C0522498,Rare,MTH,Qualitative Concept
PMC7347036,a topoisomerase i inhibitor,TREATMENT,PMC,C0594374,Topoisomerase I Inhibitors,MTH,Pharmacologic Substance
PMC7347036,a cytotoxic chemotherapeutic agent,TREATMENT,PMC,C5670694,Cytotoxic Chemotherapeutic Agent,NCI,Pharmacologic Substance
PMC7347036,multiple malignancies,PROBLEM,PMC,C0346429,Multiple malignancy,SNOMEDCT_US,Neoplastic Process
PMC7347036,colorectal pancreatic cervical esophageal gastric and lung origin,PROBLEM,PMC,,,,
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,irinotecan,TREATMENT,PMC,C0123931,irinotecan,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7347036,effective management strategies,TREATMENT,PMC,C5934120,Effective weight management strategies,NOC,Finding
PMC7347036,pancreatic malignancy,PROBLEM,PMC,C1328479,Pancreatic Endocrine Carcinoma,MTH,Neoplastic Process
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,a chemotherapy regimen,TREATMENT,PMC,C0392920,Chemotherapy Regimen,MTH,Therapeutic or Preventive Procedure
PMC7347036,irinotecan,TREATMENT,PMC,C0123931,irinotecan,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7347036,firstline folfirinox,TREATMENT,PMC,,,,
PMC7347036,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,irinotecan,TREATMENT,PMC,C0123931,irinotecan,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,a transient adverse drug reaction,PROBLEM,PMC,,,,
PMC7347036,irinotecan infusion,TREATMENT,PMC,C4048962,5 ML irinotecan hydrochloride 20 MG/ML Injection,MTH,Clinical Drug
PMC7347036,pausing infusion,TREATMENT,PMC,,,,
PMC7347036,any longterm sequalae,PROBLEM,PMC,,,,
PMC7347036,physical and neurological examinations,TEST,PMC,C0027853,Neurologic Examination,MTH,Diagnostic Procedure
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,abnormalities,PROBLEM,PMC,C0000768,Congenital Abnormality,MTH,Congenital Abnormality
PMC7347036,distal extremity paresthesia,PROBLEM,PMC,,,,
PMC7347036,oxaliplatininduced acute neurotoxicity,PROBLEM,PMC,,,,
PMC7347036,diaphoresis,PROBLEM,PMC,C0700590,Increased sweating,MTH,Finding
PMC7347036,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC7347036,increased infusion time,TREATMENT,PMC,,,,
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,subsequent infusions,TREATMENT,PMC,C2890081,"Leakage of infusion catheter, subsequent encounter",MTH,Injury or Poisoning
PMC7347036,irinotecanassociated dysarthria,PROBLEM,PMC,,,,
PMC7347036,a rare mild and selflimiting phenomenon,PROBLEM,PMC,,,,
PMC7347036,withholding therapy,TREATMENT,PMC,C0205026,Withholding feed from animal,SNOMEDCT_VET,Therapeutic or Preventive Procedure
PMC7347036,extending irinotecan infusion time,TREATMENT,PMC,,,,
PMC7347036,dose reduction,TREATMENT,PMC,C1827449,Drug Tapering,MSH,Therapeutic or Preventive Procedure
PMC7347036,treatment discontinuation,TREATMENT,PMC,C2026123,central IV discontinuation,MEDCIN,Therapeutic or Preventive Procedure
PMC7347036,a practical clinical management strategy,TREATMENT,PMC,,,,
PMC7347036,recurrent dysarthria,PROBLEM,PMC,,,,
PMC7347036,irinotecan infusion,TREATMENT,PMC,C4048962,5 ML irinotecan hydrochloride 20 MG/ML Injection,MTH,Clinical Drug
PMC7347036,irinotecanassociated dysarthria,PROBLEM,PMC,,,,
PMC7347036,a rare adverse effect,PROBLEM,PMC,,,,
PMC7347036,the drug administration,TREATMENT,PMC,C0001559,Inhalation Drug Administration,MTH,Health Care Activity
PMC7347036,neurological manifestations,PROBLEM,PMC,C0027854,Neurologic Manifestations,MSH,Finding
PMC7347036,changes in speech,PROBLEM,PMC,C3693400,sudden unexplained change in speech,MEDCIN,Sign or Symptom
PMC7347036,difficulty swallowing,PROBLEM,PMC,C0011168,Deglutition Disorders,MTH,Disease or Syndrome
PMC7347036,enunciating words,PROBLEM,PMC,C1735543,"Spell unusual words after clearly enunciating them, if requested",NIC,Health Care Activity
PMC7347036,a thick tongue,PROBLEM,PMC,C0151610,Edema of the tongue,SNOMEDCT_US,Pathologic Function
PMC7347036,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC7347036,longterm sequelae,PROBLEM,PMC,,,,
PMC7347036,ct scan,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC7347036,various management measures,TREATMENT,PMC,,,,
PMC7347036,increasing infusion time,TREATMENT,PMC,,,,
PMC7347036,pausing infusion,TREATMENT,PMC,,,,
PMC7347036,our study,TEST,PMC,,,,
PMC7347036,the retrospective study design,TEST,PMC,,,,
PMC7347036,prospective trials,TEST,PMC,,,,
PMC7347036,pharmacokinetic studies,TEST,PMC,C0201734,Pharmacokinetic study,MTH,Research Activity
PMC7347036,extending infusion time,TREATMENT,PMC,,,,
PMC7347036,irinotecanassociated dysarthria,PROBLEM,PMC,,,,
PMC7347036,predisposing factors,PROBLEM,PMC,C0032946,Predisposing Factors,MSH,Temporal Concept
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,histologically proven,PROBLEM,PMC,,,,
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC4362006,symptom onset,PROBLEM,PMC,C4086878,Symptom Onset,MTH,Temporal Concept
PMC4362006,disease diagnosis,PROBLEM,PMC,C0338067,Disease/diagnosis,PDQ,Disease or Syndrome
PMC4362006,the common presenting symptoms,PROBLEM,PMC,C5911768,"Ensure personnel are familiar with signs, symptoms, and common onset presentations of persons exposed to bioterrorism agents",NIC,Health Care Activity
PMC4362006,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC4362006,discomfort,PROBLEM,PMC,C2364135,Discomfort,MTH,Sign or Symptom
PMC4362006,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC4362006,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC4362006,stage 4 pancreatic cancer,PROBLEM,PMC,,,,
PMC4362006,the most common metastatic,PROBLEM,PMC,,,,
PMC4362006,the survival rates,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC4362006,the multivariate analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC4362006,the staging,TEST,PMC,C0332305,With staging,SNOMEDCT_US,Functional Concept
PMC4362006,serum albumin level,TEST,PMC,C0728877,Serum albumin level,MTH,Laboratory or Test Result
PMC4362006,tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC4362006,the survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC4362006,endoscopic ultrasoundfineneedle,TEST,PMC,,,,
PMC4362006,the sensitivity rate,TEST,PMC,,,,
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,the disease in caucasians,PROBLEM,PMC,,,,
PMC4362006,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,current multimodality treatments,TREATMENT,PMC,,,,
PMC4362006,the regimens,TREATMENT,PMC,C0392920,Chemotherapy Regimen,MTH,Therapeutic or Preventive Procedure
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,a challenging disease,PROBLEM,PMC,C5213406,Fabry disease | DBS | Chemistry - non-challenge,LNC,Disease or Syndrome
PMC4362006,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4362006,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC4362006,the same regimen,TREATMENT,PMC,C4531724,"Previous rehabilitation therapy regimen (speech, occupational, &or physical therapy) ended, & regimen now resumed at exactly the same level for each discipline",LNC,Finding
PMC4362006,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7282238,a,PROBLEM,PMC,,,,
PMC7282238,great urgency,PROBLEM,PMC,,,,
PMC7282238,an effective drug,TREATMENT,PMC,C0678791,effective drug concentration,AOD,Quantitative Concept
PMC7282238,pancreatic cancerbetulinic,PROBLEM,PMC,,,,
PMC7282238,a major triterpene,PROBLEM,PMC,,,,
PMC7282238,several studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC7282238,its low toxicity,PROBLEM,PMC,,,,
PMC7282238,side effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC7282238,malaria,PROBLEM,PMC,C0024530,Malaria,MTH,Disease or Syndrome
PMC7282238,inflammation,PROBLEM,PMC,C0021368,Inflammation,MTH,Pathologic Function
PMC7282238,relevant studies,TEST,PMC,C2114265,pre-procedure checklist: relevant imaging studies confirmed in chart,MEDCIN,Health Care Activity
PMC7282238,betulinic,PROBLEM,PMC,C0053529,betulin,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7282238,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7282238,betulinic,PROBLEM,PMC,C0053529,betulin,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,the counting kit8 assay,TEST,PMC,,,,
PMC7282238,colony formation,PROBLEM,PMC,C0009385,Colony-Forming Units Assay,MSH,Laboratory Procedure
PMC7282238,transwell invasion assay,TEST,PMC,,,,
PMC7282238,wound healing assay,TEST,PMC,,,,
PMC7282238,flow cytometry,TEST,PMC,C0016263,Flow Cytometry,MSH,Laboratory Procedure
PMC7282238,xenograft nude mice model,TREATMENT,PMC,,,,
PMC7282238,betulinic acid,TREATMENT,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,the proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC7282238,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC7282238,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7282238,betulinic,PROBLEM,PMC,C0053529,betulin,RXNORM,"Organic Chemical, Pharmacologic Substance"
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,betulinic acid inhibited pancreatic cancer,PROBLEM,PMC,,,,
PMC7282238,betulinic acid,TEST,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,valuable anticancer agent,TREATMENT,PMC,,,,
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,betulinic acid,TREATMENT,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,betulinic acid,TEST,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,valuable anticancer agent,TREATMENT,PMC,,,,
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,betulinic acid,TREATMENT,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,cell and mouse experiments,TEST,PMC,,,,
PMC7282238,betulinic acid,TREATMENT,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,betulinic acid,TREATMENT,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7282238,betulinic acid inhibited,PROBLEM,PMC,,,,
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,betulinic acid induces apoptosis,PROBLEM,PMC,,,,
PMC7282238,betulinic acid acts,TREATMENT,PMC,,,,
PMC7282238,valuable anticancer agent,TREATMENT,PMC,,,,
PMC7282238,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7282238,betulinic acid,TREATMENT,PMC,C0053530,betulinic acid,MTH,"Organic Chemical, Pharmacologic Substance"
PMC10830814,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10830814,the most lethal neoplasms,PROBLEM,PMC,,,,
PMC10830814,the overall survival rate,TEST,PMC,,,,
PMC10830814,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10830814,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC10830814,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC10830814,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC10830814,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC10830814,systemic therapy,TREATMENT,PMC,C1515119,Systemic Therapy,NCI,Therapeutic or Preventive Procedure
PMC10830814,some cases radiotherapy,TREATMENT,PMC,,,,
PMC10830814,molecular targeted therapies,TREATMENT,PMC,C2699893,Molecular Targeted Therapy,MSH,Therapeutic or Preventive Procedure
PMC10830814,cancer control,TREATMENT,PMC,C1516188,Cancer Control,NCI,Health Care Activity
PMC10830814,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10830814,current treatment options,TREATMENT,PMC,C3693904,"options general patient not currently suitable for therapy, will reevaluate",MEDCIN,Functional Concept
PMC10830814,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC10830814,new treatment strategies,TREATMENT,PMC,,,,
PMC10830814,the moleculedirected approach,TREATMENT,PMC,,,,
PMC10830814,validated molecular biomarkers,TEST,PMC,,,,
PMC10830814,new biomarkers,TEST,PMC,,,,
PMC10830814,new clinical trials,TREATMENT,PMC,C5446612,Australia New Zealand Clinical Trial Registry,NCI,Intellectual Product
PMC10830814,several ongoing studies,TEST,PMC,,,,
PMC8726483,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8726483,malignant tumors in the pancreas,PROBLEM,PMC,C0346648,Malignant tumor of exocrine pancreas,SNOMEDCT_US,Neoplastic Process
PMC8726483,high mortality rates,PROBLEM,PMC,,,,
PMC8726483,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC8726483,surgical treatment,TREATMENT,PMC,C0543467,Operative Surgical Procedures,MTH,Therapeutic or Preventive Procedure
PMC8726483,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8726483,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC8726483,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8726483,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,a,TREATMENT,PMC,,,,
PMC8726483,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC8726483,liquid biopsies,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC8726483,certain cancers,PROBLEM,PMC,,,,
PMC8726483,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8726483,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8726483,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC8726483,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8726483,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,liver gastric and breast cancers,PROBLEM,PMC,,,,
PMC8726483,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,early cancer diagnosis,PROBLEM,PMC,C2350269,Early Diagnosis of Cancer,MSH,Diagnostic Procedure
PMC8726483,investigation,TEST,PMC,C1552578,Act Class - investigation,MTH,Intellectual Product
PMC8726483,potential biomarkers,PROBLEM,PMC,,,,
PMC8726483,disease onset,PROBLEM,PMC,C0277793,Onset of illness,MTH,Temporal Concept
PMC8726483,lifeextending treatments,TREATMENT,PMC,,,,
PMC8726483,treatment plans,TREATMENT,PMC,C0599880,Treatment Plan,MTH,Intellectual Product
PMC8726483,liquid biopsy,TEST,PMC,C4505151,Liquid Biopsy,MSH,Diagnostic Procedure
PMC8726483,an effective technique,TREATMENT,PMC,C1821022,Effective pushing techniques,NOC,Finding
PMC8726483,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8726483,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8726483,our detection methodologies,TEST,PMC,,,,
PMC8227498,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8227498,an aggressive disease,PROBLEM,PMC,C0543961,Sexual aggression disease or syndrome,SNM,Mental or Behavioral Dysfunction
PMC8227498,pharmacological properties,TREATMENT,PMC,,,,
PMC8227498,aromatherapy,TREATMENT,PMC,C0376547,Aromatherapy,MTH,Therapeutic or Preventive Procedure
PMC8227498,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8227498,essential oil,TREATMENT,PMC,C0028910,"Oils, Volatile",MSH,Organic Chemical
PMC8227498,panc1 human pancreatic cancer cell line,PROBLEM,PMC,,,,
PMC8227498,the cell growth inhibitory concentration,TEST,PMC,,,,
PMC8227498,selective index,TEST,PMC,C1318232,Protein selectivity index result,MTH,Laboratory or Test Result
PMC8227498,eol analyses,TEST,PMC,,,,
PMC8227498,combination index ci analysis,TEST,PMC,,,,
PMC8227498,moderate synergism,PROBLEM,PMC,,,,
PMC8227498,eol,TREATMENT,PMC,C3883822,"EOL-1 protein, C elegans",MSH,"Amino Acid, Peptide, or Protein"
PMC8227498,2 deoxydglucose 2dg treatments,TREATMENT,PMC,,,,
PMC8227498,the treatments,TREATMENT,PMC,C1718338,Skin treatments,LNC,Therapeutic or Preventive Procedure
PMC8227498,panc1 cells,PROBLEM,PMC,,,,
PMC8227498,eol,TREATMENT,PMC,C3883822,"EOL-1 protein, C elegans",MSH,"Amino Acid, Peptide, or Protein"
PMC8227498,eol2dg,TEST,PMC,,,,
PMC8227498,depolarization of mitochondrial membrane potential,PROBLEM,PMC,,,,
PMC8227498,cell growth arrest,PROBLEM,PMC,,,,
PMC8227498,apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC8227498,the molecular mechanism,PROBLEM,PMC,C0872220,molecular mechanics,CSP,Spatial Concept
PMC8227498,the antiproliferative effect,PROBLEM,PMC,,,,
PMC8227498,pronounced upregulation,PROBLEM,PMC,,,,
PMC8227498,quantitative mrna expression analysis,TEST,PMC,C5884297,"Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) of genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma",CPT,Diagnostic Procedure
PMC8227498,the current data,TEST,PMC,C1716609,Can recall current season:Find:Pt:^Patient:Ord:MDS,LNC,Clinical Attribute
PMC8227498,two antiproliferative agents,TREATMENT,PMC,,,,
PMC8227498,eol and,TREATMENT,PMC,C3883822,"EOL-1 protein, C elegans",MSH,"Amino Acid, Peptide, or Protein"
PMC8227498,therapeutic treatments,TREATMENT,PMC,C0032202,Therapeutic plateletpheresis,MTH,Therapeutic or Preventive Procedure
PMC8227498,potentiating agents,TREATMENT,PMC,C3544186,Exposure to potentially toxic agent,MDR,Injury or Poisoning
PMC8227498,conventional therapy,TREATMENT,PMC,C2945704,Conventional Treatment,MTH,Therapeutic or Preventive Procedure
PMC8227498,human pancreatic cancer,PROBLEM,PMC,C4286572,"IVD Panels, Human Genetics, Cancer, Familial, Pancreatic, Mutation",UMD,Medical Device
PMC8227498,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8227498,eol fromg,TEST,PMC,,,,
PMC8227498,atroviridisin,TREATMENT,PMC,,,,
PMC8227498,panc1 cells,PROBLEM,PMC,,,,
PMC8227498,ldh,TEST,PMC,C0022917,Lactate Dehydrogenase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8227498,mmp,TREATMENT,PMC,C0919336,MMP gene,MTH,Gene or Genome
PMC8227498,apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC8227498,cell cycle arrest,PROBLEM,PMC,C1155873,Cell Cycle Arrest,MTH,Cell Function
PMC8227498,the s phase,TEST,PMC,C0080129,S Phase,MSH,Temporal Concept
PMC8227498,the mrna expression analyses,TEST,PMC,C4537676,multianalyte assays with algorithmic analyses for oncology with real-time RT-PCR mRNA expression analysis,MEDCIN,Laboratory Procedure
PMC8227498,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8227498,2dg,TREATMENT,PMC,C3530018,cypate-2DG,MSH,"Organic Chemical, Pharmacologic Substance"
PMC8227498,promoting panc1 cell death,PROBLEM,PMC,,,,
PMC6817490,intraabdominalclostridium perfringens,PROBLEM,PMC,,,,
PMC6817490,liver infection,PROBLEM,PMC,C1112211,Hepatic Infection,MTH,Disease or Syndrome
PMC6817490,immunodeficiency,PROBLEM,PMC,C0021051,Immunologic Deficiency Syndromes,MTH,Disease or Syndrome
PMC6817490,various factors,PROBLEM,PMC,,,,
PMC6817490,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC6817490,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC6817490,organ transplantation,TREATMENT,PMC,C0029216,Organ Transplantation,MTH,Therapeutic or Preventive Procedure
PMC6817490,grampositive bacilli,PROBLEM,PMC,,,,
PMC6817490,septicemia,PROBLEM,PMC,C0036690,Septicemia,MTH,Disease or Syndrome
PMC6817490,gasforming liver damage,PROBLEM,PMC,,,,
PMC6817490,intravascular hemolysis,PROBLEM,PMC,C0235574,Intravascular hemolysis,MTH,Finding
PMC6817490,the episode,PROBLEM,PMC,C0332189,Episode of,MTH,Temporal Concept
PMC6817490,a high mortality rate,PROBLEM,PMC,,,,
PMC6817490,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC6817490,common bile duct stenting,TREATMENT,PMC,C5441365,Common bile duct sphincterotomy and stenting,CCSR_ICD10PCS,Therapeutic or Preventive Procedure
PMC6817490,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC6817490,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC6817490,abdominal computed tomography ct,TEST,PMC,C3171951,Deprecated PhenX measure - computed tomography (CT) of the abdominal organs,MTH,Clinical Attribute
PMC6817490,gascontaining lesions in the liver,PROBLEM,PMC,,,,
PMC6817490,blood culture,TEST,PMC,C0200949,Blood culture,MTH,Laboratory Procedure
PMC6817490,admission,TEST,PMC,C0184666,Hospital admission,MTH,Health Care Activity
PMC6817490,clostridium perfringensliver infection,PROBLEM,PMC,,,,
PMC6817490,a severe prognosis,PROBLEM,PMC,,,,
PMC6817490,effective treatment,TREATMENT,PMC,C0510269,Discuss effective and ineffective methods of prior treatment,NIC,Health Care Activity
PMC6817490,clostridium perfringensliver infection,PROBLEM,PMC,,,,
PMC6817490,a severe prognosis,PROBLEM,PMC,,,,
PMC6817490,effective treatment,TREATMENT,PMC,C0510269,Discuss effective and ineffective methods of prior treatment,NIC,Health Care Activity
PMC6320463,seronegative autoimmune pancreatitis,PROBLEM,PMC,,,,
PMC6320463,a pancreatic focal lesion,PROBLEM,PMC,,,,
PMC6320463,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6320463,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC6320463,the endoscopic ultrasoundguided biopsies,TEST,PMC,,,,
PMC6320463,the pancreatic mass,PROBLEM,PMC,C2220607,computed tomography of abdomen: pancreatic mass,MEDCIN,Finding
PMC6320463,malignant cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC6320463,the pancreatic swelling,PROBLEM,PMC,,,,
PMC6320463,repeat imaging,TEST,PMC,C3476448,"Repeated disturbing memories, thoughts, or images of a stressful experience from the past in the last Mo",LNC,Finding
PMC6320463,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6320463,steroids,TREATMENT,PMC,C0038317,Steroids,MTH,"Organic Chemical, Pharmacologic Substance"
PMC6320463,corticosteroid treatment,TREATMENT,PMC,C2095490,corticosteroid injection,MEDCIN,Pharmacologic Substance
PMC6320463,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6320463,laboratory parameters,TEST,PMC,,,,
PMC6320463,a pancreatic mass,PROBLEM,PMC,C0877425,Mass of pancreas,SNOMEDCT_US,Finding
PMC6320463,seronegative aip,PROBLEM,PMC,,,,
PMC6320463,a pancreatic mass,PROBLEM,PMC,C0877425,Mass of pancreas,SNOMEDCT_US,Finding
PMC6320463,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6320463,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6320463,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC6320463,focal aip,PROBLEM,PMC,,,,
PMC6320463,pancreatic malignancy,PROBLEM,PMC,C1328479,Pancreatic Endocrine Carcinoma,MTH,Neoplastic Process
PMC6320463,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6320463,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6320463,their treatment,TREATMENT,PMC,C5447629,A Goal of Palliative Care is to Help People Better Understand Their Treatment Options,NCI,Intellectual Product
PMC8579871,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8579871,a difficult tumor,PROBLEM,PMC,,,,
PMC8579871,typical symptoms,PROBLEM,PMC,C3272268,Typical Coronary Artery Disease Symptom,NCI,Sign or Symptom
PMC8579871,effective screening methods,TEST,PMC,,,,
PMC8579871,this malignancy,PROBLEM,PMC,,,,
PMC8579871,a low survival rate,PROBLEM,PMC,,,,
PMC8579871,emodin,TREATMENT,PMC,C0013982,Emodin,MSH,"Organic Chemical, Pharmacologic Substance, Biologically Active Substance"
PMC8579871,an economical natural product,TREATMENT,PMC,,,,
PMC8579871,effective treatment,TREATMENT,PMC,C0510269,Discuss effective and ineffective methods of prior treatment,NIC,Health Care Activity
PMC8579871,cancer treatment,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC8579871,magnetic nanoparticles,TREATMENT,PMC,C3875909,Magnetic nanoparticle tracer,SNOMEDCT_US,"Indicator, Reagent, or Diagnostic Aid"
PMC8579871,multiplexed imaging,TEST,PMC,C5909513,Multiplexed Tissue Imaging,NCI,Diagnostic Procedure
PMC8579871,targeted therapy,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC8579871,functional materials,TREATMENT,PMC,C5411076,"X-ray study of swallowing function with contrast material, with videoradiography",CPT,Diagnostic Procedure
PMC8579871,fluorescent dyes,TREATMENT,PMC,C0016320,Fluorescent Dyes,MTH,"Indicator, Reagent, or Diagnostic Aid"
PMC8579871,therapeutic agents,TREATMENT,PMC,C0304231,Therapeutic agent,MTH,Manufactured Object
PMC8579871,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8579871,a multifunctional theranostic nanoplatform,TREATMENT,PMC,,,,
PMC8579871,pc diagnosis,TEST,PMC,,,,
PMC8579871,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC8579871,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8579871,emoloaded cy7functionalized pegcoated fe3o4fe3o4pegcy7emo,TREATMENT,PMC,,,,
PMC8579871,hydrodynamic size,PROBLEM,PMC,,,,
PMC8579871,zeta potentials,TEST,PMC,C0597697,Zeta Potential,NCI,Phenomenon or Process
PMC8579871,fe3o4pegcy7emo,TREATMENT,PMC,,,,
PMC8579871,fluorescence imaging,TEST,PMC,C0430876,Fluorescence Imaging,MSH,Diagnostic Procedure
PMC8579871,therapeutic treatment,TREATMENT,PMC,C3525442,Therapeutic radiology treatment planning,CPT,Therapeutic or Preventive Procedure
PMC8579871,fe3o4pegcy7emo nanoparticles,TREATMENT,PMC,,,,
PMC8579871,a core size,TEST,PMC,C4231048,Increase in the ratio between the size of the matrix and the core of the specific granules seen on EM,OMIM,Finding
PMC8579871,fimri properties,TEST,PMC,,,,
PMC8579871,biotransmission electron microscopy,TEST,PMC,,,,
PMC8579871,fe3o4pegcy7emo nanoparticles,TREATMENT,PMC,,,,
PMC8579871,prussian blue staining,TEST,PMC,C1294004,Prussian blue stain method,MTH,Laboratory Procedure
PMC8579871,bxpc3 cells,PROBLEM,PMC,,,,
PMC8579871,a stronger phagocytic ability,PROBLEM,PMC,,,,
PMC8579871,hterthpne cells,TEST,PMC,,,,
PMC8579871,fe3o4pegcy7emo,TREATMENT,PMC,,,,
PMC8579871,bxpc3 cells,TREATMENT,PMC,,,,
PMC8579871,fe3o4peg,TREATMENT,PMC,,,,
PMC8579871,emo,TREATMENT,PMC,C1170250,Emo Cort,MMSL,"Organic Chemical, Pharmacologic Substance"
PMC8579871,the hemolysis experiment,TEST,PMC,,,,
PMC8579871,fe3o4pegcy7emo,TREATMENT,PMC,,,,
PMC8579871,vivo experiments,TEST,PMC,,,,
PMC8579871,in vivo analysis,TEST,PMC,C0412502,In vivo neutron activation analysis,SNOMEDCT_US,Diagnostic Procedure
PMC8579871,fe3o4pegcy7emo,TEST,PMC,,,,
PMC8579871,fimri dualmodal imaging,TEST,PMC,,,,
PMC8579871,targeted therapy,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC8579871,pancreatic tumor,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC8579871,fe3o4pegcy7emo,TREATMENT,PMC,,,,
PMC8579871,a potential theranostic nanoplatform,TREATMENT,PMC,,,,
PMC8579871,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8579871,fe3o4pegcy7emo,TREATMENT,PMC,,,,
PMC8579871,a potential theranostic nanoplatform,TREATMENT,PMC,,,,
PMC8579871,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,the deadliest cancers,PROBLEM,PMC,,,,
PMC3672012,effective treatments,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,the current standardofcare chemotherapy,TREATMENT,PMC,,,,
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC3672012,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC3672012,the inflammatory response,PROBLEM,PMC,C1155266,Inflammatory Response,NCI,Pathologic Function
PMC3672012,tumorigenesis,PROBLEM,PMC,C0596263,Carcinogenesis,MTH,Neoplastic Process
PMC3672012,gemcitabineinduced nfb activation,PROBLEM,PMC,,,,
PMC3672012,chemoresistance,PROBLEM,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC3672012,nfb suppression,PROBLEM,PMC,,,,
PMC3672012,the novel inhibitor dimethylaminoparthenolide,TREATMENT,PMC,,,,
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,a chemoprevention trial,TREATMENT,PMC,,,,
PMC3672012,the mutant,PROBLEM,PMC,C0678941,Gene Mutant,MTH,Gene or Genome
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,treatment groups,TREATMENT,PMC,C2095591,discussed food groups,MEDCIN,Health Care Activity
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,the combination dmaptgemcitabine,TREATMENT,PMC,,,,
PMC3672012,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC3672012,ill health,PROBLEM,PMC,C2319432,twin sister in ill health,MEDCIN,Finding
PMC3672012,plasma cytokine levels,TEST,PMC,,,,
PMC3672012,a bioplex immunoassay,TEST,PMC,,,,
PMC3672012,statistical tests,TEST,PMC,C0237913,Statistical Test,NCI,Intellectual Product
PMC3672012,logrank test,TEST,PMC,,,,
PMC3672012,anova,TEST,PMC,C1334891,NOVA2 gene,MTH,Gene or Genome
PMC3672012,dunnetts posttest,TEST,PMC,,,,
PMC3672012,studentsttest,TEST,PMC,,,,
PMC3672012,fisher exact test,TEST,PMC,C1708064,Fisher's Exact Test,NCI,Intellectual Product
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,the combination dmaptgemcitabine,TREATMENT,PMC,,,,
PMC3672012,median survival,TREATMENT,PMC,C2986586,Median Survival Time,NCI,Temporal Concept
PMC3672012,pancreatic adenocarcinomas,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC3672012,the dmaptgemcitabine combination,TREATMENT,PMC,,,,
PMC3672012,significantly decreased tumor size,PROBLEM,PMC,,,,
PMC3672012,metastasis to the liver,PROBLEM,PMC,C3494607,Metastasis to liver from adenocarcinoma,MEDCIN,Neoplastic Process
PMC3672012,significant differences,PROBLEM,PMC,,,,
PMC3672012,premalignant pancreatic lesions,PROBLEM,PMC,,,,
PMC3672012,the treatment groups,TREATMENT,PMC,C2095591,discussed food groups,MEDCIN,Health Care Activity
PMC3672012,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC3672012,preneoplasia,PROBLEM,PMC,,,,
PMC3672012,low grade pancreatic lesions,PROBLEM,PMC,,,,
PMC3672012,higher grade lesions,PROBLEM,PMC,,,,
PMC3672012,gemcitabine treatment,TREATMENT,PMC,,,,
PMC3672012,the inflammatory cytokines,TEST,PMC,C5975258,Elevated inflammatory cytokines,OMIM,Finding
PMC3672012,il1,TEST,PMC,,,,
PMC3672012,il17 in mouse plasma,TEST,PMC,,,,
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,dmaptgemcitabine,TREATMENT,PMC,,,,
PMC3672012,the inflammatory,TEST,PMC,C0333348,Inflammatory,NCI,Functional Concept
PMC3672012,monocyte chemotactic protein1,TEST,PMC,,,,
PMC3672012,macrophage inflammatory protein1 beta,TEST,PMC,,,,
PMC3672012,eotaxin,TREATMENT,PMC,C0250604,Eotaxin,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC3672012,tumor necrosis factoralpha,TEST,PMC,,,,
PMC3672012,nfb,TEST,PMC,C0663914,IkappaB kinase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC3672012,further evaluation,TEST,PMC,C2068950,work restrictions decision pending further evaluation,MEDCIN,Finding
PMC3672012,agents,TREATMENT,PMC,C0003451,Antiviral Agents,MTH,Pharmacologic Substance
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,further evaluation,TEST,PMC,C2068950,work restrictions decision pending further evaluation,MEDCIN,Finding
PMC3672012,agents,TREATMENT,PMC,C0003451,Antiviral Agents,MTH,Pharmacologic Substance
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,survival statistics,TEST,PMC,,,,
PMC3672012,many cancers,PROBLEM,PMC,C3172900,How many full sisters do you have:Num:Pt:^Patient:Qn:Carolina Breast Cancer Study,LNC,Clinical Attribute
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,the deadliest diseases,PROBLEM,PMC,,,,
PMC3672012,a very poor survival rate,PROBLEM,PMC,,,,
PMC3672012,effective treatments,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,inheritable risk factors,PROBLEM,PMC,,,,
PMC3672012,premalignant pancreatic lesions,PROBLEM,PMC,,,,
PMC3672012,multiple epidemiologic risk factors,PROBLEM,PMC,,,,
PMC3672012,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC3672012,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC3672012,earlier surgical intervention,TREATMENT,PMC,,,,
PMC3672012,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC3672012,agents,TREATMENT,PMC,C0003451,Antiviral Agents,MTH,Pharmacologic Substance
PMC3672012,the progression of disease,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3672012,curative treatments,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC3672012,effective treatment strategies,TREATMENT,PMC,C4716841,Strategies to decrease treatment regimen side effects,NOC,Finding
PMC3672012,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,median survival,TREATMENT,PMC,C2986586,Median Survival Time,NCI,Temporal Concept
PMC3672012,decrease tumor size,PROBLEM,PMC,,,,
PMC3672012,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC3672012,metastasis to the liver inlslkrasg12d,PROBLEM,PMC,,,,
PMC3672012,further evaluation,TEST,PMC,C2068950,work restrictions decision pending further evaluation,MEDCIN,Finding
PMC3672012,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3672012,dmapt,TREATMENT,PMC,C2001850,LC-1 compound,MSH,Organic Chemical
PMC3672012,related agents,TREATMENT,PMC,C3653583,HORMONES AND RELATED AGENTS,ATC,"Pharmacologic Substance, Hormone"
PMC3672012,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC3672012,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,physical and psychosocial symptom burden,PROBLEM,PMC,,,,
PMC6350289,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6350289,palliative care referral,TREATMENT,PMC,C0584096,Referral to palliative care service,SNOMEDCT_US,Health Care Activity
PMC6350289,aggressive cancer care,TREATMENT,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,a retrospective cohort analysis,TEST,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,aggressive cancer care,TREATMENT,PMC,,,,
PMC6350289,chemotherapy use,TREATMENT,PMC,C5415943,"Initiation of prolonged chemotherapy infusion, more than 8 hours, requiring use of portable pump",CPT,Therapeutic or Preventive Procedure
PMC6350289,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC6350289,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC6350289,early and late pcr,PROBLEM,PMC,,,,
PMC6350289,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC6350289,a late pcr,TEST,PMC,,,,
PMC6350289,an early pcr,TEST,PMC,,,,
PMC6350289,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC6350289,early pcr,TEST,PMC,,,,
PMC6350289,late pcr,TEST,PMC,,,,
PMC6350289,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6350289,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6350289,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC6350289,a late pcr,TEST,PMC,,,,
PMC6350289,an early pcr,TEST,PMC,,,,
PMC6350289,pcr status,PROBLEM,PMC,C5204356,HPV Status by PCR,NCI,Diagnostic Procedure
PMC6350289,early pcr,TREATMENT,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,inappropriate care,TREATMENT,PMC,C4061742,Inappropriate breast care,NANDA-I,Finding
PMC6350289,modern cancer care,TREATMENT,PMC,,,,
PMC6350289,the term aggressive cancer care,TREATMENT,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,early,TREATMENT,PMC,C1279919,Early,MTH,Temporal Concept
PMC6350289,early pcr,TREATMENT,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,inappropriate care,TREATMENT,PMC,C4061742,Inappropriate breast care,NANDA-I,Finding
PMC6350289,modern cancer care,TREATMENT,PMC,,,,
PMC6350289,the term aggressive cancer care,TREATMENT,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,early,TREATMENT,PMC,C1279919,Early,MTH,Temporal Concept
PMC6350289,international studies,TEST,PMC,C1512890,International Breast Cancer Study Group,NCI,Health Care Related Organization
PMC6350289,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,futile treatment,TREATMENT,PMC,C0242650,Futile Treatment,MSH,Health Care Activity
PMC6350289,inappropriate care,TREATMENT,PMC,C4061742,Inappropriate breast care,NANDA-I,Finding
PMC6350289,aggressive cancer care,TREATMENT,PMC,,,,
PMC6350289,significant symptoms,PROBLEM,PMC,C5436457,No significant respiratory symptoms,OMIM,Finding
PMC6350289,modern cancer care,TREATMENT,PMC,,,,
PMC6350289,the term aggressive cancer care,TREATMENT,PMC,,,,
PMC6350289,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6350289,significant symptomology,PROBLEM,PMC,,,,
PMC6350289,acute services,TREATMENT,PMC,C0242934,Acute Pain Service,MSH,Health Care Related Organization
PMC6350289,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC6350289,aggressive treatments,TREATMENT,PMC,C0510615,"Encourage early, aggressive treatment for endometriosis",NIC,Therapeutic or Preventive Procedure
PMC6350289,palliative care integration,TREATMENT,PMC,C4305044,Integrated Palliative care Outcome Scale Patient Version (3 day recall period),SNOMEDCT_US,Intellectual Product
PMC6350289,alternate solutions,TREATMENT,PMC,C4710536,Inform patient of alternative views or solutions in a clear and supportive manner,NIC,Health Care Activity
PMC6350289,healthcare priorities,TREATMENT,PMC,C4263478,"Consent for healthcare agent to deviate from stated goals, preferences and priorities",LNC,Finding
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,clinical symptoms,PROBLEM,PMC,C3483785,Clinical sepsis symptoms present,LNC,Finding
PMC9893084,advanced disease,PROBLEM,PMC,C0679246,advanced disease,AOD,Finding
PMC9893084,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,risk groups,PROBLEM,PMC,C0684030,high-risk group,CHV,Population Group
PMC9893084,preclinical risk factors,PROBLEM,PMC,,,,
PMC9893084,surveillance strategies,TREATMENT,PMC,C5912527,"Use technology strategies such as pressure pads, locating devices, door alarms, surveillance, and wandering detection devices for elopement concerns",NIC,Health Care Activity
PMC9893084,hereditary genetic syndromes,PROBLEM,PMC,C5885458,Hereditary congenital myasthenic syndrome multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC9893084,close surveillance,TEST,PMC,,,,
PMC9893084,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,asymptomatic individuals,PROBLEM,PMC,C2977627,Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.,ICD10CM,Finding
PMC9893084,false positive tests,PROBLEM,PMC,C0740290,HIV test false positive,MDR,Finding
PMC9893084,cancer biomarkers,PROBLEM,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC9893084,omics technology,TREATMENT,PMC,,,,
PMC9893084,a clinical breakthrough,PROBLEM,PMC,,,,
PMC9893084,biomarker studies,TEST,PMC,C2827062,Biomarker Imaging Quality of Life Studies Funding Program,NCI,Governmental or Regulatory Activity
PMC9893084,early cancer detection,PROBLEM,PMC,C2607925,Early Detection of Cancer,MTH,Health Care Activity
PMC9893084,biopsies,TEST,PMC,C0005558,Biopsy,MTH,Diagnostic Procedure
PMC9893084,research studies,TEST,PMC,C0681814,research study,MTH,Research Activity
PMC9893084,the biomarker,TEST,PMC,C5856752,Monitoring Biomarker,NCI,Clinical Attribute
PMC9893084,a preclinical asymptomatic,PROBLEM,PMC,,,,
PMC9893084,new technologies,TREATMENT,PMC,C0683887,new technology,CHV,Intellectual Product
PMC9893084,imagebased radiomics approaches,TEST,PMC,,,,
PMC9893084,artificial intelligence,TREATMENT,PMC,C0003916,Artificial Intelligence,MSH,Occupation or Discipline
PMC9893084,various body fluids,TREATMENT,PMC,C0513559,"Monitor output of various body fluids (e.g., urine, nasogastric drainage, and chest tube)",NIC,Health Care Activity
PMC9893084,blood or urine,TEST,PMC,C3870600,Blood or Urine,LNC,Body Substance
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,various body fluids,TREATMENT,PMC,C0513559,"Monitor output of various body fluids (e.g., urine, nasogastric drainage, and chest tube)",NIC,Health Care Activity
PMC9893084,blood or urine,TEST,PMC,C3870600,Blood or Urine,LNC,Body Substance
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9893084,pdac,PROBLEM,PMC,,,,
PMC9893084,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9893084,clinical cohort,TEST,PMC,C5668315,Clinical Cohort Unique Identifier,NCI,Intellectual Product
PMC9893084,untimely deaths,PROBLEM,PMC,,,,
PMC9893084,this dreaded disease,PROBLEM,PMC,,,,
PMC9893084,earlystage pancreatic cancer,PROBLEM,PMC,,,,
PMC9893084,appropriate surgery,TREATMENT,PMC,C4709612,"Remove prosthesis before surgery, as appropriate",NIC,Health Care Activity
PMC9893084,multimodal management,TREATMENT,PMC,C5229110,Multimodal pain management was used,HCPCS,Therapeutic or Preventive Procedure
PMC9563634,new onset diabetes,PROBLEM,PMC,C3896643,New Onset Diabetes After Transplant,NCI,Disease or Syndrome
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,newonset diabetes cases,PROBLEM,PMC,,,,
PMC9563634,testing,TEST,PMC,C0039593,Testing,MTH,Functional Concept
PMC9563634,additional risk factors,PROBLEM,PMC,,,,
PMC9563634,further screening,TEST,PMC,C3844494,"Yes, patient was screened with a different standardized, validated assessment and the patient meets criteria for further evaluation for depression.",LNC,Finding
PMC9563634,22 studies,TEST,PMC,C2074589,chromosome studies Philadelphia,MEDCIN,Laboratory Procedure
PMC9563634,additional risk factors,PROBLEM,PMC,,,,
PMC9563634,the individual risk factor,PROBLEM,PMC,C2067198,"risk factor counseling individual, 45 minutes",MEDCIN,Therapeutic or Preventive Procedure
PMC9563634,a metaanalysis,TEST,PMC,C0920317,Meta-Analysis (statistical procedure),MTH,Research Activity
PMC9563634,several risk factors,PROBLEM,PMC,,,,
PMC9563634,pancreatic cancer cases,PROBLEM,PMC,,,,
PMC9563634,11 studies,TEST,PMC,C3510338,"Nerve conduction, 11-12 studies",CPT,Diagnostic Procedure
PMC9563634,newonset diabetes patients,PROBLEM,PMC,,,,
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,pancreatitis,PROBLEM,PMC,C0030305,Pancreatitis,MTH,Disease or Syndrome
PMC9563634,9 studies,TEST,PMC,C3510337,"Nerve conduction, 9-10 studies",CPT,Diagnostic Procedure
PMC9563634,gallstones,PROBLEM,PMC,C0947622,Cholecystolithiasis,MTH,Disease or Syndrome
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,highrapidly increasing glycemia,PROBLEM,PMC,,,,
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,more insulin use,TREATMENT,PMC,,,,
PMC9563634,5 studies,TEST,PMC,C3510335,"Nerve conduction, 5-6 studies",CPT,Diagnostic Procedure
PMC9563634,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC9563634,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,targeted screening,TEST,PMC,C0679817,targeted screening,AOD,Therapeutic or Preventive Procedure
PMC9563634,newonset diabetes,PROBLEM,PMC,,,,
PMC9563634,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,observational studies,TEST,PMC,C1518527,Observational Study,MTH,Research Activity
PMC9563634,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC9563634,developing pdac,PROBLEM,PMC,,,,
PMC9563634,metaanalysis,TEST,PMC,C0920317,Meta-Analysis (statistical procedure),MTH,Research Activity
PMC9563634,pooled,PROBLEM,PMC,C1709595,Pooled Sample,MTH,Body Substance
PMC9563634,twentytwo studies,TEST,PMC,,,,
PMC9563634,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC9563634,pdac,TEST,PMC,,,,
PMC9563634,pdac cases,PROBLEM,PMC,,,,
PMC9563634,11 studies,TEST,PMC,C3510338,"Nerve conduction, 11-12 studies",CPT,Diagnostic Procedure
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,pancreatitis,PROBLEM,PMC,C0030305,Pancreatitis,MTH,Disease or Syndrome
PMC9563634,9 studies,TEST,PMC,C3510337,"Nerve conduction, 9-10 studies",CPT,Diagnostic Procedure
PMC9563634,cholecystitis,PROBLEM,PMC,C0008325,Cholecystitis,MTH,Disease or Syndrome
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,highrapidly increasing glycemia,PROBLEM,PMC,,,,
PMC9563634,4 studies,TEST,PMC,C3510334,"Nerve conduction, 3-4 studies",CPT,Diagnostic Procedure
PMC9563634,more insulin use,TREATMENT,PMC,,,,
PMC9563634,5 studies,TEST,PMC,C3510335,"Nerve conduction, 5-6 studies",CPT,Diagnostic Procedure
PMC9563634,9 studies,TEST,PMC,C3510337,"Nerve conduction, 9-10 studies",CPT,Diagnostic Procedure
PMC9563634,ci,TEST,PMC,C0700085,Curie,MTH,Quantitative Concept
PMC9563634,9 studies,TEST,PMC,C3510337,"Nerve conduction, 9-10 studies",CPT,Diagnostic Procedure
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,gallstonespancreatitis,PROBLEM,PMC,,,,
PMC9563634,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9563634,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC9563634,rapid increase in glycemia,PROBLEM,PMC,,,,
PMC9563634,the identified risk factors,PROBLEM,PMC,C1821736,Identifies risk factors,NOC,Finding
PMC9563634,a diagnostic model,TEST,PMC,C0204139,Diagnostic model construction,SNMI,Diagnostic Procedure
PMC9563634,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9563634,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,prospective study,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC9563634,four prospective studies,TEST,PMC,,,,
PMC9563634,nod,TREATMENT,PMC,C0751781,Dentatorubral-Pallidoluysian Atrophy,MTH,Disease or Syndrome
PMC9563634,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9563634,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC9563634,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9563634,our analysis,TEST,PMC,,,,
PMC9563634,the mean bmi,TEST,PMC,C4264664,Activity metabolic rate/Standard resting metabolic rate^^adjusted for age+sex+race+BMI:RelEngRat:1M^mean:^Patient:Qn:Estimated,LNC,Clinical Attribute
PMC9563634,pancreatic cancer cases,PROBLEM,PMC,,,,
PMC9563634,recent weight loss,PROBLEM,PMC,C2126067,rapid recent weight loss,MEDCIN,Sign or Symptom
PMC9563634,this metaanalysis,TEST,PMC,,,,
PMC9563634,these risk factors,PROBLEM,PMC,,,,
PMC9563634,nondiabetic pdac,PROBLEM,PMC,,,,
PMC9563634,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC9563634,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,targeted testing,TEST,PMC,C1302985,Dissimilar target test,SNOMEDCT_US,Diagnostic Procedure
PMC9563634,statistical model fitting,TEST,PMC,,,,
PMC9563634,our analysis,TEST,PMC,,,,
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,pancreatitischolecystitis,PROBLEM,PMC,,,,
PMC9563634,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC9563634,rapid increase in glycemianecessity,PROBLEM,PMC,,,,
PMC9563634,insulin,TREATMENT,PMC,C0021641,Insulin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC9563634,a tendency to lower lipids,PROBLEM,PMC,,,,
PMC9563634,newly diagnosed diabetes,PROBLEM,PMC,C1320655,Newly diagnosed diabetes,SNOMEDCT_US,Finding
PMC9563634,such models,TEST,PMC,,,,
PMC9563634,those risk factors,PROBLEM,PMC,,,,
PMC9563634,screening programs,TEST,PMC,C4704706,Diagnostic Screening Programs,MSH,Diagnostic Procedure
PMC9563634,diagnose cancer,PROBLEM,PMC,C4733575,newly diagnosed non-small cell lung cancer,PDQ,Neoplastic Process
PMC9563634,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC9563634,survival extension,TREATMENT,PMC,,,,
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,pancreatic cancer screening,PROBLEM,PMC,,,,
PMC9563634,falsepositive results,PROBLEM,PMC,,,,
PMC9563634,further investigations,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC9563634,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9563634,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9563634,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC9563634,a biomarker test,TEST,PMC,C4477079,Abnormal cardiac biomarker test,HPO,Finding
PMC9563634,several studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC9563634,testing,TEST,PMC,C0039593,Testing,MTH,Functional Concept
PMC9563634,a scoring,TEST,PMC,C4291662,Linear Scoring,HL7V3.0,Intellectual Product
PMC9563634,a scoring model,TREATMENT,PMC,C4296665,Summed stress score.20 segment model,LNC,Finding
PMC9563634,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC9563634,these regional,PROBLEM,PMC,,,,
PMC9563634,pdac,PROBLEM,PMC,,,,
PMC9563634,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9563634,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9563634,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9563634,a much lower bmi,PROBLEM,PMC,,,,
PMC9563634,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9563634,a score,TEST,PMC,C0449820,Score,MTH,Finding
PMC9563634,a,TEST,PMC,,,,
PMC5472554,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5472554,cancerrelated death,PROBLEM,PMC,,,,
PMC5472554,clinical symptoms,PROBLEM,PMC,C3483785,Clinical sepsis symptoms present,LNC,Finding
PMC5472554,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC5472554,metastatic mutations,PROBLEM,PMC,C5206129,Metastatic BRCA Hereditary Breast Carcinoma,NCI,Neoplastic Process
PMC5472554,such genetic diversity,PROBLEM,PMC,,,,
PMC5472554,disease progression,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC5472554,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC5472554,digital pathology imaging,TEST,PMC,,,,
PMC5472554,early pc detection,PROBLEM,PMC,,,,
PMC5472554,treatment sensitivity,TREATMENT,PMC,C4745077,Treatment-sensitive HIV Infection,NCI,Disease or Syndrome
PMC5472554,longterm survival,TREATMENT,PMC,,,,
PMC5472554,advanced stage patients,PROBLEM,PMC,,,,
PMC5472554,serum marker,TEST,PMC,C0162491,Serum Markers,MSH,Qualitative Concept
PMC5472554,ca,TEST,PMC,C0006675,calcium,MTH,"Pharmacologic Substance, Biologically Active Substance, Element, Ion, or Isotope"
PMC5472554,ca 199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC5472554,pcspecific markers,TEST,PMC,,,,
PMC5472554,earlyscreening assays,TEST,PMC,,,,
PMC5472554,tumorderived material,PROBLEM,PMC,,,,
PMC5472554,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC5472554,detection of markers,TEST,PMC,C3516445,Analysis for detection of tumor marker,CPT,Laboratory Procedure
PMC5472554,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC5472554,tumorderived extracellular vesicles,PROBLEM,PMC,,,,
PMC5472554,a promising noninvasive method,TREATMENT,PMC,,,,
PMC5472554,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC5472554,tumor differentiation,PROBLEM,PMC,C5707474,Tumor Differentiation Assessment,NCI,Diagnostic Procedure
PMC5472554,monitoring disease progression,PROBLEM,PMC,C4718181,Monitors disease progression,NOC,Finding
PMC5472554,minimally invasive procedures,TREATMENT,PMC,C2711297,Minimally invasive procedure,SNOMEDCT_US,Functional Concept
PMC5472554,tumor origin,PROBLEM,PMC,C4525747,Tumor Tissue Origin,NCI,Conceptual Entity
PMC5472554,circulating vesicle,PROBLEM,PMC,,,,
PMC5472554,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC5472554,invasive properties,PROBLEM,PMC,,,,
PMC5472554,pc progression,PROBLEM,PMC,,,,
PMC5472554,digital pathology,TEST,PMC,C5702461,Digital Pathology Digitization Procedures,CPT,Laboratory Procedure
PMC5472554,tumorderived circulating material,PROBLEM,PMC,,,,
PMC5472554,metastatic mutations,PROBLEM,PMC,C5206129,Metastatic BRCA Hereditary Breast Carcinoma,NCI,Neoplastic Process
PMC5472554,large genetic heterogeneity,PROBLEM,PMC,,,,
PMC5472554,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC5472554,genotyping costs,TEST,PMC,,,,
PMC5472554,drug sensitivity,PROBLEM,PMC,C0237865,Propensity to adverse reactions to drug,SNOMEDCT_US,Organism Attribute
PMC5472554,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC5472554,genomic profiling,TEST,PMC,C2986505,Genetic Profile,MSH,Laboratory or Test Result
PMC5472554,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC5472554,stromal density image processing,TEST,PMC,,,,
PMC5472554,transporter expression determination,TEST,PMC,,,,
PMC5472554,digital analysis,TEST,PMC,C2348290,Digital Image Analysis,NCI,Diagnostic Procedure
PMC5472554,ct images,TEST,PMC,C5785262,Number of CT Images Used in Session,NCI,Quantitative Concept
PMC5472554,gemcitabine treatment,TREATMENT,PMC,,,,
PMC5472554,digital pathology,TEST,PMC,C5702461,Digital Pathology Digitization Procedures,CPT,Laboratory Procedure
PMC5472554,augment treatment decisions,TREATMENT,PMC,,,,
PMC5472554,personalized medicine,TREATMENT,PMC,C2718059,Precision Medicine,MSH,Therapeutic or Preventive Procedure
PMC5472554,refining existing treatment options,TREATMENT,PMC,,,,
PMC5472554,latestage pc patients,PROBLEM,PMC,,,,
PMC5472554,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC5472554,physiologically relevant markers in exosomes,PROBLEM,PMC,,,,
PMC5472554,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC5472554,testing,TEST,PMC,C0039593,Testing,MTH,Functional Concept
PMC5472554,discomfort,PROBLEM,PMC,C2364135,Discomfort,MTH,Sign or Symptom
PMC5472554,serial samples of body fluids,TREATMENT,PMC,,,,
PMC5472554,disease progression,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC5472554,invasive biopsies,TEST,PMC,C5441285,Minimally invasive CNS biopsy,CCSR_ICD10PCS,Diagnostic Procedure
PMC5472554,tests,TEST,PMC,C0392366,Tests (qualifier value),MTH,Intellectual Product
PMC5472554,pc development,PROBLEM,PMC,,,,
PMC5472554,potential solutions,TREATMENT,PMC,C2957511,nasal potential difference after chloride-free and isoproterenol solutions ___ mv,MEDCIN,Laboratory Procedure
PMC5472554,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5472554,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5472554,ctc,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC5472554,circulating tumor cells,PROBLEM,PMC,C0027625,Circulating Neoplastic Cells,MTH,Cell
PMC5472554,extracellular vesicles,PROBLEM,PMC,C3894683,Extracellular Vesicles,MSH,Cell Component
PMC5472554,cfdna,TEST,PMC,C4289789,Cell-Free DNA,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC5472554,circulating free dna,TEST,PMC,C5906853,Cell-free circulating tumor DNA test,MDR,Laboratory Procedure
PMC5472554,ctdna,TEST,PMC,C5447681,cfDNA or ctDNA Measurement,NCI,Laboratory Procedure
PMC5472554,circulating tumor dna,PROBLEM,PMC,C3827014,Circulating Tumor DNA,MSH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC4748916,compression fracture of the vertebral body,PROBLEM,PMC,C2103609,compression fracture of thoracic vertebral body,MEDCIN,Injury or Poisoning
PMC4748916,etiology,PROBLEM,PMC,C1314792,Etiology,MTH,Functional Concept
PMC4748916,osteoporosis,PROBLEM,PMC,C0029456,Osteoporosis,MTH,Disease or Syndrome
PMC4748916,cancer metastasis,PROBLEM,PMC,C0742132,cervical cancer metastasis,CHV,Neoplastic Process
PMC4748916,severe back pain,PROBLEM,PMC,C0238740,severe back pain,CHV,Sign or Symptom
PMC4748916,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC4748916,more severe fractures,PROBLEM,PMC,,,,
PMC4748916,significant pain,PROBLEM,PMC,C4537558,WHYMPI significant-other responses subscale,MEDCIN,Intellectual Product
PMC4748916,severe lower back pain,PROBLEM,PMC,C2128640,lower back pain after sleeping on back several hours,MEDCIN,Sign or Symptom
PMC4748916,intermittent abdominal fullness,PROBLEM,PMC,,,,
PMC4748916,change posture,PROBLEM,PMC,C5934253,Postural changes that affect gait,NOC,Finding
PMC4748916,severe back pain,PROBLEM,PMC,C0238740,severe back pain,CHV,Sign or Symptom
PMC4748916,plain film,TEST,PMC,C1306645,Plain x-ray,MTH,Diagnostic Procedure
PMC4748916,magnetic resonance imaging of lumbar spine,TEST,PMC,C0412720,MRI of lumbar spine,MTH,Diagnostic Procedure
PMC4748916,osteoblastic lesion at l2 spine,PROBLEM,PMC,,,,
PMC4748916,abdomen computed tomography,TEST,PMC,C5151289,Abdomen | Computed tomography | Radiology,LNC,Body Location or Region
PMC4748916,a mass at the pancreatic body,PROBLEM,PMC,,,,
PMC4748916,the pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC4748916,osteoblastic metastasis,PROBLEM,PMC,C3854652,Osteoblastic bone metastases,MDR,Neoplastic Process
PMC4748916,multimodality therapy,TREATMENT,PMC,C0009429,Combined Modality Therapy,MTH,Therapeutic or Preventive Procedure
PMC4748916,percutaneous vertebroplasty,TREATMENT,PMC,C2349722,Percutaneous vertebroplasty,ICD9CM,Therapeutic or Preventive Procedure
PMC4748916,pain,TREATMENT,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC4748916,effective,TREATMENT,PMC,C1704419,Effective,MTH,Qualitative Concept
PMC4748916,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC4748916,aggressive rehabilitation program,TREATMENT,PMC,,,,
PMC4748916,multidisciplinary cancer treatment,TREATMENT,PMC,C1302384,Multidisciplinary care conference for cancer care planning,SNOMEDCT_US,Health Care Activity
PMC4748916,the complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC4748916,immobilization,TREATMENT,PMC,C0020944,Immobilization,MTH,Therapeutic or Preventive Procedure
PMC4748916,adverse effects like musculoskeletal respiratory and cardiovascular systems,PROBLEM,PMC,,,,
PMC4748916,suitable therapies,TREATMENT,PMC,C3693904,"options general patient not currently suitable for therapy, will reevaluate",MEDCIN,Functional Concept
PMC4748916,surveys,TEST,PMC,C0038951,Surveys,MTH,Intellectual Product
PMC4748916,severe lower back pain,PROBLEM,PMC,C2128640,lower back pain after sleeping on back several hours,MEDCIN,Sign or Symptom
PMC4748916,osteoblastic metastasis,PROBLEM,PMC,C3854652,Osteoblastic bone metastases,MDR,Neoplastic Process
PMC4748916,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4748916,multimodality treatment,TREATMENT,PMC,C0009429,Combined Modality Therapy,MTH,Therapeutic or Preventive Procedure
PMC4748916,multidisciplinary cancer treatment,TREATMENT,PMC,C1302384,Multidisciplinary care conference for cancer care planning,SNOMEDCT_US,Health Care Activity
PMC4748916,the complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC4748916,immobilization,TREATMENT,PMC,C0020944,Immobilization,MTH,Therapeutic or Preventive Procedure
PMC4748916,adverse effects like musculoskeletal respiratory and cardiovascular systems,PROBLEM,PMC,,,,
PMC4748916,suitable therapies,TREATMENT,PMC,C3693904,"options general patient not currently suitable for therapy, will reevaluate",MEDCIN,Functional Concept
PMC4748916,surveys,TEST,PMC,C0038951,Surveys,MTH,Intellectual Product
PMC11491967,metastatic pancreatic ductal adenocarcinoma,PROBLEM,PMC,C5204113,Metastatic Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC11491967,pharmacological ascorbate,TREATMENT,PMC,C4744839,Pharmacological Ascorbate,NCI,"Organic Chemical, Pharmacologic Substance"
PMC11491967,intravenous vitamin c,TREATMENT,PMC,C0353458,Vitamin B+C strong intravenous injection,RCD,Clinical Drug
PMC11491967,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11491967,paschto,TREATMENT,PMC,,,,
PMC11491967,gemcitabine andnabpaclitaxel,TREATMENT,PMC,,,,
PMC11491967,metastatic pdac,PROBLEM,PMC,,,,
PMC11491967,stage iv pancreatic cancer,PROBLEM,PMC,C0854775,stage IV pancreatic cancer,MTH,Neoplastic Process
PMC11491967,gemcitabine andnabpaclitaxel,TREATMENT,PMC,,,,
PMC11491967,soc,TREATMENT,PMC,C3178983,Sense of Coherence,MTH,Mental Process
PMC11491967,concomitant pasch,TREATMENT,PMC,,,,
PMC11491967,progressionfree survival,TREATMENT,PMC,,,,
PMC11491967,adverse event incidence,PROBLEM,PMC,,,,
PMC11491967,common oncologic symptoms,PROBLEM,PMC,,,,
PMC11491967,an exploratory objective,TEST,PMC,C5235568,Trial Exploratory Objective,NCI,Idea or Concept
PMC11491967,their assigned study treatment,TREATMENT,PMC,,,,
PMC11491967,all analyses,TEST,PMC,,,,
PMC11491967,intravenous paschincreased,TREATMENT,PMC,,,,
PMC11491967,micromolar,TEST,PMC,C0439300,Micromole/liter,MTH,Quantitative Concept
PMC11491967,the gemcitabine nabpaclitaxel,TREATMENT,PMC,,,,
PMC11491967,gemcitabine nabpaclitaxel,TREATMENT,PMC,,,,
PMC11491967,median progression free survival,PROBLEM,PMC,,,,
PMC11491967,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC11491967,paschinfusions,TREATMENT,PMC,,,,
PMC11491967,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC11491967,added toxicity,PROBLEM,PMC,,,,
PMC11491967,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC11491967,added toxicity,PROBLEM,PMC,,,,
PMC3757398,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3757398,a multidisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC3757398,advanced disease at presentation,PROBLEM,PMC,,,,
PMC3757398,palliation,TREATMENT,PMC,C0679251,disease palliation,AOD,Finding
PMC3757398,biliary obstruction,PROBLEM,PMC,C0400979,Obstruction of biliary tree,SNOMEDCT_US,Disease or Syndrome
PMC3757398,gastric outlet obstruction,PROBLEM,PMC,C0162651,Gastric outlet obstruction,MTH,Disease or Syndrome
PMC3757398,cancerrelated pain,PROBLEM,PMC,,,,
PMC3757398,endoscopic stenting,TREATMENT,PMC,C0842857,Endoscopic stenting of biliary tract,ICD10AM,Therapeutic or Preventive Procedure
PMC3757398,biliary obstruction,PROBLEM,PMC,C0400979,Obstruction of biliary tree,SNOMEDCT_US,Disease or Syndrome
PMC3757398,drainage,TREATMENT,PMC,C0013103,Drainage procedure,MTH,Therapeutic or Preventive Procedure
PMC3757398,the complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC3757398,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC3757398,pruritus,PROBLEM,PMC,C0033774,Pruritus,MTH,Sign or Symptom
PMC3757398,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC3757398,liver dysfunction,PROBLEM,PMC,C0086565,Liver Dysfunction,MSH,Finding
PMC3757398,eventually failure,PROBLEM,PMC,,,,
PMC3757398,enteral stents,TREATMENT,PMC,C4528911,Enteral Stents,UMD,Medical Device
PMC3757398,gastric obstruction,PROBLEM,PMC,C0149700,Gastric Obstruction,MTH,Disease or Syndrome
PMC3757398,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC3757398,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC3757398,endoscopic procedures,TREATMENT,PMC,C0282493,Surgical Endoscopy,MTH,Diagnostic Procedure
PMC3757398,pancreatic stenting,TREATMENT,PMC,C0183516,Pancreatic stent,SNOMEDCT_US,Medical Device
PMC3757398,celiac plexus neurolysis,TREATMENT,PMC,C3899700,Celiac Plexus Neurolysis,MTH,Therapeutic or Preventive Procedure
PMC3757398,endoscopic palliation,TREATMENT,PMC,,,,
PMC3757398,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC3757398,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC3757398,very poor prognosis,PROBLEM,PMC,,,,
PMC3757398,palliative procedures,TREATMENT,PMC,C1285158,Palliative procedure,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3757398,their symptoms,PROBLEM,PMC,,,,
PMC3757398,endoscopic approaches,TREATMENT,PMC,C0442418,Endoscopic approach - access,MTH,Spatial Concept
PMC3757398,biliary obstruction,PROBLEM,PMC,C0400979,Obstruction of biliary tree,SNOMEDCT_US,Disease or Syndrome
PMC3757398,gastric outlet obstruction,PROBLEM,PMC,C0162651,Gastric outlet obstruction,MTH,Disease or Syndrome
PMC3757398,cancerrelated pain,PROBLEM,PMC,,,,
PMC3757398,endoscopic intervention,TREATMENT,PMC,C0940709,Type of previous endoscopic intervention of the papilla major,MTHMST,Intellectual Product
PMC6943146,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6943146,substantial symptom burden,PROBLEM,PMC,,,,
PMC6943146,the edmonton symptom assessment scale,TEST,PMC,C3472649,Edmonton Symptom Assessment System,SNOMEDCT_US,Intellectual Product
PMC6943146,nine symptoms,PROBLEM,PMC,C2219713,menarche before age nine,MEDCIN,Finding
PMC6943146,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6943146,publicly funded drugs,TREATMENT,PMC,,,,
PMC6943146,total symptom distress score,PROBLEM,PMC,,,,
PMC6943146,9 symptoms,PROBLEM,PMC,C1718308,Resident assessment protocol 9--Behavioral symptoms - triggered,LNC,Intellectual Product
PMC6943146,physical symptom score,PROBLEM,PMC,C4701042,WOSI physical symptoms score,MEDCIN,Finding
PMC6943146,psychological symptom,TEST,PMC,C0233397,Psychological symptom,SNOMEDCT_US,Sign or Symptom
PMC6943146,composite scores,TEST,PMC,C4067130,BASC-2 composite scores,MEDCIN,Finding
PMC6943146,phs,PROBLEM,PMC,C0265220,Pallister-Hall syndrome,MTH,Disease or Syndrome
PMC6943146,pss,TEST,PMC,C1849193,PEELING SKIN SYNDROME,MTH,Disease or Syndrome
PMC6943146,high symptom burden,PROBLEM,PMC,,,,
PMC6943146,crude os,TEST,PMC,,,,
PMC6943146,kaplanmeier method,TEST,PMC,,,,
PMC6943146,hazard ratios,TEST,PMC,C2985465,Hazard Ratio,NCI,Quantitative Concept
PMC6943146,multivariable cox models,TREATMENT,PMC,,,,
PMC6943146,analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC6943146,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC6943146,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6943146,crude median survival,TREATMENT,PMC,,,,
PMC6943146,high and low tsds,PROBLEM,PMC,,,,
PMC6943146,high tsds,PROBLEM,PMC,,,,
PMC6943146,lower os,PROBLEM,PMC,C2012629,growth on inner lower eyelid of left eye,MEDCIN,Sign or Symptom
PMC6943146,ecog status,TEST,PMC,C1520224,ECOG performance status,MTH,Intellectual Product
PMC6943146,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC6943146,high tsds,PROBLEM,PMC,,,,
PMC6943146,lower os,PROBLEM,PMC,C2012629,growth on inner lower eyelid of left eye,MEDCIN,Sign or Symptom
PMC6943146,phs,PROBLEM,PMC,C0265220,Pallister-Hall syndrome,MTH,Disease or Syndrome
PMC6943146,pss,TEST,PMC,C1849193,PEELING SKIN SYNDROME,MTH,Disease or Syndrome
PMC6943146,reduced os,PROBLEM,PMC,,,,
PMC6943146,ecog status,TEST,PMC,C1520224,ECOG performance status,MTH,Intellectual Product
PMC6943146,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6943146,patientreported symptoms,PROBLEM,PMC,,,,
PMC6943146,reduced overall survival,PROBLEM,PMC,,,,
PMC6943146,performance status,PROBLEM,PMC,C1518965,Performance Status,NCI,Finding
PMC6943146,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC6943146,reduced os,PROBLEM,PMC,,,,
PMC6943146,ecog status,TEST,PMC,C1520224,ECOG performance status,MTH,Intellectual Product
PMC6839088,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6839088,autoimmune pancreatitis,PROBLEM,PMC,C2609129,Autoimmune Pancreatitis,MTH,Disease or Syndrome
PMC6839088,laboratory results,TEST,PMC,C1254595,Laboratory Results,CPM,Laboratory or Test Result
PMC6839088,morphologic imagings,TEST,PMC,C3865790,Kidney morphological imaging,CPT,Diagnostic Procedure
PMC6839088,us,TEST,PMC,C0041703,United States,MTH,Geographic Area
PMC6839088,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC6839088,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC6839088,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC6839088,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC6839088,petct,TEST,PMC,C1699633,PET/CT scan,MTH,Diagnostic Procedure
PMC6839088,serum igg4,TEST,PMC,C2021628,serum IgG4,MEDCIN,Laboratory Procedure
PMC6839088,biopsy,TEST,PMC,C0005558,Biopsy,MTH,Diagnostic Procedure
PMC6839088,the totally different management strategy,TREATMENT,PMC,,,,
PMC6839088,the two diseases,PROBLEM,PMC,C0581375,Double coronary vessel disease,SNOMEDCT_US,Disease or Syndrome
PMC6839088,untypical aip,PROBLEM,PMC,,,,
PMC6839088,2 laparotomy,TREATMENT,PMC,,,,
PMC6839088,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6839088,a high similar characteristic,PROBLEM,PMC,,,,
PMC6839088,untypical,PROBLEM,PMC,C0580543,Untypable,LNC,Intellectual Product
PMC6839088,mild fluctuating jaundice,PROBLEM,PMC,,,,
PMC6839088,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC6839088,tumor marker,PROBLEM,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC6839088,tpa,TEST,PMC,C0032143,alteplase,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Enzyme"
PMC6839088,variable radiological tests,TEST,PMC,,,,
PMC6839088,aip mass,PROBLEM,PMC,,,,
PMC6839088,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6839088,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6839088,laparotomy,TREATMENT,PMC,C0023038,Laparotomy,MTH,Therapeutic or Preventive Procedure
PMC6839088,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6839088,mild fluctuating jaundice,PROBLEM,PMC,,,,
PMC6839088,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC6839088,tumor marker,PROBLEM,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC6839088,tpa,TEST,PMC,C0032143,alteplase,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Enzyme"
PMC6839088,variable radiological tests,TEST,PMC,,,,
PMC6839088,aip mass,PROBLEM,PMC,,,,
PMC6839088,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6839088,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6839088,laparotomy,TREATMENT,PMC,C0023038,Laparotomy,MTH,Therapeutic or Preventive Procedure
PMC6839088,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6839088,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC6839088,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC6839088,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6839088,the rare typical signs,PROBLEM,PMC,,,,
PMC6839088,untypical aip,PROBLEM,PMC,,,,
PMC6839088,routinecheck signs,TEST,PMC,,,,
PMC6839088,above routine signs,PROBLEM,PMC,,,,
PMC9200569,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9200569,a malignant tumor of the digestive tract,PROBLEM,PMC,C0346617,Malignant tumor of digestive organ,SNOMEDCT_US,Neoplastic Process
PMC9200569,atypical clinical symptoms,PROBLEM,PMC,,,,
PMC9200569,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9200569,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9200569,tcga database,TEST,PMC,,,,
PMC9200569,pancreatic cancer dataset,PROBLEM,PMC,,,,
PMC9200569,differentially expressed genes,PROBLEM,PMC,C5575824,Differential Gene Expression Level Analysis,MTH,Molecular Biology Research Technique
PMC9200569,clinical correlation analyses,TEST,PMC,,,,
PMC9200569,degs,TEST,PMC,C3539688,DEGS1 wt Allele,MTH,Gene or Genome
PMC9200569,key genes,PROBLEM,PMC,,,,
PMC9200569,dna methylation,TEST,PMC,C0376452,DNA Methylation,MTH,Molecular Function
PMC9200569,mutation,PROBLEM,PMC,C0026882,Mutation,MTH,Genetic Function
PMC9200569,copy number variation,PROBLEM,PMC,C1511518,Copy Number Polymorphism,MTH,Nucleotide Sequence
PMC9200569,genetic variants,PROBLEM,PMC,C4277630,Pharmacogenomic Variants,MSH,Genetic Function
PMC9200569,gsea,TEST,PMC,,,,
PMC9200569,a competing endogenous rna cerna network,TREATMENT,PMC,,,,
PMC9200569,the tumor microenvironment,TEST,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC9200569,chemotherapeutic drug sensitivity,TREATMENT,PMC,,,,
PMC9200569,the geo database,TEST,PMC,,,,
PMC9200569,the mrna,TEST,PMC,C0026661,mRNA Precursor,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC9200569,dna methylation,PROBLEM,PMC,C0376452,DNA Methylation,MTH,Molecular Function
PMC9200569,cnv,PROBLEM,PMC,C0600518,Choroidal Neovascularization,MTH,Pathologic Function
PMC9200569,the cell cycle,TEST,PMC,C0007586,Cell Cycle,MTH,Cell Function
PMC9200569,pathways in cancer,PROBLEM,PMC,C2984249,Cancer Pathway,NCI,Functional Concept
PMC9200569,the tme,TEST,PMC,C5783677,Xerna TME Panel,NCI,Laboratory Procedure
PMC9200569,immune scores,TEST,PMC,C5855431,PD-L1 Immune Cell Score,NCI,Finding
PMC9200569,cerna network,TEST,PMC,,,,
PMC9200569,eleven mirnas,TEST,PMC,,,,
PMC9200569,20 chemotherapeutic drugs,TREATMENT,PMC,,,,
PMC9200569,ect2,PROBLEM,PMC,C1414250,ECT2 gene,MTH,Gene or Genome
PMC9200569,ect2,TEST,PMC,C1414250,ECT2 gene,MTH,Gene or Genome
PMC9200569,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9200569,clinical diagnosis,TEST,PMC,C0332140,Clinical diagnosis,MTH,Finding
PMC9200569,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9200569,ect2,TEST,PMC,C1414250,ECT2 gene,MTH,Gene or Genome
PMC9200569,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9200569,clinical diagnosis,TEST,PMC,C0332140,Clinical diagnosis,MTH,Finding
PMC9200569,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11741095,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11741095,cancerrelated deaths,PROBLEM,PMC,,,,
PMC11741095,cancerrelated deaths,PROBLEM,PMC,,,,
PMC11741095,lung cancer,PROBLEM,PMC,C0684249,Carcinoma of lung,MTH,Neoplastic Process
PMC11741095,poor overall survival rates,PROBLEM,PMC,,,,
PMC11741095,aggressive treatment,TREATMENT,PMC,C0510615,"Encourage early, aggressive treatment for endometriosis",NIC,Therapeutic or Preventive Procedure
PMC11741095,complex symptomatology,PROBLEM,PMC,,,,
PMC11741095,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11741095,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC11741095,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11741095,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC11741095,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11741095,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC11741095,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11741095,advanced practitioners,TREATMENT,PMC,C0028657,nurse practitioner,MTH,Professional or Occupational Group
PMC11741095,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC11741095,this patient population,TREATMENT,PMC,,,,
PMC11741095,this serious disease,PROBLEM,PMC,,,,
PMC11077374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11077374,a malignancy,PROBLEM,PMC,C0346429,Multiple malignancy,SNOMEDCT_US,Neoplastic Process
PMC11077374,high mortality,PROBLEM,PMC,C0479563,Exposure to high and low air pressure and changes in air pressure as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC11077374,the few symptoms,PROBLEM,PMC,C0436355,Has symptom every few days,SNOMEDCT_US,Finding
PMC11077374,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11077374,an advanced stage,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC11077374,the high fatality rate,PROBLEM,PMC,,,,
PMC11077374,drug resistance,PROBLEM,PMC,C0013203,Drug resistance,MTH,Biologic Function
PMC11077374,appropriate treatment,TREATMENT,PMC,C3640049,Appropriate Treatment,NCI,Clinical Attribute
PMC11077374,therapeutic drugs,TREATMENT,PMC,C0580398,Drug level therapeutic,MDR,Laboratory or Test Result
PMC11077374,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11077374,the firstline drug,TREATMENT,PMC,,,,
PMC11077374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11077374,gemcitabine resistance,TREATMENT,PMC,,,,
PMC11077374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11077374,pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC11077374,long non coding rnas lncrnas,PROBLEM,PMC,,,,
PMC11077374,rna transcripts,TEST,PMC,C1519595,RNA Transcript,MTH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC11077374,some lncrnas,PROBLEM,PMC,,,,
PMC11077374,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC11077374,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC11077374,autophagy,PROBLEM,PMC,C0004391,Autophagy,MTH,Cell Function
PMC11077374,the sensitivity,PROBLEM,PMC,C0020517,Hypersensitivity,MTH,Pathologic Function
PMC11077374,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC11077374,therapeutic drugs,TREATMENT,PMC,C0580398,Drug level therapeutic,MDR,Laboratory or Test Result
PMC11077374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11077374,lncrnas,TREATMENT,PMC,C5975699,lncRNA ZNF800,OMIM,Gene or Genome
PMC11077374,therapeutic resistance,TREATMENT,PMC,C0695422,Resistive therapeutic exercise individual each 15 minutes,ALT,Therapeutic or Preventive Procedure
PMC11077374,lncrna,TREATMENT,PMC,C2982391,Long Intergenic Non-Protein Coding RNA,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC11077374,wntcatenin pathway,PROBLEM,PMC,,,,
PMC11077374,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11077374,lncrnamirnamrna,TREATMENT,PMC,,,,
PMC11077374,sponging mirna,TREATMENT,PMC,C5815049,miRNA sponge,GO,Genetic Function
PMC11077374,lncrna,TREATMENT,PMC,C2982391,Long Intergenic Non-Protein Coding RNA,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC11077374,extensive studies,TEST,PMC,C5960526,Extension Study Design,NCI,Research Activity
PMC11077374,lncrnas,TEST,PMC,C5975699,lncRNA ZNF800,OMIM,Gene or Genome
PMC11077374,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11077374,wntcatenin pathway,TREATMENT,PMC,,,,
PMC11077374,chemotherapy resistance,TREATMENT,PMC,C2363824,Chemotherapy sensitivity and resistance assay,MDR,Laboratory Procedure
PMC11077374,pc cells,PROBLEM,PMC,C3890720,PC-3 cell line,MTH,Cell
PMC11077374,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC11077374,pc resistance,PROBLEM,PMC,,,,
PMC11077374,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11077374,other drugs,TREATMENT,PMC,C2729346,Other drugs,LNC,Pharmacologic Substance
PMC11077374,pc markers,PROBLEM,PMC,,,,
PMC11077374,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11077374,strong specific expression in different tissues,PROBLEM,PMC,,,,
PMC11077374,cancers,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC11077374,the drug resistance pathway of pc,PROBLEM,PMC,,,,
PMC11997321,diagnostic evaluations,TEST,PMC,C2936631,Diagnostic Self Evaluation,MSH,Mental Process
PMC11997321,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC11997321,pancreatic tuberculosis,PROBLEM,PMC,,,,
PMC11997321,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC11997321,epigastric pain,PROBLEM,PMC,C0232493,Epigastric pain,MTH,Sign or Symptom
PMC11997321,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC11997321,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC11997321,pancreatic masses,PROBLEM,PMC,C2227740,"abdominal x-ray, AP view: pancreatic mass",MEDCIN,Finding
PMC11997321,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11997321,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11997321,fna,TEST,PMC,C1510483,Fine needle aspiration biopsy,MTH,Diagnostic Procedure
PMC11997321,subsequent histopathology,TEST,PMC,,,,
PMC11997321,tuberculosis,PROBLEM,PMC,C0041296,Tuberculosis,MTH,Disease or Syndrome
PMC11997321,granulomas,PROBLEM,PMC,C0018188,Granuloma,MTH,Pathologic Function
PMC11997321,caseous necrosis,PROBLEM,PMC,C0333512,Caseous necrosis,SNOMEDCT_US,Pathologic Function
PMC11997321,antituberculosis therapy,TREATMENT,PMC,,,,
PMC11997321,pain resolution,PROBLEM,PMC,C0547249,Obtain electrocardiogram following resolution of discomfort or pain.,PCDS,Therapeutic or Preventive Procedure
PMC11997321,followup imaging,TEST,PMC,,,,
PMC11997321,pancreatic tuberculosis,PROBLEM,PMC,,,,
PMC11997321,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC11997321,imaging findings,TEST,PMC,C5667469,Imaging Findings Comments,NCI,Intellectual Product
PMC11997321,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11997321,known risk factors,PROBLEM,PMC,,,,
PMC11997321,advanced,TREATMENT,PMC,C0205179,Advanced phase,MTH,Qualitative Concept
PMC11997321,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11997321,fna,TEST,PMC,C1510483,Fine needle aspiration biopsy,MTH,Diagnostic Procedure
PMC11997321,antituberculosis treatment,TREATMENT,PMC,,,,
PMC7653048,antibodydrug conjugate adc construction,TREATMENT,PMC,,,,
PMC7653048,common bioconjugation methods,TREATMENT,PMC,,,,
PMC7653048,drug coupling to antibodies,TREATMENT,PMC,,,,
PMC7653048,such difficulties,PROBLEM,PMC,C3261861,"How much difficulty do you currently have writing notes to yourself, such as appointments or to do lists",LNC,Intellectual Product
PMC7653048,the interchain disulfides,TREATMENT,PMC,,,,
PMC7653048,cetuximab,TREATMENT,PMC,C0995188,cetuximab,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC7653048,auristatinbearing pyridazinediones,TREATMENT,PMC,,,,
PMC7653048,a highly refined antiepidermal growth factor receptor egfr adc,TREATMENT,PMC,,,,
PMC7653048,vitro and in vivo assessment,TEST,PMC,,,,
PMC7653048,adc activity,TEST,PMC,C1149609,4-amino-4-deoxychorismate lyase activity,MTH,Molecular Function
PMC7653048,kras mutant pancreatic cancer,PROBLEM,PMC,,,,
PMC7653048,known resistance,PROBLEM,PMC,C4533488,Known bacterial drug resistant infection,MTH,Finding
PMC7653048,ctx therapy,TREATMENT,PMC,,,,
PMC7653048,computational modelling,TEST,PMC,C5544479,Computational Modelling,MTH,Machine Activity
PMC7653048,tumour response,PROBLEM,PMC,C5577645,Tumour response assessment,MDR,Diagnostic Procedure
PMC7653048,various adc dosing regimens,TREATMENT,PMC,,,,
PMC7653048,an auristatin to ctx,TREATMENT,PMC,,,,
PMC7653048,an adc,TEST,PMC,C1826409,AZIN2 gene,MTH,Gene or Genome
PMC7653048,an average drugantibody ratio,TEST,PMC,,,,
PMC7653048,human xenografts,TREATMENT,PMC,,,,
PMC7653048,the adc,TEST,PMC,C0879593,therapeutic autologous dendritic cells,MTH,"Cell, Pharmacologic Substance"
PMC7653048,tumour growth,PROBLEM,PMC,C0201601,Tumor growth factor assay,SNOMEDCT_US,Laboratory Procedure
PMC7653048,overt signs of toxicity,PROBLEM,PMC,,,,
PMC7653048,adc efficacy,TREATMENT,PMC,,,,
PMC7653048,a,TREATMENT,PMC,,,,
PMC7653048,targetmediated dispositional effects,PROBLEM,PMC,,,,
PMC7653048,antigen density,PROBLEM,PMC,C4553235,Prostate Specific Antigen Density,MTH,Laboratory Procedure
PMC7653048,tumour cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC7653048,ctx in paca therapy,TREATMENT,PMC,,,,
PMC7653048,a nextgeneration adc,TREATMENT,PMC,,,,
PMC7653048,a predictive modelling tool,TREATMENT,PMC,,,,
PMC7653048,ctx in paca therapy,TREATMENT,PMC,,,,
PMC7653048,a nextgeneration adc,TREATMENT,PMC,,,,
PMC7653048,a predictive modelling tool,TREATMENT,PMC,,,,
PMC11357715,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11357715,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11357715,a low survival rate,PROBLEM,PMC,,,,
PMC11357715,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11357715,prolonging survival,TREATMENT,PMC,,,,
PMC11357715,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC11357715,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11357715,a retrospective chart review study,TEST,PMC,,,,
PMC11357715,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11357715,clinicopathological,PROBLEM,PMC,C5547136,Australian Clinico-pathological Staging System for colorectal cancer,SNOMEDCT_US,Classification
PMC11357715,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11357715,survival,TREATMENT,PMC,C0220921,survival aspects,MTH,Functional Concept
PMC11357715,the chisquared test,TEST,PMC,,,,
PMC11357715,kaplanmeier,TEST,PMC,,,,
PMC11357715,cox,TREATMENT,PMC,C1413661,COX8A gene,MTH,Gene or Genome
PMC11357715,hazard ratios,TEST,PMC,C2985465,Hazard Ratio,NCI,Quantitative Concept
PMC11357715,statistical analysis,TEST,PMC,C0871424,statistical analysis,CHV,Research Activity
PMC11357715,the main symptom,PROBLEM,PMC,C3177142,Main presenting symptom,LNC,Sign or Symptom
PMC11357715,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11357715,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC11357715,the baseline serum carbohydrate antigen,TEST,PMC,,,,
PMC11357715,distant metastases,PROBLEM,PMC,C5786072,Distant Metastases Other Cancer,NCI,Neoplastic Process
PMC11357715,localized disease,PROBLEM,PMC,C0277565,Local disease,MTH,Disease or Syndrome
PMC11357715,locally advanced,PROBLEM,PMC,C4725077,Locally Advanced Melanoma,NCI,Neoplastic Process
PMC11357715,poorly differentiated ductal adenocarcinoma,PROBLEM,PMC,C2987141,Pancreatic Poorly Differentiated Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC11357715,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC11357715,firstline chemotherapy,TREATMENT,PMC,,,,
PMC11357715,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11357715,firstline chemotherapy,TREATMENT,PMC,,,,
PMC11357715,progressive disease,PROBLEM,PMC,C5202991,IMWG Progressive Disease,MTH,Finding
PMC11357715,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC11357715,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC11357715,disease progression,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC11357715,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11357715,a,TEST,PMC,,,,
PMC11357715,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11357715,the median,PROBLEM,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC11357715,univariate analysis,TEST,PMC,C0683962,univariate statistics,CHV,Research Activity
PMC11357715,initial metastasis presentation,PROBLEM,PMC,,,,
PMC11357715,poor eastern cooperative oncology group performance status,PROBLEM,PMC,,,,
PMC11357715,multiple metastases,PROBLEM,PMC,C5556309,Multiple Metastases,NCI,Neoplastic Process
PMC11357715,worsened survival,PROBLEM,PMC,,,,
PMC11357715,the first chemotherapy,TREATMENT,PMC,C5667497,First Progression Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC11357715,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC11357715,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11357715,our study,TEST,PMC,,,,
PMC11357715,initial metastatic presentation,PROBLEM,PMC,,,,
PMC11357715,poor ecogps,PROBLEM,PMC,,,,
PMC11357715,numerous metastases,PROBLEM,PMC,,,,
PMC11357715,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11357715,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC11357715,a firstline treatment,TREATMENT,PMC,,,,
PMC11357715,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11357715,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11357715,personalized oncology,TREATMENT,PMC,,,,
PMC11357715,this fatal malignancy,PROBLEM,PMC,,,,
PMC11357715,our study,TEST,PMC,,,,
PMC11357715,initial metastatic presentation,PROBLEM,PMC,,,,
PMC11357715,poor ecogps,PROBLEM,PMC,,,,
PMC11357715,numerous metastases,PROBLEM,PMC,,,,
PMC11357715,localized pancreatic adenocarcinoma,PROBLEM,PMC,C5239334,Localized Pancreatic Adenocarcinoma,NCI,Neoplastic Process
PMC11357715,folfirinox,TREATMENT,PMC,C4742253,folfirinox,MSH,"Organic Chemical, Pharmacologic Substance"
PMC11357715,a firstline treatment,TREATMENT,PMC,,,,
PMC11357715,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11357715,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11357715,personalized oncology,TREATMENT,PMC,,,,
PMC11357715,this fatal malignancy,PROBLEM,PMC,,,,
PMC5221644,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5221644,an individualised approach,TREATMENT,PMC,,,,
PMC5221644,curative treatment,TREATMENT,PMC,C1273390,Curative Therapy,NCI,Therapeutic or Preventive Procedure
PMC5221644,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5221644,pancreatic cancer genetics,PROBLEM,PMC,C5976080,Hereditary pancreatic cancer multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC5221644,targeted therapies,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC5221644,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5221644,both surgery,TREATMENT,PMC,C3861502,x-rays of both hips during surgery,MEDCIN,Diagnostic Procedure
PMC5221644,targeted therapies,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC5221644,their cancer,PROBLEM,PMC,C5707026,My Family or Friends Had to Permanently Quit Their Job to Help with My Care Needs Because of My Cancer Diagnosis or Treatment,NCI,Intellectual Product
PMC5221644,permanent changes in gut anatomy,PROBLEM,PMC,,,,
PMC5221644,distressing symptoms,PROBLEM,PMC,C4060677,Distressing symptoms,NANDA-I,Sign or Symptom
PMC5221644,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5221644,supportive care issues,TREATMENT,PMC,C2130237,visit for pastoral care for relationship support issues,MEDCIN,Finding
PMC5221644,a strategic approach,TREATMENT,PMC,,,,
PMC5221644,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5221644,supportive care services,TREATMENT,PMC,C5570558,"Back in service, care/support services refused",LNC,Finding
PMC5221644,patient care,TREATMENT,PMC,C0017313,patient care,MTH,Health Care Activity
PMC5221644,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5221644,a multidisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC5221644,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC5221644,oncological management,TREATMENT,PMC,C3828956,MOSAIQ Oncology Information Management System,NCI,Intellectual Product
PMC5221644,a palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC5221644,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC5221644,psychosocial support,TREATMENT,PMC,C5235202,Psychosocial Support,MTH,Health Care Activity
PMC5221644,this poor prognosis cancer,PROBLEM,PMC,,,,
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,the most intractable cancers,PROBLEM,PMC,,,,
PMC4486738,early disease symptoms,PROBLEM,PMC,C1820844,Signs and symptoms of early disease,NOC,Finding
PMC4486738,specific biomarkers,TEST,PMC,,,,
PMC4486738,advanced inoperable tumors,PROBLEM,PMC,,,,
PMC4486738,a daunting challenge,TREATMENT,PMC,,,,
PMC4486738,single chemotherapy agent,TREATMENT,PMC,C3846440,"Chemotherapy, single agent",LNC,Therapeutic or Preventive Procedure
PMC4486738,objective response rates,TEST,PMC,C0993770,Dual chamber rate responsive implantable cardiac pacemaker,SNOMEDCT_US,Medical Device
PMC4486738,combination chemotherapy regimens,TREATMENT,PMC,C0003393,Antineoplastic Combined Chemotherapy Protocols,MSH,Therapeutic or Preventive Procedure
PMC4486738,novel therapies,TREATMENT,PMC,,,,
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,the current therapies,TREATMENT,PMC,C2827774,Current Therapy,NCI,Therapeutic or Preventive Procedure
PMC4486738,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4486738,novel therapeutic strategies,TREATMENT,PMC,,,,
PMC4486738,tumor biomarkers,TEST,PMC,C0041366,"Biomarkers, Tumor",MSH,Biologically Active Substance
PMC4486738,phosphatidylserinetargeted saposin ccoupled dioleoylphosphatidylserine nanovesicles,TREATMENT,PMC,,,,
PMC4486738,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC4486738,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,a devastating disease,PROBLEM,PMC,,,,
PMC4486738,effective therapies,TREATMENT,PMC,C1264021,Effects of immunosuppressant therapy,SNOMEDCT_US,Pathologic Function
PMC4486738,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC4486738,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,unspecific symptomatology,PROBLEM,PMC,,,,
PMC4486738,robust biomarkers,PROBLEM,PMC,,,,
PMC4486738,advanced tumors,PROBLEM,PMC,C5420859,Advanced Rhabdoid Tumor,NCI,Neoplastic Process
PMC4486738,conventional chemotoxic agents,TREATMENT,PMC,,,,
PMC4486738,radiation therapy,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC4486738,targeted therapies,TREATMENT,PMC,C2985566,Targeted Therapy,NCI,Therapeutic or Preventive Procedure
PMC4486738,revolutionize,TREATMENT,PMC,,,,
PMC4486738,cancer treatment,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC4486738,the adverse side effects,PROBLEM,PMC,C5548999,Fear of adverse side effects,LNC,Finding
PMC4486738,conventional cancer treatments,TREATMENT,PMC,,,,
PMC4486738,a formidable challenge,PROBLEM,PMC,,,,
PMC4486738,most tumors,PROBLEM,PMC,C5775266,Most tumors show somatic loss of chromosome 3 and LOH of the wildtype MBD4 allele,OMIM,Finding
PMC4486738,compensatory mechanisms,TREATMENT,PMC,,,,
PMC4486738,tumor eradication,PROBLEM,PMC,C4523146,Unilateral percutaneous cryoablation for eradication of pulmonary tumor,CPT,Therapeutic or Preventive Procedure
PMC4486738,broadly expressed tumorspecific antigens,PROBLEM,PMC,,,,
PMC4486738,tumor autolysis,PROBLEM,PMC,,,,
PMC4486738,the treatment,TREATMENT,PMC,C1705169,Biomaterial Treatment,MTH,Conceptual Entity
PMC4486738,pancreatic and other cancers,PROBLEM,PMC,,,,
PMC4486738,ps targeting,PROBLEM,PMC,,,,
PMC4486738,tumor toxicity,PROBLEM,PMC,C1410366,"toxic; goiter, tumor, malignant",ICPC2ICD10ENG,Neoplastic Process
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,pstargeted nanovesicles77,TREATMENT,PMC,,,,
PMC4486738,preclinical studies,TEST,PMC,C1709631,Preclinical Study,MTH,Research Activity
PMC4486738,pstargeted sapcdops nanovesicles,TREATMENT,PMC,,,,
PMC4486738,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC4486738,therapeutic agents,TREATMENT,PMC,C0304231,Therapeutic agent,MTH,Manufactured Object
PMC4486738,metastatic tumors76789195,PROBLEM,PMC,,,,
PMC4486738,ps,PROBLEM,PMC,C0301704,phosphatidylserine,MTH,Organic Chemical
PMC4486738,acidic ph9697,TEST,PMC,,,,
PMC4486738,solid tumors,PROBLEM,PMC,C0280100,Solid Neoplasm,MTH,Neoplastic Process
PMC4486738,drug resistance,PROBLEM,PMC,C0013203,Drug resistance,MTH,Biologic Function
PMC4486738,tumor stem cells787998,PROBLEM,PMC,,,,
PMC4486738,a diagnostic and therapeutic agent,TREATMENT,PMC,C4324648,Therapeutic agent-diagnostic test interaction,MDR,Pathologic Function
PMC4486738,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4486738,clinical studies99,TEST,PMC,,,,
PMC8171946,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8171946,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8171946,very low survival,PROBLEM,PMC,,,,
PMC8171946,identifying cancers,PROBLEM,PMC,C4717610,Identifies risk factors for cancer,NOC,Finding
PMC8171946,the tumour,PROBLEM,PMC,C2362754,Tumour staging,MTH,Laboratory Procedure
PMC8171946,pc in the blood and urine,PROBLEM,PMC,,,,
PMC8171946,populationbased screening,TEST,PMC,,,,
PMC8171946,a casecontrol study,TEST,PMC,,,,
PMC8171946,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8171946,disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC8171946,individual symptoms,PROBLEM,PMC,C5927068,feeling seen as unique individual by care provider and team,MEDCIN,Finding
PMC8171946,a machine learning approach,TREATMENT,PMC,,,,
PMC8171946,a logistic regression model,TREATMENT,PMC,,,,
PMC8171946,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8171946,developing pancreatic cancer,PROBLEM,PMC,,,,
PMC8171946,auc,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC8171946,auc,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC8171946,biomarker tests,TEST,PMC,C4477079,Abnormal cardiac biomarker test,HPO,Finding
PMC8171946,tumours,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC8171946,a noninvasive biomarker test,TEST,PMC,,,,
PMC8171946,this devastating disease,PROBLEM,PMC,,,,
PMC8171946,a noninvasive biomarker test,TEST,PMC,,,,
PMC8171946,this devastating disease,PROBLEM,PMC,,,,
PMC8171946,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8171946,a,TREATMENT,PMC,,,,
PMC8171946,this approach,TREATMENT,PMC,,,,
PMC8171946,further work,TEST,PMC,C2068950,work restrictions decision pending further evaluation,MEDCIN,Finding
PMC8171946,these findings,TEST,PMC,C5848664,In 2020 was it you or who was in charge of taking care of these underage persons:Find:Pt:^Patient:Ord,MTH,Clinical Attribute
PMC8131866,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8131866,its insidious early symptoms,PROBLEM,PMC,,,,
PMC8131866,poor early detection rate,PROBLEM,PMC,,,,
PMC8131866,exosomes,TEST,PMC,C2350332,Exosomes,MSH,Cell Component
PMC8131866,pc detection,TEST,PMC,C4730032,PC Mutation Detection Reagent Kits,UMD,Medical Device
PMC8131866,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8131866,plasma exosomes,TEST,PMC,,,,
PMC8131866,pc at different stages,PROBLEM,PMC,,,,
PMC8131866,other pancreatic diseases,PROBLEM,PMC,C0029771,Other specified diseases of pancreas,ICD10,Disease or Syndrome
PMC8131866,plasma samples,TEST,PMC,C0444263,Plasma specimen,SNOMEDCT_US,Body Substance
PMC8131866,pc at stage,PROBLEM,PMC,,,,
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,welldifferentiated pancreatic neuroendocrine tumor,PROBLEM,PMC,,,,
PMC8131866,pancreatic cystic lesions,PROBLEM,PMC,C5856176,Pancreatic Cystic Lesion,NCI,Finding
PMC8131866,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC8131866,plasmaderived exosomes,TEST,PMC,,,,
PMC8131866,ultracentrifugation,TEST,PMC,C0041609,Ultracentrifugation,MSH,Laboratory Procedure
PMC8131866,isobaric tags,TEST,PMC,C5206160,Deuterium Isobaric Amine Reactive Tag,NCI,"Indicator, Reagent, or Diagnostic Aid"
PMC8131866,relative and absolute quantification,TEST,PMC,,,,
PMC8131866,proteomic analysis,TEST,PMC,C1880158,Computational Proteomics Analysis System,MTH,Intellectual Product
PMC8131866,bioinformatic analysis,TEST,PMC,C5944729,"Metagenomic next-generation RNA sequencing in cerebrospinal fluid (CSF) bioinformatic analysis, with positive pathogen identification in infectious disease",CPT,Laboratory Procedure
PMC8131866,exosomal alix,PROBLEM,PMC,,,,
PMC8131866,enzymelinked immunosorbent assay,TEST,PMC,C5979798,"Oncology (prostate), enzymelinked immunosorbent assays (elisa) for total prostatespecific antigen (psa) and free psa, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer",HCPT,Laboratory Procedure
PMC8131866,receiver operating characteristic curve analysis,TEST,PMC,,,,
PMC8131866,a novel diagnostic biomarker,TEST,PMC,,,,
PMC8131866,the proteomic profile,TEST,PMC,C3463810,Proteomic Profile,NCI,Laboratory or Test Result
PMC8131866,differential degrees of abundance,PROBLEM,PMC,,,,
PMC8131866,pcvsother pancreatic diseases,PROBLEM,PMC,,,,
PMC8131866,pnet,PROBLEM,PMC,C0684337,Peripheral Primitive Neuroectodermal Tumor,MTH,Neoplastic Process
PMC8131866,pcls,PROBLEM,PMC,C0084112,PCL-700,MSH,Organic Chemical
PMC8131866,cp,PROBLEM,PMC,C0006938,captopril,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8131866,proteomic and bioinformatic analyses,TEST,PMC,,,,
PMC8131866,exosomal alix,TEST,PMC,,,,
PMC8131866,a novel biomarker,TEST,PMC,,,,
PMC8131866,pc,TEST,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,alix expression,TEST,PMC,,,,
PMC8131866,elevated,PROBLEM,PMC,C3163633,Elevated,MTH,Qualitative Concept
PMC8131866,other pancreatic diseases,PROBLEM,PMC,C0029771,Other specified diseases of pancreas,ICD10,Disease or Syndrome
PMC8131866,hc,PROBLEM,PMC,C0020268,hydrocortisone,MTH,"Organic Chemical, Pharmacologic Substance, Hormone"
PMC8131866,tnm stage,PROBLEM,PMC,C4763496,FIGO/TNM Stage,NCI,Occupational Activity
PMC8131866,distant metastasis,PROBLEM,PMC,C5441917,Distant Metastasis,MTH,Pathologic Function
PMC8131866,exosomal alix,TEST,PMC,,,,
PMC8131866,serum ca199,TEST,PMC,,,,
PMC8131866,pcvsother pancreatic diseases,PROBLEM,PMC,,,,
PMC8131866,alix,TEST,PMC,C1418407,PDCD6IP gene,MTH,Gene or Genome
PMC8131866,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC8131866,our study,TEST,PMC,,,,
PMC8131866,proteomic profiling,TEST,PMC,C1327760,Proteomic Profiling,NCI,Laboratory Procedure
PMC8131866,the plasmaderived exosomes,TEST,PMC,,,,
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,exosomal alix,PROBLEM,PMC,,,,
PMC8131866,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,advanced stages,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC8131866,our study,TEST,PMC,,,,
PMC8131866,proteomic profiling,TEST,PMC,C1327760,Proteomic Profiling,NCI,Laboratory Procedure
PMC8131866,the plasmaderived exosomes,TEST,PMC,,,,
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,exosomal alix,PROBLEM,PMC,,,,
PMC8131866,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,advanced stages,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC8131866,a,TREATMENT,PMC,,,,
PMC8131866,screening exosomederived biomarkers,TEST,PMC,,,,
PMC8131866,pc detection,PROBLEM,PMC,C4730032,PC Mutation Detection Reagent Kits,UMD,Medical Device
PMC8131866,our study,TEST,PMC,,,,
PMC8131866,the proteomic profiling,TEST,PMC,C1327760,Proteomic Profiling,NCI,Laboratory Procedure
PMC8131866,plasmaderived exosomal proteins,PROBLEM,PMC,,,,
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,exosomal alix,PROBLEM,PMC,,,,
PMC8131866,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC8131866,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8131866,advanced stages,PROBLEM,PMC,C3161190,Advanced stage glaucoma,MTHICD9,Disease or Syndrome
PMC8131866,exosomal alix,PROBLEM,PMC,,,,
PMC9913845,oncology,TREATMENT,PMC,C0278627,oncology (field),MTH,Biomedical Occupation or Discipline
PMC9913845,gastrointestinal tumors,PROBLEM,PMC,C0017185,Gastrointestinal Neoplasms,MTH,Neoplastic Process
PMC9913845,therapeutic algorithms,TREATMENT,PMC,C4732277,"Cancer RNA gene expression profiling by whole transcriptome sequencing in fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",CPT,Laboratory Procedure
PMC9913845,multiple systemic options,TREATMENT,PMC,,,,
PMC9913845,locoregional strategies,TREATMENT,PMC,,,,
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,metastatic colorectal cancer,PROBLEM,PMC,C4721579,Metastasis from malignant neoplasm of colon and/or rectum,MTH,Neoplastic Process
PMC9913845,upper gastrointestinal neoplasms,PROBLEM,PMC,C0851764,Upper gastrointestinal neoplasms benign,MDR,Neoplastic Process
PMC9913845,the resection,TREATMENT,PMC,C1533664,Endorectal resection,MTH,Therapeutic or Preventive Procedure
PMC9913845,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9913845,systemic therapies,TREATMENT,PMC,C2936197,Systemic Enzyme Therapy,MSH,Therapeutic or Preventive Procedure
PMC9913845,metastasectomy,TREATMENT,PMC,C2363923,Metastasectomy,MSH,Therapeutic or Preventive Procedure
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,colorectal gastric and pancreatic cancers,PROBLEM,PMC,,,,
PMC9913845,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC9913845,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9913845,metastatic colorectal gastric and pancreatic cancer,PROBLEM,PMC,,,,
PMC9913845,primary tumor progression,PROBLEM,PMC,,,,
PMC9913845,severe symptoms,PROBLEM,PMC,C0436345,Symptom severe,SNOMEDCT_US,Finding
PMC9913845,effective systemic therapy,TREATMENT,PMC,C4480836,adverse effect of antineoplastic natural products,MEDCIN,Pathologic Function
PMC9913845,lifethreatening complications,PROBLEM,PMC,,,,
PMC9913845,retrospective series,TEST,PMC,,,,
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9913845,a survival advantage,TREATMENT,PMC,,,,
PMC9913845,primary tumor resection,TREATMENT,PMC,C5409380,Initial resection of primary malignant tumor of peritoneum with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC9913845,metastatic gastrointestinal colorectal gastric and pancreatic cancers,PROBLEM,PMC,,,,
PMC9913845,systemic therapies,TREATMENT,PMC,C2936197,Systemic Enzyme Therapy,MSH,Therapeutic or Preventive Procedure
PMC9913845,the oncosurgical approach,TREATMENT,PMC,,,,
PMC9913845,precision oncology,TREATMENT,PMC,,,,
PMC9913845,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC9913845,metastatic gastrointestinal malignancies,PROBLEM,PMC,C0346967,Metastatic malignant neoplasm to gastrointestinal tract,SNOMEDCT_US,Neoplastic Process
PMC9913845,crc,PROBLEM,PMC,C0009402,Colorectal Carcinoma,MTH,Neoplastic Process
PMC9913845,systemic therapy,TREATMENT,PMC,C1515119,Systemic Therapy,NCI,Therapeutic or Preventive Procedure
PMC9913845,gastrointestinal tumors,PROBLEM,PMC,C0017185,Gastrointestinal Neoplasms,MTH,Neoplastic Process
PMC9913845,the optimal management,TREATMENT,PMC,C5912150,"Optimize local wound environment through cleansing, debriding, managing bacterial balance and managing moisture balance, as appropriate",NIC,Health Care Activity
PMC9913845,a primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9913845,the lower surgical insult,PROBLEM,PMC,,,,
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,a primary lesion,PROBLEM,PMC,C1402294,Primary Lesion,NCI,Disease or Syndrome
PMC9913845,metastatic crc,PROBLEM,PMC,,,,
PMC9913845,a potentially curative oncosurgical approach,TREATMENT,PMC,,,,
PMC9913845,both colorectal,PROBLEM,PMC,,,,
PMC9913845,neverresectable distant disease,PROBLEM,PMC,,,,
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9913845,acute complications,PROBLEM,PMC,C0395901,Acute mastoiditis with complications,MEDCIN,Disease or Syndrome
PMC9913845,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC9913845,antiangiogenics,TREATMENT,PMC,C0596087,Angiogenesis Inhibitors,MTH,"Pharmacologic Substance, Biologically Active Substance"
PMC9913845,systemic therapies,TREATMENT,PMC,C2936197,Systemic Enzyme Therapy,MSH,Therapeutic or Preventive Procedure
PMC9913845,medical treatments,TREATMENT,PMC,C5828474,Undertreatment,MSH,Health Care Activity
PMC9913845,gc,TREATMENT,PMC,C1704663,GC wt Allele,MTH,Gene or Genome
PMC9913845,perioperative mortality,PROBLEM,PMC,,,,
PMC9913845,postoperative morbidity,PROBLEM,PMC,,,,
PMC9913845,colorectal resection,TREATMENT,PMC,C0192866,Sigmoid colectomy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9913845,routine practice,TREATMENT,PMC,C5913233,Determine current foot care practices and routines,NIC,Health Care Activity
PMC9913845,metastatic pc,TREATMENT,PMC,,,,
PMC9913845,this approach,TREATMENT,PMC,,,,
PMC9913845,limited disease burden,PROBLEM,PMC,,,,
PMC9913845,prolonged distant disease control,TREATMENT,PMC,,,,
PMC9913845,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9913845,clinical trials,TREATMENT,PMC,C0008976,Clinical Trials,MTH,Research Activity
PMC9913845,advanced gc,PROBLEM,PMC,,,,
PMC9913845,regatta,TREATMENT,PMC,,,,
PMC9913845,gastrectomy,TREATMENT,PMC,C0017118,Gastrectomy,MTH,Therapeutic or Preventive Procedure
PMC9913845,the first approach,TREATMENT,PMC,C4711869,Consider nonpharmacological treatments as first approach,NIC,Health Care Activity
PMC9913845,asymptomatic stage iv disease,PROBLEM,PMC,,,,
PMC9913845,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC9913845,an os advantage,TREATMENT,PMC,,,,
PMC9913845,limited metastatic involvement of distant organs or the peritoneum,PROBLEM,PMC,,,,
PMC9913845,firstline therapy,TREATMENT,PMC,,,,
PMC9913845,a stiff algorithm,TREATMENT,PMC,,,,
PMC9913845,different gastrointestinal diseases,PROBLEM,PMC,,,,
PMC9913845,crc,PROBLEM,PMC,C0009402,Colorectal Carcinoma,MTH,Neoplastic Process
PMC9913845,gc,PROBLEM,PMC,C1704663,GC wt Allele,MTH,Gene or Genome
PMC9913845,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9913845,gastrointestinal cancer,PROBLEM,PMC,C0685938,Malignant neoplasm of gastrointestinal tract,MTH,Neoplastic Process
PMC9913845,the biologic events,PROBLEM,PMC,C2047939,illness caused by biologic event,MEDCIN,Finding
PMC9913845,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC9913845,primary tumors,PROBLEM,PMC,C0677930,Primary Neoplasm,MTH,Neoplastic Process
PMC9913845,different gastrointestinal cancers,PROBLEM,PMC,,,,
PMC11898638,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11898638,effective treatment,TREATMENT,PMC,C0510269,Discuss effective and ineffective methods of prior treatment,NIC,Health Care Activity
PMC11898638,a technique,TREATMENT,PMC,C0449851,Techniques,MTH,Functional Concept
PMC11898638,diagnostic imaging,TEST,PMC,C0011923,Diagnostic Imaging,MTH,Diagnostic Procedure
PMC11898638,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC11898638,this systematic review,TEST,PMC,,,,
PMC11898638,radiomics,TREATMENT,PMC,C5828395,Radiomics,MSH,Diagnostic Procedure
PMC11898638,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11898638,ten studies,TEST,PMC,,,,
PMC11898638,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC11898638,machine learning models,TREATMENT,PMC,,,,
PMC11898638,cancerous pancreatic tissue,PROBLEM,PMC,C5976080,Hereditary pancreatic cancer multigene analysis:Find:Pt:Bld/Tiss:Doc:Molgen,LNC,Clinical Attribute
PMC11898638,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC11898638,heterogeneous findings,PROBLEM,PMC,C1268688,Heterogeneous calcification,SNOMEDCT_US,Finding
PMC11898638,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC11898638,further,TEST,PMC,C1517331,Further,NCI,Spatial Concept
PMC11898638,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11898638,an aggressive and lethal malignancy,PROBLEM,PMC,,,,
PMC11898638,low survival rate,PROBLEM,PMC,,,,
PMC11898638,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11898638,anomalies,PROBLEM,PMC,C0000769,teratologic,MTH,Functional Concept
PMC11898638,this systematic literature review,TEST,PMC,,,,
PMC11898638,radiomics,TEST,PMC,C5828395,Radiomics,MSH,Diagnostic Procedure
PMC11898638,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC11898638,pancreatic parenchyma images,TEST,PMC,,,,
PMC11898638,pdac,PROBLEM,PMC,,,,
PMC11898638,methods,TEST,PMC,C0025663,Methods,MTH,Functional Concept
PMC11898638,a systematic,TEST,PMC,C0220922,systematic,MTH,Functional Concept
PMC11898638,extraction,TEST,PMC,C0185115,Extraction,MTH,Therapeutic or Preventive Procedure
PMC11898638,analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC11898638,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC11898638,a quality assessment,TEST,PMC,C0086887,Healthcare Quality Assessment,MSH,Qualitative Concept
PMC11898638,the methodological radiomics score,TEST,PMC,,,,
PMC11898638,the metrics assessment,TEST,PMC,C1706862,Automated Neuropsychological Assessment Metrics,NCI,Intellectual Product
PMC11898638,analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC11898638,ct scan,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11898638,the diagnostic imaging,TEST,PMC,C0011923,Diagnostic Imaging,MTH,Diagnostic Procedure
PMC11898638,all the studies,TEST,PMC,C5447928,ALL Study Identifier,NCI,Intellectual Product
PMC11898638,radiomicsbased machine learning models,TREATMENT,PMC,,,,
PMC11898638,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11898638,a diagnostic accuracy,TEST,PMC,C0598285,Diagnostic Accuracy,NCI,Qualitative Concept
PMC11898638,texture and shape features,PROBLEM,PMC,,,,
PMC11898638,the metrics scoring assessment,TEST,PMC,,,,
PMC11898638,external validation,TEST,PMC,,,,
PMC11898638,the qualitative assessment,TEST,PMC,C3526443,Qualitative assessment of leukocytes in feces,CPT,Laboratory Procedure
PMC11898638,high heterogeneity,PROBLEM,PMC,,,,
PMC11898638,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11898638,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC11898638,the radiomic features,PROBLEM,PMC,,,,
PMC11898638,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC11898638,radiomics,TREATMENT,PMC,C5828395,Radiomics,MSH,Diagnostic Procedure
PMC11898638,pdac,PROBLEM,PMC,,,,
PMC11898638,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11898638,the deadliest cancers,PROBLEM,PMC,,,,
PMC11898638,diagnostic scans,TEST,PMC,C2123600,molecular diagnostics mutation scanning,MEDCIN,Laboratory Procedure
PMC11898638,pdac,PROBLEM,PMC,,,,
PMC11898638,our systematic,TEST,PMC,,,,
PMC11898638,radiomic models,TEST,PMC,,,,
PMC11898638,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11898638,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC11898638,important issues,PROBLEM,PMC,C3898227,Most Important Issue,NCI,Intellectual Product
PMC11898638,inconsistent segmentation,PROBLEM,PMC,,,,
PMC11898638,preprocessing techniques,TEST,PMC,,,,
PMC11898638,ai guidelinesfactors,TREATMENT,PMC,,,,
PMC11898638,radiomic models,TEST,PMC,,,,
PMC11898638,most studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC11898638,ct scans,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11898638,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC11898638,pdac screening,TEST,PMC,,,,
PMC11898638,standardized imaging protocols,TEST,PMC,,,,
PMC11898638,both ct,TEST,PMC,C1960905,CT of both ankles,SNOMEDCT_US,Diagnostic Procedure
PMC11898638,ct imaging,TEST,PMC,C3839509,Cone beam CT imaging - action,SNOMEDCT_US,Diagnostic Procedure
PMC11898638,model development,PROBLEM,PMC,C0920595,model development,CHV,Intellectual Product
PMC11898638,greylevel discretization,PROBLEM,PMC,,,,
PMC11898638,texture coarseness,PROBLEM,PMC,C0277959,Coarse hair,MTH,Finding
PMC11898638,deviations from sphericity in pancreatic lesions,PROBLEM,PMC,,,,
PMC11898638,large prospective studies,TEST,PMC,,,,
PMC11898638,retrospective mri data,TEST,PMC,,,,
PMC11898638,the sample,TEST,PMC,C0475880,Sample hemolyzed,MTH,Finding
PMC11898638,integrating mriderived,TEST,PMC,,,,
PMC11898638,these technologies,TEST,PMC,,,,
PMC11898638,prospective studies,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC11898638,standardized methodologies,TEST,PMC,,,,
PMC11898638,pdac,PROBLEM,PMC,,,,
PMC5237291,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5237291,cancer related mortalities,PROBLEM,PMC,,,,
PMC5237291,sigma2,TREATMENT,PMC,C1870051,"sigma-2 receptor, human",MTH,"Amino Acid, Peptide, or Protein, Receptor"
PMC5237291,several tumors,PROBLEM,PMC,,,,
PMC5237291,triggering selective pancreatic cancer cells death,PROBLEM,PMC,,,,
PMC5237291,diverse pancreatic cancer cells,PROBLEM,PMC,,,,
PMC5237291,mia,TEST,PMC,C1417154,MIA gene,MTH,Gene or Genome
PMC5237291,panc1,TEST,PMC,C2987413,siG12D LODER,DRUGBANK,"Organic Chemical, Pharmacologic Substance"
PMC5237291,a tumor model,TEST,PMC,C1710493,Tumor Model,NCI,Intellectual Product
PMC5237291,important cytotoxicity,PROBLEM,PMC,,,,
PMC5237291,the aggressive panc02 cells,TREATMENT,PMC,,,,
PMC5237291,cytotoxic activity,TEST,PMC,C3810131,Decreased cytotoxic T cell activity,OMIM,Finding
PMC5237291,both cytotoxicity,TEST,PMC,,,,
PMC5237291,caspase3 activation,PROBLEM,PMC,,,,
PMC5237291,reactive oxygen species,PROBLEM,PMC,C0162772,Reactive Oxygen Species,MTH,"Biologically Active Substance, Element, Ion, or Isotope"
PMC5237291,the lipid antioxidant tocopherol,TREATMENT,PMC,,,,
PMC5237291,the hydrophilic nacetylcysteine nac,TREATMENT,PMC,,,,
PMC5237291,crucial differences,PROBLEM,PMC,,,,
PMC5237291,oxidative stress,PROBLEM,PMC,C0242606,Oxidative Stress,MTH,Cell or Molecular Dysfunction
PMC5237291,sigma2 receptor ligands,TREATMENT,PMC,,,,
PMC5237291,mitochondrial superoxide radicals,TREATMENT,PMC,,,,
PMC5237291,a poor match,PROBLEM,PMC,,,,
PMC5237291,the in vivo efficacy,TREATMENT,PMC,,,,
PMC5237291,panc02 tumors,PROBLEM,PMC,,,,
PMC5237291,pb28,TEST,PMC,C1744172,PB28 compound,MSH,Organic Chemical
PMC5237291,the current standardofcare chemotherapeutic gemcitabine,TREATMENT,PMC,,,,
PMC5237291,systemic toxicities,PROBLEM,PMC,C4552199,Systemic toxicity,MDR,Pathologic Function
PMC5237291,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5237291,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC5237291,the mitochondrial superoxide pathway,PROBLEM,PMC,,,,
PMC5237291,a previously unrecognized sigma2 receptoractivated process,PROBLEM,PMC,,,,
PMC5237291,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC5237291,sigma2 ligandmediated cancer cell death,PROBLEM,PMC,,,,
PMC5237291,the targeted treatment,TREATMENT,PMC,C2223983,pressure targeted mechanical ventilation,MEDCIN,Therapeutic or Preventive Procedure
PMC5237291,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC5237291,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5237291,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC5237291,the mitochondrial superoxide pathway,PROBLEM,PMC,,,,
PMC5237291,a previously unrecognized sigma2 receptoractivated process,PROBLEM,PMC,,,,
PMC5237291,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC5237291,sigma2 ligandmediated cancer cell death,PROBLEM,PMC,,,,
PMC5237291,the targeted treatment,TREATMENT,PMC,C2223983,pressure targeted mechanical ventilation,MEDCIN,Therapeutic or Preventive Procedure
PMC5237291,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC5237291,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5237291,sigma2 receptors,PROBLEM,PMC,C1870051,"sigma-2 receptor, human",MTH,"Amino Acid, Peptide, or Protein, Receptor"
PMC5237291,the targeted treatment,TREATMENT,PMC,C2223983,pressure targeted mechanical ventilation,MEDCIN,Therapeutic or Preventive Procedure
PMC5237291,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC5237291,mitochondrial superoxide production,PROBLEM,PMC,,,,
PMC5237291,sigma2 receptormediated cell death,PROBLEM,PMC,,,,
PMC8867748,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8867748,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC8867748,a low overall survival rate,PROBLEM,PMC,,,,
PMC8867748,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8867748,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC8867748,biopsy,TEST,PMC,C0005558,Biopsy,MTH,Diagnostic Procedure
PMC8867748,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8867748,a new strategy,TREATMENT,PMC,C1518320,New Prevention Strategies Against Disease,NCI,Research Activity
PMC8867748,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC8867748,dopamine coated fe3o4nanoparticles,TREATMENT,PMC,,,,
PMC8867748,separate free 6carboxyfluorescein fam labeled dna,TREATMENT,PMC,,,,
PMC8867748,hybridization chain reaction,TEST,PMC,,,,
PMC8867748,three different pancreatic cancer cell lines,PROBLEM,PMC,,,,
PMC8867748,the fluorescence intensity,TEST,PMC,C5575598,Fluorescence Intensity,MTH,Qualitative Concept
PMC8867748,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC8867748,hepg2,TREATMENT,PMC,C0145466,TFI HepG2,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance"
PMC8867748,lower muc1 protein,PROBLEM,PMC,,,,
PMC8867748,the hcr amplification system,TEST,PMC,,,,
PMC8867748,the cancer cells,PROBLEM,PMC,C1956422,Cancer Stem Cells,MSH,Cell
PMC8867748,pancreatic tissue,PROBLEM,PMC,C0994638,Ectopic pancreatic tissue,HPO,Finding
PMC8867748,our strategy,TREATMENT,PMC,,,,
PMC8867748,the presented detection strategy,TEST,PMC,,,,
PMC8867748,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8867748,easy operating strategy,TREATMENT,PMC,,,,
PMC8867748,muc1 overexpressed pancreatic cancer,PROBLEM,PMC,,,,
PMC8867748,hcr,TEST,PMC,C3274833,CCHCR1 wt Allele,MTH,Gene or Genome
PMC8867748,magnetic fe3o4dop nps,TREATMENT,PMC,,,,
PMC8867748,the detection sensitivity,TEST,PMC,C5413572,"Measurement C-reactive protein for detection of infection or inflammation, high sensitivity",CPT,Laboratory Procedure
PMC8867748,the signal amplification,TEST,PMC,C3836827,signal amplification,MEDCIN,Laboratory Procedure
PMC8867748,hcr,TEST,PMC,C3274833,CCHCR1 wt Allele,MTH,Gene or Genome
PMC8867748,dopamine layer,TREATMENT,PMC,,,,
PMC8867748,muc1 aptcell,TEST,PMC,,,,
PMC8867748,the lods,TEST,PMC,C0023956,Lod Score,MSH,Quantitative Concept
PMC8867748,three pancreatic cancer cell lines,PROBLEM,PMC,,,,
PMC8867748,fe3o4dop nps,TREATMENT,PMC,,,,
PMC8867748,fluorescence background on tissues,PROBLEM,PMC,,,,
PMC8867748,enzyme,TEST,PMC,C0014442,Enzymes,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8867748,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC8867748,muc1 overexpressed cancer cells,PROBLEM,PMC,,,,
PMC8867748,other pancreatic cancer biomarkers,PROBLEM,PMC,,,,
PMC11686566,early pancreatic adenocarcinoma,PROBLEM,PMC,C5204114,Early Stage Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC11686566,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11686566,two main precancerous routes,PROBLEM,PMC,,,,
PMC11686566,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11686566,mucinous cystic lesions,PROBLEM,PMC,,,,
PMC11686566,intraductal papillary mucinous neoplasm,PROBLEM,PMC,C3160815,Intraductal papillary mucinous neoplasm,SNOMEDCT_US,Neoplastic Process
PMC11686566,mucinous cystic neoplasm,PROBLEM,PMC,C5428759,mucinous cystic neoplasm of liver,MEDCIN,Neoplastic Process
PMC11686566,pancreatic intraepithelial neoplasia,PROBLEM,PMC,C1301034,Pancreatic intraepithelial neoplasia,MTH,Neoplastic Process
PMC11686566,advanced imaging techniques,TEST,PMC,,,,
PMC11686566,endoscopic ultrasonography,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11686566,early stage pancreatic lesions,PROBLEM,PMC,,,,
PMC11686566,the survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11686566,alternative screening methods,TEST,PMC,,,,
PMC11686566,endoscopic retrograde cholangiopancreatography,TEST,PMC,C0008310,Endoscopic Retrograde Cholangiopancreatography,MTH,Diagnostic Procedure
PMC11686566,serial pancreatic juice aspiration cytology,TEST,PMC,,,,
PMC11686566,precursor lesions,PROBLEM,PMC,C5787479,Myeloid precursor lesion,SNOMEDCT_US,Neoplastic Process
PMC11686566,intraductal papillary mucinous neoplasm,PROBLEM,PMC,C3160815,Intraductal papillary mucinous neoplasm,SNOMEDCT_US,Neoplastic Process
PMC11686566,crosssectional imaging,TEST,PMC,,,,
PMC11686566,endoscopic techniques,TEST,PMC,C5880534,Endoscopic polypectomy of large intestine using lifting technique,SNOMEDCT_US,Diagnostic Procedure
PMC11686566,genetic and biological biomarkers,TEST,PMC,,,,
PMC11686566,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC11686566,early pancreatic lesions,PROBLEM,PMC,,,,
PMC11686566,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC11686566,diagnostic algorithms,TEST,PMC,C0679508,diagnostic tree,CHV,Intellectual Product
PMC11686566,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11686566,early pancreatic adenocarcinoma,PROBLEM,PMC,C5204114,Early Stage Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC11686566,a,TEST,PMC,,,,
PMC11686566,most pcs,PROBLEM,PMC,C1867791,PCS involves most of all chromosomes of a metaphase,OMIM,Finding
PMC11686566,metastatic stage,PROBLEM,PMC,C0741680,BREAST CANCER NOS METASTATIC END STAGE,CCPSS,Neoplastic Process
PMC11686566,the highly aggressive characteristics,PROBLEM,PMC,,,,
PMC11686566,typical early symptoms of pc,PROBLEM,PMC,,,,
PMC11686566,many studies,TEST,PMC,C3171825,How many Y were you regularly exposed to this material:Time:Pt:^Patient:Qn:ACSCP Study II,LNC,Clinical Attribute
PMC11686566,a slight dilatation of the mpd,PROBLEM,PMC,,,,
PMC11686566,caudal pd dilation,PROBLEM,PMC,,,,
PMC11686566,small cystic lesions,PROBLEM,PMC,,,,
PMC11686566,early markers,TEST,PMC,,,,
PMC11686566,these abnormal findings,PROBLEM,PMC,,,,
PMC11686566,hris,TEST,PMC,C4742809,"HRI protein, mouse",MSH,"Amino Acid, Peptide, or Protein"
PMC11686566,an effective screening system,TEST,PMC,,,,
PMC11686566,diagnostic imaging,TEST,PMC,C0011923,Diagnostic Imaging,MTH,Diagnostic Procedure
PMC11686566,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11686566,ercp,TEST,PMC,C1548852,Consent Type - ERCP,MTH,Health Care Activity
PMC11686566,analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC11686566,pancreatic juice,TREATMENT,PMC,C0030296,pancreatic juice,MTH,Body Substance
PMC11686566,artificial intelligence,TREATMENT,PMC,C0003916,Artificial Intelligence,MSH,Occupation or Discipline
PMC11686566,molecular genetic changes,PROBLEM,PMC,C5188357,amino acid change in blood or tissue by molecular genetics method,MEDCIN,Laboratory Procedure
PMC11686566,appropriate targeting medications,TREATMENT,PMC,,,,
PMC11686566,treatment plans,TREATMENT,PMC,C0599880,Treatment Plan,MTH,Intellectual Product
PMC11686566,the progression of panins,PROBLEM,PMC,,,,
PMC11686566,hgpanin,PROBLEM,PMC,,,,
PMC11686566,early stage disease,PROBLEM,PMC,C1836879,Early-onset end-stage renal disease,OMIM,Finding
PMC11686566,further prospective studies,TEST,PMC,,,,
PMC11686566,new methods,TEST,PMC,C1318827,New fuchsin stain method,MTH,Laboratory Procedure
PMC11686566,earlystage pc,PROBLEM,PMC,,,,
PMC11686566,therapeutic algorithms,TREATMENT,PMC,C4732277,"Cancer RNA gene expression profiling by whole transcriptome sequencing in fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",CPT,Laboratory Procedure
PMC11686566,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC11686566,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC11686566,space,TEST,PMC,C1883067,Space - property,MTH,Spatial Concept
PMC11686566,pops application,TREATMENT,PMC,C0409135,Application of plaster cast,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11686566,screening programs,TEST,PMC,C4704706,Diagnostic Screening Programs,MSH,Diagnostic Procedure
PMC11686566,genetic and molecular biomarkers,TEST,PMC,C4684828,CTRP Molecular Genetic Biomarker Terminology,NCI,Intellectual Product
PMC4765158,hematemesis,PROBLEM,PMC,C0018926,Hematemesis,MTH,Sign or Symptom
PMC4765158,an initial presenting symptom,PROBLEM,PMC,,,,
PMC4765158,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4765158,a pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,ruptured,PROBLEM,PMC,C3203359,Rupture,MTH,Injury or Poisoning
PMC4765158,fistulized into the stomach,PROBLEM,PMC,C0193589,Transposition of biliary fistulous tract into stomach,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC4765158,the pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,a pancreatic pseudocyst,PROBLEM,PMC,C0030299,Pancreatic Pseudocyst,MSH,Disease or Syndrome
PMC4765158,obstructive pancreatitis,PROBLEM,PMC,C4302455,Pancreatitis due to pancreatic duct obstruction,SNOMEDCT_US,Disease or Syndrome
PMC4765158,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4765158,transarterial embolization,TREATMENT,PMC,C3163695,Transarterial embolization,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC4765158,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC4765158,hematemesis,PROBLEM,PMC,C0018926,Hematemesis,MTH,Sign or Symptom
PMC4765158,laboratory examinations,TEST,PMC,C0260877,Laboratory examination,ICD10,Finding
PMC4765158,a low level of hemoglobin,PROBLEM,PMC,C5207071,Low Hemoglobin Level,NCI,Finding
PMC4765158,hematemesis,PROBLEM,PMC,C0018926,Hematemesis,MTH,Sign or Symptom
PMC4765158,a lowdensity mass in the pancreatic body,PROBLEM,PMC,,,,
PMC4765158,dilatation of the distal main pancreatic duct,PROBLEM,PMC,,,,
PMC4765158,a pseudocyst in the pancreatic tail,PROBLEM,PMC,,,,
PMC4765158,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC4765158,abdominal computed tomography,TEST,PMC,C5151313,Abdominal Aorta | Computed tomography | Radiology,LNC,"Body Part, Organ, or Organ Component"
PMC4765158,a pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,the pseudocyst of the pancreatic tail,PROBLEM,PMC,,,,
PMC4765158,the pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,abdominal computed tomography,TEST,PMC,C5151313,Abdominal Aorta | Computed tomography | Radiology,LNC,"Body Part, Organ, or Organ Component"
PMC4765158,emergency selective angiography,TEST,PMC,,,,
PMC4765158,the pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,transarterial embolization of the left gastroepiploic artery,TREATMENT,PMC,,,,
PMC4765158,elective distal pancreatectomy,TREATMENT,PMC,,,,
PMC4765158,splenectomy,TREATMENT,PMC,C0037995,Splenectomy,MSH,Therapeutic or Preventive Procedure
PMC4765158,regional lymph node dissection,TREATMENT,PMC,C1709883,Regional Lymph Node Dissection,NCI,Therapeutic or Preventive Procedure
PMC4765158,partial resection of the stomach,TREATMENT,PMC,C0200817,"Surgical pathology gross and microscopic examination, complex",MTH,Laboratory Procedure
PMC4765158,coil embolization,TREATMENT,PMC,C0522644,Embolization coil,SNOMEDCT_US,Medical Device
PMC4765158,pathological examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC4765158,a moderately differentiated tubular adenocarcinoma in the pancreatic body,PROBLEM,PMC,,,,
PMC4765158,regional lymph node metastasis,PROBLEM,PMC,C1275854,Regional lymph node metastasis present,SNOMEDCT_US,Finding
PMC4765158,the pseudoaneurysm rupturing,PROBLEM,PMC,C1096532,Vascular pseudoaneurysm ruptured,MDR,Disease or Syndrome
PMC4765158,the pancreatic pseudocyst,PROBLEM,PMC,C0030299,Pancreatic Pseudocyst,MSH,Disease or Syndrome
PMC4765158,tumor recurrence,PROBLEM,PMC,C0521158,Recurrent tumor,MTH,Neoplastic Process
PMC4765158,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC4765158,spontaneous rupture,PROBLEM,PMC,C0035956,"Rupture, Spontaneous",MSH,Pathologic Function
PMC4765158,a pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,lethal complication,PROBLEM,PMC,,,,
PMC4765158,a pancreatic pseudocyst,PROBLEM,PMC,C0030299,Pancreatic Pseudocyst,MSH,Disease or Syndrome
PMC4765158,alcoholism,PROBLEM,PMC,C0001973,"Alcoholic Intoxication, Chronic",MTH,Mental or Behavioral Dysfunction
PMC4765158,acute or chronic pancreatitis,PROBLEM,PMC,C0262417,Acute on chronic pancreatitis,SNOMEDCT_US,Disease or Syndrome
PMC4765158,a hemorrhagic pancreatic pseudocyst,PROBLEM,PMC,C5243899,Pancreatic pseudocyst haemorrhage,MDR,Disease or Syndrome
PMC4765158,obstructive pancreatitis,PROBLEM,PMC,C4302455,Pancreatitis due to pancreatic duct obstruction,SNOMEDCT_US,Disease or Syndrome
PMC4765158,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4765158,spontaneous rupture,PROBLEM,PMC,C0035956,"Rupture, Spontaneous",MSH,Pathologic Function
PMC4765158,a pseudoaneurysm,PROBLEM,PMC,C1510412,Pseudoaneurysm,MTH,Pathologic Function
PMC4765158,lethal complication,PROBLEM,PMC,,,,
PMC4765158,a pancreatic pseudocyst,PROBLEM,PMC,C0030299,Pancreatic Pseudocyst,MSH,Disease or Syndrome
PMC4765158,alcoholism,PROBLEM,PMC,C0001973,"Alcoholic Intoxication, Chronic",MTH,Mental or Behavioral Dysfunction
PMC4765158,acute or chronic pancreatitis,PROBLEM,PMC,C0262417,Acute on chronic pancreatitis,SNOMEDCT_US,Disease or Syndrome
PMC4765158,a hemorrhagic pancreatic pseudocyst,PROBLEM,PMC,C5243899,Pancreatic pseudocyst haemorrhage,MDR,Disease or Syndrome
PMC4765158,obstructive pancreatitis,PROBLEM,PMC,C4302455,Pancreatitis due to pancreatic duct obstruction,SNOMEDCT_US,Disease or Syndrome
PMC4765158,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4765158,a hemorrhagic pancreatic pseudocyst,PROBLEM,PMC,C5243899,Pancreatic pseudocyst haemorrhage,MDR,Disease or Syndrome
PMC4765158,ruptured into the stomach,PROBLEM,PMC,,,,
PMC4765158,obstructive pancreatitis,PROBLEM,PMC,C4302455,Pancreatitis due to pancreatic duct obstruction,SNOMEDCT_US,Disease or Syndrome
PMC4765158,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4765158,tae,TREATMENT,PMC,C2001625,TAE226,MSH,"Organic Chemical, Pharmacologic Substance"
PMC4765158,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC4765158,tae,PROBLEM,PMC,C2001625,TAE226,MSH,"Organic Chemical, Pharmacologic Substance"
PMC4765158,a hemorrhage,PROBLEM,PMC,C0019080,Hemorrhage,MTH,Pathologic Function
PMC4765158,the subsequent curative surgery,TREATMENT,PMC,,,,
PMC4765158,any accompanying images,TEST,PMC,,,,
PMC4765158,the written consent,TREATMENT,PMC,C0811746,Obtain written consent,NIC,Health Care Activity
PMC5241525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5241525,all cancers,PROBLEM,PMC,C5225783,Skin cancers - all other types,CCSR_ICD10CM,Neoplastic Process
PMC5241525,identifiable symptoms,PROBLEM,PMC,C4718335,Identifies symptoms of disease progression,NOC,Finding
PMC5241525,high resistance,PROBLEM,PMC,C4740643,High-level resistance,LNC,Organism Attribute
PMC5241525,chemo,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC5241525,radiation therapies,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC5241525,a cancer development phase,PROBLEM,PMC,,,,
PMC5241525,epithelialmesenchymal transition,PROBLEM,PMC,,,,
PMC5241525,tumour metastasis,PROBLEM,PMC,C0027627,Neoplasm Metastasis,MTH,Neoplastic Process
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,several cancers,PROBLEM,PMC,C4699388,Severe cancer,LNC,Neoplastic Process
PMC5241525,therapeutic targeting of emt,TREATMENT,PMC,,,,
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC5241525,chemoresistance,TREATMENT,PMC,C4320409,IQANK1 gene,MTH,Gene or Genome
PMC5241525,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC5241525,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC5241525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5241525,the emt process,PROBLEM,PMC,,,,
PMC5241525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,blocking extracellular signalling molecules,TREATMENT,PMC,,,,
PMC5241525,tgf1,PROBLEM,PMC,,,,
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC5241525,emt signal transduction pathways1,PROBLEM,PMC,,,,
PMC5241525,loss of ecadherinmediated cell adhesion,PROBLEM,PMC,,,,
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,subsequent invasion,PROBLEM,PMC,,,,
PMC5241525,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC5241525,transcriptional factors,PROBLEM,PMC,C0040648,TRANSCRIPTION FACTOR,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5241525,ecadherin translocation,PROBLEM,PMC,,,,
PMC5241525,loss of function,PROBLEM,PMC,C5243608,Loss of foveal function,MDR,Disease or Syndrome
PMC5241525,emt,TREATMENT,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,several studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC5241525,disruption in tgf signalling,PROBLEM,PMC,,,,
PMC5241525,pancreatic cancer3032,PROBLEM,PMC,,,,
PMC5241525,the mesenchymal transcriptional factors,PROBLEM,PMC,,,,
PMC5241525,tgf receptors,TREATMENT,PMC,,,,
PMC5241525,emtderived chemoresistance,PROBLEM,PMC,,,,
PMC5241525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5241525,emerging studies,TEST,PMC,,,,
PMC5241525,emt in cancer,PROBLEM,PMC,C3889757,SLC25A25-AS1 gene,MTH,Gene or Genome
PMC5241525,the phenotypic alteration,PROBLEM,PMC,,,,
PMC5241525,tumour cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC5241525,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC5241525,emtinducing transcriptional factors,PROBLEM,PMC,,,,
PMC5241525,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC5241525,a single targeted molecular therapy,TREATMENT,PMC,,,,
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,chemotherapy resistance,TREATMENT,PMC,C2363824,Chemotherapy sensitivity and resistance assay,MDR,Laboratory Procedure
PMC5241525,cancer cell survival pathways,PROBLEM,PMC,,,,
PMC5241525,drug,PROBLEM,PMC,C1254351,Pharmacologic Substance,MTH,Pharmacologic Substance
PMC5241525,drug metabolising enzymes,TEST,PMC,C3203673,Drug metabolising enzyme test,MDR,Laboratory Procedure
PMC5241525,novel approaches,TREATMENT,PMC,,,,
PMC5241525,inhibit chemoresistance,PROBLEM,PMC,,,,
PMC5241525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5241525,tempering cancer emt,TREATMENT,PMC,,,,
PMC5241525,a combined immunotherapy,TREATMENT,PMC,,,,
PMC5241525,moleculartargeted drug strategies,TREATMENT,PMC,,,,
PMC5241525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5241525,several signalling pathways,PROBLEM,PMC,,,,
PMC5241525,epithelialmesenchymal transition,PROBLEM,PMC,,,,
PMC5241525,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC5241525,example notch,PROBLEM,PMC,,,,
PMC5241525,transforming growth factor,PROBLEM,PMC,,,,
PMC5241525,midkine,TREATMENT,PMC,C0128479,midkine,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5241525,hypoxiainducible factor1,PROBLEM,PMC,,,,
PMC5241525,tumor necrosis factor,PROBLEM,PMC,,,,
PMC5241525,emt phenotype,PROBLEM,PMC,,,,
PMC5241525,gemcitabine resistance,TREATMENT,PMC,,,,
PMC5241525,emt factors,PROBLEM,PMC,,,,
PMC5241525,snail,PROBLEM,PMC,C0037378,Snails,MTH,Eukaryote
PMC5241525,gemcitabine resistance,TREATMENT,PMC,,,,
PMC5241525,ent1 and cnt3 upregulation,PROBLEM,PMC,,,,
PMC5241525,kpc,TEST,PMC,C1855645,Keratoconus posticus circumscriptus,MSH,Disease or Syndrome
PMC5241525,deleted snail,PROBLEM,PMC,,,,
PMC5241525,twist,PROBLEM,PMC,C0231467,Twisted,MTH,Spatial Concept
PMC5241525,emt independent pathways,PROBLEM,PMC,,,,
PMC5241525,gemcitabine resistance,TREATMENT,PMC,,,,
PMC5241525,example mapk activation,PROBLEM,PMC,,,,
PMC5241525,transporter proteins,TREATMENT,PMC,C1564132,Neurotransmitter Transport Proteins,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5241525,gemcitabine metabolising enzymes,TREATMENT,PMC,,,,
PMC5241525,cdd,PROBLEM,PMC,C2698602,CDA wt Allele,MTH,Gene or Genome
PMC5241525,mrp1,TEST,PMC,C0210995,"mismatch repair protein 1, human",MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5241525,multidrug resistance protein1,PROBLEM,PMC,,,,
PMC5241525,cdd,TEST,PMC,C2698602,CDA wt Allele,MTH,Gene or Genome
PMC5241525,cytidine deaminase,TEST,PMC,C0010723,Cytidine Deaminase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC5241525,tgf,TEST,PMC,C0076930,Transforming Growth Factor beta Receptors,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor, Receptor"
PMC5241525,transforming,TEST,PMC,C1510411,metaplastic cell transformation,MTH,Pathologic Function
PMC5241525,hif1,TEST,PMC,,,,
PMC5241525,hypoxiainducible factor1,PROBLEM,PMC,,,,
PMC5241525,tnf,TEST,PMC,C1143119,"tumor necrosis factor-alpha, CNGRC fusion protein, human",MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC5241525,tumor necrosis factor,PROBLEM,PMC,,,,
PMC5241525,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC5241525,epithelialmesenchymal transition,PROBLEM,PMC,,,,
PMC5241525,equilibrative nucleoside transporter,TREATMENT,PMC,C0533642,Equilibrative Nucleoside Transporter 1,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5241525,concentrative nucleotide transporter,TREATMENT,PMC,,,,
PMC7768873,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,this understudied malignant tumor,PROBLEM,PMC,,,,
PMC7768873,precancerous diseases,PROBLEM,PMC,C3540527,NCI CTEP SDC Head and Neck Precancerous Condition Sub-Category Terminology,MTH,Intellectual Product
PMC7768873,screening approaches,TEST,PMC,C5913442,"Work to develop policies and protocols within organizations to streamline screening, assessment, and response and ensure systematic approach to human trafficking identification and intervention",NIC,Health Care Activity
PMC7768873,prevention,TREATMENT,PMC,C2700409,prevention aspects,MTH,Qualitative Concept
PMC7768873,early detection measures,TREATMENT,PMC,,,,
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,a highly invasive malignant tumor,PROBLEM,PMC,,,,
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC7768873,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC7768873,the deadliest cancers,PROBLEM,PMC,,,,
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,previous studies,TEST,PMC,C5962734,Previous Study Subject Noncompliance,NCI,Individual Behavior
PMC7768873,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC7768873,highrisk factors,PROBLEM,PMC,,,,
PMC7768873,recent studies,TEST,PMC,C3642031,C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date,NCI,Intellectual Product
PMC7768873,abnormal metabolism of human microorganisms,PROBLEM,PMC,,,,
PMC7768873,blood type,TEST,PMC,C1383165,Blood Type,MTH,Clinical Attribute
PMC7768873,glucose and lipid levels,TEST,PMC,C4714407,"Monitor serum albumin, total protein, electrolyte, lipid profiles, glucose levels, and chemistry profile",NIC,Health Care Activity
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,the many tumor markers,PROBLEM,PMC,,,,
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,the early detection rate,TEST,PMC,,,,
PMC7768873,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7768873,the microbiologyfree system,TREATMENT,PMC,,,,
PMC7768873,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC7768873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC7768873,highrisk individuals,PROBLEM,PMC,,,,
PMC7768873,earlystage pc,PROBLEM,PMC,,,,
PMC7768873,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC7768873,optimal imaging techniques,TEST,PMC,,,,
PMC7768873,previous studies,TEST,PMC,C5962734,Previous Study Subject Noncompliance,NCI,Individual Behavior
PMC7768873,metastasis of pc,PROBLEM,PMC,,,,
PMC7768873,microorganisms,PROBLEM,PMC,C0445623,Microorganism,MTH,Organism
PMC7768873,the human microbial system,TEST,PMC,,,,
PMC7768873,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC7768873,therapeutic drugs,TREATMENT,PMC,C0580398,Drug level therapeutic,MDR,Laboratory or Test Result
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,microbial systems,PROBLEM,PMC,C0201148,"Microbial identification, Minitek yeast system",SNOMEDCT_US,Laboratory Procedure
PMC7768873,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7768873,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7768873,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC7768873,pc cells,PROBLEM,PMC,C3890720,PC-3 cell line,MTH,Cell
PMC7768873,cancer occurrence,PROBLEM,PMC,,,,
PMC7768873,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,developing methods,TREATMENT,PMC,C0178742,Method Development,NCI,Research Activity
PMC7768873,the cancerassociated microbial system,PROBLEM,PMC,,,,
PMC7768873,immunogenomics,TEST,PMC,,,,
PMC7768873,gut microgenomics,TEST,PMC,,,,
PMC7768873,microbial systems,TREATMENT,PMC,C0201148,"Microbial identification, Minitek yeast system",SNOMEDCT_US,Laboratory Procedure
PMC7768873,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC7768873,exciting clinical applications,TREATMENT,PMC,,,,
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,most immunotherapeutics,TREATMENT,PMC,,,,
PMC7768873,other malignancies,PROBLEM,PMC,C3275888,Associated with other malignancies,OMIM,Finding
PMC7768873,pancreatic tumor cells,PROBLEM,PMC,C5848150,Pancreatic Insulin-Producing Neuroendocrine Tumor,MTH,Neoplastic Process
PMC7768873,the immune tolerance mechanism,PROBLEM,PMC,,,,
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7768873,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,cancerrelated deaths,PROBLEM,PMC,,,,
PMC6396775,its toll,TEST,PMC,,,,
PMC6396775,vast differences,PROBLEM,PMC,,,,
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC6396775,cataloging of,PROBLEM,PMC,C0175912,"Cataloging, Cooperative",LCH,Occupational Activity
PMC6396775,cancer cases,PROBLEM,PMC,C5453899,Cancer case,LNC,Finding
PMC6396775,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6396775,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,the most lethal malignant neoplasms,PROBLEM,PMC,,,,
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC6396775,pancreatic carcinoma,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC6396775,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC6396775,genetic factorshelicobacter,PROBLEM,PMC,,,,
PMC6396775,nono blood group,PROBLEM,PMC,,,,
PMC6396775,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC6396775,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC6396775,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6396775,newer techniques,TEST,PMC,,,,
PMC6396775,the screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC6396775,primary prevention,TREATMENT,PMC,C0033144,Primary Prevention,MSH,Therapeutic or Preventive Procedure
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,the causative risk factors,PROBLEM,PMC,,,,
PMC6396775,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,a global problem,PROBLEM,PMC,,,,
PMC6396775,a global solution,TREATMENT,PMC,,,,
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,lifestyle changes,TREATMENT,PMC,C0870811,Lifestyle changes,MTH,Social Behavior
PMC6396775,awareness campaigns,TREATMENT,PMC,C0814368,employee education and awareness campaign,AOD,Educational Activity
PMC6396775,analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC6396775,pancreatic cancer epidemiology,PROBLEM,PMC,,,,
PMC6396775,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6396775,future cancer control strategies,TREATMENT,PMC,,,,
PMC7771041,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7771041,chemoradiotherapy,TREATMENT,PMC,C0436307,Chemoradiotherapy,MTH,Therapeutic or Preventive Procedure
PMC7771041,conversion surgery,TREATMENT,PMC,C3494226,Conversion to Open Surgery,MSH,Therapeutic or Preventive Procedure
PMC7771041,improving tumor shrinkage,PROBLEM,PMC,,,,
PMC7771041,initially unresectable locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC7771041,conversion surgeries,TREATMENT,PMC,C3494226,Conversion to Open Surgery,MSH,Therapeutic or Preventive Procedure
PMC7771041,arterial reconstruction,TREATMENT,PMC,C2937236,Reconstruction of artery,MTH,Therapeutic or Preventive Procedure
PMC7771041,initially unresectable lapc,PROBLEM,PMC,,,,
PMC7771041,safe arterial reconstruction,TREATMENT,PMC,,,,
PMC7771041,successful conversion surgery,TREATMENT,PMC,,,,
PMC7771041,initially unresectable lapc,PROBLEM,PMC,,,,
PMC7771041,splenic artery transposition,TREATMENT,PMC,,,,
PMC7771041,hepatic arterial reconstruction,TREATMENT,PMC,,,,
PMC7771041,gemcitabinenabpaclitaxel,TREATMENT,PMC,,,,
PMC7771041,evaluation,TEST,PMC,C0220825,Evaluation,MTH,Health Care Activity
PMC7771041,a pancreatic head mass,PROBLEM,PMC,C2123110,magnetic resonance cholangiopancreatography: mass of head of pancreas,MEDCIN,Finding
PMC7771041,developing diabetes,PROBLEM,PMC,C5934766,Identifies risk factors of developing type 2 diabetes,NOC,Finding
PMC7771041,unresectable lapc,PROBLEM,PMC,,,,
PMC7771041,gnp,TREATMENT,PMC,C0018250,Gross National Product,MTH,Quantitative Concept
PMC7771041,disease control,TREATMENT,PMC,C0920467,disorder control (procedure),MTH,Therapeutic or Preventive Procedure
PMC7771041,serum carbohydrate antigen,TEST,PMC,C4684410,Elevated Serum CA-125 Tumor Antigen,NCI,Finding
PMC7771041,radical subtotal stomachpreserving pancreaticoduodenectomy,TREATMENT,PMC,,,,
PMC7771041,chapha,TREATMENT,PMC,,,,
PMC7771041,portal vein pv resection,TREATMENT,PMC,,,,
PMC7771041,histopathological examination,TEST,PMC,C5578069,Histopathology examination,MDR,Laboratory Procedure
PMC7771041,r0 resection,TREATMENT,PMC,,,,
PMC7771041,a histological response,TEST,PMC,,,,
PMC7771041,evans grade iib,PROBLEM,PMC,,,,
PMC7771041,tumor recurrence,PROBLEM,PMC,C0521158,Recurrent tumor,MTH,Neoplastic Process
PMC7771041,the optimal treatment regimen,TREATMENT,PMC,,,,
PMC7771041,conversion surgery,TREATMENT,PMC,C3494226,Conversion to Open Surgery,MSH,Therapeutic or Preventive Procedure
PMC7771041,lapc,TREATMENT,PMC,,,,
PMC7771041,arterial resection,TREATMENT,PMC,C0442910,Sleeve pulmonary artery resection,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC7771041,sa transposition,TREATMENT,PMC,,,,
PMC7771041,hepatic arterial reconstruction,TREATMENT,PMC,,,,
PMC7771041,successful arterial anastomosis,TREATMENT,PMC,,,,
PMC7771041,a sa,TREATMENT,PMC,C0111695,cystatin SA,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7771041,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC7771041,sa transposition,TREATMENT,PMC,,,,
PMC7771041,hepatic artery reconstruction,TREATMENT,PMC,,,,
PMC7771041,tumor contact,PROBLEM,PMC,C4745163,Tumor Status at Date of Last Contact or Death,NCI,Finding
PMC7771041,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7771041,a sa,TREATMENT,PMC,C0111695,cystatin SA,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7771041,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC7771041,sa transposition,TREATMENT,PMC,,,,
PMC7771041,hepatic artery reconstruction,TREATMENT,PMC,,,,
PMC7771041,tumor contact,PROBLEM,PMC,C4745163,Tumor Status at Date of Last Contact or Death,NCI,Finding
PMC7771041,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC7771041,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC7771041,the optimal treatment regimen,TREATMENT,PMC,,,,
PMC7771041,conversion surgery,TREATMENT,PMC,C3494226,Conversion to Open Surgery,MSH,Therapeutic or Preventive Procedure
PMC7771041,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC7771041,arterial resection,TREATMENT,PMC,C0442910,Sleeve pulmonary artery resection,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC7771041,a sa,TREATMENT,PMC,C0111695,cystatin SA,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC7771041,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC7771041,sa transposition,TREATMENT,PMC,,,,
PMC7771041,hepatic artery reconstruction,TREATMENT,PMC,,,,
PMC7771041,tumor contact,PROBLEM,PMC,C4745163,Tumor Status at Date of Last Contact or Death,NCI,Finding
PMC7771041,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC12141374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12141374,high mortality rates,PROBLEM,PMC,,,,
PMC12141374,cancer deaths,PROBLEM,PMC,C1516192,Cancer Death Rate,NCI,Quantitative Concept
PMC12141374,curative intervention,TREATMENT,PMC,,,,
PMC12141374,risk assessment,TEST,PMC,C0086930,Risk Assessment,MTH,Health Care Activity
PMC12141374,diagnostic prediction models,TEST,PMC,,,,
PMC12141374,early pancreatic cancer,PROBLEM,PMC,,,,
PMC12141374,this mixed methods systematic review,TEST,PMC,,,,
PMC12141374,risk assessment tools,TEST,PMC,C4295185,opioid risk assessment tool,MEDCIN,Health Care Activity
PMC12141374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12141374,these tools,TEST,PMC,,,,
PMC12141374,ten studies,TEST,PMC,,,,
PMC12141374,five risk assessment tools,TEST,PMC,,,,
PMC12141374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12141374,implementation barriers,TREATMENT,PMC,C0680838,barriers to program implementation,AOD,Human-caused Phenomenon or Process
PMC12141374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12141374,risk assessment,TEST,PMC,C0086930,Risk Assessment,MTH,Health Care Activity
PMC12141374,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC12141374,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12141374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12141374,risk assessment,TEST,PMC,C0086930,Risk Assessment,MTH,Health Care Activity
PMC12141374,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC12141374,our review,TEST,PMC,,,,
PMC12141374,the tools,TREATMENT,PMC,C0037589,Software Tools,MSH,Intellectual Product
PMC12141374,primary care,TREATMENT,PMC,C0033137,Primary Health Care,MTH,Health Care Activity
PMC12141374,primary care professionals,TREATMENT,PMC,C1515117,System for Primary Care Professionals,NCI,Manufactured Object
PMC12141374,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12141374,a dedicated pancreatic cancer,PROBLEM,PMC,,,,
PMC12141374,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC12141374,patient record management systems,TREATMENT,PMC,,,,
PMC12141374,these tools,TEST,PMC,,,,
PMC12141374,clinical,TREATMENT,PMC,C0205210,Clinical,MTH,Qualitative Concept
PMC12141374,this review,TEST,PMC,C4086447,"Histological Subtype Different, Pathology Review for this Project",NCI,Finding
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,a deadly disease,PROBLEM,PMC,,,,
PMC1751121,the mutated genes,PROBLEM,PMC,C0596611,Gene Mutation,MTH,Genetic Function
PMC1751121,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC1751121,oncogenesis,PROBLEM,PMC,C0596263,Carcinogenesis,MTH,Neoplastic Process
PMC1751121,a susceptibility locus,PROBLEM,PMC,C2748800,"EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME 8",OMIM,Finding
PMC1751121,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC1751121,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC1751121,the familial pancreatic cancer,PROBLEM,PMC,C4286572,"IVD Panels, Human Genetics, Cancer, Familial, Pancreatic, Mutation",UMD,Medical Device
PMC1751121,a customized microarray,TEST,PMC,,,,
PMC1751121,pancreatic cancer susceptibility,PROBLEM,PMC,C3469525,"PANCREATIC CANCER, SUSCEPTIBILITY TO",OMIM,Finding
PMC1751121,the greatest expression change inpalladin,PROBLEM,PMC,,,,
PMC1751121,a mutation,PROBLEM,PMC,C0026882,Mutation,MTH,Genetic Function
PMC1751121,a proline hydrophobic to serine hydrophilic amino,TREATMENT,PMC,,,,
PMC1751121,the mutational change,PROBLEM,PMC,C5142322,Microorganism resistance mutation amino acid change,LNC,Finding
PMC1751121,a known single nucleotide polymorphismpalladinrna,PROBLEM,PMC,,,,
PMC1751121,quantitative rtpcr,TEST,PMC,C1514628,Quantitative Reverse Transcriptase PCR,NCI,Molecular Biology Research Technique
PMC1751121,precancerous dysplasia,PROBLEM,PMC,,,,
PMC1751121,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC1751121,sporadic disease,PROBLEM,PMC,C4511452,Sporadic Parkinson disease,SNOMEDCT_US,Disease or Syndrome
PMC1751121,transfection,TREATMENT,PMC,C0040669,Transfection,MSH,Molecular Biology Research Technique
PMC1751121,a clear phenotypic effect,PROBLEM,PMC,,,,
PMC1751121,p239s palladin,PROBLEM,PMC,,,,
PMC1751121,cytoskeletal changes,PROBLEM,PMC,,,,
PMC1751121,abnormal actin bundle assembly,PROBLEM,PMC,,,,
PMC1751121,an increased ability to migrate,PROBLEM,PMC,,,,
PMC1751121,an abnormalpalladingene,PROBLEM,PMC,,,,
PMC1751121,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC1751121,the overexpression of,PROBLEM,PMC,C3862387,SHOX overexpression,MEDCIN,Finding
PMC1751121,palladin protein,PROBLEM,PMC,C1436933,"palladin protein, mouse",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC1751121,sporadic pancreatic cancer,PROBLEM,PMC,,,,
PMC1751121,cytoskeletal changes,PROBLEM,PMC,,,,
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC1751121,abnormalpalladinin familial pancreatic cancer,PROBLEM,PMC,,,,
PMC1751121,its overexpression,PROBLEM,PMC,,,,
PMC1751121,sporadic pancreatic cancer,PROBLEM,PMC,,,,
PMC1751121,cytoskeletal changes,PROBLEM,PMC,,,,
PMC1751121,the tumors invasive and migratory abilities,PROBLEM,PMC,,,,
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,cancerrelated death,PROBLEM,PMC,,,,
PMC1751121,few symptoms,PROBLEM,PMC,C0436355,Has symptom every few days,SNOMEDCT_US,Finding
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC1751121,radio,TREATMENT,PMC,C1304639,Radio,MTH,Manufactured Object
PMC1751121,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC1751121,other cancers,PROBLEM,PMC,C5225778,Gastrointestinal cancers - all other types,CCSR_ICD10CM,Neoplastic Process
PMC1751121,the cells in pancreatic tumors,PROBLEM,PMC,C0242363,Islet Cell Tumor,MTH,Neoplastic Process
PMC1751121,acquired genetic changes,PROBLEM,PMC,,,,
PMC1751121,damaged tissue,PROBLEM,PMC,C1817415,clearance of damaged tissue during inflammatory response,GO,Cell Function
PMC1751121,other mutations,PROBLEM,PMC,C5204093,Specify Other MET Mutation,NCI,Intellectual Product
PMC1751121,the cells,PROBLEM,PMC,C0007634,Cells,MTH,Cell
PMC1751121,these mutations,PROBLEM,PMC,,,,
PMC1751121,other,TREATMENT,PMC,C0205394,Other,MTH,Qualitative Concept
PMC1751121,sporadic pancreatic cancer,PROBLEM,PMC,,,,
PMC1751121,mutated genes,PROBLEM,PMC,C0596611,Gene Mutation,MTH,Genetic Function
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC1751121,sporadic cancer,PROBLEM,PMC,C1336076,Sporadic Breast Carcinoma,NCI,Neoplastic Process
PMC1751121,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC1751121,this deadly disease,PROBLEM,PMC,,,,
PMC1751121,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC1751121,inherited pancreatic cancer,PROBLEM,PMC,,,,
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,a dna microarray,TEST,PMC,C0600596,DNA Microarray Chip,MTH,Research Device
PMC1751121,dna sequences,TEST,PMC,C0162326,DNA Sequence,MTH,Nucleotide Sequence
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,dysplastic pancreatic tissue,PROBLEM,PMC,,,,
PMC1751121,a precancerous lesion,PROBLEM,PMC,C0940937,Precancerous lesion,MDR,Neoplastic Process
PMC1751121,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC1751121,sporadic pancreatic cancers,PROBLEM,PMC,,,,
PMC1751121,the sporadic cancers,PROBLEM,PMC,C1336076,Sporadic Breast Carcinoma,NCI,Neoplastic Process
PMC1751121,palladin,TREATMENT,PMC,C2703161,"Palladin, human",MTH,"Amino Acid, Peptide, or Protein"
PMC1751121,other cytoskeletal components,PROBLEM,PMC,,,,
PMC1751121,precancerous pancreatic tissue,PROBLEM,PMC,,,,
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,this analysis,TEST,PMC,,,,
PMC1751121,sporadic and inherited pancreatic cancer development,PROBLEM,PMC,,,,
PMC1751121,sequencing of thepalladingene,TEST,PMC,,,,
PMC1751121,a mutation inpalladinthat,PROBLEM,PMC,,,,
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,precancerous lesions,PROBLEM,PMC,C0940937,Precancerous lesion,MDR,Neoplastic Process
PMC1751121,this specific mutation,PROBLEM,PMC,,,,
PMC1751121,palladins interaction,PROBLEM,PMC,,,,
PMC1751121,another cytoskeletal protein,PROBLEM,PMC,,,,
PMC1751121,sporadic cancers,PROBLEM,PMC,C1336076,Sporadic Breast Carcinoma,NCI,Neoplastic Process
PMC1751121,many sporadic cancer cell lines,PROBLEM,PMC,,,,
PMC1751121,abnormal expression of alphaactinin protein,PROBLEM,PMC,,,,
PMC1751121,palladin protein,PROBLEM,PMC,C1436933,"palladin protein, mouse",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC1751121,mutated palladin,PROBLEM,PMC,,,,
PMC1751121,a human cell line,TREATMENT,PMC,C0682523,Human Cell Line,NCI,Cell
PMC1751121,mutatedpalladinis,PROBLEM,PMC,,,,
PMC1751121,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC1751121,a mutation,PROBLEM,PMC,C0026882,Mutation,MTH,Genetic Function
PMC1751121,the increased susceptibility,PROBLEM,PMC,C3552221,Increased susceptibility to cancer,OMIM,Finding
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,the data showingpalladinoverexpression,TEST,PMC,,,,
PMC1751121,sporadic tumors,PROBLEM,PMC,C5960188,Sporadic Glomus Tumor,NCI,Neoplastic Process
PMC1751121,alterations of cell behavior,PROBLEM,PMC,,,,
PMC1751121,the involvement ofpalladinin pancreatic cancerpalladinmutations,PROBLEM,PMC,,,,
PMC1751121,the overexpression of,PROBLEM,PMC,C3862387,SHOX overexpression,MEDCIN,Finding
PMC1751121,palladin in,PROBLEM,PMC,C2703161,"Palladin, human",MTH,"Amino Acid, Peptide, or Protein"
PMC1751121,sporadic cancers,PROBLEM,PMC,C1336076,Sporadic Breast Carcinoma,NCI,Neoplastic Process
PMC1751121,cancer development in the pancreas,PROBLEM,PMC,,,,
PMC1751121,other tissues,PROBLEM,PMC,C0158370,Other soft tissue disorders,MTH,Disease or Syndrome
PMC1751121,abnormalities in palladin function,PROBLEM,PMC,,,,
PMC1751121,the changes in cell migration,PROBLEM,PMC,,,,
PMC1751121,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,pancreatic carcinoma,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,familial cancer,PROBLEM,PMC,C1333600,Hereditary Malignant Neoplasm,NCI,Neoplastic Process
PMC1751121,an abnormalpalladingene,PROBLEM,PMC,,,,
PMC1751121,familial pancreatic cancer,PROBLEM,PMC,C2931038,"Pancreatic carcinoma, familial",MTH,Neoplastic Process
PMC1751121,the overexpression of palladin protein,PROBLEM,PMC,,,,
PMC1751121,sporadic pancreatic cancer,PROBLEM,PMC,,,,
PMC1751121,cytoskeletal changes,PROBLEM,PMC,,,,
PMC1751121,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC1751121,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC11389906,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11389906,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11389906,its complex intrinsic biology,PROBLEM,PMC,,,,
PMC11389906,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11389906,benign gastrointestinal conditions,PROBLEM,PMC,,,,
PMC11389906,carbohydrate antigen ca,TEST,PMC,C1139535,Carbohydrate Antigen 50 (CA 50) Determination Reagents,UMD,"Indicator, Reagent, or Diagnostic Aid"
PMC11389906,elevation,PROBLEM,PMC,C0702240,Elevation,MTH,Spatial Concept
PMC11389906,benign hyperbilirubinaemia,PROBLEM,PMC,,,,
PMC11389906,accurate diagnostic biomarkers,TEST,PMC,,,,
PMC11389906,benign pancreatic and biliary tract conditions,PROBLEM,PMC,,,,
PMC11389906,a data analysis protocol,TEST,PMC,,,,
PMC11389906,a biomarker signature,TEST,PMC,,,,
PMC11389906,pdac,PROBLEM,PMC,,,,
PMC11389906,patient serum samples,TEST,PMC,,,,
PMC11389906,neuro endocrine and pancreatic tumours,PROBLEM,PMC,,,,
PMC11389906,pdacs,TEST,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11389906,ovarian cancer screening,TEST,PMC,C0281478,Screening for Ovarian Cancer,NCI,Therapeutic or Preventive Procedure
PMC11389906,biomarker performances,TEST,PMC,C2986107,Performed Clinical Result Biomarker Indicator,NCI,Qualitative Concept
PMC11389906,blinded samples,TEST,PMC,C1550033,Blind Sample,HL7V2.5,Idea or Concept
PMC11389906,recursive feature elimination,TREATMENT,PMC,,,,
PMC11389906,the adepts,TEST,PMC,C2092547,TRS Adept VC hook,MEDCIN,Medical Device
PMC11389906,ukctocs samples,TEST,PMC,,,,
PMC11389906,pdac,TEST,PMC,,,,
PMC11389906,predictive capabilities,PROBLEM,PMC,,,,
PMC11389906,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11389906,other individual biomarkers,TEST,PMC,,,,
PMC11389906,an auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC11389906,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11389906,the ensemble method,TEST,PMC,,,,
PMC11389906,the auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC11389906,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11389906,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11389906,ensemble signature validation,TEST,PMC,,,,
PMC11389906,an auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC11389906,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11389906,an auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC11389906,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11389906,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11389906,the benign disease controls,PROBLEM,PMC,,,,
PMC11389906,pdacs,TEST,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11389906,the diagnosticspecific signature,TEST,PMC,,,,
PMC11389906,an auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC11389906,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11389906,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11389906,auc,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC11389906,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11389906,our ensemble modelling technique,TEST,PMC,,,,
PMC11389906,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11389906,individual biomarkers,TEST,PMC,,,,
PMC11389906,concerning symptoms,PROBLEM,PMC,C0476235,"symptoms concerning nutrition, metabolism, and development",MEDCIN,Sign or Symptom
PMC11389906,pdac,PROBLEM,PMC,,,,
PMC11389906,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC11389906,cancers,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC11389906,its complex biology,PROBLEM,PMC,,,,
PMC11389906,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC11389906,benign gastrointestinal conditions,PROBLEM,PMC,,,,
PMC11389906,the standard biomarker,TEST,PMC,,,,
PMC11389906,carbohydrate antigen ca,TEST,PMC,C1139535,Carbohydrate Antigen 50 (CA 50) Determination Reagents,UMD,"Indicator, Reagent, or Diagnostic Aid"
PMC11389906,its suboptimal performance,PROBLEM,PMC,,,,
PMC11389906,elevation in benign conditions,PROBLEM,PMC,,,,
PMC11389906,better diagnostic tools,TEST,PMC,,,,
PMC11389906,our study,TEST,PMC,,,,
PMC11389906,a biomarker signature,TEST,PMC,,,,
PMC11389906,benign pancreaticbiliary conditions,PROBLEM,PMC,,,,
PMC11389906,pdac,PROBLEM,PMC,,,,
PMC11389906,serum samples,TEST,PMC,C1550100,Serum specimen,MTH,Body Substance
PMC11389906,neuro endocrine and pancreatic tumours,PROBLEM,PMC,,,,
PMC11389906,ovarian cancer,PROBLEM,PMC,C0919267,ovarian neoplasm,MTH,Neoplastic Process
PMC11389906,screening studies,TEST,PMC,C2348164,Screening Study,MTH,Research Activity
PMC11389906,patient serum samples,TEST,PMC,,,,
PMC11389906,a robust predictive signature,PROBLEM,PMC,,,,
PMC11389906,specialized machine learning methods,TREATMENT,PMC,,,,
PMC11389906,this new signature,PROBLEM,PMC,,,,
PMC11389906,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11389906,other panels,TEST,PMC,C5188800,"CPHS screen test, other set panel",MEDCIN,Laboratory Procedure
PMC11389906,this new biomarker signature,PROBLEM,PMC,,,,
PMC11389906,pdac,PROBLEM,PMC,,,,
PMC11389906,ambiguous clinical symptoms,PROBLEM,PMC,,,,
PMC11389906,our ensemble modelling technique,TEST,PMC,,,,
PMC11389906,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC11389906,individual biomarkers,TEST,PMC,,,,
PMC11389906,concerning symptoms,PROBLEM,PMC,C0476235,"symptoms concerning nutrition, metabolism, and development",MEDCIN,Sign or Symptom
PMC11389906,pdac,PROBLEM,PMC,,,,
PMC9454856,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9454856,a serious ongoing global health burden,PROBLEM,PMC,,,,
PMC9454856,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC9454856,curative surgery,TREATMENT,PMC,C1511562,Curative Surgery,NCI,Therapeutic or Preventive Procedure
PMC9454856,systemic administration,TREATMENT,PMC,C0678812,systemic administration,AOD,Therapeutic or Preventive Procedure
PMC9454856,chemoagents,TREATMENT,PMC,,,,
PMC9454856,localised interventions,TREATMENT,PMC,C0852241,Non-site specific procedural complications,MDR,Injury or Poisoning
PMC9454856,chemoagents,TREATMENT,PMC,,,,
PMC9454856,unwanted toxicity,PROBLEM,PMC,,,,
PMC9454856,novel localised interventions,TREATMENT,PMC,,,,
PMC9454856,systemic therapy,TREATMENT,PMC,C1515119,Systemic Therapy,NCI,Therapeutic or Preventive Procedure
PMC9454856,current locoregional therapies,TREATMENT,PMC,,,,
PMC9454856,pancreatic cancer therapy,TREATMENT,PMC,,,,
PMC9454856,novel localised interventions,TREATMENT,PMC,,,,
PMC9454856,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9454856,these tools,TEST,PMC,,,,
PMC9454856,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9454856,cancerrelated deaths,PROBLEM,PMC,,,,
PMC9454856,the most lethal solid malignancies,PROBLEM,PMC,,,,
PMC9454856,the symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9454856,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC9454856,an increasing incidence rate,PROBLEM,PMC,,,,
PMC9454856,metastatic tumours,PROBLEM,PMC,C0027627,Neoplasm Metastasis,MTH,Neoplastic Process
PMC9454856,the pancreatic tumours,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC9454856,local interventions,TREATMENT,PMC,,,,
PMC9454856,firstline treatments,TREATMENT,PMC,,,,
PMC9454856,locoregional interventions,TREATMENT,PMC,,,,
PMC9454856,local tumour recurrence,PROBLEM,PMC,C1282470,Local recurrence of malignant tumor of lung,SNOMEDCT_US,Neoplastic Process
PMC9454856,the side effects,PROBLEM,PMC,C0421316,HRT side-effects,SNOMEDCT_US,Finding
PMC9454856,new studies,TEST,PMC,C5707304,Treatment Investigational New Drug Study,NCI,Research Activity
PMC9454856,systemic therapy,TREATMENT,PMC,C1515119,Systemic Therapy,NCI,Therapeutic or Preventive Procedure
PMC9454856,localised interventions,TREATMENT,PMC,C0852241,Non-site specific procedural complications,MDR,Injury or Poisoning
PMC9454856,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9454856,locoregional therapies,TREATMENT,PMC,,,,
PMC9454856,various localised treatment strategies,TREATMENT,PMC,,,,
PMC9454856,localised drug delivery systems,TREATMENT,PMC,,,,
PMC9454856,local therapy,TREATMENT,PMC,C1517925,Local Therapy,NCI,Therapeutic or Preventive Procedure
PMC9454856,the effective treatment,TREATMENT,PMC,C2922311,RNAx reinforce effective timing of medication,MEDCIN,Health Care Activity
PMC9454856,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9454856,locoregional interventions,TREATMENT,PMC,,,,
PMC9454856,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9454856,significant strain,PROBLEM,PMC,,,,
PMC9454856,cancer therapy,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC9454856,localised interventions,TREATMENT,PMC,C0852241,Non-site specific procedural complications,MDR,Injury or Poisoning
PMC9454856,localised interventions,TREATMENT,PMC,C0852241,Non-site specific procedural complications,MDR,Injury or Poisoning
PMC9454856,existing therapeutics,TREATMENT,PMC,,,,
PMC9454856,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9771849,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9771849,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9771849,a significant symptom burden,PROBLEM,PMC,,,,
PMC9771849,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9771849,pubmed,TREATMENT,PMC,C1138432,PubMed,MSH,Intellectual Product
PMC9771849,medline,TEST,PMC,C0025141,MEDLINE,MTH,Intellectual Product
PMC9771849,cinahl,TEST,PMC,,,,
PMC9771849,embase databases,TEST,PMC,,,,
PMC9771849,qualitative and quantitative data,TEST,PMC,,,,
PMC9771849,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC9771849,nine studies,TEST,PMC,,,,
PMC9771849,caregiver burden,PROBLEM,PMC,C0870252,Caregiver Burden,MTH,Mental Process
PMC9771849,caregiver,PROBLEM,PMC,C0085537,Caregiver,MTH,Population Group
PMC9771849,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC9771849,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC9771849,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC9771849,all five qualitative studies,TEST,PMC,,,,
PMC9771849,three quantitative studies,TEST,PMC,,,,
PMC9771849,highquality pancreatic cancer care,TREATMENT,PMC,,,,
PMC9771849,informal caregiving,TREATMENT,PMC,C1319882,Informal Caregivers,MSH,Population Group
PMC9771849,prospective longitudinal studies,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC9771849,supportive care cancer delivery,TREATMENT,PMC,,,,
PMC9771849,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9771849,highquality pancreatic cancer care,TREATMENT,PMC,,,,
PMC9771849,informal caregiving,TREATMENT,PMC,C1319882,Informal Caregivers,MSH,Population Group
PMC9771849,prospective longitudinal studies,TEST,PMC,C0033522,Prospective Studies,MTH,Research Activity
PMC9771849,supportive care cancer delivery,TREATMENT,PMC,,,,
PMC9771849,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9771849,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9771849,patients symptoms,PROBLEM,PMC,C1317600,patient symptoms,CHV,Finding
PMC9771849,informal caregivers,TREATMENT,PMC,C1319882,Informal Caregivers,MSH,Population Group
PMC9771849,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC9771849,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC9771849,future longitudinal studies,TEST,PMC,,,,
PMC9771849,multimethod approaches,TREATMENT,PMC,C0814880,multitrait-multimethod approach,AOD,Research Activity
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,tumor response,PROBLEM,PMC,C3539879,Tumor Response Domain,MTH,Idea or Concept
PMC2857873,toxicity,PROBLEM,PMC,C0040539,Toxicity aspects,MTH,Qualitative Concept
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,survival percentages,TEST,PMC,,,,
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,locally nonresectable tumors,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant protocols,TREATMENT,PMC,C4482777,Lymph node response to neoadjuvant therapy:Find:Pt:Cancer specimen:Nom:CAP cancer protocols,LNC,Clinical Attribute
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,prolonged survival,TREATMENT,PMC,,,,
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,macroscopic tumor,PROBLEM,PMC,C1317516,Macroscopic tumor configuration,MTH,Finding
PMC2857873,a neoadjuvant approach,TREATMENT,PMC,,,,
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,nonmetastatic,PROBLEM,PMC,C1518409,Nonmetastatic,NCI,Qualitative Concept
PMC2857873,locally advanced disease,PROBLEM,PMC,C4086552,Locally Advanced Disease Clinical Trial Setting,MTH,"Manufactured Object, Health Care Related Organization"
PMC2857873,microscopic incomplete resections,TREATMENT,PMC,,,,
PMC2857873,the present analysis,TEST,PMC,,,,
PMC2857873,systematically review studies,TEST,PMC,,,,
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,tumor response,PROBLEM,PMC,C3539879,Tumor Response Domain,MTH,Idea or Concept
PMC2857873,toxicity,PROBLEM,PMC,C0040539,Toxicity aspects,MTH,Qualitative Concept
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,survival percentages,TEST,PMC,,,,
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,trials,TEST,PMC,C1293089,Animal trials,SNOMEDCT_VET,Research Activity
PMC2857873,embase,TEST,PMC,,,,
PMC2857873,retrospective and prospective studies,TEST,PMC,C0681849,retrospective study and prospective study,AOD,Research Activity
PMC2857873,neoadjuvant radiochemotherapy,TREATMENT,PMC,,,,
PMC2857873,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC2857873,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,surgical explorationresection,TEST,PMC,,,,
PMC2857873,study quality,TEST,PMC,C4524949,PQ/CMC Study Type Terminology,NCI,Intellectual Product
PMC2857873,pooled relative risks,TEST,PMC,,,,
PMC2857873,randomeffects models,TREATMENT,PMC,,,,
PMC2857873,tumor response categories,PROBLEM,PMC,,,,
PMC2857873,exploration,TEST,PMC,C1280903,Exploration procedure,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,a total of 111 studies,TEST,PMC,,,,
PMC2857873,56 phase iii trials,TREATMENT,PMC,,,,
PMC2857873,study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC2857873,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC2857873,initially resectable tumors,PROBLEM,PMC,C5409379,Initial resection of malignant tumor of ovary with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC2857873,initially nonresectable borderline resectableunresectable tumors,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant chemotherapy,TREATMENT,PMC,C5392214,Neoadjuvant Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC2857873,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC2857873,the main agents,TREATMENT,PMC,,,,
PMC2857873,5fu,TREATMENT,PMC,C0016360,fluorouracil,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC2857873,oral analogues,TREATMENT,PMC,,,,
PMC2857873,mitomycin c,TREATMENT,PMC,C0002475,mitomycin,MTH,"Organic Chemical, Antibiotic"
PMC2857873,platinum compounds,TREATMENT,PMC,C3536919,Platinum Compounds,MTH,Chemical Viewed Structurally
PMC2857873,neoadjuvant radiotherapy,TREATMENT,PMC,C5392212,Neoadjuvant Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC2857873,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC2857873,progressive disease fraction,PROBLEM,PMC,,,,
PMC2857873,resectability,TEST,PMC,C0033573,Prostatectomy,MTH,Therapeutic or Preventive Procedure
PMC2857873,higher resectionassociated morbidity,PROBLEM,PMC,,,,
PMC2857873,mortality rates,TEST,PMC,C0026565,Mortality Vital Statistics,MTH,Quantitative Concept
PMC2857873,combination chemotherapies,TREATMENT,PMC,C0013218,Combination Drug Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,resection probabilities,TREATMENT,PMC,C5820135,MAAA of 10 protein biomarkers in urine by immunoassay for probability of rapid recurrence of bladder cancer post transurethral resection,MEDCIN,Laboratory Procedure
PMC2857873,initially nonresectable tumors,PROBLEM,PMC,,,,
PMC2857873,monotherapy,TREATMENT,PMC,C4763675,Single Agent Therapy,NCI,Therapeutic or Preventive Procedure
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,initially resectable tumors,PROBLEM,PMC,C5409379,Initial resection of malignant tumor of ovary with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC2857873,resection frequencies,TREATMENT,PMC,,,,
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,primarily resected tumors,PROBLEM,PMC,,,,
PMC2857873,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC2857873,initially staged nonresectable tumor,PROBLEM,PMC,,,,
PMC2857873,resectable tumors,PROBLEM,PMC,C3248106,Resection of mediastinal tumor,CPT,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,initially resectable tumor,PROBLEM,PMC,C5409379,Initial resection of malignant tumor of ovary with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC2857873,locally nonresectable tumors,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant protocols,TREATMENT,PMC,C4482777,Lymph node response to neoadjuvant therapy:Find:Pt:Cancer specimen:Nom:CAP cancer protocols,LNC,Clinical Attribute
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,cancerrelated deaths,PROBLEM,PMC,,,,
PMC2857873,a cell in the pancreas,PROBLEM,PMC,C1179517,Acinar cell of pancreas,FMA,Cell
PMC2857873,digestive,PROBLEM,PMC,C0012238,Digestion,MTH,Organism Function
PMC2857873,insulin,TREATMENT,PMC,C0021641,Insulin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC2857873,blood sugar levels,TEST,PMC,C0428554,Finding of blood glucose level,MTH,Laboratory or Test Result
PMC2857873,genetic changes,PROBLEM,PMC,C1705285,Mutation Abnormality,MTH,Cell or Molecular Dysfunction
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,any symptoms,PROBLEM,PMC,C5706833,PRO-CTCAE V1.0 - Any Other Symptoms Reported,NCI,Intellectual Product
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,surgical removal,TREATMENT,PMC,C1293139,Surgical extraction,MTH,Therapeutic or Preventive Procedure
PMC2857873,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC2857873,this procedurethe,TREATMENT,PMC,,,,
PMC2857873,tumor,PROBLEM,PMC,C3273930,Tumor Mass,MTH,Finding
PMC2857873,the cure,TREATMENT,PMC,C0449920,Cement cure,SNOMEDCT_US,Chemical Viewed Functionally
PMC2857873,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC2857873,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC2857873,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC2857873,palliative chemotherapy,TREATMENT,PMC,C5556542,Palliative Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC2857873,slow down tumor growth,PROBLEM,PMC,,,,
PMC2857873,minimize pain,PROBLEM,PMC,C0558256,Minimizing pain,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC2857873,treatment option,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapychemotherapy,TREATMENT,PMC,,,,
PMC2857873,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC2857873,surgeryaims,TREATMENT,PMC,,,,
PMC2857873,unresectable tumors,PROBLEM,PMC,C5418826,Unresectable Rhabdoid Tumor,NCI,Neoplastic Process
PMC2857873,resectable tumors,PROBLEM,PMC,C3248106,Resection of mediastinal tumor,CPT,Therapeutic or Preventive Procedure
PMC2857873,the visible tumor,PROBLEM,PMC,C4520229,Total resection of visible brain tumor,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC2857873,removing,PROBLEM,PMC,C1883720,Removing (action),MTH,Activity
PMC2857873,cancer cells,PROBLEM,PMC,C0334227,"Tumor cells, malignant",SNOMEDCT_US,Cell
PMC2857873,randomized phase iii,TREATMENT,PMC,,,,
PMC2857873,different interventions,TREATMENT,PMC,,,,
PMC2857873,an intervention,TREATMENT,PMC,C0178362,Legal intervention,SNOMEDCT_US,Injury or Poisoning
PMC2857873,randomized phase iii,TREATMENT,PMC,,,,
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC2857873,this systematic review,TEST,PMC,,,,
PMC2857873,metaanalysis,TEST,PMC,C0920317,Meta-Analysis (statistical procedure),MTH,Research Activity
PMC2857873,several studies,TEST,PMC,C3830929,C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start),NCI,Intellectual Product
PMC2857873,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,111 studies,TEST,PMC,C0412464,Indium-111 granulocyte study,SNOMEDCT_US,Diagnostic Procedure
PMC2857873,neoadjuvant chemotherapy,TREATMENT,PMC,C5392214,Neoadjuvant Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC2857873,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC2857873,tumor response,PROBLEM,PMC,C3539879,Tumor Response Domain,MTH,Idea or Concept
PMC2857873,tumor resectability,PROBLEM,PMC,C4761063,Tumor resection,MDR,Therapeutic or Preventive Procedure
PMC2857873,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC2857873,group 1 studies,TEST,PMC,,,,
PMC2857873,preoperative examination,TEST,PMC,C2919752,Preoperative pulmonary examination,SNOMEDCT_US,Diagnostic Procedure
PMC2857873,group 2 studies,TEST,PMC,,,,
PMC2857873,borderline resectable,PROBLEM,PMC,C4763597,Borderline Operable,NCI,Finding
PMC2857873,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,the group 1 studies,TEST,PMC,,,,
PMC2857873,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,the group 2 studies,TEST,PMC,,,,
PMC2857873,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC2857873,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC2857873,tumor,PROBLEM,PMC,C3273930,Tumor Mass,MTH,Finding
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC2857873,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC2857873,resectable tumors,PROBLEM,PMC,C3248106,Resection of mediastinal tumor,CPT,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,locally advancedunresectable tumors,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,the optimum neoadjuvant therapy,TREATMENT,PMC,,,,
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC2857873,initially resectable tumors,PROBLEM,PMC,C5409379,Initial resection of malignant tumor of ovary with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC2857873,resection frequencies,TREATMENT,PMC,,,,
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,primarily resected tumors,PROBLEM,PMC,,,,
PMC2857873,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC2857873,initially staged nonresectable tumor,PROBLEM,PMC,,,,
PMC2857873,resectable tumors,PROBLEM,PMC,C3248106,Resection of mediastinal tumor,CPT,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,initially resectable tumor,PROBLEM,PMC,C5409379,Initial resection of malignant tumor of ovary with bilateral salpingo-oophorectomy and omentectomy,CPT,Therapeutic or Preventive Procedure
PMC2857873,locally nonresectable tumors,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant protocols,TREATMENT,PMC,C4482777,Lymph node response to neoadjuvant therapy:Find:Pt:Cancer specimen:Nom:CAP cancer protocols,LNC,Clinical Attribute
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,the present analysis,TEST,PMC,,,,
PMC2857873,neoadjuvant therapies,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,resectable and nonresectable pancreatic cancers,PROBLEM,PMC,,,,
PMC2857873,response,TEST,PMC,C0871261,Response process,MTH,Organism Attribute
PMC2857873,treatment toxicities,PROBLEM,PMC,C2028341,hair treatment toxicity,MEDCIN,Injury or Poisoning
PMC2857873,resection rates,TEST,PMC,,,,
PMC2857873,morbidity,PROBLEM,PMC,C0220880,morbidity aspects,MTH,Intellectual Product
PMC2857873,survival estimates,TEST,PMC,,,,
PMC2857873,resectable tumor,PROBLEM,PMC,C0854795,Resectable Malignant Liver Neoplasm,MTH,Neoplastic Process
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC2857873,survival rates,TREATMENT,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,primarily resected tumor,PROBLEM,PMC,,,,
PMC2857873,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC2857873,applied protocols,TREATMENT,PMC,C5915670,"Apply dressings, as per agency protocol",NIC,Health Care Activity
PMC2857873,the optimal chemotherapeutic,TREATMENT,PMC,,,,
PMC2857873,radiotherapeutic regimen,TREATMENT,PMC,,,,
PMC2857873,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC2857873,combination chemotherapies,TREATMENT,PMC,C0013218,Combination Drug Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,higher response rates,PROBLEM,PMC,,,,
PMC2857873,higher resection rates,TREATMENT,PMC,,,,
PMC2857873,initially nonresectable tumor,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC2857873,locally advancedunresectable tumors,PROBLEM,PMC,,,,
PMC2857873,optimal treatment protocols,TREATMENT,PMC,,,,
PMC2857873,resectabilitynonresectability,PROBLEM,PMC,,,,
PMC2857873,response evaluation,TEST,PMC,C5668128,CRF5 Response Evaluation Table,NCI,Intellectual Product
PMC2857873,locally advancedunresectable tumors,PROBLEM,PMC,,,,
PMC2857873,neoadjuvant protocols,TREATMENT,PMC,C4482777,Lymph node response to neoadjuvant therapy:Find:Pt:Cancer specimen:Nom:CAP cancer protocols,LNC,Clinical Attribute
PMC2857873,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC4462555,vaginal metastasis,PROBLEM,PMC,C2982854,Vaginal Cancer Clinical Distant Metastasis TNM Finding v7,NCI,Finding
PMC4462555,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4462555,a poor prognosis,PROBLEM,PMC,C0278252,Prognosis bad,SNOMEDCT_US,Finding
PMC4462555,pancreatic carcinoma,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4462555,metastasis to the vagina,PROBLEM,PMC,C0346997,Metastatic malignant neoplasm to vagina,SNOMEDCT_US,Neoplastic Process
PMC4462555,vaginal bleeding,PROBLEM,PMC,C0578503,Abnormal vaginal bleeding,MTH,Finding
PMC4462555,a primary pancreatic adenocarcinoma,PROBLEM,PMC,C3472164,Primary adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC4462555,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC4462555,a vaginal metastasis,PROBLEM,PMC,C2982854,Vaginal Cancer Clinical Distant Metastasis TNM Finding v7,NCI,Finding
PMC4462555,metastases to the female genital tract,PROBLEM,PMC,,,,
PMC4462555,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4462555,vagina metastases,PROBLEM,PMC,C0862601,Vaginal adenocarcinoma metastatic,MDR,Neoplastic Process
PMC4462555,adenocarcinoma of the exocrine pancreas,PROBLEM,PMC,C1409082,pancreas; islet cell adenocarcinoma with exocrine,ICPC2ICD10ENG,Neoplastic Process
PMC4462555,symptom producing vagina metastases,PROBLEM,PMC,,,,
PMC4462555,a metastatic adenocarcinoma,PROBLEM,PMC,C5788405,Metastatic sebaceous adenocarcinoma,SNOMEDCT_US,Neoplastic Process
PMC10930540,most pancreatic cancer,PROBLEM,PMC,,,,
PMC10930540,locally advanced tumors,PROBLEM,PMC,C5238469,Locally Advanced Neuroendocrine Tumor,NCI,Neoplastic Process
PMC10930540,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC10930540,other radical treatments,TREATMENT,PMC,C2095031,"radical resection of tonsil, tonsillar pillar, or retromolar trigone with closure using other flap",MEDCIN,Therapeutic or Preventive Procedure
PMC10930540,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC10930540,the significant symptoms,PROBLEM,PMC,C5436457,No significant respiratory symptoms,OMIM,Finding
PMC10930540,the local progression of pancreatic primaries,PROBLEM,PMC,,,,
PMC10930540,palliative radiotherapy dose prescriptions,TREATMENT,PMC,,,,
PMC10930540,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC10930540,palliative radiotherapy,TREATMENT,PMC,C3898008,Palliative Radiation Therapy,NCI,Therapeutic or Preventive Procedure
PMC10930540,bone brain liver and lung diseases,PROBLEM,PMC,,,,
PMC10930540,various radiotherapy strategies,TREATMENT,PMC,,,,
PMC10930540,optimizing palliative radiotherapy,TREATMENT,PMC,,,,
PMC10930540,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10930540,nonablative palliative radiotherapy,TREATMENT,PMC,,,,
PMC10930540,primary pancreatic tumors,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC10930540,palliative radiotherapy,TREATMENT,PMC,C3898008,Palliative Radiation Therapy,NCI,Therapeutic or Preventive Procedure
PMC10930540,primary noncurable locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10930540,very poor survival,PROBLEM,PMC,C4288022,Very Poor Survival after Reirradiation,NCI,Finding
PMC10930540,various palliative rt dose fractionation schemes,TREATMENT,PMC,,,,
PMC10930540,the dose fractionation schedules,TREATMENT,PMC,,,,
PMC10930540,high c dose groups,TREATMENT,PMC,,,,
PMC10930540,the different dose prescriptions,TREATMENT,PMC,,,,
PMC10930540,cohortn,TEST,PMC,,,,
PMC10930540,stage ivn,PROBLEM,PMC,,,,
PMC10930540,t4n,TEST,PMC,,,,
PMC10930540,tumor location,PROBLEM,PMC,C5667396,Specify Tumor Location,NCI,Intellectual Product
PMC10930540,prior systemic therapyn,TREATMENT,PMC,,,,
PMC10930540,most common dose fractionations,TREATMENT,PMC,,,,
PMC10930540,median overall survival,TREATMENT,PMC,,,,
PMC10930540,median,TEST,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC10930540,median,TEST,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC10930540,nonablative palliative rt,TREATMENT,PMC,,,,
PMC10930540,their primary pancreatic tumors,PROBLEM,PMC,,,,
PMC10930540,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10930540,t4 tumors of the pancreatic head,PROBLEM,PMC,,,,
PMC10930540,prior systemic therapy,TREATMENT,PMC,C4745075,Prior Systemic Therapy for Current Cancer,NCI,Finding
PMC10930540,a significant survival benefit,PROBLEM,PMC,,,,
PMC10930540,the high doselonger rt fractionation group,TREATMENT,PMC,,,,
PMC10930540,an rt effect,TREATMENT,PMC,,,,
PMC10930540,an infield progression,PROBLEM,PMC,,,,
PMC10930540,rt,TREATMENT,PMC,C1418752,POMT1 gene,MTH,Gene or Genome
PMC10930540,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10930540,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10930540,nonablative palliative rt,TREATMENT,PMC,,,,
PMC10930540,their primary tumors,PROBLEM,PMC,,,,
PMC10930540,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC10930540,prior systemic therapy,TREATMENT,PMC,C4745075,Prior Systemic Therapy for Current Cancer,NCI,Finding
PMC10930540,t4 tumors of the pancreatic head,PROBLEM,PMC,,,,
PMC10930540,longer rt fractionation schedules,TREATMENT,PMC,,,,
PMC10930540,shorter schedules,TREATMENT,PMC,,,,
PMC10930540,rt,TREATMENT,PMC,C1418752,POMT1 gene,MTH,Gene or Genome
PMC10930540,an infield progression,PROBLEM,PMC,,,,
PMC10930540,rt,TREATMENT,PMC,C1418752,POMT1 gene,MTH,Gene or Genome
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,highly malignant,PROBLEM,PMC,C3831753,"Abnormal Colorectal Exam, Highly Suspicious for Malignancy",NCI,Finding
PMC5466735,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC5466735,treatment outcomes,TREATMENT,PMC,C0085415,Treatment outcome,MTH,Qualitative Concept
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,a crosssectional study,TEST,PMC,,,,
PMC5466735,a questionnaire,TEST,PMC,C0451054,Cage questionnaire,SNOMEDCT_US,Intellectual Product
PMC5466735,the risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC5466735,clinical manifestations,PROBLEM,PMC,C1400703,"infection; tuberculous, without clinical manifestations",ICPC2ICD10ENG,Disease or Syndrome
PMC5466735,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,professional,TEST,PMC,C2698884,Professional Occupation,MTH,Occupation or Discipline
PMC5466735,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,several knowledge gaps,PROBLEM,PMC,,,,
PMC5466735,type 2 diabetes,PROBLEM,PMC,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",MTH,Disease or Syndrome
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,pancreatic neoplasmthe,PROBLEM,PMC,,,,
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,ultrasound,TEST,PMC,C0220934,Ultrasonic,MTH,Functional Concept
PMC5466735,screening pancreatic cancer,PROBLEM,PMC,,,,
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,mri,TEST,PMC,C0376248,Maori Language,MTH,Language
PMC5466735,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,overall surgeons,PROBLEM,PMC,,,,
PMC5466735,resident surgeons,TREATMENT,PMC,C0808119,Surgeon.resident name,MTH,Intellectual Product
PMC5466735,some areas,PROBLEM,PMC,C5555940,Smoking Not Allowed in Some Work Areas,NCI,Finding
PMC5466735,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,continuing medical education programs,TREATMENT,PMC,,,,
PMC5466735,supplementary material,TREATMENT,PMC,C2936424,Electronic Supplementary Materials,MSH,Intellectual Product
PMC5466735,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5466735,continuing medical education programs,TREATMENT,PMC,,,,
PMC5466735,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC5466735,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5466735,considerable knowledge gap,PROBLEM,PMC,,,,
PMC5466735,continuing medical education,TREATMENT,PMC,C0013632,"Education, Medical, Continuing",MSH,Educational Activity
PMC5466735,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,lamberteaton myasthenic syndrome,PROBLEM,PMC,,,,
PMC10628391,an autoimmune disorder of the neuromuscular junction,PROBLEM,PMC,,,,
PMC10628391,a paraneoplastic disorder,PROBLEM,PMC,C0030472,Paraneoplastic Syndromes,MSH,Neoplastic Process
PMC10628391,carcinomas,PROBLEM,PMC,C0007097,Carcinoma,MTH,Neoplastic Process
PMC10628391,small cell lung cancer,PROBLEM,PMC,C0149925,Small cell carcinoma of lung,MTH,Neoplastic Process
PMC10628391,an autoimmune disease,PROBLEM,PMC,C0004364,Autoimmune Diseases,MTH,Disease or Syndrome
PMC10628391,lems,PROBLEM,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,myasthenia gravis,PROBLEM,PMC,C0026896,Myasthenia Gravis,MTH,Disease or Syndrome
PMC10628391,an oncological sequela,PROBLEM,PMC,,,,
PMC10628391,lems,PROBLEM,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pancreatic carcinoma,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,a newly diagnosed pancreatic tumor,PROBLEM,PMC,,,,
PMC10628391,weakness,PROBLEM,PMC,C3714552,Weakness,MTH,Sign or Symptom
PMC10628391,fatigue in his lower extremities,PROBLEM,PMC,,,,
PMC10628391,the weakness,PROBLEM,PMC,C3714552,Weakness,MTH,Sign or Symptom
PMC10628391,his proximal upper extremity muscles,PROBLEM,PMC,,,,
PMC10628391,dysphonia,PROBLEM,PMC,C1527344,Dysphonia,MTH,Mental or Behavioral Dysfunction
PMC10628391,dysarthria,PROBLEM,PMC,C0013362,Dysarthria,MTH,Mental or Behavioral Dysfunction
PMC10628391,decreased appetite,PROBLEM,PMC,C0232462,Decrease in appetite,MTH,Sign or Symptom
PMC10628391,significant weight loss,PROBLEM,PMC,,,,
PMC10628391,a computed tomography ct scan,TEST,PMC,C5202483,CT scan for biomechanical computed tomography analysis,CPT,Diagnostic Procedure
PMC10628391,a 3 cm locally resectable cystic tumor in the pancreatic head,PROBLEM,PMC,,,,
PMC10628391,blood tests,TEST,PMC,C0018941,Hematologic Tests,MTH,Laboratory Procedure
PMC10628391,elevated carbohydrate antigen 199,PROBLEM,PMC,,,,
PMC10628391,carcinoembryonic antigen cea levels,TEST,PMC,C2229606,serum carcinoembryonic antigen (CEA) level,MEDCIN,Laboratory Procedure
PMC10628391,a whipple procedure,TREATMENT,PMC,C4038811,History of Whipple procedure,SNOMEDCT_US,Finding
PMC10628391,a poorly differentiated pancreatic adenocarcinoma,PROBLEM,PMC,C2987141,Pancreatic Poorly Differentiated Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC10628391,an intraductal pancreatic mucinous neoplasm,PROBLEM,PMC,C4511687,Pancreatic Intraductal Papillary Mucinous Neoplasm,MSH,Neoplastic Process
PMC10628391,spontaneous breathing,PROBLEM,PMC,C1828139,Trial of spontaneous breathing,SNOMEDCT_US,Health Care Activity
PMC10628391,manifested areflexia signs,PROBLEM,PMC,,,,
PMC10628391,peripheral nerve,TEST,PMC,C0031119,Peripheral Nerves,MTH,"Body Part, Organ, or Organ Component"
PMC10628391,pyridostigmine therapy,TREATMENT,PMC,,,,
PMC10628391,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10628391,the extubation,TREATMENT,PMC,C0553891,Tracheal Extubation,MSH,Therapeutic or Preventive Procedure
PMC10628391,further diagnostic tests,TEST,PMC,,,,
PMC10628391,a lems,TREATMENT,PMC,C0023295,Genus Lemmus (organism),MTH,Mammal
PMC10628391,an intravenous therapy,TREATMENT,PMC,C0455142,Intravenous therapy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10628391,cumulative 100 g immunoglobulin ig g,TREATMENT,PMC,,,,
PMC10628391,lems treatment,TREATMENT,PMC,,,,
PMC10628391,paraneoplastic syndromes,PROBLEM,PMC,C0030472,Paraneoplastic Syndromes,MSH,Neoplastic Process
PMC10628391,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC10628391,abdominal symptoms,PROBLEM,PMC,C0740651,Abdominal symptom,HPO,Sign or Symptom
PMC10628391,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC10628391,paraneoplastic symptoms,PROBLEM,PMC,,,,
PMC10628391,lems,TREATMENT,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,paraneoplastic syndromes,PROBLEM,PMC,C0030472,Paraneoplastic Syndromes,MSH,Neoplastic Process
PMC10628391,pancreatic cancer management,TREATMENT,PMC,C1262320,"SYSTEM, TEST, CARBOHYDRATE ANTIGEN (CA19-9), FOR MONITORING AND MANAGEMENT OF PANCREATIC CANCER",SPN,Medical Device
PMC10628391,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC10628391,the diagnostic approach,TEST,PMC,C2406624,"Drainage of Anus, External Approach, Diagnostic",ICD10PCS,Diagnostic Procedure
PMC10628391,lems,TREATMENT,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,paraneoplastic syndromes,PROBLEM,PMC,C0030472,Paraneoplastic Syndromes,MSH,Neoplastic Process
PMC10628391,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC10628391,abdominal symptoms,PROBLEM,PMC,C0740651,Abdominal symptom,HPO,Sign or Symptom
PMC10628391,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC10628391,paraneoplastic symptoms,PROBLEM,PMC,,,,
PMC10628391,lems,TREATMENT,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,paraneoplastic syndromes,PROBLEM,PMC,C0030472,Paraneoplastic Syndromes,MSH,Neoplastic Process
PMC10628391,pancreatic cancer management,TREATMENT,PMC,C1262320,"SYSTEM, TEST, CARBOHYDRATE ANTIGEN (CA19-9), FOR MONITORING AND MANAGEMENT OF PANCREATIC CANCER",SPN,Medical Device
PMC10628391,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC10628391,the diagnostic approach,TEST,PMC,C2406624,"Drainage of Anus, External Approach, Diagnostic",ICD10PCS,Diagnostic Procedure
PMC10628391,lems,TREATMENT,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,pns,PROBLEM,PMC,C0206417,Peripheral Nervous System,MTH,Body System
PMC10628391,pns,PROBLEM,PMC,C0206417,Peripheral Nervous System,MTH,Body System
PMC10628391,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC10628391,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC10628391,pns,PROBLEM,PMC,C0206417,Peripheral Nervous System,MTH,Body System
PMC10628391,abdominal complaints,PROBLEM,PMC,C0221098,Acute abdominal complaint,SNMI,Sign or Symptom
PMC10628391,the successful treatment,TREATMENT,PMC,C0521982,Response to treatment,MTH,Clinical Attribute
PMC10628391,the underlying malignant disease,PROBLEM,PMC,,,,
PMC10628391,paraneoplastic symptoms,PROBLEM,PMC,,,,
PMC10628391,recurrence of pns,PROBLEM,PMC,,,,
PMC10628391,tumor recurrence,PROBLEM,PMC,C0521158,Recurrent tumor,MTH,Neoplastic Process
PMC10628391,lems,PROBLEM,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pancreatic adenocarcinomas,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,lems symptoms,PROBLEM,PMC,,,,
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10628391,lung cancer,PROBLEM,PMC,C0684249,Carcinoma of lung,MTH,Neoplastic Process
PMC10628391,lems,TREATMENT,PMC,C0022972,Lambert-Eaton Myasthenic Syndrome,MTH,Disease or Syndrome
PMC10628391,pns,PROBLEM,PMC,C0206417,Peripheral Nervous System,MTH,Body System
PMC10628391,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,a cancer,PROBLEM,PMC,C0346627,Intestinal Cancer,MTH,Neoplastic Process
PMC11302827,all malignancies,PROBLEM,PMC,C5552884,ALL Secondary Malignant Neoplasm Table,MTH,Intellectual Product
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,nonmodifiable risk factors,PROBLEM,PMC,,,,
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,surgical resection,TREATMENT,PMC,C0015252,removal technique,MTH,Therapeutic or Preventive Procedure
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,resectable disease,PROBLEM,PMC,C0844745,"Resection of large intestine or rectum for Hirschsprung's disease, with stoma formation",ICD10AM,Therapeutic or Preventive Procedure
PMC11302827,the morbidities,PROBLEM,PMC,C2609234,Neoplasm related morbidities,MDR,Neoplastic Process
PMC11302827,surgeries,TREATMENT,PMC,C0543467,Operative Surgical Procedures,MTH,Therapeutic or Preventive Procedure
PMC11302827,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC11302827,the postoperative mortality,TREATMENT,PMC,,,,
PMC11302827,study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,associated factors,PROBLEM,PMC,C1136066,TATA-Binding Protein Associated Factors,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC11302827,surgical management,TREATMENT,PMC,C1515089,Surgical Management,NCI,Health Care Activity
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,palliative intents,TREATMENT,PMC,C1285530,Palliative,MTH,Qualitative Concept
PMC11302827,the study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC11302827,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC11302827,associated risk factors,PROBLEM,PMC,C1269826,Assessment of hypovolemia risk factors,SNOMEDCT_US,Health Care Activity
PMC11302827,comorbidities,PROBLEM,PMC,C0009488,Comorbidity,MTH,Finding
PMC11302827,biochemical parameters,TEST,PMC,C4314556,"No abnormalities in standard biochemical peroxisomal parameters in plasma, erythrocytes, or cultured skin fibroblasts",OMIM,Finding
PMC11302827,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC11302827,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11302827,short term treatment outcome,TREATMENT,PMC,,,,
PMC11302827,the data,TEST,PMC,C1511726,Data,MTH,Idea or Concept
PMC11302827,potential risk factors,PROBLEM,PMC,C0548253,Identify potential risk factors for skin breakdown.,PCDS,Therapeutic or Preventive Procedure
PMC11302827,medical comorbidities,PROBLEM,PMC,C4540934,Significant medical comorbidity,NANDA-I,Finding
PMC11302827,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11302827,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC11302827,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC11302827,significant weight loss,PROBLEM,PMC,,,,
PMC11302827,jaundice,PROBLEM,PMC,C2010848,jaundice,MTH,Finding
PMC11302827,clinical evaluation,TEST,PMC,C4084924,Clinical Evaluation,MTH,Health Care Activity
PMC11302827,jaundiced,PROBLEM,PMC,C0022346,Icterus,MTH,Sign or Symptom
PMC11302827,a palpable gallbladder,PROBLEM,PMC,C0426694,Gallbladder palpable,SNOMEDCT_US,Finding
PMC11302827,advanced disease,PROBLEM,PMC,C0679246,advanced disease,AOD,Finding
PMC11302827,the tumors,PROBLEM,PMC,C0260037,Multiple tumors,MTH,Neoplastic Process
PMC11302827,the surgeries,TREATMENT,PMC,C1456587,Bariatric Surgery,MSH,Therapeutic or Preventive Procedure
PMC11302827,postoperative morbidity,PROBLEM,PMC,,,,
PMC11302827,mortality,TEST,PMC,C0026565,Mortality Vital Statistics,MTH,Quantitative Concept
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,advanced condition,PROBLEM,PMC,C5789321,Boston Advance Conditioning Solution,MMSL,Manufactured Object
PMC11302827,palliative measures,TREATMENT,PMC,C3699590,interRAI palliative care:Find:Pt:{Setting}:Doc:{Role},LNC,Clinical Attribute
PMC11302827,the postoperative morbidity,PROBLEM,PMC,,,,
PMC11302827,similar studies,TEST,PMC,,,,
PMC11302827,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,advanced condition,PROBLEM,PMC,C5789321,Boston Advance Conditioning Solution,MMSL,Manufactured Object
PMC11302827,palliative measures,TREATMENT,PMC,C3699590,interRAI palliative care:Find:Pt:{Setting}:Doc:{Role},LNC,Clinical Attribute
PMC11302827,the postoperative morbidity,PROBLEM,PMC,,,,
PMC11302827,similar studies,TEST,PMC,,,,
PMC11302827,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,associated risk factors,PROBLEM,PMC,C1269826,Assessment of hypovolemia risk factors,SNOMEDCT_US,Health Care Activity
PMC11302827,proper screening,TEST,PMC,C4316138,Documentation of a chlamydia screening test with proper follow-up,HCPCS,Finding
PMC11302827,advanced disease,PROBLEM,PMC,C0679246,advanced disease,AOD,Finding
PMC11302827,palliative measures,TREATMENT,PMC,C3699590,interRAI palliative care:Find:Pt:{Setting}:Doc:{Role},LNC,Clinical Attribute
PMC11302827,the patients survival,TREATMENT,PMC,C4692556,Normal development in patients who are treated and survive infancy,OMIM,Finding
PMC11302827,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11302827,abdominal ultrasonography,TEST,PMC,C2455220,Ultrasonography of Abdominal Aorta,ICD10PCS,Diagnostic Procedure
PMC11302827,ct scan,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11302827,adjuvant therapy,TREATMENT,PMC,C0677850,Adjuvant therapy,MDR,Therapeutic or Preventive Procedure
PMC11302827,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11302827,a multidisciplinary approach,TREATMENT,PMC,C0870721,Interdisciplinary Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC8318663,effective treatment strategies,TREATMENT,PMC,C4716841,Strategies to decrease treatment regimen side effects,NOC,Finding
PMC8318663,unresectable locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC8318663,convincing oncological outcomes,PROBLEM,PMC,,,,
PMC8318663,carbon ion radiotherapy,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC8318663,this modern radiation technique,TREATMENT,PMC,,,,
PMC8318663,carbon ion facilities,TREATMENT,PMC,,,,
PMC8318663,carbon ion radiotherapy,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC8318663,lapc,TREATMENT,PMC,,,,
PMC8318663,carbon ions,TREATMENT,PMC,C0596255,Carbon ion,MTH,"Pharmacologic Substance, Element, Ion, or Isotope"
PMC8318663,a total dose of 48,TREATMENT,PMC,,,,
PMC8318663,concomitant chemotherapy,TREATMENT,PMC,,,,
PMC8318663,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC8318663,toxicity rates,TEST,PMC,C4710848,"Monitor for digitalis toxicity (e.g., report serum levels higher than therapeutic range, monitor heart rate and rhythm before administering dose, and monitor for side effects)",NIC,Health Care Activity
PMC8318663,overall survival,TREATMENT,PMC,C4086681,Overall Survival,NCI,Quantitative Concept
PMC8318663,progression free survival,TREATMENT,PMC,C0242792,Progression-Free Survival,MTH,Quantitative Concept
PMC8318663,local control,TREATMENT,PMC,C1550023,Local Control Request,HL7V2.5,Idea or Concept
PMC8318663,locoregional control,TREATMENT,PMC,,,,
PMC8318663,kaplanmeier estimates,TEST,PMC,,,,
PMC8318663,ascites,PROBLEM,PMC,C0003962,Ascites,MTH,Disease or Syndrome
PMC8318663,ctcae grade,PROBLEM,PMC,C2919019,CTCAE v4 Grade 3,MTH,Finding
PMC8318663,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC8318663,metachronous peritoneal carcinomatosis,PROBLEM,PMC,,,,
PMC8318663,further highergraded toxicity,PROBLEM,PMC,,,,
PMC8318663,the most common symptoms,PROBLEM,PMC,,,,
PMC8318663,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC8318663,abdominal pain,PROBLEM,PMC,C0000737,Abdominal Pain,MTH,Sign or Symptom
PMC8318663,the median,TREATMENT,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC8318663,locoregional control rates,TEST,PMC,,,,
PMC8318663,carbon ion radiotherapy of lapc patients,TREATMENT,PMC,,,,
PMC8318663,local,TREATMENT,PMC,C0205276,Local,MTH,Spatial Concept
PMC8318663,historical,TEST,PMC,C1552658,Historical - ParameterizedDataType,MTH,Intellectual Product
PMC8318663,an,TREATMENT,PMC,C1423519,DIAPH3 gene,MTH,Gene or Genome
PMC8318663,prior chemotherapy,TREATMENT,PMC,C1514457,Prior Chemotherapy,NCI,Clinical Attribute
PMC8318663,distant metastases,PROBLEM,PMC,C5786072,Distant Metastases Other Cancer,NCI,Neoplastic Process
PMC8318663,additional chemotherapy,TREATMENT,PMC,C5415938,Each additional intravenous push administration of chemotherapy,CPT,Therapeutic or Preventive Procedure
PMC8318663,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC8318663,carbon ion radiotherapy of lapc patients,TREATMENT,PMC,,,,
PMC8318663,local,TREATMENT,PMC,C0205276,Local,MTH,Spatial Concept
PMC8318663,historical,TEST,PMC,C1552658,Historical - ParameterizedDataType,MTH,Intellectual Product
PMC8318663,an,TREATMENT,PMC,C1423519,DIAPH3 gene,MTH,Gene or Genome
PMC8318663,prior chemotherapy,TREATMENT,PMC,C1514457,Prior Chemotherapy,NCI,Clinical Attribute
PMC8318663,distant metastases,PROBLEM,PMC,C5786072,Distant Metastases Other Cancer,NCI,Neoplastic Process
PMC8318663,additional chemotherapy,TREATMENT,PMC,C5415938,Each additional intravenous push administration of chemotherapy,CPT,Therapeutic or Preventive Procedure
PMC8318663,further studies,TEST,PMC,C4288176,Study Further Information Contact,NCI,Human
PMC6713682,earlyonset pancreatic cancer,PROBLEM,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,longterm survival,TREATMENT,PMC,,,,
PMC6713682,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,lateronset pancreatic cancer,PROBLEM,PMC,,,,
PMC6713682,lopc,PROBLEM,PMC,C1568355,"ClpX protein, E coli",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6713682,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6713682,propensity score matching,TEST,PMC,,,,
PMC6713682,cancerspecific,PROBLEM,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,lopc,PROBLEM,PMC,C1568355,"ClpX protein, E coli",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6713682,tumor location,PROBLEM,PMC,C5667396,Specify Tumor Location,NCI,Intellectual Product
PMC6713682,tumor size,PROBLEM,PMC,C0475440,Tumor size,MTH,Finding
PMC6713682,ajcc,TEST,PMC,C0441915,American Joint Committee on Cancer (tumor staging),MTH,Classification
PMC6713682,treatment details,TREATMENT,PMC,C2224473,normal pregnancy delivery details forceps assist,MEDCIN,Therapeutic or Preventive Procedure
PMC6713682,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,a more advanced ajcc stage,PROBLEM,PMC,,,,
PMC6713682,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC6713682,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6713682,radiation,TREATMENT,PMC,C0851346,Radiation,MTH,Natural Phenomenon or Process
PMC6713682,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6713682,propensity score matching,TEST,PMC,,,,
PMC6713682,any covariate differences,PROBLEM,PMC,,,,
PMC6713682,the matched analysis,TEST,PMC,C0085145,Matched-Pair Analysis,MSH,Qualitative Concept
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,multivariable cox regression analysis,TEST,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,adverse os,PROBLEM,PMC,C5555726,OS Adverse Event Table,NCI,Intellectual Product
PMC6713682,subgroup analyses,TEST,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,adverse 5year os,PROBLEM,PMC,,,,
PMC6713682,multivariable analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6713682,any significant,PROBLEM,PMC,C2136959,denial of any significant medical history,MEDCIN,Finding
PMC6713682,the largest study,TEST,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,lopc,PROBLEM,PMC,C1568355,"ClpX protein, E coli",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6713682,propensity score matching methodology,TREATMENT,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,the matched survival analysis,TEST,PMC,,,,
PMC6713682,reduced os,PROBLEM,PMC,,,,
PMC6713682,css,TEST,PMC,C0265338,Coffin-Siris syndrome,MSH,Disease or Syndrome
PMC6713682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6713682,a unique tumor biology,PROBLEM,PMC,,,,
PMC6713682,risk stratification,TEST,PMC,C5239338,AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer,NCI,Intellectual Product
PMC6713682,patient counseling,TREATMENT,PMC,C0600047,Patient counseling,MTH,Therapeutic or Preventive Procedure
PMC6713682,the largest study,TEST,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,lopc,PROBLEM,PMC,C1568355,"ClpX protein, E coli",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6713682,propensity score matching methodology,TREATMENT,PMC,,,,
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,the matched survival analysis,TEST,PMC,,,,
PMC6713682,reduced os,PROBLEM,PMC,,,,
PMC6713682,css,TEST,PMC,C0265338,Coffin-Siris syndrome,MSH,Disease or Syndrome
PMC6713682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6713682,a unique tumor biology,PROBLEM,PMC,,,,
PMC6713682,risk stratification,TEST,PMC,C5239338,AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer,NCI,Intellectual Product
PMC6713682,patient counseling,TREATMENT,PMC,C0600047,Patient counseling,MTH,Therapeutic or Preventive Procedure
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6713682,eopc,PROBLEM,PMC,,,,
PMC6713682,matched survival analysis,TEST,PMC,,,,
PMC6713682,inferior outcomes,PROBLEM,PMC,,,,
PMC6713682,genomic,TEST,PMC,C0887950,Genomics,MTH,Biomedical Occupation or Discipline
PMC6713682,eopc,TEST,PMC,,,,
PMC6713682,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9152722,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9152722,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9152722,symptom distress,PROBLEM,PMC,C4084760,Symptom Distress Scale,MTH,Intellectual Product
PMC9152722,a high burden of selfcare,TREATMENT,PMC,,,,
PMC9152722,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC9152722,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9152722,mhealth tools,TREATMENT,PMC,,,,
PMC9152722,symptom assessment,TEST,PMC,C3494437,Symptom Assessment,MSH,Health Care Activity
PMC9152722,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC9152722,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC9152722,chemotherapy treatment,TREATMENT,PMC,C5239596,Prephase Chemotherapy Treatment,NCI,Therapeutic or Preventive Procedure
PMC9152722,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9152722,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9152722,alarming symptoms,PROBLEM,PMC,C2215678,alarm symptoms assessed,MEDCIN,Therapeutic or Preventive Procedure
PMC9152722,transcribed interviews,TEST,PMC,,,,
PMC9152722,qualitative thematic analysis,TEST,PMC,,,,
PMC9152722,mhealth,TREATMENT,PMC,C2718080,Mobile Health,MSH,Health Care Activity
PMC9152722,personcentered care,TREATMENT,PMC,,,,
PMC9152722,structural prerequisites,PROBLEM,PMC,,,,
PMC9152722,personcentered care,TREATMENT,PMC,,,,
PMC9152722,mhealth tools,TREATMENT,PMC,,,,
PMC9152722,a clinical routine,TREATMENT,PMC,C4273504,Young Person's Clinical Outcomes in Routine Evaluation,SNOMEDCT_US,Intellectual Product
PMC9152722,personcentered care,TREATMENT,PMC,,,,
PMC9152722,mhealth tools,TREATMENT,PMC,,,,
PMC9152722,a clinical routine,TREATMENT,PMC,C4273504,Young Person's Clinical Outcomes in Routine Evaluation,SNOMEDCT_US,Intellectual Product
PMC9152722,personcentered care,TREATMENT,PMC,,,,
PMC9152722,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9152722,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9152722,interaktor,TREATMENT,PMC,,,,
PMC9152722,the app,TREATMENT,PMC,C4723949,Smartphone Application,MTH,Intellectual Product
PMC9192299,nanoparticles,TREATMENT,PMC,C1450054,Artificial nanoparticles,MTH,Manufactured Object
PMC9192299,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9192299,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9192299,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9192299,operation,TREATMENT,PMC,C3241922,Operation Activity,MTH,Activity
PMC9192299,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9192299,surgical treatment,TREATMENT,PMC,C0543467,Operative Surgical Procedures,MTH,Therapeutic or Preventive Procedure
PMC9192299,nanotube artificial tubes,TREATMENT,PMC,,,,
PMC9192299,nylon tube,TREATMENT,PMC,C0464208,Payne 0712 nylon stud+tube,RCD,Medical Device
PMC9192299,abdominal ct,TEST,PMC,C0412626,CT of abdominal aorta,SNOMEDCT_US,Diagnostic Procedure
PMC9192299,basic clinical data,TEST,PMC,,,,
PMC9192299,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9192299,surgical resection of pancreaticoduodenum,TREATMENT,PMC,,,,
PMC9192299,reconstruction of pancreaticoduodenal papillary duct,TREATMENT,PMC,,,,
PMC9192299,nanocomposite artificial tube,TREATMENT,PMC,,,,
PMC9192299,nanocomposite artificial tube,TREATMENT,PMC,,,,
PMC9192299,drainage tube,TREATMENT,PMC,C0184114,Tube drain,SNOMEDCT_US,Medical Device
PMC9192299,drain,TREATMENT,PMC,C0180499,Drain device,MTH,Medical Device
PMC9192299,the peritoneal effusion,PROBLEM,PMC,C5441966,Peritoneal Effusion,MTH,Pathologic Function
PMC9192299,the effusion,PROBLEM,PMC,C0013687,effusion,MTH,Pathologic Function
PMC9192299,abdominal hypertension,PROBLEM,PMC,C2242710,Intra-Abdominal Hypertension,MSH,Disease or Syndrome
PMC9192299,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC9192299,postoperative bleeding,PROBLEM,PMC,C0032788,Postoperative Hemorrhage,MTH,Pathologic Function
PMC9192299,operation,TREATMENT,PMC,C3241922,Operation Activity,MTH,Activity
PMC9192299,postoperative concomitant symptoms,PROBLEM,PMC,,,,
PMC9192299,the reconstruction of pancreaticoduodenal papillary duct,TREATMENT,PMC,,,,
PMC9192299,postoperative recovery,TREATMENT,PMC,C4304804,Postoperative recovery status,SNOMEDCT_US,Finding
PMC9192299,postoperative complications,PROBLEM,PMC,C0032787,Postoperative Complications,MSH,Pathologic Function
PMC9192299,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC9192299,the reconstruction of pancreaticoduodenal papillary duct,TREATMENT,PMC,,,,
PMC9192299,postoperative recovery,TREATMENT,PMC,C4304804,Postoperative recovery status,SNOMEDCT_US,Finding
PMC9192299,postoperative complications,PROBLEM,PMC,C0032787,Postoperative Complications,MSH,Pathologic Function
PMC9192299,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC9470333,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9470333,antipd1 immunotherapy,TREATMENT,PMC,,,,
PMC9470333,gemcitabine chemotherapy,TREATMENT,PMC,,,,
PMC9470333,multiline treatment,TREATMENT,PMC,,,,
PMC9470333,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9470333,a retrospective analysis,TEST,PMC,,,,
PMC9470333,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9470333,sintilimab regimen,TREATMENT,PMC,,,,
PMC9470333,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC9470333,followup content,TEST,PMC,,,,
PMC9470333,routine blood liver and kidney functions,TEST,PMC,,,,
PMC9470333,tumor markers,TEST,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC9470333,plain or,TEST,PMC,C1306645,Plain x-ray,MTH,Diagnostic Procedure
PMC9470333,enhanced abdominal ct,TEST,PMC,C3871349,"Patient underwent abdominal imaging with ultrasound, contrast enhanced ct or contrast mri for hcc",HCPCS,Finding
PMC9470333,abdominal mri examinations,TEST,PMC,,,,
PMC9470333,mrecist criteria,TEST,PMC,C5555902,MRECIST Armato Mesothelioma 2018 Oncology Response Criteria,NCI,Intellectual Product
PMC9470333,adverse effects,PROBLEM,PMC,C0879626,Adverse effects,MTH,Pathologic Function
PMC9470333,adverse events,PROBLEM,PMC,C0877248,Adverse event,MTH,Pathologic Function
PMC9470333,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9470333,sintilimab,TREATMENT,PMC,C4760864,sintilimab,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9470333,adverse reactions,PROBLEM,PMC,C0559546,Adverse reactions,MTH,Pathologic Function
PMC9470333,sintilimab,TREATMENT,PMC,C4760864,sintilimab,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9470333,the total response rate,TEST,PMC,,,,
PMC9470333,disease control rate,TEST,PMC,,,,
PMC9470333,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9470333,the median,TEST,PMC,C2348144,Sample Median,MTH,Quantitative Concept
PMC9470333,the median progressionfree,TEST,PMC,,,,
PMC9470333,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9470333,the levels,TEST,PMC,C4724289,2 levels,MTH,Spatial Concept
PMC9470333,tumor markers ca125,TEST,PMC,C2347296,Mucin-16,MTH,"Amino Acid, Peptide, or Protein"
PMC9470333,cea,TEST,PMC,C5401240,CEACAM3 wt Allele,MTH,Gene or Genome
PMC9470333,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC9470333,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9470333,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9470333,the blood routine indexes ddimer,TEST,PMC,,,,
PMC9470333,crp,TEST,PMC,C1413716,CRP gene,MTH,Gene or Genome
PMC9470333,nlr,TEST,PMC,C4277661,NLR Proteins,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC9470333,mlr,TEST,PMC,C1417835,NR3C2 gene,MTH,Gene or Genome
PMC9470333,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC9470333,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9470333,the adverse reactions,PROBLEM,PMC,C0559546,Adverse reactions,MTH,Pathologic Function
PMC9470333,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC9470333,rash,PROBLEM,PMC,C5779628,Skin rash,MTH,Sign or Symptom
PMC9470333,hypothyroidism,PROBLEM,PMC,C0020676,Hypothyroidism,MTH,Disease or Syndrome
PMC9470333,hyperuricemia,PROBLEM,PMC,C0740394,Hyperuricemia,MTH,Disease or Syndrome
PMC9470333,renal insufficiency,PROBLEM,PMC,C1565489,Renal Insufficiency,MTH,Disease or Syndrome
PMC9470333,grade 3 fatigue symptom,PROBLEM,PMC,,,,
PMC9470333,adverse reactions,PROBLEM,PMC,C0559546,Adverse reactions,MTH,Pathologic Function
PMC9470333,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9470333,all patients adverse reactions,PROBLEM,PMC,,,,
PMC9470333,symptomatic treatment,TREATMENT,PMC,C5243901,Symptomatic treatment,MTH,Therapeutic or Preventive Procedure
PMC9470333,gemcitabine chemotherapy,TREATMENT,PMC,,,,
PMC9470333,multiline treatment,TREATMENT,PMC,,,,
PMC9470333,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9470333,sintilimab,TREATMENT,PMC,C4760864,sintilimab,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9470333,serious adverse reactions,PROBLEM,PMC,C4684772,Serious Adverse Drug Reaction,NCI,Pathologic Function
PMC9470333,gemcitabine chemotherapy,TREATMENT,PMC,,,,
PMC9470333,multiline treatment,TREATMENT,PMC,,,,
PMC9470333,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC9470333,sintilimab,TREATMENT,PMC,C4760864,sintilimab,MSH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9470333,serious adverse reactions,PROBLEM,PMC,C4684772,Serious Adverse Drug Reaction,NCI,Pathologic Function
PMC9897716,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9897716,duodenal obstruction,PROBLEM,PMC,C0013292,Duodenal Obstruction,MTH,Disease or Syndrome
PMC9897716,obstructive jaundice,PROBLEM,PMC,C0022354,"Jaundice, Obstructive",MTH,Disease or Syndrome
PMC9897716,tumor invasion,PROBLEM,PMC,C1269955,Tumor Cell Invasion,MTH,Neoplastic Process
PMC9897716,selfexpandable metal stent sems placement,TREATMENT,PMC,,,,
PMC9897716,duodenal obstruction,PROBLEM,PMC,C0013292,Duodenal Obstruction,MTH,Disease or Syndrome
PMC9897716,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9897716,malignant obstruction in the third portion of the duodenum,PROBLEM,PMC,,,,
PMC9897716,the upper gastrointestinal endoscope,TREATMENT,PMC,C5437255,Flexible video upper and/or lower gastrointestinal endoscope,SNOMEDCT_US,Medical Device
PMC9897716,sems placement,TREATMENT,PMC,,,,
PMC9897716,successful sems placement,TREATMENT,PMC,,,,
PMC9897716,a colonoscope,TREATMENT,PMC,C0180022,Colonoscopes,MSH,Medical Device
PMC9897716,the obstruction of the third portion of the duodenum,PROBLEM,PMC,,,,
PMC9897716,uncinate process cancer,PROBLEM,PMC,,,,
PMC9897716,palliative treatment,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC9897716,unresectable pancreatic cancer,PROBLEM,PMC,C0854776,Pancreatic carcinoma non-resectable,MDR,Neoplastic Process
PMC9897716,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC9897716,vomiting,PROBLEM,PMC,C0042963,Vomiting,MTH,Sign or Symptom
PMC9897716,computed tomography ct scans,TEST,PMC,C5202483,CT scan for biomechanical computed tomography analysis,CPT,Diagnostic Procedure
PMC9897716,the tumor,PROBLEM,PMC,C0023267,Fibroid Tumor,MTH,Neoplastic Process
PMC9897716,delayed enhancement in the pancreatic uncinate process,PROBLEM,PMC,,,,
PMC9897716,esophagogastroduodenoscopy,TEST,PMC,C0079304,Esophagogastroduodenoscopy,MTH,Diagnostic Procedure
PMC9897716,gastrografin enema,TREATMENT,PMC,C0554746,Gastrografin enema,SNOMEDCT_US,Diagnostic Procedure
PMC9897716,the stenosis,PROBLEM,PMC,C1261287,Stenosis,MTH,Pathologic Function
PMC9897716,tumor invasion,PROBLEM,PMC,C1269955,Tumor Cell Invasion,MTH,Neoplastic Process
PMC9897716,the stenosis,PROBLEM,PMC,C1261287,Stenosis,MTH,Pathologic Function
PMC9897716,his symptom,PROBLEM,PMC,C4712283,"Instruct patient on how to manage his or her illness symptoms, if appropriate",NIC,Health Care Activity
PMC9897716,pcfq260az endoscope,TREATMENT,PMC,,,,
PMC9897716,the stenosis,PROBLEM,PMC,C1261287,Stenosis,MTH,Pathologic Function
PMC9897716,a 22 mm  80 mm uncovered sems,TREATMENT,PMC,,,,
PMC9897716,the stenosis,PROBLEM,PMC,C1261287,Stenosis,MTH,Pathologic Function
PMC9897716,sems placement,TREATMENT,PMC,,,,
PMC9897716,his symptoms,PROBLEM,PMC,C4712283,"Instruct patient on how to manage his or her illness symptoms, if appropriate",NIC,Health Care Activity
PMC9897716,uncinate process cancer,PROBLEM,PMC,,,,
PMC9897716,the obstruction,PROBLEM,PMC,C0028778,Obstruction,MTH,Finding
PMC9897716,a colonoscope,TREATMENT,PMC,C0180022,Colonoscopes,MSH,Medical Device
PMC9897716,sems placement,TREATMENT,PMC,,,,
PMC9897716,malignant obstruction in the third portion of the duodenum,PROBLEM,PMC,,,,
PMC9897716,successful sems placement,TREATMENT,PMC,,,,
PMC9897716,a colonoscope,TREATMENT,PMC,C0180022,Colonoscopes,MSH,Medical Device
PMC9897716,the malignant obstruction,PROBLEM,PMC,C3888580,Malignant Bowel Obstruction,MTH,Anatomical Abnormality
PMC9897716,uncinate process cancer,PROBLEM,PMC,,,,
PMC9897716,uncinate process cancer,PROBLEM,PMC,,,,
PMC9897716,malignant obstruction in the third portion of the duodenum,PROBLEM,PMC,,,,
PMC9897716,obstruction,PROBLEM,PMC,C0028778,Obstruction,MTH,Finding
PMC9897716,sems placement,TREATMENT,PMC,,,,
PMC9897716,a colonoscope,TREATMENT,PMC,C0180022,Colonoscopes,MSH,Medical Device
PMC6250924,pancreatic adenocarcinoma risk,PROBLEM,PMC,,,,
PMC6250924,diagnostics,TEST,PMC,C1875013,"DIAGNOSTICS,OTHER",VANDF,"Indicator, Reagent, or Diagnostic Aid"
PMC6250924,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC6250924,this understudied malignancy,PROBLEM,PMC,,,,
PMC6250924,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC6250924,a lethal condition,PROBLEM,PMC,,,,
PMC6250924,cancer death,PROBLEM,PMC,C4722463,Cancer-Related Death,MTH,Finding
PMC6250924,all cancer sites,PROBLEM,PMC,,,,
PMC6250924,the risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC6250924,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6250924,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC6250924,early detection measures,TREATMENT,PMC,,,,
PMC6250924,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC6250924,premalignant conditions,PROBLEM,PMC,C1335471,Premalignant Hematologic Condition,NCI,Disease or Syndrome
PMC6250924,pancreatic intraepithelial neoplasia,PROBLEM,PMC,C1301034,Pancreatic intraepithelial neoplasia,MTH,Neoplastic Process
PMC6250924,intraductal papillary mucinous neoplasms,PROBLEM,PMC,C3160815,Intraductal papillary mucinous neoplasm,SNOMEDCT_US,Neoplastic Process
PMC6250924,mucinous cystic neoplasms,PROBLEM,PMC,C5428759,mucinous cystic neoplasm of liver,MEDCIN,Neoplastic Process
PMC6250924,an acceptable screening test,TEST,PMC,,,,
PMC6250924,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6250924,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC6250924,new surgical techniques,TREATMENT,PMC,,,,
PMC6250924,medical therapies,TREATMENT,PMC,C0418981,Medical therapy,MTH,Therapeutic or Preventive Procedure
PMC6250924,laparoscopic techniques,TREATMENT,PMC,C2223453,"laparoscopic appendectomy, standard Hasson technique to enter abdomen",MTH,Therapeutic or Preventive Procedure
PMC6250924,neoadjuvant chemoradiotherapy,TREATMENT,PMC,C5392215,Neoadjuvant Chemoradiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6250924,novel biomarkers,PROBLEM,PMC,,,,
PMC6250924,a precision medicine era,TREATMENT,PMC,,,,
PMC6250924,pancreatic cancer therapy,TREATMENT,PMC,,,,
PMC6250924,unnecessary treatments,TREATMENT,PMC,C1710572,Unnecessary Therapy,NCI,Finding
PMC6250924,new agents,TREATMENT,PMC,C1518316,New Agents,NCI,Classification
PMC6250924,delivery systems,TREATMENT,PMC,C0449914,Delivery system,SNOMEDCT_US,Functional Concept
PMC6250924,the burden,PROBLEM,PMC,C2828008,Burden,NCI,Idea or Concept
PMC6250924,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6250924,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC6250924,other cancer sites,PROBLEM,PMC,C3166347,Site of other cancer,LNC,Finding
PMC6250924,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC6250924,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6250924,significant gaps,PROBLEM,PMC,,,,
PMC6250924,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC6250924,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC6250924,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6250924,other cancer sites,PROBLEM,PMC,C3166347,Site of other cancer,LNC,Finding
PMC11781101,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11781101,a,TREATMENT,PMC,,,,
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,patient care,TREATMENT,PMC,C0017313,patient care,MTH,Health Care Activity
PMC11781101,a qualitative phenomenological study,TEST,PMC,,,,
PMC11781101,a national cancer,TREATMENT,PMC,C1513887,National Cancer Program,MTH,Health Care Related Organization
PMC11781101,cancer care,TREATMENT,PMC,C0920687,cancer care,CHV,Therapeutic or Preventive Procedure
PMC11781101,a comprehensive pros management programme,TREATMENT,PMC,,,,
PMC11781101,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11781101,our,TEST,PMC,C4296191,Can pronounce our,LNC,Finding
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,symptom management,TREATMENT,PMC,C1536570,Symptom Management,MTH,Therapeutic or Preventive Procedure
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11781101,treatment decisions,TREATMENT,PMC,C5934487,Participates in treatment decisions,NOC,Finding
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,advanced cancer care,TREATMENT,PMC,C5771657,Advancing cancer care mips value pathways,HCPCS,Health Care Activity
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11781101,treatment decisions,TREATMENT,PMC,C5934487,Participates in treatment decisions,NOC,Finding
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,advanced cancer care,TREATMENT,PMC,C5771657,Advancing cancer care mips value pathways,HCPCS,Health Care Activity
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11781101,treatment decisions,TREATMENT,PMC,C5934487,Participates in treatment decisions,NOC,Finding
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,pros management,TREATMENT,PMC,C4042852,"Crew Resource Management, Healthcare",MSH,Health Care Activity
PMC11781101,advanced cancer care,TREATMENT,PMC,C5771657,Advancing cancer care mips value pathways,HCPCS,Health Care Activity
PMC5865497,plasma micrornas,TEST,PMC,,,,
PMC5865497,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5865497,prediagnostic plasma samples,TEST,PMC,,,,
PMC5865497,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5865497,late presenting symptoms,PROBLEM,PMC,,,,
PMC5865497,early metastasis,PROBLEM,PMC,,,,
PMC5865497,circulating mirnas,TEST,PMC,C4055233,Circulating MicroRNA,MSH,"Nucleic Acid, Nucleoside, or Nucleotide"
PMC5865497,altered,PROBLEM,PMC,C0392747,Changing,MTH,Functional Concept
PMC5865497,an initial screen,TEST,PMC,C3844397,Initial screening,LNC,Health Care Activity
PMC5865497,a,TEST,PMC,,,,
PMC5865497,earlystage pc,PROBLEM,PMC,,,,
PMC5865497,significantly altered mirnas,PROBLEM,PMC,,,,
PMC5865497,plasma samples,TEST,PMC,C0444263,Plasma specimen,SNOMEDCT_US,Body Substance
PMC5865497,carbohydrate antigen,TEST,PMC,C0443758,Carbohydrate antigen,SNOMEDCT_US,"Organic Chemical, Immunologic Factor"
PMC5865497,our initial screen,TEST,PMC,,,,
PMC5865497,23 stage iii pc cases,PROBLEM,PMC,,,,
PMC5865497,15 candidate mirnas,PROBLEM,PMC,,,,
PMC5865497,plasma samples,TEST,PMC,C0444263,Plasma specimen,SNOMEDCT_US,Body Substance
PMC5865497,a multivariate statistical model,TEST,PMC,,,,
PMC5865497,receiveroperating characteristics analysis,TEST,PMC,,,,
PMC5865497,the candidate mirnas,TEST,PMC,,,,
PMC5865497,prediagnostic plasma samples,TEST,PMC,,,,
PMC5865497,ca 199 levels,TEST,PMC,,,,
PMC5865497,plasma mirnas,TEST,PMC,,,,
PMC5865497,the candidate mirnas,PROBLEM,PMC,,,,
PMC5865497,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC5865497,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC5865497,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC5865497,a panel,TEST,PMC,C0200382,Lipid panel,MTH,Laboratory Procedure
PMC5865497,15 circulating mirnas,TEST,PMC,,,,
PMC5865497,these 15 mirnas,TEST,PMC,,,,
PMC5865497,early detection biomarkers,TEST,PMC,,,,
PMC5865497,the alterations,PROBLEM,PMC,C4709340,Gene Alterations,MED-RT,Cell Function
PMC5865497,the disease course,PROBLEM,PMC,C3807869,Hyporeflexia (later in disease course),OMIM,Finding
PMC6149195,pancreatic ductal adenocarcinomas,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6149195,poor prognostic cancers,PROBLEM,PMC,,,,
PMC6149195,all cancer cases,PROBLEM,PMC,,,,
PMC6149195,the disease process,PROBLEM,PMC,C1820919,Specific disease process,NOC,Finding
PMC6149195,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC6149195,gastrointestinalgi symptoms,PROBLEM,PMC,,,,
PMC6149195,investigations,TEST,PMC,C1261322,Evaluation procedure,MTH,Health Care Activity
PMC6149195,gi symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6149195,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC6149195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6149195,gi investigations,TEST,PMC,,,,
PMC6149195,retrospective cohort study,TEST,PMC,C2985505,Retrospective Cohort Study,NCI,Research Activity
PMC6149195,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC6149195,a gi investigation,TEST,PMC,,,,
PMC6149195,the pancreatic cancer,PROBLEM,PMC,C0280222,"stage, pancreatic cancer",PDQ,Neoplastic Process
PMC6149195,gi investigations,TEST,PMC,,,,
PMC6149195,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6149195,disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC6149195,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC6149195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6149195,gastrointestinal investigations,TEST,PMC,C0430681,Gastrointestinal investigation,MTH,Diagnostic Procedure
PMC6149195,gastrointestinal investigations,TEST,PMC,C0430681,Gastrointestinal investigation,MTH,Diagnostic Procedure
PMC6149195,demographic data,TEST,PMC,C4684639,Demographic Data,MTH,Intellectual Product
PMC6149195,significant delays,PROBLEM,PMC,C3553876,"Developmental delay, significant",OMIM,Finding
PMC6149195,gi investigations,TEST,PMC,,,,
PMC6149195,disease stage,PROBLEM,PMC,C0699749,disease stage,MTH,Clinical Attribute
PMC6149195,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC6149195,gi investigations,TEST,PMC,,,,
PMC6149195,prediagnostic gi investigations,TEST,PMC,,,,
PMC6149195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6149195,early ultrasound,TEST,PMC,C0746966,OB ULTRASOUND DISPARITY EARLY LATE,CCPSS,Finding
PMC6149195,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC6149195,gi symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6149195,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC6149195,screening tests,TEST,PMC,C0871311,Screening test,MTH,Health Care Activity
PMC6149195,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC6149195,gastrointestinal symptomsthis,PROBLEM,PMC,,,,
PMC6149195,endoscopic gastrointestinal investigations,TEST,PMC,,,,
PMC6149195,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC6149195,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6149195,endoscopic gastrointestinal investigations,TEST,PMC,,,,
PMC6149195,these delays,PROBLEM,PMC,,,,
PMC6149195,survival,TEST,PMC,C0220921,survival aspects,MTH,Functional Concept
PMC6149195,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC6149195,prediagnostic gi investigations,TEST,PMC,,,,
PMC6149195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6149195,early ultrasound,TEST,PMC,C0746966,OB ULTRASOUND DISPARITY EARLY LATE,CCPSS,Finding
PMC6149195,ct,TEST,PMC,C1418396,PCYT1A gene,MTH,Gene or Genome
PMC6149195,gi symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6149195,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC6149195,screening tests,TEST,PMC,C0871311,Screening test,MTH,Health Care Activity
PMC6149195,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC6149195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6149195,asymptomatic,PROBLEM,PMC,C0231221,Asymptomatic (finding),MTH,Finding
PMC6149195,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6149195,other investigations,TEST,PMC,C0841577,"Other diagnostic tests, measures or investigations",ICD10AM,Diagnostic Procedure
PMC6149195,gi endoscopies,TEST,PMC,C0079278,"Endoscopy, Gastrointestinal",MTH,Diagnostic Procedure
PMC6149195,current poor survival outcomes,PROBLEM,PMC,,,,
PMC6149195,this significantly impacts,PROBLEM,PMC,,,,
PMC6149195,overall survival,TREATMENT,PMC,C4086681,Overall Survival,NCI,Quantitative Concept
PMC6149195,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6149195,screening blood tests,TEST,PMC,C5551535,blood chemistry screening tests,MEDCIN,Health Care Activity
PMC6149195,this condition,PROBLEM,PMC,C3260370,Have you had this clinician diagnosed condition,LNC,Intellectual Product
PMC9170865,brain metastasis,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9170865,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9170865,chemotherapeutic agents,TREATMENT,PMC,C0729502,Chemotherapeutic agent,MTH,Pharmacologic Substance
PMC9170865,brain metastasis,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9170865,successful chemotherapy,TREATMENT,PMC,,,,
PMC9170865,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC9170865,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9170865,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9170865,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9170865,distal pancreatectomy,TREATMENT,PMC,C0176940,Distal subtotal pancreatectomy,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC9170865,d2 lymph node dissection,TREATMENT,PMC,C2960517,D2 lymph node dissection,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC9170865,resectable pancreatic tail cancer,PROBLEM,PMC,,,,
PMC9170865,invasive ductal carcinoma of pancreas,PROBLEM,PMC,,,,
PMC9170865,malignant tumors,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC9170865,s1 adjuvant chemotherapy,TREATMENT,PMC,,,,
PMC9170865,ca199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC9170865,contrastenhanced computed tomography ct,TEST,PMC,,,,
PMC9170865,fluorodeoxyglucosepositron emission tomography,TEST,PMC,,,,
PMC9170865,local recurrence in the paraaortic lymph nodes,PROBLEM,PMC,,,,
PMC9170865,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9170865,a combined regimen,TREATMENT,PMC,C3846439,"Chemotherapy, multiple agents (combination regimen)",LNC,Therapeutic or Preventive Procedure
PMC9170865,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC9170865,nabpaclitaxel,TREATMENT,PMC,,,,
PMC9170865,tumor markers,TEST,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC9170865,recurrence,PROBLEM,PMC,C0034897,Recurrence,MTH,Phenomenon or Process
PMC9170865,contrastenhanced ct,TEST,PMC,,,,
PMC9170865,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9170865,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9170865,raised intracranial pressure,PROBLEM,PMC,C0151740,Intracranial Hypertension,MTH,Finding
PMC9170865,magnetic resonance imaging,TEST,PMC,C0024485,Magnetic Resonance Imaging,MTH,Diagnostic Procedure
PMC9170865,two metastatic lesions,PROBLEM,PMC,,,,
PMC9170865,quasiemergency resection,TREATMENT,PMC,,,,
PMC9170865,the metastatic brain tumors,PROBLEM,PMC,C0686402,Metastatic malignant neoplasm to brain stem,SNOMEDCT_US,Neoplastic Process
PMC9170865,pathological examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC9170865,the resected specimens,TEST,PMC,C0586652,Resected lung specimen,SNOMEDCT_US,Tissue
PMC9170865,primary pancreatic cancer,PROBLEM,PMC,C1880617,Exocrine Pancreatic Cancer Pathologic Primary Tumor TNM Finding v6,NCI,Finding
PMC9170865,any complications,PROBLEM,PMC,C0844806,Complicated or large local skin flap of any site,ICD10AM,Therapeutic or Preventive Procedure
PMC9170865,local brain radiation therapy,TREATMENT,PMC,,,,
PMC9170865,blood carcinoembryonic antigen level,TEST,PMC,,,,
PMC9170865,all other tumor markers,TEST,PMC,,,,
PMC9170865,tumor markers,TEST,PMC,C0041365,Tumor Markers,MTH,Biologically Active Substance
PMC9170865,the cerebrospinal fluid,TEST,PMC,C0007806,Cerebrospinal Fluid,MTH,Body Substance
PMC9170865,markedly reduced,PROBLEM,PMC,C5678340,Markedly reduced power,OMIM,Finding
PMC9170865,the cytology,TEST,PMC,C0010819,Cytology,MTH,Biomedical Occupation or Discipline
PMC9170865,tumor cells,PROBLEM,PMC,C5551176,Tumor cells,MTH,Cell
PMC9170865,complete resection,TREATMENT,PMC,C5421113,Complete Resection,MTH,Therapeutic or Preventive Procedure
PMC9170865,the metastatic brain tumors,PROBLEM,PMC,C0686402,Metastatic malignant neoplasm to brain stem,SNOMEDCT_US,Neoplastic Process
PMC9170865,aggressive resection,TREATMENT,PMC,,,,
PMC9170865,salvage stereotactic radiotherapy,TREATMENT,PMC,,,,
PMC9170865,metastatic brain tumors,PROBLEM,PMC,C0686402,Metastatic malignant neoplasm to brain stem,SNOMEDCT_US,Neoplastic Process
PMC9170865,aggressive resection,TREATMENT,PMC,,,,
PMC9170865,salvage stereotactic radiotherapy,TREATMENT,PMC,,,,
PMC9170865,metastatic brain tumors,PROBLEM,PMC,C0686402,Metastatic malignant neoplasm to brain stem,SNOMEDCT_US,Neoplastic Process
PMC9170865,brain metastases,PROBLEM,PMC,C0220650,Metastatic malignant neoplasm to brain,MTH,Neoplastic Process
PMC9170865,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9170865,drugs,TREATMENT,PMC,C3687832,Drugs - dental services,MTH,Therapeutic or Preventive Procedure
PMC9170865,resection,TREATMENT,PMC,C0728940,Excision,MTH,Therapeutic or Preventive Procedure
PMC9170865,resectable brain metastases,PROBLEM,PMC,,,,
PMC9170865,aggressive resection,TREATMENT,PMC,,,,
PMC9170865,salvage sr,TREATMENT,PMC,,,,
PMC6162953,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6162953,higher surgical invasiveness,PROBLEM,PMC,,,,
PMC6162953,many other cancers,PROBLEM,PMC,,,,
PMC6162953,associated psychiatric symptoms,PROBLEM,PMC,,,,
PMC6162953,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC6162953,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC6162953,perioperative depression,PROBLEM,PMC,,,,
PMC6162953,surgical stress,PROBLEM,PMC,C3522858,Surgical laparoscopy with sling operation for stress incontinence,CPT,Therapeutic or Preventive Procedure
PMC6162953,relevant interventions,TREATMENT,PMC,C4710493,"Place relevant variables (e.g., outcomes, interventions, laboratory and diagnostic tests, consultations, patient and family education) sequentially on a decision tree",NIC,Health Care Activity
PMC6162953,chronological depressive changes,PROBLEM,PMC,,,,
PMC6162953,subjective physical symptoms,PROBLEM,PMC,,,,
PMC6162953,pancreatic tumor surgery,TREATMENT,PMC,,,,
PMC6162953,the selfrating depression scale,PROBLEM,PMC,,,,
PMC6162953,functional assessment,TEST,PMC,C0278372,Functional assessment,SNOMEDCT_US,Diagnostic Procedure
PMC6162953,cancer therapy,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC6162953,hepatobiliary cancer,PROBLEM,PMC,C3544266,Hepatobiliary cancer,MDR,Neoplastic Process
PMC6162953,jmp,TREATMENT,PMC,C3811068,PSMB8 wt Allele,MTH,Gene or Genome
PMC6162953,spearmans rank correlation coefficient,TEST,PMC,C0242929,Spearman Rank Correlation Coefficient,MSH,Quantitative Concept
PMC6162953,multiple regression analysis,TEST,PMC,,,,
PMC6162953,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6162953,sds score,TEST,PMC,,,,
PMC6162953,benign tumors,PROBLEM,PMC,C0086692,Benign Neoplasm,MTH,Neoplastic Process
PMC6162953,malignantbenign,PROBLEM,PMC,,,,
PMC6162953,sds scores,TEST,PMC,,,,
PMC6162953,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6162953,malignancy,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6162953,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC6162953,sds scores,TEST,PMC,,,,
PMC6162953,8 physical symptomrelated,PROBLEM,PMC,,,,
PMC6162953,lowtomoderate correlation,PROBLEM,PMC,,,,
PMC6162953,multiple regression analysis,TEST,PMC,,,,
PMC6162953,facthep symptoms,PROBLEM,PMC,,,,
PMC6162953,sds scores,TEST,PMC,,,,
PMC6162953,cramps,PROBLEM,PMC,C0026821,Muscle Cramp,MTH,Sign or Symptom
PMC6162953,persistently high levels of depression,PROBLEM,PMC,,,,
PMC6162953,associated subjective symptoms,PROBLEM,PMC,,,,
PMC6162953,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6162953,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6162953,umin clinical trials registry000009592,TREATMENT,PMC,,,,
PMC6162953,persistently high levels of depression,PROBLEM,PMC,,,,
PMC6162953,associated subjective symptoms,PROBLEM,PMC,,,,
PMC6162953,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6162953,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6162953,persistently high levels of depression,PROBLEM,PMC,,,,
PMC6162953,psychological support,TREATMENT,PMC,C0600015,Emotional support,MTH,Health Care Activity
PMC6162953,malignant tumors,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC6162953,several physical symptoms,PROBLEM,PMC,,,,
PMC6162953,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC6162953,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC6162953,gastrointestinal symptoms,PROBLEM,PMC,C0426576,Gastrointestinal symptom,SNOMEDCT_US,Sign or Symptom
PMC6162953,the major subjective physical symptoms,PROBLEM,PMC,,,,
PMC6162953,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC6162953,depression,PROBLEM,PMC,C0011570,Mental Depression,MTH,Mental or Behavioral Dysfunction
PMC6162953,longterm symptom management,TREATMENT,PMC,,,,
PMC6162953,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC6162953,psychiatric interventions,TREATMENT,PMC,C2065413,psychiatric therapy environmental intervention,MEDCIN,Therapeutic or Preventive Procedure
PMC7865852,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7865852,a highly lethal tumor,PROBLEM,PMC,,,,
PMC7865852,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7865852,signs or symptoms,PROBLEM,PMC,C0037088,Signs and Symptoms,MTH,Sign or Symptom
PMC7865852,a surgical resection,TREATMENT,PMC,C0749561,TOE SURGICAL RESECTION,CCPSS,Therapeutic or Preventive Procedure
PMC7865852,a cure,TREATMENT,PMC,C0254681,maximum cure,MSH,Biomedical or Dental Material
PMC7865852,these lesions,PROBLEM,PMC,,,,
PMC7865852,metastatic stages,PROBLEM,PMC,C0744286,GASTRIC CANCER METASTATIC STAGE STAGEVAL,CCPSS,Neoplastic Process
PMC7865852,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7865852,new therapeutic options,TREATMENT,PMC,,,,
PMC7865852,the pancreatic cancer treatment,TREATMENT,PMC,C5668483,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Phase III Module Version,NCI,Intellectual Product
PMC7865852,alterations to metabolic pathways,PROBLEM,PMC,,,,
PMC7865852,cancer treatments,TREATMENT,PMC,C0920425,cancer treatment,MEDCIN,Therapeutic or Preventive Procedure
PMC7865852,many studies,TEST,PMC,C3171825,How many Y were you regularly exposed to this material:Time:Pt:^Patient:Qn:ACSCP Study II,LNC,Clinical Attribute
PMC7865852,targeting glutaminase,TREATMENT,PMC,,,,
PMC7865852,many cancers,PROBLEM,PMC,C3172900,How many full sisters do you have:Num:Pt:^Patient:Qn:Carolina Breast Cancer Study,LNC,Clinical Attribute
PMC7865852,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7865852,tfeb,TREATMENT,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,glutaminasemediated glutamine metabolism,TREATMENT,PMC,,,,
PMC7865852,pancreatic cancer therapy,TREATMENT,PMC,,,,
PMC7865852,transcription,PROBLEM,PMC,C0040649,"Transcription, Genetic",MTH,Genetic Function
PMC7865852,lysosomal function,TEST,PMC,C1372391,Increased Lysosomal Function,MED-RT,Cell Function
PMC7865852,autophagy,TEST,PMC,C0004391,Autophagy,MTH,Cell Function
PMC7865852,tfeb,TEST,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,nutrient sensing,TEST,PMC,C1154615,detection of nutrient,GO,Cell Function
PMC7865852,cellular stress responses,PROBLEM,PMC,C1516374,Cellular Stress Response,MTH,Cell Function
PMC7865852,immune,TEST,PMC,C0439662,Immune,MTH,Finding
PMC7865852,tfeb,TREATMENT,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,pancreatic cancer growth,PROBLEM,PMC,,,,
PMC7865852,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7865852,a significantly elevated tfeb expression,PROBLEM,PMC,,,,
PMC7865852,the genetic inhibition of tfeb,TREATMENT,PMC,,,,
PMC7865852,a significant inhibition in both glutamine and mitochondrial metabolism,PROBLEM,PMC,,,,
PMC7865852,the pdac growth,PROBLEM,PMC,,,,
PMC7865852,high basal levels of autophagy,PROBLEM,PMC,,,,
PMC7865852,pancreatic cancer growth,PROBLEM,PMC,,,,
PMC7865852,the tfeb knockdown,TEST,PMC,,,,
PMC7865852,significant effect,PROBLEM,PMC,C4713633,Discuss the effect of changes in sexuality on significant other,NIC,Health Care Activity
PMC7865852,the autophagic flux,TEST,PMC,,,,
PMC7865852,a profound reduction in glutaminase gls transcription,PROBLEM,PMC,,,,
PMC7865852,an inhibition of glutamine metabolism,PROBLEM,PMC,,,,
PMC7865852,tfeb gene promotors,TREATMENT,PMC,,,,
PMC7865852,the glutamate supplementation,TREATMENT,PMC,C0061472,glutamic acid,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Biologically Active Substance"
PMC7865852,the pdac growth,PROBLEM,PMC,,,,
PMC7865852,a,TEST,PMC,,,,
PMC7865852,our current data,TEST,PMC,,,,
PMC7865852,tfeb,TEST,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,the pdac cell growth,PROBLEM,PMC,,,,
PMC7865852,glutaminasemediated glutamine,PROBLEM,PMC,,,,
PMC7865852,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC7865852,tfeb,TREATMENT,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,the pdac growth,PROBLEM,PMC,,,,
PMC7865852,tfebmediated glutaminolysis,TREATMENT,PMC,,,,
PMC7865852,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC7865852,a significantly elevated tfeb expression,PROBLEM,PMC,,,,
PMC7865852,tfeb,TEST,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,the pdac growth,PROBLEM,PMC,,,,
PMC7865852,the genetic suppression,TREATMENT,PMC,C0038855,"Suppression, Genetic",MSH,Genetic Function
PMC7865852,tfeb,TREATMENT,PMC,C1420699,TFEB gene,MTH,Gene or Genome
PMC7865852,a significant inhibition in glutamine metabolic pathways,PROBLEM,PMC,,,,
PMC7865852,the pdac growth,PROBLEM,PMC,,,,
PMC6592596,early detection methods,TEST,PMC,,,,
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,a casecontrol study,TEST,PMC,,,,
PMC6592596,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC6592596,a,TREATMENT,PMC,,,,
PMC6592596,multivariable logistic regression,TREATMENT,PMC,,,,
PMC6592596,16 risk factors,PROBLEM,PMC,,,,
PMC6592596,prediagnostic symptoms,PROBLEM,PMC,,,,
PMC6592596,pdac,PROBLEM,PMC,,,,
PMC6592596,pdac diagnosis,TEST,PMC,,,,
PMC6592596,pdac,TEST,PMC,,,,
PMC6592596,sensitivity analyses,TEST,PMC,,,,
PMC6592596,the prediction model,TEST,PMC,C0451318,Mortality prediction model,SNOMEDCT_US,Intellectual Product
PMC6592596,auc,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC6592596,the auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC6592596,newonset diabetes patients,PROBLEM,PMC,,,,
PMC6592596,the prediction models,TEST,PMC,C0451318,Mortality prediction model,SNOMEDCT_US,Intellectual Product
PMC6592596,internal validation,TEST,PMC,,,,
PMC6592596,the bootstrap method,TEST,PMC,,,,
PMC6592596,clinical risk factors,PROBLEM,PMC,C0404588,Finding related to risk factor in pregnancy,MTH,Finding
PMC6592596,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,pdac,PROBLEM,PMC,,,,
PMC6592596,clinical risk factors,PROBLEM,PMC,C0404588,Finding related to risk factor in pregnancy,MTH,Finding
PMC6592596,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,pdac,PROBLEM,PMC,,,,
PMC6592596,a pdac prediction model,TREATMENT,PMC,,,,
PMC6592596,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6592596,population screening,TEST,PMC,C2347632,Population Covered by Screening,NCI,Population Group
PMC6592596,pdac diagnosis,TEST,PMC,,,,
PMC6592596,sensitivity analyses,TEST,PMC,,,,
PMC6592596,health changes,PROBLEM,PMC,C0518281,Monitors health status changes,NOC,Finding
PMC6592596,pdac,TEST,PMC,,,,
PMC6592596,prediction,TEST,PMC,C0681842,Prediction,NCI,Idea or Concept
PMC6592596,pdac,PROBLEM,PMC,,,,
PMC7717574,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7717574,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC7717574,endoscopic ultrasonography,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC7717574,computed tomography scanning,TEST,PMC,C0936234,Computed Tomography Scanning Systems,MTH,Medical Device
PMC7717574,physical examination,TEST,PMC,C0031809,Physical Examination,MTH,Health Care Activity
PMC7717574,validated questionnaire,TEST,PMC,C4712851,"Use a valid and reliable chronic pain assessment tool (e.g., Brief Pain Inventory-Short Form, McGill Pain Questionnaire-Short Form, Fibromyalgia Impact Questionnaire)",NIC,Health Care Activity
PMC7717574,survival rates,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC7717574,lower body mass index,PROBLEM,PMC,,,,
PMC7717574,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC7717574,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7717574,a tumor,PROBLEM,PMC,C0007095,Carcinoid Tumor,MTH,Neoplastic Process
PMC7717574,potential confounders,PROBLEM,PMC,C5916610,"Identify previous abdominal surgeries, scars, tumors, ascites, visceral distension, or other anatomical features with potential to confound bladder evaluation",NIC,Health Care Activity
PMC7717574,risk factors,PROBLEM,PMC,C0035648,risk factors,MTH,Finding
PMC7717574,more symptoms,PROBLEM,PMC,C3251062,neuropsychiatric assessment showed one or more symptoms,MEDCIN,Therapeutic or Preventive Procedure
PMC7717574,each increasing symptom,PROBLEM,PMC,,,,
PMC7717574,opium,TREATMENT,PMC,C0029112,opium,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7717574,a tumor,PROBLEM,PMC,C0007095,Carcinoid Tumor,MTH,Neoplastic Process
PMC7717574,an advanced tumor stage,PROBLEM,PMC,C5880995,Lugano classification advanced stage Hodgkin lymphoma,SNOMEDCT_US,Classification
PMC7717574,increased risk of mortality,PROBLEM,PMC,,,,
PMC7717574,potential confounders,PROBLEM,PMC,C5916610,"Identify previous abdominal surgeries, scars, tumors, ascites, visceral distension, or other anatomical features with potential to confound bladder evaluation",NIC,Health Care Activity
PMC7717574,death,PROBLEM,PMC,C1306577,Death (finding),MTH,Finding
PMC7717574,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7717574,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7717574,very poor longterm survival,PROBLEM,PMC,,,,
PMC7717574,tumors stage,PROBLEM,PMC,C0862437,Kidney tumors stage I,MDR,Neoplastic Process
PMC7717574,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7717574,opium,TREATMENT,PMC,C0029112,opium,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7717574,mortality,PROBLEM,PMC,C0026565,Mortality Vital Statistics,MTH,Quantitative Concept
PMC7717574,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7717574,very poor longterm survival,PROBLEM,PMC,,,,
PMC7717574,tumors stage,PROBLEM,PMC,C0862437,Kidney tumors stage I,MDR,Neoplastic Process
PMC7717574,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7717574,opium,TREATMENT,PMC,C0029112,opium,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7717574,mortality,PROBLEM,PMC,C0026565,Mortality Vital Statistics,MTH,Quantitative Concept
PMC7717574,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7717574,the stage and pathologic features of pc,PROBLEM,PMC,,,,
PMC7717574,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC7717574,opium,TREATMENT,PMC,C0029112,opium,MTH,"Organic Chemical, Pharmacologic Substance"
PMC7717574,pc survival,TREATMENT,PMC,,,,
PMC7861334,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7861334,cancerspecific symptoms,PROBLEM,PMC,,,,
PMC7861334,a reliable screening tool,TEST,PMC,,,,
PMC7861334,an artificial neural network,TREATMENT,PMC,,,,
PMC7861334,pancreatic lung colorectal and ovarian cancer,PROBLEM,PMC,,,,
PMC7861334,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7861334,pancreatic cancer risk,PROBLEM,PMC,C1842408,increased risk of pancreatic cancer,HPO,Finding
PMC7861334,a sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC7861334,a specificity,TEST,PMC,C0037791,Specificity,MTH,Quantitative Concept
PMC7861334,the receiver operating characteristic curve,TEST,PMC,,,,
PMC7861334,the training and,TEST,PMC,C0220931,Training,MTH,Educational Activity
PMC7861334,testing cohorts,TEST,PMC,,,,
PMC7861334,pancreatic cancer risk,PROBLEM,PMC,C1842408,increased risk of pancreatic cancer,HPO,Finding
PMC7861334,high discriminatory power,PROBLEM,PMC,,,,
PMC7861334,a novel approach,TREATMENT,PMC,,,,
PMC7861334,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7861334,tailored screening,TEST,PMC,,,,
PMC7861334,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC7861334,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7861334,an auc,TEST,PMC,C1708492,Increased Drug AUC,NCI,Finding
PMC7861334,tailored screening,TEST,PMC,,,,
PMC7861334,risk management,TREATMENT,PMC,C0035649,Risk Management,MSH,Health Care Activity
PMC7861334,current screening techniques,TEST,PMC,C4713409,"Screen for current decreased energy level, inability to concentrate, or other concurrent symptoms that may interfere with cognitive ability to focus on relaxation technique",NIC,Health Care Activity
PMC7861334,more,TEST,PMC,C0205172,More,MTH,Quantitative Concept
PMC7861334,testing,TEST,PMC,C0039593,Testing,MTH,Functional Concept
PMC4014591,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4014591,the most lethal cancers,PROBLEM,PMC,,,,
PMC4014591,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC4014591,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC4014591,specific symptoms,PROBLEM,PMC,C0014591,Epistaxis,MTH,Pathologic Function
PMC4014591,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC4014591,several growth factor receptors,PROBLEM,PMC,,,,
PMC4014591,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4014591,an rna interference approach,TREATMENT,PMC,,,,
PMC4014591,pancreatic cancer growth,PROBLEM,PMC,,,,
PMC4014591,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC4014591,igf1r inhibition,TREATMENT,PMC,C5669515,IGF-1R Inhibition,NCI,Therapeutic or Preventive Procedure
PMC4014591,small interfering rna sirnas,TREATMENT,PMC,C1099354,"RNA, Small Interfering",MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Biologically Active Substance"
PMC4014591,tumor growth,PROBLEM,PMC,C0598934,tumor growth,CHV,Neoplastic Process
PMC4014591,metastasis in hpac,PROBLEM,PMC,,,,
PMC4014591,panc1 pancreatic cancer cell lines,PROBLEM,PMC,,,,
PMC4014591,silencing igf1r,PROBLEM,PMC,,,,
PMC4014591,pancreatic cancer growth,PROBLEM,PMC,,,,
PMC4014591,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC4014591,blocking key signaling pathways,PROBLEM,PMC,,,,
PMC4014591,aktpi3k,TEST,PMC,,,,
PMC4014591,mapk,TEST,PMC,C1370600,MAP Kinase Gene,MTH,Gene or Genome
PMC4014591,jakstat,TEST,PMC,,,,
PMC4014591,emt,TEST,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC4014591,silencing igf1r,TREATMENT,PMC,,,,
PMC4014591,an antiproliferative effect,PROBLEM,PMC,,,,
PMC4014591,hpac pancreatic cancer cell lines,PROBLEM,PMC,,,,
PMC4014591,matrigel invasion,PROBLEM,PMC,C1513015,Matrigel Invasion Assay,NCI,Laboratory Procedure
PMC4014591,transwell migration,TEST,PMC,,,,
PMC4014591,wound healing assays,TEST,PMC,,,,
PMC4014591,igf1r,PROBLEM,PMC,C1334088,IGF1R gene,MTH,Gene or Genome
PMC4014591,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4014591,western blotting analysis,TEST,PMC,C0949466,Western Blot,MTH,Laboratory Procedure
PMC4014591,key intermediates,PROBLEM,PMC,,,,
PMC4014591,proliferation,PROBLEM,PMC,C1514485,Proliferation,MTH,Functional Concept
PMC4014591,epithelial mesenchymal transition,PROBLEM,PMC,C1523298,epithelial to mesenchymal transition,MTH,Cell Function
PMC4014591,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC4014591,soft agar assays,TEST,PMC,C1519406,Soft Agar Assay,NCI,Laboratory Procedure
PMC4014591,silencing igf1r,PROBLEM,PMC,,,,
PMC4014591,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4014591,flow cytometric analysis,TEST,PMC,,,,
PMC4014591,apoptosis in igf1r silenced cells,PROBLEM,PMC,,,,
PMC4014591,silencing igf1r,PROBLEM,PMC,,,,
PMC4014591,insulin receptor,TREATMENT,PMC,C0034818,Insulin Receptor,MTH,"Amino Acid, Peptide, or Protein, Enzyme, Receptor"
PMC4014591,pancreatic cancer cell growth,PROBLEM,PMC,,,,
PMC4014591,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC4014591,igf1r,PROBLEM,PMC,C1334088,IGF1R gene,MTH,Gene or Genome
PMC4014591,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4014591,our study,TEST,PMC,,,,
PMC4014591,silencing igf1r,PROBLEM,PMC,,,,
PMC4014591,colony forming capability,PROBLEM,PMC,,,,
PMC4014591,invasivemetastatic potential,PROBLEM,PMC,,,,
PMC4014591,pancreatic ductal adenocarcinoma cells,PROBLEM,PMC,C1880425,Ductal Cell Adenocarcinoma of the Rat Pancreas,NCI,Neoplastic Process
PMC4014591,apoptosis,PROBLEM,PMC,C0162638,Apoptosis,MTH,Cell Function
PMC4014591,emt,PROBLEM,PMC,C0013963,Emergency Medical Technicians,MTH,Professional or Occupational Group
PMC4014591,key molecular pathways,PROBLEM,PMC,,,,
PMC4014591,igf1r,PROBLEM,PMC,C1334088,IGF1R gene,MTH,Gene or Genome
PMC4014591,pdac,TEST,PMC,,,,
PMC4014591,pi3kakt,TEST,PMC,,,,
PMC4014591,mapkerk,TEST,PMC,,,,
PMC4014591,jakstat signaling cascades,TEST,PMC,,,,
PMC4014591,igfirtargeting drugs,TREATMENT,PMC,,,,
PMC4014591,pdac,PROBLEM,PMC,,,,
PMC4014591,igf1r,TREATMENT,PMC,C1334088,IGF1R gene,MTH,Gene or Genome
PMC4014591,pdac tumorigenesis,PROBLEM,PMC,,,,
PMC4014591,pdac treatment,TREATMENT,PMC,,,,
PMC4014591,harmful offtarget physiologic effects,PROBLEM,PMC,,,,
PMC4014591,pancreatic cancer cells,PROBLEM,PMC,C3824982,Pancreatic acinar cells--Cancer,LCH_NW,Cell
PMC4014591,igf1r,TREATMENT,PMC,C1334088,IGF1R gene,MTH,Gene or Genome
PMC11256648,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11256648,a clinically challenging tumor,PROBLEM,PMC,,,,
PMC11256648,available therapies,TREATMENT,PMC,C5914805,"Ensure pulse oximetry available to monitor response to therapy, as indicated",NIC,Health Care Activity
PMC11256648,early symptoms,PROBLEM,PMC,C0343666,Early congenital syphilis with symptoms,MTH,Disease or Syndrome
PMC11256648,known detectable biomarkers,PROBLEM,PMC,,,,
PMC11256648,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC11256648,pc biology,PROBLEM,PMC,,,,
PMC11256648,cancerimmune cell interactions,PROBLEM,PMC,,,,
PMC11256648,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11256648,circulating immune cells,PROBLEM,PMC,,,,
PMC11256648,tumor development,PROBLEM,PMC,C1850355,Propensity to tumor development,OMIM,Finding
PMC11256648,an increasingly immunogenic microenvironment,PROBLEM,PMC,,,,
PMC11256648,tumor homeostasis,PROBLEM,PMC,,,,
PMC11256648,the feedback loop between thetumorimmunemicroenvironment,TREATMENT,PMC,,,,
PMC11256648,pancreatic precancerous lesions,PROBLEM,PMC,,,,
PMC11256648,disease development,PROBLEM,PMC,C0494698,Dental Developmental Disorder,MTH,Disease or Syndrome
PMC11256648,liquid biopsy biomarkers,TEST,PMC,,,,
PMC11256648,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11256648,new molecular therapeutic targets,PROBLEM,PMC,,,,
PMC11256648,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC11256648,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11256648,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11256648,dynamic biomarkers,TEST,PMC,,,,
PMC11256648,early detection,TEST,PMC,C0596473,Early Diagnosis,MSH,Diagnostic Procedure
PMC11256648,these biomarkers,TEST,PMC,,,,
PMC11256648,inflammatory cytokines,PROBLEM,PMC,C5975258,Elevated inflammatory cytokines,OMIM,Finding
PMC11256648,chemokines,TEST,PMC,C0282554,chemokine,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC11256648,growth factors,PROBLEM,PMC,C0018284,Growth Factor,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC11256648,the inflammatory processes,PROBLEM,PMC,C0749224,SYSTEMIC INFLAMMATORY PROCESS,CCPSS,Disease or Syndrome
PMC11256648,tumor progression,PROBLEM,PMC,C0178874,Tumor Progression,MTH,Neoplastic Process
PMC11256648,integrative approaches,TREATMENT,PMC,C5932536,Uses integrative approaches to tobacco-alcohol therapy with medications for nicotine dependence,NOC,Finding
PMC11256648,pc onset,PROBLEM,PMC,,,,
PMC11256648,this integrated analysis,TEST,PMC,,,,
PMC11256648,blood biomarkers,TEST,PMC,C5876322,"gene expression profiling by RNA sequencing of 15 biomarkers, in whole blood, for anxiety disorder risk",MEDCIN,Laboratory Procedure
PMC11256648,bidirectional,TREATMENT,PMC,C1706937,Bidirectional,NCI,Qualitative Concept
PMC11256648,early pc lesions,PROBLEM,PMC,,,,
PMC11256648,clinical trials,TREATMENT,PMC,C0008976,Clinical Trials,MTH,Research Activity
PMC11256648,these biomarkers,TEST,PMC,,,,
PMC11256648,diagnostic strategies,TREATMENT,PMC,,,,
PMC11256648,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11256648,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC11256648,a systemic disease,PROBLEM,PMC,C0442893,Systemic disease,MTH,Disease or Syndrome
PMC11256648,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC11256648,comprehensive studies,TEST,PMC,C2697864,Label Comprehension Studies,NCI,Regulation or Law
PMC11256648,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11256648,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9476854,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9476854,prevention,TREATMENT,PMC,C2700409,prevention aspects,MTH,Qualitative Concept
PMC9476854,effective treatment,TREATMENT,PMC,C0510269,Discuss effective and ineffective methods of prior treatment,NIC,Health Care Activity
PMC9476854,hepatitis b virus hbv,PROBLEM,PMC,C0019169,hepatitis B virus,MTH,Virus
PMC9476854,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC9476854,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9476854,previous hbv infection,PROBLEM,PMC,,,,
PMC9476854,viral biomarkers,PROBLEM,PMC,,,,
PMC9476854,pancreatic ductal adenocarcinoma,PROBLEM,PMC,C1335302,Pancreatic Ductal Adenocarcinoma,MTH,Neoplastic Process
PMC9476854,the virus,PROBLEM,PMC,C0042776,Virus,MTH,Virus
PMC9476854,this cancer,PROBLEM,PMC,C4697846,Evidence of this Cancer,LNC,Finding
PMC9476854,hepatitis b surface antigennegative,TEST,PMC,,,,
PMC9476854,the final analysis,TEST,PMC,C3897773,Raw Dataset for Final Analysis,NCI,Intellectual Product
PMC9476854,pdac,TEST,PMC,,,,
PMC9476854,cytology,TEST,PMC,C0010819,Cytology,MTH,Biomedical Occupation or Discipline
PMC9476854,histology,TEST,PMC,C0019638,Histology,MTH,Biomedical Occupation or Discipline
PMC9476854,hbv biomarkers,TEST,PMC,,,,
PMC9476854,hepatitis b core antigen,TEST,PMC,C0019166,Hepatitis B Core Antigen,MTH,Immunologic Factor
PMC9476854,antibody,TEST,PMC,C0003241,Antibodies,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9476854,hepatitis b surface antigen,TEST,PMC,C0019168,Hepatitis B Surface Antigens,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC9476854,hbv dna,TEST,PMC,C1256114,Hbv DNA Test,CPM,Laboratory Procedure
PMC9476854,pdac,PROBLEM,PMC,,,,
PMC9476854,biomarkers in resected pancreatic tissues,PROBLEM,PMC,,,,
PMC9476854,hbv pregenomic rna,PROBLEM,PMC,,,,
PMC9476854,covalently closed circular dna,PROBLEM,PMC,,,,
PMC9476854,immunohistochemistry staining,TEST,PMC,C3469417,stool immunohistochemistry stain,MEDCIN,Laboratory Procedure
PMC9476854,pancreatic tissues,TEST,PMC,C0994638,Ectopic pancreatic tissue,HPO,Finding
PMC9476854,hepatitis b virus x antigen,PROBLEM,PMC,C0062529,hepatitis B virus X protein,MSH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC9476854,ki67 protein,TEST,PMC,,,,
PMC9476854,nonparametric statistics,TEST,PMC,C0242932,"Statistics, Nonparametric",MSH,Quantitative Concept
PMC9476854,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC9476854,antihbc,TEST,PMC,,,,
PMC9476854,pdac,TREATMENT,PMC,,,,
PMC9476854,pdac,PROBLEM,PMC,,,,
PMC9476854,previous hbv infection,PROBLEM,PMC,,,,
PMC9476854,hbv dna,TEST,PMC,C1256114,Hbv DNA Test,CPM,Laboratory Procedure
PMC9476854,pdac,TEST,PMC,,,,
PMC9476854,the pancreatic tumor,PROBLEM,PMC,C0941236,Pancreatic/biliary tumor,MTHMST,Neoplastic Process
PMC9476854,antihbc,TEST,PMC,,,,
PMC9476854,blood hbv dna,TEST,PMC,,,,
PMC9476854,the serum antihbc test,TEST,PMC,,,,
PMC9476854,pdac,TEST,PMC,,,,
PMC9476854,replicative competence,PROBLEM,PMC,C2612402,replication-competent complex,GO,Cell Component
PMC9476854,the virus,PROBLEM,PMC,C0042776,Virus,MTH,Virus
PMC9476854,pregenomic,PROBLEM,PMC,,,,
PMC9476854,the pancreatic tumor tissue samples,PROBLEM,PMC,,,,
PMC9476854,hepatitis b virus x antigen expression,PROBLEM,PMC,,,,
PMC9476854,active cell proliferation,PROBLEM,PMC,C1326160,activated T cell proliferation,GO,Cell Function
PMC9476854,immunohistochemistry,TEST,PMC,C0021044,Immunohistochemistry,MTH,Diagnostic Procedure
PMC9476854,pdac in the pancreatic tumor tissue samples,PROBLEM,PMC,,,,
PMC9476854,pdac,PROBLEM,PMC,,,,
PMC9476854,viral replication,PROBLEM,PMC,C0042774,Virus Replication,MSH,Cell Function
PMC9476854,hepatitis b virus x protein expression,PROBLEM,PMC,,,,
PMC9476854,the tumor tissue,PROBLEM,PMC,C5237816,Percent Tumor Tissue,NCI,Quantitative Concept
PMC9476854,hbv infection,PROBLEM,PMC,C3854623,Perinatal HBV infection,MDR,Disease or Syndrome
PMC9476854,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9476854,pdac,PROBLEM,PMC,,,,
PMC9476854,viral replication,PROBLEM,PMC,C0042774,Virus Replication,MSH,Cell Function
PMC9476854,hepatitis b virus x protein expression,PROBLEM,PMC,,,,
PMC9476854,the tumor tissue,PROBLEM,PMC,C5237816,Percent Tumor Tissue,NCI,Quantitative Concept
PMC9476854,hbv infection,PROBLEM,PMC,C3854623,Perinatal HBV infection,MDR,Disease or Syndrome
PMC9476854,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9476854,pdac,PROBLEM,PMC,,,,
PMC9476854,hbsagnegative,TEST,PMC,,,,
PMC9476854,antihbcpositive,TEST,PMC,,,,
PMC9476854,silent viral replication,PROBLEM,PMC,,,,
PMC9476854,prooncogenic hbx protein expression,PROBLEM,PMC,,,,
PMC9476854,the tumor tissue,PROBLEM,PMC,C5237816,Percent Tumor Tissue,NCI,Quantitative Concept
PMC9476854,hbv infection,PROBLEM,PMC,C3854623,Perinatal HBV infection,MDR,Disease or Syndrome
PMC9476854,pc development,PROBLEM,PMC,,,,
PMC9476854,pbi,PROBLEM,PMC,C1424926,APOBEC3C gene,MTH,Gene or Genome
PMC9476854,pdac,PROBLEM,PMC,,,,
PMC8444192,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8444192,a lethal malignancy,PROBLEM,PMC,C0908283,"L3MBTL1 protein, human",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8444192,its prevalence rate,TEST,PMC,,,,
PMC8444192,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8444192,metastatic pc,PROBLEM,PMC,,,,
PMC8444192,latestage stage iv pc,PROBLEM,PMC,,,,
PMC8444192,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8444192,any specific clinical manifestations,PROBLEM,PMC,,,,
PMC8444192,inoperable,PROBLEM,PMC,C0205187,Inoperable,SNOMEDCT_US,Qualitative Concept
PMC8444192,curativeintent surgery,TREATMENT,PMC,,,,
PMC8444192,complications,PROBLEM,PMC,C0009566,Complication,MTH,Pathologic Function
PMC8444192,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC8444192,postoperative pancreatic fistula,PROBLEM,PMC,,,,
PMC8444192,recurrence,PROBLEM,PMC,C0034897,Recurrence,MTH,Phenomenon or Process
PMC8444192,metastatic foci,PROBLEM,PMC,,,,
PMC8444192,the management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC8444192,metastatic pc,PROBLEM,PMC,,,,
PMC8444192,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC8444192,a formidable challenge,PROBLEM,PMC,,,,
PMC8444192,metastatic pc,PROBLEM,PMC,,,,
PMC8444192,epithelialmesenchymal transition,PROBLEM,PMC,,,,
PMC8444192,nfb,TEST,PMC,C0663914,IkappaB kinase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8444192,kras,TEST,PMC,C1537502,KRAS gene,MTH,Gene or Genome
PMC8444192,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC8444192,early detection,TEST,PMC,C0596473,Early Diagnosis,MSH,Diagnostic Procedure
PMC8444192,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC8444192,carbohydrate antigen,TEST,PMC,C0443758,Carbohydrate antigen,SNOMEDCT_US,"Organic Chemical, Immunologic Factor"
PMC8444192,prostate cancerassociated,PROBLEM,PMC,,,,
PMC8444192,fboxlrrrepeat protein,TEST,PMC,,,,
PMC8444192,tumor stroma,PROBLEM,PMC,C1276696,Tumor invasion into stroma,SNOMEDCT_US,Finding
PMC8444192,metastatic pc,PROBLEM,PMC,,,,
PMC8444192,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8444192,a less feasible screening protocol,TREATMENT,PMC,,,,
PMC8444192,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC8444192,early detection,TEST,PMC,C0596473,Early Diagnosis,MSH,Diagnostic Procedure
PMC8444192,signaling pathways,PROBLEM,PMC,C0037080,Signal Pathways,MSH,Molecular Function
PMC8444192,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC8444192,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC8444192,pathological changes,PROBLEM,PMC,C0234769,Pathologic change of voice,SNOMEDCT_US,Sign or Symptom
PMC8444192,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC4304507,pancreatic cancer therapy,TREATMENT,PMC,,,,
PMC4304507,borderline resectable pancreatic cancer,PROBLEM,PMC,C4763562,Borderline Resectable Pancreatic Ductal Adenocarcinoma,NCI,Neoplastic Process
PMC4304507,resectable and locally advanced pancreatic cancers,PROBLEM,PMC,,,,
PMC4304507,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4304507,a cancer,PROBLEM,PMC,C0346627,Intestinal Cancer,MTH,Neoplastic Process
PMC4304507,r2 resection,TREATMENT,PMC,C1621003,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; post r1 or r2 resection with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC4304507,marginnegative resection,TREATMENT,PMC,,,,
PMC4304507,a fundamental requirement,PROBLEM,PMC,,,,
PMC4304507,curing pancreatic cancer,PROBLEM,PMC,,,,
PMC4304507,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4304507,brpc,PROBLEM,PMC,C1702277,4-bromopyrrole-2-carboxy-N(epsilon)lysine,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC4304507,recent issues,PROBLEM,PMC,,,,
PMC4304507,current available surgical techniques,TREATMENT,PMC,,,,
PMC4304507,pd,TREATMENT,PMC,C5575533,ITMIG MRECIST Progressive Disease,MTH,Classification
PMC4304507,vascular resection,TREATMENT,PMC,C3523926,Resection of extradural vascular lesion of clivus,CPT,Therapeutic or Preventive Procedure
PMC4304507,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4304507,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4304507,locally advanced cancer,PROBLEM,PMC,C0677984,Locally Advanced Malignant Neoplasm,MTH,Neoplastic Process
PMC4304507,extensive biologic properties,PROBLEM,PMC,,,,
PMC4304507,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC4304507,anatomic relationships between tumor and vessels,PROBLEM,PMC,,,,
PMC4304507,brpc,PROBLEM,PMC,C1702277,4-bromopyrrole-2-carboxy-N(epsilon)lysine,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC4304507,current surgical techniques,TREATMENT,PMC,,,,
PMC4304507,isolated venous involvement,PROBLEM,PMC,,,,
PMC4304507,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4304507,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC4304507,this specific tumor conditionrecently,PROBLEM,PMC,,,,
PMC4304507,pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC4304507,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC4304507,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4304507,current available surgical techniques,TREATMENT,PMC,,,,
PMC4304507,pd,TREATMENT,PMC,C5575533,ITMIG MRECIST Progressive Disease,MTH,Classification
PMC4304507,vascular resection,TREATMENT,PMC,C3523926,Resection of extradural vascular lesion of clivus,CPT,Therapeutic or Preventive Procedure
PMC4304507,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4304507,vascular involvement,PROBLEM,PMC,C5384620,Hb-SS disease with cerebral vascular involvement,ICD10CM,Disease or Syndrome
PMC4304507,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4304507,locally advanced cancer,PROBLEM,PMC,C0677984,Locally Advanced Malignant Neoplasm,MTH,Neoplastic Process
PMC4304507,extensive biologic properties,PROBLEM,PMC,,,,
PMC4304507,preoperative neoadjuvant therapy,TREATMENT,PMC,,,,
PMC4304507,radiotherapy,TREATMENT,PMC,C0034619,radiotherapeutic,MTH,Intellectual Product
PMC4304507,anatomic relationships between tumor and vessels,PROBLEM,PMC,,,,
PMC4304507,brpc,PROBLEM,PMC,C1702277,4-bromopyrrole-2-carboxy-N(epsilon)lysine,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC4304507,current surgical techniques,TREATMENT,PMC,,,,
PMC4304507,isolated venous involvement,PROBLEM,PMC,,,,
PMC4304507,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4304507,neoadjuvant treatment,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC4304507,this specific tumor condition,PROBLEM,PMC,,,,
PMC4304507,pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC4304507,neoadjuvant therapy,TREATMENT,PMC,C0600558,Neoadjuvant Therapy,MTH,Therapeutic or Preventive Procedure
PMC4304507,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC4304507,brpc,PROBLEM,PMC,C1702277,4-bromopyrrole-2-carboxy-N(epsilon)lysine,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC4304507,neoadjuvnat therapy protocol,TREATMENT,PMC,,,,
PMC4304507,operative,TEST,PMC,C1882154,Operative,NCI,Temporal Concept
PMC4304507,pathologic examination,TEST,PMC,C4086729,Pathologic Examination,NCI,Diagnostic Procedure
PMC4304507,histologic response,PROBLEM,PMC,,,,
PMC4304507,pancreatectomy,TREATMENT,PMC,C0030279,Pancreatectomy,MTH,Therapeutic or Preventive Procedure
PMC4304507,neoadjuvnat therapy,TREATMENT,PMC,,,,
PMC4304507,brpc,PROBLEM,PMC,C1702277,4-bromopyrrole-2-carboxy-N(epsilon)lysine,MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC12112120,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12112120,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC12112120,nonspecific symptoms,PROBLEM,PMC,C0232486,"Nonspecific abdominal symptom, NOS",SNMI,Sign or Symptom
PMC12112120,precursor lesions,PROBLEM,PMC,C5787479,Myeloid precursor lesion,SNOMEDCT_US,Neoplastic Process
PMC12112120,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC12112120,cafs,PROBLEM,PMC,C4277548,Cancer-Associated Fibroblasts,MTH,Cell
PMC12112120,cancer progression,PROBLEM,PMC,C1947901,Cancer Progression,MTH,Pathologic Function
PMC12112120,invasion,PROBLEM,PMC,C2699153,Cell Invasion,MTH,Pathologic Function
PMC12112120,metastasis,PROBLEM,PMC,C4255448,Metastasis,MTH,Pathologic Function
PMC12112120,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC12112120,mrna data,TEST,PMC,,,,
PMC12112120,pc samples,TEST,PMC,,,,
PMC12112120,cafrelated genes,PROBLEM,PMC,,,,
PMC12112120,drugs,TREATMENT,PMC,C3687832,Drugs - dental services,MTH,Therapeutic or Preventive Procedure
PMC12112120,pc treatment,TREATMENT,PMC,C0962074,PC protocol (ovarian cancer treatment),MTH,Therapeutic or Preventive Procedure
PMC12112120,algorithms,TREATMENT,PMC,C0002045,algorithm,MTH,Intellectual Product
PMC12112120,epic,TREATMENT,PMC,C3810536,Epic Health Record System,MTH,Intellectual Product
PMC12112120,xcell,TREATMENT,PMC,C4723176,"DRESSING,XCELL BIOSYN 3.5IN X 3.5IN",VANDF,Medical Device
PMC12112120,mcpcounter,TREATMENT,PMC,,,,
PMC12112120,tide,TREATMENT,PMC,C0599962,Red Tide,MSH,Natural Phenomenon or Process
PMC12112120,caf infiltration,PROBLEM,PMC,,,,
PMC12112120,weighted gene coexpression network analysis,TEST,PMC,,,,
PMC12112120,our analyses,TEST,PMC,,,,
PMC12112120,eight prognostic genes,PROBLEM,PMC,,,,
PMC12112120,a sixgene model,TREATMENT,PMC,,,,
PMC12112120,correlation analysis,TEST,PMC,C0010101,Correlation Study,MSH,Research Activity
PMC12112120,the caf risk score,PROBLEM,PMC,,,,
PMC12112120,caf infiltration,PROBLEM,PMC,,,,
PMC12112120,related,TEST,PMC,C0445223,Related (finding),MTH,Finding
PMC12112120,significant differences between,PROBLEM,PMC,,,,
PMC12112120,highcaf and lowcaf risk groups,PROBLEM,PMC,,,,
PMC12112120,high caf risk scores,PROBLEM,PMC,,,,
PMC12112120,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC12112120,higher tumor mutation burdens,PROBLEM,PMC,,,,
PMC12112120,gsea,TEST,PMC,,,,
PMC12112120,these scores,TEST,PMC,,,,
PMC12112120,tumor microenvironment pathways,PROBLEM,PMC,,,,
PMC12112120,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC12112120,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC12112120,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12112120,future clinical strategies,TREATMENT,PMC,,,,
PMC12112120,our study,TEST,PMC,,,,
PMC12112120,mfap5,TEST,PMC,C1428886,MFAP5 gene,MTH,Gene or Genome
PMC12112120,ctsk,TEST,PMC,C1413815,CTSK gene,MTH,Gene or Genome
PMC12112120,mmp2,TEST,PMC,C1334522,MMP2 gene,MTH,Gene or Genome
PMC12112120,fstl1,TEST,PMC,C1414831,FSTL1 gene,MTH,Gene or Genome
PMC12112120,prrx1through,TEST,PMC,,,,
PMC12112120,weighted gene coexpression network analysis,TEST,PMC,,,,
PMC12112120,cancerassociated fibroblast caf infiltration,PROBLEM,PMC,,,,
PMC12112120,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC12112120,both chemotherapy,TREATMENT,PMC,C5439719,Patient received adjuvant treatment course including both chemotherapy and her2-targeted therapy,HCPCS,Therapeutic or Preventive Procedure
PMC12112120,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC12112120,the tumor microenvironment,PROBLEM,PMC,C2936626,Tumor Microenvironment,MSH,Natural Phenomenon or Process
PMC12112120,pancreatic cancer progression,PROBLEM,PMC,C1618370,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC12112120,treatment efficacy,TREATMENT,PMC,C0087113,Treatment Effectiveness,MTH,Qualitative Concept
PMC12112120,further exploration,TEST,PMC,,,,
PMC12112120,the tmes,TEST,PMC,C5783677,Xerna TME Panel,NCI,Laboratory Procedure
PMC12112120,caf infiltration,PROBLEM,PMC,,,,
PMC12112120,the clinical management,TREATMENT,PMC,C1516615,Clinical Management,NCI,Health Care Activity
PMC12112120,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC12112120,optimizing,TREATMENT,PMC,C2698650,Optimization,NCI,Activity
PMC12112120,therapeutic strategies,TREATMENT,PMC,C5913765,Use therapeutic communication strategies to acknowledge pain experience and convey acceptance of response to pain,NIC,Health Care Activity
PMC12112120,targeted approaches,TREATMENT,PMC,C0814387,matching target group and prevention approach,AOD,Therapeutic or Preventive Procedure
PMC12112120,cafrelated dynamics,PROBLEM,PMC,,,,
PMC12112120,the tme,TEST,PMC,C5783677,Xerna TME Panel,NCI,Laboratory Procedure
PMC12112120,these molecular markers,TEST,PMC,,,,
PMC12112120,effective treatment protocols,TREATMENT,PMC,,,,
PMC12112120,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,helicobacter pylorih pylori,PROBLEM,PMC,,,,
PMC8371525,an infectious agent,PROBLEM,PMC,C0314732,Infectious agent,SNOMEDCT_US,Organism
PMC8371525,several diseases,PROBLEM,PMC,C4740692,Severe disease,LNC,Finding
PMC8371525,gastric and duodenal peptic ulcer,PROBLEM,PMC,,,,
PMC8371525,gastric adenocarcinoma,PROBLEM,PMC,C0278701,Gastric Adenocarcinoma,MTH,Neoplastic Process
PMC8371525,mucosaassociated lymphoid tissue lymphoma of the stomach,PROBLEM,PMC,,,,
PMC8371525,other extragastric manifestations,PROBLEM,PMC,,,,
PMC8371525,pyloriinfection,PROBLEM,PMC,,,,
PMC8371525,neurological disorders,PROBLEM,PMC,C0027765,nervous system disorder,MTH,Disease or Syndrome
PMC8371525,alzheimers disease,PROBLEM,PMC,C0002395,Alzheimer's Disease,MTH,Disease or Syndrome
PMC8371525,demyelinating multiple sclerosis,PROBLEM,PMC,C0856260,Demyelinating disease (excl multiple sclerosis),MDR,Disease or Syndrome
PMC8371525,parkinsons disease,PROBLEM,PMC,C0030567,Parkinson Disease,MTH,Disease or Syndrome
PMC8371525,a relationship betweenh,PROBLEM,PMC,,,,
PMC8371525,pyloriinfection,PROBLEM,PMC,,,,
PMC8371525,such dermatological diseases,PROBLEM,PMC,,,,
PMC8371525,psoriasis,PROBLEM,PMC,C0033860,Psoriasis,MSH,Disease or Syndrome
PMC8371525,rosacea,PROBLEM,PMC,C0035854,Rosacea,MTH,Disease or Syndrome
PMC8371525,infection,PROBLEM,PMC,C3714514,Infection,MTH,Pathologic Function
PMC8371525,openangle glaucoma,PROBLEM,PMC,,,,
PMC8371525,pyloriinfection,PROBLEM,PMC,,,,
PMC8371525,diseases of the pancreas,PROBLEM,PMC,C0030286,Pancreatic Diseases,MTH,Disease or Syndrome
PMC8371525,pancreatic diseases,PROBLEM,PMC,C0030286,Pancreatic Diseases,MTH,Disease or Syndrome
PMC8371525,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC8371525,chronic pancreatitis,PROBLEM,PMC,C0149521,"Pancreatitis, Chronic",MTH,Disease or Syndrome
PMC8371525,modestly increased pancreatic cancer risk inh,PROBLEM,PMC,,,,
PMC8371525,pyloripositive patients,PROBLEM,PMC,,,,
PMC8371525,this increase,PROBLEM,PMC,C5913994,Avoid dropping solution directly onto cornea as this causes increased discomfort,NIC,Health Care Activity
PMC8371525,reduction of antral dcells inh,TREATMENT,PMC,,,,
PMC8371525,pyloripositive patients,PROBLEM,PMC,,,,
PMC8371525,a suppression of somatostatin secretion,PROBLEM,PMC,,,,
PMC8371525,increased secretin secretion,PROBLEM,PMC,,,,
PMC8371525,pancreatic growth,PROBLEM,PMC,C1566942,Human Pancreatic Growth Hormone-Releasing Factor,MSH,"Amino Acid, Peptide, or Protein, Hormone"
PMC8371525,carcinogenesis,PROBLEM,PMC,C0596263,Carcinogenesis,MTH,Neoplastic Process
PMC8371525,pylori,PROBLEM,PMC,C0079488,Helicobacter pylori,MTH,Bacterium
PMC8371525,microbiome dysbiosis,PROBLEM,PMC,,,,
PMC8371525,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC8371525,cellular proliferation,PROBLEM,PMC,C0596290,Cell Proliferation,MTH,Cell Function
PMC8371525,the role ofh,TREATMENT,PMC,,,,
PMC8371525,the inflammation,PROBLEM,PMC,C0029877,Ear Inflammation,MTH,Disease or Syndrome
PMC8371525,autoimmune pancreatitis,PROBLEM,PMC,C2609129,Autoimmune Pancreatitis,MTH,Disease or Syndrome
PMC8371525,molecular mimicry,PROBLEM,PMC,C0242943,Molecular Mimicry,MSH,Molecular Function
PMC8371525,pyloriand pancreatic tissue,PROBLEM,PMC,,,,
PMC8371525,autoimmune pancreatitis,PROBLEM,PMC,C2609129,Autoimmune Pancreatitis,MTH,Disease or Syndrome
PMC8371525,antibodies,PROBLEM,PMC,C0003241,Antibodies,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC8371525,pyloriproteinsh,PROBLEM,PMC,,,,
PMC8371525,pylori,PROBLEM,PMC,C0079488,Helicobacter pylori,MTH,Bacterium
PMC8371525,microbiome dysbiosis,PROBLEM,PMC,,,,
PMC8371525,autoimmune inflammation of the pancreas,PROBLEM,PMC,,,,
PMC8371525,pathologists,TEST,PMC,C0334866,Medical pathologist,MTH,Professional or Occupational Group
PMC8371525,more studies,TEST,PMC,C3510339,"Nerve conduction, 13 or more studies",CPT,Diagnostic Procedure
PMC8371525,further,TEST,PMC,C1517331,Further,NCI,Spatial Concept
PMC8371525,systematic research,TEST,PMC,,,,
PMC8371525,nextgeneration sequencing,TEST,PMC,C5979779,"Infectious disease (acid-fast bacteria and invasive fungi), dna (673 organisms), nextgeneration sequencing, plasm",HCPT,Laboratory Procedure
PMC8371525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,h pyloriinfection,PROBLEM,PMC,,,,
PMC8371525,diseases of the stomach and duodenum,PROBLEM,PMC,C0156086,Other diseases of stomach and duodenum,ICD10CM,Disease or Syndrome
PMC8371525,peptic gastroduodenal ulcer disease,PROBLEM,PMC,C0842867,Partial gastrectomy with gastroduodenal anastomosis following previous procedure for peptic ulcer disease,ICD10AM,Therapeutic or Preventive Procedure
PMC8371525,gastritis,PROBLEM,PMC,C0017152,Gastritis,MTH,Disease or Syndrome
PMC8371525,carcinomas,PROBLEM,PMC,C0007097,Carcinoma,MTH,Neoplastic Process
PMC8371525,mucosaassociated lymphoid tissue lymphoma of the stomach,PROBLEM,PMC,,,,
PMC8371525,pancreatic carcinogenesis,PROBLEM,PMC,,,,
PMC8371525,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC8371525,pyloriinfection,PROBLEM,PMC,,,,
PMC8371525,these diseases,PROBLEM,PMC,,,,
PMC8371525,oral bacteria,PROBLEM,PMC,C0597134,oral bacteria,MTH,Bacterium
PMC8371525,gut bacteriah,PROBLEM,PMC,,,,
PMC8371525,pyloriand intratumor bacteria,PROBLEM,PMC,,,,
PMC8371525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,this process,PROBLEM,PMC,C3845109,"No, but this work is in process",LNC,Finding
PMC8371525,bacteria,PROBLEM,PMC,C0004611,Bacteria,MTH,Bacterium
PMC8371525,chronic inflammation,PROBLEM,PMC,C0021376,Chronic inflammation,OMIM,Pathologic Function
PMC8371525,inflammatory mediators,PROBLEM,PMC,C5543552,Increased levels of inflammatory mediators and cytokines,OMIM,Finding
PMC8371525,cell proliferation,PROBLEM,PMC,C0596290,Cell Proliferation,MTH,Cell Function
PMC8371525,mutagenesis,PROBLEM,PMC,C0079866,Mutagenesis Process,MTH,Molecular Function
PMC8371525,oncogene activation,PROBLEM,PMC,C1518575,Oncogene Activation Process,NCI,Cell or Molecular Dysfunction
PMC8371525,angiogenesis,PROBLEM,PMC,C0302600,Angiogenic Process,MTH,Organ or Tissue Function
PMC8371525,bacteria,PROBLEM,PMC,C0004611,Bacteria,MTH,Bacterium
PMC8371525,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC8371525,activating nfkappa b,PROBLEM,PMC,,,,
PMC8371525,inhibiting cellular apoptosis,PROBLEM,PMC,C4317102,Baculoviral IAP Repeat-Containing 3 Protein,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8371525,bacteria,PROBLEM,PMC,C0004611,Bacteria,MTH,Bacterium
PMC8371525,bacteria,PROBLEM,PMC,C0004611,Bacteria,MTH,Bacterium
PMC8371525,bacterial dysbiosis,PROBLEM,PMC,,,,
PMC8371525,the oncobiome,TEST,PMC,,,,
PMC8371525,bacterial metabolites,PROBLEM,PMC,,,,
PMC8371525,secondary bile acids,TREATMENT,PMC,C5686387,Secondary bile acid malabsorption,SNOMEDCT_US,Disease or Syndrome
PMC8371525,polyamines,TREATMENT,PMC,C0032433,Polyamines,MSH,Organic Chemical
PMC8371525,indole derivatives,TREATMENT,PMC,C3653426,"Indole derivatives, antipsychotic",ATC,"Organic Chemical, Pharmacologic Substance"
PMC8371525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,nextgeneration sequencing,TEST,PMC,C5979779,"Infectious disease (acid-fast bacteria and invasive fungi), dna (673 organisms), nextgeneration sequencing, plasm",HCPT,Laboratory Procedure
PMC8371525,noninvasive diagnostic,TEST,PMC,C3248364,Other noninvasive vascular diagnostic study,CPT,Diagnostic Procedure
PMC8371525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,a positive association between bacteria,PROBLEM,PMC,,,,
PMC8371525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,related immune inflammation,PROBLEM,PMC,,,,
PMC8371525,increased nitrosamine exposure,TREATMENT,PMC,,,,
PMC8371525,bacterial stimulation,PROBLEM,PMC,,,,
PMC8371525,chronic inflammation,PROBLEM,PMC,C0021376,Chronic inflammation,OMIM,Pathologic Function
PMC8371525,autoimmune mechanisms,PROBLEM,PMC,,,,
PMC8371525,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC8371525,pyloriseems,TREATMENT,PMC,,,,
PMC8371525,inflammation stimulationviamechanisms,PROBLEM,PMC,,,,
PMC8371525,molecular mimicry,PROBLEM,PMC,C0242943,Molecular Mimicry,MSH,Molecular Function
PMC8371525,pyloriand pancreatic tissue,PROBLEM,PMC,,,,
PMC8371525,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC8371525,antibodies,PROBLEM,PMC,C0003241,Antibodies,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC8371525,pyloriproteins,PROBLEM,PMC,,,,
PMC8371525,microbiome dysbiosish,PROBLEM,PMC,,,,
PMC8371525,pyloriis,PROBLEM,PMC,,,,
PMC8371525,autoimmune inflammation of the pancreas,PROBLEM,PMC,,,,
PMC8371525,aip,PROBLEM,PMC,C1836668,AURKAIP1 gene,MTH,Gene or Genome
PMC8371525,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8371525,a potential risk factor,PROBLEM,PMC,C0548253,Identify potential risk factors for skin breakdown.,PCDS,Therapeutic or Preventive Procedure
PMC11141771,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11141771,cancerrelated death,PROBLEM,PMC,,,,
PMC11141771,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC11141771,chemoradiation therapies,TREATMENT,PMC,C3468348,chemoradiation therapy,MEDCIN,Therapeutic or Preventive Procedure
PMC11141771,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11141771,cryoablation,TREATMENT,PMC,C0010408,Cryosurgery,MTH,Therapeutic or Preventive Procedure
PMC11141771,effective therapy,TREATMENT,PMC,C3494935,More effective medication therapy available,SNOMEDCT_US,Finding
PMC11141771,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11141771,symptom,TREATMENT,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11141771,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC11141771,disseminated intravascular coagulation,PROBLEM,PMC,C0012739,Disseminated Intravascular Coagulation,MTH,Disease or Syndrome
PMC11141771,cryoablation,TREATMENT,PMC,C0010408,Cryosurgery,MTH,Therapeutic or Preventive Procedure
PMC11141771,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11141771,a whipple procedure,TREATMENT,PMC,C4038811,History of Whipple procedure,SNOMEDCT_US,Finding
PMC11141771,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC11141771,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11141771,paclitaxel,TREATMENT,PMC,C0144576,paclitaxel,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11141771,the abdominal lymph nodes peritoneum right femur,PROBLEM,PMC,,,,
PMC11141771,surrounding soft tissue metastases,PROBLEM,PMC,,,,
PMC11141771,systemic palliative chemotherapy,TREATMENT,PMC,,,,
PMC11141771,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC11141771,paclitaxel,TREATMENT,PMC,C0144576,paclitaxel,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11141771,right femur tumor excision,TREATMENT,PMC,,,,
PMC11141771,open reduction,TREATMENT,PMC,C2370853,Open reduction,MTH,Therapeutic or Preventive Procedure
PMC11141771,internal fixation,TREATMENT,PMC,C0016642,"Fracture Fixation, Internal",MSH,Therapeutic or Preventive Procedure
PMC11141771,radiation therapy,TREATMENT,PMC,C1522449,Radiation therapy (procedure),MTH,Therapeutic or Preventive Procedure
PMC11141771,persistent pain,PROBLEM,PMC,C0406836,Persistent wound pain,SNOMEDCT_US,Finding
PMC11141771,palliative percutaneous cryoablation,TREATMENT,PMC,,,,
PMC11141771,the metastatic tumor,PROBLEM,PMC,C4744823,Metastatic Tumor Sample,MTH,Body Substance
PMC11141771,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11141771,ultrasound guidance,TEST,PMC,C0442973,Ultrasonic guidance procedure,SNOMEDCT_US,Diagnostic Procedure
PMC11141771,procedure,TREATMENT,PMC,C1546467,Act Class - procedure,MTH,Occupational Activity
PMC11141771,slow but continuous blood oozing at the ablation site,PROBLEM,PMC,,,,
PMC11141771,compression dressings,TREATMENT,PMC,C0179212,Pressure bandage,SNOMEDCT_US,Medical Device
PMC11141771,reinforcement sutures,TREATMENT,PMC,C2223869,fourth degree vaginal laceration second layer interrupted 3-0 chromic suture reinforce rectal closure,MEDCIN,Therapeutic or Preventive Procedure
PMC11141771,local thrombin powder,TREATMENT,PMC,,,,
PMC11141771,hypotensive,PROBLEM,PMC,C0857353,Hypotensive,MTH,Pathologic Function
PMC11141771,tachycardic,PROBLEM,PMC,,,,
PMC11141771,petechiae in both lower extremities,PROBLEM,PMC,,,,
PMC11141771,laboratory studies,TEST,PMC,C0681827,laboratory studies,MEDCIN,Laboratory Procedure
PMC11141771,dic,TEST,PMC,C0010927,dacarbazine,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11141771,peripheral blood smear,TEST,PMC,C0747518,PERIPHERAL BLOOD SMEAR ABNORMAL,CCPSS,Finding
PMC11141771,multiple schistocytes,PROBLEM,PMC,,,,
PMC11141771,ct angiogram,TEST,PMC,C5849477,CT brain angiogram,MDR,Diagnostic Procedure
PMC11141771,any bleeding vessel,PROBLEM,PMC,,,,
PMC11141771,embolization,TREATMENT,PMC,C0013931,"Embolization, Therapeutic",MSH,Therapeutic or Preventive Procedure
PMC11141771,red blood cells,TREATMENT,PMC,C1277078,"Red blood cells, blood product",MTH,Pharmacologic Substance
PMC11141771,platelets,TEST,PMC,C0005821,Blood Platelets,MTH,Cell
PMC11141771,fresh frozen plasma,TREATMENT,PMC,C0016709,Fresh frozen plasma,MTH,Body Substance
PMC11141771,cryoprecipitate,TREATMENT,PMC,C5553020,Cryoprecipitated Plasma,MTH,Pharmacologic Substance
PMC11141771,multiple daily transfusions,TREATMENT,PMC,,,,
PMC11141771,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC11141771,persistently thrombocytopenic,PROBLEM,PMC,C3805226,Persistent immune thrombocytopenic purpura,MDR,Disease or Syndrome
PMC11141771,coagulopathic,PROBLEM,PMC,,,,
PMC11141771,comfort care measures,TREATMENT,PMC,C0943984,Comfortable and well cared for:Find:Pt:^Patient:Ord:Reported.living-HIV,LNC,Clinical Attribute
PMC11141771,dic,PROBLEM,PMC,C0010927,dacarbazine,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11141771,lifethreatening complication,PROBLEM,PMC,,,,
PMC11141771,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC11141771,dic,PROBLEM,PMC,C0010927,dacarbazine,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11141771,a lifethreatening complication,PROBLEM,PMC,,,,
PMC11141771,advanced pc,PROBLEM,PMC,,,,
PMC11141771,large volume cryoablation,TREATMENT,PMC,,,,
PMC11141771,more studies,TEST,PMC,C3510339,"Nerve conduction, 13 or more studies",CPT,Diagnostic Procedure
PMC11141771,cryoablation,TREATMENT,PMC,C0010408,Cryosurgery,MTH,Therapeutic or Preventive Procedure
PMC11141771,antitumor immunity,TREATMENT,PMC,,,,
PMC11141771,life threatening dic,PROBLEM,PMC,,,,
PMC5384142,dendritic cells,PROBLEM,PMC,C0011306,Dendritic Cells,MTH,Cell
PMC5384142,antitumor immune response,TREATMENT,PMC,,,,
PMC5384142,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC5384142,dcbased immunotherapy,TREATMENT,PMC,,,,
PMC5384142,tolllike receptor,TREATMENT,PMC,,,,
PMC5384142,a promising approach,TREATMENT,PMC,,,,
PMC5384142,harnessing immunity,TREATMENT,PMC,,,,
PMC5384142,metastatic,PROBLEM,PMC,C0036525,Metastatic to,MTH,Functional Concept
PMC5384142,locally advanced unresectable pancreatic cancer,PROBLEM,PMC,,,,
PMC5384142,autologous dcs,TREATMENT,PMC,C4725931,Autologous Tumor-specific Antigen-loaded Dendritic Cells,NCI,Cell
PMC5384142,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC5384142,dcs,TEST,PMC,C0010590,cycloserine,MTH,"Amino Acid, Peptide, or Protein, Antibiotic"
PMC5384142,three distinct a2restricted peptides,TREATMENT,PMC,,,,
PMC5384142,human telomerase reverse transcriptase,TREATMENT,PMC,C1958471,"telomerase reverse transcriptase p572Y, human",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC5384142,carcinoembryonic antigen,TEST,PMC,C0007082,Carcinoembryonic Antigen,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC5384142,cap16d,TEST,PMC,,,,
PMC5384142,survivin,TREATMENT,PMC,C0664336,survivin,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC5384142,four intradermal injections,TREATMENT,PMC,,,,
PMC5384142,1  107peptidepulsed dc vaccines,TREATMENT,PMC,,,,
PMC5384142,intramuscular administration of,TREATMENT,PMC,C1556154,Intramuscular Route of Administration,MTH,Functional Concept
PMC5384142,polyiclc,TREATMENT,PMC,,,,
PMC5384142,safety,TEST,PMC,C0036043,Safety,MTH,Human-caused Phenomenon or Process
PMC5384142,feasibility,TEST,PMC,C5235660,Feasibility,NCI,Qualitative Concept
PMC5384142,dc vaccination,TREATMENT,PMC,C2348036,DC-OVA Vaccine,NCI,"Pharmacologic Substance, Immunologic Factor"
PMC5384142,immune,TREATMENT,PMC,C0439662,Immune,MTH,Finding
PMC5384142,patient t cells,TREATMENT,PMC,C4687977,Orvacabtagene autoleucel,DRUGBANK,Cell
PMC5384142,apheresis,TREATMENT,PMC,C0005791,Apheresis (procedure),MTH,Therapeutic or Preventive Procedure
PMC5384142,metastatic disease,PROBLEM,PMC,C2939420,Metastatic Neoplasm,MTH,Neoplastic Process
PMC5384142,locally advanced unresectable disease,PROBLEM,PMC,,,,
PMC5384142,vaccines,TREATMENT,PMC,C0042210,Vaccines,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC5384142,this treatment,TREATMENT,PMC,C3174560,Did this relative have this strabismus treatment,LNC,Intellectual Product
PMC5384142,the most common symptoms,PROBLEM,PMC,,,,
PMC5384142,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC5384142,selflimiting flulike symptoms,PROBLEM,PMC,,,,
PMC5384142,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC5384142,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC5384142,disease progression,PROBLEM,PMC,C0242656,Disease Progression,MTH,Pathologic Function
PMC5384142,the median overall survival,TREATMENT,PMC,,,,
PMC5384142,leukapheresis,TREATMENT,PMC,C0023416,Leukapheresis,MSH,Therapeutic or Preventive Procedure
PMC5384142,mhc class i tetramer analysis,TEST,PMC,,,,
PMC5384142,vaccination,TREATMENT,PMC,C0042196,Vaccination,MTH,Therapeutic or Preventive Procedure
PMC5384142,antigenspecific t cells,TREATMENT,PMC,,,,
PMC5384142,stable disease,PROBLEM,PMC,C0677946,Stable Disease,MTH,Finding
PMC5384142,vaccination,TREATMENT,PMC,C0042196,Vaccination,MTH,Therapeutic or Preventive Procedure
PMC5384142,peptidepulsed dcs,TREATMENT,PMC,,,,
PMC5384142,polyiclc,TREATMENT,PMC,,,,
PMC5384142,a measurable tumor specific t cell population,PROBLEM,PMC,,,,
PMC5384142,advanced pc,PROBLEM,PMC,,,,
PMC5384142,nct01410968,TEST,PMC,,,,
PMC5384142,supplementary material,TREATMENT,PMC,C2936424,Electronic Supplementary Materials,MSH,Intellectual Product
PMC5384142,vaccination,TREATMENT,PMC,C0042196,Vaccination,MTH,Therapeutic or Preventive Procedure
PMC5384142,peptidepulsed dcs,TREATMENT,PMC,,,,
PMC5384142,polyiclc,TREATMENT,PMC,,,,
PMC5384142,a measurable tumor specific t cell population,PROBLEM,PMC,,,,
PMC5384142,advanced pc,PROBLEM,PMC,,,,
PMC5384142,our study,TEST,PMC,,,,
PMC5384142,tumor peptide epitope pulsed autologus dc vaccination,TREATMENT,PMC,,,,
PMC5384142,tlr ligands,TREATMENT,PMC,,,,
PMC5384142,a promising approach,TREATMENT,PMC,,,,
PMC5384142,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10712702,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10712702,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10712702,associated symptoms,PROBLEM,PMC,C0521989,Signs and Symptoms Associated with Chief Complaint,NCI,Sign or Symptom
PMC10712702,a crosssectional study,TEST,PMC,,,,
PMC10712702,prediagnosis pc pain,PROBLEM,PMC,,,,
PMC10712702,an,TEST,PMC,C1423519,DIAPH3 gene,MTH,Gene or Genome
PMC10712702,numerical rating scale,TEST,PMC,C5237698,Numerical Rating Scale 6-Point,NCI,Intellectual Product
PMC10712702,descriptive statistics,TEST,PMC,C5236893,Statistical Analysis Plan Version Description,NCI,Intellectual Product
PMC10712702,all bivariate analyses,TEST,PMC,,,,
PMC10712702,chisquare,TEST,PMC,,,,
PMC10712702,fishers exact tests,TEST,PMC,C1708064,Fisher's Exact Test,NCI,Intellectual Product
PMC10712702,pc pain,PROBLEM,PMC,C4273905,Pain Catastrophizing Scale,SNOMEDCT_US,Intellectual Product
PMC10712702,prediagnosis symptom,PROBLEM,PMC,,,,
PMC10712702,prediagnostic pc pain,PROBLEM,PMC,,,,
PMC10712702,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC10712702,prediagnostic pc pain,PROBLEM,PMC,,,,
PMC10712702,higher pain intensities,PROBLEM,PMC,,,,
PMC10712702,postdiagnosis symptoms,PROBLEM,PMC,,,,
PMC10712702,cramping,PROBLEM,PMC,C0026821,Muscle Cramp,MTH,Sign or Symptom
PMC10712702,indigestion,PROBLEM,PMC,C0235309,Upset stomach,MTH,Sign or Symptom
PMC10712702,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC10712702,increased resource utilization,PROBLEM,PMC,,,,
PMC10712702,pc pain management,TREATMENT,PMC,,,,
PMC10712702,analgesic prescriptionsp,TREATMENT,PMC,,,,
PMC10712702,high pain intensity scores,PROBLEM,PMC,,,,
PMC10712702,pc pain,PROBLEM,PMC,C4273905,Pain Catastrophizing Scale,SNOMEDCT_US,Intellectual Product
PMC10712702,a prominent pc symptom,PROBLEM,PMC,,,,
PMC10712702,prediagnosis pc pain,PROBLEM,PMC,,,,
PMC10712702,increased gi metastasis,PROBLEM,PMC,,,,
PMC10712702,symptoms burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC10712702,novel treatments,TREATMENT,PMC,C0683465,novel AODU treatment method,AOD,Therapeutic or Preventive Procedure
PMC10712702,ongoing pain management,TREATMENT,PMC,,,,
PMC10712702,surveillance,TEST,PMC,C0684245,legal surveillance,MTH,Occupational Activity
PMC10712702,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10712702,pancreatic cancer pain,PROBLEM,PMC,,,,
PMC10712702,associated symptoms,PROBLEM,PMC,C0521989,Signs and Symptoms Associated with Chief Complaint,NCI,Sign or Symptom
PMC10712702,pc pain,PROBLEM,PMC,C4273905,Pain Catastrophizing Scale,SNOMEDCT_US,Intellectual Product
PMC10712702,a prominent pc symptom,PROBLEM,PMC,,,,
PMC10712702,prediagnosis pc pain,PROBLEM,PMC,,,,
PMC10712702,increased gi metastasis,PROBLEM,PMC,,,,
PMC10712702,symptoms burden,PROBLEM,PMC,C4717145,Symptom Burden,MSH,Finding
PMC10712702,novel treatments,TREATMENT,PMC,C0683465,novel AODU treatment method,AOD,Therapeutic or Preventive Procedure
PMC10712702,ongoing pain management,TREATMENT,PMC,,,,
PMC10712702,surveillance,TEST,PMC,C0684245,legal surveillance,MTH,Occupational Activity
PMC10712702,pc pain,PROBLEM,PMC,C4273905,Pain Catastrophizing Scale,SNOMEDCT_US,Intellectual Product
PMC10712702,a prominent pc symptom,PROBLEM,PMC,,,,
PMC10712702,all pc stages,PROBLEM,PMC,,,,
PMC10712702,dynamic in intensity,PROBLEM,PMC,C5784726,Three-Dimensional Dynamic Intensity Entropy Transformation Magnetic Resonance Imaging,NCI,Diagnostic Procedure
PMC10712702,pain,PROBLEM,PMC,C0030193,Pain,MTH,Sign or Symptom
PMC10712702,a modifiable risk factor,PROBLEM,PMC,C0814292,modifiability of risk or protective factors,AOD,Qualitative Concept
PMC10712702,poor outcomes,PROBLEM,PMC,C3841289,Previous poor pregnancy outcome,LNC,Finding
PMC10712702,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10712702,undermanaged pc pain,PROBLEM,PMC,,,,
PMC10712702,ongoing pain management,TREATMENT,PMC,,,,
PMC10712702,tumor reduction,TREATMENT,PMC,C4523152,Unilateral percutaneous cryoablation for reduction of pulmonary tumor,CPT,Therapeutic or Preventive Procedure
PMC10712702,patient symptom reduction,TREATMENT,PMC,C0512450,Instruct patient/significant other to recognize signs and symptoms of fatigue that require reduction in activity,NIC,Educational Activity
PMC10712702,overall survival,TREATMENT,PMC,C4086681,Overall Survival,NCI,Quantitative Concept
PMC3546942,salvage chemoradiotherapy,TREATMENT,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC3546942,the retrospective analysis,TEST,PMC,,,,
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,unacceptable toxicity,PROBLEM,PMC,C5855504,Unacceptable Toxicity,NCI,Finding
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,local tumor progression,PROBLEM,PMC,,,,
PMC3546942,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3546942,interstitial pneumonitis,PROBLEM,PMC,C5887144,Interstitial pneumonitis,MTH,Disease or Syndrome
PMC3546942,gemcitabine,TREATMENT,PMC,C0045093,gemcitabine,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3546942,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,s1,TREATMENT,PMC,C3715215,S1,MTH,Finding
PMC3546942,5fu,TREATMENT,PMC,C0016360,fluorouracil,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3546942,toxicities,PROBLEM,PMC,C0600688,Toxic effect,MTH,Injury or Poisoning
PMC3546942,generally mild and selflimiting,PROBLEM,PMC,,,,
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,multivariate analysis,TEST,PMC,C0026777,Multivariate Analysis,MSH,Quantitative Concept
PMC3546942,a lower precrt,PROBLEM,PMC,,,,
PMC3546942,a single regimen,TREATMENT,PMC,C5205681,Single-agent Therapeutic Regimens,NCI,Therapeutic or Preventive Procedure
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,the mst,TEST,PMC,C1417246,MPST gene,MTH,Gene or Genome
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,moderate antitumor activity,PROBLEM,PMC,,,,
PMC3546942,lapc,TREATMENT,PMC,,,,
PMC3546942,gemcitabinebased primary chemotherapy,TREATMENT,PMC,,,,
PMC3546942,failure,PROBLEM,PMC,C5200924,Failure,MTH,Idea or Concept
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,distant metastasis,PROBLEM,PMC,C5441917,Distant Metastasis,MTH,Pathologic Function
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,a treatment of choice,TREATMENT,PMC,C5855020,Treatment of Choice,NCI,Therapeutic or Preventive Procedure
PMC3546942,a secondline therapy,TREATMENT,PMC,,,,
PMC3546942,relatively low serum ca199 levels,PROBLEM,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,higher survival,TREATMENT,PMC,,,,
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3546942,a primary treatment,TREATMENT,PMC,C4727086,Primary Immune Deficiency Treatment Consortium,NCI,Health Care Related Organization
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,salvage intent,TREATMENT,PMC,,,,
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,moderate antitumor activity,PROBLEM,PMC,,,,
PMC3546942,lapc,TREATMENT,PMC,,,,
PMC3546942,gemcitabinebased primary chemotherapy,TREATMENT,PMC,,,,
PMC3546942,failure,PROBLEM,PMC,C5200924,Failure,MTH,Idea or Concept
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,distant metastasis,PROBLEM,PMC,C5441917,Distant Metastasis,MTH,Pathologic Function
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,a treatment of choice,TREATMENT,PMC,C5855020,Treatment of Choice,NCI,Therapeutic or Preventive Procedure
PMC3546942,a secondline therapy,TREATMENT,PMC,,,,
PMC3546942,relatively low serum ca199 levels,PROBLEM,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,higher survival,TREATMENT,PMC,,,,
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3546942,a primary treatment,TREATMENT,PMC,C4727086,Primary Immune Deficiency Treatment Consortium,NCI,Health Care Related Organization
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,salvage intent,TREATMENT,PMC,,,,
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,s1,TREATMENT,PMC,C3715215,S1,MTH,Finding
PMC3546942,5fu,TREATMENT,PMC,C0016360,fluorouracil,MTH,"Nucleic Acid, Nucleoside, or Nucleotide, Pharmacologic Substance"
PMC3546942,moderate antitumor activity,PROBLEM,PMC,,,,
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,gembased primary chemotherapy,TREATMENT,PMC,,,,
PMC3546942,failure,PROBLEM,PMC,C5200924,Failure,MTH,Idea or Concept
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,distant metastasis,PROBLEM,PMC,C5441917,Distant Metastasis,MTH,Pathologic Function
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,a treatment of choice,TREATMENT,PMC,C5855020,Treatment of Choice,NCI,Therapeutic or Preventive Procedure
PMC3546942,a secondline therapy,TREATMENT,PMC,,,,
PMC3546942,a relatively low serum ca199 level,PROBLEM,PMC,,,,
PMC3546942,primary chemotherapy,TREATMENT,PMC,C0199951,"Treatment planning for chemotherapy, primary course",SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC3546942,additional survival benefit,TREATMENT,PMC,,,,
PMC3546942,salvage crt,TREATMENT,PMC,,,,
PMC3546942,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC3546942,a primary treatment,TREATMENT,PMC,C4727086,Primary Immune Deficiency Treatment Consortium,NCI,Health Care Related Organization
PMC3546942,lapc,PROBLEM,PMC,,,,
PMC3546942,crt,TREATMENT,PMC,C2987048,CALR wt Allele,MTH,Gene or Genome
PMC3546942,salvage intent,TREATMENT,PMC,,,,
PMC8507697,growth differentiation factor,PROBLEM,PMC,C0253373,growth differentiation factor 5,MTH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8507697,a stress responsive cytokine,PROBLEM,PMC,,,,
PMC8507697,body weight,TEST,PMC,C0005910,Body Weight,MTH,Organism Attribute
PMC8507697,circulating gdf15 level,TEST,PMC,,,,
PMC8507697,cachexia symptoms,PROBLEM,PMC,,,,
PMC8507697,loss of skeletal muscle mass,PROBLEM,PMC,C0872084,Sarcopenia,MSH,Disease or Syndrome
PMC8507697,systemic inflammatory reaction,PROBLEM,PMC,C0161781,"infection and inflammatory reaction due to nervous system device, implant, or graft",MEDCIN,Pathologic Function
PMC8507697,poor performance status,PROBLEM,PMC,C1831741,Poor Performance Status,NCI,Finding
PMC8507697,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC8507697,shortened survival time,PROBLEM,PMC,,,,
PMC8507697,biological tumor activity,PROBLEM,PMC,,,,
PMC8507697,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC8507697,the cutoff,TEST,PMC,C1442160,Cutoff,NCI,Functional Concept
PMC8507697,serum gdf15,TEST,PMC,C5936465,High serum levels of GDF15 during pregnancy,OMIM,Finding
PMC8507697,benign pancreatic disease,PROBLEM,PMC,,,,
PMC8507697,apc,TEST,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC8507697,high serum gdf15,PROBLEM,PMC,C5936465,High serum levels of GDF15 during pregnancy,OMIM,Finding
PMC8507697,worsened performance,PROBLEM,PMC,C2242580,Eastern Cooperative Oncology Group performance status worsened,MDR,Finding
PMC8507697,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC8507697,elevations of inflammatory and tumor burden,PROBLEM,PMC,,,,
PMC8507697,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC8507697,activation of akt,PROBLEM,PMC,C4684420,Activating AKT1 Gene Mutation,NCI,Cell or Molecular Dysfunction
PMC8507697,jnk in tumor gdf15producing,PROBLEM,PMC,,,,
PMC8507697,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8507697,tumordriven gdf15,PROBLEM,PMC,,,,
PMC8507697,cachexia symptoms,PROBLEM,PMC,,,,
PMC8507697,apc,PROBLEM,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC8507697,circulating growth differentiation factor,PROBLEM,PMC,,,,
PMC8507697,cachexia symptoms,PROBLEM,PMC,,,,
PMC8507697,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC8507697,treatmentnave,TREATMENT,PMC,,,,
PMC8507697,liver metastasis,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC8507697,benign pancreatic disease,PROBLEM,PMC,,,,
PMC8507697,clinical data,TEST,PMC,C1516606,Clinical Data,MTH,Intellectual Product
PMC8507697,blood samples,TEST,PMC,C0178913,Blood specimen,MTH,Body Substance
PMC8507697,biopsy specimens,TEST,PMC,C0677862,Biopsy specimen,SNOMEDCT_US,Tissue
PMC8507697,liver metastasis,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC8507697,anticancer treatment,TREATMENT,PMC,C3176985,"Do you take cortisone, predniSONE, other steroids, or anticancer drugs, or have you had radiation treatments",LNC,Intellectual Product
PMC8507697,serum gdf15 levels,TEST,PMC,C5936464,Low serum levels of GDF15 in the nonpregnant state,OMIM,Finding
PMC8507697,multiple protein expressions in lysates,PROBLEM,PMC,,,,
PMC8507697,liver metastasis,PROBLEM,PMC,C0494165,Metastatic malignant neoplasm to liver,SNOMEDCT_US,Neoplastic Process
PMC8507697,enzymelinked immunosorbent assay,TEST,PMC,C5979798,"Oncology (prostate), enzymelinked immunosorbent assays (elisa) for total prostatespecific antigen (psa) and free psa, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer",HCPT,Laboratory Procedure
PMC8507697,reversephase protein array,TEST,PMC,,,,
PMC8507697,the cutoff,TEST,PMC,C1442160,Cutoff,NCI,Functional Concept
PMC8507697,serum gdf15,TEST,PMC,C5936465,High serum levels of GDF15 during pregnancy,OMIM,Finding
PMC8507697,benign pancreatic disease,PROBLEM,PMC,,,,
PMC8507697,low karnofsky performance status,PROBLEM,PMC,,,,
PMC8507697,poor eastern cooperative oncology group performance status,PROBLEM,PMC,,,,
PMC8507697,severe appetite loss,PROBLEM,PMC,C3827434,Worst Severity Past Seven Days Decreased Appetite,NCI,Intellectual Product
PMC8507697,high serum levels,PROBLEM,PMC,C4013976,High serum leptin levels,OMIM,Finding
PMC8507697,carbohydrate antigen,TEST,PMC,C0443758,Carbohydrate antigen,SNOMEDCT_US,"Organic Chemical, Immunologic Factor"
PMC8507697,creactive protein,TEST,PMC,,,,
PMC8507697,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC8507697,phosphorylated pjnk,TEST,PMC,,,,
PMC8507697,pakt,TEST,PMC,C5708829,Phosphorylated RAC Serine/Threonine Kinase Family Protein,NCI,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8507697,apc,PROBLEM,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC8507697,high serum gdf15,PROBLEM,PMC,C5936465,High serum levels of GDF15 during pregnancy,OMIM,Finding
PMC8507697,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC8507697,activation of the signaling pathways,PROBLEM,PMC,C1511454,CREB Activation Signaling Pathway,NCI,Molecular Function
PMC8507697,akt and jnk in the tumor,PROBLEM,PMC,,,,
PMC8507697,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8507697,circulating gdf15,PROBLEM,PMC,,,,
PMC8507697,cachectic symptoms,PROBLEM,PMC,,,,
PMC8507697,apc,PROBLEM,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC8507697,apc,PROBLEM,PMC,C0162832,APC gene,MTH,Gene or Genome
PMC8507697,high serum gdf15,PROBLEM,PMC,C5936465,High serum levels of GDF15 during pregnancy,OMIM,Finding
PMC8507697,worsened performance status,PROBLEM,PMC,C2242580,Eastern Cooperative Oncology Group performance status worsened,MDR,Finding
PMC8507697,anorexia,PROBLEM,PMC,C0003123,Anorexia,MTH,Disease or Syndrome
PMC8507697,elevations of inflammation,PROBLEM,PMC,C5394085,Elevated markers of inflammation,OMIM,Finding
PMC8507697,tumor burden,PROBLEM,PMC,C1449699,Tumor Burden,MSH,Diagnostic Procedure
PMC8507697,cachexia,PROBLEM,PMC,C0006625,Cachexia,MTH,Sign or Symptom
PMC8507697,activation of akt,PROBLEM,PMC,C4684420,Activating AKT1 Gene Mutation,NCI,Cell or Molecular Dysfunction
PMC8507697,jnk in tumor gdf15producing,PROBLEM,PMC,,,,
PMC8507697,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC8507697,circulating gdf15,PROBLEM,PMC,,,,
PMC8507697,cachectic symptoms,PROBLEM,PMC,,,,
PMC7388804,diabetes mellitus,PROBLEM,PMC,C0011849,Diabetes Mellitus,MTH,Disease or Syndrome
PMC7388804,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC7388804,newonset diabetes,PROBLEM,PMC,,,,
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,screening tests,TEST,PMC,C0871311,Screening test,MTH,Health Care Activity
PMC7388804,early pc diagnosis,PROBLEM,PMC,,,,
PMC7388804,pancreaticoduodenectomy,TREATMENT,PMC,C0085162,Pancreaticoduodenectomy,MSH,Therapeutic or Preventive Procedure
PMC7388804,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC7388804,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC7388804,intracellular mechanisms,PROBLEM,PMC,,,,
PMC7388804,the clinical signs,PROBLEM,PMC,C2826635,Vital Signs Clinical Significance,NCI,Clinical Attribute
PMC7388804,immunological and metabolic biomarkers,TEST,PMC,,,,
PMC7388804,early,PROBLEM,PMC,C1279919,Early,MTH,Temporal Concept
PMC7388804,the 34 studies,TEST,PMC,C0798594,Service comment 34:Imp:Pt:XXX:Nom,MTH,Clinical Attribute
PMC7388804,longterm diabetes mellitus,PROBLEM,PMC,,,,
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,six studies,TEST,PMC,,,,
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,fourteen studies,TEST,PMC,,,,
PMC7388804,clinical,PROBLEM,PMC,C0205210,Clinical,MTH,Qualitative Concept
PMC7388804,biomarker levels,TEST,PMC,C4740659,No significant level of biomarkers detected,LNC,Finding
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,six studies,TEST,PMC,,,,
PMC7388804,nod,PROBLEM,PMC,C0751781,Dentatorubral-Pallidoluysian Atrophy,MTH,Disease or Syndrome
PMC7388804,three studies,TEST,PMC,C3863089,"SPECT bone scan, three phase study",MEDCIN,Diagnostic Procedure
PMC7388804,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC7388804,pancreatic resection,TREATMENT,PMC,C0854522,Pancreatic resection,MDR,Therapeutic or Preventive Procedure
PMC7388804,ltdm,PROBLEM,PMC,,,,
PMC7388804,pc development,PROBLEM,PMC,,,,
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,screening protocols,TEST,PMC,C3656617,CCHD newborn screening protocol used,LNC,Finding
PMC7388804,tests,TEST,PMC,C0392366,Tests (qualifier value),MTH,Intellectual Product
PMC7388804,further testing,TEST,PMC,C4700027,Further testing indicated,LNC,Finding
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,impaired glucose levels,PROBLEM,PMC,,,,
PMC7388804,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,ltdm,PROBLEM,PMC,,,,
PMC7388804,pc development,PROBLEM,PMC,,,,
PMC7388804,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC7388804,screening tests,TEST,PMC,C0871311,Screening test,MTH,Health Care Activity
PMC7388804,earlystage pc,PROBLEM,PMC,,,,
PMC7388804,dm and pc,PROBLEM,PMC,,,,
PMC7388804,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC7388804,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC7388804,more,TEST,PMC,C0205172,More,MTH,Quantitative Concept
PMC7388804,interventional studies,TEST,PMC,C3274035,Interventional Study,MTH,Research Activity
PMC7388804,definitive early screening tests,TEST,PMC,,,,
PMC7388804,pc in nod,PROBLEM,PMC,,,,
PMC7388804,postoperative management,TREATMENT,PMC,C0520255,Postoperative Management Only,CPT,Health Care Activity
PMC7388804,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC5486521,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC5486521,a disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC5486521,its treatment,TREATMENT,PMC,C0280957,psychosocial effects of cancer and its treatment,MTH,Finding
PMC5486521,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5486521,optimize pc management,TREATMENT,PMC,,,,
PMC5486521,a,TREATMENT,PMC,,,,
PMC5486521,the modified delphi methodology,TREATMENT,PMC,,,,
PMC5486521,a screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC5486521,potential symptoms,PROBLEM,PMC,C5914429,Consider potential adverse drug event as cause of any new symptom,NIC,Health Care Activity
PMC5486521,diagnostic tests,TEST,PMC,C0086143,Diagnostic tests,MTH,Diagnostic Procedure
PMC5486521,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5486521,a screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC5486521,potential symptoms,PROBLEM,PMC,C5914429,Consider potential adverse drug event as cause of any new symptom,NIC,Health Care Activity
PMC5486521,diagnostic tests,TEST,PMC,C0086143,Diagnostic tests,MTH,Diagnostic Procedure
PMC5486521,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5486521,alarm,PROBLEM,PMC,C0336648,Alarm device,MTH,Medical Device
PMC5486521,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC5486521,centralizing management,TREATMENT,PMC,C0854640,Central line management,MDR,Therapeutic or Preventive Procedure
PMC5486521,this complex disease,PROBLEM,PMC,,,,
PMC5486521,its diagnostic methods,TREATMENT,PMC,,,,
PMC5486521,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC5486521,curative intention,TREATMENT,PMC,C0805793,Curative intent of Rx,LNC,Intellectual Product
PMC5486521,disseminated disease,PROBLEM,PMC,C2367186,disseminated lyme disease,MEDCIN,Disease or Syndrome
PMC5486521,support treatment,TREATMENT,PMC,C1320989,Family support during treatment,SNOMEDCT_US,Social Behavior
PMC5486521,nutrition,TREATMENT,PMC,C1521729,Nutritional Study,MTH,Research Activity
PMC5486521,this complex pathology,PROBLEM,PMC,,,,
PMC10587919,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10587919,insidious symptoms,PROBLEM,PMC,C0240008,INSIDIOUS ONSET OF SYMPTOMS,DXP,Finding
PMC10587919,evidencebased screening,TEST,PMC,,,,
PMC10587919,palliative cares,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10587919,management,TREATMENT,PMC,C0376636,Disease Management,MTH,Health Care Activity
PMC10587919,cancer directed treatment,TREATMENT,PMC,C0804721,Date non cancer directed surgery Rx as part of 1st cancer:Date:Pt:Cancer.XXX:Qn,LNC,Clinical Attribute
PMC10587919,our study,TEST,PMC,,,,
PMC10587919,the palliative care acceptance rate,TREATMENT,PMC,,,,
PMC10587919,medical resource utilization,TREATMENT,PMC,,,,
PMC10587919,a prospective cohort study,TEST,PMC,C1709709,Prospective Cohort Study,MTH,Research Activity
PMC10587919,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10587919,medical resource utilization,TREATMENT,PMC,,,,
PMC10587919,the sop model,TREATMENT,PMC,,,,
PMC10587919,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10587919,our study,TEST,PMC,,,,
PMC10587919,palliative care,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10587919,the sop model,TEST,PMC,,,,
PMC10587919,the hospitalization rate,TEST,PMC,C0598610,hospital admission rate,CSP,Quantitative Concept
PMC10587919,the rate,TEST,PMC,C1521828,Rate,MTH,Quantitative Concept
PMC10587919,er,TEST,PMC,C1706324,EREG wt Allele,MTH,Gene or Genome
PMC10587919,statistically difference,PROBLEM,PMC,,,,
PMC10587919,the modified sop model,TREATMENT,PMC,,,,
PMC10587919,palliative cares,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10587919,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10587919,the sop model,TREATMENT,PMC,,,,
PMC10587919,systematic approach,TREATMENT,PMC,C0589378,Systematic surgical approaches,RCD,Spatial Concept
PMC10587919,the modified sop model,TREATMENT,PMC,,,,
PMC10587919,palliative cares,TREATMENT,PMC,C0030231,Palliative Care,MTH,Therapeutic or Preventive Procedure
PMC10587919,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10587919,the sop model,TREATMENT,PMC,,,,
PMC10587919,systematic approach,TREATMENT,PMC,C0589378,Systematic surgical approaches,RCD,Spatial Concept
PMC10587919,the sop model,TREATMENT,PMC,,,,
PMC10587919,multidisciplinary palliative care,TREATMENT,PMC,,,,
PMC10587919,advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC10587919,this sdm process,TREATMENT,PMC,,,,
PMC10587919,the sop model,TREATMENT,PMC,,,,
PMC10587919,cancer management,TREATMENT,PMC,C0392921,Cancer Pain Management,NCI,Therapeutic or Preventive Procedure
PMC10587919,a,TREATMENT,PMC,,,,
PMC10587919,the model,TREATMENT,PMC,C3161035,Model,MTH,Intellectual Product
PMC10587919,ideal goalconcordant care,TREATMENT,PMC,,,,
PMC6134575,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6134575,a very high mortality rate,PROBLEM,PMC,,,,
PMC6134575,extensive vascular involvement,PROBLEM,PMC,,,,
PMC6134575,surgical intervention,TREATMENT,PMC,C0549433,Surgical intervention (finding),MTH,Finding
PMC6134575,locally advanced pancreatic cancer,PROBLEM,PMC,,,,
PMC6134575,r0 conversion surgery,TREATMENT,PMC,,,,
PMC6134575,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC6134575,carbonion radiotherapy,TREATMENT,PMC,,,,
PMC6134575,longterm relapsefree survival,PROBLEM,PMC,,,,
PMC6134575,epigastralgia,PROBLEM,PMC,C0232493,Epigastric pain,MTH,Sign or Symptom
PMC6134575,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC6134575,ct4,TEST,PMC,C5761462,cT4 (AJCC),SNOMEDCT_US,Classification
PMC6134575,cch1,TEST,PMC,C3252401,"Cch1 protein, S pombe",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC6134575,cdu1,TEST,PMC,,,,
PMC6134575,cs1,TEST,PMC,C4085253,Carnegie stage 1,MTH,Temporal Concept
PMC6134575,crp1,TEST,PMC,C1413766,CSRP1 gene,MTH,Gene or Genome
PMC6134575,cpl1,TEST,PMC,C1143521,"CPL1 protein, Arabidopsis",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC6134575,cvsm0,TEST,PMC,,,,
PMC6134575,casm1,TEST,PMC,,,,
PMC6134575,an unresectable lapc,PROBLEM,PMC,,,,
PMC6134575,induction chemotherapy,TREATMENT,PMC,C3179010,Induction Chemotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,nanoparticle albuminbound nab paclitaxel,TREATMENT,PMC,,,,
PMC6134575,cirt,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,concurrent gemcitabine,TREATMENT,PMC,,,,
PMC6134575,significant shrinkage of,PROBLEM,PMC,,,,
PMC6134575,the primary tumor,PROBLEM,PMC,C4745081,New Primary Tumor,NCI,Finding
PMC6134575,frequent cholangitis,PROBLEM,PMC,,,,
PMC6134575,duodenal stenosis,PROBLEM,PMC,C0238093,Stenosis of duodenum,MTH,Anatomical Abnormality
PMC6134575,continued chemotherapy,TREATMENT,PMC,C1881814,Metronomic Chemotherapy,NCI,Therapeutic or Preventive Procedure
PMC6134575,a radical subtotal stomachpreserving pancreaticoduodenectomy,TREATMENT,PMC,,,,
PMC6134575,histopathologic examination,TEST,PMC,C0677043,Histopathology,MTH,Biomedical Occupation or Discipline
PMC6134575,the resected tissue,PROBLEM,PMC,C0449818,Weight of resected tissue,SNOMEDCT_US,Quantitative Concept
PMC6134575,a r0 resection,TREATMENT,PMC,C1619389,"Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post r0 resection without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)",HCPCS,Therapeutic or Preventive Procedure
PMC6134575,a histological response,TEST,PMC,,,,
PMC6134575,evans grade iib,PROBLEM,PMC,,,,
PMC6134575,adjuvant chemotherapy,TREATMENT,PMC,C0085533,"Chemotherapy, Adjuvant",MTH,Therapeutic or Preventive Procedure
PMC6134575,recurrence,PROBLEM,PMC,C0034897,Recurrence,MTH,Phenomenon or Process
PMC6134575,successful conversion surgery,TREATMENT,PMC,,,,
PMC6134575,an initially unresectable lapc,PROBLEM,PMC,,,,
PMC6134575,rapid induction gem,TREATMENT,PMC,,,,
PMC6134575,nabptx chemotherapy,TREATMENT,PMC,,,,
PMC6134575,cirt,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,rapid induction gem,TREATMENT,PMC,,,,
PMC6134575,nabptx chemotherapy,TREATMENT,PMC,,,,
PMC6134575,cirt,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,lapc,TREATMENT,PMC,,,,
PMC6134575,a safe,TREATMENT,PMC,C0597728,Safe Sex,MSH,Social Behavior
PMC6134575,effective treatment option,TREATMENT,PMC,,,,
PMC6134575,successful conversion surgery,TREATMENT,PMC,,,,
PMC6134575,an initially unresectable lapc,PROBLEM,PMC,,,,
PMC6134575,rapid induction gem,TREATMENT,PMC,,,,
PMC6134575,nabptx chemotherapy,TREATMENT,PMC,,,,
PMC6134575,cirt,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,rapid induction gem,TREATMENT,PMC,,,,
PMC6134575,nabptx chemotherapy,TREATMENT,PMC,,,,
PMC6134575,cirt,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,lapc,TREATMENT,PMC,,,,
PMC6134575,a safe,TREATMENT,PMC,C0597728,Safe Sex,MSH,Social Behavior
PMC6134575,effective treatment option,TREATMENT,PMC,,,,
PMC6134575,conversion surgery,TREATMENT,PMC,C3494226,Conversion to Open Surgery,MSH,Therapeutic or Preventive Procedure
PMC6134575,rapid induction gem,TREATMENT,PMC,,,,
PMC6134575,nabptx therapy,TREATMENT,PMC,,,,
PMC6134575,cirt,TREATMENT,PMC,C3494442,Carbon Ion Radiotherapy,MSH,Therapeutic or Preventive Procedure
PMC6134575,an initially unresectable lapc,PROBLEM,PMC,,,,
PMC6134575,relapsefree survival,TREATMENT,PMC,,,,
PMC6134575,multidisciplinary treatment,TREATMENT,PMC,C5881239,Multidisciplinary care management,SNOMEDCT_US,Health Care Activity
PMC6134575,a powerful systemic chemotherapy,TREATMENT,PMC,,,,
PMC6134575,a local therapy,TREATMENT,PMC,C1517925,Local Therapy,NCI,Therapeutic or Preventive Procedure
PMC11390448,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11390448,specific signs,PROBLEM,PMC,C2830463,Symptoms and signs specifically associated with systemic inflammation and infection,ICD10CM,Sign or Symptom
PMC11390448,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11390448,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11390448,breast or colon or prostate cancer,PROBLEM,PMC,,,,
PMC11390448,screening tests,TEST,PMC,C0871311,Screening test,MTH,Health Care Activity
PMC11390448,tests,TEST,PMC,C0392366,Tests (qualifier value),MTH,Intellectual Product
PMC11390448,pancreatic cancers,PROBLEM,PMC,C0346647,Malignant neoplasm of pancreas,MTH,Neoplastic Process
PMC11390448,most pancreatic cancers,PROBLEM,PMC,,,,
PMC11390448,treatment options,TREATMENT,PMC,C0683525,treatment options,MTH,Finding
PMC11390448,systemic therapy,TREATMENT,PMC,C1515119,Systemic Therapy,NCI,Therapeutic or Preventive Procedure
PMC11390448,radiation,TREATMENT,PMC,C0851346,Radiation,MTH,Natural Phenomenon or Process
PMC11390448,surgical interventions,TREATMENT,PMC,C0543467,Operative Surgical Procedures,MTH,Therapeutic or Preventive Procedure
PMC11390448,a twostage weakly supervised deep learningbased model,TREATMENT,PMC,,,,
PMC11390448,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11390448,computed tomography ct images,TEST,PMC,C5411082,Screening computed tomography (CT) colonography with image postprocessing,CPT,Diagnostic Procedure
PMC11390448,the nnunet supervised segmentation model,TREATMENT,PMC,,,,
PMC11390448,established pancreatic tumors,PROBLEM,PMC,,,,
PMC11390448,a multiinstance learningbased weakly supervised classification model,TREATMENT,PMC,,,,
PMC11390448,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11390448,images,TEST,PMC,C2708290,Key images,LNC,Finding
PMC11390448,deep learning model,TREATMENT,PMC,,,,
PMC11390448,the,TREATMENT,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11390448,an accuracy,TEST,PMC,C4035952,Data Accuracy,MSH,Qualitative Concept
PMC11390448,sensitivity,TEST,PMC,C2349185,Signal Sensitivity,MTH,Qualitative Concept
PMC11390448,specificity,TEST,PMC,C0037791,Specificity,MTH,Quantitative Concept
PMC11390448,auc,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC11390448,the twostage framework,TREATMENT,PMC,,,,
PMC11390448,pancreatic tumor,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC11390448,nontumor pancreas,PROBLEM,PMC,,,,
PMC11390448,the hfh dataset,TEST,PMC,,,,
PMC11390448,significantly enhanced,PROBLEM,PMC,,,,
PMC11390448,a tumor in the pancreas,PROBLEM,PMC,C0345933,Carcinoid tumor of the pancreas,HPO,Neoplastic Process
PMC11390448,ct images,TEST,PMC,C5785262,Number of CT Images Used in Session,NCI,Quantitative Concept
PMC11390448,an endtoend model,TREATMENT,PMC,,,,
PMC11390448,accurate pancreatic tumor prediction,PROBLEM,PMC,,,,
PMC11390448,the nnunet architecture,TREATMENT,PMC,,,,
PMC11390448,multiinstance,TREATMENT,PMC,,,,
PMC11390448,the pancreatic tumor samples,PROBLEM,PMC,,,,
PMC11390448,the segmented image,TEST,PMC,C4073072,Abnormal posterior segment imaging,HPO,Finding
PMC11390448,a bag,TREATMENT,PMC,C0179419,Breathing bag,SNOMEDCT_US,Medical Device
PMC11390448,the multiinstance learning model,TREATMENT,PMC,,,,
PMC11390448,classification,TEST,PMC,C0008902,Classification,MTH,Classification
PMC11390448,the cropped image,TEST,PMC,,,,
PMC11390448,our experimental findings,TEST,PMC,,,,
PMC11390448,the hfh test dataset,TEST,PMC,,,,
PMC11390448,patient radiographic imaging,TEST,PMC,,,,
PMC11390448,early pancreatic tumor detection,PROBLEM,PMC,,,,
PMC11390448,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11390448,patient care,TREATMENT,PMC,C0017313,patient care,MTH,Health Care Activity
PMC11390448,employing,TREATMENT,PMC,C0557351,Employed,MTH,Finding
PMC11390448,autoencoding dnn,TREATMENT,PMC,,,,
PMC9777348,surgical,TREATMENT,PMC,C0587668,Surgical service,MTH,Health Care Activity
PMC9777348,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9777348,routine medical checkups,TEST,PMC,,,,
PMC9777348,asymptomatic people,PROBLEM,PMC,,,,
PMC9777348,operable pcs,PROBLEM,PMC,,,,
PMC9777348,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC9777348,medical checkups,TEST,PMC,,,,
PMC9777348,abdominal ultrasonography,TEST,PMC,C2455220,Ultrasonography of Abdominal Aorta,ICD10PCS,Diagnostic Procedure
PMC9777348,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9777348,the diagnostic approach,TEST,PMC,C2406624,"Drainage of Anus, External Approach, Diagnostic",ICD10PCS,Diagnostic Procedure
PMC9777348,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9777348,us,TEST,PMC,C0041703,United States,MTH,Geographic Area
PMC9777348,medical checkup,TEST,PMC,,,,
PMC9777348,asymptomatic individuals,PROBLEM,PMC,C2977627,Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.,ICD10CM,Finding
PMC9777348,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC9777348,excision ratio,TEST,PMC,,,,
PMC9777348,survival rate,TEST,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC9777348,us,TEST,PMC,C0041703,United States,MTH,Geographic Area
PMC9777348,medical checkup,TEST,PMC,,,,
PMC9777348,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9777348,us,TEST,PMC,C0041703,United States,MTH,Geographic Area
PMC9777348,asymptomatic individuals,PROBLEM,PMC,C2977627,Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.,ICD10CM,Finding
PMC9777348,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9777348,pcs,PROBLEM,PMC,C1864389,PREMATURE CHROMATID SEPARATION TRAIT,MTH,Disease or Syndrome
PMC9777348,medical checkup,TEST,PMC,,,,
PMC9777348,asymptomatic individuals,PROBLEM,PMC,C2977627,Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease.,ICD10CM,Finding
PMC9777348,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC9777348,pc screening,TEST,PMC,C3161523,traumatic event screening: PC-PTSD,MEDCIN,Finding
PMC9777348,asymptomatic,PROBLEM,PMC,C0231221,Asymptomatic (finding),MTH,Finding
PMC9777348,cancer screening,TEST,PMC,C0199230,Screening for cancer,MTH,Diagnostic Procedure
PMC9777348,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9777348,any modalities,TEST,PMC,C3176548,Any modality hallucinations notes,LNC,Intellectual Product
PMC9777348,cect,TEST,PMC,C0047122,3-(2-carboxyethyl)cytosine,MSH,Organic Chemical
PMC9777348,mrcp,TEST,PMC,C0994163,"Cholangiopancreatography, Magnetic Resonance",MSH,Diagnostic Procedure
PMC9777348,eus,TEST,PMC,C0376443,Endoscopic Ultrasound,MTH,Diagnostic Procedure
PMC9777348,us,TEST,PMC,C0041703,United States,MTH,Geographic Area
PMC10485404,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10485404,significant weight loss,PROBLEM,PMC,,,,
PMC10485404,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC10485404,patient management,TREATMENT,PMC,C1610129,Patient Management,CPT,Health Care Activity
PMC10485404,treatment outcomes,TREATMENT,PMC,C0085415,Treatment outcome,MTH,Qualitative Concept
PMC10485404,an observational retrospective study,TEST,PMC,,,,
PMC10485404,metastatic pc mpc,PROBLEM,PMC,,,,
PMC10485404,firstline chemotherapy withnabpaclitaxel,TREATMENT,PMC,,,,
PMC10485404,nutritional support,TREATMENT,PMC,C0242739,Nutritional Support,MTH,Therapeutic or Preventive Procedure
PMC10485404,pancreatic enzyme replacement therapy,TREATMENT,PMC,C4523842,Pancreatic enzyme replacement therapy,MDR,Therapeutic or Preventive Procedure
PMC10485404,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC10485404,ancillary dietary interventions,TREATMENT,PMC,,,,
PMC10485404,the therapeutic regimen,TREATMENT,PMC,C1276413,Therapeutic regimen,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC10485404,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC10485404,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC10485404,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC10485404,nutritional parameters,TEST,PMC,C0547798,Plot nutrition parameters on growth chart (for pediatrics).,PCDS,Health Care Activity
PMC10485404,phase angle,TEST,PMC,C4285040,Phase.max^W stress:Angle:Pt:Heart.ventricle.left:Qn:NM.SPECT,LNC,Clinical Attribute
PMC10485404,anticancer treatment,TREATMENT,PMC,C3176985,"Do you take cortisone, predniSONE, other steroids, or anticancer drugs, or have you had radiation treatments",LNC,Intellectual Product
PMC10485404,the positive impact on os,PROBLEM,PMC,,,,
PMC10485404,karnofsky performance status deterioration,PROBLEM,PMC,,,,
PMC10485404,maldigestionrelated symptoms,PROBLEM,PMC,,,,
PMC10485404,our data,TEST,PMC,,,,
PMC10485404,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC10485404,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10485404,significant weight loss,PROBLEM,PMC,,,,
PMC10485404,malnutrition,PROBLEM,PMC,C0162429,Malnutrition,MTH,Disease or Syndrome
PMC10485404,a study,TEST,PMC,C2603343,Study,MTH,Research Activity
PMC10485404,metastatic pancreatic cancer,PROBLEM,PMC,C0346976,Metastatic malignant neoplasm to pancreas,SNOMEDCT_US,Neoplastic Process
PMC10485404,firstline chemotherapy withnabpaclitaxel,TREATMENT,PMC,,,,
PMC10485404,nutritional support,TREATMENT,PMC,C0242739,Nutritional Support,MTH,Therapeutic or Preventive Procedure
PMC10485404,pancreatic enzyme replacement therapy,TREATMENT,PMC,C4523842,Pancreatic enzyme replacement therapy,MDR,Therapeutic or Preventive Procedure
PMC10485404,our data,TEST,PMC,,,,
PMC10485404,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC10485404,a retrospective study,TEST,PMC,C0035363,Retrospective Studies,MTH,Research Activity
PMC10485404,mpc,PROBLEM,PMC,C0026604,"Motion Therapy, Continuous Passive",MTH,Therapeutic or Preventive Procedure
PMC10485404,firstline chemotherapy,TREATMENT,PMC,,,,
PMC10485404,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10485404,a multimodal and multidisciplinary approach,TREATMENT,PMC,,,,
PMC10485404,supportive simultaneous therapies,TREATMENT,PMC,,,,
PMC10485404,mpc management,TREATMENT,PMC,,,,
PMC10485404,both pert,TREATMENT,PMC,,,,
PMC10485404,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC10485404,a,TREATMENT,PMC,,,,
PMC10485404,higher disease control,TREATMENT,PMC,,,,
PMC10485404,pert,TEST,PMC,C0599890,pert,CHV,Hormone
PMC10485404,maldigestionrelated symptoms,PROBLEM,PMC,,,,
PMC10485404,weight loss,PROBLEM,PMC,C1262477,Weight Loss,MTH,Finding
PMC10485404,kps deterioration,PROBLEM,PMC,,,,
PMC10485404,pert,TREATMENT,PMC,C0599890,pert,CHV,Hormone
PMC10485404,further highquality studies,TEST,PMC,,,,
PMC11060269,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11060269,early pancreatic cancer,PROBLEM,PMC,,,,
PMC11060269,a locally advanced or metastatic stage,PROBLEM,PMC,,,,
PMC11060269,symptoms,PROBLEM,PMC,C1457887,Symptoms,MTH,Sign or Symptom
PMC11060269,this striking disparity in survival,PROBLEM,PMC,,,,
PMC11060269,intervention,TREATMENT,PMC,C1273869,Intervention regimes,MTH,Health Care Activity
PMC11060269,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC11060269,an early pancreatic cancer,PROBLEM,PMC,,,,
PMC11060269,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11060269,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC11060269,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11060269,early pancreatic cancer detection,PROBLEM,PMC,,,,
PMC11060269,highrisk populations,PROBLEM,PMC,,,,
PMC11060269,current screening initiatives,TREATMENT,PMC,,,,
PMC11060269,highrisk individuals,PROBLEM,PMC,,,,
PMC11060269,novel imaging modalities,TEST,PMC,,,,
PMC11060269,early pancreatic cancer,PROBLEM,PMC,,,,
PMC11060269,the novel imaging techniques,TEST,PMC,,,,
PMC11060269,a large scale,TREATMENT,PMC,C3655246,Cancer related large scale gene,LNC,Gene or Genome
PMC11060269,pancreatic,PROBLEM,PMC,C0030274,Pancreas,MTH,"Body Part, Organ, or Organ Component"
PMC11060269,the low disease incidence,PROBLEM,PMC,,,,
PMC11060269,high costs,PROBLEM,PMC,C0039425,"Technology, High-Cost",MSH,Occupation or Discipline
PMC11060269,asymptomatic highgrade precursor lesions,PROBLEM,PMC,,,,
PMC11060269,noninvasive pdac,TEST,PMC,,,,
PMC11060269,targeted screening,TEST,PMC,C0679817,targeted screening,AOD,Therapeutic or Preventive Procedure
PMC11060269,highrisk populations,PROBLEM,PMC,,,,
PMC11060269,resectable lesions,PROBLEM,PMC,C0198412,Resection of mediastinal lesion,SNOMEDCT_US,Therapeutic or Preventive Procedure
PMC11060269,pdac,PROBLEM,PMC,,,,
PMC11060269,individual screening trials,TREATMENT,PMC,,,,
PMC11060269,the multimodality approach,TREATMENT,PMC,C0871821,Multimodal Treatment Approach,PSY,Therapeutic or Preventive Procedure
PMC11060269,pancreatic imaging,TEST,PMC,C2021737,magnetic resonance imaging of abdomen: pancreatic phlegmon,MEDCIN,Finding
PMC11060269,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11060269,treatment,TREATMENT,PMC,C1522326,Treating,MTH,Functional Concept
PMC11060269,imaging modalities,TEST,PMC,C1275506,Imaging modality,MTH,Functional Concept
PMC11060269,cuttingedge imaging techniques,TEST,PMC,,,,
PMC11060269,dwi,TEST,PMC,C1171335,Driving While Intoxicated,MTH,Individual Behavior
PMC11060269,dcemri,TEST,PMC,,,,
PMC11060269,hyperpolarized mri,TEST,PMC,C4730242,Hyperpolarization MRI Systems,UMD,Medical Device
PMC11060269,mre,TEST,PMC,C1518156,Magnetic Resonance Elastography,MTH,Diagnostic Procedure
PMC11060269,dualenergy contrastenhanced ct,TEST,PMC,,,,
PMC11060269,nanomaterials,TREATMENT,PMC,C1450053,Nanostructured Materials,MTH,Manufactured Object
PMC11060269,molecular imaging,TEST,PMC,C1537028,Molecular Imaging,MSH,Diagnostic Procedure
PMC11060269,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11060269,this disease,PROBLEM,PMC,C1548571,Infectious disease: this location can be used for isolation,HL7V2.5,Intellectual Product
PMC11060269,these novel imaging modalities,TEST,PMC,,,,
PMC11060269,screening,TEST,PMC,C1710032,Screening,MTH,Health Care Activity
PMC11060269,therapy,TREATMENT,PMC,C0039798,therapeutic aspects,MTH,Functional Concept
PMC11060269,the tumour microenvironment,PROBLEM,PMC,,,,
PMC11060269,driver mutations,PROBLEM,PMC,C5668169,ALK Driver Mutation Negative,NCI,Laboratory or Test Result
PMC11060269,early screening,TEST,PMC,C4718257,Obtains screening for early detection,NOC,Finding
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC4855757,biliary stricture,PROBLEM,PMC,C0597984,Biliary stricture,SNOMEDCT_US,Anatomical Abnormality
PMC4855757,further treatment,TREATMENT,PMC,C5239246,Subject/Guardian Refused Further Treatment,NCI,Finding
PMC4855757,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4855757,transpapillary biliary biopsy,TEST,PMC,,,,
PMC4855757,malignant biliary strictures,PROBLEM,PMC,,,,
PMC4855757,cholangiocarcinoma,PROBLEM,PMC,C0206698,Cholangiocarcinoma,MTH,Neoplastic Process
PMC4855757,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4855757,biliary strictures,PROBLEM,PMC,C0597984,Biliary stricture,SNOMEDCT_US,Anatomical Abnormality
PMC4855757,transpapillary forceps biopsy,TEST,PMC,,,,
PMC4855757,sphincterotomy,TREATMENT,PMC,C0748895,Sphincterotomy,MSH,Therapeutic or Preventive Procedure
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC4855757,the diagnostic sensitivity,TEST,PMC,C1511883,Diagnostic Sensitivity,MTH,Quantitative Concept
PMC4855757,specificity,TEST,PMC,C0037791,Specificity,MTH,Quantitative Concept
PMC4855757,positive predictive value,TEST,PMC,C1514243,Positive Predictive Value,MSH,Quantitative Concept
PMC4855757,forceps biopsy,TEST,PMC,C5445114,Forceps Biopsy,MTH,Diagnostic Procedure
PMC4855757,both cholangiocarcinoma,PROBLEM,PMC,,,,
PMC4855757,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4855757,malignant strictures,PROBLEM,PMC,C0341129,Malignant esophageal stricture,SNOMEDCT_US,Disease or Syndrome
PMC4855757,benign strictures,PROBLEM,PMC,C0341130,Benign esophageal stricture,SNOMEDCT_US,Disease or Syndrome
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC4855757,the malignant group,PROBLEM,PMC,C4687504,Mediastinal Malignant Germ Cell Tumor Stage,NCI,Classification
PMC4855757,a significantly higher serum bilirubin level,PROBLEM,PMC,,,,
PMC4855757,serum carcinoembryonic antigen,TEST,PMC,C4763512,Serum CEA Measurement,NCI,Laboratory Procedure
PMC4855757,carbohydrate antigen,TEST,PMC,C0443758,Carbohydrate antigen,SNOMEDCT_US,"Organic Chemical, Immunologic Factor"
PMC4855757,alkaline phosphatase,TEST,PMC,C0002059,Alkaline Phosphatase,MTH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC4855757,the sensitivity,TEST,PMC,C0020517,Hypersensitivity,MTH,Pathologic Function
PMC4855757,specificity,TEST,PMC,C0037791,Specificity,MTH,Quantitative Concept
PMC4855757,ppv,TEST,PMC,C0379986,PPV protocol,MSH,Therapeutic or Preventive Procedure
PMC4855757,npv,TEST,PMC,C0028586,Nucleopolyhedrovirus,MTH,Virus
PMC4855757,forceps biopsy,TEST,PMC,C5445114,Forceps Biopsy,MTH,Diagnostic Procedure
PMC4855757,biliary stricture,PROBLEM,PMC,C0597984,Biliary stricture,SNOMEDCT_US,Anatomical Abnormality
PMC4855757,the cholangiocarcinoma group,PROBLEM,PMC,,,,
PMC4855757,a higher sensitivity,PROBLEM,PMC,,,,
PMC4855757,lower ca 199 level,PROBLEM,PMC,,,,
PMC4855757,more common hepatic duct strictures,PROBLEM,PMC,,,,
PMC4855757,serum cea,TEST,PMC,C5206280,Serum CEA Level Low,NCI,Finding
PMC4855757,ca 199,TEST,PMC,C0201551,CA 19-9 measurement,MTH,Laboratory Procedure
PMC4855757,the alkaline phosphatase level,TEST,PMC,C0427395,Neutrophil alkaline phosphatase level,MTH,Laboratory or Test Result
PMC4855757,serum bilirubin level,TEST,PMC,C1287366,Finding of serum bilirubin level,MTH,Laboratory or Test Result
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC4855757,forceps biopsy,TEST,PMC,C5445114,Forceps Biopsy,MTH,Diagnostic Procedure
PMC4855757,pancreatobiliary strictures,PROBLEM,PMC,,,,
PMC4855757,major bleeding,PROBLEM,PMC,C5243991,Major bleeding - TIMI classification,MDR,Pathologic Function
PMC4855757,perforation,PROBLEM,PMC,C0549099,Perforation (morphologic abnormality),MTH,Finding
PMC4855757,our study,TEST,PMC,,,,
PMC4855757,transpapillary forceps biopsy,TEST,PMC,,,,
PMC4855757,biliary strictures,PROBLEM,PMC,C0597984,Biliary stricture,SNOMEDCT_US,Anatomical Abnormality
PMC4855757,sphincterotomy,TREATMENT,PMC,C0748895,Sphincterotomy,MSH,Therapeutic or Preventive Procedure
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC4855757,a significantly higher sensitive method in cholangiocarcinoma,PROBLEM,PMC,,,,
PMC4855757,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4855757,transpapillary forceps biopsy,TEST,PMC,,,,
PMC4855757,biliary strictures,PROBLEM,PMC,C0597984,Biliary stricture,SNOMEDCT_US,Anatomical Abnormality
PMC4855757,sphincterotomy,TREATMENT,PMC,C0748895,Sphincterotomy,MSH,Therapeutic or Preventive Procedure
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC4855757,a significantly higher sensitive method in cholangiocarcinoma,PROBLEM,PMC,,,,
PMC4855757,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4855757,forceps biopsy,TEST,PMC,C5445114,Forceps Biopsy,MTH,Diagnostic Procedure
PMC4855757,biliary stricture,PROBLEM,PMC,C0597984,Biliary stricture,SNOMEDCT_US,Anatomical Abnormality
PMC4855757,significantly sensitive in cholangiocarcinoma,PROBLEM,PMC,,,,
PMC4855757,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4855757,tissue sampling,TEST,PMC,C4266460,Tissue sampling,LNC,Diagnostic Procedure
PMC8950951,transient receptor potential channels trps,TREATMENT,PMC,,,,
PMC8950951,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC8950951,trp,PROBLEM,PMC,C0041249,tryptophan,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Biologically Active Substance"
PMC8950951,a trpsrelated gene signature,PROBLEM,PMC,,,,
PMC8950951,the cox regression,TEST,PMC,C0010235,Cox Proportional Hazards Models,MSH,Quantitative Concept
PMC8950951,a tcgapaad cohort,TEST,PMC,,,,
PMC8950951,receiver operating,TEST,PMC,C0034772,Receiver Operating Characteristic,MSH,Quantitative Concept
PMC8950951,a,TEST,PMC,,,,
PMC8950951,the mutation analysis,TEST,PMC,C5204073,MET Mutation Analysis,NCI,Laboratory Procedure
PMC8950951,gene set enrichment analysis,TEST,PMC,,,,
PMC8950951,virtual interventions screening,TEST,PMC,,,,
PMC8950951,a four trpsrelated gene signature,PROBLEM,PMC,,,,
PMC8950951,the area under the curve,TEST,PMC,C2827759,Area Under the Curve All,NCI,Quantitative Concept
PMC8950951,kaplanmeier analysis,TEST,PMC,,,,
PMC8950951,elevated signature score,PROBLEM,PMC,,,,
PMC8950951,a highrisk group,PROBLEM,PMC,,,,
PMC8950951,significantly shorter recurrence free,PROBLEM,PMC,,,,
PMC8950951,the gene prediction,TEST,PMC,C5196969,"Gm12185 protein, mouse",MSH,"Amino Acid, Peptide, or Protein, Enzyme"
PMC8950951,shortened overall survival,PROBLEM,PMC,,,,
PMC8950951,diseasespecific survival,PROBLEM,PMC,,,,
PMC8950951,auc,TEST,PMC,C0376690,Area Under Curve,MTH,Quantitative Concept
PMC8950951,gsea enrichment,TEST,PMC,,,,
PMC8950951,several cancerrelated pathways,PROBLEM,PMC,,,,
PMC8950951,trpc3 mrna,TEST,PMC,,,,
PMC8950951,elevated,PROBLEM,PMC,C3163633,Elevated,MTH,Qualitative Concept
PMC8950951,cancer tissue,PROBLEM,PMC,C1654781,dental tissue cancer,CSP,Neoplastic Process
PMC8950951,control,PROBLEM,PMC,C0243148,control aspects,MTH,Qualitative Concept
PMC8950951,augmented in tumors,PROBLEM,PMC,C5784969,CD40L-augmented Autologous Tumor Infiltrating Lymphocytes,NCI,Cell
PMC8950951,lymph node invasion,PROBLEM,PMC,C0475291,Abdominal lymph node tumor invasion status,SNOMEDCT_US,Intellectual Product
PMC8950951,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC8950951,lymph node invasion,PROBLEM,PMC,C0475291,Abdominal lymph node tumor invasion status,SNOMEDCT_US,Intellectual Product
PMC8950951,virtual substance screening,TEST,PMC,,,,
PMC8950951,four small molecular compounds,PROBLEM,PMC,,,,
PMC8950951,trpc3 protein,PROBLEM,PMC,C1739921,"Trpc3 protein, rat",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC8950951,a four trprelated,TREATMENT,PMC,,,,
PMC8950951,paad,PROBLEM,PMC,C1538757,PYDC1 gene,MTH,Gene or Genome
PMC8950951,sensory ion channels trpc3,TREATMENT,PMC,,,,
PMC8950951,trpc7,TREATMENT,PMC,C1427112,TRPC7 gene,MTH,Gene or Genome
PMC8950951,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8950951,trpc3,PROBLEM,PMC,C1421170,TRPC3 gene,MTH,Gene or Genome
PMC8950951,dysregulating mitochondrial functions,PROBLEM,PMC,,,,
PMC8950951,paad genesis,PROBLEM,PMC,,,,
PMC8950951,sensory ion channels,PROBLEM,PMC,,,,
PMC8950951,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC8950951,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC8950951,invasive potential,PROBLEM,PMC,,,,
PMC8950951,functional validation,TEST,PMC,C3534875,Patient queried about pain and pain interference with function using a valid and reliable instrument (DSP),CPT,Health Care Activity
PMC8316912,modern medical technology,TREATMENT,PMC,,,,
PMC8316912,many cancers,PROBLEM,PMC,C3172900,How many full sisters do you have:Num:Pt:^Patient:Qn:Carolina Breast Cancer Study,LNC,Clinical Attribute
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,a highly lethal gastrointestinal cancer,PROBLEM,PMC,,,,
PMC8316912,a low 5year survival rate,PROBLEM,PMC,,,,
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,obvious clinical symptoms,PROBLEM,PMC,C3534869,"Patient has clear clinical symptoms and signs that are highly suggestive of neuropathy AND cannot be attributed to another condition, AND has an obvious cause for the neuropathy (DSP)",CPT,Finding
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,an increase in pancreatic cancer,PROBLEM,PMC,C1842408,increased risk of pancreatic cancer,HPO,Finding
PMC8316912,high mortality,PROBLEM,PMC,C0479563,Exposure to high and low air pressure and changes in air pressure as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,the nonmodifiable factors,PROBLEM,PMC,,,,
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,reliable screening strategies,TEST,PMC,,,,
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,the modifiable risk factors,PROBLEM,PMC,C4717889,Acknowledges ability to change modifiable risk factors,NOC,Finding
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,earlier interventions,TREATMENT,PMC,,,,
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,a comprehensive prevention and control strategy,TREATMENT,PMC,,,,
PMC8316912,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC8316912,effective tobaccocontrol policy,TREATMENT,PMC,,,,
PMC8316912,enlarging coverage of screening,TREATMENT,PMC,,,,
PMC8316912,education,TREATMENT,PMC,C0013658,Educational Status,MTH,Finding
PMC8316912,vaccination programmes,TREATMENT,PMC,C0206082,Immunization Programs,MSH,Health Care Activity
PMC8316912,precautions,TREATMENT,PMC,C1882442,Precaution,NCI,Conceptual Entity
PMC4029741,recent experimental studies,TEST,PMC,,,,
PMC4029741,various cytokines,PROBLEM,PMC,,,,
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC4029741,a broad panel of cytokines,TEST,PMC,,,,
PMC4029741,interleukin il1,TEST,PMC,C3536785,Interleukin-1 Receptor Antagonist [EPC],MTH,Pharmacologic Substance
PMC4029741,il6,TEST,PMC,C1334122,IL6 gene,MTH,Gene or Genome
PMC4029741,il8,TEST,PMC,C1366571,CXCL8 gene,MTH,Gene or Genome
PMC4029741,il10,TREATMENT,PMC,C1334098,IL10 gene,MTH,Gene or Genome
PMC4029741,il12,TREATMENT,PMC,C0123759,interleukin-12,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC4029741,il17,TREATMENT,PMC,C1825592,IL17A gene,MTH,Gene or Genome
PMC4029741,il23,TREATMENT,PMC,C0963088,interleukin-23,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4029741,tumor necrosis factor alpha,TEST,PMC,C1456820,Tumor Necrosis Factor-alpha,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4029741,granulocytecolony stimulating factor,TREATMENT,PMC,,,,
PMC4029741,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC4029741,other pancreatic malignancies,PROBLEM,PMC,,,,
PMC4029741,solid pseudopapillary tumors,PROBLEM,PMC,C5686320,Solid pseudopapillary neoplasm,MTH,Neoplastic Process
PMC4029741,il6,TEST,PMC,C1334122,IL6 gene,MTH,Gene or Genome
PMC4029741,il8,TEST,PMC,C1366571,CXCL8 gene,MTH,Gene or Genome
PMC4029741,il10,TEST,PMC,C1334098,IL10 gene,MTH,Gene or Genome
PMC4029741,tnf,PROBLEM,PMC,C1143119,"tumor necrosis factor-alpha, CNGRC fusion protein, human",MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,cancer,PROBLEM,PMC,C0998265,Cancer <Cancridae>,MTH,Eukaryote
PMC4029741,lower il23 concentrations,PROBLEM,PMC,,,,
PMC4029741,malignancies,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC4029741,il6,TEST,PMC,C1334122,IL6 gene,MTH,Gene or Genome
PMC4029741,il8,TEST,PMC,C1366571,CXCL8 gene,MTH,Gene or Genome
PMC4029741,il10,TEST,PMC,C1334098,IL10 gene,MTH,Gene or Genome
PMC4029741,il23,TREATMENT,PMC,C0963088,interleukin-23,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4029741,circulating bone marrow bmderived mesenchymal,PROBLEM,PMC,,,,
PMC4029741,very small embryonicepiblastlike stem cells scs,PROBLEM,PMC,,,,
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,our study,TEST,PMC,,,,
PMC4029741,il6,TEST,PMC,C1334122,IL6 gene,MTH,Gene or Genome
PMC4029741,il8,TEST,PMC,C1366571,CXCL8 gene,MTH,Gene or Genome
PMC4029741,il10,TEST,PMC,C1334098,IL10 gene,MTH,Gene or Genome
PMC4029741,il23,TEST,PMC,C0963088,interleukin-23,MTH,"Amino Acid, Peptide, or Protein, Immunologic Factor"
PMC4029741,tnf levels,TEST,PMC,,,,
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,other pancreatic tumors,PROBLEM,PMC,,,,
PMC4029741,diseases,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC4029741,acute and chronic pancreatitis,PROBLEM,PMC,C0262417,Acute on chronic pancreatitis,SNOMEDCT_US,Disease or Syndrome
PMC4029741,postpancreatitis cysts,PROBLEM,PMC,,,,
PMC4029741,sensitivity and specificity,TEST,PMC,C0036668,Sensitivity and Specificity,MSH,Quantitative Concept
PMC4029741,our study,TEST,PMC,,,,
PMC4029741,selected cytokines,PROBLEM,PMC,C0879595,Selective Cytokine Inhibitory Drug CC-1088,NCI,"Organic Chemical, Pharmacologic Substance"
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,selected interleukins,PROBLEM,PMC,C5666966,Pegylated CD25/CD122-selective Interleukin-2 Mutein STK-012,NCI,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC4029741,intensified bmscs trafficking,PROBLEM,PMC,,,,
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,several cytokines,PROBLEM,PMC,,,,
PMC4029741,pancreatic cancer in humans,PROBLEM,PMC,C0961213,"PCD1 protein, human",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC4029741,our study,TEST,PMC,,,,
PMC4029741,selected cytokines,PROBLEM,PMC,C0879595,Selective Cytokine Inhibitory Drug CC-1088,NCI,"Organic Chemical, Pharmacologic Substance"
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,selected interleukins,PROBLEM,PMC,C5666966,Pegylated CD25/CD122-selective Interleukin-2 Mutein STK-012,NCI,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Immunologic Factor"
PMC4029741,intensified bmscs trafficking,PROBLEM,PMC,,,,
PMC4029741,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC4029741,several cytokines,PROBLEM,PMC,,,,
PMC4029741,pancreatic cancer in humans,PROBLEM,PMC,C0961213,"PCD1 protein, human",MSH,"Amino Acid, Peptide, or Protein, Biologically Active Substance"
PMC10162946,the pancreatic cancer disease impact,PROBLEM,PMC,,,,
PMC10162946,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10162946,a methodological and crosssectional study,TEST,PMC,,,,
PMC10162946,the cpacadi score,TEST,PMC,,,,
PMC10162946,the cronbachs alpha coefficient,TEST,PMC,,,,
PMC10162946,the cpacadi score,TEST,PMC,,,,
PMC10162946,the correlation coefficient,TEST,PMC,C0871052,Pearson Correlation Coefficient,NCI,Quantitative Concept
PMC10162946,skin itchiness score,PROBLEM,PMC,,,,
PMC10162946,the total score,TEST,PMC,C2964552,Total score,MTH,Quantitative Concept
PMC10162946,the correlation coefficients,TEST,PMC,C0871052,Pearson Correlation Coefficient,NCI,Quantitative Concept
PMC10162946,the scale,TEST,PMC,C0222045,Integumentary scale,MTH,"Body Part, Organ, or Organ Component"
PMC10162946,the cpacadi score,TEST,PMC,,,,
PMC10162946,the eq5d vas score,TEST,PMC,,,,
PMC10162946,paindiscomfort,PROBLEM,PMC,,,,
PMC10162946,anxiety,PROBLEM,PMC,C0003467,Anxiety,MTH,Mental or Behavioral Dysfunction
PMC10162946,loss of appetite,PROBLEM,PMC,C3814874,Loss of Appetite question,MTH,Intellectual Product
PMC10162946,fatigue,PROBLEM,PMC,C0015672,Fatigue,MTH,Sign or Symptom
PMC10162946,nausea,PROBLEM,PMC,C0027497,Nausea,MTH,Sign or Symptom
PMC10162946,the corresponding symptoms,PROBLEM,PMC,,,,
PMC10162946,the edmonton symptom assessment system scale,TEST,PMC,C3472649,Edmonton Symptom Assessment System,SNOMEDCT_US,Intellectual Product
PMC10162946,significant symptom differences,PROBLEM,PMC,,,,
PMC10162946,treatment modalities,TREATMENT,PMC,C5234956,Physical Therapy Modalities,MTH,Therapeutic or Preventive Procedure
PMC10162946,the cpacadi score,TEST,PMC,,,,
PMC10162946,a suitable diseasespecific tool,PROBLEM,PMC,,,,
PMC10162946,multiple symptoms,PROBLEM,PMC,C0231217,Multiple symptoms,SNOMEDCT_US,Sign or Symptom
PMC10162946,the cpacadi score,TEST,PMC,,,,
PMC10162946,a suitable diseasespecific tool,PROBLEM,PMC,,,,
PMC10162946,multiple symptoms,PROBLEM,PMC,C0231217,Multiple symptoms,SNOMEDCT_US,Sign or Symptom
PMC10162946,this study,TEST,PMC,C3172868,Was this on a farm:Find:Pt:^Patient:Nom:PEG Study,LNC,Clinical Attribute
PMC10162946,the pacadi score,TEST,PMC,,,,
PMC10162946,the,TEST,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC10162946,the cpacadi score,TEST,PMC,,,,
PMC10162946,a suitable diseasespecific,PROBLEM,PMC,,,,
PMC10162946,multiple symptoms,PROBLEM,PMC,C0231217,Multiple symptoms,SNOMEDCT_US,Sign or Symptom
PMC9308974,type 2 diabetes mellitus,PROBLEM,PMC,C0011860,"Diabetes Mellitus, Non-Insulin-Dependent",MTH,Disease or Syndrome
PMC9308974,its potential complications,PROBLEM,PMC,,,,
PMC9308974,cancers,PROBLEM,PMC,C0006826,Malignant Neoplasms,MTH,Neoplastic Process
PMC9308974,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9308974,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9308974,sedentary lifestyles,TREATMENT,PMC,C1532253,Sedentary lifestyle,MTH,Finding
PMC9308974,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC9308974,cancer mortality,PROBLEM,PMC,C1516192,Cancer Death Rate,NCI,Quantitative Concept
PMC9308974,its generic symptoms,PROBLEM,PMC,,,,
PMC9308974,latestage presentation,PROBLEM,PMC,,,,
PMC9308974,rapid metastasis,PROBLEM,PMC,,,,
PMC9308974,t2dm,PROBLEM,PMC,,,,
PMC9308974,pc development,PROBLEM,PMC,,,,
PMC9308974,chronic inflammation,PROBLEM,PMC,C0021376,Chronic inflammation,OMIM,Pathologic Function
PMC9308974,insulin resistance,PROBLEM,PMC,C0021655,Insulin Resistance,MTH,Pathologic Function
PMC9308974,hyperinsulinemia,PROBLEM,PMC,C0020459,Hyperinsulinism,MTH,Disease or Syndrome
PMC9308974,hyperglycemia,PROBLEM,PMC,C0020456,Hyperglycemia,MTH,Disease or Syndrome
PMC9308974,abnormalities in the insulin,PROBLEM,PMC,C0861018,Insulin abnormal NOS,MDR,Finding
PMC9308974,the disease association,PROBLEM,PMC,C1511978,Disease Association,NCI,Temporal Concept
PMC9308974,these two conditions,PROBLEM,PMC,,,,
PMC9308974,this literature review,TEST,PMC,,,,
PMC9308974,relevant studies,TEST,PMC,C2114265,pre-procedure checklist: relevant imaging studies confirmed in chart,MEDCIN,Health Care Activity
PMC9308974,diabetes,PROBLEM,PMC,C0011847,Diabetes,MTH,Disease or Syndrome
PMC9308974,pc development,PROBLEM,PMC,,,,
PMC9308974,antidiabetic agents,TREATMENT,PMC,C0935929,Antidiabetics,MSH,Pharmacologic Substance
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,extensive studies,TEST,PMC,C5960526,Extension Study Design,NCI,Research Activity
PMC9308974,t2dm,PROBLEM,PMC,,,,
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,further investigation,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC9308974,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9308974,dietary patterns,PROBLEM,PMC,C1517289,Dietary Patterns,MSH,Individual Behavior
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,preventive measures,TREATMENT,PMC,C0033107,prevention & control,MTH,Qualitative Concept
PMC9308974,modifiable risk factors,PROBLEM,PMC,C0814292,modifiability of risk or protective factors,AOD,Qualitative Concept
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,antidiabetic drugs,TREATMENT,PMC,C0935929,Antidiabetics,MSH,Pharmacologic Substance
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,metformin,TREATMENT,PMC,C0025598,metformin,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9308974,inhibiting pc,PROBLEM,PMC,,,,
PMC9308974,insulin,TREATMENT,PMC,C0021641,Insulin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,future novel therapies,TREATMENT,PMC,,,,
PMC9308974,these two disease states,PROBLEM,PMC,,,,
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,a deadly disease,PROBLEM,PMC,,,,
PMC9308974,studies,TEST,PMC,C0947630,Scientific Study,MTH,Research Activity
PMC9308974,t2dm individuals,PROBLEM,PMC,,,,
PMC9308974,treatments,TREATMENT,PMC,C0087111,Therapeutic procedure,MTH,Therapeutic or Preventive Procedure
PMC9308974,chemotherapy,TREATMENT,PMC,C3665472,Chemotherapy,MTH,Therapeutic or Preventive Procedure
PMC9308974,immunotherapy,TREATMENT,PMC,C0021083,Immunotherapy,MTH,Therapeutic or Preventive Procedure
PMC9308974,the overall median survival,TREATMENT,PMC,,,,
PMC9308974,the total survival,TREATMENT,PMC,C5211483,Total score:Score:Pt:^Patient:Qn:QWLQ-CS,LNC,Clinical Attribute
PMC9308974,t2dm triggers pc,PROBLEM,PMC,,,,
PMC9308974,future studies,TEST,PMC,,,,
PMC9308974,dm,PROBLEM,PMC,C0439199,decimeter,MTH,Quantitative Concept
PMC9308974,obesity,PROBLEM,PMC,C0028754,Obesity,MTH,Disease or Syndrome
PMC9308974,dietary patterns,PROBLEM,PMC,C1517289,Dietary Patterns,MSH,Individual Behavior
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,the modifiable risk factors,PROBLEM,PMC,C4717889,Acknowledges ability to change modifiable risk factors,NOC,Finding
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,antidiabetic agents,TREATMENT,PMC,C0935929,Antidiabetics,MSH,Pharmacologic Substance
PMC9308974,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC9308974,metformin,TREATMENT,PMC,C0025598,metformin,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9308974,pc risk,PROBLEM,PMC,C5381638,Aggressive prostate cancer risk:Score:Pt:^Patient:Qn:Calculated.ExoDx,LNC,Clinical Attribute
PMC9308974,insulin,TREATMENT,PMC,C0021641,Insulin,MTH,"Amino Acid, Peptide, or Protein, Pharmacologic Substance, Hormone"
PMC9308974,further investigations,TEST,PMC,C4296499,Physical health needs that require further investigation,LNC,Finding
PMC9308974,metformin,TREATMENT,PMC,C0025598,metformin,MTH,"Organic Chemical, Pharmacologic Substance"
PMC9308974,an antitumor effect,PROBLEM,PMC,,,,
PMC9308974,a breakthrough in improving pc prognosis,PROBLEM,PMC,,,,
PMC9308974,the different biomarkers,TEST,PMC,,,,
PMC10080704,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC10080704,a low incidence rate,PROBLEM,PMC,,,,
PMC10080704,a high mortality,PROBLEM,PMC,C0479563,Exposure to high and low air pressure and changes in air pressure as an external cause of morbidity and mortality,ICD10,Injury or Poisoning
PMC10080704,the disease,PROBLEM,PMC,C0012634,Disease,MTH,Disease or Syndrome
PMC10080704,early neoplastic lesions,PROBLEM,PMC,,,,
PMC10080704,surgery,TREATMENT,PMC,C0038894,Surgery specialty,MTH,Biomedical Occupation or Discipline
PMC10080704,preneoplastic lesions of the pancreas,PROBLEM,PMC,,,,
PMC10080704,pancreatic intraepithelial neoplasia,PROBLEM,PMC,C1301034,Pancreatic intraepithelial neoplasia,MTH,Neoplastic Process
PMC10080704,mucinous cystic neoplasms,PROBLEM,PMC,C5428759,mucinous cystic neoplasm of liver,MEDCIN,Neoplastic Process
PMC10080704,intraductal papillary mucinous neoplasms,PROBLEM,PMC,C3160815,Intraductal papillary mucinous neoplasm,SNOMEDCT_US,Neoplastic Process
PMC10080704,our study,TEST,PMC,,,,
PMC10080704,predicting pc,PROBLEM,PMC,,,,
PMC10080704,early signs,PROBLEM,PMC,C4715167,Identifies early signs of anger,NOC,Finding
PMC10080704,noninvasive techniques,TEST,PMC,,,,
PMC10080704,a systematic english literature search,TEST,PMC,,,,
PMC10080704,pancreatic neoplasms,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC10080704,our study,TEST,PMC,,,,
PMC10080704,ai algorithms,TREATMENT,PMC,,,,
PMC10080704,pancreatic lesions,PROBLEM,PMC,C5856176,Pancreatic Cystic Lesion,NCI,Finding
PMC10080704,ai algorithms,TEST,PMC,,,,
PMC10080704,ai,TEST,PMC,C0003504,Aortic Valve Insufficiency,MTH,Disease or Syndrome
PMC10080704,a screening program,TEST,PMC,C0679819,mandatory screening program,AOD,Health Care Activity
PMC10080704,aibased screening models,TEST,PMC,,,,
PMC10080704,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC10080704,medical and imaging data,TEST,PMC,C4035777,"Stage 2 - Clinical Data Repository (CDR), Controlled Medical Vocabulary, Clinical Decision Support (CDS), may have Document Imaging; Health Information Exchange (HIE) capable",LNC,Finding
PMC10080704,investment in medical infrastructures,TREATMENT,PMC,,,,
PMC10080704,our analysis,TEST,PMC,,,,
PMC10080704,the current diagnostic methods,TEST,PMC,,,,
PMC10080704,detecting pc,PROBLEM,PMC,C4730032,PC Mutation Detection Reagent Kits,UMD,Medical Device
PMC10080704,early lesions,PROBLEM,PMC,C0343828,Early yaws skin lesion,SNOMEDCT_US,Disease or Syndrome
PMC10080704,published studies,TEST,PMC,,,,
PMC10080704,early lesions in pc,PROBLEM,PMC,,,,
PMC10080704,pc diagnosis,TEST,PMC,,,,
PMC10080704,noninvasive tests,TEST,PMC,C5197797,Noninvasive Prenatal Testing,MSH,Diagnostic Procedure
PMC10080704,imaging,TEST,PMC,C0079595,Imaging Techniques,MTH,Diagnostic Procedure
PMC10080704,tumor marker analysis,TEST,PMC,C3516445,Analysis for detection of tumor marker,CPT,Laboratory Procedure
PMC10080704,populationbased studies,TEST,PMC,,,,
PMC10080704,ai algorithms,TREATMENT,PMC,,,,
PMC10080704,subtle changes,PROBLEM,PMC,C4015148,Subtle foveal changes,OMIM,Finding
PMC10080704,pancreatic lesions,PROBLEM,PMC,C5856176,Pancreatic Cystic Lesion,NCI,Finding
PMC10080704,pancreatic neoplasia,PROBLEM,PMC,C4315004,Pancreatic endocrine neoplasia,OMIM,Finding
PMC10080704,published studies,TEST,PMC,,,,
PMC10080704,small samples,PROBLEM,PMC,C0586709,Small bowel resection specimen,SNOMEDCT_US,Tissue
PMC10080704,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC10080704,these studies,TEST,PMC,,,,
PMC10080704,personal data,TEST,PMC,C4552910,Protected Personal Data,MTH,Conceptual Entity
PMC10080704,biomarkers,TEST,PMC,C0005516,Biological Markers,MTH,Clinical Attribute
PMC10080704,genomic features,PROBLEM,PMC,C1880951,Genomic Feature Physical Location,NCI,Spatial Concept
PMC10080704,a physician analyses,TEST,PMC,C0547284,Analyze the wave form and report unresolved abnormalities to the physician.,PCDS,Therapeutic or Preventive Procedure
PMC10080704,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC10080704,the studies,TEST,PMC,C0554756,Doppler studies,MTH,Diagnostic Procedure
PMC10080704,internal validation,TEST,PMC,,,,
PMC10080704,a specific ai algorithm,TREATMENT,PMC,,,,
PMC10080704,ai algorithms,TEST,PMC,,,,
PMC10080704,tumors,PROBLEM,PMC,C0027651,Neoplasms,MTH,Neoplastic Process
PMC10080704,an aidriven automated volumetric segmentation algorithm,TEST,PMC,,,,
PMC10080704,the variations in shape,PROBLEM,PMC,C0332481,Normal variation in shape,SNOMEDCT_US,Qualitative Concept
PMC10080704,the small size of the pancreas,PROBLEM,PMC,,,,
PMC10080704,pancreatic tumors,PROBLEM,PMC,C0030297,Pancreatic Neoplasm,MTH,Neoplastic Process
PMC10080704,inconspicuous borders,PROBLEM,PMC,,,,
PMC10080704,radiomics analysis,TEST,PMC,,,,
PMC10080704,early lesion diagnosis,PROBLEM,PMC,C0343828,Early yaws skin lesion,SNOMEDCT_US,Disease or Syndrome
PMC10080704,ai methods,TEST,PMC,,,,
PMC10080704,pancreatic lesions,PROBLEM,PMC,C5856176,Pancreatic Cystic Lesion,NCI,Finding
PMC10080704,the surgical management,TREATMENT,PMC,C1515089,Surgical Management,NCI,Health Care Activity
PMC10080704,pc,PROBLEM,PMC,C1418288,PC gene,MTH,Gene or Genome
PMC11185363,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11185363,preinvasive stage,PROBLEM,PMC,,,,
PMC11185363,pancreatic cancer,PROBLEM,PMC,C0235974,Pancreatic carcinoma,MTH,Neoplastic Process
PMC11185363,this deadly disease,PROBLEM,PMC,,,,
PMC11185363,premalignant lesions,PROBLEM,PMC,C0850639,Premalignant Lesion,NCI,Neoplastic Process
PMC11185363,intraductal papillary mucinous neoplasms,PROBLEM,PMC,C3160815,Intraductal papillary mucinous neoplasm,SNOMEDCT_US,Neoplastic Process
PMC11185363,mucinous cystic neoplasms of the pancreas,PROBLEM,PMC,C4531085,Mucinous cystic neoplasm of the pancreas,HPO,Neoplastic Process
PMC11185363,imaging exams,TEST,PMC,C5411262,"Imaging of organ, complimenting routine exam",CPT,Diagnostic Procedure
PMC11185363,their management,TREATMENT,PMC,C2585093,Client involvement in management of their money,SNOMEDCT_US,Health Care Activity
PMC11185363,pancreatic intraepithelial neoplasms,PROBLEM,PMC,,,,
PMC11185363,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11185363,the,PROBLEM,PMC,C0304113,rose oil,MTH,"Organic Chemical, Pharmacologic Substance"
PMC11185363,pdac,PROBLEM,PMC,,,,
PMC11185363,panins,PROBLEM,PMC,C1212070,Panine betaherpesvirus 2,NCBI,Virus
PMC11185363,radiologic exams,TEST,PMC,C0748230,RADIOLOGICAL EXAM,CCPSS,Health Care Activity
PMC11185363,indirect imaging signs,TEST,PMC,,,,
PMC11185363,a followup strategy,TREATMENT,PMC,,,,
PMC11185363,blood test,TEST,PMC,C0994779,Blood test device,MTH,Medical Device
PMC11185363,serial imaging test,TEST,PMC,,,,
PMC11185363,computed tomography,TEST,PMC,C0040405,X-Ray Computed Tomography,MTH,Diagnostic Procedure
PMC11185363,magnetic resonance imaging,TEST,PMC,C0024485,Magnetic Resonance Imaging,MTH,Diagnostic Procedure
PMC11185363,resection surgery,TREATMENT,PMC,C0746399,MANDIBLE SURGERY RESECTION,CCPSS,Therapeutic or Preventive Procedure
PMC11185363,moderate or high grade dysplasia,PROBLEM,PMC,,,,
PMC11185363,the final histopathology,TEST,PMC,,,,
PMC11185363,a diagnostic technique,TEST,PMC,C0949688,Molecular Diagnostic Techniques,MSH,Molecular Biology Research Technique
PMC11185363,highgrade panin lesions,PROBLEM,PMC,,,,
PMC11185363,the cytology,TEST,PMC,C0010819,Cytology,MTH,Biomedical Occupation or Discipline
PMC11185363,pancreatic juice,TEST,PMC,C0030296,pancreatic juice,MTH,Body Substance
PMC11185363,nasopancreatic intubation,TEST,PMC,,,,
PMC11185363,early malignant lesions,PROBLEM,PMC,,,,
PMC11185363,invasive padc,PROBLEM,PMC,,,,
PMC11185363,pancreatic adenocarcinoma,PROBLEM,PMC,C0281361,Adenocarcinoma of pancreas,SNOMEDCT_US,Neoplastic Process
PMC11185363,an invasive stage,PROBLEM,PMC,C0862389,Invasive bladder cancer stage II,MDR,Neoplastic Process
PMC11185363,highgrade panin,PROBLEM,PMC,,,,
PMC11185363,pdac,TREATMENT,PMC,,,,
PMC11185363,a survival rate,TREATMENT,PMC,C0038954,Survival Rate,MSH,Quantitative Concept
PMC11185363,this deadly disease,PROBLEM,PMC,,,,
PMC11185363,the analysis,TEST,PMC,C0936012,Analysis,MTH,Research Activity
PMC11185363,cytology of pancreatic juice,TEST,PMC,,,,
PMC11185363,a technique,TREATMENT,PMC,C0449851,Techniques,MTH,Functional Concept
